Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" ABCB1 "ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1" ENSG00000085563 "ATP binding cassette subfamily B member 1" P08183 7 87503633-87713323 "Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 57.8;intestine: 49.6" "Cell line enhanced" "Detected in some" "CACO-2: 29.4;HEK 293: 9.0;HEL: 16.3;Hep G2: 8.1;RPTEC TERT1: 11.3;SH-SY5Y: 36.0" "Cancer enhanced" "Detected in many" "renal cancer: 14.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 19.2" "Group enriched" "Detected in many" 8 "NK-cells: 11.4;T-cells: 19.2" "CAB001716, HPA002199" Enhanced Approved "Nucleoplasm,Focal adhesion sites,Cytosol" "Nucleoplasm, Focal adhesion sites, Cytosol" "CAB001716: , HPA002199: AB_1844428" "unprognostic (5.38e-3)" "unprognostic (2.45e-2)" "unprognostic (1.42e-1)" "unprognostic (1.06e-1)" "unprognostic (2.25e-2)" "unprognostic (9.99e-5)" "unprognostic (2.23e-3)" "unprognostic (5.65e-3)" "unprognostic (1.14e-1)" "unprognostic (5.17e-2)" "prognostic favourable (3.33e-4)" "unprognostic (5.19e-1)" "prognostic favourable (2.95e-4)" "unprognostic (2.06e-1)" "unprognostic (1.50e-1)" "unprognostic (3.83e-1)" "unprognostic (6.12e-2)" 2.6 57.8 9.4 3.2 11.5 1.2 3.4 5.1 10.5 5.5 22.7 3.8 2.0 14.4 9.4 3.5 2.0 3.2 9.0 1.8 9.2 6.6 19.1 15.6 3.8 2.2 9.4 5.7 2.2 1.5 1.7 1.3 3.1 11.1 2.7 10.7 7.6 1.5 2.1 1.1 1.3 49.6 5.7 9.0 2.4 1.7 1.3 8.6 0.1 2.4 1.4 2.2 2.6 5.9 1.9 0.0 0.1 0.0 11.4 19.2 1.5 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 29.4 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 9.0 16.3 1.9 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.4 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 11.3 0.0 0.4 36.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.8 0.0 0.4 3.2 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 7.8 0.0 19.2 0.4 2.0 4.7 0.0 1.9 1.2 4.8 0.1 11.4 0.0 0.0 0.0 1.5 9.4 11.5 5.1 10.5 9.2 6.6 9.4 5.7 11.1 8.6 ABCG2 "ABCP, BCRP, CD338, EST157481, MXR" ENSG00000118777 "ATP binding cassette subfamily G member 2 (Junior blood group)" Q9UNQ0 4 88090264-88231322 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ductus deferens: 49.6;intestine: 56.6;seminal vesicle: 61.0" "Cell line enhanced" "Detected in many" "A549: 19.9;BEWO: 34.7;MCF7: 11.5;RPMI-8226: 17.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "MAIT T-cell: 5.7" "Low lineage specificity" "Detected in many" "CAB037299, HPA054719" Enhanced Supported "Nucleoplasm,Plasma membrane" "Plasma membrane" Nucleoplasm "CAB037299: AB_476804, HPA054719: " "unprognostic (5.04e-1)" "unprognostic (3.05e-2)" "unprognostic (2.01e-1)" "unprognostic (1.10e-1)" "unprognostic (1.01e-3)" "unprognostic (9.19e-2)" "unprognostic (1.09e-1)" "unprognostic (1.30e-1)" "unprognostic (9.14e-2)" "unprognostic (1.37e-1)" "unprognostic (3.01e-3)" "unprognostic (4.52e-2)" "unprognostic (1.67e-3)" "unprognostic (8.82e-3)" "unprognostic (7.04e-2)" "unprognostic (1.30e-1)" "unprognostic (1.92e-1)" 2.8 2.5 11.6 0.8 14.8 1.2 2.4 4.3 9.7 13.6 12.5 8.4 49.6 24.9 14.4 4.2 1.5 6.1 3.3 2.0 16.0 12.2 2.3 19.7 3.0 0.8 17.6 5.6 5.6 0.6 3.2 7.0 12.3 17.0 5.5 8.1 6.9 2.9 61.0 0.4 0.6 56.6 11.8 15.7 0.9 1.2 1.9 5.5 0.0 3.8 0.8 1.3 2.0 3.1 1.2 0.5 0.0 0.2 2.4 5.7 0.7 0.7 19.9 5.9 0.0 0.2 0.0 34.7 0.7 0.6 1.0 1.7 4.4 0.2 0.0 0.2 0.1 5.8 0.2 0.6 1.5 5.6 0.9 0.2 0.1 5.9 0.0 0.3 0.0 0.1 2.4 2.3 0.1 1.8 0.4 0.0 0.6 11.5 2.7 0.1 2.0 0.0 1.3 0.0 17.4 0.0 4.2 0.1 0.2 4.1 0.4 0.5 0.1 0.0 0.0 0.8 0.7 0.2 0.0 5.5 2.1 0.0 1.5 0.0 0.8 0.0 0.0 0.0 1.9 0.0 5.7 0.1 0.7 0.6 0.0 1.2 0.7 0.3 0.0 2.4 0.2 0.5 1.7 0.7 11.6 14.8 4.3 9.7 16.0 12.2 17.6 5.6 17.0 5.5 ACE "ACE1, CD143, DCP1" ENSG00000159640 "Angiotensin I converting enzyme" P12821 17 63477061-63498380 "Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Carboxypeptidase, Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "intestine: 205.6" "Group enriched" "Detected in some" 4 "ASC TERT1: 35.9;HUVEC TERT2: 18.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "memory B-cell: 3.7" "Group enriched" "Detected in many" 23 "B-cells: 3.7;monocytes: 2.0;T-cells: 1.9" "CAB002426, CAB002921, HPA029298, HPA069790" Enhanced Approved Vesicles "Secreted to blood" 121920000 92000000 Vesicles "CAB002426: AB_442052, CAB002921: , HPA029298: AB_10960255, HPA069790: " "unprognostic (4.72e-2)" "unprognostic (4.16e-1)" "unprognostic (1.93e-3)" "unprognostic (6.06e-2)" "unprognostic (2.78e-1)" "unprognostic (1.35e-2)" "unprognostic (4.37e-1)" "unprognostic (1.54e-1)" "unprognostic (1.56e-1)" "unprognostic (1.25e-2)" "unprognostic (3.13e-2)" "unprognostic (2.38e-1)" "unprognostic (7.66e-2)" "unprognostic (9.07e-2)" "unprognostic (1.66e-1)" "unprognostic (1.08e-1)" "unprognostic (2.76e-2)" 6.8 2.0 0.5 2.4 4.2 0.0 2.9 0.5 1.1 5.3 83.2 0.7 37.7 46.4 4.5 5.1 1.7 1.5 4.4 4.7 0.6 0.7 2.6 1.4 16.3 2.2 0.4 0.7 1.4 3.0 3.6 3.6 3.6 0.8 3.4 1.4 1.7 2.5 20.1 3.6 1.3 205.6 2.4 0.6 1.4 1.9 32.6 1.3 0.5 6.9 3.1 2.2 1.7 1.6 3.7 0.1 0.0 2.0 0.0 1.9 0.4 0.0 0.0 0.0 0.0 1.5 35.9 0.4 1.3 2.6 0.0 0.0 0.5 3.1 0.7 1.0 6.1 0.0 1.7 0.0 0.0 0.0 0.7 3.4 0.0 0.0 0.8 0.0 0.0 2.4 0.0 0.0 0.0 18.3 3.0 0.0 0.0 0.6 0.0 0.7 0.2 0.3 0.1 0.2 0.5 0.0 0.0 4.5 3.2 0.0 0.0 0.0 1.6 0.2 0.0 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.4 0.6 0.9 3.7 1.9 1.4 0.1 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.4 0.5 4.2 0.5 1.1 0.6 0.7 0.4 0.7 0.8 1.3 ACKR1 "CCBP1, CD234, DARC, Dfy, FY, GPD" ENSG00000213088 "Atypical chemokine receptor 1 (Duffy blood group)" Q16570 1 159203307-159206500 "Blood group antigen proteins, CD markers, G-protein coupled receptors, Predicted membrane proteins" "Blood group antigen, G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 109.8" "Group enriched" "Detected in some" 6 "HEL: 22.0;HSkMC: 23.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016421, HPA017672" Enhanced "HPA016421: AB_1849219, HPA017672: AB_1849221" "unprognostic (8.74e-3)" "prognostic favourable (2.52e-5)" "unprognostic (9.73e-2)" "unprognostic (1.91e-1)" "unprognostic (2.34e-3)" "unprognostic (3.84e-3)" "prognostic favourable (1.48e-4)" "unprognostic (7.80e-2)" "unprognostic (2.22e-1)" "unprognostic (3.46e-2)" "unprognostic (1.65e-3)" "unprognostic (1.81e-1)" "unprognostic (3.82e-3)" "unprognostic (5.17e-3)" "unprognostic (2.40e-1)" "prognostic unfavourable (9.76e-4)" "unprognostic (2.30e-2)" 109.8 4.0 6.7 16.2 4.2 5.7 54.5 23.3 5.4 40.1 13.1 2.4 10.2 6.5 28.8 23.0 32.6 27.1 26.9 47.1 9.1 3.4 5.7 1.3 27.8 36.8 19.2 0.6 22.3 8.1 3.9 2.0 5.8 14.0 29.1 7.1 5.3 12.8 9.8 38.3 19.8 11.5 36.6 9.4 25.0 13.0 21.6 6.4 3.0 16.5 29.9 15.5 42.3 24.2 0.0 0.0 0.0 0.4 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 22.0 0.0 0.0 4.1 0.0 0.0 23.9 0.0 0.0 3.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.1 0.0 0.0 0.0 0.0 1.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 6.7 4.2 23.3 5.3 9.1 3.4 19.2 0.6 14.0 6.4 ADAM10 "CD156c, HsT18717, kuz, MADM" ENSG00000137845 "ADAM metallopeptidase domain 10" O14672 15 58588807-58749978 "Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Notch signaling pathway" "Hydrolase, Metalloprotease, Protease" "Alzheimer disease, Amyloidosis, Cancer-related genes, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-2197: 76.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001709, HPA050670" Approved Supported "Nucleoplasm,Vesicles,Plasma membrane" "Intracellular and membrane" 8200000 "Plasma membrane" "Nucleoplasm, Vesicles" "CAB001709: , HPA050670: " "unprognostic (1.43e-1)" "unprognostic (1.38e-1)" "unprognostic (2.77e-1)" "unprognostic (5.04e-2)" "unprognostic (3.09e-1)" "unprognostic (2.70e-3)" "unprognostic (7.48e-2)" "prognostic unfavourable (8.46e-5)" "unprognostic (3.99e-2)" "unprognostic (1.19e-1)" "prognostic unfavourable (1.90e-4)" "unprognostic (6.69e-2)" "unprognostic (2.57e-2)" "unprognostic (2.57e-3)" "unprognostic (9.14e-2)" "unprognostic (2.09e-2)" "unprognostic (1.60e-2)" 25.9 11.1 15.5 17.1 17.7 15.6 20.0 25.2 17.6 18.6 20.1 15.7 12.7 13.9 19.9 11.8 17.1 13.8 18.0 18.8 17.6 13.7 20.8 14.8 25.0 26.1 23.1 12.4 13.9 13.1 10.9 11.6 36.1 14.5 23.6 16.7 14.6 12.4 19.1 8.9 15.4 15.6 12.8 30.4 40.4 18.4 8.5 18.9 38.5 27.3 9.2 14.9 30.0 19.1 6.2 12.7 26.9 23.7 9.8 12.2 12.8 11.8 26.9 7.3 8.0 9.4 13.6 18.5 10.2 30.4 7.5 10.5 12.4 15.7 5.5 31.6 9.1 24.3 4.4 10.8 10.0 8.2 5.6 9.4 9.8 11.5 10.5 6.6 27.2 11.9 8.0 5.2 7.7 14.6 5.9 15.0 13.2 4.4 21.9 7.6 10.0 3.8 9.1 24.0 14.1 17.5 32.1 8.0 5.2 11.1 12.9 17.6 7.7 13.3 10.3 9.9 11.0 76.0 9.8 8.4 18.1 6.0 13.8 12.9 17.3 12.9 18.8 10.4 8.1 21.5 12.2 5.3 8.0 7.1 12.7 6.2 8.4 7.0 26.9 9.8 23.7 5.8 10.3 12.8 15.5 17.7 25.2 16.9 17.6 13.7 23.1 12.4 14.5 18.9 ADAM17 "CD156B, cSVP, TACE" ENSG00000151694 "ADAM metallopeptidase domain 17" P78536 2 9488486-9555792 "CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Notch signaling pathway" "Hydrolase, Metalloprotease, Protease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010738, CAB025906, HPA051575" Approved Supported Cytosol "Intracellular and membrane" 27000 Cytosol "CAB025906: , HPA010738: AB_1078100, HPA051575: " "unprognostic (2.28e-1)" "unprognostic (1.29e-3)" "unprognostic (1.28e-1)" "unprognostic (3.51e-3)" "unprognostic (1.57e-1)" "unprognostic (5.15e-2)" "unprognostic (2.12e-3)" "unprognostic (1.55e-1)" "unprognostic (4.09e-2)" "unprognostic (3.69e-1)" "unprognostic (3.53e-3)" "unprognostic (3.13e-1)" "unprognostic (3.82e-3)" "unprognostic (8.63e-2)" "unprognostic (2.61e-1)" "unprognostic (4.48e-2)" "prognostic unfavourable (4.23e-5)" 18.6 11.0 13.6 15.4 13.8 21.9 14.7 20.4 15.5 14.0 11.7 13.8 8.3 8.7 14.2 15.8 18.7 10.7 17.4 13.4 11.2 12.4 12.4 7.8 24.7 15.0 11.6 11.7 18.1 9.6 10.9 11.9 29.0 11.2 8.2 9.4 10.6 12.5 9.8 12.3 16.7 11.1 13.9 14.3 21.4 8.9 17.4 12.3 14.7 12.5 13.9 20.3 12.3 14.4 7.0 7.7 16.0 10.2 6.0 7.9 6.0 7.7 12.7 13.4 13.9 26.5 19.8 24.2 8.1 13.8 9.4 13.9 11.2 18.7 22.1 11.8 10.2 14.2 9.9 17.2 12.9 8.8 9.9 11.3 9.6 9.9 37.5 11.0 12.7 22.1 17.4 15.0 29.1 23.5 15.3 8.5 10.0 7.3 8.3 11.1 11.1 5.2 9.6 13.2 10.5 12.5 12.9 7.9 19.8 9.1 11.1 19.3 5.7 14.2 18.8 16.7 8.7 11.7 15.4 11.1 10.0 19.2 13.8 7.1 19.8 16.0 9.8 7.6 6.1 10.2 7.9 7.0 5.0 5.1 7.7 5.1 4.5 4.6 11.8 6.0 9.5 4.3 5.7 6.0 13.6 13.8 20.4 13.1 11.2 12.4 11.6 11.7 11.2 12.3 ADAM8 "CD156, CD156a, MS2" ENSG00000151651 "ADAM metallopeptidase domain 8" P78325 10 133262403-133276868 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 56.8;bone marrow: 37.1;lymphoid tissue: 28.3" "Cell line enhanced" "Detected in some" "A-431: 22.3;BEWO: 32.2;CAPAN-2: 27.3;HaCaT: 26.8;HDLM-2: 17.2;U-87 MG: 13.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 4 "basophil: 20.7;eosinophil: 56.8;neutrophil: 32.9" "Lineage enriched" "Detected in all" 7 "granulocytes: 56.8" "Not detected" "Not detected" "Not detected" "Not detected" HPA064637 Approved "Intracellular and membrane" "HPA064637: " "unprognostic (8.24e-2)" "unprognostic (6.07e-3)" "unprognostic (1.27e-3)" "unprognostic (5.18e-2)" "unprognostic (8.26e-2)" "unprognostic (6.47e-2)" "unprognostic (5.59e-2)" "unprognostic (2.22e-1)" "unprognostic (2.57e-1)" "unprognostic (1.94e-3)" "unprognostic (3.37e-2)" "unprognostic (5.47e-2)" "prognostic unfavourable (3.99e-10)" "unprognostic (1.92e-1)" "unprognostic (3.02e-2)" "unprognostic (1.28e-1)" "unprognostic (9.32e-2)" 4.8 1.0 0.7 18.0 1.6 37.1 3.1 1.7 1.2 3.8 4.8 0.9 0.2 3.5 1.8 1.6 2.8 3.6 10.1 4.1 0.8 1.1 2.8 4.3 13.0 25.0 1.0 0.2 1.7 2.4 0.1 2.0 7.5 1.6 2.9 0.9 2.9 5.5 0.7 1.5 1.9 6.0 1.6 1.5 28.3 6.9 2.3 0.5 6.6 2.0 1.8 19.7 12.0 2.8 2.5 8.6 56.8 5.4 5.5 5.5 4.6 22.3 0.6 0.2 0.3 0.1 0.0 32.2 0.2 0.5 0.1 0.1 1.7 27.3 0.4 0.6 0.0 26.8 0.0 4.6 0.0 17.2 0.3 0.3 0.1 0.0 0.2 1.3 6.3 0.1 0.4 0.2 0.4 0.0 1.2 0.9 0.0 1.8 0.0 7.6 0.1 0.6 0.1 0.2 2.4 0.3 0.5 0.0 0.3 0.1 0.1 0.4 0.4 0.7 0.6 0.0 0.6 0.2 0.3 1.3 0.8 0.2 13.7 0.7 0.1 20.7 5.4 56.8 5.5 2.1 4.0 2.5 3.7 5.2 8.6 1.5 1.4 2.0 32.9 5.5 2.0 0.1 3.8 4.6 0.7 1.6 1.7 1.2 0.8 1.1 1.0 0.2 1.6 0.5 ADGRE2 "CD312, EMR2" ENSG00000127507 "Adhesion G protein-coupled receptor E2" Q9UHX3 19 14732393-14778541 "CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins" "Cell adhesion, Inflammatory response" "G-protein coupled receptor, Receptor, Transducer" "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.7;lymphoid tissue: 38.9" "Cell line enhanced" "Detected in some" "HEL: 10.1;HMC-1: 16.3;NB-4: 9.8;RPMI-8226: 7.2;U-937: 12.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "basophil: 19.6;eosinophil: 24.2;intermediate monocyte: 15.7;neutrophil: 19.1;non-classical monocyte: 28.7" "Group enriched" "Detected in many" 8 "granulocytes: 24.2;monocytes: 28.7" HPA055200 Uncertain Vesicles,Cytosol Vesicles Cytosol "HPA055200: " "unprognostic (2.46e-2)" "unprognostic (3.58e-2)" "unprognostic (2.21e-1)" "unprognostic (1.66e-1)" "unprognostic (9.10e-2)" "unprognostic (3.58e-2)" "unprognostic (2.77e-2)" "unprognostic (3.88e-2)" "unprognostic (4.28e-1)" "unprognostic (1.22e-1)" "unprognostic (2.32e-1)" "unprognostic (2.70e-2)" "prognostic unfavourable (4.35e-6)" "unprognostic (1.46e-1)" "unprognostic (2.45e-3)" "unprognostic (2.50e-1)" "unprognostic (1.01e-1)" 6.3 3.1 1.7 22.9 1.9 7.2 4.4 1.0 1.3 14.9 8.1 2.5 0.9 2.4 12.0 1.0 1.9 2.3 3.3 7.3 2.0 1.8 3.4 4.3 15.6 37.4 2.2 0.0 5.3 3.5 0.7 1.6 10.9 2.4 3.8 2.5 3.2 2.4 3.9 3.5 3.0 3.0 2.0 3.1 38.9 2.0 2.2 1.4 2.8 3.4 5.2 2.8 7.5 2.1 0.1 3.1 24.2 28.7 1.2 0.0 1.8 0.2 1.0 0.1 0.2 0.1 0.3 1.1 0.8 1.1 0.0 0.0 0.2 0.2 0.2 0.1 0.6 1.7 0.3 0.1 0.0 0.2 0.2 10.1 3.2 0.2 0.5 3.7 16.3 0.8 1.4 3.6 0.6 0.1 2.3 0.4 1.2 0.5 1.3 9.8 0.4 0.2 0.1 1.4 7.2 0.0 0.3 0.1 0.2 2.1 1.7 0.4 0.3 4.7 0.3 0.3 0.2 0.2 0.1 0.2 0.1 0.2 1.0 12.9 0.5 19.6 4.4 24.2 0.0 15.7 0.0 0.0 0.0 0.0 3.1 0.1 0.0 0.0 19.1 1.2 28.7 0.6 0.0 1.8 1.7 1.9 1.0 1.3 2.0 1.8 2.2 0.0 2.4 1.4 ADGRE5 "CD97, TM7LN1" ENSG00000123146 "Adhesion G protein-coupled receptor E5" P48960 19 14380501-14408725 "CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Cell adhesion" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 95.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA013707 Enhanced Approved Cytosol "Secreted to blood" 10000000 930000 Cytosol "HPA013707: AB_1846345" "unprognostic (3.16e-1)" "unprognostic (1.80e-1)" "unprognostic (5.10e-2)" "unprognostic (2.30e-1)" "unprognostic (2.85e-2)" "unprognostic (7.24e-2)" "prognostic unfavourable (3.73e-5)" "unprognostic (7.51e-2)" "unprognostic (6.06e-3)" "unprognostic (3.14e-2)" "unprognostic (1.08e-3)" "unprognostic (2.37e-1)" "prognostic unfavourable (1.87e-6)" "unprognostic (2.08e-2)" "unprognostic (4.14e-2)" "unprognostic (2.44e-2)" "unprognostic (6.41e-2)" 17.7 8.9 2.5 23.0 4.0 55.3 14.3 1.1 5.2 21.7 15.9 12.9 0.5 12.9 56.9 18.5 11.6 19.1 27.1 16.4 3.0 2.4 10.7 15.5 30.3 41.1 6.3 3.2 10.7 16.2 2.4 3.3 18.2 5.9 11.3 9.0 6.9 17.0 3.6 12.5 6.0 22.2 36.2 4.2 56.9 15.0 6.9 4.9 24.3 8.6 3.7 22.5 34.7 12.4 3.9 13.3 95.3 43.2 22.8 25.8 23.3 30.6 21.8 0.2 20.9 9.3 15.2 3.3 21.2 34.3 15.3 16.8 6.2 31.1 3.5 21.5 27.3 7.3 5.6 10.3 6.9 19.1 6.4 6.9 32.2 2.7 11.4 14.8 32.1 6.6 0.3 15.5 5.3 1.5 9.0 27.5 16.6 6.9 0.9 19.8 0.6 27.1 2.0 9.2 16.0 5.1 2.7 0.2 0.7 12.1 17.4 15.1 4.5 13.7 3.7 5.2 8.6 21.6 34.9 0.0 0.1 0.2 18.6 26.5 19.4 42.0 18.6 95.3 25.8 36.7 17.3 3.9 13.1 17.8 13.3 2.6 9.4 12.8 82.7 22.8 43.2 6.4 9.0 23.3 2.5 4.0 1.1 5.2 3.0 2.4 6.3 3.2 5.9 4.9 ALCAM "CD166, MEMD" ENSG00000170017 "Activated leukocyte cell adhesion molecule" Q13740 3 105366909-105576900 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters" "Adaptive immunity, Cell adhesion, Immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 122.5" "Cell line enhanced" "Detected in many" "hTERT-HME1: 64.6;U-138 MG: 77.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "myeloid DC: 20.7" "Lineage enriched" "Detected in many" 6 "dendritic cells: 20.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002148, HPA010926" Enhanced "Intracellular and membrane" 1800000000 "CAB002148: AB_442053, HPA010926: AB_1078449" "unprognostic (6.82e-2)" "unprognostic (2.66e-1)" "unprognostic (2.13e-1)" "unprognostic (2.19e-1)" "unprognostic (9.48e-3)" "unprognostic (2.08e-2)" "unprognostic (1.63e-3)" "unprognostic (3.89e-2)" "unprognostic (1.75e-1)" "unprognostic (4.01e-2)" "unprognostic (1.09e-1)" "unprognostic (1.07e-1)" "prognostic favourable (3.15e-4)" "unprognostic (3.15e-1)" "unprognostic (4.47e-2)" "unprognostic (9.57e-2)" "unprognostic (7.76e-2)" 16.6 14.1 23.6 5.2 31.1 4.2 34.2 4.2 25.3 12.9 8.2 25.0 13.9 7.2 7.0 15.4 4.0 20.6 9.9 4.7 23.2 24.3 9.6 19.4 29.6 4.2 45.1 19.7 24.6 15.3 122.5 11.9 5.3 31.5 14.0 6.6 3.0 17.9 17.5 0.9 5.9 7.3 10.8 35.3 3.0 14.2 2.3 43.8 2.2 25.6 2.7 6.2 9.9 5.5 3.5 20.7 3.7 3.2 0.4 1.6 2.0 38.4 14.8 10.7 5.4 16.2 7.1 0.1 31.5 18.4 20.3 28.6 0.1 8.0 2.7 13.1 44.3 29.8 1.7 25.0 60.2 2.5 2.6 0.3 11.4 0.7 18.2 15.6 0.1 12.6 18.7 26.0 64.6 22.3 0.0 4.6 26.6 2.6 2.2 5.7 2.2 16.8 1.4 0.9 0.1 30.8 4.3 7.7 21.5 3.2 3.1 2.0 6.0 10.3 46.2 77.9 26.6 3.4 37.2 0.0 0.0 0.2 17.7 3.3 33.2 0.0 3.2 2.4 0.4 1.5 1.4 3.5 1.1 0.7 20.7 2.2 0.2 0.2 3.7 0.4 0.8 7.4 1.6 2.0 23.6 31.1 4.2 24.6 23.2 24.3 45.1 19.7 31.5 43.8 ALK CD246 ENSG00000171094 "ALK receptor tyrosine kinase" Q9UM73 2 29192774-29921566 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 8.1;pituitary gland: 17.9" "Cell line enriched" "Detected in some" 6 "SH-SY5Y: 26.4" "Group enriched" "Detected in some" 5 "glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010694 Approved Supported "Plasma membrane" "Plasma membrane" "HPA010694: AB_1078133" "unprognostic (4.96e-2)" "unprognostic (1.11e-2)" "unprognostic (1.45e-1)" "unprognostic (4.56e-7)" "unprognostic (7.17e-2)" "unprognostic (1.71e-1)" "unprognostic (9.07e-3)" "unprognostic (6.29e-3)" "unprognostic (1.18e-1)" "unprognostic (1.01e-1)" "unprognostic (2.67e-4)" "unprognostic (3.70e-2)" "unprognostic (2.06e-2)" "unprognostic (7.15e-2)" "unprognostic (1.98e-1)" "unprognostic (1.38e-1)" "unprognostic (3.61e-2)" 1.8 3.1 3.6 1.2 4.4 0.3 1.1 0.5 8.1 0.7 2.1 2.0 0.0 0.7 0.5 0.5 0.6 0.5 1.2 0.4 3.4 4.9 0.4 0.5 1.1 0.5 2.7 4.2 0.6 0.4 0.4 17.9 0.5 5.5 0.5 1.2 2.4 0.9 0.8 0.3 0.9 1.5 0.9 2.1 0.5 0.8 4.9 0.9 0.0 1.6 0.0 0.3 0.6 1.2 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 3.5 0.0 0.0 0.1 0.3 26.4 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 3.1 0.0 4.0 0.0 0.1 0.0 0.7 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 3.6 4.4 0.5 5.9 3.4 4.9 2.7 4.2 5.5 0.9 ANPEP "CD13, gp150, LAP1, p150, PEPN" ENSG00000166825 "Alanyl aminopeptidase, membrane" P15144 15 89784889-89815401 "CD markers, Enzymes, Plasma proteins, Predicted membrane proteins" "Angiogenesis, Differentiation, Host-virus interaction" "Aminopeptidase, Developmental protein, Host cell receptor for virus entry, Hydrolase, Metalloprotease, Protease, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 195.3;kidney: 78.7;pancreas: 93.9" "Cell line enhanced" "Detected in many" "ASC TERT1: 77.0;BJ: 76.7;BJ hTERT+: 109.7;HMC-1: 69.8;HSkMC: 67.4;HUVEC TERT2: 85.8;TIME: 85.8;U-2197: 93.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in many" 5 "neutrophil: 59.4" "Lineage enriched" "Detected in many" 5 "granulocytes: 59.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in single" "CAB002417, HPA004625" Enhanced Supported "Plasma membrane" 1500000000 "Plasma membrane" "CAB002417: AB_563491, HPA004625: " "unprognostic (6.31e-2)" "unprognostic (7.94e-3)" "unprognostic (6.91e-2)" "unprognostic (2.16e-1)" "unprognostic (2.50e-1)" "unprognostic (1.13e-1)" "unprognostic (2.23e-2)" "unprognostic (1.89e-1)" "unprognostic (2.50e-1)" "unprognostic (7.73e-2)" "unprognostic (5.28e-3)" "unprognostic (3.96e-1)" "unprognostic (4.04e-3)" "unprognostic (3.20e-2)" "unprognostic (2.01e-2)" "unprognostic (4.61e-3)" "unprognostic (1.99e-2)" 21.3 1.1 0.6 2.9 0.8 9.5 17.0 1.0 1.3 8.2 21.2 0.8 0.5 195.3 1.4 8.4 3.6 1.4 27.7 3.7 0.4 0.3 78.7 37.7 9.7 9.3 0.9 0.9 1.8 93.9 0.0 0.7 14.7 1.3 8.6 4.7 4.0 6.6 1.8 1.6 4.9 155.8 4.3 1.2 7.2 0.8 4.7 0.2 5.6 1.5 4.2 3.8 4.7 3.0 0.0 6.9 59.4 12.8 0.0 0.0 5.5 0.0 4.9 0.0 0.0 60.1 77.0 0.5 76.7 109.7 9.4 8.3 0.5 0.0 0.0 0.9 65.8 0.0 0.5 0.0 3.7 0.0 0.0 14.5 0.4 11.4 35.4 1.0 69.8 67.4 0.1 29.7 0.0 85.8 0.4 0.1 3.6 0.0 0.0 34.1 0.2 5.2 0.0 0.0 0.8 42.9 0.0 0.1 0.7 0.0 0.1 0.0 0.0 6.7 85.8 41.4 0.0 93.5 0.0 0.0 0.0 0.0 0.1 0.0 2.2 5.7 12.8 10.4 0.0 7.0 0.0 0.0 0.0 0.0 6.9 0.0 0.0 0.0 59.4 0.0 12.0 0.1 0.0 5.5 0.6 0.8 1.0 1.3 0.4 0.3 0.9 0.9 1.3 0.2 ART1 "ART2, CD296" ENSG00000129744 "ADP-ribosyltransferase 1" P52961 11 3645128-3664416 "CD markers, Enzymes, Predicted membrane proteins" "Glycosyltransferase, Transferase" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Group enriched" "Detected in some" 20 "skeletal muscle: 50.9;tongue: 13.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA051148 Uncertain "HPA051148: " "unprognostic (3.73e-1)" "unprognostic (4.58e-2)" "unprognostic (3.12e-2)" "unprognostic (1.35e-1)" "unprognostic (3.01e-1)" "unprognostic (1.19e-1)" "unprognostic (1.06e-1)" "unprognostic (1.73e-1)" 1.5 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.6 0.1 0.0 0.2 0.1 0.1 0.4 0.0 0.3 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.3 0.2 0.1 50.9 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 13.7 0.5 0.0 0.0 0.5 0.0 0.6 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.3 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.5 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.2 0.4 0.0 ART4 "CD297, DO, DOK1" ENSG00000111339 "ADP-ribosyltransferase 4 (Dombrock blood group)" Q93070 12 14825569-14843533 "Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins" "Blood group antigen, Glycosyltransferase, Transferase" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 33.7;lymphoid tissue: 17.8;placenta: 17.8" "Cell line enhanced" "Detected in some" "AN3-CA: 5.1;HEL: 10.0;Hep G2: 6.0;HUVEC TERT2: 22.9" "Cancer enhanced" "Detected in some" "liver cancer: 3.8" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Region enhanced" "Detected in single" "olfactory region: 2.2" "Low region specificity" "Detected in many" HPA075664 Approved "Rods & Rings" "Secreted to blood" 11000000 "Rods & Rings" "HPA075664: " "unprognostic (2.50e-2)" "unprognostic (1.12e-1)" "unprognostic (1.57e-1)" "unprognostic (1.18e-2)" "unprognostic (1.55e-1)" "unprognostic (1.37e-2)" "unprognostic (1.92e-1)" "unprognostic (1.90e-2)" "unprognostic (1.10e-1)" "unprognostic (2.64e-1)" "unprognostic (1.37e-1)" "unprognostic (1.90e-2)" "unprognostic (2.62e-3)" "unprognostic (4.33e-3)" "unprognostic (1.25e-3)" "unprognostic (1.05e-1)" "unprognostic (1.71e-1)" 2.7 2.0 0.2 1.7 0.2 2.4 2.1 0.2 0.2 1.4 1.3 0.1 1.9 0.0 1.1 3.7 3.1 1.9 6.1 10.1 0.2 0.2 6.6 33.7 2.1 17.0 0.2 0.0 1.3 1.9 0.0 0.4 17.8 0.3 0.8 0.2 0.0 0.7 0.4 1.9 0.5 0.8 1.5 0.2 17.8 0.5 1.4 0.0 0.1 4.6 1.3 1.3 1.3 1.2 0.6 0.6 1.4 0.4 0.6 1.3 0.3 0.0 0.0 0.2 5.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 6.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 22.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.4 0.4 0.5 0.3 0.4 0.5 0.3 0.3 0.2 0.6 0.5 1.3 1.4 0.6 0.2 0.6 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.3 0.0 ATP1B3 "CD298, FLJ29027" ENSG00000069849 "ATPase Na+/K+ transporting subunit beta 3" P54709 3 141876124-141926514 "CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB020697, HPA048963" Enhanced Supported "Plasma membrane" 100000 "Plasma membrane" "CAB020697: , HPA048963: " "unprognostic (2.31e-1)" "unprognostic (1.11e-3)" "unprognostic (2.75e-1)" "prognostic favourable (5.19e-5)" "unprognostic (2.60e-2)" "unprognostic (3.31e-2)" "prognostic unfavourable (6.32e-6)" "unprognostic (8.11e-3)" "unprognostic (6.99e-2)" "unprognostic (5.37e-3)" "unprognostic (1.48e-2)" "unprognostic (1.43e-1)" "prognostic unfavourable (1.29e-5)" "unprognostic (5.14e-2)" "unprognostic (2.04e-1)" "unprognostic (7.19e-3)" "unprognostic (6.15e-2)" 50.5 79.9 12.7 26.3 23.3 17.5 105.9 25.7 35.1 17.7 48.2 9.1 16.8 37.3 17.9 14.6 36.9 20.0 47.8 44.0 16.0 18.9 24.9 7.7 44.9 43.4 21.3 12.8 34.7 11.5 6.3 33.8 32.6 43.3 20.5 58.1 23.9 18.4 24.8 7.4 85.4 57.3 24.3 28.4 16.5 13.5 21.1 13.6 14.5 15.6 41.4 18.4 21.9 31.5 10.4 26.8 13.6 60.9 7.8 20.0 22.5 46.3 28.8 27.1 25.4 72.9 21.2 62.2 54.4 49.5 39.6 44.9 44.8 23.3 37.9 49.2 41.3 101.8 26.9 26.0 45.1 20.6 34.1 33.0 32.5 29.0 28.8 27.2 26.0 22.5 62.1 31.0 30.0 42.2 22.7 33.6 40.5 21.1 27.6 45.5 37.7 13.8 37.9 20.3 38.5 33.2 35.8 22.4 15.2 71.0 33.1 73.0 25.2 33.1 29.3 34.8 13.4 52.0 31.6 25.1 32.2 61.0 45.4 29.6 28.6 13.6 27.1 8.9 19.2 44.5 14.1 10.4 15.6 20.0 26.8 7.5 9.2 16.7 1.9 7.8 60.9 16.4 16.9 22.5 12.7 23.3 25.7 35.1 16.0 18.9 21.3 12.8 43.3 13.6 BCAM "CD239, LU" ENSG00000187244 "Basal cell adhesion molecule (Lutheran blood group)" P50895 19 44809059-44821421 "Blood group antigen proteins, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Blood group antigen, Receptor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 101.8" "Cell line enhanced" "Detected in many" "BEWO: 30.8;HaCaT: 62.8;SK-BR-3: 58.9;T-47d: 33.4;U-2 OS: 28.9" "Cancer enhanced" "Detected in all" "ovarian cancer: 493.9" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005654 Uncertain Approved "Nucleoli fibrillar center" 16000000 "Nucleoli fibrillar center" "HPA005654: " "unprognostic (5.63e-2)" "unprognostic (2.98e-2)" "prognostic unfavourable (2.31e-4)" "prognostic unfavourable (1.24e-5)" "unprognostic (1.60e-2)" "unprognostic (1.23e-3)" "unprognostic (2.01e-1)" "unprognostic (2.25e-2)" "unprognostic (1.60e-1)" "unprognostic (6.17e-2)" "unprognostic (2.61e-3)" "unprognostic (1.41e-1)" "prognostic favourable (5.94e-6)" "unprognostic (1.83e-2)" "unprognostic (5.74e-2)" "unprognostic (2.14e-2)" "unprognostic (9.97e-3)" 28.9 7.2 4.9 8.1 5.4 1.4 33.1 3.4 8.7 33.5 8.5 4.4 17.8 5.7 24.8 26.5 15.6 46.3 23.2 23.8 4.5 4.2 101.8 13.2 41.6 5.8 4.4 6.5 30.4 17.8 5.8 9.8 28.7 7.0 42.7 2.4 21.4 17.8 27.3 16.7 12.7 7.4 12.5 3.8 14.2 9.6 13.6 2.6 5.7 93.0 23.7 8.5 14.2 30.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 7.1 9.2 0.2 25.6 0.1 0.1 30.8 2.8 1.3 2.3 1.5 13.8 17.6 0.0 14.2 0.3 62.8 2.2 15.7 0.7 0.0 1.6 0.0 1.9 19.1 5.2 0.0 3.4 2.5 6.1 0.8 0.9 1.4 1.4 0.1 0.3 3.6 0.0 0.2 2.9 3.2 0.1 3.0 0.7 19.2 4.5 0.0 0.1 11.4 58.9 0.6 33.4 1.0 3.7 0.6 28.9 0.7 1.3 0.1 0.2 0.0 0.2 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 4.9 5.4 3.4 8.7 4.5 4.2 4.4 6.5 7.0 2.6 BMPR1A "ACVRLK3, ALK3, CD292" ENSG00000107779 "Bone morphogenetic protein receptor type 1A" P36894 10 86756601-86932838 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB019398 Approved Approved Cytosol Cytosol "CAB019398: " "unprognostic (1.36e-1)" "unprognostic (2.46e-1)" "unprognostic (3.34e-1)" "unprognostic (9.61e-2)" "unprognostic (1.05e-3)" "unprognostic (9.34e-2)" "prognostic unfavourable (8.93e-4)" "unprognostic (3.64e-1)" "unprognostic (2.38e-2)" "unprognostic (1.53e-1)" "unprognostic (9.24e-2)" "unprognostic (9.42e-2)" "unprognostic (4.32e-2)" "unprognostic (1.80e-1)" "unprognostic (1.47e-1)" "unprognostic (1.01e-2)" "unprognostic (1.07e-1)" 8.9 7.0 9.4 7.9 12.4 0.9 10.7 14.1 9.2 19.4 20.6 10.9 7.7 6.2 16.3 12.3 8.4 10.9 10.8 11.0 7.7 6.1 8.2 4.6 7.4 2.9 7.3 7.6 16.1 10.6 10.0 14.0 7.4 8.5 12.8 9.3 10.9 12.6 14.2 8.4 11.3 9.8 16.5 12.2 3.4 12.1 7.8 9.2 0.3 19.4 7.8 5.7 16.0 11.4 1.8 1.1 3.6 0.8 0.9 1.4 0.3 7.5 3.8 14.7 12.5 7.7 5.0 2.6 7.6 8.0 4.5 5.2 6.5 6.7 2.3 3.5 9.7 8.1 6.5 8.3 6.6 2.5 3.7 2.9 3.6 10.7 4.1 4.0 20.4 4.4 3.5 6.0 4.4 0.0 4.5 1.6 5.2 3.2 2.6 3.2 8.0 1.8 0.0 5.8 0.0 9.2 7.2 1.5 4.8 8.5 4.3 5.1 7.3 2.0 3.8 3.2 5.2 6.6 7.0 0.4 7.0 2.9 2.8 2.7 2.6 2.0 0.8 0.6 1.4 0.5 0.9 1.8 1.4 1.2 0.3 1.5 1.0 1.1 3.6 0.9 0.6 1.1 0.7 0.3 9.4 12.4 14.1 9.2 7.7 6.1 7.3 7.6 8.5 9.2 BMPR1B "ALK6, CDw293" ENSG00000138696 "Bone morphogenetic protein receptor type 1B" O00238 4 94757968-95158448 "CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Chondrogenesis "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 28.0;ductus deferens: 25.1;prostate: 25.3;seminal vesicle: 32.0" "Cell line enhanced" "Detected in many" "A549: 18.3;MCF7: 9.2;SH-SY5Y: 15.3" "Cancer enhanced" "Detected in many" "breast cancer: 32.4;prostate cancer: 24.7" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "unprognostic (2.25e-1)" "unprognostic (1.80e-2)" "unprognostic (1.40e-3)" "prognostic favourable (2.84e-4)" "unprognostic (1.57e-1)" "unprognostic (4.22e-2)" "unprognostic (1.92e-1)" "unprognostic (2.86e-2)" "unprognostic (2.95e-2)" "unprognostic (1.01e-1)" "unprognostic (3.97e-2)" "unprognostic (3.93e-1)" "unprognostic (1.62e-3)" "unprognostic (7.89e-4)" "unprognostic (6.22e-2)" "unprognostic (3.81e-3)" "unprognostic (2.63e-2)" 1.1 5.6 12.7 0.8 15.0 0.7 1.7 11.6 12.7 28.0 1.2 5.5 25.1 0.7 5.3 3.2 1.1 14.3 3.4 1.3 13.4 5.9 9.3 1.4 2.4 0.5 5.4 8.6 7.6 1.7 0.6 2.4 1.2 12.1 25.3 0.8 0.7 1.4 32.0 3.3 1.4 0.6 1.2 7.5 1.4 2.8 4.3 11.2 10.8 0.8 0.1 0.6 0.7 0.7 0.4 0.5 1.9 0.9 0.8 1.6 0.3 0.0 18.3 4.9 0.0 1.9 4.5 0.1 0.1 0.0 0.1 0.4 0.0 0.1 0.0 0.2 0.8 1.0 2.9 6.7 0.0 0.0 4.5 0.0 1.1 0.0 0.5 0.4 0.0 2.8 7.5 2.8 5.6 0.0 0.0 0.0 7.0 9.2 0.6 0.1 1.8 3.1 0.1 2.7 0.1 3.5 0.1 0.2 15.3 0.2 2.5 2.5 1.9 0.0 0.0 3.9 3.1 0.1 3.3 0.0 0.0 0.0 1.5 0.0 0.4 1.9 0.3 0.5 0.4 0.5 0.7 0.4 0.6 0.3 0.3 0.3 0.5 0.5 0.8 0.8 0.9 0.5 1.6 0.3 12.7 15.0 11.6 11.8 13.4 5.9 5.4 8.6 12.1 11.2 BSG "CD147, EMMPRIN, OK" ENSG00000172270 "Basigin (Ok blood group)" P35613 19 571277-583493 "Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Blood group antigen" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002427, HPA036048, HPA074870" Enhanced Approved Vesicles 3400000 Vesicles "CAB002427: AB_563501, HPA036048: , HPA074870: " "unprognostic (1.88e-1)" "unprognostic (4.85e-2)" "unprognostic (9.53e-3)" "prognostic favourable (2.59e-4)" "unprognostic (3.34e-1)" "unprognostic (1.38e-2)" "prognostic unfavourable (5.48e-6)" "unprognostic (1.54e-3)" "unprognostic (1.55e-1)" "unprognostic (9.46e-2)" "unprognostic (4.48e-3)" "unprognostic (2.61e-2)" "prognostic favourable (1.95e-6)" "unprognostic (1.22e-1)" "unprognostic (1.03e-1)" "unprognostic (7.30e-2)" "unprognostic (3.22e-1)" 53.0 74.8 60.0 33.3 73.0 86.3 42.3 36.2 103.0 41.7 93.4 57.8 37.3 50.1 56.0 62.2 35.1 48.8 52.0 205.8 58.5 45.9 78.5 39.1 36.1 22.6 57.6 44.0 51.3 64.2 28.2 48.2 96.2 57.9 49.5 39.6 109.4 44.0 48.4 97.4 38.1 45.5 52.9 34.9 28.3 63.9 76.8 30.4 31.8 61.9 45.9 31.2 48.5 31.5 22.0 43.8 89.4 58.7 30.9 44.5 65.5 63.7 86.1 41.1 92.3 122.3 52.6 87.4 53.1 66.4 64.1 55.8 68.6 69.1 22.9 61.7 48.0 104.1 41.6 64.5 22.2 48.0 89.2 15.7 72.8 92.8 77.3 37.9 74.0 54.7 65.5 36.8 41.1 45.9 73.9 108.2 37.6 114.5 27.6 72.7 96.4 44.1 55.5 33.6 75.4 75.7 47.9 63.7 58.0 110.2 44.5 78.8 46.7 117.3 50.5 61.5 39.1 101.9 80.1 69.8 70.2 21.7 116.7 52.6 76.1 32.0 58.7 62.0 44.5 45.2 39.5 22.0 30.2 42.6 39.9 18.3 23.1 29.1 89.4 30.9 48.3 43.8 35.1 65.5 60.0 73.0 36.2 103.0 58.5 45.9 57.6 44.0 57.9 30.4 BST1 CD157 ENSG00000109743 "Bone marrow stromal cell antigen 1" Q10588 4 15702950-15738313 "CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins" "Hydrolase, Transferase" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 59.5;bone marrow: 54.9;intestine: 61.3" "Cell line enhanced" "Detected in many" "THP-1: 36.3;TIME: 20.0;U-937: 23.7;WM-115: 21.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "classical monocyte: 52.7;neutrophil: 59.5" "Group enriched" "Detected in many" 105 "dendritic cells: 16.6;granulocytes: 59.5;monocytes: 52.7" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA050121 Uncertain "Intracellular and membrane" 170000000 "HPA050121: " "unprognostic (2.95e-1)" "unprognostic (3.61e-1)" "unprognostic (1.27e-1)" "unprognostic (4.00e-2)" "unprognostic (7.49e-2)" "unprognostic (2.89e-1)" "unprognostic (4.55e-2)" "unprognostic (2.70e-1)" "unprognostic (1.75e-1)" "unprognostic (1.84e-1)" "unprognostic (1.08e-1)" "unprognostic (4.06e-2)" "unprognostic (4.83e-3)" "unprognostic (1.94e-3)" "unprognostic (3.11e-1)" "unprognostic (1.57e-2)" "unprognostic (1.95e-1)" 14.3 2.0 1.1 5.6 2.0 54.9 6.6 0.8 1.5 7.2 33.8 1.5 2.1 20.4 6.4 7.0 4.6 5.6 10.3 14.5 1.8 0.8 6.6 3.7 9.4 9.6 1.3 1.9 5.5 1.0 0.4 1.3 8.0 1.3 7.5 4.0 5.4 2.8 2.2 3.4 3.5 61.3 7.9 1.5 13.6 2.4 2.4 1.2 2.8 3.5 2.9 1.8 7.5 16.1 0.4 16.6 59.5 52.7 0.1 0.3 19.6 0.2 5.4 0.5 0.4 13.2 3.1 0.7 10.3 0.9 9.4 10.6 0.1 5.6 0.3 0.9 5.2 0.1 1.5 0.2 8.0 0.3 0.2 2.4 0.3 0.2 3.4 3.2 7.1 2.7 0.7 6.0 0.5 1.4 0.3 0.2 5.5 0.1 1.0 1.9 1.2 1.1 0.3 0.7 0.2 0.3 0.3 0.7 2.0 0.2 0.3 6.8 0.2 36.3 20.0 0.3 0.4 3.7 0.4 0.2 0.0 0.2 1.3 23.7 21.6 7.6 52.7 3.9 0.2 19.8 0.3 0.4 0.1 0.1 16.6 0.2 0.2 0.1 59.5 0.1 13.6 5.5 0.2 19.6 1.1 2.0 0.8 1.5 1.8 0.8 1.3 1.9 1.3 1.2 BST2 "CD317, tetherin" ENSG00000130303 "Bone marrow stromal cell antigen 2" Q10589 19 17402939-17405648 "CD markers, Plasma proteins, Predicted membrane proteins" "Antiviral defense, B-cell activation, Immunity, Innate immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 101.0" "Cell line enhanced" "Detected in many" "BJ hTERT+ SV40 Large T+ RasG12V: 78.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA017060 Enhanced Supported "Golgi apparatus,Plasma membrane,Cytosol" "Golgi apparatus, Plasma membrane, Cytosol" "HPA017060: AB_1845467" "prognostic favourable (6.69e-4)" "unprognostic (1.75e-1)" "unprognostic (8.42e-3)" "unprognostic (8.93e-3)" "unprognostic (4.87e-2)" "unprognostic (2.25e-1)" "unprognostic (2.26e-1)" "unprognostic (1.07e-1)" "unprognostic (3.25e-1)" "unprognostic (6.46e-2)" "unprognostic (6.56e-3)" "unprognostic (1.64e-1)" "prognostic unfavourable (3.56e-9)" "unprognostic (1.05e-1)" "prognostic unfavourable (4.22e-4)" "unprognostic (1.08e-1)" "unprognostic (2.46e-2)" 29.6 72.2 8.4 31.1 9.8 13.6 27.9 2.5 7.6 14.4 12.0 5.6 24.8 6.9 13.4 36.7 8.6 26.8 30.1 13.9 7.9 4.9 24.7 30.8 44.9 16.6 10.0 5.2 101.0 6.9 0.3 8.6 31.5 8.8 15.6 4.8 8.4 11.4 17.5 6.0 3.2 14.0 11.3 9.0 32.9 12.3 8.5 9.4 10.3 10.3 5.9 12.3 14.0 42.4 26.2 74.1 35.8 66.4 57.9 32.6 54.5 39.2 0.0 0.1 18.1 0.0 0.1 6.2 0.1 3.0 58.0 78.1 18.4 35.4 30.4 42.9 24.2 0.1 26.4 2.9 1.8 33.5 0.2 0.4 63.6 17.9 33.2 14.3 38.6 0.1 0.0 19.1 0.0 14.7 17.3 75.8 0.0 10.7 6.8 25.1 19.9 50.8 12.8 0.1 63.5 13.8 0.1 0.0 0.1 40.1 1.5 48.2 30.4 20.3 0.1 0.2 1.4 0.0 0.4 39.1 51.0 20.1 0.1 56.7 0.2 35.8 61.6 21.0 32.6 66.4 30.8 21.0 27.5 30.2 50.7 26.2 22.5 25.6 20.3 57.9 59.3 74.1 24.8 54.5 8.4 9.8 2.5 7.6 7.9 4.9 10.0 5.2 8.8 9.4 BTLA "BTLA1, CD272" ENSG00000186265 "B and T lymphocyte associated" Q7Z6A9 3 112463968-112499561 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 37.2;lymphoid tissue: 30.9" "Group enriched" "Detected in some" 4 "ASC diff: 2.4;Daudi: 1.9;U-698: 6.1" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "memory B-cell: 22.6;naive B-cell: 37.2" "Lineage enriched" "Detected in many" 4 "B-cells: 37.2" "Not detected" "Not detected" "HPA047211, HPA062029" Enhanced "HPA047211: , HPA062029: " "unprognostic (1.13e-3)" "unprognostic (2.13e-3)" "unprognostic (5.79e-4)" "unprognostic (1.01e-4)" "unprognostic (7.08e-2)" "unprognostic (7.74e-6)" "unprognostic (6.20e-3)" "unprognostic (7.59e-3)" "unprognostic (5.98e-2)" "unprognostic (1.53e-5)" "unprognostic (2.33e-2)" "unprognostic (1.23e-1)" "unprognostic (1.57e-5)" "unprognostic (2.57e-1)" "unprognostic (2.46e-2)" "unprognostic (1.65e-1)" "unprognostic (1.42e-2)" 0.6 0.3 0.3 20.3 0.4 1.2 1.1 0.4 0.3 0.5 1.2 0.1 0.0 0.9 0.4 0.1 2.3 0.5 1.0 0.4 0.3 0.3 1.0 0.5 1.2 30.9 0.3 0.0 0.4 0.3 0.0 0.4 0.3 0.1 0.5 0.9 0.2 5.7 0.4 0.3 0.5 6.0 0.2 0.4 18.6 1.7 0.6 0.0 14.6 0.9 1.1 19.4 2.8 0.5 37.2 8.6 0.1 0.0 0.1 5.1 2.4 0.0 0.0 0.0 0.3 2.4 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 1.9 0.1 0.1 0.0 0.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.3 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.4 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.1 0.1 0.0 0.0 0.0 0.0 0.0 4.1 0.0 3.1 22.6 5.1 2.4 1.5 37.2 4.8 4.7 0.1 0.1 0.0 8.6 1.1 2.4 0.3 0.4 0.4 0.3 0.3 0.3 0.3 0.0 0.1 0.0 BTN3A1 "BT3.1, BTF5, BTN3.1, CD277" ENSG00000026950 "Butyrophilin subfamily 3 member A1" O00481 6 26402237-26415216 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" HPA012565 Approved Uncertain Vesicles Vesicles "HPA012565: AB_1845494" "unprognostic (2.82e-2)" "unprognostic (6.43e-2)" "unprognostic (1.45e-3)" "unprognostic (4.72e-3)" "unprognostic (1.41e-2)" "unprognostic (1.42e-1)" "unprognostic (3.10e-2)" "unprognostic (9.31e-2)" "unprognostic (9.81e-2)" "unprognostic (8.60e-3)" "unprognostic (1.19e-1)" "unprognostic (2.41e-1)" "prognostic unfavourable (4.15e-5)" "unprognostic (2.45e-1)" "unprognostic (5.02e-2)" "unprognostic (3.26e-2)" "prognostic favourable (4.81e-4)" 11.3 14.3 6.7 33.5 5.4 10.3 10.2 10.7 5.9 18.5 14.9 10.0 10.1 11.5 22.3 14.1 13.1 9.6 16.5 9.0 5.3 6.1 9.7 11.4 29.9 24.1 7.1 5.4 15.5 9.4 5.6 11.2 8.5 7.8 17.9 12.1 12.3 16.7 10.0 4.8 9.7 20.6 10.2 9.0 45.2 12.5 4.9 6.7 16.5 8.5 9.8 32.9 11.6 12.9 9.8 4.4 17.4 5.9 18.4 23.4 12.1 3.7 3.2 4.7 4.8 13.6 14.5 0.5 3.0 12.0 6.9 20.3 0.1 8.1 9.7 10.6 5.5 2.5 1.5 4.8 4.0 9.5 3.3 5.1 3.9 2.2 6.1 4.7 4.7 7.8 2.7 6.0 2.8 9.7 1.2 12.7 2.8 0.3 8.5 2.9 0.5 1.0 11.8 2.1 22.0 4.2 4.7 2.5 5.0 1.7 3.6 6.8 3.3 1.9 2.4 5.3 1.3 1.5 2.9 21.7 22.1 3.5 8.1 10.6 4.1 17.4 5.3 13.5 23.4 5.7 20.9 9.8 14.6 21.7 4.4 5.3 12.7 16.8 11.9 18.4 5.9 2.1 16.9 12.1 6.7 5.4 10.7 5.9 5.3 6.1 7.1 5.4 7.8 6.7 C5AR1 "C5A, C5AR, C5R1, CD88" ENSG00000197405 "Complement C5a receptor 1" P21730 19 47290023-47322066 "CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" Chemotaxis "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 75.8" "Cell line enhanced" "Detected in many" "CAPAN-2: 5.8;HMC-1: 7.4;U-87 MG: 8.8;U-937: 8.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 75.8" "Group enriched" "Detected in many" 42 "granulocytes: 75.8;monocytes: 20.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002720, HPA014520, HPA048012" Approved Supported Vesicles Vesicles "CAB002720: , HPA014520: AB_1846337, HPA048012: " "unprognostic (5.95e-2)" "prognostic favourable (4.71e-4)" "unprognostic (1.70e-2)" "unprognostic (1.25e-1)" "unprognostic (4.08e-2)" "unprognostic (1.11e-1)" "unprognostic (1.80e-2)" "unprognostic (4.41e-2)" "unprognostic (5.45e-2)" "prognostic unfavourable (9.55e-4)" "unprognostic (2.02e-1)" "unprognostic (9.56e-2)" "prognostic unfavourable (1.16e-4)" "unprognostic (1.96e-3)" "prognostic unfavourable (7.99e-4)" "unprognostic (1.82e-2)" "unprognostic (6.54e-2)" 33.7 8.0 1.9 34.9 7.0 46.2 8.7 0.7 3.0 5.6 6.0 3.7 1.6 1.0 4.1 4.9 3.5 14.3 16.5 11.7 7.6 3.2 5.3 9.1 38.1 26.9 3.8 1.2 7.6 3.6 1.3 27.9 12.8 10.9 4.2 1.9 7.8 2.9 1.1 7.0 1.1 3.0 11.4 11.2 48.8 4.2 6.3 1.3 2.3 2.5 1.7 3.4 12.2 2.7 0.1 1.1 75.8 20.5 0.1 0.1 2.6 1.4 5.3 0.3 0.5 1.0 0.4 1.1 1.0 0.6 0.3 0.1 0.2 5.8 0.4 1.1 1.2 2.0 0.7 0.8 0.2 1.0 0.7 0.2 4.9 0.8 0.6 2.6 7.4 0.8 3.0 0.6 0.9 0.0 0.3 2.6 0.2 1.5 0.3 3.4 1.8 0.8 0.3 0.1 0.4 1.8 1.2 0.0 0.1 0.5 0.5 0.8 0.4 3.0 0.0 0.1 3.1 0.4 0.3 0.4 0.4 0.3 8.8 8.9 0.3 7.0 8.9 6.9 0.1 15.1 0.0 0.0 0.0 0.0 1.1 0.1 0.0 0.0 75.8 0.1 20.5 0.2 0.0 2.6 1.9 7.0 0.7 3.0 7.6 3.2 3.8 1.2 10.9 1.3 CCR1 "CD191, CKR-1, CMKBR1, MIP1aR, SCYAR1" ENSG00000163823 "C-C motif chemokine receptor 1" P32246 3 46201709-46208396 "CD markers, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 34.0;lymphoid tissue: 40.2" "Cell line enhanced" "Detected in some" "Karpas-707: 76.5;RPMI-8226: 35.1;U-266/70: 13.4;U-266/84: 39.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "unprognostic (3.95e-1)" "unprognostic (2.17e-1)" "unprognostic (1.20e-1)" "unprognostic (2.16e-1)" "unprognostic (1.05e-1)" "unprognostic (6.66e-2)" "unprognostic (1.16e-1)" "unprognostic (8.82e-2)" "unprognostic (4.91e-3)" "unprognostic (2.20e-3)" "unprognostic (1.09e-1)" "unprognostic (9.60e-2)" "prognostic unfavourable (1.01e-4)" "unprognostic (1.08e-1)" "unprognostic (5.52e-3)" "unprognostic (1.47e-1)" "unprognostic (2.38e-1)" 21.2 6.0 5.1 23.8 8.4 11.2 4.9 1.0 3.7 1.9 2.9 7.2 0.5 3.9 2.0 5.1 2.0 4.5 6.7 4.1 5.4 3.2 4.4 9.6 11.6 26.3 9.0 1.6 2.8 2.3 1.0 2.6 14.9 6.9 2.3 4.1 2.9 3.3 1.3 1.4 1.4 4.5 8.5 11.6 40.2 2.9 1.2 8.7 2.2 1.8 1.0 5.5 6.9 1.5 0.9 15.3 32.5 34.0 22.1 15.3 11.8 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 76.5 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 35.1 0.0 1.2 0.0 0.0 0.0 0.1 0.3 0.0 8.0 0.0 0.2 0.0 0.0 0.0 13.4 39.6 0.0 6.8 6.0 0.1 21.5 34.0 6.8 3.1 21.4 15.3 0.9 0.0 2.5 15.3 0.0 0.0 0.4 32.5 22.1 13.1 5.5 0.0 11.8 5.1 8.4 1.0 3.3 5.4 3.2 9.0 1.6 6.9 8.7 CCR2 "CC-CKR-2, CD192, CKR2, CMKBR2, FLJ78302, MCP-1-R" ENSG00000121807 "C-C motif chemokine receptor 2" P41597 3 46353734-46360928 "CD markers, G-protein coupled receptors, Predicted membrane proteins" "Host-virus interaction, Inflammatory response" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 96.3;lymphoid tissue: 36.1" "Cell line enhanced" "Detected in some" "Karpas-707: 47.4;THP-1: 22.5;U-266/70: 109.2;U-266/84: 43.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in many" "basophil: 96.3" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in some" "Low region specificity" "Detected in single" CAB003793 Approved "CAB003793: AB_344889" "unprognostic (1.09e-2)" "unprognostic (6.28e-4)" "unprognostic (3.49e-2)" "unprognostic (6.35e-4)" "unprognostic (1.89e-2)" "unprognostic (4.16e-4)" "unprognostic (8.06e-2)" "prognostic favourable (5.87e-4)" "unprognostic (6.33e-2)" "unprognostic (3.27e-2)" "unprognostic (3.12e-1)" "unprognostic (1.56e-1)" "unprognostic (5.52e-3)" "unprognostic (1.29e-1)" "unprognostic (3.35e-2)" "unprognostic (4.88e-2)" "unprognostic (4.19e-1)" 2.5 1.3 0.6 20.7 0.8 0.9 1.9 0.5 0.8 4.3 5.8 0.5 1.5 5.6 2.6 2.4 6.1 2.2 2.5 1.8 0.6 0.6 3.7 1.8 8.6 30.1 1.6 0.1 1.7 1.7 0.0 0.8 2.1 1.8 3.7 4.0 2.6 10.2 3.5 0.8 1.3 7.3 5.6 1.5 36.1 3.7 1.5 0.5 3.6 2.0 3.5 5.9 5.8 1.7 1.6 29.0 96.3 28.4 2.5 19.3 13.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 22.5 0.0 0.0 0.0 0.0 0.0 109.2 43.5 0.0 0.0 0.8 0.0 96.3 28.4 0.4 2.5 2.6 19.3 1.6 5.2 4.2 29.0 0.3 0.1 0.1 0.7 2.5 0.0 23.0 2.3 13.5 0.6 0.8 0.5 0.8 0.6 0.6 1.6 0.1 1.8 0.5 CCR3 "CC-CKR-3, CD193, CKR3, CMKBR3" ENSG00000183625 "C-C motif chemokine receptor 3" P51677 3 46163604-46266706 "CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "Host-virus interaction" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 25 "blood: 175.9" "Cell line enriched" "Detected in some" 9 "RPMI-8226: 24.9" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 22 "basophil: 175.9;eosinophil: 152.0" "Lineage enriched" "Detected in many" 92 "granulocytes: 175.9" "Not detected" "Not detected" "Not detected" "Not detected" CAB003795 Uncertain "CAB003795: AB_562259" "unprognostic (1.56e-2)" "unprognostic (6.65e-3)" "unprognostic (1.01e-1)" "unprognostic (3.98e-2)" "unprognostic (1.41e-1)" "unprognostic (3.25e-3)" "unprognostic (3.11e-7)" "unprognostic (4.36e-2)" "unprognostic (3.35e-2)" "unprognostic (3.43e-2)" "unprognostic (4.81e-2)" "unprognostic (3.94e-2)" "unprognostic (3.17e-6)" "unprognostic (1.35e-2)" "unprognostic (1.72e-2)" "unprognostic (2.41e-1)" "unprognostic (9.81e-2)" 0.6 0.2 0.3 2.9 1.1 0.4 0.3 0.2 0.8 0.3 1.3 0.2 0.2 2.9 0.8 0.2 0.4 0.5 1.3 0.3 0.2 0.2 0.5 1.2 5.8 0.6 0.3 0.2 0.2 0.3 0.0 0.3 7.0 0.7 1.0 1.4 0.9 2.4 0.2 3.2 3.6 5.1 1.6 0.5 2.7 2.2 0.4 0.2 0.6 1.8 2.8 0.6 4.0 0.3 0.0 0.2 175.9 0.0 0.0 1.9 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.6 2.2 0.0 0.7 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 1.1 0.0 0.0 0.0 0.0 1.0 0.0 0.4 0.1 0.3 0.1 0.0 0.2 0.0 24.9 0.0 2.0 0.1 0.0 0.0 0.7 0.0 0.0 0.6 0.0 0.1 0.2 0.0 0.1 2.7 2.1 0.0 0.0 0.5 0.0 175.9 0.0 152.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 7.3 0.0 0.0 0.2 1.9 0.3 0.3 1.1 0.2 0.8 0.2 0.2 0.3 0.2 0.7 0.2 CCR4 "CC-CKR-4, CD194, ChemR13, CKR4, CMKBR4, k5-5" ENSG00000183813 "C-C motif chemokine receptor 4" P51679 3 32951574-32956349 "CD markers, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 28.9;lymphoid tissue: 57.1" "Cell line enriched" "Detected in some" 17 "HDLM-2: 65.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 5 "T-reg: 28.9" "Lineage enriched" "Detected in single" 48 "T-cells: 28.9" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA031613 Approved Supported "Plasma membrane" "Plasma membrane" "HPA031613: AB_10601096" "unprognostic (4.63e-3)" "unprognostic (8.70e-3)" "unprognostic (2.82e-3)" "unprognostic (2.64e-3)" "unprognostic (1.18e-1)" "unprognostic (4.59e-7)" "unprognostic (3.02e-1)" "unprognostic (5.05e-3)" "unprognostic (1.53e-2)" "unprognostic (1.69e-2)" "unprognostic (1.75e-1)" "unprognostic (2.17e-1)" "unprognostic (9.88e-3)" "unprognostic (2.04e-1)" "unprognostic (5.53e-4)" "unprognostic (1.54e-1)" "unprognostic (1.40e-1)" 1.5 0.6 0.3 12.6 0.4 1.5 1.1 0.3 0.3 1.1 1.1 0.1 0.7 0.4 1.0 0.6 1.6 0.8 3.8 0.8 0.3 0.3 1.8 0.9 6.0 24.1 0.3 0.0 0.5 0.5 0.5 0.5 0.1 0.1 1.5 1.2 0.8 4.3 0.2 1.8 2.2 5.0 0.4 0.4 10.2 1.3 2.7 0.0 57.1 1.3 2.8 29.7 8.6 1.1 0.2 0.2 0.5 0.1 0.1 28.9 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 65.5 0.0 3.9 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 1.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.1 0.1 0.2 0.1 0.2 0.1 6.0 1.8 0.0 0.2 0.1 0.1 0.5 0.1 0.1 0.2 28.9 0.8 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.0 0.1 0.0 CCR5 "CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22" ENSG00000160791 "C-C motif chemokine receptor 5 (gene/pseudogene)" P51681 3 46370854-46376206 "CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "Host-virus interaction" "G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer" "Diabetes mellitus, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 24.5" "Group enriched" "Detected in some" 17 "Karpas-707: 11.8;U-266/84: 5.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "MAIT T-cell: 24.5" "Lineage enriched" "Detected in many" 4 "T-cells: 24.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "unprognostic (4.32e-3)" "unprognostic (1.94e-3)" "unprognostic (1.89e-3)" "prognostic favourable (7.42e-5)" "unprognostic (1.80e-2)" "prognostic favourable (9.33e-5)" "unprognostic (3.38e-3)" "unprognostic (9.90e-3)" "unprognostic (7.65e-2)" "unprognostic (6.22e-2)" "unprognostic (1.36e-1)" "unprognostic (5.34e-2)" "unprognostic (1.14e-3)" "unprognostic (8.34e-2)" "unprognostic (4.69e-2)" "unprognostic (3.14e-2)" "unprognostic (2.42e-2)" 7.1 2.3 3.4 13.8 6.1 0.8 2.1 0.8 2.5 2.3 3.0 3.0 0.8 3.8 3.7 4.0 2.6 2.6 5.0 3.6 1.6 2.0 2.7 3.0 9.3 11.9 8.1 0.5 3.0 2.1 0.4 1.9 1.2 4.0 2.8 3.8 3.5 4.4 2.5 0.8 1.1 7.2 2.9 6.1 14.6 6.0 0.9 5.9 2.0 2.6 1.5 13.9 5.7 2.0 0.3 5.5 5.6 2.1 3.2 24.5 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.8 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.2 0.0 0.0 0.0 0.0 0.4 5.0 0.0 0.0 0.3 0.0 5.6 1.1 0.0 6.7 2.1 24.5 0.3 2.9 9.7 5.5 0.0 0.3 2.6 0.3 3.2 0.0 5.2 4.5 1.5 3.4 6.1 0.8 2.5 1.6 2.0 8.1 0.5 4.0 5.9 CCR6 "BN-1, CD196, CKR-L3, CMKBR6, DCR2, DRY-6, GPR-CY4, GPR29, STRL22" ENSG00000112486 "C-C motif chemokine receptor 6" P51684 6 167111807-167139696 "CD markers, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 30.7;intestine: 9.9;lymphoid tissue: 33.7" "Cell line enriched" "Detected in some" 5 "Hep G2: 14.1" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Group enriched" "Detected in many" 4 "MAIT T-cell: 30.7;memory B-cell: 23.8;memory CD4 T-cell: 11.9;naive B-cell: 28.2;T-reg: 20.9" "Group enriched" "Detected in many" 5 "B-cells: 28.2;T-cells: 30.7" "Region enriched" "Detected in single" 8 "basal ganglia: 0.9" "Not detected" "Not detected" "CAB006820, HPA014488" Approved "CAB006820: , HPA014488: AB_1846639" "unprognostic (1.12e-2)" "unprognostic (2.92e-2)" "unprognostic (2.07e-3)" "unprognostic (2.08e-1)" "unprognostic (8.43e-2)" "unprognostic (2.05e-4)" "unprognostic (2.39e-1)" "unprognostic (4.98e-3)" "unprognostic (1.29e-1)" "unprognostic (1.40e-1)" "unprognostic (4.19e-2)" "unprognostic (4.26e-2)" "unprognostic (2.68e-4)" "unprognostic (3.74e-2)" "unprognostic (7.96e-2)" "unprognostic (2.26e-1)" "unprognostic (1.77e-1)" 0.5 0.3 1.0 24.4 1.5 1.3 1.1 0.3 1.1 0.6 3.0 0.1 0.0 1.4 0.3 0.8 2.1 0.5 3.1 0.3 0.9 0.9 1.0 0.5 3.3 27.3 0.6 0.0 0.3 0.3 0.0 0.4 0.5 0.2 0.5 1.2 0.3 5.0 0.8 0.3 1.1 9.9 0.0 0.4 23.4 2.2 2.7 0.1 3.7 0.6 2.1 33.7 4.8 0.4 28.2 5.4 0.2 0.0 0.4 30.7 2.5 0.1 0.2 0.2 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.5 0.2 1.3 0.3 0.0 0.0 0.3 0.2 0.1 2.6 0.7 0.1 0.3 14.1 0.0 0.7 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.1 0.2 0.1 0.0 0.2 0.2 0.2 0.4 0.0 0.8 0.4 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.8 0.1 0.3 0.5 0.3 0.4 0.0 0.2 0.6 0.0 0.0 0.1 1.6 0.0 30.7 23.8 11.9 4.7 5.4 28.2 0.1 0.0 0.2 0.4 0.0 0.6 20.9 2.5 1.0 1.5 0.3 1.1 0.9 0.9 0.6 0.0 0.2 0.1 CCR7 "BLR2, CD197, CDw197, CMKBR7, EBI1" ENSG00000126353 "C-C motif chemokine receptor 7" P32248 17 40553769-40565472 "Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 11 "blood: 252.3;lymphoid tissue: 110.6" "Cell line enriched" "Detected in some" 79 "HDLM-2: 171.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 252.3" "Lineage enriched" "Detected in many" 4 "T-cells: 252.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB003796, HPA031383, HPA074467" Enhanced Approved Mitochondria Mitochondria "CAB003796: AB_562261, HPA031383: , HPA074467: " "prognostic favourable (3.84e-4)" "prognostic favourable (8.03e-6)" "unprognostic (2.26e-3)" "unprognostic (1.32e-3)" "unprognostic (2.35e-3)" "prognostic favourable (7.61e-7)" "unprognostic (2.71e-4)" "unprognostic (2.58e-2)" "unprognostic (4.48e-2)" "unprognostic (4.68e-4)" "unprognostic (1.10e-2)" "unprognostic (3.11e-1)" "unprognostic (1.08e-3)" "unprognostic (3.12e-1)" "prognostic unfavourable (7.72e-4)" "unprognostic (1.02e-1)" "unprognostic (7.95e-2)" 2.8 0.4 0.2 26.0 0.2 5.2 1.7 0.2 0.3 2.2 1.2 0.3 0.8 0.3 1.2 0.5 1.4 2.3 2.0 1.9 0.2 0.2 1.5 1.7 3.4 110.6 0.3 0.2 1.5 0.3 0.0 1.0 1.0 0.4 1.3 2.1 0.7 8.4 0.2 0.2 1.1 16.2 0.2 0.4 20.3 1.8 1.2 0.3 57.1 2.0 1.2 53.8 4.2 1.3 58.8 2.9 2.3 0.3 44.1 252.3 109.3 0.0 0.1 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 171.5 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.9 0.1 1.1 0.2 0.0 0.0 1.1 0.3 0.2 3.1 0.1 3.6 37.2 53.3 15.3 0.2 58.8 252.3 133.9 2.3 44.1 0.2 2.9 30.3 109.3 0.2 0.2 0.2 0.3 0.2 0.2 0.3 0.2 0.4 0.3 CCR8 "CDw198, CKR-L1, CMKBR8, CMKBRL2, CY6, GPR-CY6, TER1" ENSG00000179934 "C-C motif chemokine receptor 8" P51685 3 39329706-39333511 "CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "blood: 19.8;lymphoid tissue: 19.3;urinary bladder: 5.3" "Cell line enriched" "Detected in some" 22 "HDLM-2: 48.9" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 5 "T-reg: 19.8" "Lineage enriched" "Detected in single" 30 "T-cells: 19.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA042383 Enhanced "HPA042383: " "unprognostic (2.16e-1)" "unprognostic (2.12e-2)" "unprognostic (2.91e-2)" "unprognostic (1.04e-1)" "unprognostic (2.38e-2)" "unprognostic (7.63e-4)" "unprognostic (3.31e-1)" "unprognostic (1.27e-1)" "unprognostic (2.30e-3)" "unprognostic (3.37e-2)" "unprognostic (7.40e-2)" "unprognostic (2.99e-1)" "unprognostic (4.65e-8)" "unprognostic (7.96e-2)" "unprognostic (2.24e-2)" "unprognostic (2.56e-1)" "unprognostic (4.14e-1)" 0.3 0.2 0.2 3.1 0.2 0.0 0.3 0.2 0.2 0.3 0.5 0.1 0.1 0.0 0.3 0.1 0.8 0.1 2.1 0.2 0.2 0.2 0.5 0.3 1.4 2.8 0.1 0.1 0.2 0.3 0.0 0.2 0.1 0.1 0.4 1.3 0.1 0.5 0.1 0.2 1.0 1.2 0.1 0.4 1.7 0.8 0.3 0.1 19.3 0.4 1.2 3.5 5.3 0.3 0.0 0.0 0.0 0.0 0.6 19.8 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 48.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.2 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 1.8 0.0 0.0 0.2 0.0 0.0 0.6 0.0 0.0 19.8 0.6 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.1 CCR9 "CDw199, GPR-9-6, GPR28" ENSG00000173585 "C-C motif chemokine receptor 9" P51686 3 45886504-45903177 "CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "Host-virus interaction" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "lymphoid tissue: 130.2" "Cell line enriched" "Detected in single" 324 "MOLT-4: 48.7" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "memory B-cell: 17.5;naive B-cell: 9.2;T-reg: 5.7" "Group enriched" "Detected in many" 42 "B-cells: 17.5;T-cells: 5.7" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" CAB006839 Uncertain "CAB006839: " "unprognostic (3.08e-3)" "unprognostic (3.37e-1)" "unprognostic (5.56e-2)" "unprognostic (1.78e-1)" "unprognostic (8.65e-3)" "unprognostic (7.88e-3)" "unprognostic (4.54e-1)" "unprognostic (2.94e-2)" "unprognostic (3.00e-1)" "unprognostic (1.77e-1)" "unprognostic (8.06e-2)" "unprognostic (1.16e-1)" "unprognostic (2.59e-2)" "unprognostic (1.88e-1)" "unprognostic (4.34e-1)" "unprognostic (2.27e-1)" "unprognostic (7.20e-3)" 0.1 0.1 0.1 1.8 0.1 0.7 0.1 0.1 0.3 0.1 2.2 0.1 0.1 7.0 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.4 0.2 0.2 0.8 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.3 0.1 0.1 0.2 0.2 0.1 10.7 0.1 0.2 2.2 0.3 0.1 0.1 130.2 0.1 0.1 0.7 0.1 0.1 17.5 0.2 0.0 0.0 0.0 5.7 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 48.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 17.5 2.2 1.8 0.2 9.2 0.3 0.1 0.0 0.0 0.0 0.2 5.7 1.8 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 CD101 "IGSF2, V7" ENSG00000134256 "CD101 molecule" Q93033 1 117001750-117036476 "CD markers, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 33.7;lung: 17.5" "Cell line enriched" "Detected in some" 9 "HMC-1: 24.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "eosinophil: 33.7" "Group enriched" "Detected in many" 17 "dendritic cells: 12.2;granulocytes: 33.7;monocytes: 17.4" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA049527, HPA057763" Approved Uncertain Mitochondria 42000 Mitochondria "HPA049527: , HPA057763: " "unprognostic (1.25e-1)" "unprognostic (7.95e-3)" "unprognostic (5.40e-3)" "unprognostic (4.10e-3)" "unprognostic (2.62e-1)" "unprognostic (4.00e-2)" "unprognostic (3.03e-2)" "unprognostic (3.58e-3)" "unprognostic (3.57e-2)" "unprognostic (7.29e-3)" "unprognostic (3.15e-1)" "unprognostic (4.54e-2)" "unprognostic (7.15e-6)" "unprognostic (7.00e-2)" "unprognostic (8.07e-2)" "unprognostic (5.05e-2)" "unprognostic (5.28e-2)" 0.9 1.7 0.8 11.3 1.1 5.7 0.8 0.2 1.1 1.3 5.0 0.6 1.2 4.6 1.7 0.4 1.8 1.5 1.4 2.6 1.1 0.5 1.3 0.8 17.5 4.0 1.3 0.2 1.0 2.3 0.0 0.8 0.5 1.1 1.6 3.2 0.7 2.1 1.3 0.5 1.8 10.9 1.6 2.0 7.8 1.8 0.9 1.2 6.4 0.9 2.4 7.4 2.4 1.8 0.1 12.2 33.7 17.4 0.0 1.2 2.5 0.4 0.0 0.8 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 1.2 1.8 0.1 0.0 0.0 1.0 0.1 0.8 0.0 0.0 0.1 24.7 0.3 1.2 0.0 0.1 0.2 0.1 0.6 0.1 1.5 0.0 2.8 0.8 0.0 0.0 0.5 0.0 0.6 0.6 0.4 0.6 0.4 0.5 0.3 0.9 0.6 0.5 0.1 0.4 0.5 0.2 0.2 0.1 0.0 0.7 1.9 1.5 0.0 7.6 33.7 0.1 10.0 0.7 0.1 0.2 1.2 12.2 0.0 0.3 1.2 0.3 0.0 17.4 0.0 1.1 2.5 0.8 1.1 0.2 1.1 1.1 0.5 1.3 0.2 1.1 1.2 CD109 "CPAMD7, DKFZp762L1111, FLJ38569" ENSG00000156535 "CD109 molecule" Q6YHK3 6 73695785-73828316 "CD markers, Plasma proteins, Predicted membrane proteins" "Protease inhibitor, Serine protease inhibitor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "parathyroid gland: 203.4" "Cell line enhanced" "Detected in many" "ASC TERT1: 61.6;BJ hTERT+: 37.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "myeloid DC: 2.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA008992, HPA015723" Enhanced Supported "Plasma membrane" 120000000 "Plasma membrane" "HPA008992: , HPA015723: " "unprognostic (2.28e-1)" "unprognostic (1.03e-1)" "unprognostic (7.76e-2)" "unprognostic (1.52e-2)" "unprognostic (9.17e-3)" "unprognostic (1.36e-1)" "unprognostic (1.03e-3)" "unprognostic (1.23e-3)" "unprognostic (7.49e-2)" "unprognostic (2.47e-1)" "unprognostic (1.15e-3)" "unprognostic (8.81e-2)" "prognostic unfavourable (2.65e-4)" "prognostic unfavourable (7.96e-5)" "unprognostic (9.50e-2)" "unprognostic (2.02e-1)" "prognostic unfavourable (4.68e-4)" 27.4 1.5 1.6 1.9 2.2 1.9 6.5 0.4 1.9 15.0 7.1 3.4 2.0 1.5 22.5 8.5 22.4 3.4 2.4 8.2 1.8 1.4 3.5 1.4 14.5 1.4 1.7 1.4 2.8 1.2 203.4 0.6 5.0 3.0 7.1 2.1 0.6 4.2 2.2 4.1 12.4 2.4 12.6 4.5 1.7 1.5 3.3 2.8 6.3 1.7 16.8 4.7 8.7 8.0 0.3 2.6 1.4 0.4 0.6 0.4 0.3 9.2 8.3 0.5 0.0 12.7 61.6 0.0 8.4 37.8 2.8 6.1 0.0 5.4 0.0 5.2 17.3 26.1 0.9 16.9 3.7 2.5 1.4 3.3 6.8 1.4 2.7 0.0 0.0 16.9 13.4 5.2 21.1 20.0 0.0 0.0 12.6 0.2 0.2 0.0 0.6 5.4 0.7 2.4 11.4 1.2 1.0 0.0 0.0 19.1 0.1 8.3 0.2 1.5 18.5 26.4 3.7 4.7 7.2 0.1 5.2 0.0 10.6 0.0 23.4 0.6 0.4 0.3 0.2 0.2 0.1 0.2 0.3 0.2 2.6 0.3 0.4 0.2 1.4 0.6 0.2 1.4 0.1 0.3 1.6 2.2 0.4 1.9 1.8 1.4 1.7 1.4 3.0 2.8 CD14 ENSG00000170458 "CD14 molecule" P08571 5 140631728-140633701 "Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins" "Immunity, Inflammatory response, Innate immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "blood: 189.4;liver: 165.8" "Cell line enhanced" "Detected in many" "A549: 8.9;CACO-2: 13.6;SiHa: 16.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 189.4" "Group enriched" "Detected in many" 5 "granulocytes: 52.3;monocytes: 189.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001887, HPA002127, CAB033631, CAB072865, CAB072866" Enhanced Supported Vesicles "Secreted to blood" 2752500000 15000000000 Vesicles "CAB033631: AB_781932, CAB072865: , CAB072866: , HPA001887: AB_1078442, HPA002127: AB_1078440" "unprognostic (1.92e-1)" "unprognostic (1.68e-1)" "unprognostic (3.42e-3)" "unprognostic (3.89e-2)" "unprognostic (3.29e-2)" "unprognostic (1.54e-1)" "unprognostic (4.71e-3)" "unprognostic (4.88e-2)" "unprognostic (2.16e-1)" "unprognostic (1.06e-1)" "unprognostic (1.83e-1)" "unprognostic (2.43e-1)" "prognostic unfavourable (6.80e-5)" "unprognostic (1.20e-2)" "unprognostic (6.87e-3)" "unprognostic (8.12e-2)" "unprognostic (6.92e-2)" 27.9 44.1 9.0 42.7 25.2 9.8 11.7 3.5 8.9 5.6 10.0 6.0 1.8 5.4 5.6 24.0 4.5 12.0 14.6 18.9 11.7 7.4 12.7 165.8 23.8 34.7 21.6 2.9 14.2 5.3 4.3 10.1 37.3 18.9 8.5 9.2 14.6 28.5 5.8 10.2 3.5 12.1 21.4 18.2 35.5 6.6 6.5 17.3 2.2 7.9 5.8 6.6 15.9 3.8 0.5 23.6 52.3 189.4 0.2 0.4 124.2 0.1 8.9 0.1 0.5 1.2 0.3 0.4 0.8 4.1 1.3 1.6 13.6 2.1 0.4 0.6 4.9 3.8 0.0 1.6 0.2 0.1 0.9 0.3 0.5 1.8 4.8 1.0 0.4 3.9 0.2 0.2 1.3 0.0 0.2 0.2 1.2 0.3 0.0 0.5 0.2 0.3 0.3 0.4 1.1 0.2 0.0 2.4 1.0 16.3 0.4 0.5 0.3 1.7 0.6 0.2 0.3 1.5 1.2 0.7 0.9 0.5 0.4 0.4 0.1 0.4 189.4 1.0 0.3 36.6 0.4 0.5 0.2 0.2 23.6 0.1 0.3 0.2 52.3 0.2 4.8 1.3 0.1 124.2 9.0 25.2 3.5 8.9 11.7 7.4 21.6 2.9 18.9 17.3 CD151 "PETA-3, RAPH, SFA-1, TSPAN24" ENSG00000177697 "CD151 molecule (Raph blood group)" P48509 11 832843-839831 "Blood group antigen proteins, CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Host-virus interaction" "Blood group antigen" "Deafness, Epidermolysis bullosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 113.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002428, HPA011906" Supported 680000 "CAB002428: AB_564129, HPA011906: AB_1846245" "unprognostic (1.50e-1)" "unprognostic (1.12e-2)" "unprognostic (5.47e-2)" "unprognostic (5.45e-3)" "unprognostic (4.10e-3)" "unprognostic (2.45e-2)" "prognostic unfavourable (5.58e-4)" "prognostic unfavourable (9.46e-4)" "unprognostic (5.47e-2)" "unprognostic (2.41e-1)" "unprognostic (1.02e-3)" "unprognostic (3.31e-1)" "unprognostic (4.39e-2)" "unprognostic (6.23e-3)" "unprognostic (3.24e-1)" "prognostic favourable (6.92e-4)" "unprognostic (7.83e-2)" 63.1 28.1 7.4 19.1 8.1 3.4 133.2 7.9 11.3 39.8 36.0 9.5 37.8 23.2 55.7 45.3 43.1 29.3 63.0 85.2 7.3 7.9 52.8 47.2 45.8 16.3 7.5 10.3 29.8 82.7 27.8 14.1 58.6 10.7 52.0 16.5 31.2 62.9 41.1 19.2 17.1 46.0 62.4 6.7 15.8 31.7 20.8 5.5 2.4 43.2 27.1 16.1 35.9 34.9 2.1 8.1 14.9 14.3 5.2 4.8 6.5 39.5 54.8 7.9 23.7 113.5 47.2 12.4 62.0 42.3 31.3 26.5 28.5 56.5 0.0 24.8 92.6 36.1 7.0 54.7 7.9 14.8 26.9 10.9 16.9 21.7 43.2 8.8 15.2 45.6 36.6 18.3 32.3 36.9 13.3 5.1 46.7 22.2 0.2 10.4 5.2 65.8 2.0 16.4 8.5 69.6 11.5 10.9 12.2 57.4 32.0 10.8 12.9 10.7 63.1 42.6 21.1 13.7 34.3 6.9 7.1 0.4 42.0 9.2 23.5 14.9 12.0 9.6 4.2 12.6 4.8 2.1 3.5 3.6 8.1 1.5 1.5 2.2 5.7 5.2 14.3 1.3 2.1 6.5 7.4 8.1 7.9 11.3 7.3 7.9 7.5 10.3 10.7 5.5 CD160 "BY55, NK1, NK28" ENSG00000117281 "CD160 molecule" O95971 1 145719471-145739288 "CD markers, Predicted intracellular proteins" "Adaptive immunity, Angiogenesis, Immunity, Innate immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 33.9;brain: 15.2;intestine: 19.9;lymphoid tissue: 17.4" "Low cell line specificity" "Detected in many" "Not detected" "Not detected" "Region enriched" "Detected in many" 5 "cerebellum: 15.2" "Group enriched" "Detected in many" 9 "gdT-cell: 33.9;MAIT T-cell: 14.4;memory CD8 T-cell: 22.9;naive CD8 T-cell: 27.3;NK-cell: 23.2" "Group enriched" "Detected in many" 11 "NK-cells: 23.2;T-cells: 33.9" "Not detected" "Not detected" "Intracellular and membrane" "unprognostic (6.54e-4)" "unprognostic (1.06e-1)" "unprognostic (4.25e-2)" "unprognostic (6.91e-2)" "unprognostic (3.33e-1)" "unprognostic (3.40e-2)" "unprognostic (1.35e-1)" "unprognostic (8.25e-3)" "unprognostic (5.76e-2)" "unprognostic (2.68e-1)" "unprognostic (2.24e-2)" "unprognostic (7.49e-3)" "unprognostic (3.48e-5)" "unprognostic (4.05e-2)" "unprognostic (2.03e-1)" "unprognostic (2.89e-2)" "unprognostic (2.92e-4)" 0.6 0.2 2.2 3.6 2.6 5.1 0.6 15.2 3.1 0.8 9.3 0.4 0.3 5.6 0.8 1.4 0.9 0.6 1.2 0.6 1.6 2.2 0.5 5.9 3.8 6.0 1.6 0.3 1.1 2.2 0.0 0.4 1.8 0.6 1.3 1.0 0.9 3.0 0.4 1.0 1.1 19.9 1.4 1.0 17.4 0.8 0.8 0.3 2.9 0.4 0.3 3.1 0.7 0.3 0.2 0.3 2.7 0.4 23.2 33.9 20.2 1.3 1.0 1.6 0.9 0.0 0.3 0.3 0.1 0.0 0.2 0.1 0.6 0.1 1.7 1.3 0.2 1.6 0.2 0.2 0.1 3.5 1.6 3.1 4.6 1.2 0.1 2.0 3.2 0.2 0.4 0.1 0.3 0.0 0.8 1.5 0.1 1.5 1.2 4.0 1.1 2.8 0.3 0.2 1.0 0.0 0.6 1.2 1.5 0.9 1.3 0.6 1.5 2.0 1.8 1.3 0.6 0.7 3.0 2.3 1.6 0.6 0.7 2.4 0.2 2.7 0.1 0.1 33.9 0.1 14.4 0.2 0.4 22.9 0.0 0.2 0.2 27.3 1.7 23.2 0.4 0.3 0.0 20.2 2.2 2.6 15.2 3.1 1.6 2.2 1.6 0.3 0.6 0.3 CD163 "M130, MM130, SCARI1" ENSG00000177575 "CD163 molecule" Q86VB7 12 7470813-7503893 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Acute phase, Inflammatory response" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 113.6" "Cell line enhanced" "Detected in some" "ASC diff: 2.1;CACO-2: 1.9;HSkMC: 5.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 10 "classical monocyte: 28.2;myeloid DC: 25.3" "Group enriched" "Detected in many" 40 "dendritic cells: 25.3;monocytes: 28.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in single" "CAB002432, HPA046404, HPA051974" Enhanced Approved "Plasma membrane" "Secreted to blood" 903333333 1600000000 "Plasma membrane" "CAB002432: AB_563510, HPA046404: AB_2679655, HPA051974: AB_2681678" "unprognostic (1.13e-1)" "unprognostic (2.13e-1)" "unprognostic (5.02e-3)" "unprognostic (2.72e-1)" "unprognostic (6.17e-3)" "unprognostic (2.09e-1)" "unprognostic (1.02e-1)" "unprognostic (1.21e-1)" "unprognostic (2.78e-1)" "prognostic unfavourable (7.27e-4)" "unprognostic (1.04e-1)" "unprognostic (6.50e-2)" "unprognostic (1.84e-2)" "unprognostic (8.77e-2)" "unprognostic (4.95e-2)" "unprognostic (1.61e-1)" "unprognostic (1.20e-2)" 66.7 23.8 2.1 44.6 7.2 4.1 23.2 2.8 4.9 11.3 25.3 1.6 1.4 3.5 7.2 16.8 11.3 20.1 13.2 15.7 2.8 1.8 43.9 38.9 81.0 99.8 6.9 0.5 10.3 6.7 3.1 11.7 31.9 9.9 6.8 6.5 9.8 8.6 2.2 15.2 4.0 12.5 37.2 5.7 113.6 10.2 19.6 4.3 3.4 15.5 2.9 3.5 20.1 8.3 0.0 25.3 0.6 28.2 0.0 0.0 6.3 0.0 0.0 0.0 0.0 2.1 1.1 0.4 0.0 0.1 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 0.0 0.6 0.3 5.9 0.0 0.4 0.6 0.0 0.0 0.0 0.2 0.0 0.1 0.6 0.6 0.0 0.1 1.0 0.1 0.0 0.0 0.3 0.6 0.1 0.2 0.0 0.0 0.3 0.0 1.1 0.3 0.2 0.0 0.3 0.0 0.0 0.3 0.0 0.1 0.5 28.2 0.1 0.0 2.5 0.0 0.0 0.0 0.0 25.3 0.0 0.0 0.0 0.6 0.0 0.0 0.3 0.0 6.3 2.1 7.2 2.8 2.4 2.8 1.8 6.9 0.5 9.9 4.3 CD163L1 "CD163B, M160, SCARI2, WC1" ENSG00000177675 "CD163 molecule like 1" Q9NR16 12 7346685-7479897 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 18.4;lymphoid tissue: 31.2" "Cell line enhanced" "Detected in many" "HDLM-2: 8.2;HUVEC TERT2: 8.8;TIME: 8.3;U-87 MG: 19.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" HPA015663 Enhanced Approved Nucleoplasm,Centrosome,Cytosol "Intracellular and membrane" 170000 "Centrosome, Cytosol" Nucleoplasm "HPA015663: AB_2072575" "unprognostic (1.25e-3)" "unprognostic (1.77e-1)" "unprognostic (1.42e-2)" "unprognostic (7.46e-3)" "unprognostic (2.29e-2)" "unprognostic (7.79e-2)" "unprognostic (9.39e-2)" "unprognostic (4.44e-3)" "unprognostic (1.07e-1)" "unprognostic (8.35e-2)" "unprognostic (1.08e-1)" "unprognostic (3.08e-1)" "unprognostic (1.26e-6)" "unprognostic (8.59e-2)" "unprognostic (1.17e-1)" "unprognostic (1.52e-1)" "unprognostic (1.69e-1)" 5.0 1.7 1.2 19.1 1.2 0.0 2.5 0.8 1.6 1.4 9.2 0.3 1.0 5.5 1.2 8.5 1.8 1.3 2.6 3.2 1.2 1.0 1.7 1.5 2.8 14.6 1.1 0.7 1.0 1.0 0.1 1.4 6.8 3.3 1.4 15.1 2.7 2.5 1.4 1.1 1.4 18.4 1.8 1.0 31.2 2.6 4.6 0.2 9.5 1.7 6.4 12.9 4.3 1.2 0.2 0.7 0.7 0.8 0.0 0.0 0.2 0.2 0.4 0.2 0.0 1.0 0.3 0.0 0.8 1.8 0.2 0.8 0.0 1.4 0.0 0.3 0.8 0.0 0.0 1.1 1.4 8.2 0.0 0.0 0.4 1.2 0.0 0.5 0.0 0.3 0.0 0.2 3.3 8.8 0.1 4.7 5.2 0.0 0.0 6.5 0.2 0.0 1.5 1.5 1.8 0.0 0.0 1.2 5.5 4.3 6.8 0.0 0.0 5.4 8.3 3.0 2.7 0.3 0.0 0.1 0.1 0.0 19.4 0.4 5.7 0.0 0.8 0.7 0.0 0.8 0.0 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.2 1.2 0.8 1.6 1.2 1.0 1.1 0.7 3.3 0.2 CD164 "DFNA66, MGC-24, MUC-24" ENSG00000135535 "CD164 molecule" Q04900 6 109366514-109382812 "CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Myogenesis" "Deafness, Non-syndromic deafness" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA010636 Uncertain "Intracellular and membrane" "HPA010636: AB_1078447" "unprognostic (1.23e-2)" "unprognostic (1.61e-2)" "unprognostic (3.89e-2)" "unprognostic (2.21e-1)" "unprognostic (1.47e-1)" "unprognostic (1.04e-2)" "unprognostic (1.97e-3)" "unprognostic (1.80e-1)" "unprognostic (1.30e-1)" "unprognostic (1.09e-1)" "unprognostic (8.88e-2)" "unprognostic (1.38e-1)" "unprognostic (7.11e-2)" "unprognostic (1.29e-1)" "unprognostic (1.84e-1)" "unprognostic (3.01e-1)" "unprognostic (1.51e-1)" 85.0 37.6 17.1 37.2 28.5 38.0 72.9 11.2 19.2 34.2 55.2 31.1 57.4 50.5 35.6 44.4 29.6 31.7 58.1 32.0 18.6 22.6 67.4 66.1 52.5 60.9 45.2 16.7 38.0 49.2 30.4 55.0 106.6 28.2 33.4 57.4 44.1 75.1 49.6 38.5 30.6 100.2 41.5 42.8 43.2 55.8 38.1 30.2 50.7 73.3 25.0 34.7 40.3 37.2 32.6 54.2 66.1 48.9 61.1 46.7 83.2 20.2 11.3 6.0 38.1 87.1 84.2 36.9 38.1 48.1 34.3 49.4 22.7 30.9 16.4 36.9 41.2 20.0 22.6 24.4 53.0 33.5 22.6 27.8 12.1 27.3 51.7 32.8 66.4 65.9 48.4 33.9 31.0 31.7 26.5 43.7 47.3 21.2 30.9 40.9 9.0 18.5 20.4 17.8 20.6 50.5 27.3 6.4 13.0 23.2 31.1 55.5 27.2 43.5 32.0 22.4 16.4 32.1 30.1 16.6 23.3 18.9 40.3 38.5 23.0 66.1 47.6 39.9 44.7 48.9 46.4 32.6 36.5 40.9 47.1 28.8 38.3 40.7 32.7 61.1 45.5 54.2 46.7 83.2 17.1 28.5 11.2 19.2 18.6 22.6 45.2 16.7 28.2 30.2 CD180 "LY64, Ly78, RP105" ENSG00000134061 "CD180 molecule" Q99467 5 67179613-67196799 "CD markers, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 29.2;lymphoid tissue: 38.7" "Group enriched" "Detected in some" 10 "Daudi: 22.8;Karpas-707: 21.4;U-266/70: 17.4;U-266/84: 24.2;U-698: 6.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "memory B-cell: 28.7;naive B-cell: 29.2" "Group enriched" "Detected in many" 23 "B-cells: 29.2;dendritic cells: 8.5;monocytes: 11.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA003740 Enhanced "HPA003740: AB_1078450" "unprognostic (9.33e-2)" "unprognostic (4.58e-2)" "unprognostic (2.81e-3)" "unprognostic (5.85e-3)" "unprognostic (2.25e-2)" "unprognostic (4.04e-3)" "unprognostic (1.09e-1)" "unprognostic (4.95e-2)" "unprognostic (5.83e-2)" "unprognostic (3.71e-1)" "unprognostic (2.16e-1)" "unprognostic (1.46e-1)" "unprognostic (2.09e-1)" "unprognostic (1.16e-1)" "unprognostic (3.70e-2)" "unprognostic (1.21e-1)" "unprognostic (2.18e-2)" 9.6 1.6 1.4 24.3 3.2 1.9 5.7 0.6 1.3 1.0 2.1 1.6 0.0 1.8 0.9 1.0 1.7 1.3 1.5 4.6 1.2 1.1 2.5 2.7 3.0 30.4 4.1 0.6 1.5 1.0 0.2 1.1 2.9 2.2 1.5 2.5 0.4 3.1 0.4 0.6 0.7 8.4 1.6 3.5 38.7 1.9 0.8 2.8 1.9 1.2 0.2 31.3 4.1 0.8 29.2 8.5 0.3 11.6 0.7 0.0 2.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.4 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.3 0.1 17.4 24.2 6.4 0.0 1.4 0.0 0.0 4.1 0.3 0.0 7.4 0.0 28.7 0.0 0.0 8.0 29.2 0.0 0.0 0.3 0.7 11.6 8.5 0.0 2.8 1.4 3.2 0.6 1.3 1.2 1.1 4.1 0.6 2.2 2.8 CD19 ENSG00000177455 "CD19 molecule" P15391 16 28931939-28939346 "CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Adaptive immunity, Immunity" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "blood: 47.6;intestine: 16.7;lymphoid tissue: 40.3" "Cell line enhanced" "Detected in some" "Daudi: 52.1;REH: 27.6;U-698: 11.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 93 "memory B-cell: 36.0;naive B-cell: 47.6" "Lineage enriched" "Detected in single" 106 "B-cells: 47.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB016110 Enhanced "CAB016110: AB_626952" "unprognostic (3.27e-3)" "unprognostic (1.19e-3)" "unprognostic (6.63e-2)" "unprognostic (1.09e-2)" "unprognostic (8.68e-3)" "unprognostic (3.11e-5)" "unprognostic (2.61e-1)" "unprognostic (6.96e-3)" "unprognostic (1.29e-2)" "unprognostic (4.29e-3)" "unprognostic (1.12e-1)" "unprognostic (1.30e-1)" "unprognostic (5.41e-6)" "unprognostic (2.06e-1)" "unprognostic (1.83e-1)" "unprognostic (1.36e-1)" "unprognostic (2.07e-1)" 0.4 0.2 0.2 37.0 0.2 2.3 0.2 0.1 0.2 0.2 0.9 0.1 0.0 0.2 0.2 0.1 1.4 0.3 0.2 0.2 0.2 0.2 0.7 0.3 1.4 32.0 0.2 0.0 0.3 0.2 0.0 0.2 0.0 0.0 0.4 0.5 0.1 5.9 0.0 0.1 0.1 16.7 0.0 0.2 40.3 1.3 1.9 0.0 2.4 0.7 0.2 38.7 1.8 0.3 47.6 0.0 0.4 0.1 0.0 0.1 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 52.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 27.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.8 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 36.0 0.0 0.0 0.0 47.6 0.1 0.0 0.3 0.0 0.1 0.0 0.0 1.8 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.0 0.0 0.0 CD1A CD1 ENSG00000158477 "CD1a molecule" P06126 1 158254137-158258269 "CD markers, Predicted membrane proteins" "Adaptive immunity, Immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "lymphoid tissue: 105.1" "Cell line enriched" "Detected in single" 106 "MOLT-4: 35.7" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 23 "classical monocyte: 5.9;intermediate monocyte: 3.7;memory B-cell: 6.8;myeloid DC: 10.2;naive B-cell: 5.4" "Group enriched" "Detected in many" 35 "B-cells: 6.8;dendritic cells: 10.2;monocytes: 5.9" "CAB000009, HPA010734" Enhanced "CAB000009: AB_2073290, HPA010734: AB_1078452" "unprognostic (7.21e-5)" "prognostic favourable (6.37e-4)" "unprognostic (1.37e-5)" "unprognostic (2.55e-2)" "unprognostic (2.83e-1)" "unprognostic (1.16e-2)" "unprognostic (9.93e-4)" "unprognostic (1.49e-2)" "unprognostic (3.12e-1)" "unprognostic (3.86e-2)" "unprognostic (6.99e-2)" "unprognostic (5.12e-2)" "unprognostic (5.49e-5)" "unprognostic (5.58e-2)" "unprognostic (1.72e-1)" "unprognostic (1.76e-1)" "unprognostic (8.81e-2)" 0.1 0.0 0.1 0.9 0.1 0.0 1.0 0.1 0.1 0.9 0.1 0.1 0.1 0.0 0.2 0.1 8.0 0.0 0.6 0.1 0.1 0.0 0.2 0.1 1.8 1.9 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 1.2 0.1 0.9 0.1 0.1 20.9 0.3 0.1 0.1 1.4 0.3 0.2 0.1 105.1 0.1 1.0 2.7 0.4 1.1 6.8 10.2 0.0 5.9 0.0 0.2 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 35.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 5.9 0.0 0.0 3.7 0.2 6.8 0.0 0.0 10.2 5.4 0.1 0.0 0.0 0.0 0.2 0.2 0.0 1.5 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 CD1B CD1 ENSG00000158485 "CD1b molecule" P29016 1 158327951-158331531 "CD markers, Predicted membrane proteins" "Adaptive immunity, Immunity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "lymphoid tissue: 188.8" "Cell line enriched" "Detected in single" 1104 "MOLT-4: 110.4" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 6 "myeloid DC: 16.3" "Lineage enriched" "Detected in many" 6 "dendritic cells: 16.3" HPA021824 Approved "HPA021824: AB_1846262" "unprognostic (7.72e-3)" "unprognostic (1.55e-4)" "unprognostic (1.66e-5)" "unprognostic (1.04e-2)" "unprognostic (1.06e-3)" "unprognostic (1.81e-1)" "unprognostic (2.89e-4)" "unprognostic (2.27e-2)" "unprognostic (2.19e-1)" "unprognostic (1.33e-1)" "unprognostic (9.53e-2)" "unprognostic (3.23e-1)" "unprognostic (3.52e-1)" "unprognostic (1.56e-1)" "unprognostic (1.89e-1)" "unprognostic (3.53e-2)" 0.8 0.1 0.2 1.9 0.2 0.0 0.6 0.2 0.2 0.8 0.6 0.3 0.2 0.0 0.3 0.2 0.9 0.7 1.3 0.2 0.2 0.0 0.6 0.3 1.7 4.0 0.2 0.2 0.3 0.3 0.0 0.2 0.2 0.2 0.2 5.6 0.2 0.6 0.2 0.2 6.2 0.8 0.3 0.2 1.9 0.9 0.2 0.2 188.8 0.4 0.4 2.4 0.5 0.8 0.0 16.3 0.0 2.9 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 110.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 2.3 0.0 0.0 0.0 0.0 16.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 CD1C CD1 ENSG00000158481 "CD1c molecule" P29017 1 158289786-158293630 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "blood: 70.8;lymphoid tissue: 111.4" "Cell line enriched" "Detected in some" 14 "MOLT-4: 34.7" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "memory B-cell: 18.6;myeloid DC: 70.8" "Group enriched" "Detected in many" 8 "B-cells: 18.6;dendritic cells: 70.8" 240000 "unprognostic (2.55e-3)" "prognostic favourable (1.79e-5)" "unprognostic (1.75e-5)" "unprognostic (3.09e-5)" "unprognostic (3.12e-2)" "unprognostic (8.13e-3)" "unprognostic (2.01e-1)" "unprognostic (3.80e-3)" "unprognostic (7.11e-3)" "unprognostic (1.87e-1)" "unprognostic (7.41e-2)" "unprognostic (1.93e-1)" "unprognostic (1.04e-1)" "unprognostic (1.46e-1)" "unprognostic (1.67e-1)" "unprognostic (8.05e-2)" "unprognostic (1.99e-1)" 1.8 0.4 0.5 8.2 0.6 0.0 2.2 0.5 0.5 1.1 1.2 0.5 1.3 0.4 1.4 1.2 1.8 1.6 5.1 0.6 0.5 0.3 1.6 1.5 2.8 13.2 0.6 0.5 0.7 0.7 0.0 0.6 0.7 0.6 1.0 4.8 0.9 3.0 1.0 0.6 5.5 11.7 1.3 0.5 24.6 1.2 0.8 0.5 111.4 1.0 2.4 20.5 1.4 1.3 18.6 70.8 0.2 5.9 0.9 0.1 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 34.7 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.6 0.0 0.1 5.9 0.0 0.0 5.1 0.0 18.6 0.0 0.0 70.8 9.3 0.0 0.0 0.2 0.9 0.6 0.3 0.1 3.3 0.5 0.6 0.5 0.5 0.5 0.3 0.6 0.5 0.6 0.5 CD1D ENSG00000158473 "CD1d molecule" P15813 1 158179947-158184896 "Cancer-related genes, CD markers, Predicted membrane proteins" "Immunity, Innate immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 49.5;lymphoid tissue: 17.8" "Cell line enhanced" "Detected in some" "HBEC3-KT: 9.1;HHSteC: 14.1;MOLT-4: 18.6;THP-1: 11.4" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 6 "classical monocyte: 49.5;intermediate monocyte: 22.4;myeloid DC: 49.5" "Group enriched" "Detected in many" 8 "dendritic cells: 49.5;monocytes: 49.5" "Low region specificity" "Detected in all" "CAB016107, HPA072662" Enhanced Supported "Endoplasmic reticulum" 720000 "Endoplasmic reticulum" "CAB016107: AB_626960, HPA072662: " "unprognostic (8.67e-2)" "unprognostic (6.99e-2)" "unprognostic (2.48e-1)" "unprognostic (1.48e-2)" "unprognostic (1.05e-1)" "unprognostic (1.42e-1)" "unprognostic (3.85e-1)" "unprognostic (9.67e-3)" "unprognostic (2.37e-1)" "unprognostic (3.52e-1)" "unprognostic (2.23e-2)" "unprognostic (4.46e-2)" "prognostic unfavourable (2.12e-5)" "unprognostic (9.31e-3)" "unprognostic (2.35e-1)" "unprognostic (2.32e-2)" "unprognostic (3.38e-1)" 1.5 1.2 0.0 8.6 0.0 2.6 1.2 0.0 0.0 0.8 2.5 9.5 1.5 0.0 0.4 1.4 2.0 1.4 0.0 0.1 1.6 10.5 2.3 5.5 0.2 0.3 0.7 0.0 0.6 0.0 1.4 3.7 0.7 0.3 0.6 0.0 12.2 2.2 0.4 17.8 1.4 1.4 1.8 3.4 1.6 0.5 6.3 49.5 2.5 49.5 0.1 0.1 23.5 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 3.2 0.0 4.8 0.0 9.1 0.0 0.0 0.1 0.2 0.0 0.0 14.1 0.1 0.0 5.3 0.7 0.0 1.1 0.0 0.0 0.0 0.0 0.0 18.6 1.8 0.8 0.0 0.0 0.0 0.0 0.9 0.0 1.8 0.0 0.0 0.0 0.0 0.0 11.4 0.0 0.0 2.9 0.0 0.0 0.5 0.0 0.5 0.0 5.2 0.7 0.0 49.5 0.1 0.0 22.4 0.1 6.3 0.0 0.0 49.5 4.7 0.0 0.0 2.5 0.1 3.6 0.5 0.0 23.5 CD1E ENSG00000158488 "CD1e molecule" P15812 1 158353696-158357553 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 10 "lymphoid tissue: 308.0" "Cell line enriched" "Detected in single" 1338 "MOLT-4: 167.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 13 "myeloid DC: 29.7" "Lineage enriched" "Detected in many" 13 "dendritic cells: 29.7" "Low region specificity" "Detected in all" HPA057769 Uncertain "Intracellular and membrane" "HPA057769: " "unprognostic (7.94e-3)" "unprognostic (1.85e-5)" "unprognostic (1.47e-2)" "unprognostic (1.64e-2)" "unprognostic (1.76e-2)" "unprognostic (1.29e-2)" "unprognostic (2.33e-1)" "unprognostic (1.54e-3)" "unprognostic (1.24e-1)" "unprognostic (1.74e-1)" "unprognostic (1.60e-1)" "unprognostic (8.55e-2)" "unprognostic (1.69e-2)" "unprognostic (1.50e-1)" "unprognostic (2.49e-1)" "unprognostic (8.50e-2)" "unprognostic (2.45e-1)" 1.0 0.2 0.7 2.8 0.7 0.0 1.1 0.7 0.7 1.5 1.0 0.7 0.7 1.2 0.9 0.7 7.0 1.9 3.9 0.7 0.7 0.2 2.0 0.7 2.4 4.7 0.7 0.7 0.7 0.8 0.0 0.7 0.7 0.7 1.8 4.8 0.8 1.9 0.8 0.8 11.5 2.1 0.8 0.7 3.8 3.1 0.9 0.7 308.0 1.0 1.3 8.1 2.4 2.7 0.0 29.7 0.0 2.2 0.0 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 167.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 1.1 0.1 0.0 0.0 0.0 29.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.7 0.7 0.7 0.7 0.7 0.2 0.7 0.7 0.7 0.7 CD2 SRBC ENSG00000116824 "CD2 molecule" P06729 1 116754385-116769228 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 101.7;lymphoid tissue: 164.4" "Group enriched" "Detected in some" 25 "HDLM-2: 61.1;MOLT-4: 44.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Group enriched" "Detected in many" 6 "gdT-cell: 44.4;MAIT T-cell: 42.5;memory CD4 T-cell: 65.3;memory CD8 T-cell: 74.2;naive CD4 T-cell: 34.2;naive CD8 T-cell: 52.4;NK-cell: 101.7;T-reg: 62.3" "Group enriched" "Detected in many" 9 "NK-cells: 101.7;T-cells: 74.2" "Region enhanced" "Detected in single" "basal ganglia: 0.3" "Low region specificity" "Detected in many" "CAB002430, HPA003883" Enhanced "CAB002430: AB_442057, HPA003883: AB_1846263" "prognostic favourable (4.36e-4)" "prognostic favourable (1.47e-4)" "unprognostic (3.34e-3)" "prognostic favourable (1.69e-5)" "unprognostic (1.52e-1)" "prognostic favourable (7.46e-5)" "unprognostic (9.32e-3)" "unprognostic (1.61e-2)" "prognostic favourable (3.97e-5)" "prognostic favourable (7.72e-4)" "unprognostic (4.18e-2)" "unprognostic (3.31e-1)" "prognostic unfavourable (4.82e-6)" "unprognostic (6.16e-2)" "unprognostic (6.61e-2)" "unprognostic (2.73e-2)" "unprognostic (7.63e-3)" 3.0 1.1 0.6 14.5 0.5 2.4 1.7 0.5 0.6 2.9 6.0 0.6 0.6 4.8 1.7 2.1 3.8 3.1 4.8 1.4 0.6 0.6 3.3 2.5 8.1 33.0 1.2 0.6 1.9 1.6 0.0 1.0 1.0 1.0 2.9 4.7 2.3 4.1 1.3 1.0 1.2 18.8 0.9 1.8 28.8 6.5 1.1 0.8 164.4 3.5 3.4 30.8 7.7 2.7 0.3 9.3 1.4 0.5 101.7 74.2 45.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 61.1 0.0 0.1 0.0 0.0 0.0 0.1 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 44.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.7 0.5 0.1 44.4 0.3 42.5 0.3 65.3 74.2 9.3 0.2 34.2 52.4 1.4 101.7 0.2 2.0 62.3 45.9 0.6 0.5 0.5 0.6 0.6 0.6 1.2 0.6 1.0 0.8 CD200 "MOX1, MOX2, MRC, OX-2" ENSG00000091972 "CD200 molecule" P41217 3 112332347-112362812 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 63.5" "Cell line enhanced" "Detected in some" "AF22: 31.2;HHSteC: 11.5;NTERA-2: 19.5;REH: 16.7;SK-MEL-30: 11.5;WM-115: 34.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 16 "memory B-cell: 9.9;naive B-cell: 36.4" "Lineage enriched" "Detected in many" 25 "B-cells: 36.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031149 Approved "HPA031149: AB_10600694" "unprognostic (1.84e-1)" "unprognostic (5.08e-2)" "unprognostic (1.79e-1)" "unprognostic (2.03e-3)" "unprognostic (4.97e-1)" "unprognostic (1.21e-2)" "unprognostic (9.29e-2)" "unprognostic (2.25e-2)" "unprognostic (3.06e-1)" "unprognostic (3.14e-2)" "unprognostic (1.21e-2)" "unprognostic (1.27e-1)" "unprognostic (8.97e-2)" "unprognostic (1.06e-2)" "unprognostic (2.80e-1)" "unprognostic (4.49e-2)" "unprognostic (1.22e-2)" 12.8 9.5 18.1 10.9 34.3 1.8 7.1 20.9 38.3 16.0 4.5 11.0 1.5 2.6 21.4 5.7 7.0 20.3 10.1 5.8 17.3 42.4 4.9 1.0 7.2 17.7 12.7 19.3 9.3 3.8 10.9 27.9 63.5 19.6 9.7 6.5 7.5 5.4 13.0 1.4 2.8 4.3 13.9 8.4 4.4 3.4 2.3 6.7 12.7 12.4 1.6 17.6 13.9 3.9 36.4 1.1 1.2 0.1 0.6 1.4 1.3 0.0 0.0 31.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 1.7 0.0 0.0 3.3 0.1 0.1 0.1 0.3 0.0 0.1 0.2 11.5 0.0 0.0 0.2 0.1 0.6 0.0 4.4 0.0 0.3 0.0 0.0 0.4 0.1 19.5 0.0 16.7 0.0 0.2 0.2 0.0 8.2 9.6 0.0 0.1 11.5 0.0 0.1 0.0 0.1 1.1 0.0 0.1 0.0 0.1 0.0 0.3 0.0 34.0 1.2 0.1 0.1 0.1 0.0 1.4 9.9 0.8 0.2 0.5 36.4 0.9 0.5 0.7 0.6 0.1 1.1 0.4 1.3 18.1 34.3 20.9 38.3 17.3 42.4 12.7 19.3 19.6 6.7 CD207 "CLEC4K, Langerin" ENSG00000116031 "CD207 molecule" Q9UJ71 2 70830214-70835822 "CD markers, Disease related genes, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 16.5;skin 1: 42.3" "Cell line enriched" "Detected in some" 4 "AN3-CA: 13.7" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 18 "myeloid DC: 4.0" "Lineage enriched" "Detected in single" 18 "dendritic cells: 4.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002222, HPA011216" Enhanced Approved Cytosol Cytosol "CAB002222: AB_563850, HPA011216: AB_1078453" "unprognostic (1.45e-2)" "unprognostic (8.28e-3)" "unprognostic (9.34e-2)" "unprognostic (1.65e-1)" "unprognostic (1.38e-1)" "unprognostic (2.23e-1)" "unprognostic (3.02e-1)" "unprognostic (1.27e-3)" "unprognostic (1.05e-1)" "unprognostic (4.86e-2)" "unprognostic (3.45e-1)" "unprognostic (1.63e-1)" "unprognostic (7.92e-4)" "unprognostic (2.13e-2)" "unprognostic (1.81e-1)" "unprognostic (1.98e-1)" "unprognostic (2.46e-2)" 0.5 0.1 0.1 1.8 0.1 0.0 1.4 0.1 0.1 2.4 1.7 0.1 0.1 1.6 1.1 0.4 9.7 0.3 2.9 0.3 0.1 0.1 0.2 0.9 3.7 0.2 0.1 0.1 0.2 0.2 0.0 1.1 0.1 0.1 1.0 1.1 0.4 1.2 0.2 0.1 42.3 2.6 0.1 0.1 1.5 0.4 0.4 0.1 3.3 0.2 11.3 16.5 0.3 1.9 0.0 4.0 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 13.7 0.1 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.0 0.1 1.9 0.0 0.0 0.0 2.4 0.0 0.5 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 CD209 "CDSIGN, CLEC4L, DC-SIGN, DC-SIGN1" ENSG00000090659 "CD209 molecule" Q9NNX6 19 7739994-7747564 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Cell adhesion, Endocytosis, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 47.9" "Cell line enriched" "Detected in single" 14 "THP-1: 8.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "classical monocyte: 3.7;intermediate monocyte: 3.5;myeloid DC: 3.4" "Low lineage specificity" "Detected in many" "CAB032436, CAB033831" Supported "Intracellular and membrane" 970000 "CAB032436: AB_639039, CAB033831: AB_1121347" "unprognostic (2.76e-1)" "unprognostic (1.15e-2)" "unprognostic (5.36e-3)" "unprognostic (1.25e-1)" "unprognostic (4.43e-2)" "unprognostic (1.40e-1)" "unprognostic (5.45e-2)" "unprognostic (3.83e-2)" "unprognostic (2.10e-2)" "unprognostic (1.24e-1)" "unprognostic (9.65e-2)" "unprognostic (1.39e-1)" "prognostic unfavourable (1.15e-5)" "unprognostic (1.70e-1)" "unprognostic (5.51e-2)" "unprognostic (6.17e-2)" "unprognostic (1.09e-1)" 20.3 4.5 0.5 4.1 1.8 0.0 6.8 4.5 0.9 2.0 5.6 0.7 0.3 7.2 1.1 7.3 2.4 3.3 4.4 7.8 0.4 0.7 2.2 5.0 3.7 47.9 1.1 0.5 1.8 3.8 0.4 1.0 12.1 1.8 3.6 7.4 3.2 3.0 0.7 3.5 1.6 10.1 5.2 0.9 1.4 2.6 2.1 0.3 2.3 2.1 2.1 1.3 6.8 1.6 0.3 3.4 0.9 3.7 0.3 0.2 1.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.1 0.1 0.2 0.6 0.0 0.1 0.0 0.2 8.6 0.1 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.5 3.7 0.2 0.2 3.5 0.1 0.2 0.1 0.1 3.4 0.3 0.1 0.2 0.9 0.3 0.1 0.3 0.1 1.0 0.5 1.8 4.5 0.9 0.4 0.7 1.1 0.5 1.8 0.3 CD22 "SIGLEC-2, SIGLEC2" ENSG00000012124 "CD22 molecule" P20273 19 35319261-35347355 "CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 39.3;lymphoid tissue: 77.8;ovary: 35.4" "Cell line enhanced" "Detected in some" "Daudi: 68.2;REH: 20.2;U-698: 54.2;WM-115: 12.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 25 "memory B-cell: 29.8;naive B-cell: 39.3" "Lineage enriched" "Detected in many" 28 "B-cells: 39.3" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "CAB002418, HPA024353" Enhanced "CAB002418: AB_563529, HPA024353: AB_10600695" "unprognostic (2.80e-3)" "unprognostic (3.99e-2)" "unprognostic (6.79e-3)" "unprognostic (9.17e-2)" "unprognostic (3.07e-1)" "unprognostic (6.45e-3)" "unprognostic (3.79e-1)" "unprognostic (3.32e-2)" "unprognostic (1.79e-1)" "unprognostic (2.47e-1)" "unprognostic (1.75e-3)" "unprognostic (1.98e-2)" "unprognostic (1.48e-2)" "unprognostic (9.05e-2)" "unprognostic (3.04e-1)" "unprognostic (2.35e-2)" "unprognostic (1.48e-1)" 2.1 1.0 5.5 57.9 6.8 3.1 0.5 0.7 3.2 1.4 1.0 0.9 0.5 0.4 1.4 0.9 4.4 7.9 2.9 0.8 9.9 4.2 1.4 0.6 5.5 52.6 9.8 0.5 35.4 0.5 0.0 0.7 1.0 0.9 2.8 1.5 1.1 5.9 1.1 0.5 0.0 11.6 2.0 13.5 64.1 1.4 1.2 0.6 5.0 1.1 2.3 77.8 4.3 0.9 39.3 1.3 0.3 0.3 0.0 0.0 1.4 0.2 0.4 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.1 0.0 1.2 68.2 1.4 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.5 0.0 0.0 3.1 0.0 0.0 0.0 1.0 0.0 0.3 0.0 0.6 0.1 0.0 0.0 0.0 0.1 20.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.6 0.1 0.0 0.0 0.6 0.3 0.0 0.0 0.0 0.0 54.2 0.5 0.2 12.4 0.0 0.0 0.0 0.0 0.3 0.0 29.8 0.0 0.0 1.3 39.3 0.0 0.0 0.3 0.0 0.2 1.1 0.0 1.4 5.5 6.8 0.7 3.2 9.9 4.2 9.8 0.5 0.9 0.6 CD226 "DNAM-1, DNAM1, PTA1, TLiSA1" ENSG00000150637 "CD226 molecule" Q15762 18 69831158-69961803 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 31.9;parathyroid gland: 82.5" "Group enriched" "Detected in some" 6 "HEL: 44.3;HMC-1: 19.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 8 "gdT-cell: 19.4;MAIT T-cell: 7.3;memory CD4 T-cell: 16.1;memory CD8 T-cell: 11.8;naive CD4 T-cell: 9.0;naive CD8 T-cell: 9.7;NK-cell: 14.0;T-reg: 5.5" "Group enriched" "Detected in many" 11 "NK-cells: 14.0;T-cells: 19.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA015715, HPA050348" Supported Uncertain Midbody 27000000 Midbody "HPA015715: AB_1846278, HPA050348: " "unprognostic (1.42e-4)" "unprognostic (1.30e-3)" "unprognostic (9.01e-3)" "unprognostic (3.49e-5)" "unprognostic (4.15e-1)" "unprognostic (9.52e-4)" "unprognostic (3.68e-3)" "unprognostic (2.93e-2)" "unprognostic (3.43e-1)" "unprognostic (3.31e-3)" "unprognostic (8.36e-2)" "unprognostic (1.43e-1)" "unprognostic (2.72e-3)" "unprognostic (2.20e-1)" "unprognostic (3.91e-2)" "unprognostic (2.27e-1)" "unprognostic (3.58e-2)" 1.2 0.6 1.0 7.5 2.0 1.7 0.8 0.7 0.9 1.5 2.9 0.3 0.1 1.1 1.0 1.4 0.8 0.8 1.4 0.9 1.9 1.3 1.3 3.1 5.2 14.0 1.7 0.0 1.0 0.6 82.5 2.4 0.6 1.3 0.9 1.2 2.4 5.4 0.6 1.1 0.4 6.0 1.3 4.2 31.9 1.4 1.8 0.5 6.4 1.8 2.6 10.1 2.0 1.6 0.4 1.5 0.9 0.6 14.0 19.4 6.6 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 2.3 0.0 44.3 0.1 0.0 0.0 0.3 19.7 0.0 0.5 0.1 0.3 0.0 0.1 4.5 0.2 0.0 0.3 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.1 0.0 0.1 5.4 0.1 0.0 0.1 0.0 0.2 0.1 0.0 0.5 19.4 0.4 7.3 0.4 16.1 11.8 1.5 0.1 9.0 9.7 0.9 14.0 0.6 0.1 5.5 6.6 1.0 2.0 0.7 0.9 1.9 1.3 1.7 0.0 1.3 0.5 CD244 "2B4, NAIL, NKR2B4, Nmrk, SLAMF4" ENSG00000122223 "CD244 molecule" Q9BZW8 1 160830160-160862855 "CD markers, Plasma proteins, Predicted membrane proteins" "Adaptive immunity, Immunity, Innate immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 75.8;lymphoid tissue: 22.1" "Cell line enhanced" "Detected in some" "HEL: 10.6;HMC-1: 37.4;NB-4: 7.4;U-937: 14.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in many" "basophil: 75.8" "Lineage enriched" "Detected in many" 5 "granulocytes: 75.8" "Not detected" "Not detected" "unprognostic (6.11e-3)" "unprognostic (1.54e-2)" "unprognostic (1.85e-2)" "unprognostic (6.95e-6)" "unprognostic (5.79e-2)" "unprognostic (1.43e-4)" "unprognostic (1.93e-2)" "unprognostic (7.36e-2)" "unprognostic (3.36e-1)" "unprognostic (2.85e-1)" "unprognostic (1.60e-1)" "unprognostic (2.32e-1)" "unprognostic (5.40e-4)" "unprognostic (1.71e-1)" "unprognostic (1.51e-1)" "unprognostic (1.87e-1)" "unprognostic (1.79e-1)" 2.9 0.4 0.5 3.3 0.5 8.6 0.6 0.3 0.7 0.9 3.1 0.4 1.6 2.8 1.4 0.7 1.0 0.7 1.7 2.0 0.5 0.5 0.7 4.1 5.3 7.4 1.7 0.0 1.6 0.5 0.0 0.5 1.8 1.1 1.6 1.2 1.0 1.6 0.9 1.1 0.5 6.0 2.6 1.5 22.1 0.8 2.8 0.6 0.7 0.6 0.0 4.0 1.5 0.8 0.0 7.9 75.8 13.2 14.0 14.8 11.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.6 0.0 0.0 0.2 3.4 37.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.0 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.0 0.0 1.4 0.5 0.0 0.0 14.9 0.0 75.8 8.2 20.1 14.8 11.2 7.3 0.0 0.8 8.1 7.9 0.0 1.1 7.8 0.6 14.0 13.2 0.4 0.0 11.3 0.5 0.5 0.3 0.7 0.5 0.5 1.7 0.0 1.1 0.6 CD247 "CD3H, CD3Q, CD3Z" ENSG00000198821 "CD247 molecule" P20963 1 167430640-167518610 "CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 62.8;lymphoid tissue: 129.5" "Group enriched" "Detected in some" 28 "HDLM-2: 47.8;MOLT-4: 50.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 26 "gdT-cell: 62.8;MAIT T-cell: 35.4;memory CD4 T-cell: 32.4;memory CD8 T-cell: 36.7;naive CD4 T-cell: 41.3;naive CD8 T-cell: 33.5;NK-cell: 33.4;T-reg: 39.0" "Group enriched" "Detected in many" 31 "NK-cells: 33.4;T-cells: 62.8" "Region enhanced" "Detected in single" "thalamus: 0.7" "Low region specificity" "Detected in all" "CAB004651, HPA008750" Enhanced "CAB004651: AB_425347, HPA008750: AB_1857863" "prognostic favourable (9.12e-4)" "unprognostic (3.21e-3)" "unprognostic (7.09e-3)" "prognostic favourable (8.63e-6)" "unprognostic (1.99e-2)" "prognostic favourable (3.98e-4)" "unprognostic (1.79e-2)" "unprognostic (1.11e-2)" "unprognostic (5.46e-3)" "unprognostic (9.73e-3)" "unprognostic (1.33e-2)" "unprognostic (2.50e-1)" "prognostic unfavourable (9.94e-6)" "unprognostic (1.60e-1)" "unprognostic (5.33e-2)" "unprognostic (4.02e-2)" "unprognostic (5.94e-3)" 2.3 0.5 0.9 13.5 2.1 17.8 1.3 1.2 1.1 1.4 4.4 0.7 0.7 2.9 1.5 1.6 1.4 1.2 2.9 1.0 0.8 1.4 1.9 3.2 7.3 24.3 1.0 0.5 1.0 0.5 0.0 0.6 1.3 0.7 2.0 1.8 1.7 3.3 0.4 1.4 0.6 9.8 0.8 0.9 28.6 2.7 0.9 0.5 129.5 1.8 0.9 18.1 3.5 1.4 1.5 0.4 1.4 0.2 33.4 62.8 31.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 47.8 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 50.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 1.0 0.1 0.0 62.8 0.2 35.4 1.5 32.4 36.7 0.2 0.5 41.3 33.5 1.4 33.4 0.1 0.4 39.0 31.4 0.9 2.1 1.2 1.1 0.8 1.4 1.0 0.5 0.7 0.5 CD248 "CD164L1, TEM1" ENSG00000174807 "CD248 molecule" Q9HCU0 11 66314487-66317044 "CD markers, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 71.0" "Cell line enhanced" "Detected in some" "ASC diff: 66.6;ASC TERT1: 65.7;BJ hTERT+: 43.3;fHDF/TERT166: 58.0;HSkMC: 70.0;U-2197: 104.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 6 "naive CD8 T-cell: 17.8" "Lineage enriched" "Detected in single" 122 "T-cells: 17.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA051856 Enhanced Approved "Nucleoplasm,Plasma membrane" 27000000 "Plasma membrane" Nucleoplasm "HPA051856: " "unprognostic (2.26e-1)" "unprognostic (1.72e-1)" "unprognostic (8.95e-2)" "unprognostic (2.77e-2)" "unprognostic (1.14e-2)" "unprognostic (2.61e-1)" "unprognostic (7.21e-3)" "unprognostic (1.36e-2)" "unprognostic (1.01e-1)" "unprognostic (2.82e-2)" "unprognostic (6.31e-2)" "unprognostic (4.77e-2)" "prognostic unfavourable (2.69e-7)" "unprognostic (1.90e-2)" "unprognostic (2.92e-2)" "unprognostic (1.25e-1)" "unprognostic (1.30e-2)" 59.2 3.5 0.8 14.4 2.5 0.0 55.2 0.6 2.2 21.2 7.6 1.9 6.3 2.7 14.1 22.9 14.8 17.7 12.3 18.2 1.2 0.5 5.3 1.7 9.3 16.2 1.3 1.6 15.6 4.9 1.4 2.3 71.0 2.1 10.6 2.7 11.5 4.6 8.0 6.7 13.3 7.5 27.6 1.2 1.9 7.5 8.0 0.7 4.1 9.4 6.6 4.5 19.5 17.6 0.1 0.0 0.0 0.0 0.0 17.8 1.9 0.0 0.0 0.6 0.0 66.6 65.7 0.0 28.8 43.3 2.1 2.0 0.0 0.0 0.0 0.7 58.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.4 13.2 0.0 0.0 70.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.3 0.1 1.2 0.0 0.0 0.0 0.0 0.3 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 104.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.8 0.0 0.0 2.3 0.0 0.1 2.8 17.8 0.0 0.0 0.0 0.0 0.0 1.9 0.8 2.5 0.6 2.2 1.2 0.5 1.3 1.6 2.1 0.7 CD27 "S152, TNFRSF7, Tp55" ENSG00000139193 "CD27 molecule" P26842 12 6444867-6451718 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins" Apoptosis Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 82.3;lymphoid tissue: 60.4" "Group enriched" "Detected in some" 141 "Daudi: 63.7;U-698: 35.3" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "T-reg: 82.3" "Group enriched" "Detected in many" 7 "B-cells: 41.8;T-cells: 82.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002420, HPA038936" Enhanced 28000 "CAB002420: AB_563539, HPA038936: " "unprognostic (2.75e-3)" "prognostic favourable (3.77e-5)" "unprognostic (8.87e-3)" "prognostic favourable (2.90e-4)" "unprognostic (2.35e-1)" "prognostic favourable (6.65e-7)" "unprognostic (3.56e-2)" "unprognostic (9.37e-2)" "prognostic favourable (5.50e-4)" "unprognostic (1.31e-3)" "unprognostic (4.32e-2)" "unprognostic (2.74e-1)" "prognostic unfavourable (1.19e-6)" "unprognostic (2.80e-1)" "unprognostic (3.15e-1)" "unprognostic (1.28e-1)" "unprognostic (7.35e-2)" 1.1 0.6 0.4 40.8 0.5 2.0 1.2 0.4 0.4 1.7 10.0 0.2 0.5 5.3 0.8 0.6 4.9 1.6 3.7 0.9 0.4 0.4 1.7 1.0 2.9 49.5 0.4 0.1 1.0 0.5 0.0 0.6 0.4 0.2 1.3 2.9 1.2 10.7 1.4 0.4 0.6 19.4 0.2 0.6 45.7 3.7 0.5 0.1 33.5 3.1 2.3 60.4 9.1 1.2 41.8 0.3 0.8 0.1 8.3 82.3 22.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 63.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.3 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 35.3 0.0 0.0 0.0 0.8 0.1 0.1 16.7 0.1 28.7 41.8 40.1 37.5 0.1 10.5 55.6 39.1 0.8 8.3 0.1 0.3 82.3 22.1 0.4 0.5 0.4 0.4 0.4 0.4 0.4 0.1 0.2 0.1 CD274 "B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1" ENSG00000120217 "CD274 molecule" Q9NZQ7 9 5450503-5470566 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lung: 23.9;placenta: 56.0" "Cell line enhanced" "Detected in many" "HDLM-2: 33.4;HHSteC: 22.3;U-251 MG: 37.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 8.4" "Group enriched" "Detected in many" 6 "granulocytes: 8.4;T-cells: 2.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB076385 Enhanced "CAB076385: AB_2687655" "prognostic favourable (8.89e-4)" "unprognostic (4.54e-2)" "prognostic favourable (1.64e-5)" "unprognostic (1.27e-2)" "unprognostic (2.96e-2)" "unprognostic (1.08e-1)" "unprognostic (4.61e-2)" "unprognostic (1.44e-1)" "unprognostic (1.68e-2)" "unprognostic (5.67e-4)" "unprognostic (7.39e-3)" "unprognostic (1.69e-2)" "unprognostic (1.24e-2)" "unprognostic (1.35e-1)" "unprognostic (1.49e-2)" "unprognostic (2.67e-1)" "unprognostic (9.02e-2)" 3.4 2.1 1.7 10.8 3.2 1.4 2.2 2.5 3.3 2.0 2.3 2.5 2.8 2.6 1.7 2.4 3.0 1.9 4.3 9.5 1.4 3.7 3.0 3.6 23.9 6.4 2.3 0.7 1.7 2.7 3.8 7.4 56.0 3.2 2.9 2.2 3.3 1.7 1.6 4.3 1.3 2.7 2.3 2.4 12.8 1.9 1.2 1.0 11.6 3.7 2.1 5.8 3.1 1.9 0.9 0.0 8.4 0.1 0.4 2.4 0.7 5.8 0.1 0.0 0.2 0.0 0.0 0.0 11.7 9.9 3.0 4.1 0.0 1.9 0.0 0.2 0.3 0.2 0.0 5.0 9.7 33.4 0.0 3.3 0.1 0.0 22.3 0.0 0.0 0.2 0.0 6.1 9.1 5.7 0.0 1.1 9.0 0.0 0.1 0.0 0.0 0.1 0.0 1.6 0.3 0.6 0.1 0.0 0.1 0.1 0.9 0.7 0.0 0.1 10.7 6.3 2.0 0.1 37.0 0.2 0.1 0.1 2.1 0.1 0.0 8.4 0.1 0.3 1.2 0.1 2.1 0.9 2.4 1.8 0.0 0.2 1.3 0.7 5.7 0.4 0.0 0.0 1.1 0.7 1.7 3.2 2.5 3.3 1.4 3.7 2.3 0.7 3.2 1.0 CD276 "B7-H3, B7H3, B7RP-2" ENSG00000103855 "CD276 molecule" Q5ZPR3 15 73683966-73714518 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-2197: 54.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 4 "neutrophil: 4.0" "Lineage enriched" "Detected in single" 5 "granulocytes: 4.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009285, HPA017139, CAB017826" Enhanced Approved Vesicles 8900000 Vesicles "CAB017826: , HPA009285: AB_1078258, HPA017139: AB_1845246" "unprognostic (1.05e-1)" "unprognostic (4.74e-3)" "unprognostic (4.57e-3)" "unprognostic (9.62e-2)" "unprognostic (1.26e-2)" "unprognostic (5.50e-3)" "prognostic unfavourable (9.81e-4)" "unprognostic (2.57e-3)" "unprognostic (1.89e-1)" "unprognostic (3.75e-2)" "unprognostic (1.54e-2)" "unprognostic (3.29e-2)" "prognostic unfavourable (6.31e-5)" "unprognostic (1.17e-1)" "unprognostic (9.22e-2)" "unprognostic (1.21e-1)" "unprognostic (1.34e-3)" 32.3 16.6 5.8 9.2 3.9 0.6 17.1 3.6 5.3 19.4 8.3 5.1 4.2 8.8 17.2 17.9 6.3 8.1 14.3 12.3 5.6 3.6 7.2 22.9 9.3 6.7 4.6 3.8 16.8 14.3 3.5 5.3 27.7 7.9 16.5 4.2 20.5 12.8 7.8 7.1 12.6 7.0 13.8 4.4 7.4 8.4 9.9 3.9 1.2 7.8 8.3 4.7 12.4 13.6 0.4 0.5 4.0 0.6 0.8 0.2 0.0 9.7 12.1 8.3 18.1 15.2 9.2 25.3 11.4 9.4 7.5 6.8 21.2 20.4 0.1 18.6 10.8 41.6 8.8 10.1 1.2 7.4 20.1 0.7 12.6 10.2 4.6 0.1 12.1 7.3 4.9 6.8 4.4 9.8 3.1 0.2 1.7 15.0 0.1 0.5 20.1 8.8 0.1 12.2 1.6 6.5 13.5 5.7 13.8 10.5 5.2 20.5 8.7 5.3 11.4 16.6 14.9 54.4 11.5 0.2 0.2 0.2 27.5 0.8 11.4 0.9 0.3 0.5 0.1 0.6 0.2 0.2 0.1 0.2 0.2 0.4 0.2 0.1 4.0 0.8 0.3 0.5 0.1 0.0 5.8 3.9 3.6 5.2 5.6 3.6 4.6 3.8 7.9 3.9 CD28 ENSG00000178562 "CD28 molecule" P10747 2 203706475-203738912 "CD markers, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 32.7;lymphoid tissue: 48.6" "Group enriched" "Detected in some" 14 "Karpas-707: 72.1;RPMI-8226: 33.0;U-266/70: 59.3;U-266/84: 53.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "T-reg: 32.7" "Lineage enriched" "Detected in many" 6 "T-cells: 32.7" "Region enhanced" "Detected in single" "olfactory region: 1.3" "Low region specificity" "Detected in all" HPA070003 Enhanced "HPA070003: " "unprognostic (5.54e-2)" "unprognostic (2.16e-4)" "unprognostic (1.90e-3)" "unprognostic (2.49e-3)" "unprognostic (3.44e-2)" "unprognostic (6.07e-5)" "unprognostic (9.09e-2)" "unprognostic (4.66e-2)" "unprognostic (3.40e-1)" "unprognostic (1.15e-1)" "unprognostic (2.65e-1)" "unprognostic (1.68e-1)" "unprognostic (5.78e-5)" "unprognostic (4.77e-2)" "unprognostic (2.93e-2)" "unprognostic (7.79e-2)" "unprognostic (8.96e-2)" 5.1 0.6 0.4 14.2 0.5 1.9 3.3 0.3 0.4 1.1 1.6 0.4 0.2 0.6 1.1 2.3 1.5 2.1 3.0 4.5 0.4 0.5 1.7 1.5 3.8 23.3 0.5 0.2 1.4 0.6 0.0 0.6 11.0 0.2 1.2 1.3 1.2 3.1 0.8 0.7 1.0 7.2 0.9 0.8 9.0 1.6 0.9 0.0 48.6 1.5 0.8 29.9 4.5 1.4 0.1 0.0 5.1 0.2 0.0 32.7 4.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 72.1 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 33.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 59.3 53.0 0.5 0.0 0.0 0.0 0.5 0.2 0.3 3.0 0.1 18.2 0.1 19.4 9.5 0.0 0.1 17.0 6.5 5.1 0.0 0.1 0.0 32.7 4.7 0.4 0.5 0.3 0.4 0.4 0.5 0.5 0.2 0.2 0.0 CD300A "CMRF-35-H9, CMRF35H, IGSF12, IRC1, IRC2, Irp60" ENSG00000167851 "CD300a molecule" Q9UGN4 17 74466416-74484796 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 81.1;brain: 28.7;lymphoid tissue: 57.8" "Group enriched" "Detected in some" 5 "HMC-1: 41.3;NB-4: 16.8;RPMI-8226: 32.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" HPA011645 Approved "Intracellular and membrane" 2800000 "HPA011645: AB_1846988" "unprognostic (1.99e-1)" "unprognostic (4.60e-2)" "unprognostic (3.88e-2)" "unprognostic (3.30e-2)" "unprognostic (2.73e-1)" "unprognostic (2.01e-1)" "unprognostic (1.04e-2)" "unprognostic (2.63e-1)" "unprognostic (1.11e-1)" "unprognostic (1.17e-2)" "unprognostic (7.87e-2)" "unprognostic (1.07e-1)" "prognostic unfavourable (1.91e-5)" "unprognostic (5.97e-2)" "unprognostic (5.45e-3)" "unprognostic (1.36e-1)" "unprognostic (5.72e-2)" 8.6 4.5 9.8 16.0 17.7 11.9 4.4 2.2 11.5 2.0 4.8 3.7 0.0 6.0 1.9 1.3 2.1 2.1 7.7 3.4 7.3 4.2 3.0 7.5 10.6 19.0 20.1 0.3 1.5 2.1 0.3 3.0 6.9 12.6 2.8 4.7 2.3 3.0 1.3 1.1 2.3 7.4 6.0 28.7 57.8 2.4 1.5 17.4 4.1 1.9 0.5 6.0 5.4 2.1 2.2 19.4 81.1 45.7 52.1 29.5 19.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 1.9 41.3 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.5 16.8 0.0 0.0 0.0 0.0 32.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 6.3 0.0 81.1 20.4 57.3 29.5 45.7 6.2 2.2 6.1 8.7 19.4 0.6 2.3 7.1 71.6 52.1 44.2 18.1 0.3 19.2 9.8 17.7 2.2 11.5 7.3 4.2 20.1 0.3 12.6 17.4 CD300C "CMRF-35A, CMRF35, CMRF35A, IGSF16, LIR" ENSG00000167850 "CD300c molecule" Q08708 17 74541108-74546143 "CD markers, Predicted membrane proteins" Immunity Receptor "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "blood: 46.8" "Cell line enhanced" "Detected in some" "HEL: 5.2;HMC-1: 25.6;THP-1: 4.8;U-937: 12.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 4 "classical monocyte: 28.6;intermediate monocyte: 46.8;myeloid DC: 32.5;non-classical monocyte: 46.4" "Group enriched" "Detected in many" 5 "dendritic cells: 32.5;monocytes: 46.8" "HPA014523, HPA060349" Approved Uncertain "Golgi apparatus,Vesicles,Mitochondria" "Golgi apparatus" "Vesicles, Mitochondria" "HPA014523: AB_1846293, HPA060349: " "unprognostic (1.55e-2)" "unprognostic (2.60e-1)" "unprognostic (9.99e-3)" "unprognostic (3.79e-1)" "unprognostic (1.21e-1)" "unprognostic (3.47e-2)" "unprognostic (3.81e-2)" "unprognostic (2.19e-1)" "unprognostic (1.68e-2)" "unprognostic (7.51e-2)" "unprognostic (6.51e-2)" "unprognostic (1.50e-2)" "unprognostic (1.37e-3)" "unprognostic (6.27e-2)" "prognostic unfavourable (8.53e-5)" "unprognostic (1.16e-2)" "unprognostic (1.09e-1)" 9.8 2.8 3.6 9.0 4.6 10.9 1.8 0.4 2.9 1.2 1.7 2.9 0.0 1.5 1.4 1.9 1.0 1.9 2.8 3.4 2.0 1.7 1.9 2.1 11.2 12.3 5.3 1.3 1.1 1.3 0.5 1.2 3.8 3.9 1.9 1.8 1.8 1.8 0.7 1.1 0.9 2.3 4.1 7.1 14.2 1.6 0.9 2.7 0.1 1.6 0.1 1.4 3.5 1.1 0.4 32.5 8.4 46.8 8.6 0.1 10.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.0 0.0 0.0 2.4 25.6 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 2.6 0.0 0.1 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 4.8 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.7 12.1 0.0 8.4 28.6 1.4 0.1 46.8 0.1 0.4 0.0 0.0 32.5 0.3 0.0 0.0 1.0 8.6 46.4 2.1 0.0 10.7 3.6 4.6 0.4 2.9 2.0 1.7 5.3 1.3 3.9 2.7 CD300E "CD300LE, CLM2, IREM2" ENSG00000186407 "CD300e molecule" Q496F6 17 74609887-74623738 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Immunity Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 36.5;bone marrow: 22.5;lymphoid tissue: 21.0" "Cell line enhanced" "Detected in some" "HeLa: 1.7;SCLC-21H: 1.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 5 "classical monocyte: 22.7;intermediate monocyte: 36.5;non-classical monocyte: 36.3" "Lineage enriched" "Detected in many" 6 "monocytes: 36.5" "Low region specificity" "Detected in single" HPA015570 Uncertain "HPA015570: AB_1846294" "unprognostic (1.70e-1)" "unprognostic (6.82e-2)" "unprognostic (1.76e-1)" "unprognostic (2.63e-2)" "unprognostic (1.42e-2)" "unprognostic (2.12e-1)" "unprognostic (1.68e-2)" "unprognostic (7.80e-3)" "unprognostic (4.51e-1)" "unprognostic (1.53e-1)" "unprognostic (2.69e-2)" "unprognostic (5.15e-2)" "unprognostic (4.19e-7)" "unprognostic (1.90e-2)" "unprognostic (2.00e-4)" "unprognostic (7.38e-3)" "unprognostic (1.19e-1)" 8.5 0.7 0.5 21.0 0.6 22.5 0.7 1.2 1.0 0.5 1.2 0.3 0.0 0.0 0.7 3.0 0.9 1.5 1.9 2.0 0.5 0.5 2.5 1.1 14.3 9.4 0.5 0.2 1.0 0.8 0.0 0.5 1.7 0.7 0.6 0.2 1.1 0.6 1.6 1.6 0.6 0.7 5.3 0.9 14.3 0.8 0.7 0.3 0.2 1.2 0.8 0.8 1.8 0.6 0.0 5.9 0.5 36.5 0.0 0.0 11.6 0.2 0.0 1.1 0.1 0.0 0.1 0.2 0.2 0.2 0.0 0.1 1.1 0.0 0.5 0.2 0.3 0.2 0.0 0.1 0.0 0.1 0.1 0.0 1.7 0.8 0.0 0.9 0.3 0.1 0.3 0.0 0.0 0.0 0.2 0.5 0.0 0.9 0.2 0.8 0.5 0.4 0.2 0.0 0.2 0.1 0.6 1.5 0.5 0.3 0.0 0.1 0.6 0.0 0.0 0.5 0.7 0.7 0.2 0.9 0.0 0.1 0.0 0.6 0.5 0.0 22.7 0.1 0.0 36.5 0.0 0.0 0.0 0.0 5.9 0.0 0.0 0.0 0.5 0.0 36.3 0.1 0.0 11.6 0.5 0.6 1.2 1.0 0.5 0.5 0.5 0.2 0.7 0.3 CD300LB "CLM7, TREM5" ENSG00000178789 "CD300 molecule like family member b" A8K4G0 17 74521174-74531474 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Immunity Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "adipose tissue: 20.7;blood: 30.7;bone marrow: 8.8;lymphoid tissue: 10.9" "Group enriched" "Detected in some" 6 "HL-60: 4.5;NB-4: 5.9;THP-1: 4.6;U-937: 2.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in many" "eosinophil: 30.7" "Group enriched" "Detected in many" 52 "dendritic cells: 10.5;granulocytes: 30.7;monocytes: 13.0" "unprognostic (1.39e-1)" "unprognostic (2.44e-2)" "unprognostic (1.37e-1)" "unprognostic (4.39e-2)" "unprognostic (3.59e-2)" "unprognostic (1.15e-1)" "unprognostic (6.41e-2)" "unprognostic (7.69e-2)" "unprognostic (2.05e-1)" "unprognostic (2.95e-2)" "unprognostic (6.24e-2)" "unprognostic (3.32e-1)" "unprognostic (2.49e-4)" "unprognostic (2.92e-2)" "unprognostic (1.79e-2)" "unprognostic (7.08e-2)" "unprognostic (4.01e-2)" 20.7 0.9 0.2 10.9 0.5 8.8 2.0 0.4 0.5 0.6 0.8 0.3 0.1 0.7 0.7 1.0 1.1 1.2 2.8 1.6 1.5 0.4 1.2 1.0 4.4 6.5 1.2 0.1 2.0 2.3 0.0 0.7 1.1 1.0 0.8 1.1 1.6 1.2 0.1 0.3 0.4 2.0 2.2 0.6 6.6 0.7 0.7 0.1 0.9 0.6 0.1 2.2 2.6 0.7 0.0 10.5 30.7 13.0 0.3 0.1 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.4 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.7 2.7 0.0 0.6 13.0 30.7 0.0 5.6 0.1 0.0 0.0 0.0 10.5 0.0 0.0 0.1 13.8 0.3 0.7 6.6 0.0 4.2 0.2 0.5 0.4 0.5 1.5 0.4 1.2 0.1 1.0 0.1 CD300LD "CD300D, CMRF35A4" ENSG00000204345 "CD300 molecule like family member d" Q6UXZ3 17 74579365-74592283 "CD markers, Predicted membrane proteins" Immunity Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 8.5;bone marrow: 3.2" "Cell line enhanced" "Detected in some" "HMC-1: 4.4;RPMI-8226: 2.7" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 7 "neutrophil: 8.5" "Lineage enriched" "Detected in many" 7 "granulocytes: 8.5" HPA027756 Uncertain "HPA027756: AB_10601097" "unprognostic (8.03e-2)" "unprognostic (3.30e-1)" 0.3 0.2 0.1 2.2 0.1 3.2 0.2 0.2 0.3 0.4 0.2 0.0 0.2 0.0 0.2 0.4 0.3 0.3 0.1 0.1 0.1 0.2 0.9 0.7 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 1.1 0.0 0.1 1.6 0.9 0.1 0.1 1.4 0.2 1.7 0.1 0.6 0.4 0.1 0.5 0.7 8.5 0.7 0.8 1.3 0.2 0.4 0.3 0.5 1.0 0.6 0.0 0.3 0.0 0.0 0.0 0.1 0.3 0.4 0.5 0.3 0.5 0.5 0.3 0.5 0.0 0.5 0.2 0.2 1.5 0.7 0.0 1.1 4.4 0.6 0.4 0.3 0.5 0.0 0.5 1.7 0.2 1.4 0.2 0.6 0.5 0.6 0.4 0.6 2.7 0.5 0.8 0.5 0.5 0.7 0.4 0.0 0.6 0.1 0.5 0.6 0.5 1.1 0.0 0.8 0.3 0.6 0.2 0.3 0.3 0.8 0.4 0.4 0.4 0.7 0.2 0.3 0.3 0.2 0.7 0.5 0.5 0.4 8.5 0.8 0.4 0.5 1.3 0.2 CD300LF "CD300f, CLM1, IGSF13, IREM1, NKIR" ENSG00000186074 "CD300 molecule like family member f" Q8TDQ1 17 74694311-74712978 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Immunity Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 47.8;bone marrow: 18.2;lung: 24.1;lymphoid tissue: 29.1" "Group enriched" "Detected in some" 6 "THP-1: 15.6;U-937: 30.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "eosinophil: 47.8" "Group enriched" "Detected in many" 46 "dendritic cells: 13.5;granulocytes: 47.8;monocytes: 38.1" HPA013712 Supported "HPA013712: " "unprognostic (6.51e-2)" "unprognostic (1.49e-3)" "unprognostic (3.81e-2)" "unprognostic (4.00e-2)" "unprognostic (8.51e-2)" "unprognostic (6.74e-2)" "unprognostic (1.79e-1)" "unprognostic (3.17e-3)" "unprognostic (1.53e-2)" "unprognostic (1.77e-1)" "unprognostic (9.81e-2)" "unprognostic (2.41e-1)" "unprognostic (1.95e-1)" "unprognostic (9.60e-2)" "unprognostic (4.14e-2)" "unprognostic (7.75e-2)" "unprognostic (4.79e-2)" 3.3 1.0 1.2 9.8 3.1 18.2 0.9 1.5 1.3 0.8 2.3 3.1 0.0 2.7 0.7 0.7 0.9 1.1 1.9 2.4 1.3 1.2 1.1 1.5 24.1 15.6 3.8 0.5 0.9 0.9 0.0 1.0 2.1 2.6 1.4 2.6 0.8 1.9 0.3 0.5 0.5 3.4 2.3 5.8 29.1 1.0 0.7 2.4 1.1 0.8 0.0 4.2 2.8 0.8 0.0 13.5 47.8 38.1 0.7 0.1 8.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.6 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.6 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 30.2 0.0 8.4 20.2 47.8 0.0 34.4 0.1 0.0 0.0 0.0 13.5 0.0 0.0 0.0 15.9 0.7 38.1 1.4 0.0 8.2 1.2 3.1 1.5 1.3 1.3 1.2 3.8 0.5 2.6 2.4 CD300LG "CLM9, Trem4" ENSG00000161649 "CD300 molecule like family member g" Q6UXG3 17 43847148-43863629 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Immunity Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 76.1;breast: 45.4" "Cell line enhanced" "Detected in some" "BEWO: 2.0;NB-4: 1.1" "Low cancer specificity" "Detected in single" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 2.4" "Low lineage specificity" "Detected in many" 870000 "unprognostic (2.38e-2)" "unprognostic (2.06e-3)" "unprognostic (2.63e-1)" "unprognostic (2.72e-1)" "unprognostic (3.18e-1)" "unprognostic (2.73e-1)" "unprognostic (1.40e-4)" "unprognostic (1.77e-1)" "unprognostic (1.33e-1)" "unprognostic (2.01e-2)" "unprognostic (4.08e-3)" "unprognostic (8.69e-4)" "unprognostic (2.12e-5)" "unprognostic (1.30e-3)" "unprognostic (1.45e-1)" "unprognostic (1.76e-2)" "unprognostic (1.57e-1)" 76.1 0.9 0.1 2.8 0.2 0.0 45.4 0.1 0.5 2.2 6.1 0.1 1.2 0.0 1.7 5.4 1.5 1.8 1.7 10.5 0.1 0.0 1.9 1.4 4.6 0.5 0.1 0.2 0.8 1.1 0.2 0.1 25.2 0.2 2.6 0.1 1.4 1.7 0.8 8.2 3.1 0.9 0.3 0.1 1.1 1.0 16.0 0.1 2.1 1.2 1.7 0.2 1.5 7.8 0.5 1.6 2.4 0.2 0.6 0.2 0.1 0.1 0.0 0.1 0.3 0.0 0.0 2.0 0.3 0.0 0.6 0.2 0.0 0.2 0.0 1.0 0.0 0.1 0.0 0.4 0.3 0.4 0.0 0.5 1.0 0.4 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.1 0.0 1.1 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.3 0.7 0.0 0.1 0.2 0.2 0.1 0.0 0.2 0.6 0.4 0.3 0.1 0.6 0.3 0.4 0.1 0.1 2.4 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.2 1.6 0.5 0.2 0.2 1.2 0.6 0.1 0.4 0.1 0.1 0.1 0.2 0.1 0.4 0.1 0.0 0.1 0.2 0.2 0.1 CD302 "BIMLEC, CLEC13A, DCL-1, KIAA0022" ENSG00000241399 "CD302 molecule" Q8IX05 2 159768630-159798255 "CD markers, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 113.8" "Cell line enriched" "Detected in many" 5 "ASC diff: 76.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 190 "dendritic cells: 17.0;granulocytes: 19.1;monocytes: 20.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" 16000 "unprognostic (2.52e-1)" "unprognostic (5.44e-2)" "unprognostic (1.19e-2)" "unprognostic (1.50e-1)" "unprognostic (2.03e-1)" "unprognostic (6.88e-2)" "unprognostic (1.68e-2)" "unprognostic (9.12e-3)" "unprognostic (5.29e-3)" "unprognostic (2.37e-2)" "unprognostic (4.38e-2)" "unprognostic (2.14e-1)" "unprognostic (4.67e-3)" "unprognostic (1.75e-2)" "unprognostic (6.61e-2)" "unprognostic (7.45e-2)" "unprognostic (3.61e-3)" 27.1 9.4 5.0 6.1 5.9 10.1 28.6 3.3 4.3 13.8 13.8 4.0 2.6 8.7 11.4 11.0 7.9 9.7 11.7 13.7 5.6 3.3 9.3 113.8 22.9 23.3 5.9 2.7 16.3 9.0 4.7 4.0 7.0 6.3 11.5 7.7 13.7 7.7 7.8 6.1 4.9 13.9 12.1 8.7 18.9 8.5 9.2 5.9 0.7 26.6 6.3 3.4 12.4 23.8 0.0 17.0 19.1 20.8 0.0 0.0 7.5 0.0 0.5 0.4 0.0 76.1 15.9 0.0 1.9 7.6 2.2 3.3 0.6 0.7 0.1 0.8 4.0 0.0 1.6 0.8 3.1 0.5 2.6 2.9 0.5 1.1 3.8 5.7 2.1 12.6 0.4 2.4 0.0 5.6 0.2 2.7 2.8 0.2 0.0 4.1 0.7 2.3 0.0 0.6 0.0 0.4 0.1 0.9 1.0 0.6 1.8 1.7 1.5 5.5 1.9 4.4 0.0 0.1 1.2 0.3 0.0 0.0 3.0 0.5 0.9 6.2 20.8 19.1 0.0 16.4 0.0 0.0 0.0 0.0 17.0 0.0 0.0 0.0 19.1 0.0 15.6 4.5 0.0 7.5 5.0 5.9 3.3 4.3 5.6 3.3 5.9 2.7 6.3 5.9 CD320 "8D6, 8D6A" ENSG00000167775 "CD320 molecule" Q9NPF0 19 8302127-8308356 "CD markers, Disease related genes, Predicted membrane proteins" "Growth factor" "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NB-4: 74.9;RPMI-8226: 68.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA014500, HPA073489" Approved Approved Cytosol 400000 Cytosol "HPA014500: AB_1846295, HPA073489: " "unprognostic (9.97e-2)" "unprognostic (2.62e-1)" "unprognostic (3.51e-1)" "unprognostic (2.54e-3)" "unprognostic (2.17e-1)" "unprognostic (2.39e-2)" "prognostic unfavourable (4.02e-4)" "unprognostic (4.19e-2)" "unprognostic (7.13e-2)" "unprognostic (1.31e-1)" "unprognostic (9.35e-3)" "unprognostic (1.25e-1)" "unprognostic (2.03e-1)" "unprognostic (1.07e-1)" "unprognostic (8.92e-2)" "unprognostic (3.14e-1)" "unprognostic (9.90e-2)" 23.1 20.1 13.1 13.4 14.9 6.3 39.0 12.6 19.1 12.0 23.2 9.7 10.5 16.6 15.8 58.1 11.4 14.9 28.9 20.7 13.2 18.7 15.2 16.3 15.1 18.0 18.0 8.5 14.0 27.6 7.6 11.9 38.0 19.9 19.7 14.2 18.6 16.5 12.8 14.0 6.4 17.4 11.9 11.9 32.8 21.3 23.7 9.3 14.3 22.4 9.3 8.6 12.1 19.6 10.3 25.0 0.8 0.6 18.0 51.3 15.0 12.7 13.0 2.9 37.3 9.4 4.9 6.8 6.6 9.0 13.4 10.3 13.9 7.7 11.5 21.0 4.9 8.2 0.0 10.6 2.6 16.1 39.9 5.5 11.2 19.8 6.3 10.5 13.9 4.7 2.5 7.8 6.5 13.1 16.8 39.6 5.2 12.0 11.1 74.9 20.4 54.5 13.7 3.9 68.0 10.0 0.3 27.0 11.7 13.8 5.9 16.8 0.4 4.7 7.3 15.4 11.4 23.0 21.0 37.7 23.6 12.5 11.0 38.6 16.7 0.0 0.6 0.0 51.3 0.6 29.2 10.3 34.0 27.4 1.1 9.9 23.1 26.0 0.8 18.0 0.4 25.0 21.7 15.0 13.1 14.9 12.6 19.1 13.2 18.7 18.0 8.5 19.9 9.3 CD33 "FLJ00391, p67, SIGLEC-3, SIGLEC3" ENSG00000105383 "CD33 molecule" P20138 19 51225064-51243860 "CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins" "Cell adhesion" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 49.3;lymphoid tissue: 45.4" "Cell line enhanced" "Detected in some" "HEL: 27.9;HL-60: 37.1;HMC-1: 27.8;NB-4: 17.7;RPMI-8226: 20.0;THP-1: 21.8;U-937: 27.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 7 "classical monocyte: 37.6;intermediate monocyte: 27.3;myeloid DC: 49.3;non-classical monocyte: 12.6" "Group enriched" "Detected in many" 9 "dendritic cells: 49.3;monocytes: 37.6" "CAB011442, HPA035832, HPA064807" Approved Supported "Nucleoplasm,Plasma membrane" 1400000 "Nucleoplasm, Plasma membrane" "CAB011442: , HPA035832: , HPA064807: " "unprognostic (1.18e-2)" "unprognostic (1.45e-2)" "unprognostic (2.80e-2)" "unprognostic (7.14e-2)" "unprognostic (3.71e-1)" "unprognostic (9.43e-2)" "unprognostic (2.59e-1)" "unprognostic (5.90e-3)" "unprognostic (1.76e-1)" "unprognostic (1.56e-1)" "unprognostic (2.53e-1)" "unprognostic (6.28e-2)" "unprognostic (6.88e-4)" "unprognostic (7.79e-2)" "unprognostic (3.35e-2)" "unprognostic (6.49e-2)" "unprognostic (1.67e-1)" 10.2 4.3 3.6 8.4 6.0 23.0 6.5 0.8 3.5 2.6 2.7 4.4 0.3 2.5 2.3 5.2 1.7 3.9 5.3 7.5 3.1 2.5 4.1 6.4 11.6 45.4 6.4 1.8 1.9 1.9 0.5 1.7 5.4 5.2 2.6 3.4 2.6 2.9 2.1 1.2 2.5 4.0 5.6 9.9 31.6 2.8 1.5 5.8 2.5 1.7 0.2 2.7 4.7 2.3 0.1 49.3 4.6 37.6 3.3 0.2 14.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 1.7 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 27.9 0.1 0.0 0.0 37.1 27.8 0.0 0.0 0.0 0.0 0.0 5.1 7.0 0.0 0.0 0.0 17.7 0.0 8.5 0.0 1.4 20.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 21.8 0.2 4.8 0.4 0.6 0.0 0.1 2.4 0.0 3.2 27.4 0.1 3.3 37.6 2.3 0.0 27.3 0.1 0.0 0.0 0.1 49.3 0.1 0.0 0.0 4.6 3.3 12.6 1.4 0.2 14.7 3.6 6.0 0.8 3.5 3.1 2.5 6.4 1.8 5.2 5.8 CD34 ENSG00000174059 "CD34 molecule" P28906 1 207880972-207911402 "CD markers, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in some" 6 "HUVEC TERT2: 31.8;MOLT-4: 31.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000018, HPA036722, HPA036723" Enhanced Approved "Nucleoplasm,Plasma membrane,Cell Junctions" 69000000 "Plasma membrane, Cell Junctions" Nucleoplasm "CAB000018: AB_2063006, HPA036722: , HPA036723: " "unprognostic (3.82e-1)" "unprognostic (1.67e-1)" "unprognostic (1.04e-1)" "unprognostic (3.09e-1)" "unprognostic (1.24e-1)" "prognostic favourable (5.93e-5)" "unprognostic (1.25e-2)" "unprognostic (7.74e-2)" "unprognostic (7.65e-2)" "unprognostic (3.53e-1)" "unprognostic (1.37e-3)" "unprognostic (6.95e-2)" "prognostic unfavourable (8.47e-4)" "unprognostic (1.51e-2)" "unprognostic (1.30e-1)" "unprognostic (1.60e-1)" "unprognostic (1.01e-2)" 61.9 8.8 4.6 12.8 7.6 1.9 37.5 3.1 6.7 38.3 15.9 5.2 20.5 5.0 41.4 40.3 33.8 22.3 20.6 51.2 5.4 4.9 18.8 2.2 25.0 11.9 8.1 6.7 20.7 8.6 7.8 3.6 78.9 6.3 21.0 7.4 12.8 12.4 20.5 39.7 21.2 12.1 42.3 4.7 9.2 11.3 23.1 4.7 3.5 25.8 35.9 11.0 33.6 33.1 0.6 1.7 1.6 0.3 0.6 0.5 1.5 0.0 0.0 0.0 0.0 1.6 0.1 0.1 0.2 1.1 0.3 0.9 0.0 0.0 0.0 3.1 0.3 0.0 0.0 0.0 0.3 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 31.8 0.0 0.0 0.8 0.0 31.4 0.1 0.2 0.0 0.0 1.8 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.0 1.1 0.0 4.8 0.1 1.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 1.6 0.2 0.3 0.5 0.2 0.5 0.3 0.3 0.2 0.2 0.6 0.3 0.3 1.1 0.6 0.3 1.7 0.2 1.5 4.6 7.6 3.1 6.7 5.4 4.9 8.1 6.7 6.3 4.7 CD36 "FAT, GP3B, GP4, GPIV, SCARB3" ENSG00000135218 "CD36 molecule" P16671 7 80369575-80679277 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Cell adhesion, Transport" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 464.3;breast: 156.1" "Group enriched" "Detected in some" 5 "ASC diff: 80.8;HEL: 38.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 4 "classical monocyte: 104.4;intermediate monocyte: 30.4;myeloid DC: 56.9" "Group enriched" "Detected in many" 45 "dendritic cells: 56.9;monocytes: 104.4" "Low region specificity" "Detected in many" "HPA002018, CAB025866, HPA071026" Enhanced Enhanced "Golgi apparatus" 92000000 "Golgi apparatus" "CAB025866: , HPA002018: AB_1078464, HPA071026: " "unprognostic (7.16e-2)" "unprognostic (1.80e-2)" "unprognostic (1.06e-3)" "unprognostic (6.52e-2)" "unprognostic (2.05e-1)" "unprognostic (1.28e-1)" "unprognostic (2.63e-1)" "unprognostic (9.35e-2)" "unprognostic (2.64e-2)" "unprognostic (1.97e-1)" "unprognostic (1.23e-3)" "unprognostic (1.18e-1)" "unprognostic (1.84e-3)" "prognostic unfavourable (4.47e-4)" "unprognostic (7.05e-3)" "unprognostic (4.87e-2)" "unprognostic (2.73e-3)" 464.3 3.6 1.2 8.9 1.3 10.9 156.1 0.5 0.5 1.8 31.8 0.6 3.3 9.8 1.8 7.5 7.5 3.3 7.2 76.8 1.8 1.9 2.2 13.3 11.5 4.8 0.6 0.3 2.5 3.9 3.1 0.8 37.9 2.9 9.2 3.5 0.8 4.6 2.3 23.6 5.4 23.4 4.7 0.8 42.8 5.0 6.0 0.5 2.7 13.6 15.3 1.4 9.4 19.2 0.3 56.9 1.8 104.4 0.7 0.2 60.2 0.0 0.0 0.2 0.1 80.8 0.8 0.1 0.2 2.7 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 1.0 0.1 0.0 0.1 0.1 38.4 0.1 6.1 0.0 0.0 0.0 7.8 3.1 0.0 0.0 0.2 1.3 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.2 0.3 0.2 0.1 0.0 2.7 4.4 0.0 0.1 0.5 0.1 0.0 0.0 0.1 0.1 0.0 13.2 10.2 0.9 104.4 0.3 0.2 30.4 0.2 0.3 0.0 0.0 56.9 0.0 0.1 0.0 1.8 0.7 7.5 14.3 0.1 60.2 1.2 1.3 0.5 0.5 1.8 1.9 0.6 0.3 2.9 0.5 CD37 TSPAN26 ENSG00000104894 "CD37 molecule" P11049 19 49335171-49343335 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 163.4;lymphoid tissue: 109.6" "Cell line enhanced" "Detected in some" "Daudi: 65.7;HMC-1: 65.1;RPMI-8226: 23.4;THP-1: 23.4;U-937: 17.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002492, HPA032120, HPA032121" Enhanced "CAB002492: AB_563554, HPA032120: AB_2674162, HPA032121: AB_2674163" "unprognostic (4.30e-3)" "unprognostic (2.39e-3)" "unprognostic (8.85e-2)" "prognostic favourable (4.51e-4)" "unprognostic (5.46e-2)" "unprognostic (4.59e-3)" "unprognostic (1.76e-1)" "unprognostic (6.23e-2)" "unprognostic (5.34e-2)" "unprognostic (2.23e-1)" "unprognostic (1.22e-1)" "unprognostic (3.06e-1)" "unprognostic (2.45e-3)" "unprognostic (7.12e-2)" "unprognostic (3.35e-2)" "unprognostic (7.22e-2)" "unprognostic (7.71e-2)" 7.3 3.1 3.4 62.9 4.8 48.7 3.7 1.0 3.1 1.9 4.2 8.5 0.0 3.2 2.0 2.2 5.9 2.9 5.2 10.4 3.8 3.8 4.3 2.7 25.3 109.6 6.9 1.7 2.5 1.6 0.5 1.9 5.4 4.7 3.5 1.7 2.7 10.7 1.4 1.1 2.0 39.3 1.7 14.5 88.1 5.1 2.9 5.0 47.9 3.4 1.7 86.8 10.2 2.4 163.4 53.7 84.4 62.8 27.9 43.5 58.8 0.0 0.1 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 65.7 0.0 0.0 0.1 0.0 0.0 0.0 10.4 0.0 11.5 0.0 0.1 0.0 1.9 65.1 0.0 0.0 0.0 0.0 0.0 0.6 3.6 0.0 0.0 0.1 1.2 0.0 0.0 0.6 0.0 23.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.4 0.1 0.0 0.2 0.0 0.0 0.0 0.0 14.5 0.0 17.4 0.0 42.8 58.2 71.7 34.3 53.4 34.7 137.2 41.8 36.4 41.1 163.4 43.5 36.3 84.4 27.9 62.8 53.7 40.9 58.8 3.4 4.8 1.0 3.1 3.8 3.8 6.9 1.7 4.7 5.0 CD38 ENSG00000004468 "CD38 molecule" P28907 4 15778275-15853230 "Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins" "Hydrolase, Receptor, Transferase" "Cancer-related genes, Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "lymphoid tissue: 94.9;seminal vesicle: 104.1" "Cell line enhanced" "Detected in some" "Daudi: 49.8;Karpas-707: 13.9;MOLT-4: 12.6;REH: 10.0;U-266/70: 10.8;U-698: 9.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "NK-cell: 15.3" "Group enriched" "Detected in all" 4 "B-cells: 9.0;dendritic cells: 5.1;NK-cells: 15.3" "Low region specificity" "Detected in all" "CAB002493, HPA022132, CAB025255, HPA052381" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB002493: AB_563556, CAB025255: , HPA022132: AB_1846300, HPA052381: AB_2681807" "unprognostic (1.27e-2)" "unprognostic (8.06e-3)" "unprognostic (1.06e-2)" "prognostic favourable (9.68e-4)" "unprognostic (1.13e-1)" "unprognostic (1.82e-3)" "unprognostic (2.74e-1)" "unprognostic (8.51e-2)" "unprognostic (5.87e-2)" "unprognostic (6.15e-6)" "unprognostic (5.23e-1)" "unprognostic (4.34e-1)" "unprognostic (6.63e-6)" "unprognostic (1.79e-1)" "unprognostic (5.74e-2)" "unprognostic (2.12e-2)" "unprognostic (2.13e-1)" 4.1 3.3 3.8 17.6 8.5 9.3 2.6 0.7 12.0 1.0 3.2 10.4 14.6 4.3 0.7 0.9 2.3 2.4 1.5 5.0 4.0 4.2 1.2 5.4 4.7 16.1 4.9 3.1 0.6 0.7 0.0 2.5 0.6 3.1 10.8 2.7 4.4 2.8 104.1 14.2 0.5 6.2 0.9 1.8 20.6 2.0 0.7 2.5 94.9 2.8 2.0 13.2 7.6 0.9 9.0 5.1 1.3 2.2 15.3 2.3 3.7 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 49.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 13.9 0.0 0.0 12.6 3.0 0.0 0.0 10.0 0.0 7.8 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.0 2.2 0.2 0.0 0.0 0.0 0.0 10.8 0.1 9.4 0.1 2.4 0.1 0.0 1.7 0.0 1.1 2.2 0.3 9.0 1.4 1.2 4.1 6.6 2.3 1.8 1.3 15.3 1.4 5.1 2.1 3.7 3.8 8.5 0.7 6.2 4.0 4.2 4.9 3.1 3.1 2.5 CD3D T3D ENSG00000167286 "CD3d molecule" P04234 11 118338954-118342744 "CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "blood: 108.7;lymphoid tissue: 181.4" "Cell line enriched" "Detected in some" 5 "MOLT-4: 152.7" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 53 "gdT-cell: 105.6;MAIT T-cell: 68.6;memory CD4 T-cell: 88.1;memory CD8 T-cell: 97.6;naive CD4 T-cell: 78.8;naive CD8 T-cell: 98.6;T-reg: 108.7" "Lineage enriched" "Detected in many" 63 "T-cells: 108.7" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" CAB013055 Enhanced "CAB013055: " "prognostic favourable (3.00e-4)" "prognostic favourable (8.46e-5)" "unprognostic (1.05e-2)" "prognostic favourable (1.73e-7)" "unprognostic (6.00e-2)" "prognostic favourable (1.70e-4)" "unprognostic (3.82e-1)" "unprognostic (2.40e-2)" "unprognostic (2.24e-3)" "unprognostic (1.01e-2)" "unprognostic (5.69e-2)" "unprognostic (2.55e-1)" "prognostic unfavourable (3.07e-5)" "unprognostic (9.00e-2)" "unprognostic (2.02e-1)" "unprognostic (3.66e-2)" "prognostic favourable (6.16e-4)" 2.6 0.8 0.5 17.4 0.7 4.8 1.7 0.5 0.7 1.3 4.1 0.7 0.8 4.1 1.2 1.6 3.2 1.9 2.9 1.0 0.7 0.4 2.6 1.9 6.1 40.8 0.9 0.5 1.0 1.2 0.0 0.7 0.8 0.7 2.2 4.3 1.1 9.0 0.8 0.7 1.3 19.3 1.0 1.5 28.6 4.4 0.8 0.5 181.4 2.7 2.8 32.6 5.7 2.4 0.5 0.3 1.7 0.3 0.2 108.7 64.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 5.8 0.0 0.0 0.0 152.7 28.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.5 0.3 0.2 105.6 0.2 68.6 0.5 88.1 97.6 0.3 0.2 78.8 98.6 1.7 0.2 0.3 0.3 108.7 64.9 0.5 0.7 0.5 0.7 0.7 0.4 0.9 0.5 0.7 0.5 CD3E ENSG00000198851 "CD3e molecule" P07766 11 118304545-118316175 "CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 294.2" "Cell line enriched" "Detected in some" 77 "MOLT-4: 118.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 36 "gdT-cell: 59.5;MAIT T-cell: 50.2;memory CD4 T-cell: 50.7;memory CD8 T-cell: 55.7;naive CD4 T-cell: 61.3;naive CD8 T-cell: 62.0;NK-cell: 21.8;T-reg: 46.8" "Group enriched" "Detected in many" 29 "NK-cells: 21.8;T-cells: 62.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB000010, HPA040957, HPA043955, CAB072863, CAB072864" Enhanced "CAB000010: AB_2631163, CAB072863: , CAB072864: , HPA040957: AB_2677222, HPA043955: AB_2678747" "prognostic favourable (1.72e-4)" "prognostic favourable (1.62e-4)" "unprognostic (1.51e-2)" "prognostic favourable (2.30e-6)" "unprognostic (4.31e-2)" "prognostic favourable (1.32e-4)" "unprognostic (3.60e-3)" "unprognostic (3.85e-2)" "prognostic favourable (1.18e-4)" "unprognostic (6.11e-3)" "unprognostic (1.59e-1)" "unprognostic (3.59e-1)" "prognostic unfavourable (1.12e-5)" "unprognostic (5.46e-2)" "unprognostic (9.28e-2)" "unprognostic (3.13e-2)" "unprognostic (1.12e-2)" 3.9 1.0 0.5 16.7 0.7 6.8 1.9 0.5 0.7 2.1 4.7 0.9 0.7 4.4 2.0 1.4 3.3 3.0 4.0 1.4 0.5 0.5 3.3 2.6 7.3 40.9 1.3 0.6 1.5 1.3 0.0 0.9 1.2 0.9 2.6 3.9 1.9 6.4 1.1 0.8 1.3 21.1 1.1 1.9 34.5 4.6 1.2 0.5 294.2 3.4 2.1 37.8 6.3 3.0 0.2 0.9 1.4 0.2 21.8 62.0 32.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 118.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.2 1.5 0.0 0.1 0.0 1.3 0.2 0.2 59.5 0.1 50.2 0.1 50.7 55.7 0.1 0.2 61.3 62.0 1.4 21.8 0.2 0.9 46.8 32.9 0.5 0.7 0.5 0.7 0.5 0.5 1.3 0.6 0.9 0.5 CD3G ENSG00000160654 "CD3g molecule" P09693 11 118344344-118355161 "CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 187.6" "Cell line enriched" "Detected in single" 78 "MOLT-4: 64.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 30 "gdT-cell: 43.5;MAIT T-cell: 25.6;memory CD4 T-cell: 36.1;memory CD8 T-cell: 37.1;naive CD4 T-cell: 37.6;naive CD8 T-cell: 46.7;T-reg: 34.2" "Lineage enriched" "Detected in many" 37 "T-cells: 46.7" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB017520, HPA038494" Enhanced Supported "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "CAB017520: AB_831094, HPA038494: " "prognostic favourable (6.33e-4)" "prognostic favourable (2.61e-4)" "unprognostic (4.58e-3)" "unprognostic (3.12e-5)" "unprognostic (6.30e-2)" "prognostic favourable (3.00e-4)" "unprognostic (1.98e-2)" "unprognostic (1.54e-2)" "unprognostic (8.25e-3)" "unprognostic (1.08e-3)" "unprognostic (1.54e-2)" "unprognostic (2.19e-1)" "prognostic unfavourable (9.33e-5)" "unprognostic (1.60e-1)" "unprognostic (2.37e-2)" "unprognostic (4.13e-2)" "unprognostic (2.10e-3)" 1.1 0.6 0.4 7.1 0.4 0.5 0.8 0.3 0.3 0.7 2.3 0.4 0.4 2.0 0.9 0.6 1.5 1.1 1.9 0.6 0.4 0.4 1.2 0.9 2.4 17.2 0.5 0.2 0.7 0.7 0.0 0.5 0.4 0.3 1.0 1.6 0.9 2.9 0.3 5.9 0.6 8.1 0.2 0.8 11.5 2.4 0.5 0.2 187.6 1.4 1.7 19.2 2.5 1.1 0.1 0.2 1.2 0.2 0.2 46.7 14.1 0.0 0.1 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.8 0.2 0.0 0.2 64.9 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.0 0.6 0.2 0.2 43.5 0.1 25.6 0.1 36.1 37.1 0.1 0.1 37.6 46.7 1.2 0.2 0.1 0.2 34.2 14.1 0.4 0.4 0.3 0.3 0.4 0.4 0.5 0.2 0.3 0.2 CD4 ENSG00000010610 "CD4 molecule" P01730 12 6786858-6820808 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity" "Host cell receptor for virus entry, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 111.5;parathyroid gland: 78.4" "Group enriched" "Detected in some" 6 "HEL: 33.5;HL-60: 13.5;NB-4: 19.3;THP-1: 38.1;U-937: 35.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 17 "classical monocyte: 42.2;intermediate monocyte: 42.5;memory CD4 T-cell: 29.1;myeloid DC: 29.3;naive CD4 T-cell: 24.8;non-classical monocyte: 33.3;plasmacytoid DC: 46.7;T-reg: 26.4" "Group enriched" "Detected in many" 20 "dendritic cells: 46.7;monocytes: 42.5;T-cells: 29.1" "Region enriched" "Detected in single" 15 "basal ganglia: 41.4" "Low region specificity" "Detected in many" "CAB000011, HPA004252, HPA004472, CAB068180" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB000011: AB_442062, CAB068180: , HPA004252: AB_1078466, HPA004472: AB_1078465" "unprognostic (1.39e-2)" "unprognostic (1.12e-2)" "unprognostic (2.75e-2)" "prognostic favourable (2.16e-4)" "unprognostic (7.76e-2)" "unprognostic (4.82e-3)" "unprognostic (3.70e-2)" "unprognostic (2.74e-2)" "unprognostic (7.04e-2)" "unprognostic (2.40e-1)" "unprognostic (1.13e-1)" "unprognostic (1.92e-1)" "prognostic unfavourable (7.45e-4)" "unprognostic (1.06e-1)" "unprognostic (4.65e-3)" "unprognostic (9.08e-3)" "unprognostic (2.95e-1)" 13.8 5.4 6.1 16.0 5.8 4.4 5.6 1.2 4.3 4.5 5.1 8.6 1.8 3.6 3.5 8.3 3.0 5.5 7.3 5.4 4.9 4.4 6.1 32.2 24.0 30.8 6.3 3.1 3.0 3.1 78.4 3.4 10.9 6.2 4.1 6.5 5.7 5.4 3.9 1.9 3.5 9.5 5.2 10.2 49.1 3.9 2.8 5.7 111.5 3.9 4.1 18.6 8.6 3.2 0.1 46.7 1.9 42.5 0.3 29.1 33.6 0.0 0.0 1.2 0.0 0.0 0.0 0.1 0.0 0.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 33.5 0.0 0.2 3.7 13.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 19.3 0.3 0.0 0.0 0.0 4.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 38.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 35.9 0.0 0.1 42.2 0.3 0.3 42.5 1.1 0.0 29.1 0.1 29.3 0.1 24.8 0.1 1.9 0.3 33.3 46.7 26.4 33.6 6.1 5.8 1.2 4.3 4.9 4.4 6.3 3.1 6.2 5.7 CD40 "Bp50, p50, TNFRSF5" ENSG00000101017 "CD40 molecule" P25942 20 46118272-46129863 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Immunity Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 26.7;EFO-21: 46.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "memory B-cell: 36.1;naive B-cell: 41.3" "Group enriched" "Detected in many" 6 "B-cells: 41.3;monocytes: 10.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB002495, HPA031567, HPA031568, CAB072868" Enhanced "Secreted to blood" 16000 "CAB002495: AB_563562, CAB072868: , HPA031567: AB_2673936, HPA031568: AB_2673937" "unprognostic (6.41e-2)" "unprognostic (1.55e-2)" "unprognostic (7.08e-3)" "unprognostic (6.21e-2)" "unprognostic (4.23e-3)" "unprognostic (1.25e-1)" "unprognostic (7.64e-3)" "unprognostic (1.34e-1)" "unprognostic (4.15e-2)" "unprognostic (7.16e-2)" "unprognostic (2.48e-2)" "unprognostic (7.04e-2)" "prognostic unfavourable (4.48e-4)" "unprognostic (1.22e-1)" "unprognostic (4.95e-2)" "unprognostic (1.60e-2)" "unprognostic (2.28e-2)" 13.0 4.6 3.6 38.6 4.7 1.1 11.6 9.7 4.4 11.3 9.2 3.6 7.8 6.5 9.6 8.6 9.9 9.7 8.6 9.5 4.5 2.6 10.0 10.0 18.8 34.7 3.3 3.2 14.8 14.0 12.1 5.9 6.5 5.4 14.7 5.2 13.7 13.0 11.6 7.5 9.0 11.8 10.0 4.6 30.1 8.4 4.4 4.4 11.5 16.5 6.7 46.0 12.5 13.8 41.3 4.1 1.0 10.8 0.6 1.4 4.8 9.0 1.4 0.0 4.5 1.7 0.9 1.8 1.6 0.5 1.3 1.3 0.0 26.7 14.5 46.9 0.3 1.1 0.8 5.7 1.4 9.7 0.0 3.4 0.0 2.5 13.4 0.0 4.6 6.0 2.2 5.5 0.0 10.1 1.1 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.3 0.3 1.5 11.8 0.1 0.0 0.0 7.9 4.5 0.0 0.9 4.8 0.0 0.0 15.0 0.0 0.0 0.0 0.0 9.9 3.4 1.7 0.0 1.0 7.7 0.1 1.3 10.8 0.9 36.1 0.7 0.5 4.1 41.3 1.4 1.0 0.7 0.6 7.5 2.1 1.0 4.8 3.6 4.7 9.7 4.4 4.5 2.6 3.3 3.2 5.4 4.4 CD40LG "CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP" ENSG00000102245 "CD40 ligand" P29965 X 136648193-136660390 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Cytokine "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 29.2;intestine: 8.7;lymphoid tissue: 33.7" "Cell line enriched" "Detected in single" 72 "MOLT-4: 22.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "gdT-cell: 9.4;MAIT T-cell: 22.9;memory CD4 T-cell: 29.2;naive CD4 T-cell: 28.1" "Lineage enriched" "Detected in single" 58 "T-cells: 29.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA045827 Enhanced "Secreted to blood" 433000 "HPA045827: AB_10959606" "unprognostic (1.94e-5)" "unprognostic (1.24e-2)" "unprognostic (3.26e-1)" "unprognostic (1.27e-3)" "unprognostic (4.71e-2)" "unprognostic (3.56e-5)" "unprognostic (3.66e-2)" "unprognostic (5.48e-3)" "unprognostic (2.77e-1)" "unprognostic (2.14e-4)" "unprognostic (1.87e-1)" "unprognostic (1.55e-1)" "unprognostic (6.70e-4)" "unprognostic (2.15e-1)" "unprognostic (5.19e-2)" "unprognostic (2.36e-3)" "unprognostic (2.92e-2)" 2.0 0.5 0.3 22.4 0.3 1.4 1.2 0.3 0.3 2.0 3.3 0.1 0.0 1.7 1.5 1.3 1.6 1.6 2.6 1.1 0.4 0.4 1.6 1.1 4.0 14.6 0.4 0.0 0.7 0.6 0.0 0.4 0.2 0.3 1.0 3.1 1.0 4.9 1.3 0.4 1.1 8.7 0.5 0.6 9.9 1.7 0.6 0.1 33.7 1.4 2.0 26.1 3.0 1.4 0.0 0.0 0.5 0.0 0.2 29.2 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 9.4 0.0 22.9 0.0 29.2 4.1 0.0 0.0 28.1 0.2 0.5 0.2 0.0 0.0 3.3 4.7 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.0 0.3 0.1 CD44 "CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1" ENSG00000026508 "CD44 molecule (Indian blood group)" P16070 11 35138870-35232402 "Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cell adhesion" "Blood group antigen, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000112, CAB000316, HPA005785" Enhanced Enhanced "Golgi apparatus,Plasma membrane" "Secreted - unknown location" 2400000000 "Plasma membrane" "Golgi apparatus" "CAB000112: , CAB000316: AB_2076596, HPA005785: AB_1078467" "unprognostic (5.33e-2)" "unprognostic (1.85e-1)" "unprognostic (4.97e-2)" "unprognostic (9.90e-3)" "unprognostic (3.50e-3)" "unprognostic (1.46e-2)" "unprognostic (1.56e-2)" "unprognostic (8.12e-2)" "unprognostic (1.57e-1)" "unprognostic (4.18e-2)" "unprognostic (1.51e-3)" "unprognostic (4.63e-2)" "prognostic unfavourable (1.78e-8)" "unprognostic (6.41e-2)" "unprognostic (4.14e-2)" "unprognostic (3.93e-2)" "unprognostic (7.98e-2)" 45.5 9.0 10.5 42.5 21.7 53.0 35.6 4.7 13.4 43.2 19.5 26.3 8.3 10.6 80.5 20.3 66.5 18.6 48.0 11.7 14.9 9.3 12.4 9.1 43.4 48.4 31.5 6.1 12.8 83.9 0.8 3.8 19.4 40.7 30.1 24.5 30.2 148.2 22.4 15.9 107.7 18.9 44.5 100.5 30.9 19.9 7.2 20.3 17.9 20.6 53.9 53.7 55.0 54.2 22.7 41.0 19.1 65.2 54.6 53.1 59.9 41.5 37.6 0.3 0.1 22.7 62.8 0.1 81.5 63.8 45.4 25.3 2.5 13.1 0.0 10.9 115.5 71.7 0.8 88.6 62.4 8.9 0.4 1.5 18.5 0.0 22.4 21.1 97.8 28.3 70.0 61.1 49.6 15.9 0.3 13.6 43.5 0.2 1.9 13.9 0.8 11.1 0.1 7.7 0.6 66.5 12.0 0.1 0.1 15.4 0.4 36.9 2.2 1.2 45.6 56.6 10.2 69.4 83.7 23.6 25.4 0.2 85.9 11.9 82.2 19.1 65.2 6.0 26.2 45.7 37.0 22.7 39.8 34.9 41.0 16.2 34.5 28.7 16.4 54.6 59.3 14.2 53.1 59.9 10.5 21.7 4.7 13.4 14.9 9.3 31.5 6.1 40.7 20.3 CD46 "MCP, MGC26544, MIC10, TLX, TRA2.10" ENSG00000117335 "CD46 molecule" P15529 1 207752057-207795513 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins" "Complement pathway, Fertilization, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, Disease mutation, Hemolytic uremic syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "basophil: 41.7;eosinophil: 63.7;neutrophil: 69.8" "Lineage enriched" "Detected in all" 5 "granulocytes: 69.8" "CAB010401, HPA016903" Enhanced Uncertain "Plasma membrane" 1000000 "Plasma membrane" "CAB010401: AB_2291289, HPA016903: AB_1846309" "unprognostic (1.42e-2)" "prognostic unfavourable (8.54e-5)" "unprognostic (3.94e-2)" "unprognostic (2.14e-2)" "unprognostic (3.28e-2)" "unprognostic (6.30e-2)" "unprognostic (1.91e-2)" "unprognostic (1.82e-1)" "unprognostic (1.25e-1)" "unprognostic (2.74e-1)" "unprognostic (8.79e-2)" "unprognostic (2.50e-1)" "unprognostic (6.78e-3)" "prognostic favourable (2.38e-4)" "unprognostic (1.76e-1)" "unprognostic (8.23e-2)" "unprognostic (1.49e-2)" 38.0 78.0 13.0 22.9 20.5 18.5 57.0 12.9 17.8 27.5 35.4 25.3 64.3 32.9 39.7 32.6 43.2 30.4 25.2 20.6 16.1 15.5 50.8 57.8 43.6 25.0 21.4 13.2 27.6 47.9 86.6 32.7 119.6 29.1 47.0 28.5 26.7 68.4 60.5 18.8 18.4 39.8 25.0 21.8 26.9 33.9 16.5 20.7 20.3 25.3 21.8 30.3 37.2 27.0 7.7 8.1 69.8 14.1 7.5 13.5 14.9 26.2 14.8 13.9 6.4 44.0 43.5 21.2 19.7 28.7 13.0 17.7 14.6 69.9 4.0 20.1 19.6 35.6 10.4 27.0 19.9 20.2 14.8 8.7 16.3 26.1 28.0 19.0 30.4 37.4 40.3 19.6 15.5 36.4 18.3 17.5 20.0 12.3 9.0 16.7 15.9 14.8 6.1 22.1 24.7 53.3 52.0 14.1 9.6 24.9 56.1 32.3 44.1 16.3 31.2 14.0 12.5 29.4 22.4 23.6 28.5 12.1 20.5 12.5 13.1 41.7 13.5 63.7 9.2 14.0 12.5 7.7 11.7 10.1 8.1 6.0 13.5 11.2 69.8 7.5 14.1 4.2 10.1 14.9 13.0 20.5 12.9 17.8 16.1 15.5 21.4 13.2 29.1 20.7 CD47 "IAP, MER6, OA3" ENSG00000196776 "CD47 molecule" Q08722 3 108043094-108091862 "CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016055, HPA044659" Approved Supported "Vesicles,Plasma membrane" 2000000 "Plasma membrane" Vesicles "CAB016055: AB_627086, HPA044659: AB_2679040" "unprognostic (3.54e-2)" "unprognostic (4.74e-2)" "unprognostic (3.19e-2)" "prognostic unfavourable (2.44e-4)" "unprognostic (4.49e-2)" "unprognostic (2.14e-1)" "unprognostic (2.05e-3)" "unprognostic (8.77e-3)" "unprognostic (7.35e-2)" "unprognostic (1.53e-1)" "unprognostic (1.69e-2)" "unprognostic (2.87e-1)" "prognostic unfavourable (1.69e-4)" "unprognostic (7.37e-2)" "unprognostic (3.78e-1)" "prognostic favourable (7.29e-5)" "unprognostic (1.83e-1)" 16.2 24.3 23.0 28.8 46.5 58.0 29.0 44.0 55.5 20.5 25.7 42.5 13.4 19.8 16.2 30.4 46.7 31.7 26.0 26.7 24.1 24.4 19.1 22.1 49.6 35.1 27.4 28.8 16.2 25.7 11.5 34.8 23.3 43.6 40.2 29.0 15.7 43.8 18.9 18.1 19.3 21.2 21.0 37.7 29.0 33.4 20.6 25.0 34.4 30.1 22.0 42.5 25.1 29.1 40.1 35.6 44.1 64.4 45.1 65.3 51.7 45.4 8.2 16.4 9.3 23.6 25.4 21.7 17.2 26.9 13.4 22.9 0.4 25.7 20.9 27.9 16.5 31.2 9.1 17.3 17.5 12.3 6.3 53.1 7.6 0.7 13.7 37.8 71.8 16.3 10.6 12.8 10.3 13.2 12.5 49.6 19.9 23.3 45.9 14.2 6.8 20.9 24.5 12.1 29.5 34.0 18.1 12.5 7.8 10.2 20.4 17.4 36.9 12.4 12.7 34.7 6.4 19.4 11.6 19.2 13.0 29.3 25.3 19.0 9.5 31.7 24.7 44.1 40.2 48.1 35.0 40.1 47.0 42.0 35.6 39.2 35.4 38.3 30.1 45.1 64.4 27.7 65.3 51.7 23.0 46.5 44.0 55.5 24.1 24.4 27.4 28.8 43.6 25.0 CD48 "BCM1, BLAST, hCD48, mCD48, SLAMF2" ENSG00000117091 "CD48 molecule" P09326 1 160678746-160711851 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 81.3;lymphoid tissue: 86.3" "Cell line enhanced" "Detected in some" "Daudi: 38.0;HMC-1: 42.5;U-266/70: 90.0;U-266/84: 60.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB002497, HPA055146" Enhanced Supported "Nucleoli fibrillar center,Plasma membrane,Cytosol" "Intracellular and membrane" 2600000 "Plasma membrane" "Nucleoli fibrillar center, Cytosol" "CAB002497: AB_563586, HPA055146: " "prognostic favourable (3.91e-4)" "unprognostic (1.72e-3)" "prognostic favourable (4.17e-4)" "unprognostic (1.58e-3)" "unprognostic (2.36e-1)" "unprognostic (1.71e-3)" "unprognostic (2.09e-2)" "unprognostic (2.19e-2)" "unprognostic (1.92e-1)" "unprognostic (3.02e-2)" "unprognostic (1.38e-1)" "unprognostic (1.65e-1)" "prognostic unfavourable (3.36e-4)" "unprognostic (3.21e-1)" "unprognostic (4.69e-2)" "unprognostic (9.38e-2)" "unprognostic (8.51e-2)" 5.5 1.4 1.0 44.6 0.9 23.1 2.8 0.6 0.7 3.2 5.0 0.5 1.1 3.2 1.9 2.5 7.3 2.1 4.8 1.8 1.0 1.0 3.6 3.1 15.4 86.3 1.6 0.3 2.3 1.5 0.0 1.3 2.2 0.8 2.8 5.7 2.4 13.9 1.5 1.3 1.2 21.2 1.7 3.8 66.6 5.0 1.3 0.2 50.8 2.9 3.6 58.0 8.6 2.6 34.6 53.6 35.8 74.1 24.9 57.9 81.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 38.0 0.0 0.0 0.1 0.0 0.0 0.0 1.0 0.0 0.3 0.0 0.0 0.0 4.5 42.5 0.0 0.0 0.0 0.0 0.0 0.0 13.9 0.0 0.0 13.2 6.5 0.0 0.0 0.8 0.0 5.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 90.0 60.1 15.4 0.0 11.4 0.0 28.2 52.2 35.8 42.4 74.1 57.9 34.6 48.3 48.8 53.6 27.9 49.7 52.5 13.4 24.9 73.5 9.4 36.4 81.3 1.0 0.9 0.6 0.7 1.0 1.0 1.6 0.3 0.8 0.2 CD5 "LEU1, T1" ENSG00000110448 "CD5 molecule" P06127 11 61102395-61127852 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 36.3;lymphoid tissue: 96.2" "Cell line enriched" "Detected in single" 99 "MOLT-4: 38.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 20 "gdT-cell: 12.9;MAIT T-cell: 9.3;memory CD4 T-cell: 31.2;memory CD8 T-cell: 20.6;naive CD4 T-cell: 25.9;naive CD8 T-cell: 19.5;T-reg: 36.3" "Lineage enriched" "Detected in many" 32 "T-cells: 36.3" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB015392, CAB020308, HPA043416, HPA060839" Enhanced "CAB015392: AB_2075324, CAB020308: , HPA043416: , HPA060839: " "prognostic favourable (4.05e-4)" "prognostic favourable (9.16e-5)" "unprognostic (2.33e-1)" "prognostic favourable (9.00e-5)" "unprognostic (1.02e-2)" "prognostic favourable (7.41e-6)" "unprognostic (2.45e-3)" "unprognostic (1.37e-2)" "prognostic favourable (3.93e-4)" "unprognostic (1.25e-2)" "unprognostic (5.00e-2)" "unprognostic (2.14e-1)" "prognostic unfavourable (8.94e-5)" "unprognostic (4.78e-2)" "unprognostic (1.02e-2)" "unprognostic (2.38e-1)" "unprognostic (1.06e-1)" 2.1 0.6 0.5 19.4 0.4 6.5 1.3 0.3 0.6 1.6 2.5 0.3 0.3 1.7 1.1 1.7 1.9 1.4 3.9 0.8 0.6 1.3 1.9 1.1 7.1 28.8 0.4 0.1 1.1 0.9 0.0 0.8 0.4 0.3 1.4 1.5 1.6 15.5 1.3 0.6 1.3 10.2 0.4 0.7 13.8 4.8 1.3 0.1 96.2 1.7 2.4 42.2 5.4 1.5 1.1 1.1 0.4 0.7 0.1 36.3 14.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 38.4 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 12.9 0.1 9.3 0.4 31.2 20.6 0.9 1.1 25.9 19.5 0.4 0.1 0.7 1.1 36.3 14.6 0.5 0.4 0.3 0.6 0.6 1.3 0.4 0.1 0.3 0.1 CD52 "CDW52, EDDM5, HE5" ENSG00000169442 "CD52 molecule" P31358 1 26317957-26320523 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 495.7;epididymis: 978.9" "Group enriched" "Detected in some" 9 "Daudi: 74.4;REH: 108.7;U-266/84: 108.6;U-698: 120.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "prognostic favourable (1.85e-5)" "unprognostic (3.28e-3)" "unprognostic (1.93e-2)" "prognostic favourable (2.06e-4)" "unprognostic (4.18e-2)" "prognostic favourable (4.45e-4)" "unprognostic (9.11e-2)" "unprognostic (2.98e-2)" "unprognostic (7.73e-3)" "unprognostic (6.27e-2)" "unprognostic (4.58e-1)" "unprognostic (1.70e-1)" "prognostic unfavourable (5.85e-4)" "unprognostic (3.64e-1)" "unprognostic (6.14e-2)" "unprognostic (7.95e-2)" "unprognostic (1.26e-1)" 9.5 0.9 0.8 23.0 1.4 5.7 4.7 0.3 0.8 0.9 3.7 0.3 93.2 1.0 1.1 978.9 2.9 1.5 2.2 1.5 0.6 0.2 3.5 3.2 43.4 54.6 0.8 0.6 0.8 1.0 0.0 0.7 0.7 0.7 1.7 2.5 1.3 5.7 2.9 0.4 1.9 39.6 1.1 1.2 98.7 2.7 5.3 0.4 24.7 3.2 2.1 30.4 4.3 1.7 292.0 87.6 258.4 194.6 94.3 308.1 495.7 0.2 0.0 0.0 0.0 0.0 0.1 1.5 0.0 0.1 0.0 0.0 0.0 0.0 74.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.1 0.0 0.7 11.6 0.0 0.0 0.0 0.0 0.0 2.4 0.1 0.0 0.4 0.8 6.6 0.3 0.0 108.7 0.1 1.6 0.0 0.0 0.2 1.0 0.0 0.1 0.1 0.0 1.3 0.1 0.0 0.2 0.0 0.1 0.3 108.6 120.3 0.0 1.8 0.0 12.4 126.8 258.4 194.7 194.6 155.1 292.0 244.1 190.3 87.6 273.7 166.6 171.2 9.6 94.3 167.6 28.6 308.1 495.7 0.8 1.4 0.3 0.8 0.6 0.2 0.8 0.6 0.7 0.4 CD53 "MOX44, TSPAN25" ENSG00000143119 "CD53 molecule" P19397 1 110873154-110899928 "CD markers, Predicted membrane proteins, Transporters" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 146.7;lymphoid tissue: 103.0" "Cell line enhanced" "Detected in some" "Daudi: 85.8;HDLM-2: 36.9;HMC-1: 54.0;Karpas-707: 33.7;U-266/70: 46.6;U-698: 26.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA047216 Enhanced "HPA047216: " "unprognostic (2.93e-2)" "unprognostic (1.25e-2)" "unprognostic (7.45e-3)" "unprognostic (1.02e-3)" "unprognostic (8.88e-2)" "unprognostic (3.78e-2)" "unprognostic (2.96e-1)" "unprognostic (6.07e-2)" "unprognostic (2.83e-2)" "unprognostic (2.03e-1)" "unprognostic (5.09e-2)" "unprognostic (1.62e-1)" "prognostic unfavourable (2.60e-4)" "unprognostic (9.58e-2)" "unprognostic (4.95e-2)" "unprognostic (1.33e-1)" "unprognostic (7.72e-2)" 29.7 8.1 6.1 50.6 10.3 20.4 6.6 1.6 5.8 4.5 9.6 7.6 1.2 6.7 4.3 6.0 5.5 9.9 11.0 6.4 6.4 5.9 9.6 8.8 28.9 93.8 13.3 2.7 4.7 3.8 0.8 3.1 10.6 8.5 5.2 10.5 4.5 10.1 2.3 2.3 2.2 35.2 10.0 14.9 103.0 7.5 4.8 10.0 37.2 4.6 4.1 82.1 15.2 4.0 97.5 74.6 138.0 97.0 59.2 91.8 146.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 85.8 0.0 0.0 0.0 0.0 0.0 0.0 36.9 0.0 4.5 0.0 0.0 0.0 10.3 54.0 0.0 0.0 0.0 0.0 0.0 1.9 33.7 0.0 0.0 17.4 12.2 0.0 0.0 16.9 0.1 17.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.4 3.0 0.0 0.0 0.0 0.0 46.6 21.1 26.6 0.2 11.9 0.6 138.0 87.0 54.1 91.8 93.3 82.8 97.5 67.5 80.8 74.6 83.3 49.2 70.8 136.2 59.2 97.0 61.4 85.0 146.7 6.1 10.3 1.6 5.8 6.4 5.9 13.3 2.7 8.5 10.0 CD55 "CR, CROM, DAF, TC" ENSG00000196352 "CD55 molecule (Cromer blood group)" P08174 1 207321376-207386804 "Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Complement pathway, Host-virus interaction, Immunity, Innate immunity" "Blood group antigen, Host cell receptor for virus entry, Receptor" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HeLa: 77.5;HMC-1: 103.6;PC-3: 61.7;U-2197: 62.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 101.4" "Low lineage specificity" "Detected in all" "HPA002190, CAB010454, HPA024386" Enhanced "Secreted to blood" 32300000 310000000 "CAB010454: AB_2075970, HPA002190: AB_1078472, HPA024386: AB_1846319" "unprognostic (4.08e-2)" "unprognostic (3.22e-1)" "unprognostic (3.41e-1)" "unprognostic (1.63e-1)" "unprognostic (9.05e-2)" "unprognostic (1.08e-2)" "unprognostic (1.05e-1)" "unprognostic (1.22e-1)" "unprognostic (1.06e-1)" "unprognostic (3.57e-2)" "unprognostic (1.55e-2)" "unprognostic (1.86e-1)" "prognostic unfavourable (9.36e-4)" "unprognostic (3.41e-2)" "unprognostic (2.04e-1)" "unprognostic (9.70e-2)" "unprognostic (2.33e-2)" 21.8 63.2 5.8 27.2 20.2 31.9 17.9 4.6 10.5 34.0 14.8 13.8 7.8 12.8 16.3 11.9 36.1 10.4 18.0 32.0 7.5 10.1 9.6 16.7 114.6 41.1 16.7 4.7 31.3 9.1 8.1 12.8 107.0 11.9 9.7 12.4 8.2 82.3 12.8 108.8 37.5 26.0 23.5 11.4 30.4 17.7 10.2 18.8 4.2 13.2 31.4 19.1 39.3 19.1 18.6 18.3 101.4 31.6 19.0 16.9 20.3 4.7 6.5 0.0 2.1 8.3 8.9 33.9 9.0 15.8 5.2 5.6 20.4 6.8 9.2 7.5 5.3 2.7 10.4 2.0 4.8 4.2 3.8 11.9 77.5 3.3 27.0 7.2 103.6 4.2 24.4 6.4 28.1 26.8 12.8 4.4 2.9 5.1 0.7 5.0 6.6 61.7 1.0 6.4 7.2 8.6 4.5 2.6 0.0 48.7 9.9 7.8 8.4 6.1 11.7 2.6 5.0 62.8 3.4 3.7 4.3 6.2 7.1 2.9 11.9 39.3 26.9 35.9 5.5 26.3 8.2 16.9 7.4 5.8 18.3 18.6 16.9 16.4 101.4 19.0 31.6 9.8 5.0 20.3 5.8 20.2 4.6 10.5 7.5 10.1 16.7 4.7 11.9 18.8 CD58 LFA3 ENSG00000116815 "CD58 molecule" P19256 1 116514535-116571039 "CD markers, Predicted membrane proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Karpas-707: 45.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" 7100000 "unprognostic (4.48e-3)" "unprognostic (3.20e-1)" "unprognostic (2.95e-2)" "unprognostic (4.03e-2)" "unprognostic (8.45e-2)" "unprognostic (1.95e-1)" "prognostic unfavourable (2.32e-6)" "unprognostic (9.84e-2)" "unprognostic (7.17e-2)" "unprognostic (4.72e-2)" "prognostic unfavourable (5.60e-4)" "unprognostic (2.82e-1)" "unprognostic (1.66e-2)" "unprognostic (1.86e-1)" "unprognostic (3.68e-2)" "unprognostic (2.17e-2)" "unprognostic (9.66e-2)" 21.5 9.6 5.9 17.6 8.7 29.9 15.2 2.2 7.7 15.8 24.7 5.9 10.4 17.0 12.4 15.3 22.1 11.0 19.2 23.9 7.3 4.8 32.8 11.0 22.4 14.5 9.6 3.7 6.5 6.6 6.5 12.0 10.0 9.3 9.4 17.9 6.4 18.4 15.3 8.8 14.9 48.3 16.3 11.5 23.1 11.1 6.5 8.8 9.3 12.0 22.9 18.2 15.4 16.2 6.0 12.4 47.3 17.1 4.9 17.8 9.5 11.7 6.8 4.9 4.7 8.4 14.2 3.1 6.0 10.5 10.5 10.3 3.0 22.8 2.1 11.2 10.5 15.2 3.7 10.3 11.2 11.5 4.2 10.6 12.4 4.2 5.4 14.6 14.8 3.8 14.1 8.8 7.8 6.0 9.3 45.9 6.4 21.1 6.2 11.1 2.4 7.4 12.4 16.9 2.8 21.2 9.7 1.7 3.5 12.1 9.0 34.0 4.7 5.5 11.2 7.6 5.8 10.3 15.4 6.9 12.3 1.4 17.5 7.3 37.7 28.7 14.7 24.4 11.5 14.2 7.9 6.0 10.1 9.5 12.4 2.1 1.4 5.8 47.3 4.9 17.1 1.4 17.8 9.5 5.9 8.7 2.2 7.7 7.3 4.8 9.6 3.7 9.3 8.8 CD59 "16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20" ENSG00000085063 "CD59 molecule (CD59 blood group)" P13987 11 33703010-33736491 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes, Disease mutation, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 285.5" "Cell line enhanced" "Detected in many" "TIME: 213.3;U-2197: 176.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "CAB001448, HPA026494" Supported Uncertain "Golgi apparatus,Vesicles" "Intracellular and membrane" 98000000 "Golgi apparatus, Vesicles" "CAB001448: AB_563604, HPA026494: AB_1846321" "unprognostic (2.07e-2)" "prognostic unfavourable (3.81e-5)" "unprognostic (7.40e-2)" "unprognostic (1.14e-2)" "unprognostic (2.11e-2)" "prognostic unfavourable (3.10e-5)" "unprognostic (5.65e-2)" "unprognostic (1.46e-1)" "unprognostic (4.47e-2)" "unprognostic (2.98e-1)" "prognostic unfavourable (2.92e-5)" "unprognostic (1.66e-2)" "prognostic favourable (1.39e-10)" "prognostic unfavourable (9.03e-4)" "unprognostic (1.31e-1)" "unprognostic (1.03e-2)" "unprognostic (3.09e-1)" 96.7 41.0 36.7 26.3 44.3 23.8 76.0 25.9 32.7 44.8 36.9 24.0 57.9 16.5 45.4 132.8 68.4 53.2 67.6 90.5 35.6 38.4 100.0 61.0 86.4 39.8 39.7 25.8 39.3 52.3 60.6 48.0 285.5 68.7 47.4 37.7 51.4 114.8 62.6 70.6 43.4 25.0 52.4 32.9 26.2 54.7 28.1 23.1 16.1 85.9 57.7 40.0 51.2 63.4 13.5 20.5 42.8 4.8 17.7 60.4 11.1 16.5 15.5 4.6 13.5 107.8 84.5 2.7 94.2 105.1 23.6 27.7 7.2 49.8 1.2 16.8 101.4 18.7 8.5 93.9 33.2 26.3 12.9 1.7 54.9 10.8 29.4 9.9 5.7 39.2 23.8 20.0 96.4 144.0 11.6 38.3 148.6 15.1 4.6 4.1 2.5 80.9 1.7 14.4 13.3 71.3 28.3 3.2 4.3 32.8 15.2 17.3 11.6 1.0 213.3 54.3 13.0 176.7 32.6 17.0 33.2 1.6 46.7 0.0 94.3 30.5 4.8 42.8 11.3 1.6 14.4 13.5 24.0 12.7 20.5 10.6 15.7 9.3 28.4 17.7 0.9 10.5 60.4 11.1 36.7 44.3 25.9 32.7 35.6 38.4 39.7 25.8 68.7 23.1 CD6 Tp120 ENSG00000013725 "CD6 molecule" P30203 11 60971680-61020377 "CD markers, Predicted membrane proteins, Predicted secreted proteins" "Adaptive immunity, Cell adhesion, Immunity, Innate immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 23.0;lymphoid tissue: 58.1" "Cell line enriched" "Detected in some" 18 "MOLT-4: 28.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in many" 34 "gdT-cell: 12.4;MAIT T-cell: 11.1;memory CD4 T-cell: 23.0;memory CD8 T-cell: 21.4;naive CD4 T-cell: 15.5;naive CD8 T-cell: 11.1;T-reg: 10.1" "Lineage enriched" "Detected in single" 52 "T-cells: 23.0" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB002489, CAB016252" Enhanced "Secreted to blood" 5270000 110000 "CAB002489: AB_563605, CAB016252: AB_631163" "prognostic favourable (1.95e-4)" "prognostic favourable (1.57e-5)" "unprognostic (4.47e-2)" "prognostic favourable (2.41e-4)" "unprognostic (2.06e-2)" "prognostic favourable (5.10e-6)" "unprognostic (8.45e-3)" "unprognostic (8.21e-3)" "unprognostic (2.87e-3)" "unprognostic (5.32e-3)" "unprognostic (2.07e-1)" "unprognostic (5.35e-1)" "prognostic unfavourable (1.82e-4)" "unprognostic (1.77e-1)" "unprognostic (4.95e-2)" "unprognostic (6.19e-2)" "unprognostic (5.96e-2)" 1.5 0.5 0.8 26.4 0.4 5.5 0.9 0.5 1.4 1.3 3.3 0.6 0.8 2.2 1.4 1.5 1.9 1.3 5.0 1.3 0.7 1.8 1.6 1.1 6.9 25.6 1.7 0.5 0.7 0.8 0.0 0.6 0.6 0.4 1.2 1.6 1.2 7.0 0.3 0.3 0.9 13.0 0.7 0.9 18.4 3.4 0.9 0.1 58.1 1.6 1.9 42.0 3.7 1.3 0.4 0.1 0.3 0.0 0.0 23.0 5.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 28.6 0.0 0.1 0.1 0.1 0.0 0.6 0.0 0.1 0.1 0.2 0.0 0.3 0.0 0.2 0.3 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 12.4 0.0 11.1 0.4 23.0 21.4 0.1 0.4 15.5 11.1 0.3 0.0 0.0 0.0 10.1 5.1 0.8 0.4 0.5 1.4 0.7 1.8 1.7 0.5 0.4 0.1 CD63 "ME491, MLA1, TSPAN30" ENSG00000135404 "CD63 molecule" P08962 12 55725323-55729707 "CD markers, Plasma proteins, Predicted membrane proteins, Transporters" "Protein transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC diff: 272.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010088, CAB026356" Supported Supported Vesicles "Intracellular and membrane" Vesicles "CAB026356: AB_629864, HPA010088: AB_1846323" "unprognostic (8.76e-3)" "unprognostic (8.81e-2)" "unprognostic (1.27e-1)" "unprognostic (1.28e-3)" "unprognostic (9.48e-2)" "unprognostic (3.66e-3)" "prognostic unfavourable (1.37e-4)" "unprognostic (1.11e-1)" "unprognostic (6.50e-2)" "unprognostic (1.08e-1)" "unprognostic (1.66e-2)" "unprognostic (3.10e-1)" "unprognostic (2.70e-2)" "unprognostic (4.82e-2)" "unprognostic (5.21e-2)" "unprognostic (1.85e-3)" "unprognostic (9.02e-2)" 115.3 88.2 42.5 44.9 37.2 67.4 106.3 13.7 33.1 80.6 84.7 34.4 71.5 39.9 99.7 177.9 70.9 60.4 102.7 154.4 36.9 39.0 106.6 92.5 109.6 113.8 49.8 27.2 93.8 187.1 33.3 49.3 176.9 50.8 82.9 81.8 102.1 105.0 83.7 92.7 38.5 72.4 88.2 43.6 107.7 74.8 52.1 30.5 17.6 108.1 50.7 47.4 96.3 82.2 9.6 40.3 147.4 50.8 58.4 29.8 56.6 21.9 38.3 21.0 20.4 272.1 170.6 27.7 89.3 163.9 52.9 57.7 42.7 44.3 6.3 28.5 133.0 20.4 15.2 37.0 68.1 17.8 14.3 34.5 29.9 23.5 108.3 15.3 82.2 125.6 36.8 58.8 53.9 58.3 19.4 44.2 168.3 35.1 3.1 20.8 19.1 44.5 6.9 46.1 15.8 89.5 74.8 8.2 21.0 24.5 18.5 160.6 26.1 51.2 43.3 34.2 25.0 47.2 29.9 18.1 11.2 4.4 98.1 9.9 62.5 89.6 50.8 147.4 29.8 38.5 21.8 9.6 11.9 23.7 40.3 6.5 5.3 18.1 55.7 58.4 26.1 27.0 10.0 56.6 42.5 37.2 13.7 33.1 36.9 39.0 49.8 27.2 50.8 30.5 CD68 "DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1" ENSG00000129226 "CD68 molecule" P34810 17 7579467-7582113 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 179.1;lymphoid tissue: 139.1" "Cell line enhanced" "Detected in many" "ASC diff: 73.3;U-87 MG: 115.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 155.1;intermediate monocyte: 179.1;non-classical monocyte: 170.1" "Group enriched" "Detected in many" 11 "dendritic cells: 68.4;monocytes: 179.1" "Low region specificity" "Detected in all" "CAB000051, CAB000066, HPA048982, CAB072861, CAB072862" Enhanced Supported "Golgi apparatus,Vesicles" "Golgi apparatus, Vesicles" "CAB000051: AB_2314148, CAB000066: AB_2074844, CAB072861: , CAB072862: , HPA048982: " "unprognostic (2.16e-2)" "unprognostic (1.47e-2)" "unprognostic (6.46e-2)" "unprognostic (1.49e-3)" "unprognostic (1.78e-2)" "unprognostic (1.97e-1)" "unprognostic (4.75e-4)" "unprognostic (2.83e-2)" "unprognostic (1.31e-1)" "unprognostic (6.85e-2)" "unprognostic (1.04e-1)" "unprognostic (2.59e-1)" "prognostic unfavourable (1.14e-5)" "unprognostic (1.58e-1)" "unprognostic (8.91e-2)" "unprognostic (1.61e-1)" "unprognostic (1.65e-2)" 118.4 28.5 12.5 46.8 21.6 46.8 40.9 2.9 11.2 27.1 38.1 15.5 2.1 57.0 9.6 24.1 26.9 17.3 33.7 39.0 10.1 6.9 20.9 43.1 84.4 102.5 21.1 4.4 15.8 7.5 2.1 8.5 34.7 15.7 12.1 18.5 12.8 22.2 4.4 16.1 9.4 58.3 15.6 26.0 139.1 17.6 9.4 16.3 13.3 8.8 12.3 21.1 31.4 19.1 3.7 68.4 11.0 179.1 0.9 0.5 125.6 35.1 7.1 0.4 0.5 73.3 28.0 0.3 11.2 30.7 14.9 17.4 1.5 10.6 0.4 12.8 32.6 1.5 0.1 7.1 10.1 0.3 1.3 5.6 1.7 8.5 6.2 2.7 31.7 8.8 1.4 31.2 23.0 3.9 2.2 3.6 14.4 0.2 0.2 2.4 0.4 5.2 0.4 0.6 20.7 3.0 1.5 0.2 0.4 9.3 4.7 10.9 0.2 21.6 12.2 19.0 1.1 19.0 14.6 0.2 0.2 0.2 115.5 6.9 9.6 10.1 155.1 0.9 0.4 179.1 0.5 3.7 0.2 0.3 40.9 2.0 0.3 0.2 11.0 0.9 170.1 68.4 0.3 125.6 12.5 21.6 2.9 11.2 10.1 6.9 21.1 4.4 15.7 16.3 CD69 CLEC2C ENSG00000110848 "CD69 molecule" Q07108 12 9752486-9760901 "CD markers, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 52.1;lymphoid tissue: 56.4" "Cell line enhanced" "Detected in some" "HL-60: 12.4;K-562: 24.0;MOLT-4: 8.6;U-266/70: 9.8;U-698: 11.1;U-937: 41.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 4 "NK-cells: 14.8;T-cells: 18.3" "Not detected" "Not detected" "Not detected" "Not detected" "CAB002503, HPA050525" Enhanced "CAB002503: AB_563625, HPA050525: " "prognostic favourable (3.31e-5)" "unprognostic (1.84e-2)" "unprognostic (1.80e-2)" "unprognostic (1.73e-2)" "unprognostic (1.66e-1)" "unprognostic (7.10e-3)" "unprognostic (4.76e-3)" "unprognostic (9.53e-3)" "unprognostic (9.73e-3)" "unprognostic (1.64e-2)" "unprognostic (1.96e-2)" "unprognostic (1.75e-1)" "prognostic unfavourable (7.87e-5)" "unprognostic (2.88e-2)" "unprognostic (3.32e-2)" "unprognostic (4.28e-2)" "unprognostic (1.65e-1)" 10.1 2.2 1.3 19.9 1.4 52.1 7.0 0.5 0.9 9.0 9.6 4.6 0.8 2.8 5.1 5.1 10.6 6.4 13.6 3.1 2.0 2.2 4.7 6.2 27.0 31.6 4.5 0.6 3.4 1.4 0.9 3.4 1.9 3.5 7.4 8.0 3.3 6.0 2.0 1.5 3.3 14.3 5.0 8.3 43.3 4.3 4.5 1.6 56.4 5.5 6.1 26.7 27.4 5.9 3.9 0.0 3.1 0.1 14.8 18.3 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 5.1 0.0 0.0 0.6 12.4 0.5 0.0 0.0 0.0 0.0 0.2 24.0 0.0 0.0 0.0 8.6 2.5 0.0 0.0 0.0 0.0 0.0 0.3 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.8 1.1 11.1 0.0 41.1 0.0 0.7 0.1 3.1 13.7 0.0 18.3 3.3 8.7 9.9 0.0 3.9 12.6 9.2 0.2 14.8 0.0 0.0 4.3 3.8 1.3 1.4 0.5 0.9 2.0 2.2 4.5 0.6 3.5 1.6 CD7 "GP40, LEU-9, Tp40, TP41" ENSG00000173762 "CD7 molecule" P09564 17 82314868-82317602 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 54.1;lymphoid tissue: 127.6" "Group enriched" "Detected in some" 6 "Hep G2: 21.1;MOLT-4: 48.0" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "NK-cell: 54.1" "Group enriched" "Detected in many" 21 "NK-cells: 54.1;T-cells: 19.0" "CAB002594, HPA039079" Enhanced "CAB002594: , HPA039079: " "unprognostic (3.14e-3)" "prognostic favourable (5.51e-4)" "unprognostic (1.89e-2)" "prognostic favourable (2.03e-5)" "unprognostic (7.69e-3)" "unprognostic (1.09e-3)" "unprognostic (3.28e-2)" "unprognostic (1.34e-1)" "prognostic favourable (2.69e-4)" "unprognostic (3.16e-2)" "unprognostic (1.03e-1)" "unprognostic (2.24e-1)" "prognostic unfavourable (7.75e-11)" "unprognostic (4.69e-2)" "unprognostic (1.55e-1)" "unprognostic (1.97e-1)" "unprognostic (1.55e-3)" 4.7 0.7 0.5 23.4 0.4 14.5 1.7 0.4 0.3 1.9 8.0 0.3 0.5 7.7 1.8 1.9 3.4 2.4 3.5 1.4 0.5 0.6 2.8 4.1 9.5 50.2 0.9 0.0 1.6 1.0 0.0 1.0 4.0 0.4 2.7 1.0 1.8 6.0 1.1 0.5 1.0 17.5 0.5 1.6 33.0 4.6 0.9 0.1 127.6 2.2 1.0 33.3 4.6 2.2 0.1 1.7 0.6 0.1 54.1 19.0 7.1 0.0 0.0 0.0 0.0 0.0 0.1 5.5 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.2 21.1 0.2 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 48.0 0.0 0.0 0.1 0.0 0.0 0.9 0.1 0.0 0.1 0.1 0.7 0.4 0.0 0.0 0.0 0.0 0.1 0.1 0.4 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 17.6 0.0 15.1 0.1 7.9 12.8 0.0 0.0 19.0 18.9 0.6 54.1 0.1 1.7 6.8 7.1 0.5 0.4 0.4 0.3 0.5 0.6 0.9 0.0 0.4 0.1 CD70 "CD27L, CD27LG, TNFSF7" ENSG00000125726 "CD70 molecule" P32970 19 6583183-6604103 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" Cytokine "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 23.3;lymphoid tissue: 12.7" "Cell line enhanced" "Detected in many" "SiHa: 36.0;THP-1: 29.6;U-251 MG: 43.8;U-266/70: 78.0;U-266/84: 56.4" "Cancer enhanced" "Detected in many" "renal cancer: 24.7" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "memory B-cell: 13.9;T-reg: 23.3" "Group enriched" "Detected in many" 38 "B-cells: 13.9;T-cells: 23.3" HPA046582 Uncertain Nucleoplasm Nucleoplasm "HPA046582: " "unprognostic (8.71e-2)" "unprognostic (9.91e-2)" "unprognostic (1.61e-1)" "unprognostic (2.33e-4)" "unprognostic (1.73e-2)" "unprognostic (1.51e-2)" "unprognostic (1.61e-1)" "prognostic unfavourable (6.29e-4)" "unprognostic (1.36e-2)" "unprognostic (1.25e-1)" "unprognostic (1.92e-1)" "unprognostic (1.72e-1)" "prognostic unfavourable (3.22e-4)" "unprognostic (2.57e-2)" "unprognostic (1.40e-1)" "unprognostic (2.27e-1)" "unprognostic (2.08e-1)" 5.3 0.2 0.2 9.3 0.2 1.4 2.2 0.9 0.9 1.4 4.1 0.2 0.1 1.0 0.4 1.8 4.0 0.7 0.8 0.4 0.2 0.2 1.7 0.4 1.9 6.1 0.4 0.1 0.3 0.4 0.0 0.3 0.3 0.2 0.9 3.1 0.2 3.1 1.2 1.2 3.3 5.2 0.7 0.5 11.8 1.7 1.9 0.1 3.2 0.8 1.8 12.7 3.1 1.1 13.9 0.1 0.2 0.0 0.4 23.3 0.9 0.2 7.4 0.0 14.5 0.3 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.1 13.9 0.8 0.0 10.1 8.9 0.7 0.0 0.0 0.3 0.0 11.0 0.0 0.0 0.0 0.4 0.1 0.0 8.5 6.1 0.0 0.2 0.4 0.2 0.0 0.2 17.5 0.1 13.4 3.7 0.0 3.0 4.7 0.0 0.0 0.0 36.0 0.0 0.1 0.1 29.6 0.2 0.1 6.5 0.0 43.8 78.0 56.4 25.1 8.0 4.4 2.8 0.2 0.0 0.0 1.9 0.0 4.8 13.9 3.2 5.0 0.0 4.0 0.4 1.3 0.1 0.4 0.0 0.1 23.3 0.9 0.2 0.2 0.9 0.9 0.2 0.2 0.4 0.1 0.2 0.1 CD72 "CD72b, LYB2" ENSG00000137101 "CD72 molecule" P21854 9 35609533-35646810 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 13 "blood: 75.5;lymphoid tissue: 59.7" "Cell line enhanced" "Detected in some" "Daudi: 12.4;Karpas-707: 8.0;REH: 5.2;U-698: 27.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 16 "memory B-cell: 34.3;naive B-cell: 75.5" "Lineage enriched" "Detected in many" 22 "B-cells: 75.5" "Region enriched" "Detected in single" 7 "basal ganglia: 3.6" "Low region specificity" "Detected in all" "CAB002505, HPA044658" Enhanced Approved Nucleoplasm,Mitochondria "Nucleoplasm, Mitochondria" "CAB002505: AB_563629, HPA044658: " "unprognostic (1.13e-2)" "unprognostic (1.26e-2)" "unprognostic (1.21e-2)" "unprognostic (8.82e-2)" "unprognostic (1.87e-2)" "unprognostic (7.81e-2)" "unprognostic (7.11e-2)" "unprognostic (2.95e-1)" "unprognostic (3.29e-2)" "unprognostic (2.02e-2)" "unprognostic (1.95e-1)" "unprognostic (2.89e-1)" "prognostic unfavourable (2.49e-8)" "unprognostic (1.42e-1)" "unprognostic (2.32e-2)" "unprognostic (1.23e-1)" "unprognostic (3.59e-2)" 1.9 1.2 0.8 16.6 1.1 2.6 1.3 0.6 0.6 0.7 0.9 0.2 0.5 0.3 0.8 2.1 0.8 0.7 1.6 0.6 0.8 0.7 1.5 2.3 2.2 26.8 0.8 0.1 0.5 1.4 0.5 1.6 1.5 1.1 0.9 0.3 1.1 3.4 0.1 0.5 0.8 5.2 0.6 1.8 59.7 0.8 0.8 0.2 1.5 1.4 0.3 22.2 4.9 0.6 75.5 3.4 0.2 0.6 1.7 0.7 2.5 0.1 0.0 0.4 0.2 0.7 3.8 0.1 0.2 0.1 0.3 0.5 0.0 0.1 12.4 0.0 0.2 0.0 0.0 0.1 0.4 1.2 0.3 0.4 0.0 0.0 0.4 0.2 2.8 1.1 0.0 0.2 0.3 0.0 0.0 8.0 0.7 0.0 0.2 1.6 0.1 0.1 5.2 0.0 3.8 0.0 0.0 0.2 0.4 0.0 0.1 0.0 0.1 0.1 0.0 0.5 0.1 0.1 0.0 0.1 0.2 27.7 0.5 0.4 0.0 0.0 0.3 0.0 0.5 0.6 0.7 34.3 0.2 0.3 3.4 75.5 0.1 0.4 0.2 1.7 0.0 1.8 0.3 2.5 0.8 1.1 0.6 0.6 0.8 0.7 0.8 0.1 1.1 0.2 CD74 DHLAG ENSG00000019582 "CD74 molecule" P04233 5 150401637-150412929 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 504.7" "Cell line enhanced" "Detected in many" "CAPAN-2: 115.7;Daudi: 178.0;HDLM-2: 255.6;REH: 154.1;RPMI-8226: 104.9;U-266/70: 85.9;U-698: 98.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "classical monocyte: 191.6;intermediate monocyte: 303.5;memory B-cell: 467.7;myeloid DC: 437.9;naive B-cell: 504.7;non-classical monocyte: 140.0;plasmacytoid DC: 303.2" "Group enriched" "Detected in all" 5 "B-cells: 504.7;dendritic cells: 437.9;monocytes: 303.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002506, HPA010592" Enhanced Supported "Golgi apparatus" 90000 "Golgi apparatus" "CAB002506: AB_563630, HPA010592: AB_1078482" "prognostic favourable (1.06e-4)" "unprognostic (1.48e-2)" "unprognostic (4.80e-3)" "prognostic favourable (6.53e-6)" "unprognostic (1.41e-1)" "unprognostic (4.53e-2)" "unprognostic (2.05e-1)" "unprognostic (3.69e-3)" "unprognostic (1.54e-2)" "unprognostic (3.48e-2)" "unprognostic (2.20e-2)" "unprognostic (2.64e-1)" "unprognostic (5.44e-3)" "unprognostic (1.73e-1)" "unprognostic (4.95e-2)" "unprognostic (2.05e-1)" "unprognostic (4.24e-2)" 137.8 95.7 53.2 177.0 81.4 40.7 104.2 8.4 43.5 89.6 68.2 79.0 30.0 98.3 60.0 73.9 43.6 68.1 81.3 104.1 46.9 43.5 168.3 60.1 222.5 310.1 78.3 23.1 53.4 34.1 15.1 51.0 27.9 79.8 72.6 63.6 72.9 123.0 55.4 40.5 56.6 182.8 55.1 123.1 372.1 77.3 23.7 68.1 201.1 83.4 45.6 288.2 91.7 47.0 504.7 437.9 76.1 303.5 42.2 41.2 238.1 1.9 0.0 0.0 0.1 0.1 0.1 0.6 0.0 0.0 0.0 0.0 23.1 115.7 178.0 7.2 0.0 0.5 0.0 0.0 0.0 255.6 0.0 5.8 0.1 14.1 0.3 0.4 0.3 1.4 0.0 0.0 0.0 0.0 0.4 70.9 0.0 0.0 0.2 0.8 0.3 0.0 154.1 0.2 104.9 0.5 7.5 0.2 0.5 0.3 0.2 5.1 4.7 21.3 0.2 0.6 0.5 0.5 0.2 85.9 9.2 98.6 41.3 8.0 37.7 6.3 191.6 76.1 16.8 303.5 18.7 467.7 14.8 24.8 437.9 504.7 7.8 13.5 16.8 42.2 140.0 303.2 41.2 238.1 53.2 81.4 8.4 43.5 46.9 43.5 78.3 23.1 79.8 68.1 CD79A "IGA, MB-1" ENSG00000105369 "CD79a molecule" P11912 19 41877120-41881372 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 125.3;intestine: 43.5;lymphoid tissue: 119.2" "Group enriched" "Detected in some" 24 "Daudi: 155.5;REH: 48.3;U-698: 135.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 38 "memory B-cell: 106.4;naive B-cell: 125.3" "Lineage enriched" "Detected in many" 41 "B-cells: 125.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB000019 Enhanced "CAB000019: AB_2244527" "prognostic favourable (8.45e-5)" "unprognostic (1.63e-3)" "unprognostic (4.13e-3)" "unprognostic (1.31e-3)" "unprognostic (2.02e-1)" "prognostic favourable (1.18e-5)" "unprognostic (1.23e-2)" "unprognostic (8.11e-3)" "unprognostic (9.41e-3)" "unprognostic (1.12e-2)" "unprognostic (2.53e-1)" "unprognostic (2.32e-1)" "prognostic unfavourable (2.15e-5)" "unprognostic (6.08e-2)" "unprognostic (3.39e-1)" "unprognostic (1.17e-1)" "unprognostic (1.46e-1)" 1.3 0.6 0.5 103.8 0.5 5.4 1.3 0.5 0.5 1.8 6.3 0.1 0.1 4.9 0.6 0.2 4.4 1.0 2.3 0.8 0.5 0.5 2.3 0.9 4.3 114.9 0.5 0.1 0.6 0.6 0.0 0.5 0.5 0.1 1.0 3.4 1.8 13.6 1.2 0.5 0.5 43.5 0.2 0.5 108.1 9.7 0.8 0.1 32.0 2.4 1.9 119.2 6.8 1.0 125.3 3.0 0.7 0.3 0.2 2.3 4.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 155.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.1 0.9 0.0 0.0 48.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.1 0.0 0.4 0.0 0.0 0.7 0.1 135.4 0.0 4.6 0.0 0.7 0.1 0.5 0.1 0.1 0.0 106.4 0.3 0.1 0.2 125.3 0.4 2.3 0.4 0.2 0.3 3.0 0.8 4.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.1 0.1 0.1 CD79B "B29, IGB" ENSG00000007312 "CD79b molecule" P40259 17 63928740-63932354 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 138.8;lymphoid tissue: 56.6" "Cell line enhanced" "Detected in some" "Daudi: 114.9;REH: 37.8;U-698: 157.4" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "memory B-cell: 100.6;naive B-cell: 138.8" "Lineage enriched" "Detected in many" 6 "B-cells: 138.8" "Not detected" "Not detected" "Not detected" "Not detected" "HPA009178, CAB009751" Enhanced "CAB009751: AB_2275844, HPA009178: AB_1078483" "unprognostic (3.90e-3)" "unprognostic (1.61e-3)" "unprognostic (5.21e-2)" "unprognostic (3.45e-3)" "unprognostic (4.22e-3)" "prognostic favourable (2.35e-4)" "unprognostic (1.82e-1)" "unprognostic (9.25e-3)" "unprognostic (3.89e-2)" "unprognostic (1.48e-1)" "unprognostic (1.04e-1)" "unprognostic (2.87e-2)" "unprognostic (2.50e-3)" "unprognostic (1.89e-1)" "unprognostic (1.44e-1)" "unprognostic (4.28e-2)" "unprognostic (2.75e-1)" 1.7 0.7 0.4 50.6 0.4 11.1 1.2 0.3 0.4 0.6 1.7 0.3 0.3 0.7 0.6 0.5 2.6 0.6 1.4 3.4 0.4 0.2 2.3 1.7 1.3 56.6 0.4 0.3 0.6 1.6 0.0 9.0 0.5 0.3 1.0 1.3 0.8 8.9 0.9 1.2 0.9 22.4 0.5 0.4 56.0 1.8 0.6 0.3 3.7 1.4 1.7 46.6 4.5 0.9 138.8 4.2 0.5 25.0 3.4 9.2 9.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 114.9 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 6.3 0.0 0.0 0.0 2.4 0.0 0.0 37.8 0.1 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.7 0.1 0.0 0.4 0.0 0.0 5.8 5.6 157.4 0.0 0.2 0.0 0.5 1.1 0.0 4.2 16.5 4.8 100.6 5.4 2.8 4.2 138.8 3.7 2.2 0.5 3.4 25.0 0.6 9.2 9.0 0.4 0.4 0.3 0.4 0.4 0.2 0.4 0.3 0.3 0.3 CD80 "B7-1, B7.1, CD28LG, CD28LG1" ENSG00000121594 "CD80 molecule" P33681 3 119524293-119559602 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Host-virus interaction" "Host cell receptor for virus entry, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lymphoid tissue: 17.5" "Cell line enhanced" "Detected in some" "Daudi: 8.0;HDLM-2: 28.3;Karpas-707: 11.8;U-266/70: 5.1" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "memory B-cell: 4.3;non-classical monocyte: 1.1;T-reg: 3.3" "Group enriched" "Detected in many" 24 "B-cells: 4.3;monocytes: 1.1;T-cells: 3.3" "Low region specificity" "Detected in all" "CAB025368, HPA050092" Enhanced "Intracellular and membrane" "CAB025368: , HPA050092: " "unprognostic (2.36e-1)" "unprognostic (1.55e-2)" "unprognostic (5.91e-2)" "unprognostic (1.24e-1)" "unprognostic (3.14e-1)" "unprognostic (1.18e-1)" "unprognostic (1.86e-2)" "unprognostic (4.14e-3)" "unprognostic (1.02e-2)" "unprognostic (4.96e-3)" "unprognostic (1.16e-2)" "unprognostic (1.15e-1)" "unprognostic (9.03e-8)" "unprognostic (3.20e-1)" "unprognostic (3.65e-2)" "unprognostic (7.81e-3)" "unprognostic (1.94e-2)" 0.7 0.6 0.4 11.7 0.3 1.5 1.2 0.3 0.3 0.6 0.7 0.3 0.7 1.3 0.4 0.6 0.7 0.3 1.0 0.5 0.9 0.3 0.7 2.0 6.2 7.4 0.4 0.0 0.3 0.9 0.0 1.1 0.7 0.6 0.6 1.7 0.8 3.9 0.2 0.5 0.4 2.4 0.2 0.8 17.5 0.6 0.4 0.0 5.6 1.6 0.8 17.2 1.8 0.4 4.3 0.1 0.0 1.1 0.0 3.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 0.0 0.0 0.0 0.0 0.0 0.0 28.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 11.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 5.1 0.2 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 4.3 0.5 0.3 0.1 0.6 0.0 0.0 0.0 0.0 1.1 0.0 3.3 0.2 0.4 0.3 0.3 0.3 0.9 0.3 0.4 0.0 0.6 0.0 CD81 "TAPA-1, TAPA1, TSPAN28" ENSG00000110651 "CD81 molecule" P60033 11 2376177-2397419 "CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Adaptive immunity, Host-virus interaction, Immunity" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 231.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "memory B-cell: 41.4;naive B-cell: 37.6" "Lineage enriched" "Detected in all" 4 "B-cells: 41.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002507, HPA007234" Supported Supported "Plasma membrane" 1900000 "Plasma membrane" "CAB002507: AB_563639, HPA007234: AB_1846333" "unprognostic (2.96e-1)" "unprognostic (3.40e-1)" "prognostic unfavourable (7.56e-4)" "unprognostic (1.84e-2)" "prognostic unfavourable (8.21e-5)" "unprognostic (6.03e-2)" "unprognostic (1.75e-1)" "unprognostic (1.31e-1)" "unprognostic (2.09e-1)" "unprognostic (1.24e-1)" "prognostic favourable (3.86e-4)" "unprognostic (3.07e-3)" "unprognostic (2.08e-1)" "unprognostic (3.55e-2)" "unprognostic (1.67e-1)" "unprognostic (2.06e-1)" "unprognostic (2.06e-1)" 102.5 43.7 52.8 40.1 57.0 9.6 79.3 31.7 63.2 124.7 88.9 75.8 261.4 21.1 143.5 141.5 56.8 123.1 86.8 101.2 46.6 52.8 65.5 123.9 107.4 82.4 70.4 51.3 77.9 62.4 41.4 42.9 61.2 63.0 89.3 34.0 46.6 59.7 263.3 22.6 59.6 39.7 138.9 59.3 64.5 52.1 57.6 53.3 25.3 66.3 38.5 37.9 93.5 80.2 41.4 2.1 5.7 1.8 3.5 9.9 2.7 24.5 25.5 20.5 31.3 231.4 131.6 17.2 46.5 103.0 37.6 38.0 23.9 0.1 21.0 16.8 130.3 32.3 12.6 33.1 15.5 9.9 38.9 3.2 9.7 0.0 76.6 13.6 27.6 95.6 47.3 15.3 23.3 35.9 14.3 36.9 52.5 18.8 11.5 17.4 24.6 20.7 23.7 10.3 13.4 40.4 16.6 22.1 24.5 14.8 39.0 28.0 12.9 24.9 47.8 19.2 14.2 35.9 15.9 27.3 6.2 38.3 27.9 8.1 32.8 0.2 0.9 5.7 6.0 1.4 9.9 41.4 4.3 9.4 0.6 37.6 2.6 5.0 0.3 3.5 1.8 2.1 3.0 2.7 52.8 57.0 31.7 63.2 46.6 52.8 70.4 51.3 63.0 53.3 CD82 "IA4, KAI1, R2, ST6, TSPAN27" ENSG00000085117 "CD82 molecule" P27701 11 44564427-44620363 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HMC-1: 77.3;LHCN-M2: 45.7;U-87 MG: 54.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 80.5" "Group enriched" "Detected in all" 6 "B-cells: 51.1;granulocytes: 80.5;T-cells: 25.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002508, HPA028900, HPA061418" Supported Approved Vesicles Vesicles "CAB002508: AB_563640, HPA028900: AB_10603558, HPA061418: " "unprognostic (5.31e-2)" "unprognostic (4.62e-1)" "unprognostic (2.38e-2)" "unprognostic (1.33e-1)" "unprognostic (2.79e-1)" "unprognostic (1.37e-2)" "unprognostic (1.78e-1)" "unprognostic (7.29e-2)" "unprognostic (3.48e-1)" "unprognostic (2.97e-1)" "unprognostic (2.58e-2)" "unprognostic (1.58e-1)" "unprognostic (3.48e-3)" "unprognostic (1.86e-3)" "unprognostic (2.33e-2)" "unprognostic (2.88e-2)" "unprognostic (6.30e-2)" 14.7 4.9 16.3 21.6 23.1 43.6 13.8 6.3 13.6 17.5 20.7 23.0 53.0 25.9 4.8 13.5 58.3 19.8 21.7 12.7 16.9 13.3 10.2 18.8 38.8 22.8 17.9 9.2 9.0 11.6 2.8 3.9 20.7 14.0 14.3 6.8 18.6 29.8 55.2 10.5 34.6 36.0 8.9 10.2 21.9 22.5 4.5 12.6 23.9 8.3 23.5 33.5 16.3 28.1 51.1 6.7 80.5 9.1 7.2 25.6 9.5 5.0 0.7 6.6 1.3 4.5 17.2 0.2 2.9 23.6 5.1 13.0 0.3 3.4 5.2 3.5 1.4 19.2 0.9 15.0 11.8 23.2 0.4 32.5 1.5 0.1 3.3 8.9 77.3 23.7 17.6 21.4 11.4 9.0 0.2 1.6 45.7 3.6 8.6 16.7 0.2 0.3 0.2 27.6 7.3 3.0 4.9 0.2 0.3 1.8 27.6 3.8 26.3 8.8 5.0 16.2 2.1 0.3 27.5 0.6 0.0 0.1 54.7 4.9 8.6 48.4 9.1 16.0 4.9 4.8 8.5 51.1 24.9 11.6 2.2 30.9 8.6 3.8 80.5 7.2 3.4 6.7 25.6 9.5 16.3 23.1 6.3 13.6 16.9 13.3 17.9 9.2 14.0 12.6 CD83 "BL11, HB15" ENSG00000112149 "CD83 molecule" Q01151 6 14117256-14136918 "CD markers, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 70.0;lymphoid tissue: 64.5" "Cell line enhanced" "Detected in many" "Daudi: 28.6;HDLM-2: 25.7;U-698: 44.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002509, HPA041454" Enhanced "CAB002509: AB_563641, HPA041454: " "unprognostic (2.22e-3)" "unprognostic (1.92e-2)" "unprognostic (1.22e-1)" "unprognostic (6.39e-2)" "unprognostic (5.83e-2)" "unprognostic (3.02e-2)" "unprognostic (1.00e-2)" "unprognostic (9.05e-3)" "unprognostic (9.05e-2)" "unprognostic (3.91e-2)" "unprognostic (7.37e-2)" "unprognostic (6.68e-2)" "prognostic favourable (3.49e-4)" "unprognostic (2.30e-1)" "unprognostic (7.07e-2)" "unprognostic (1.40e-2)" "unprognostic (2.46e-2)" 14.0 8.3 6.1 64.5 5.7 70.0 7.5 14.2 11.8 17.0 2.0 24.7 3.4 1.8 3.7 8.3 3.6 1.8 9.9 2.6 7.3 12.7 9.7 6.0 29.0 19.5 7.8 2.2 9.7 1.6 2.2 4.1 3.4 10.8 5.2 3.8 3.5 16.4 7.8 1.8 2.6 6.9 2.7 11.1 16.5 2.2 4.0 2.8 33.8 2.3 6.2 57.5 16.4 9.8 19.1 5.2 1.3 15.4 2.6 3.6 2.3 6.5 0.3 4.9 6.8 7.2 1.6 0.1 1.8 6.7 3.2 5.6 0.5 4.3 28.6 5.5 0.5 0.7 1.8 2.0 10.6 25.7 2.7 3.9 8.5 0.7 0.2 5.7 6.3 1.9 0.9 3.0 1.0 0.1 0.8 0.0 0.3 2.4 4.5 10.8 2.0 1.3 4.4 10.7 4.0 2.3 6.5 1.0 1.9 0.4 0.2 4.9 1.1 4.6 0.1 4.9 3.1 0.7 4.4 0.3 0.0 44.0 1.0 7.8 7.4 0.0 1.7 1.1 2.7 10.7 2.9 11.5 2.5 2.2 5.2 19.1 1.8 2.1 1.3 2.6 15.4 1.8 3.6 2.3 6.1 5.7 14.2 11.8 7.3 12.7 7.8 2.2 10.8 2.8 CD84 "hCD84, mCD84, SLAMF5" ENSG00000066294 "CD84 molecule" Q9UIB8 1 160541095-160579516 "CD markers, Predicted membrane proteins" "Adaptive immunity, Autophagy, Cell adhesion, Immunity, Innate immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 26.0" "Cell line enhanced" "Detected in some" "Daudi: 12.4;HEL: 23.7;HL-60: 6.7;HMC-1: 27.1;MOLT-4: 6.6;U-698: 16.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA063316, HPA068020, HPA070502" Enhanced Enhanced "Vesicles,Plasma membrane" 36000000 "Plasma membrane" Vesicles "HPA063316: , HPA068020: , HPA070502: " "unprognostic (4.38e-2)" "unprognostic (6.16e-3)" "unprognostic (1.00e-2)" "unprognostic (8.16e-2)" "unprognostic (2.35e-1)" "unprognostic (2.00e-2)" "unprognostic (3.84e-1)" "unprognostic (2.54e-2)" "unprognostic (8.60e-2)" "unprognostic (1.80e-1)" "unprognostic (8.26e-2)" "unprognostic (1.57e-1)" "unprognostic (1.30e-2)" "unprognostic (2.15e-1)" "unprognostic (4.14e-2)" "unprognostic (1.24e-1)" "unprognostic (1.08e-1)" 15.9 4.8 3.8 18.5 4.5 6.7 3.7 1.3 3.4 3.3 3.2 7.9 7.7 2.5 2.5 4.3 2.7 3.1 6.4 5.0 3.8 3.0 3.1 5.1 9.2 26.0 6.0 2.2 1.8 4.3 0.9 1.9 7.1 5.3 3.7 4.7 2.4 4.3 9.8 1.6 2.7 9.6 4.1 11.1 25.6 3.5 2.8 5.9 13.8 2.9 2.3 16.3 5.8 2.7 5.1 5.4 21.0 7.3 1.0 8.2 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.7 0.0 0.0 0.0 6.7 27.1 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 6.6 5.0 0.0 0.0 0.2 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.7 0.0 1.5 0.0 21.0 7.3 11.0 6.9 6.3 5.2 5.1 5.9 8.2 5.4 4.7 3.5 6.3 1.0 1.0 2.4 3.2 7.9 6.1 3.8 4.5 1.3 3.4 3.8 3.0 6.0 2.2 5.3 5.9 CD86 "B7-2, B7.2, CD28LG2" ENSG00000114013 "CD86 molecule" P42081 3 122055366-122121139 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity" "Host cell receptor for virus entry, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 27.0;brain: 26.1" "Cell line enriched" "Detected in some" 7 "HDLM-2: 78.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 8 "classical monocyte: 25.6;intermediate monocyte: 26.4;memory B-cell: 13.6;myeloid DC: 25.9;naive B-cell: 8.0;non-classical monocyte: 27.0" "Group enriched" "Detected in many" 17 "B-cells: 13.6;dendritic cells: 25.9;monocytes: 27.0" "Low region specificity" "Detected in all" CAB004319 Approved 220000 "CAB004319: AB_627200" "unprognostic (1.81e-1)" "unprognostic (3.78e-3)" "unprognostic (3.04e-2)" "unprognostic (3.52e-2)" "unprognostic (1.36e-1)" "unprognostic (2.79e-1)" "unprognostic (1.15e-1)" "unprognostic (8.56e-2)" "unprognostic (7.72e-3)" "unprognostic (1.21e-1)" "unprognostic (1.28e-1)" "unprognostic (1.98e-1)" "prognostic unfavourable (9.83e-5)" "unprognostic (9.72e-2)" "unprognostic (1.70e-2)" "unprognostic (9.78e-2)" "unprognostic (8.67e-2)" 10.5 4.7 7.1 23.6 9.5 6.0 3.6 1.5 6.3 2.9 4.3 9.8 0.6 2.5 2.6 5.2 2.8 3.3 10.4 3.5 7.3 6.0 4.0 7.8 13.0 17.8 11.7 3.0 2.5 2.3 2.1 2.6 10.3 8.1 3.1 5.6 3.0 3.6 1.8 1.3 2.4 6.9 5.1 26.1 22.5 3.4 2.4 10.3 7.7 2.3 2.1 15.0 9.2 2.2 13.6 25.9 0.3 27.0 1.2 0.4 9.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.7 0.0 0.0 0.0 0.0 0.0 0.0 78.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 8.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.0 4.2 0.1 9.4 0.0 0.2 0.0 0.0 25.6 0.2 0.0 26.4 0.0 13.6 0.1 0.1 25.9 8.0 0.0 0.0 0.3 1.2 27.0 2.6 0.4 9.3 7.1 9.5 1.5 6.3 7.3 6.0 11.7 3.0 8.1 10.3 CD8A CD8 ENSG00000153563 "CD8a molecule" P01732 2 86784610-86808396 "CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 14 "blood: 82.2;lymphoid tissue: 262.3" "Cell line enriched" "Detected in some" 4 "MOLT-4: 17.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 13 "MAIT T-cell: 36.7;memory CD8 T-cell: 82.2;naive CD8 T-cell: 77.8" "Lineage enriched" "Detected in many" 20 "T-cells: 82.2" "Low region specificity" "Detected in all" "CAB000012, HPA037756, CAB075722" Enhanced Supported "Plasma membrane" "Intracellular and membrane" 500000 "Plasma membrane" "CAB000012: AB_2075537, CAB075722: , HPA037756: " "unprognostic (1.29e-3)" "prognostic favourable (4.54e-4)" "unprognostic (9.26e-3)" "prognostic favourable (6.15e-6)" "unprognostic (7.28e-2)" "unprognostic (2.79e-3)" "unprognostic (1.03e-2)" "unprognostic (2.00e-2)" "unprognostic (1.35e-2)" "unprognostic (4.50e-3)" "unprognostic (1.09e-1)" "unprognostic (1.14e-1)" "prognostic unfavourable (1.91e-5)" "unprognostic (1.36e-1)" "unprognostic (1.48e-1)" "unprognostic (6.74e-2)" "unprognostic (1.56e-2)" 2.4 1.4 1.4 7.4 2.8 6.8 1.5 1.4 1.2 2.1 5.3 0.8 0.8 4.2 1.5 2.1 2.0 2.1 4.5 1.6 1.2 1.6 1.3 2.1 6.0 23.8 1.0 0.5 1.7 1.2 0.0 0.9 0.6 0.7 2.3 1.9 1.8 3.0 1.1 0.8 0.7 12.2 0.7 1.7 46.4 5.4 1.0 0.5 262.3 2.2 1.6 8.1 3.8 1.9 0.0 0.1 0.6 0.1 4.0 82.2 17.4 0.3 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.4 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.3 0.0 0.8 17.4 1.1 0.6 0.3 0.1 0.9 3.9 0.0 0.4 0.9 2.4 0.2 0.1 0.0 0.4 0.5 0.0 0.0 0.6 0.1 0.0 0.1 0.3 0.9 0.0 0.0 0.1 0.1 0.1 0.0 4.8 0.0 36.7 0.0 0.3 82.2 0.0 0.0 0.3 77.8 0.6 4.0 0.1 0.1 0.1 17.4 1.4 2.8 1.4 1.2 1.2 1.6 1.0 0.5 0.7 0.5 CD8B CD8B1 ENSG00000172116 "CD8b molecule" P10966 2 86815339-86861924 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 132.1;lymphoid tissue: 61.5" "Cell line enriched" "Detected in some" 55 "RPMI-8226: 154.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 10 "memory CD8 T-cell: 73.5;naive CD8 T-cell: 132.1" "Lineage enriched" "Detected in many" 40 "T-cells: 132.1" "CAB004353, HPA029164" Enhanced Supported "Plasma membrane" "Intracellular and membrane" "Plasma membrane" "CAB004353: AB_627211, HPA029164: " "unprognostic (1.83e-3)" "unprognostic (1.98e-3)" "unprognostic (2.22e-2)" "prognostic favourable (7.88e-7)" "unprognostic (6.23e-2)" "unprognostic (7.05e-3)" "unprognostic (1.11e-2)" "unprognostic (2.59e-2)" "unprognostic (5.50e-3)" "unprognostic (5.91e-2)" "unprognostic (9.25e-2)" "unprognostic (4.60e-1)" "prognostic unfavourable (7.11e-6)" "unprognostic (7.84e-2)" "unprognostic (3.00e-1)" "unprognostic (1.86e-2)" "unprognostic (4.33e-2)" 1.2 0.7 1.0 5.3 1.0 3.9 1.0 1.3 1.3 21.2 1.1 1.0 1.0 2.5 1.2 1.0 1.0 1.1 1.8 1.0 1.0 1.8 1.0 1.0 2.7 14.4 1.7 1.0 1.3 1.0 6.4 7.4 1.0 2.2 1.3 1.3 1.0 1.0 1.0 1.0 0.9 11.4 1.0 1.5 12.7 2.3 1.0 1.0 61.5 1.5 1.0 8.1 1.8 1.3 0.1 0.1 3.2 0.1 0.1 132.1 36.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 154.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 3.2 0.1 0.0 2.0 0.1 10.0 0.0 0.2 73.5 0.0 0.1 0.5 132.1 0.7 0.1 0.1 0.1 0.2 36.3 1.0 1.0 1.3 1.3 1.0 1.8 1.7 1.0 2.2 1.0 CD9 "BA2, MIC3, MRP-1, P24, TSPAN29" ENSG00000010278 "CD9 molecule" P21926 12 6199715-6238271 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Fertilization" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 127.8;HUVEC TERT2: 82.6;RT4: 94.7;TIME: 188.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 21 "basophil: 137.8;eosinophil: 98.3" "Lineage enriched" "Detected in many" 24 "granulocytes: 137.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB002490 Supported Supported "Plasma membrane" 68000000 "Plasma membrane" "CAB002490: AB_563643" "unprognostic (1.38e-1)" "unprognostic (6.36e-3)" "unprognostic (8.27e-3)" "unprognostic (6.98e-3)" "unprognostic (3.89e-1)" "unprognostic (2.81e-1)" "unprognostic (1.32e-1)" "unprognostic (2.08e-2)" "unprognostic (2.90e-1)" "unprognostic (2.60e-2)" "prognostic unfavourable (1.59e-4)" "unprognostic (2.30e-1)" "prognostic favourable (6.49e-5)" "unprognostic (6.10e-2)" "unprognostic (1.77e-1)" "prognostic favourable (8.93e-5)" "unprognostic (9.26e-2)" 38.1 44.5 20.0 24.1 36.2 3.1 48.2 6.8 29.6 55.0 68.3 63.1 151.6 19.5 36.2 43.4 139.8 38.4 23.2 39.2 30.3 15.6 39.9 12.2 61.1 8.2 43.3 23.3 14.1 23.3 89.5 15.2 13.0 28.7 77.9 73.5 25.5 91.6 180.4 11.3 60.1 29.6 62.2 48.9 12.2 27.7 10.4 47.7 6.0 63.6 112.3 85.8 54.5 76.0 1.9 0.9 137.8 5.6 0.2 1.1 5.6 33.9 14.9 0.3 9.2 14.7 15.1 12.9 20.1 40.2 6.9 10.6 10.9 127.8 0.1 5.0 4.3 74.5 7.8 40.2 5.3 1.7 5.5 0.1 11.3 2.3 6.3 0.1 42.8 0.0 29.9 12.6 10.9 82.6 1.5 0.1 4.3 48.6 0.1 3.7 11.6 15.0 0.3 24.6 43.2 67.6 94.7 0.0 2.9 20.0 16.6 17.2 7.7 3.5 188.9 0.7 18.9 0.7 2.4 0.1 0.1 5.1 11.8 0.0 18.6 137.8 5.6 98.3 0.1 1.8 0.2 0.5 0.1 0.1 0.9 1.9 0.4 1.1 2.6 0.2 0.0 0.3 0.0 5.6 20.0 36.2 6.8 29.6 30.3 15.6 43.3 23.3 28.7 47.7 CD93 "C1qR(P), C1QR1, C1qRP, CDw93, dJ737E23.1, ECSM3, MXRA4" ENSG00000125810 "CD93 molecule" Q9NPY3 20 23079349-23086340 "CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in some" 4 "HUVEC TERT2: 57.0;TIME: 72.2;U-937: 96.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "classical monocyte: 14.4;neutrophil: 17.4" "Group enriched" "Detected in many" 40 "dendritic cells: 5.5;granulocytes: 17.4;monocytes: 14.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009300, HPA012368" Enhanced Approved "Vesicles,Plasma membrane" 440000000 "Vesicles, Plasma membrane" "HPA009300: AB_1846342, HPA012368: AB_1846341" "unprognostic (2.05e-1)" "unprognostic (2.85e-1)" "unprognostic (1.07e-1)" "unprognostic (4.83e-2)" "unprognostic (2.31e-1)" "unprognostic (2.66e-2)" "unprognostic (6.45e-2)" "unprognostic (2.77e-1)" "unprognostic (4.51e-1)" "unprognostic (3.74e-2)" "unprognostic (2.61e-1)" "unprognostic (1.81e-1)" "prognostic unfavourable (2.74e-4)" "unprognostic (8.81e-3)" "unprognostic (6.13e-2)" "unprognostic (4.49e-2)" "unprognostic (3.11e-2)" 50.5 6.1 2.4 15.0 3.4 4.7 31.4 1.0 3.0 13.6 8.1 1.7 3.9 3.2 14.3 12.5 10.0 13.6 14.2 33.3 2.4 2.2 10.8 10.9 34.8 25.3 4.1 1.2 11.6 5.9 5.1 4.3 48.9 5.3 9.7 4.3 4.9 5.9 3.9 16.2 6.8 7.7 15.4 4.3 17.5 7.5 6.9 3.3 6.9 12.3 9.3 4.5 15.6 12.2 0.0 5.5 17.4 14.4 0.0 0.3 4.7 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 57.0 0.1 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.1 0.0 4.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.0 72.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 96.6 0.0 0.0 14.4 0.2 0.2 10.3 0.0 0.0 0.1 0.0 5.5 0.0 0.0 0.0 17.4 0.0 4.2 0.7 0.3 4.7 2.4 3.4 1.0 3.0 2.4 2.2 4.1 1.2 5.3 3.3 CD96 TACTILE ENSG00000153283 "CD96 molecule" P40200 3 111292719-111665750 "CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Craniosynostosis, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 32.0;lymphoid tissue: 82.4" "Cell line enhanced" "Detected in some" "HEL: 6.7;MOLT-4: 29.2;RT4: 27.1;U-937: 24.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 5 "NK-cells: 20.0;T-cells: 32.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA066754 Enhanced 37000 "HPA066754: " "unprognostic (1.06e-3)" "unprognostic (3.95e-3)" "unprognostic (4.16e-3)" "unprognostic (1.91e-5)" "unprognostic (4.72e-3)" "prognostic favourable (5.52e-4)" "unprognostic (2.12e-2)" "unprognostic (3.48e-2)" "unprognostic (6.06e-2)" "unprognostic (4.84e-3)" "unprognostic (2.44e-2)" "unprognostic (2.77e-1)" "prognostic unfavourable (2.02e-6)" "unprognostic (3.12e-1)" "unprognostic (4.42e-2)" "unprognostic (3.90e-2)" "prognostic favourable (5.23e-5)" 5.7 0.9 0.4 18.6 0.5 8.6 3.1 0.6 0.4 2.2 7.1 0.6 0.5 3.6 1.7 1.8 3.4 2.1 3.5 1.3 0.4 0.5 2.3 2.7 9.7 21.9 1.5 0.2 1.4 0.8 0.0 1.1 1.1 1.0 2.6 3.7 2.5 4.0 1.6 0.6 1.3 13.4 1.4 2.0 14.2 3.5 1.0 0.4 82.4 4.8 2.3 23.9 9.9 3.2 5.5 0.1 3.8 0.2 20.0 32.0 11.2 0.0 0.0 0.1 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.8 0.1 0.1 0.0 0.3 0.0 0.0 0.0 0.1 0.0 6.7 0.0 0.1 0.0 0.3 0.6 0.0 0.0 0.0 0.1 0.0 0.1 0.9 0.0 0.0 29.2 0.1 0.3 0.0 0.0 0.9 0.2 0.2 27.1 0.0 0.0 0.1 0.4 0.0 0.1 0.1 0.0 0.1 0.5 0.1 0.0 2.6 0.8 0.0 0.1 24.2 5.2 0.5 0.1 3.8 20.2 0.0 32.0 2.8 18.6 23.5 0.1 5.5 19.4 23.6 0.8 20.0 0.2 0.1 11.8 11.2 0.4 0.5 0.6 0.4 0.4 0.5 1.5 0.2 1.0 0.4 CD99 MIC2 ENSG00000002586 "CD99 molecule (Xg blood group)" P14209 X 2691133-2741309 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 359.1;breast: 433.0;heart muscle: 347.0" "Cell line enhanced" "Detected in many" "ASC diff: 124.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000020, HPA035304" Supported Approved "Golgi apparatus" 34000000 "Golgi apparatus" "CAB000020: AB_2076419, HPA035304: AB_10672861" "unprognostic (3.71e-3)" "unprognostic (2.90e-1)" "unprognostic (5.97e-3)" "unprognostic (7.01e-3)" "unprognostic (2.14e-2)" "unprognostic (6.98e-3)" "unprognostic (3.89e-3)" "unprognostic (1.54e-2)" "unprognostic (1.06e-1)" "unprognostic (1.05e-1)" "unprognostic (1.59e-2)" "unprognostic (1.87e-1)" "prognostic unfavourable (5.87e-7)" "unprognostic (2.11e-2)" "unprognostic (2.18e-1)" "unprognostic (5.37e-2)" "unprognostic (3.61e-2)" 45.7 14.1 85.8 14.4 100.5 11.1 433.0 45.7 60.9 243.9 31.8 4.5 4.5 19.9 258.4 18.3 26.1 22.2 35.2 347.0 103.4 14.7 66.4 24.6 24.5 16.6 161.0 56.6 187.4 28.9 3.3 67.0 138.7 185.5 30.5 20.6 4.5 18.1 37.7 18.9 28.0 23.8 31.1 359.1 18.5 21.7 23.3 101.3 4.5 15.2 4.5 16.1 24.7 208.8 32.7 62.6 4.3 47.1 32.1 107.1 103.6 23.8 27.4 30.6 41.4 124.2 94.2 18.4 64.0 100.3 40.2 58.6 39.5 16.8 1.6 12.5 88.7 9.3 12.2 16.1 33.4 32.4 30.8 4.6 19.1 34.3 39.4 7.3 36.5 58.5 19.9 22.0 15.5 73.3 5.7 0.0 37.9 18.7 63.6 24.9 10.0 29.9 10.8 25.6 45.2 23.2 16.4 0.1 13.5 15.4 13.8 38.4 12.2 22.8 67.6 49.6 8.4 47.3 21.5 0.1 0.0 10.4 33.2 18.3 30.9 1.8 47.1 1.5 107.1 11.6 60.4 32.7 72.6 94.6 44.6 20.2 26.8 57.1 4.3 32.1 2.6 62.6 74.3 103.6 85.8 100.5 45.7 60.9 103.4 14.7 161.0 56.6 185.5 101.3 CDCP1 "CD318, SIMA135" ENSG00000163814 "CUB domain containing protein 1" Q9H5V8 3 45082278-45146422 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CAPAN-2: 23.3;HBEC3-KT: 26.6;hTEC/SVTERT24-B: 66.0;hTERT-HME1: 44.8;PC-3: 20.6;RPTEC TERT1: 20.4" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in some" 5 "pons and medulla: 5.5" "Group enriched" "Detected in some" 5 "myeloid DC: 4.0;neutrophil: 1.8;NK-cell: 7.1" "Group enriched" "Detected in many" 5 "dendritic cells: 4.0;granulocytes: 1.8;NK-cells: 7.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA010978, HPA010979, CAB025637" Enhanced "Intracellular and membrane" "CAB025637: , HPA010978: AB_1846403, HPA010979: AB_1846401" "unprognostic (9.31e-2)" "unprognostic (4.50e-2)" "unprognostic (1.67e-2)" "unprognostic (2.66e-1)" "unprognostic (1.11e-2)" "unprognostic (1.51e-3)" "unprognostic (2.94e-2)" "prognostic unfavourable (1.41e-5)" "unprognostic (2.15e-1)" "unprognostic (1.00e-1)" "prognostic unfavourable (1.48e-4)" "unprognostic (2.14e-2)" "unprognostic (9.98e-3)" "unprognostic (3.59e-2)" "unprognostic (2.99e-1)" "unprognostic (1.21e-1)" "unprognostic (1.34e-1)" 2.3 0.7 0.5 5.6 1.0 0.2 4.4 0.3 0.7 6.9 17.4 1.1 10.1 11.4 3.2 11.1 28.6 2.4 9.8 0.8 1.0 0.5 4.4 0.8 7.1 1.4 0.6 0.3 1.6 13.9 0.0 2.3 4.0 5.5 5.2 11.3 0.5 11.4 13.0 0.6 15.2 29.8 1.8 1.3 0.8 10.8 1.3 0.5 1.0 21.8 19.2 19.1 7.3 11.7 0.2 4.0 1.8 0.9 7.1 0.3 0.3 12.0 3.6 0.0 0.0 0.0 0.6 2.9 2.2 0.3 1.1 1.0 5.1 23.3 0.0 2.7 0.7 9.7 0.0 26.6 2.2 0.0 0.0 0.0 4.1 0.0 2.0 0.0 0.9 0.9 14.0 66.0 44.8 0.2 7.0 0.0 3.4 0.0 0.0 0.2 1.7 20.6 0.0 0.0 2.0 20.4 9.8 0.8 0.0 4.5 1.2 0.0 5.6 0.1 0.9 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.4 0.9 0.1 0.1 0.1 0.0 0.1 0.3 0.1 4.0 0.2 0.2 0.1 1.8 7.1 0.0 0.1 0.0 0.3 0.5 1.0 0.3 0.7 1.0 0.5 0.6 0.3 5.5 0.5 CDH1 "CD324, UVO, uvomorulin" ENSG00000039068 "Cadherin 1" P12830 16 68737225-68835548 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 125.5" "Cell line enhanced" "Detected in some" "BEWO: 105.6;CACO-2: 35.5;CAPAN-2: 49.6;HaCaT: 47.9;hTCEpi: 33.8;MCF7: 29.3;RT4: 36.5;T-47d: 31.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 12 "myeloid DC: 2.8;plasmacytoid DC: 8.5" "Lineage enriched" "Detected in single" 18 "dendritic cells: 8.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857" Enhanced Supported "Golgi apparatus,Plasma membrane,Cell Junctions" 22000000 "Plasma membrane, Cell Junctions" "Golgi apparatus" "CAB000087: AB_2533003, CAB028364: AB_2076812, CAB072855: , CAB072856: , CAB072857: , HPA004812: AB_1078369" "unprognostic (3.95e-2)" "unprognostic (1.91e-1)" "unprognostic (1.12e-3)" "unprognostic (1.13e-1)" "unprognostic (1.42e-1)" "unprognostic (2.78e-1)" "unprognostic (5.04e-3)" "unprognostic (1.63e-1)" "unprognostic (5.47e-2)" "unprognostic (2.85e-1)" "unprognostic (1.19e-2)" "unprognostic (3.61e-1)" "prognostic favourable (2.06e-4)" "unprognostic (1.21e-1)" "unprognostic (2.62e-1)" "unprognostic (2.51e-1)" "unprognostic (5.92e-2)" 1.1 0.7 1.3 14.8 1.5 0.5 15.3 0.8 1.1 14.4 63.8 1.8 42.4 25.5 4.7 18.6 48.5 9.7 48.9 0.8 1.5 1.0 24.2 64.9 24.4 0.5 1.8 0.9 5.6 71.5 62.2 13.2 55.2 2.8 28.9 25.9 11.8 66.6 43.7 0.8 30.5 125.5 1.5 1.1 3.5 21.6 2.1 1.8 11.7 83.0 26.2 32.6 16.8 21.7 0.0 8.5 0.0 0.0 0.3 0.4 0.1 21.3 2.2 0.0 0.0 0.0 0.0 105.6 0.0 0.0 0.0 0.0 35.5 49.6 0.0 0.4 0.0 47.9 0.0 23.8 0.0 4.1 0.6 0.0 0.1 7.6 0.0 0.0 0.2 0.0 33.8 0.0 0.0 0.0 0.0 0.0 0.0 29.3 0.0 0.1 0.8 0.1 0.0 0.0 0.3 8.7 36.5 1.3 0.1 0.2 0.0 9.0 31.5 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 2.8 0.0 0.0 0.0 0.0 0.3 0.0 8.5 0.1 0.1 1.3 1.5 0.8 1.1 1.5 1.0 1.8 0.9 2.8 1.8 CDH2 "CD325, CDHN, NCAD" ENSG00000170558 "Cadherin 2" P19022 18 27950966-28177446 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 77.6;parathyroid gland: 35.4" "Cell line enhanced" "Detected in many" "AF22: 56.4;BJ: 40.7;fHDF/TERT166: 84.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "basophil: 4.4;neutrophil: 4.1" "Lineage enriched" "Detected in single" 5 "granulocytes: 4.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000141, CAB018580, HPA058574, CAB078686" Enhanced Supported "Plasma membrane,Cell Junctions" 160000000 "Plasma membrane, Cell Junctions" "CAB000141: , CAB018580: AB_626778, CAB078686: , HPA058574: " "unprognostic (9.42e-2)" "unprognostic (2.69e-3)" "unprognostic (9.07e-3)" "unprognostic (5.45e-2)" "unprognostic (1.14e-1)" "unprognostic (9.30e-2)" "unprognostic (3.97e-2)" "unprognostic (2.53e-3)" "unprognostic (6.70e-3)" "unprognostic (1.00e-2)" "unprognostic (7.53e-2)" "unprognostic (3.51e-2)" "unprognostic (3.02e-2)" "unprognostic (1.93e-3)" "unprognostic (6.69e-2)" "unprognostic (1.33e-1)" "unprognostic (2.59e-3)" 0.6 29.6 9.8 1.5 9.4 0.5 0.5 5.7 16.1 3.2 2.0 8.0 0.2 0.8 3.1 1.9 0.6 4.7 1.7 77.6 9.9 9.6 9.2 23.3 0.7 1.1 6.0 9.1 3.4 0.7 35.4 5.4 0.5 5.9 1.4 0.8 6.8 0.5 4.6 0.4 0.5 0.9 3.2 6.7 5.9 2.5 19.6 7.4 0.9 2.8 0.0 1.0 1.0 1.3 0.0 0.0 4.4 0.0 0.7 0.9 0.0 0.0 4.5 56.4 0.0 8.9 1.8 0.0 40.7 12.4 16.6 15.2 0.0 0.0 0.0 21.9 84.2 6.0 9.2 0.0 23.6 0.1 5.9 0.0 15.2 14.0 8.5 0.0 0.0 0.8 0.1 38.1 6.7 14.5 0.0 0.0 12.9 0.0 10.2 0.0 7.5 4.9 0.0 6.7 7.7 0.0 1.8 14.7 25.5 0.0 0.0 4.5 0.0 0.0 2.2 36.0 11.5 0.5 29.4 0.0 0.0 0.0 6.9 0.0 27.7 4.4 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 4.1 0.7 0.0 0.0 0.0 0.0 9.8 9.4 5.7 10.1 9.9 9.6 6.0 9.1 5.9 7.4 CDH5 "7B4, CD144" ENSG00000179776 "Cadherin 5" P33151 16 66366622-66404786 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 96.6" "Group enriched" "Detected in some" 6 "HUVEC TERT2: 111.2;TIME: 95.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB028366, HPA075875" Approved Supported "Nucleoplasm,Nuclear membrane,Plasma membrane" 1000000000 "Plasma membrane" "Nucleoplasm, Nuclear membrane" "CAB028366: AB_2276033, HPA075875: " "unprognostic (1.05e-1)" "unprognostic (8.13e-2)" "unprognostic (6.11e-2)" "unprognostic (4.89e-2)" "unprognostic (4.96e-2)" "unprognostic (5.50e-3)" "unprognostic (9.38e-2)" "unprognostic (5.28e-2)" "unprognostic (1.32e-1)" "unprognostic (1.46e-1)" "unprognostic (2.33e-2)" "unprognostic (2.32e-1)" "prognostic unfavourable (5.14e-4)" "unprognostic (9.49e-3)" "unprognostic (3.01e-2)" "unprognostic (2.22e-1)" "unprognostic (3.15e-2)" 48.7 5.6 4.0 6.2 5.8 0.6 28.1 2.6 4.8 11.1 6.6 3.4 5.5 3.7 18.7 11.2 8.4 7.2 12.6 21.7 4.5 4.3 7.8 12.7 43.7 9.7 6.5 2.8 7.7 3.6 5.0 3.5 96.6 7.6 9.0 4.8 8.5 5.2 4.4 19.0 7.0 6.8 12.1 5.4 10.8 5.7 6.7 3.3 1.2 16.6 15.7 4.5 11.7 11.3 0.0 0.6 0.4 0.8 0.1 0.1 1.1 0.0 0.0 0.6 0.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 111.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 95.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.8 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.4 0.0 0.1 0.0 0.4 0.1 0.0 0.6 0.1 1.1 4.0 5.8 2.6 4.8 4.5 4.3 6.5 2.8 7.6 3.3 CEACAM1 "BGP, BGP1, CD66a" ENSG00000079385 "Carcinoembryonic antigen related cell adhesion molecule 1" P13688 19 42507304-42561234 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 58.7;liver: 46.1;lymphoid tissue: 46.5" "Group enriched" "Detected in some" 4 "CAPAN-2: 12.5;Hep G2: 35.4;RT4: 23.3;SK-MEL-30: 26.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 9 "eosinophil: 20.6;neutrophil: 12.7" "Lineage enriched" "Detected in many" 11 "granulocytes: 20.6" "CAB002146, HPA011041" Enhanced "Intracellular and membrane" 180000000 "CAB002146: AB_563614, HPA011041: AB_1078481" "unprognostic (7.13e-3)" "unprognostic (2.15e-1)" "unprognostic (2.67e-2)" "prognostic favourable (6.32e-7)" "unprognostic (3.04e-1)" "unprognostic (1.80e-3)" "unprognostic (1.21e-1)" "unprognostic (4.45e-2)" "unprognostic (4.43e-1)" "unprognostic (5.46e-3)" "unprognostic (4.87e-2)" "unprognostic (4.03e-1)" "unprognostic (1.92e-2)" "unprognostic (1.88e-1)" "unprognostic (1.06e-1)" "unprognostic (7.55e-2)" "unprognostic (5.52e-3)" 5.3 5.0 0.4 30.2 0.7 15.8 5.3 0.5 0.5 7.7 58.7 0.9 2.5 11.8 3.5 1.5 35.6 1.7 4.3 3.8 0.5 0.5 24.0 46.1 5.4 8.6 1.8 0.0 2.5 1.0 0.0 3.7 16.8 1.0 8.8 35.6 1.7 20.7 5.4 0.9 1.7 54.9 3.0 1.5 5.5 3.6 1.3 0.7 1.2 2.3 18.5 46.5 7.8 12.7 1.9 0.1 20.6 1.8 0.0 1.5 0.3 0.1 2.3 0.1 0.1 0.0 0.0 6.0 0.0 0.1 0.4 0.2 0.9 12.5 0.7 5.0 0.0 0.3 0.0 3.4 0.1 0.0 0.2 0.1 0.1 35.4 0.7 0.0 5.1 0.0 0.0 0.0 0.0 0.3 0.0 1.6 0.0 0.4 0.1 0.0 0.1 0.7 0.7 0.0 0.5 0.2 23.3 0.1 0.0 0.0 0.0 26.2 0.1 0.0 0.8 0.1 0.2 0.1 0.1 0.7 0.0 1.3 0.0 0.1 0.1 0.4 0.0 20.6 0.0 0.9 0.2 1.9 0.5 0.2 0.1 0.3 0.4 0.1 12.7 0.0 1.8 0.0 1.5 0.3 0.4 0.7 0.5 0.5 0.5 0.5 1.8 0.0 1.0 0.7 CEACAM3 "CD66d, CGM1" ENSG00000170956 "Carcinoembryonic antigen related cell adhesion molecule 3" P40198 19 41796437-41811553 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 60.0;bone marrow: 35.4" "Cell line enhanced" "Detected in single" "PC-3: 3.7" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in some" 7 "neutrophil: 60.0" "Lineage enriched" "Detected in many" 7 "granulocytes: 60.0" HPA011041 Approved "HPA011041: AB_1078481" "unprognostic (1.60e-1)" "unprognostic (1.14e-1)" "unprognostic (2.23e-2)" "unprognostic (2.95e-2)" "unprognostic (2.19e-1)" "unprognostic (8.09e-3)" "unprognostic (1.44e-1)" "unprognostic (2.85e-1)" "unprognostic (1.49e-1)" "unprognostic (3.19e-2)" "unprognostic (1.62e-1)" "unprognostic (8.07e-2)" "unprognostic (1.32e-2)" "unprognostic (1.32e-1)" "unprognostic (4.68e-2)" "unprognostic (8.44e-2)" "unprognostic (2.83e-1)" 0.9 0.3 0.3 3.6 0.8 35.4 0.7 0.2 0.8 0.6 1.0 0.0 0.0 0.2 0.4 0.2 1.2 0.7 0.4 5.1 0.4 0.3 0.4 1.1 14.0 11.5 1.8 0.1 0.7 1.0 0.2 0.3 4.6 0.5 0.3 0.3 1.4 0.8 0.2 1.5 0.2 0.6 0.4 0.3 10.7 0.4 0.9 0.2 1.6 0.5 0.3 2.7 0.8 0.6 0.0 0.8 60.0 8.9 0.0 0.0 0.6 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.8 0.0 0.0 3.9 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 60.0 0.0 8.9 0.0 0.0 0.6 0.3 0.8 0.2 0.8 0.4 0.3 1.8 0.1 0.5 0.2 CEACAM5 "CD66e, CEA" ENSG00000105388 "Carcinoembryonic antigen related cell adhesion molecule 5" P06731 19 41708585-41729798 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Cell adhesion" "Cancer-related genes, Oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 103.5;intestine: 118.2;lymphoid tissue: 100.6" "Cell line enriched" "Detected in some" 6 "HaCaT: 17.0" "Cancer enhanced" "Detected in many" "colorectal cancer: 1007.1" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "CAB000021, CAB000022, HPA011041, HPA019758" Enhanced Supported "Plasma membrane" "Intracellular and membrane" 19000000 "Plasma membrane" "CAB000021: , CAB000022: AB_2335697, HPA011041: AB_1078481, HPA019758: AB_1846326" "unprognostic (1.54e-2)" "unprognostic (7.59e-2)" "unprognostic (5.49e-3)" "unprognostic (1.80e-1)" "unprognostic (1.38e-2)" "unprognostic (2.22e-1)" "unprognostic (3.49e-1)" "unprognostic (2.11e-1)" "unprognostic (2.19e-2)" "unprognostic (2.89e-1)" "unprognostic (8.67e-9)" "unprognostic (2.92e-1)" "unprognostic (2.71e-2)" "unprognostic (6.31e-2)" "unprognostic (1.85e-1)" 0.1 0.1 0.1 78.8 0.1 0.0 0.1 0.1 0.2 12.5 117.1 0.2 0.1 2.5 0.9 0.1 103.5 0.3 1.2 0.1 0.1 0.1 0.1 0.1 3.3 0.1 0.1 0.1 0.2 0.2 0.0 0.2 0.5 0.1 0.3 118.2 0.2 6.8 0.1 0.1 0.6 12.8 3.3 0.1 0.1 20.1 0.2 0.1 0.6 0.2 29.4 100.6 2.0 14.1 0.6 0.6 1.8 0.7 0.6 0.5 0.3 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.7 2.6 0.0 0.1 0.0 17.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 1.2 0.2 0.0 0.4 1.4 0.3 0.0 0.1 0.0 0.5 0.9 0.2 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.4 0.0 0.4 0.4 0.0 0.0 0.1 0.1 0.2 1.2 0.3 0.8 0.3 0.2 0.1 0.5 0.2 0.3 0.6 0.6 0.4 0.5 1.8 0.6 0.7 0.5 0.3 0.3 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 CEACAM6 "CD66c, NCA" ENSG00000086548 "Carcinoembryonic antigen related cell adhesion molecule 6" P40199 19 41750977-41772208 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Apoptosis, Cell adhesion" "Cancer-related genes, Oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 81.4;gallbladder: 75.7;lung: 129.1" "Cell line enriched" "Detected in some" 8 "A549: 57.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "neutrophil: 2.6" "Group enriched" "Detected in many" 6 "granulocytes: 2.6;monocytes: 1.3" "CAB008370, HPA011041" Enhanced 79000000 "CAB008370: AB_592067, HPA011041: AB_1078481" "unprognostic (1.00e-2)" "unprognostic (2.05e-1)" "unprognostic (2.62e-2)" "unprognostic (8.22e-2)" "unprognostic (1.39e-1)" "unprognostic (9.06e-3)" "unprognostic (2.32e-2)" "unprognostic (1.37e-1)" "unprognostic (2.49e-1)" "unprognostic (5.22e-2)" "unprognostic (3.70e-3)" "unprognostic (1.93e-1)" "unprognostic (2.42e-4)" "unprognostic (4.08e-1)" "unprognostic (8.71e-3)" "unprognostic (2.85e-1)" "unprognostic (7.68e-2)" 0.3 0.3 0.3 7.4 0.3 29.7 0.3 0.3 0.3 16.8 35.3 0.2 0.1 5.8 0.9 0.2 81.4 1.1 75.7 2.3 0.3 0.3 0.3 0.8 129.1 0.1 0.3 0.1 0.3 1.7 0.0 0.3 32.1 0.2 0.9 43.1 0.2 50.1 0.1 0.3 2.1 12.8 0.9 0.3 0.8 2.6 0.3 0.1 1.0 0.3 25.3 58.1 2.3 21.0 0.1 0.3 2.6 1.3 0.1 0.3 5.2 0.0 57.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.9 1.6 0.0 0.0 0.0 6.9 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.9 0.0 0.0 0.1 1.6 0.0 0.0 0.0 0.3 0.2 0.6 0.0 0.0 1.5 0.0 0.2 0.6 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.3 1.3 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 2.6 0.1 0.5 0.3 0.0 5.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.1 0.2 0.1 CEACAM8 "CD66b, CGM6" ENSG00000124469 "Carcinoembryonic antigen related cell adhesion molecule 8" P31997 19 42580241-42595055 "CD markers, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "bone marrow: 71.0;placenta: 35.6" "Low cell line specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "neutrophil: 4.2;non-classical monocyte: 3.0" "Group enriched" "Detected in many" 6 "granulocytes: 4.2;monocytes: 3.0" CAB033676 Approved "Intracellular and membrane" 15000000 "CAB033676: AB_1125678" "unprognostic (2.01e-1)" "unprognostic (4.52e-2)" "unprognostic (3.31e-1)" "unprognostic (6.30e-2)" "unprognostic (2.68e-1)" "unprognostic (1.62e-1)" "unprognostic (1.71e-2)" "unprognostic (7.77e-2)" "unprognostic (9.62e-2)" 0.2 0.0 0.1 0.0 0.1 71.0 0.1 0.1 0.4 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 6.6 0.1 0.1 0.1 0.4 4.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 35.6 0.1 0.0 0.1 0.0 0.1 0.0 0.7 0.2 0.0 0.0 0.1 10.1 0.0 0.1 0.1 1.9 0.1 0.0 0.0 0.0 0.7 0.5 0.1 4.2 3.0 0.6 0.4 4.1 0.8 0.2 1.1 2.1 0.0 0.5 0.3 1.3 0.0 0.0 0.1 0.2 0.4 1.2 0.3 0.5 0.5 0.0 0.3 0.0 0.2 0.3 0.5 0.7 0.7 0.1 0.8 0.6 0.0 0.1 0.1 0.1 0.0 0.7 1.5 0.0 0.3 0.4 0.9 0.5 0.1 0.5 0.5 1.3 0.4 0.5 0.7 0.8 0.1 0.3 1.2 1.3 0.9 0.8 1.4 0.3 1.5 0.5 1.5 1.3 0.7 0.8 1.3 0.7 0.6 0.5 0.5 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.5 0.3 0.4 4.2 0.6 3.0 0.1 0.1 4.1 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.0 0.1 0.1 CLEC10A "CD301, CLECSF13, CLECSF14, HML, HML2" ENSG00000132514 "C-type lectin domain containing 10A" Q8IUN9 17 7074537-7080307 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Endocytosis, Immunity, Innate immunity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 81.1;lymphoid tissue: 49.3" "Cell line enhanced" "Detected in some" "HUVEC TERT2: 1.6;NB-4: 4.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in some" 12 "myeloid DC: 81.1" "Lineage enriched" "Detected in many" 12 "dendritic cells: 81.1" HPA021937 Approved "HPA021937: AB_1846905" "unprognostic (3.96e-3)" "unprognostic (1.71e-3)" "unprognostic (2.95e-2)" "unprognostic (2.04e-3)" "unprognostic (4.54e-2)" "prognostic favourable (1.26e-5)" "unprognostic (1.07e-1)" "prognostic favourable (9.24e-4)" "unprognostic (2.70e-2)" "unprognostic (1.41e-1)" "unprognostic (1.12e-1)" "unprognostic (2.30e-1)" "unprognostic (6.12e-2)" "unprognostic (1.43e-1)" "prognostic unfavourable (4.22e-4)" "unprognostic (3.23e-1)" "unprognostic (3.65e-1)" 12.7 4.0 0.4 14.3 0.5 0.6 6.6 0.4 0.6 4.9 9.7 0.8 1.7 7.9 6.4 31.3 6.9 6.1 12.2 17.5 0.4 0.4 4.4 6.2 22.0 49.3 0.6 0.6 4.1 3.3 0.4 2.0 1.3 2.0 7.2 9.7 3.8 5.0 5.9 6.1 5.1 14.3 9.6 0.9 10.2 4.4 3.7 0.5 5.4 4.7 9.9 10.4 9.8 4.6 0.0 81.1 0.3 6.6 0.3 0.0 3.3 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.3 0.3 0.0 0.0 0.0 4.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.3 0.3 0.6 0.0 0.0 0.1 0.0 0.1 0.0 5.5 0.0 0.0 6.6 0.0 0.0 0.0 0.0 81.1 0.0 0.0 0.0 0.3 0.3 0.0 1.6 0.0 3.3 0.4 0.5 0.4 0.6 0.4 0.4 0.6 0.6 2.0 0.5 CLEC4C "BDCA2, CD303, CLECSF11, CLECSF7, DLEC, HECL" ENSG00000198178 "C-type lectin domain family 4 member C" Q8WTT0 12 7729415-7751605 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity, Innate immunity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "blood: 80.0" "Cell line enriched" "Detected in some" 4 "HDLM-2: 6.5" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 16 "plasmacytoid DC: 80.0" "Lineage enriched" "Detected in many" 16 "dendritic cells: 80.0" HPA029432 Approved "HPA029432: AB_10601259" "unprognostic (3.55e-3)" "unprognostic (3.01e-2)" "unprognostic (1.03e-1)" "unprognostic (3.70e-2)" "unprognostic (7.37e-5)" "unprognostic (2.36e-2)" "unprognostic (2.06e-1)" "unprognostic (2.55e-2)" "unprognostic (6.98e-2)" "unprognostic (1.39e-1)" "unprognostic (1.88e-3)" "unprognostic (2.82e-2)" "unprognostic (3.18e-3)" "unprognostic (2.36e-2)" "unprognostic (1.25e-1)" 0.3 0.2 0.2 1.6 0.2 1.8 2.0 0.2 0.6 0.2 0.2 0.1 0.1 0.0 0.2 0.1 0.3 0.5 1.2 0.3 0.2 0.2 0.5 0.3 1.5 7.0 0.2 0.1 0.4 0.2 0.0 0.2 0.1 0.1 0.2 0.0 0.4 0.3 2.0 0.2 0.3 0.3 0.1 0.2 4.6 0.3 9.9 0.1 6.7 0.3 0.1 7.1 1.9 0.3 0.5 80.0 4.9 0.1 0.5 0.0 0.5 0.2 0.0 0.3 0.3 0.5 0.0 0.4 0.0 0.0 0.1 0.0 0.5 0.6 0.3 0.0 0.0 0.3 0.0 0.0 0.2 6.5 0.1 0.3 0.7 0.2 0.0 0.6 1.3 0.4 0.3 0.0 0.0 0.1 0.2 1.0 0.0 0.1 0.1 0.8 1.4 0.2 0.1 0.0 0.1 0.1 0.4 0.2 0.2 0.1 0.1 0.0 0.9 0.1 0.4 0.4 0.2 0.1 0.1 0.6 0.2 1.4 0.1 0.3 0.3 0.9 0.1 4.9 0.0 0.0 0.0 0.1 0.0 0.0 0.7 0.5 0.0 0.0 2.6 0.5 0.0 80.0 0.0 0.5 0.2 0.2 0.2 0.6 0.2 0.2 0.2 0.1 0.1 0.1 CLEC4M "CD209L, CD299, DC-SIGN2, DC-SIGNR, DCSIGNR, HP10347, LSIGN" ENSG00000104938 "C-type lectin domain family 4 member M" Q9H2X3 19 7763149-7769605 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Endocytosis, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "liver: 38.5;lymphoid tissue: 30.1" "Group enriched" "Detected in some" 6 "HUVEC TERT2: 2.5;K-562: 3.4;Karpas-707: 1.3;RPMI-8226: 1.7" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 7 "memory B-cell: 1.7" "Lineage enriched" "Detected in single" 18 "B-cells: 1.7" "CAB033689, CAB033691, HPA042661" Supported "Intracellular and membrane" 890000 "CAB033689: AB_831088, CAB033691: AB_2081354, HPA042661: " "unprognostic (1.56e-1)" "unprognostic (3.03e-1)" "unprognostic (1.00e-1)" "unprognostic (1.71e-2)" "unprognostic (1.26e-2)" "unprognostic (1.64e-1)" "unprognostic (6.58e-2)" "unprognostic (1.27e-1)" "unprognostic (4.58e-3)" "unprognostic (4.60e-2)" "unprognostic (5.15e-2)" "unprognostic (1.43e-1)" 0.9 0.9 0.1 0.5 0.1 0.0 0.1 0.2 0.1 0.1 0.3 0.1 0.1 0.0 0.3 0.1 1.2 0.6 0.1 0.1 0.1 0.0 0.1 38.5 2.5 30.1 0.1 0.1 2.7 0.1 0.0 0.1 4.8 0.2 0.1 0.0 0.1 0.8 0.1 0.1 0.0 0.5 0.1 0.1 0.2 0.0 1.4 0.1 0.1 0.2 0.1 0.2 0.1 0.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.5 3.4 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.7 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.2 0.1 CR1 "CD35, KN" ENSG00000203710 "Complement C3b/C4b receptor 1 (Knops blood group)" P17927 1 207496147-207641765 "Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins" "Complement pathway, Host-virus interaction, Immunity, Innate immunity" "Blood group antigen, Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 23.2;lymphoid tissue: 42.3" "Group enriched" "Detected in some" 9 "HL-60: 8.8;HMC-1: 20.6;NB-4: 8.2" "Low cancer specificity" "Detected in single" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 5 "basophil: 23.2;eosinophil: 9.4;neutrophil: 9.1" "Lineage enriched" "Detected in many" 8 "granulocytes: 23.2" "CAB002491, CAB016271, HPA042455, HPA043579, HPA049348" Enhanced 27000000 "CAB002491: AB_563553, CAB016271: AB_627040, HPA042455: , HPA043579: , HPA049348: " "unprognostic (1.74e-1)" "unprognostic (3.16e-2)" "unprognostic (2.75e-2)" "unprognostic (6.12e-2)" "unprognostic (1.58e-2)" "unprognostic (7.14e-2)" "unprognostic (2.84e-1)" "unprognostic (3.86e-2)" "unprognostic (2.02e-1)" "unprognostic (2.80e-1)" "unprognostic (1.32e-1)" "unprognostic (1.84e-1)" "unprognostic (2.29e-3)" "unprognostic (4.38e-2)" "unprognostic (3.32e-2)" "unprognostic (6.45e-2)" "unprognostic (3.50e-3)" 9.0 1.1 0.6 17.0 0.6 5.8 1.5 0.4 0.5 0.6 1.7 0.2 0.0 0.5 0.7 5.6 1.4 2.2 1.1 8.0 0.6 0.5 2.3 3.8 4.0 42.3 0.6 0.0 1.7 1.2 0.0 0.6 5.5 1.0 1.7 0.7 0.5 1.9 0.0 0.8 0.5 5.1 3.6 0.7 42.0 1.1 0.9 0.1 1.3 0.7 0.0 11.1 3.2 1.3 2.8 0.2 23.2 2.3 0.0 0.6 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 8.8 20.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 8.2 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 23.2 2.3 9.4 0.0 1.4 0.4 2.8 0.6 0.3 0.2 1.4 0.1 0.1 9.1 0.0 1.2 0.0 0.0 0.6 0.6 0.6 0.4 0.5 0.6 0.5 0.6 0.0 1.0 0.1 CR2 "C3DR, CD21" ENSG00000117322 "Complement C3d receptor 2" P20023 1 207454230-207489895 "CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Complement pathway, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Receptor" "Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "lymphoid tissue: 97.2" "Cell line enhanced" "Detected in some" "Daudi: 21.1;MOLT-4: 11.5;RPMI-8226: 4.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "memory B-cell: 13.3;naive B-cell: 16.2" "Lineage enriched" "Detected in many" 9 "B-cells: 16.2" "Low region specificity" "Detected in some" "Low region specificity" "Detected in some" "CAB002659, HPA052942, HPA060715" Enhanced 150000000 "CAB002659: , HPA052942: AB_2681994, HPA060715: AB_2684349" "prognostic favourable (6.90e-4)" "unprognostic (1.22e-1)" "unprognostic (9.95e-2)" "unprognostic (3.64e-2)" "unprognostic (2.65e-1)" "unprognostic (1.27e-3)" "unprognostic (1.18e-1)" "unprognostic (6.62e-3)" "unprognostic (1.91e-2)" "unprognostic (1.79e-1)" "unprognostic (1.20e-1)" "unprognostic (7.95e-2)" "unprognostic (2.14e-1)" "unprognostic (1.12e-1)" "unprognostic (2.19e-1)" "unprognostic (2.09e-2)" "unprognostic (3.35e-2)" 0.5 0.3 0.4 97.2 0.3 0.0 0.4 0.3 0.3 0.3 1.2 0.0 0.0 0.0 0.3 0.0 2.8 0.3 0.3 0.3 0.4 0.4 1.4 0.4 2.0 72.8 0.4 0.0 0.4 0.4 0.0 0.3 0.0 0.0 0.5 0.9 0.0 6.0 0.0 0.4 0.3 11.5 0.0 0.4 63.4 1.4 0.5 0.0 6.5 0.7 0.3 56.3 0.6 0.3 16.2 0.0 0.2 0.0 0.0 1.8 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 21.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 11.5 0.0 1.9 0.2 0.0 0.2 4.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.5 13.3 0.7 0.5 0.0 16.2 1.8 1.6 0.2 0.0 0.0 0.0 0.0 1.1 0.4 0.3 0.3 0.3 0.4 0.4 0.4 0.0 0.0 0.0 CRTAM CD355 ENSG00000109943 "Cytotoxic and regulatory T cell molecule" O95727 11 122838500-122872639 "CD markers, Predicted membrane proteins" "Adaptive immunity, Immunity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 140.8" "Cell line enriched" "Detected in single" 34 "SCLC-21H: 17.0" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in some" 24 "cerebellum: 140.8" "Cell type enhanced" "Detected in many" "NK-cell: 25.7" "Group enriched" "Detected in many" 5 "NK-cells: 25.7;T-cells: 16.7" "Region enriched" "Detected in single" 44 "cerebellum: 115.2" "Low region specificity" "Detected in all" 3200000 "unprognostic (3.51e-3)" "unprognostic (6.73e-4)" "unprognostic (1.33e-2)" "unprognostic (3.73e-3)" "unprognostic (2.40e-2)" "unprognostic (5.25e-4)" "unprognostic (1.25e-1)" "unprognostic (3.66e-2)" "unprognostic (5.27e-2)" "unprognostic (1.71e-1)" "unprognostic (5.49e-3)" "unprognostic (2.32e-1)" "unprognostic (1.83e-4)" "unprognostic (6.01e-2)" "unprognostic (4.26e-2)" "unprognostic (3.87e-2)" "unprognostic (6.59e-2)" 0.4 0.3 0.3 2.7 0.4 1.9 0.4 140.8 0.4 0.3 0.4 0.2 0.1 0.4 0.8 0.4 0.3 0.3 1.8 0.3 0.3 0.3 0.3 1.0 2.2 10.6 0.4 0.1 0.3 0.3 0.0 0.3 0.2 5.8 0.3 0.5 0.3 0.7 0.1 0.3 0.3 1.3 0.2 1.2 4.4 0.7 0.3 0.1 3.3 0.3 0.2 4.3 1.1 0.3 0.1 1.7 0.6 4.4 25.7 16.7 2.8 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.5 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 2.2 0.2 6.7 2.7 6.5 0.0 0.7 13.5 1.7 0.1 2.2 16.7 0.6 25.7 4.4 0.1 0.0 2.8 0.3 0.4 140.8 0.4 0.3 0.3 0.4 0.1 5.8 0.1 CSF1R "C-FMS, CD115, CSFR, FMS" ENSG00000182578 "Colony stimulating factor 1 receptor" P07333 5 150053291-150113372 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Immunity, Inflammatory response, Innate immunity" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 82.5;lymphoid tissue: 82.6" "Group enriched" "Detected in some" 5 "BEWO: 50.6;SK-BR-3: 19.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "intermediate monocyte: 60.7;non-classical monocyte: 82.5" "Lineage enriched" "Detected in many" 4 "monocytes: 82.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008970, HPA012323" Uncertain Supported "Vesicles,Plasma membrane" "Intracellular and membrane" 1500000000 "Vesicles, Plasma membrane" "CAB008970: , HPA012323: AB_1848977" "unprognostic (3.82e-2)" "unprognostic (1.31e-1)" "unprognostic (1.86e-3)" "unprognostic (9.83e-2)" "unprognostic (1.20e-1)" "unprognostic (7.33e-2)" "unprognostic (1.03e-1)" "unprognostic (1.45e-1)" "unprognostic (9.37e-2)" "unprognostic (1.11e-2)" "unprognostic (2.49e-1)" "unprognostic (1.65e-1)" "prognostic unfavourable (1.08e-4)" "unprognostic (3.67e-2)" "prognostic unfavourable (4.92e-4)" "unprognostic (1.72e-2)" "unprognostic (4.61e-2)" 20.9 12.4 18.2 28.1 18.9 1.8 7.7 2.8 13.5 9.3 8.3 25.4 1.1 9.2 5.9 13.1 8.4 7.9 16.1 8.7 16.4 13.7 7.8 15.1 13.7 25.4 21.3 6.0 5.3 5.2 5.9 6.4 52.1 17.1 8.5 8.4 16.8 8.0 8.7 3.0 5.8 14.5 16.2 25.8 82.6 9.0 4.9 23.0 3.1 4.2 2.9 8.2 16.4 4.7 0.0 19.1 2.9 82.5 0.0 0.1 13.9 1.7 0.0 0.0 0.0 0.8 0.2 50.6 0.1 0.0 0.0 0.0 1.5 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.0 0.1 0.0 19.3 0.0 0.0 7.2 0.0 0.3 0.0 0.0 1.3 0.0 0.1 0.0 2.6 0.9 0.0 0.4 18.1 0.5 0.1 60.7 0.0 0.0 0.0 0.0 19.1 0.0 0.0 0.0 2.9 0.0 82.5 1.4 0.0 13.9 18.2 18.9 2.8 13.4 16.4 13.7 21.3 6.0 17.1 23.0 CSF2RA "alphaGMR, CD116, CSF2R" ENSG00000198223 "Colony stimulating factor 2 receptor alpha subunit" P15509 X 1268800-1310381 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 60.2;placenta: 79.5" "Group enriched" "Detected in some" 7 "BEWO: 59.0;HMC-1: 17.7;SK-MEL-30: 41.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 30.0;eosinophil: 36.0;intermediate monocyte: 17.7;myeloid DC: 31.9;neutrophil: 60.2;plasmacytoid DC: 30.5" "Group enriched" "Detected in many" 28 "dendritic cells: 31.9;granulocytes: 60.2;monocytes: 30.0" CAB016148 Uncertain "Secreted to blood" 9400000 "CAB016148: AB_626868" "unprognostic (4.19e-2)" "prognostic favourable (2.38e-5)" "unprognostic (5.47e-2)" "unprognostic (4.33e-2)" "unprognostic (4.88e-2)" "prognostic favourable (2.81e-4)" "unprognostic (8.24e-2)" "unprognostic (2.17e-1)" "unprognostic (5.55e-2)" "unprognostic (8.48e-2)" "unprognostic (8.89e-2)" "unprognostic (3.80e-1)" "unprognostic (2.89e-2)" "unprognostic (8.91e-3)" "prognostic unfavourable (5.53e-4)" "unprognostic (3.60e-1)" "unprognostic (9.44e-2)" 8.7 2.3 11.8 11.1 11.1 8.9 17.7 3.4 9.6 3.1 2.2 0.6 0.6 2.2 4.4 0.6 2.1 2.2 5.7 3.7 15.0 4.7 2.4 1.7 11.2 8.3 18.8 6.5 3.5 1.0 0.2 2.1 79.5 13.2 1.5 3.3 0.6 3.1 1.0 0.6 1.8 3.3 2.9 25.5 12.6 1.7 0.6 16.3 0.6 2.5 0.6 10.4 4.2 1.5 0.3 31.9 60.2 30.0 1.4 0.2 10.1 0.1 3.4 0.2 0.0 0.0 0.0 59.0 0.0 0.1 0.1 0.0 1.2 0.3 0.0 3.8 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 2.4 0.0 0.0 1.3 17.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 5.4 0.5 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 1.0 0.0 41.3 2.7 4.9 0.0 0.0 1.7 0.3 0.0 0.1 0.1 0.1 0.0 5.3 0.0 2.4 30.0 36.0 0.0 17.7 0.2 0.3 0.0 0.0 31.9 0.1 0.0 0.0 60.2 1.4 8.4 30.5 0.1 10.1 11.8 11.1 3.4 9.6 15.0 4.7 18.8 6.5 13.2 16.3 CSF2RB "betaGMR, CD131, IL3RB, IL5RB" ENSG00000100368 "Colony stimulating factor 2 receptor beta common subunit" P32927 22 36913628-36940449 "CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 53.1;placenta: 73.6" "Group enriched" "Detected in some" 6 "HEL: 26.3;HMC-1: 82.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 6 "basophil: 53.1;neutrophil: 20.1" "Lineage enriched" "Detected in many" 14 "granulocytes: 53.1" "Low region specificity" "Detected in all" HPA078677 Approved "Golgi apparatus" "Golgi apparatus" "HPA078677: " "unprognostic (1.67e-2)" "unprognostic (9.44e-3)" "unprognostic (1.03e-2)" "unprognostic (6.66e-3)" "unprognostic (1.51e-1)" "prognostic favourable (7.47e-5)" "unprognostic (1.86e-1)" "unprognostic (1.94e-2)" "unprognostic (4.38e-1)" "unprognostic (9.57e-2)" "unprognostic (1.33e-1)" "unprognostic (3.21e-1)" "unprognostic (1.82e-3)" "unprognostic (5.76e-2)" "unprognostic (3.65e-2)" "unprognostic (1.95e-1)" "unprognostic (8.52e-2)" 8.5 1.8 1.5 28.9 1.5 21.7 6.0 0.6 1.0 3.0 5.9 2.0 0.4 4.5 2.2 2.8 4.0 3.6 5.5 4.2 1.4 1.4 2.4 3.5 12.6 34.1 2.9 0.2 2.5 1.9 0.3 1.2 73.6 2.4 3.5 3.8 2.8 9.7 1.0 2.6 3.8 10.2 3.0 2.9 25.2 3.9 2.1 1.9 8.2 3.4 4.8 30.5 8.2 4.3 0.4 3.8 53.1 2.1 0.0 0.6 1.8 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.0 26.3 0.0 0.0 0.0 0.4 82.6 0.0 0.0 0.0 0.0 4.6 0.0 3.2 0.0 0.0 0.0 2.7 0.0 0.0 2.6 0.0 9.8 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 2.3 0.0 0.2 0.0 0.0 0.0 0.4 0.2 1.6 0.0 3.8 0.0 53.1 1.9 5.8 0.0 2.1 0.0 0.4 0.0 0.0 1.2 0.3 0.0 0.0 20.1 0.0 1.7 3.8 0.6 1.8 1.5 1.5 0.6 1.0 1.4 1.4 2.9 0.2 2.4 1.9 CSF3R "CD114, GCSFR" ENSG00000119535 "Colony stimulating factor 3 receptor" Q99062 1 36466043-36483278 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 167.3;bone marrow: 88.9;lymphoid tissue: 71.4;placenta: 152.7" "Group enriched" "Detected in some" 18 "BEWO: 34.1;NB-4: 9.2;THP-1: 22.4;U-937: 21.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 8 "neutrophil: 167.3" "Lineage enriched" "Detected in many" 8 "granulocytes: 167.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB017116, HPA048086" Enhanced "Intracellular and membrane" "CAB017116: , HPA048086: " "unprognostic (5.57e-3)" "unprognostic (8.05e-2)" "unprognostic (7.23e-2)" "unprognostic (3.87e-2)" "unprognostic (2.88e-1)" "unprognostic (2.92e-2)" "unprognostic (2.86e-2)" "unprognostic (1.35e-1)" "unprognostic (1.83e-1)" "unprognostic (5.65e-2)" "unprognostic (2.47e-1)" "unprognostic (3.44e-1)" "prognostic unfavourable (5.72e-4)" "unprognostic (6.33e-2)" "prognostic unfavourable (3.79e-4)" "unprognostic (2.03e-1)" "unprognostic (2.31e-2)" 8.5 1.5 2.9 39.5 3.2 88.9 2.4 0.7 2.9 1.1 1.1 4.2 0.4 0.6 0.7 1.1 1.2 6.9 4.3 5.6 2.6 2.0 1.7 4.5 26.9 27.5 7.2 1.1 1.1 1.3 0.3 1.1 152.7 3.8 1.3 0.5 2.1 1.6 0.5 0.6 0.3 1.6 3.1 7.1 71.4 2.2 1.4 3.3 1.1 1.0 0.4 0.9 4.6 3.9 0.0 8.2 167.3 22.1 0.2 0.0 10.3 0.0 0.0 0.0 0.0 0.0 0.0 34.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 9.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 22.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 21.6 0.0 0.0 22.1 0.6 0.0 4.8 0.0 0.0 0.0 0.0 8.2 0.0 0.0 0.0 167.3 0.2 1.8 0.2 0.0 10.3 2.9 3.2 0.7 2.9 2.6 2.0 7.2 1.1 3.8 3.3 CTLA4 "CD, CD152, CELIAC3, GSE, IDDM12" ENSG00000163599 "Cytotoxic T-lymphocyte associated protein 4" P16410 2 203867786-203873960 "CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Diabetes mellitus, Disease mutation, FDA approved drug targets, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 24.8;lymphoid tissue: 31.2" "Cell line enhanced" "Detected in some" "SK-MEL-30: 3.8;U-266/70: 5.8;U-266/84: 16.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in some" 6 "T-reg: 24.8" "Lineage enriched" "Detected in single" 248 "T-cells: 24.8" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Intracellular and membrane" "unprognostic (1.92e-2)" "unprognostic (9.13e-3)" "unprognostic (1.47e-3)" "unprognostic (9.89e-6)" "unprognostic (1.86e-1)" "prognostic favourable (4.48e-5)" "unprognostic (1.02e-1)" "unprognostic (1.75e-2)" "unprognostic (1.84e-3)" "unprognostic (2.65e-3)" "unprognostic (2.77e-1)" "unprognostic (3.76e-1)" "unprognostic (9.86e-10)" "unprognostic (4.13e-2)" "unprognostic (7.45e-2)" "unprognostic (4.94e-2)" "unprognostic (1.19e-2)" 1.6 0.2 0.2 24.1 0.3 2.9 1.3 0.2 0.6 0.8 1.6 0.1 0.6 0.2 1.1 0.1 2.0 1.2 3.6 0.5 0.3 0.5 1.6 0.6 5.8 27.9 0.3 0.3 0.7 0.3 0.1 0.6 0.1 1.7 1.1 1.7 0.8 1.4 0.6 0.2 1.0 10.3 0.3 1.5 6.7 1.2 1.7 0.1 14.2 1.9 3.3 31.2 4.6 1.3 0.0 0.0 0.0 0.0 0.0 24.8 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.2 0.0 0.5 0.0 0.3 0.0 5.8 16.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 4.0 0.4 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.0 24.8 0.4 0.2 0.3 0.2 0.6 0.3 0.5 0.3 0.3 1.7 0.1 CXCR1 "CD181, CDw128a, CKR-1, CMKAR1, IL8RA" ENSG00000163464 "C-X-C motif chemokine receptor 1" P25024 2 218162845-218166995 "Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins" Chemotaxis "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 144.6" "Cell line enriched" "Detected in single" 26 "HMC-1: 11.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in some" 16 "neutrophil: 144.6" "Lineage enriched" "Detected in many" 59 "granulocytes: 144.6" "Not detected" "Not detected" HPA031991 Uncertain "HPA031991: " "unprognostic (2.80e-1)" "unprognostic (2.91e-2)" "unprognostic (3.53e-2)" "unprognostic (5.74e-2)" "unprognostic (1.19e-1)" "unprognostic (1.68e-1)" "unprognostic (2.14e-2)" "unprognostic (3.36e-2)" "unprognostic (2.32e-1)" "unprognostic (1.57e-1)" "unprognostic (8.27e-2)" "unprognostic (2.15e-2)" "unprognostic (2.88e-1)" "unprognostic (5.47e-2)" "unprognostic (2.97e-1)" "unprognostic (1.30e-1)" "unprognostic (8.85e-2)" 11.5 0.4 0.8 21.1 0.7 7.3 0.6 0.9 2.6 0.6 0.6 0.2 0.0 0.0 0.5 0.1 1.3 2.8 3.6 3.8 0.9 0.6 0.7 2.9 20.3 33.4 5.9 0.0 1.7 1.2 0.0 0.8 2.1 2.3 0.9 0.1 1.4 0.6 0.0 1.0 0.5 0.6 1.4 3.4 33.7 1.0 1.4 0.7 0.1 0.9 0.6 0.4 4.5 4.1 0.0 0.0 144.6 0.2 0.1 2.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.3 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.7 0.2 0.2 2.4 0.0 0.0 0.0 0.2 0.6 0.0 0.0 0.0 0.9 144.6 0.1 0.2 0.0 0.0 0.7 0.8 0.7 0.9 2.6 0.9 0.6 5.9 0.0 2.3 0.7 CXCR2 "CD182, CMKAR2, IL8RB" ENSG00000180871 "C-X-C motif chemokine receptor 2" P25025 2 218125289-218137253 "Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" Chemotaxis "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "blood: 216.1" "Group enriched" "Detected in some" 11 "BEWO: 12.1;HL-60: 6.7;HMC-1: 14.1;THP-1: 12.8;U-937: 12.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in many" 59 "neutrophil: 216.1" "Lineage enriched" "Detected in many" 109 "granulocytes: 216.1" "Low region specificity" "Detected in single" "CAB016268, HPA031999, HPA032017" Enhanced Supported "Nucleoplasm,Plasma membrane,Microtubules,Mitotic spindle" "Plasma membrane" "Nucleoplasm, Microtubules, Mitotic spindle" "CAB016268: AB_626893, HPA031999: AB_2674105, HPA032017: AB_2674112" "unprognostic (4.89e-2)" "unprognostic (2.01e-1)" "unprognostic (5.63e-2)" "unprognostic (1.10e-2)" "unprognostic (1.58e-1)" "unprognostic (3.13e-1)" "unprognostic (1.33e-1)" "unprognostic (2.13e-1)" "unprognostic (5.96e-2)" "unprognostic (1.22e-2)" "unprognostic (5.67e-2)" "unprognostic (1.41e-1)" "unprognostic (7.54e-2)" "unprognostic (1.04e-1)" "unprognostic (7.23e-2)" "unprognostic (8.18e-2)" "unprognostic (5.48e-2)" 9.3 0.9 1.3 25.6 1.5 4.0 0.6 1.2 1.3 5.2 0.6 0.5 2.5 0.0 0.8 1.1 18.1 3.3 5.2 4.3 1.5 0.6 0.7 4.6 16.7 40.5 6.6 0.0 1.2 1.7 0.0 0.7 4.5 1.7 1.9 0.3 1.8 3.3 2.6 0.6 3.0 0.7 1.4 4.1 30.6 1.0 1.1 0.7 0.6 0.6 4.8 10.1 5.4 6.4 0.0 1.6 216.1 1.9 0.4 1.9 1.0 0.0 0.0 0.1 0.0 0.0 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 6.7 14.1 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.3 1.0 0.2 0.0 0.3 0.0 1.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 12.8 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 12.6 0.0 3.6 1.9 3.2 1.9 0.5 0.0 0.0 0.0 0.4 0.8 0.0 0.0 0.7 216.1 0.4 0.2 1.6 0.0 1.0 1.3 1.5 1.2 1.3 1.5 0.6 6.6 0.0 1.7 0.7 CXCR3 "CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR" ENSG00000186810 "C-X-C motif chemokine receptor 3" P49682 X 71615916-71618517 "CD markers, G-protein coupled receptors, Predicted membrane proteins" "Angiogenesis, Apoptosis, Chemotaxis" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 61.7;lymphoid tissue: 24.5" "Cell line enriched" "Detected in some" 15 "RPMI-8226: 31.7" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 61.7" "Group enriched" "Detected in many" 4 "dendritic cells: 61.7;NK-cells: 38.1;T-cells: 26.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA045942 Enhanced "HPA045942: " "unprognostic (4.84e-3)" "unprognostic (3.05e-3)" "unprognostic (1.61e-1)" "prognostic favourable (3.44e-6)" "unprognostic (3.93e-2)" "prognostic favourable (3.35e-4)" "unprognostic (1.01e-2)" "unprognostic (5.24e-2)" "prognostic favourable (2.90e-4)" "unprognostic (6.32e-2)" "unprognostic (1.34e-1)" "unprognostic (2.39e-1)" "prognostic unfavourable (1.67e-6)" "unprognostic (4.67e-2)" "unprognostic (2.18e-1)" "unprognostic (2.91e-2)" "unprognostic (5.76e-2)" 0.9 0.9 0.4 9.0 0.4 6.0 0.6 0.3 0.3 1.9 2.4 0.4 0.5 5.4 3.3 1.4 1.3 1.1 2.6 2.4 0.3 0.4 1.9 0.8 4.5 19.0 0.4 0.1 1.6 0.8 0.0 0.6 0.7 0.5 2.9 0.8 1.5 3.9 1.0 0.4 0.5 9.1 0.3 0.7 13.9 2.6 0.6 0.0 14.0 1.9 1.7 24.5 1.7 1.8 9.8 61.7 0.4 0.0 38.1 26.6 6.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.1 1.0 0.0 0.0 0.0 0.0 31.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.1 0.0 0.0 0.0 0.0 17.3 0.0 8.9 9.8 19.6 26.6 1.6 1.8 1.2 11.1 0.4 38.1 0.0 61.7 17.8 6.3 0.4 0.4 0.3 0.3 0.3 0.4 0.4 0.1 0.5 0.0 CXCR4 "CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R" ENSG00000121966 "C-X-C motif chemokine receptor 4" P61073 2 136114349-136118165 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Host-virus interaction" "G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 149.9;lymphoid tissue: 186.3" "Cell line enhanced" "Detected in many" "Daudi: 75.5;Karpas-707: 40.5;MOLT-4: 68.5;REH: 36.3;U-266/70: 87.9;U-698: 88.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "unprognostic (1.19e-1)" "unprognostic (1.46e-2)" "unprognostic (2.69e-1)" "unprognostic (5.97e-2)" "unprognostic (1.29e-2)" "unprognostic (1.12e-2)" "unprognostic (4.99e-2)" "unprognostic (9.25e-2)" "unprognostic (6.06e-2)" "prognostic favourable (2.05e-4)" "unprognostic (1.23e-1)" "unprognostic (2.66e-1)" "prognostic unfavourable (1.41e-7)" "prognostic unfavourable (5.67e-4)" "unprognostic (1.57e-1)" "unprognostic (3.47e-2)" "unprognostic (9.33e-2)" 15.4 26.5 3.0 39.1 3.4 149.9 9.7 0.8 2.1 7.7 8.7 6.8 1.5 1.6 8.3 3.8 16.4 9.1 12.0 5.4 4.1 4.7 8.2 7.1 29.3 94.5 6.5 1.3 6.3 3.1 0.7 8.1 7.8 6.1 6.8 7.0 10.0 10.6 2.2 3.2 2.3 57.8 3.8 22.9 82.4 8.0 7.2 3.4 186.3 9.2 4.6 97.5 50.0 6.6 47.3 16.8 37.8 7.2 4.0 32.0 11.9 0.1 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 75.5 0.2 0.0 0.0 0.2 0.0 0.0 3.8 0.9 4.5 12.0 0.0 0.0 10.4 8.2 0.0 0.0 0.0 0.0 7.2 0.1 40.5 0.0 0.2 68.5 9.3 1.2 0.3 36.3 8.4 13.2 0.6 0.0 4.2 3.5 0.0 0.2 0.0 0.0 20.5 1.0 0.0 0.2 0.0 0.0 87.9 14.8 88.4 0.0 17.2 0.0 17.9 7.2 29.6 22.9 3.8 18.7 30.1 21.1 21.7 6.6 47.3 32.0 30.1 37.8 4.0 2.1 16.8 18.9 11.9 3.0 3.4 0.8 2.1 4.1 4.7 6.5 1.3 6.1 3.4 CXCR5 "BLR1, CD185, MDR15" ENSG00000160683 "C-X-C motif chemokine receptor 5" P32302 11 118883766-118897799 "CD markers, G-protein coupled receptors, Predicted membrane proteins" "B-cell activation" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 35.5;lymphoid tissue: 45.6" "Group enriched" "Detected in some" 10 "Daudi: 10.3;U-698: 36.2" "Not detected" "Not detected" "Region enriched" "Detected in single" 4 "cerebellum: 4.0" "Group enriched" "Detected in some" 8 "memory B-cell: 24.2;naive B-cell: 35.5" "Lineage enriched" "Detected in many" 9 "B-cells: 35.5" "Not detected" "Not detected" "Low region specificity" "Detected in some" "CAB026149, HPA042432" Enhanced "CAB026149: , HPA042432: " "unprognostic (8.51e-2)" "unprognostic (1.52e-2)" "unprognostic (1.68e-1)" "unprognostic (1.19e-1)" "unprognostic (4.02e-5)" "unprognostic (2.08e-2)" "unprognostic (3.23e-3)" "unprognostic (1.19e-2)" "unprognostic (3.66e-1)" "unprognostic (2.41e-3)" "unprognostic (1.52e-5)" "unprognostic (4.21e-1)" "unprognostic (2.03e-3)" "unprognostic (1.38e-1)" "unprognostic (1.90e-1)" 0.4 0.8 0.6 31.8 0.6 7.3 0.1 4.0 0.9 0.1 3.6 0.2 0.1 0.1 0.2 0.1 2.6 0.0 0.5 0.9 0.7 0.5 0.8 1.0 0.9 31.5 0.3 0.1 0.3 0.5 0.0 0.9 0.1 0.2 2.9 0.3 0.3 3.6 0.1 1.3 0.9 8.6 0.1 0.3 45.6 1.3 0.1 0.1 1.9 0.7 1.3 41.8 3.9 0.9 35.5 0.0 0.0 0.0 0.0 3.9 1.9 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 10.3 0.2 0.0 0.6 0.0 0.0 0.0 0.0 0.1 2.3 0.0 0.0 0.0 0.2 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.4 0.9 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.3 0.4 0.0 0.0 0.4 0.1 0.5 0.0 0.2 0.4 0.0 0.0 0.2 0.0 36.2 0.0 0.4 0.0 0.0 0.0 0.0 0.3 0.0 0.3 24.2 3.9 1.0 0.0 35.5 0.4 0.3 0.0 0.0 0.0 0.0 0.5 1.9 0.6 0.6 4.0 0.9 0.7 0.5 0.3 0.1 0.2 0.1 CXCR6 "BONZO, CD186, STRL33, TYMSTR" ENSG00000172215 "C-X-C motif chemokine receptor 6" O00574 3 45940933-45948353 "CD markers, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "blood: 81.3" "Group enriched" "Detected in some" 6 "BEWO: 4.1;CAPAN-2: 15.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in many" 4 "MAIT T-cell: 81.3" "Lineage enriched" "Detected in many" 6 "T-cells: 81.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "unprognostic (2.05e-3)" "prognostic favourable (4.92e-4)" "unprognostic (1.77e-3)" "prognostic favourable (6.74e-6)" "unprognostic (6.67e-2)" "prognostic favourable (2.16e-4)" "unprognostic (2.09e-2)" "unprognostic (1.51e-2)" "unprognostic (1.93e-2)" "unprognostic (3.65e-4)" "unprognostic (8.57e-2)" "unprognostic (1.07e-1)" "prognostic unfavourable (2.42e-5)" "unprognostic (2.25e-2)" "unprognostic (4.42e-2)" "unprognostic (3.46e-2)" "unprognostic (1.57e-2)" 2.5 1.1 0.5 7.6 0.5 0.5 2.1 0.4 0.5 2.3 9.9 1.1 1.5 3.0 2.7 3.2 3.0 2.4 5.2 1.7 0.6 0.6 2.5 2.5 9.2 10.4 0.6 0.2 3.7 1.6 0.0 0.9 18.9 1.0 2.6 2.6 3.0 3.3 0.2 7.7 1.1 10.8 1.0 1.3 22.3 6.0 2.3 0.2 5.2 4.1 5.3 14.6 5.2 2.6 0.0 0.1 0.1 0.0 13.4 81.3 3.8 0.3 0.1 0.0 0.3 0.0 0.0 4.1 0.2 0.0 0.0 0.0 1.1 15.4 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.7 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.2 0.8 0.2 0.3 0.6 0.1 0.0 0.0 0.0 1.7 0.0 0.1 0.3 0.9 0.0 0.2 0.8 0.4 1.5 0.7 0.0 0.1 0.1 0.0 0.2 0.2 0.1 0.1 0.0 0.0 0.0 17.3 0.0 81.3 0.0 4.9 20.3 0.0 0.0 0.2 3.1 0.1 13.4 0.0 0.1 14.5 3.8 0.5 0.5 0.4 0.5 0.6 0.6 0.6 0.2 1.0 0.2 DDR1 "CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6" ENSG00000204580 "Discoidin domain receptor tyrosine kinase 1" Q08345 6 30876421-30900156 "CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Lactation, Pregnancy" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HaCaT: 31.2;HBEC3-KT: 24.0;RT4: 31.9;T-47d: 35.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010162, CAB025656, HPA057194" Approved Approved "Nucleoplasm,Cell Junctions" "Intracellular and membrane" 2100000 "Nucleoplasm, Cell Junctions" "CAB010162: AB_2092090, CAB025656: , HPA057194: " "unprognostic (2.11e-2)" "unprognostic (9.31e-2)" "unprognostic (1.01e-1)" "unprognostic (1.09e-1)" "unprognostic (2.07e-1)" "unprognostic (7.75e-3)" "unprognostic (6.43e-2)" "unprognostic (1.92e-1)" "unprognostic (1.73e-1)" "unprognostic (1.42e-1)" "unprognostic (1.50e-1)" "unprognostic (4.41e-2)" "prognostic favourable (3.31e-10)" "unprognostic (1.42e-1)" "unprognostic (2.53e-1)" "unprognostic (5.49e-3)" "unprognostic (4.09e-2)" 6.7 11.3 23.5 7.9 36.2 2.2 12.5 6.8 42.2 9.7 25.2 57.4 17.6 16.8 7.7 10.5 30.5 31.7 18.9 8.7 27.8 20.8 19.8 3.5 13.2 3.1 55.7 19.8 11.3 20.9 28.2 14.6 13.3 34.7 17.7 14.9 4.0 28.3 20.5 9.1 41.3 32.1 3.1 43.2 5.1 52.2 5.1 37.0 8.7 20.9 10.5 7.6 16.3 16.6 1.8 0.4 0.0 0.2 0.0 1.8 0.9 19.3 6.4 9.1 1.9 0.6 0.8 5.6 0.5 0.1 0.2 0.0 8.6 10.3 0.1 10.8 1.7 31.2 1.9 24.0 0.1 10.7 3.4 0.0 5.8 2.2 1.8 0.0 0.4 1.2 12.4 0.1 0.2 0.7 5.6 0.2 1.3 12.2 0.6 0.0 1.5 1.3 1.3 6.8 0.7 4.6 31.9 1.6 0.8 1.8 14.4 7.0 35.8 0.2 1.4 4.5 4.2 0.4 4.5 0.2 0.0 0.8 2.9 0.0 3.9 0.0 0.2 0.0 1.1 0.0 0.8 0.4 0.2 0.7 0.4 1.8 1.2 1.8 0.0 0.0 0.0 0.4 0.0 0.9 23.5 36.2 6.8 25.0 27.8 20.8 55.7 19.8 34.7 37.0 DDR2 "NTRKR3, TKT, TYRO10" ENSG00000162733 "Discoidin domain receptor tyrosine kinase 2" Q16832 1 162631373-162787400 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Osteogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 60.6;ASC TERT1: 59.9;BJ hTERT+: 44.3;fHDF/TERT166: 31.7;HSkMC: 42.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 1.1;MAIT T-cell: 1.3" "Lineage enriched" "Detected in single" 5 "T-cells: 1.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA070112 Supported "Plasma membrane,Actin filaments" 850000 "Plasma membrane, Actin filaments" "HPA070112: " "unprognostic (4.12e-2)" "unprognostic (2.73e-1)" "unprognostic (6.97e-3)" "unprognostic (4.52e-2)" "unprognostic (1.17e-1)" "unprognostic (8.16e-2)" "unprognostic (1.81e-1)" "unprognostic (1.19e-1)" "unprognostic (6.62e-2)" "unprognostic (2.24e-2)" "unprognostic (1.00e-1)" "unprognostic (1.15e-1)" "prognostic unfavourable (1.73e-7)" "unprognostic (1.56e-3)" "unprognostic (8.26e-3)" "unprognostic (7.57e-2)" "unprognostic (4.10e-3)" 42.1 43.5 4.7 10.9 6.9 0.2 15.6 7.9 7.1 30.3 30.4 9.0 18.6 3.3 24.2 17.7 25.0 13.4 16.6 15.4 7.9 4.7 4.0 3.3 8.9 5.1 12.9 3.4 26.4 2.2 2.1 4.0 6.6 12.7 21.8 9.1 30.7 6.4 19.3 5.2 6.1 10.1 34.3 19.7 3.4 14.1 8.3 7.5 0.0 8.6 12.8 4.1 29.0 18.3 0.1 0.2 0.0 0.0 0.2 1.3 0.0 0.1 0.0 0.0 16.0 60.6 59.9 0.2 23.6 44.3 10.3 14.9 0.0 0.0 0.0 0.0 31.7 0.0 0.0 0.1 14.1 12.7 0.1 0.0 0.0 0.0 26.3 0.0 0.0 42.5 0.1 18.2 0.4 11.8 0.1 5.0 9.4 0.0 0.0 0.0 0.1 0.1 0.0 6.7 0.1 0.0 0.0 0.0 9.7 0.0 0.0 0.8 0.0 0.0 0.6 16.5 3.6 8.3 3.2 0.7 1.3 0.0 14.9 0.0 16.7 0.0 0.0 0.0 1.1 0.0 1.3 0.0 0.8 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 4.7 6.9 7.9 7.1 7.9 4.7 12.9 3.4 12.7 7.5 DPP4 "ADCP2, CD26, DPPIV" ENSG00000197635 "Dipeptidyl peptidase 4" P27487 2 161992241-162074542 "CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cell adhesion" "Aminopeptidase, Hydrolase, Protease, Receptor, Serine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 133.1;parathyroid gland: 75.5" "Cell line enhanced" "Detected in some" "ASC diff: 41.8;ASC TERT1: 42.4;BJ hTERT+: 38.9;RPTEC TERT1: 56.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in many" "MAIT T-cell: 26.7" "Lineage enriched" "Detected in many" 10 "T-cells: 26.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" CAB045970 Enhanced "Secreted in other tissues" 170000000 "CAB045970: AB_11140529" "unprognostic (4.47e-2)" "unprognostic (4.47e-2)" "unprognostic (8.89e-2)" "unprognostic (3.36e-1)" "unprognostic (7.25e-2)" "unprognostic (5.40e-2)" "unprognostic (2.78e-1)" "unprognostic (3.54e-2)" "unprognostic (3.58e-1)" "unprognostic (4.73e-1)" "unprognostic (2.36e-1)" "prognostic unfavourable (1.98e-4)" "prognostic favourable (1.35e-6)" "unprognostic (4.68e-2)" "unprognostic (6.33e-2)" "prognostic favourable (4.99e-4)" "unprognostic (1.21e-2)" 9.5 2.9 0.3 3.2 0.5 0.0 5.0 0.3 1.4 2.2 50.0 0.2 36.9 19.1 2.2 3.5 1.2 1.2 5.2 2.1 0.4 0.3 29.1 12.2 5.4 2.1 0.4 0.2 2.7 1.8 75.5 0.3 24.0 0.2 21.1 2.8 0.6 46.9 38.8 2.4 4.4 133.1 0.9 0.8 5.0 1.2 0.6 0.1 6.2 1.0 1.4 1.1 1.0 2.6 0.1 2.1 0.3 0.0 2.6 26.7 2.5 0.0 0.0 0.1 0.0 41.8 42.4 0.1 7.7 38.9 2.1 7.6 7.8 0.2 0.0 2.9 13.4 0.2 0.1 0.0 1.3 2.4 0.1 0.0 0.0 11.7 17.1 0.0 0.0 4.8 0.0 13.1 0.1 1.2 0.0 0.0 0.7 0.0 0.7 0.1 0.4 16.0 0.0 0.0 0.1 56.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 6.9 4.5 0.2 0.2 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 3.2 0.0 26.7 0.1 8.3 5.2 0.6 0.0 8.3 3.3 0.3 2.6 0.0 2.1 0.9 2.5 0.3 0.5 0.3 1.4 0.4 0.3 0.4 0.2 0.2 0.1 ENG "CD105, END, HHT1, ORW, ORW1" ENSG00000106991 Endoglin P17813 9 127815012-127854756 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins" "Angiogenesis, Cell adhesion" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 66.9;TIME: 136.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 12.2;intermediate monocyte: 17.7;myeloid DC: 6.4;NK-cell: 4.6;non-classical monocyte: 13.0" "Group enriched" "Detected in many" 4 "dendritic cells: 6.4;monocytes: 17.7;NK-cells: 4.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000096, HPA011862, HPA067440, CAB072873" Enhanced Supported "Nuclear bodies,Plasma membrane" 260000000 "Plasma membrane" "Nuclear bodies" "CAB000096: AB_563482, CAB072873: , HPA011862: AB_1846217, HPA067440: " "unprognostic (2.28e-1)" "unprognostic (1.13e-1)" "unprognostic (3.87e-2)" "unprognostic (2.96e-2)" "unprognostic (1.77e-1)" "prognostic favourable (6.61e-4)" "prognostic favourable (5.62e-6)" "unprognostic (2.15e-1)" "unprognostic (4.06e-1)" "unprognostic (3.87e-2)" "unprognostic (2.20e-2)" "unprognostic (8.98e-2)" "prognostic unfavourable (4.26e-4)" "unprognostic (3.33e-3)" "unprognostic (7.35e-2)" "unprognostic (2.84e-1)" "unprognostic (1.27e-1)" 40.3 19.3 6.4 26.6 10.5 5.5 52.7 3.9 8.6 26.3 14.0 7.6 18.5 11.2 27.0 25.2 17.2 23.2 28.3 105.4 8.0 5.0 40.8 26.8 66.7 44.1 10.6 7.0 66.4 9.6 8.6 12.5 60.2 10.1 23.1 6.4 35.5 9.9 51.7 24.1 10.1 14.5 23.1 8.7 52.4 11.6 37.2 7.7 6.7 35.4 19.3 11.0 20.3 44.8 1.1 6.4 0.3 17.7 4.6 2.3 4.6 0.1 0.1 0.9 0.0 16.8 11.5 29.6 19.5 14.0 10.4 6.1 0.0 0.1 0.1 9.5 35.8 0.3 0.0 3.1 3.4 0.0 0.0 5.5 11.0 0.6 13.1 2.6 0.0 19.7 0.7 13.5 4.9 66.9 0.0 0.1 12.1 0.1 0.0 0.2 0.2 0.5 8.7 1.7 0.1 0.0 0.0 0.1 0.2 10.3 9.0 2.6 1.8 3.9 136.5 34.1 1.8 22.2 0.0 0.7 0.1 0.1 9.2 6.8 11.2 0.0 12.2 0.3 1.3 17.7 0.4 0.4 2.1 2.3 6.4 1.1 1.3 2.0 0.3 4.6 13.0 2.4 0.8 4.6 6.4 10.5 3.9 8.6 8.0 5.0 10.6 7.0 10.1 7.7 ENPEP "CD249, gp160" ENSG00000138792 "Glutamyl aminopeptidase" Q07075 4 110365733-110565285 "CD markers, Enzymes, Plasma proteins, Predicted membrane proteins" "Aminopeptidase, Hydrolase, Metalloprotease, Protease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 165.1;kidney: 63.8" "Cell line enhanced" "Detected in some" "BEWO: 4.5;HEK 293: 12.1;MOLT-4: 2.9" "Cancer enriched" "Detected in many" 8 "renal cancer: 41.0" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA005128 Enhanced 37000000 "HPA005128: AB_1844795" "unprognostic (2.73e-3)" "unprognostic (2.84e-3)" "unprognostic (5.16e-3)" "unprognostic (3.48e-1)" "unprognostic (2.90e-1)" "unprognostic (8.74e-2)" "unprognostic (3.34e-2)" "unprognostic (1.03e-1)" "unprognostic (1.35e-2)" "unprognostic (1.22e-1)" "unprognostic (1.93e-1)" "unprognostic (9.47e-2)" "unprognostic (4.49e-3)" "unprognostic (3.43e-3)" "unprognostic (1.52e-2)" "unprognostic (8.46e-2)" "unprognostic (2.49e-3)" 5.8 1.0 0.4 0.4 0.6 0.0 2.8 0.3 1.0 1.1 54.4 0.4 0.7 11.1 5.3 2.4 0.8 1.4 1.1 2.3 0.5 0.3 63.8 14.5 2.7 0.5 0.4 0.3 1.0 1.0 33.3 0.8 4.4 0.5 1.4 0.0 0.8 0.6 0.5 2.3 0.4 165.1 3.1 0.5 4.7 0.7 0.4 0.4 1.4 2.4 2.0 0.4 1.0 1.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.4 0.1 0.0 0.1 0.3 4.5 0.6 0.0 0.2 0.4 0.1 0.0 0.0 0.2 0.1 0.0 0.2 0.0 0.1 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.6 2.9 0.5 0.5 0.0 0.2 0.0 0.5 0.0 0.5 0.1 0.3 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.2 2.2 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.6 0.3 1.0 0.5 0.3 0.4 0.3 0.5 0.4 ENPP1 "M6S1, NPPS, PC-1, PCA1, PDNP1" ENSG00000197594 "Ectonucleotide pyrophosphatase/phosphodiesterase 1" P22413 6 131808016-131895155 "CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins" Biomineralization Hydrolase "Diabetes mellitus, Disease mutation, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 22.6;LHCN-M2: 13.5;U-138 MG: 18.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in some" "NK-cell: 4.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB032904, HPA062066" Enhanced "Secreted - unknown location" 2500000 "CAB032904: AB_2099635, HPA062066: " "unprognostic (1.47e-1)" "unprognostic (1.23e-1)" "unprognostic (2.15e-1)" "unprognostic (1.60e-3)" "unprognostic (2.40e-1)" "unprognostic (1.11e-1)" "unprognostic (2.00e-1)" "unprognostic (1.60e-2)" "unprognostic (7.22e-3)" "unprognostic (8.96e-2)" "unprognostic (1.95e-1)" "unprognostic (3.00e-1)" "unprognostic (2.61e-2)" "unprognostic (1.41e-1)" "unprognostic (1.96e-1)" "unprognostic (1.84e-1)" "unprognostic (3.28e-3)" 17.2 2.1 0.5 1.9 0.5 0.0 30.5 0.6 0.4 8.5 2.8 1.6 8.3 1.1 25.7 7.1 1.5 6.4 2.6 1.9 0.5 0.7 10.9 19.4 2.0 0.7 1.1 0.0 7.3 17.5 22.2 27.0 28.9 0.8 3.3 1.2 13.4 5.4 6.5 2.1 1.7 2.6 6.8 2.0 1.2 1.7 4.6 0.3 2.0 13.2 6.9 1.4 3.2 7.7 0.6 2.2 1.4 0.3 4.6 1.7 0.1 0.0 0.8 0.8 0.0 22.6 3.5 0.0 5.8 6.0 2.3 6.3 2.5 0.7 0.0 0.5 3.7 0.0 0.8 0.1 9.7 0.2 1.1 0.0 0.7 7.5 0.7 0.0 2.7 5.8 0.2 6.2 0.2 2.7 0.0 1.2 13.5 1.6 0.0 0.0 5.1 0.8 0.0 6.6 0.1 0.1 0.3 2.2 0.0 0.1 0.8 2.6 2.5 0.0 1.8 18.1 0.6 1.2 5.7 2.2 0.0 0.0 8.3 0.0 2.2 1.4 0.2 0.3 0.3 0.2 1.7 0.3 0.3 0.3 2.2 0.6 0.3 0.3 1.0 4.6 0.3 0.3 0.2 0.1 0.5 0.5 0.6 0.4 0.5 0.7 1.1 0.0 0.8 0.3 ENPP3 "B10, CD203c, gp130RB13-6, PD-IBETA, PDNP3" ENSG00000154269 "Ectonucleotide pyrophosphatase/phosphodiesterase 3" O14638 6 131628442-131747418 "CD markers, Enzymes, Predicted intracellular proteins, Predicted secreted proteins" Hydrolase "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ductus deferens: 29.0;intestine: 45.4;seminal vesicle: 70.7" "Group enriched" "Detected in some" 18 "HEL: 5.0;Hep G2: 16.6;HMC-1: 7.4" "Cancer enriched" "Detected in many" 8 "renal cancer: 49.6" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in single" 74 "basophil: 18.2" "Lineage enriched" "Detected in single" 74 "granulocytes: 18.2" "Low region specificity" "Detected in some" HPA043772 Enhanced "Secreted - unknown location" 480000 "HPA043772: AB_10795616" "unprognostic (2.74e-1)" "unprognostic (1.99e-2)" "unprognostic (1.84e-1)" "unprognostic (5.41e-3)" "unprognostic (6.07e-2)" "unprognostic (4.86e-5)" "unprognostic (1.13e-1)" "unprognostic (7.20e-3)" "unprognostic (1.17e-1)" "unprognostic (1.13e-1)" "unprognostic (2.21e-3)" "unprognostic (2.34e-1)" "prognostic unfavourable (1.96e-4)" "unprognostic (2.80e-2)" "unprognostic (7.85e-2)" "unprognostic (2.29e-1)" "unprognostic (1.31e-3)" 0.8 7.9 0.5 2.0 0.5 0.0 4.0 2.1 0.4 19.0 18.5 0.2 29.0 9.3 6.2 7.2 0.5 2.3 1.8 0.2 0.4 0.7 11.9 2.7 1.7 0.2 0.5 0.2 0.9 0.2 0.0 0.5 0.4 0.2 3.7 4.8 0.6 14.9 70.7 0.2 0.8 45.4 1.9 0.4 0.5 0.7 1.0 0.2 4.1 0.5 1.2 0.5 0.9 1.2 0.0 0.0 18.2 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.1 5.0 0.0 16.6 0.0 0.1 7.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.2 0.1 0.0 0.0 18.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.5 2.1 0.4 0.4 0.7 0.5 0.2 0.2 0.2 ENTPD1 "ATPDase, CD39, NTPDase-1, SPG64" ENSG00000138185 "Ectonucleoside triphosphate diphosphohydrolase 1" P49961 10 95711779-95869695 "CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" Hydrolase "Disease mutation, Hereditary spastic paraplegia, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "endometrium 1: 59.4" "Group enriched" "Detected in some" 7 "HDLM-2: 56.0;Karpas-707: 46.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 37.4" "Low lineage specificity" "Detected in many" "CAB002494, HPA014067" Enhanced Uncertain Microtubules Microtubules "CAB002494: AB_563557, HPA014067: AB_1848178" "unprognostic (1.14e-1)" "unprognostic (1.01e-2)" "unprognostic (3.11e-1)" "unprognostic (5.67e-2)" "unprognostic (9.68e-3)" "unprognostic (3.45e-3)" "unprognostic (6.31e-2)" "unprognostic (5.26e-3)" "unprognostic (2.73e-1)" "unprognostic (1.28e-2)" "unprognostic (6.40e-2)" "unprognostic (1.41e-1)" "prognostic unfavourable (5.33e-5)" "unprognostic (9.79e-2)" "unprognostic (2.30e-1)" "prognostic favourable (7.89e-4)" "unprognostic (5.09e-2)" 10.4 7.5 7.4 16.2 8.4 15.6 8.8 7.6 6.9 18.9 12.7 13.1 8.7 5.8 59.4 12.8 13.2 15.6 22.2 6.8 7.4 7.4 6.2 3.9 14.8 14.5 8.5 4.9 10.3 2.8 3.0 4.3 24.0 9.9 14.7 9.1 10.8 6.7 12.7 3.3 5.5 12.2 37.2 17.9 25.3 7.5 5.4 7.2 3.5 13.4 12.5 21.1 25.2 12.4 6.0 11.8 37.4 15.2 0.5 5.1 4.6 0.1 0.3 0.9 0.8 0.0 0.0 0.5 0.5 0.4 0.0 0.0 0.5 0.1 1.0 0.6 0.0 0.2 0.0 0.0 0.0 56.0 0.7 0.6 0.4 0.7 0.0 1.5 0.2 0.0 0.0 0.2 0.0 7.4 0.6 46.0 0.0 0.6 0.4 1.5 0.6 0.2 2.3 0.3 0.7 0.5 0.2 0.7 1.0 0.3 1.1 0.7 0.5 1.6 0.8 0.4 0.2 0.6 0.6 6.6 0.9 0.0 0.6 3.1 0.2 0.1 15.2 37.4 0.1 10.7 0.3 6.0 0.6 0.3 11.8 4.6 0.1 0.1 26.7 0.5 2.4 0.7 5.1 4.6 7.4 8.4 7.6 6.9 7.4 7.4 8.5 4.9 9.9 7.2 EPCAM "17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1" ENSG00000119888 "Epithelial cell adhesion molecule" P16422 2 47345158-47387601 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Tumor antigen" "Cancer-related genes, Disease mutation, FDA approved drug targets, Hereditary nonpolyposis colorectal cancer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 303.2" "Cell line enhanced" "Detected in many" "A-431: 58.3;CACO-2: 75.6;CAPAN-2: 106.4;RPTEC TERT1: 45.4;SCLC-21H: 41.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.9" "Lineage enriched" "Detected in single" 5 "dendritic cells: 1.9" "Not detected" "Not detected" "Low region specificity" "Detected in some" "CAB003809, HPA026761, CAB030012, CAB055098, HPA067463" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB003809: AB_562285, CAB030012: AB_756075, CAB055098: AB_2335685, HPA026761: AB_1848198, HPA067463: " "unprognostic (6.79e-2)" "unprognostic (2.28e-1)" "unprognostic (1.59e-2)" "unprognostic (1.16e-2)" "unprognostic (1.61e-1)" "unprognostic (3.49e-2)" "unprognostic (2.01e-1)" "unprognostic (3.61e-2)" "unprognostic (3.40e-1)" "prognostic favourable (3.30e-4)" "unprognostic (5.27e-2)" "unprognostic (3.28e-2)" "prognostic favourable (1.04e-6)" "unprognostic (6.38e-3)" "unprognostic (1.28e-1)" "unprognostic (6.45e-3)" "unprognostic (6.08e-2)" 0.4 2.1 1.8 49.8 3.0 0.2 8.9 0.6 1.0 10.8 155.8 0.7 31.5 66.8 4.4 35.2 2.8 10.2 41.6 0.4 1.7 2.7 60.2 1.2 22.6 0.4 1.2 0.4 3.8 54.1 19.8 38.7 2.2 0.9 9.0 70.5 0.7 47.2 25.0 0.5 2.0 303.2 1.7 1.4 0.5 15.3 5.5 0.9 1.7 83.6 4.2 4.1 4.1 2.1 0.2 1.9 0.4 0.2 0.0 0.0 0.6 58.3 0.6 0.0 0.1 0.0 0.0 37.0 0.0 0.0 0.0 0.0 75.6 106.4 0.0 16.4 0.1 27.5 0.5 6.9 0.2 0.0 6.7 0.0 0.3 29.7 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.1 17.4 0.0 0.0 29.8 0.0 2.8 19.1 3.8 0.0 0.0 14.8 45.4 25.8 41.1 0.3 0.4 21.7 0.0 18.3 0.1 0.0 0.0 0.7 0.2 0.1 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 1.9 0.0 0.6 1.8 3.0 0.6 1.0 1.7 2.7 1.2 0.4 0.9 0.9 ERBB2 "CD340, HER-2, HER2, NEU, NGL" ENSG00000141736 "Erb-b2 receptor tyrosine kinase 2" P04626 17 39687914-39730426 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" "Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enriched" "Detected in many" 27 "SK-BR-3: 263.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 8.8" "Lineage enriched" "Detected in many" 4 "T-cells: 8.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555" Enhanced Supported "Plasma membrane,Cytosol" 430000 "Plasma membrane" Cytosol "CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: , HPA001060: , HPA001338: , HPA001383: AB_1078500" "unprognostic (1.97e-1)" "unprognostic (6.60e-3)" "unprognostic (6.21e-2)" "prognostic unfavourable (8.99e-8)" "unprognostic (2.96e-2)" "unprognostic (1.40e-2)" "unprognostic (1.97e-2)" "unprognostic (9.04e-2)" "unprognostic (1.79e-2)" "unprognostic (1.20e-3)" "prognostic unfavourable (9.17e-4)" "unprognostic (3.92e-1)" "prognostic favourable (2.41e-14)" "unprognostic (9.29e-2)" "unprognostic (1.40e-1)" "unprognostic (3.75e-2)" "unprognostic (1.96e-1)" 5.8 2.4 5.2 10.4 7.0 0.1 20.1 4.2 7.0 19.1 46.5 9.1 55.2 21.6 14.9 18.7 40.9 22.7 26.6 24.8 6.3 3.1 37.5 21.5 17.6 3.7 5.1 5.6 19.3 16.2 27.7 8.1 60.8 7.5 23.6 16.6 15.9 28.7 58.1 8.9 35.3 47.2 10.9 4.5 4.0 17.1 6.5 3.7 2.8 35.7 20.8 22.9 19.7 20.3 1.3 0.3 2.1 0.4 0.9 8.8 2.2 3.1 3.8 4.2 2.7 5.1 3.6 5.7 2.2 3.7 4.9 4.2 2.8 8.6 0.2 4.6 5.1 9.8 0.2 5.1 2.3 0.4 3.2 0.1 3.0 4.5 3.0 0.0 0.0 3.5 4.8 3.0 1.8 2.0 0.4 0.1 3.6 4.8 0.5 0.2 7.6 0.9 0.3 1.7 0.4 5.0 9.8 0.8 0.2 4.2 263.9 1.3 7.4 0.1 0.2 2.5 3.3 3.2 1.4 0.4 0.2 0.2 0.2 0.0 8.2 1.6 0.4 0.8 8.8 0.3 0.7 0.9 0.5 2.5 0.3 1.3 1.0 2.5 2.1 0.9 0.2 0.2 0.4 2.2 5.2 7.0 4.2 7.0 6.3 3.1 5.1 5.6 7.5 3.7 EVI2B "CD361, D17S376, EVDB" ENSG00000185862 "Ecotropic viral integration site 2B" P34910 17 31303766-31314112 "CD markers, Predicted membrane proteins" Proto-oncogene "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 133.6;lymphoid tissue: 72.8" "Cell line enhanced" "Detected in many" "Daudi: 23.7;HL-60: 26.7;HMC-1: 37.7;Karpas-707: 26.7;NB-4: 21.1;RPMI-8226: 39.0;THP-1: 33.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 133.6" "Group enriched" "Detected in all" 4 "granulocytes: 133.6;monocytes: 34.3" "Low region specificity" "Detected in all" HPA007436 Enhanced "HPA007436: AB_1848307" "unprognostic (1.07e-2)" "unprognostic (1.20e-2)" "unprognostic (5.97e-2)" "unprognostic (4.09e-3)" "unprognostic (2.99e-2)" "unprognostic (1.41e-2)" "unprognostic (3.06e-1)" "unprognostic (3.36e-2)" "unprognostic (1.93e-2)" "unprognostic (1.48e-1)" "unprognostic (1.78e-2)" "unprognostic (2.34e-1)" "prognostic unfavourable (2.05e-4)" "unprognostic (1.56e-2)" "unprognostic (3.32e-2)" "unprognostic (8.64e-2)" "unprognostic (2.73e-2)" 15.0 3.6 4.4 37.7 5.8 44.0 4.2 1.7 4.4 3.7 10.7 6.5 0.3 6.0 2.8 4.8 7.1 4.7 8.1 6.7 6.4 4.4 7.8 7.1 38.5 37.5 10.2 2.6 3.8 2.7 0.4 2.1 4.8 7.8 5.3 8.1 2.5 6.6 1.5 2.3 2.4 23.3 4.2 22.0 72.8 8.0 3.7 6.7 26.1 4.0 3.0 43.0 13.0 7.6 18.6 14.6 133.6 34.3 4.1 16.4 19.8 0.1 0.1 0.0 0.0 1.9 2.5 0.0 0.2 1.6 1.9 3.7 0.0 0.9 23.7 0.0 1.5 0.1 0.0 0.3 2.2 0.0 0.0 0.5 0.0 0.0 19.5 26.7 37.7 4.5 0.0 1.1 1.5 1.9 0.3 26.7 5.6 0.0 7.8 21.1 0.0 0.0 13.6 0.1 39.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 33.7 2.0 0.5 0.0 0.2 1.9 5.1 0.2 5.1 2.4 9.2 0.6 78.9 30.5 74.5 8.2 23.2 7.9 18.6 12.6 10.6 14.6 14.3 9.7 9.1 133.6 4.1 34.3 8.4 16.4 19.8 4.4 5.8 1.7 4.4 6.4 4.4 10.2 2.6 7.8 6.7 F11R "CD321, JAM-1, JAM-A, JAM1, JAMA, JCAM, PAM-1" ENSG00000158769 "F11 receptor" Q9Y624 1 160995211-161021348 "CD markers, Plasma proteins, Predicted membrane proteins" "Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 37.7;HaCaT: 49.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "eosinophil: 44.5;neutrophil: 32.2" "Lineage enriched" "Detected in all" 5 "granulocytes: 44.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB004671, HPA043616, HPA061700" Enhanced Supported "Cell Junctions,Microtubules" 41000000 Microtubules "Cell Junctions" "CAB004671: AB_425964, HPA043616: , HPA061700: " "unprognostic (1.60e-2)" "unprognostic (5.78e-3)" "unprognostic (1.78e-3)" "unprognostic (2.24e-1)" "unprognostic (4.99e-2)" "unprognostic (4.89e-2)" "unprognostic (2.28e-1)" "unprognostic (2.55e-1)" "unprognostic (6.35e-2)" "unprognostic (1.98e-3)" "unprognostic (1.87e-2)" "unprognostic (1.24e-1)" "unprognostic (1.78e-1)" "unprognostic (2.50e-1)" "unprognostic (1.59e-1)" "unprognostic (9.72e-3)" "unprognostic (5.01e-2)" 20.7 13.3 3.0 9.6 3.6 6.4 11.8 2.0 3.5 14.5 36.3 3.9 21.4 20.5 8.6 11.2 41.5 12.3 30.5 10.0 3.4 3.2 35.9 69.8 55.0 10.4 3.6 1.8 10.9 37.9 18.5 16.3 61.8 5.3 17.8 19.5 5.7 59.3 23.7 9.0 22.0 59.8 4.9 4.0 27.0 18.8 11.0 3.3 8.1 52.2 25.8 29.9 16.8 19.7 1.3 7.0 44.5 8.9 2.2 3.8 6.6 28.5 3.7 1.1 0.3 0.8 0.0 23.3 0.1 0.0 1.0 1.0 26.4 37.7 2.1 19.4 0.0 49.4 5.8 24.5 1.5 1.6 4.3 6.0 1.5 12.0 1.1 5.6 17.8 0.3 31.0 0.1 8.2 23.2 8.1 0.6 0.1 12.3 1.7 3.2 19.7 5.3 2.6 0.0 9.2 16.6 21.7 8.2 2.1 6.9 29.7 6.1 32.3 10.0 13.9 0.1 0.7 0.1 0.2 6.9 13.6 0.7 4.4 5.5 1.8 7.6 8.9 44.5 3.8 4.5 2.0 1.3 3.5 2.3 7.0 0.9 3.4 2.7 32.2 2.2 3.4 5.3 1.5 6.6 3.0 3.6 2.0 3.5 3.4 3.2 3.6 1.8 5.3 3.3 F3 "CD142, TF" ENSG00000117525 "Coagulation factor III, tissue factor" P13726 1 94529225-94541800 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 115.2;HaCaT: 54.6;HBEC3-KT: 141.7;U-2197: 53.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 2.8" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB009438, HPA049292, HPA069132" Uncertain Approved Vesicles "Secreted to blood" 7733431000 Vesicles "CAB009438: AB_668005, HPA049292: , HPA069132: " "unprognostic (3.86e-2)" "unprognostic (1.19e-1)" "unprognostic (8.04e-2)" "unprognostic (1.64e-1)" "unprognostic (2.69e-2)" "unprognostic (1.23e-3)" "unprognostic (4.93e-2)" "unprognostic (8.00e-2)" "unprognostic (5.88e-1)" "unprognostic (1.35e-1)" "prognostic unfavourable (1.07e-4)" "unprognostic (1.25e-1)" "prognostic unfavourable (2.02e-8)" "unprognostic (4.84e-2)" "unprognostic (4.08e-1)" "unprognostic (1.23e-1)" "unprognostic (1.08e-1)" 45.5 9.8 27.0 14.1 42.9 2.1 55.1 3.4 27.9 14.8 18.7 20.9 18.7 18.3 30.5 23.7 21.3 25.4 30.9 18.8 26.9 14.5 6.6 2.8 31.4 5.8 14.1 20.3 41.6 35.0 6.1 28.8 65.4 39.2 29.7 22.2 49.9 29.2 33.0 2.4 17.7 19.2 5.9 46.3 2.9 18.2 16.4 16.0 0.0 21.8 17.3 11.9 24.7 22.3 0.5 0.9 2.8 0.8 0.7 0.4 0.2 115.2 0.2 0.2 0.0 12.6 6.2 6.5 16.4 9.8 17.8 19.4 2.0 24.7 0.0 8.4 20.3 54.6 1.4 141.7 29.3 0.1 0.1 0.0 3.5 0.3 4.2 0.0 0.0 10.7 3.2 8.4 41.1 0.1 0.1 0.1 12.4 0.2 0.1 2.4 1.1 0.2 0.1 1.1 0.0 2.2 0.3 0.1 0.3 13.1 5.4 0.4 0.1 1.5 0.0 10.8 0.3 53.8 4.9 0.1 0.1 0.0 8.2 0.6 0.4 1.7 0.8 0.1 0.3 0.3 0.4 0.2 0.3 0.2 0.2 0.5 0.3 0.3 2.8 0.7 0.2 0.9 0.2 0.2 27.0 42.9 3.4 27.1 26.9 14.5 14.1 20.3 39.2 16.0 FAS "APO-1, APT1, CD95, FAS1, TNFRSF6" ENSG00000026103 "Fas cell surface death receptor" P25445 10 88990582-89015785 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Apoptosis "Calmodulin-binding, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 43.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 40.1" "Group enriched" "Detected in all" 5 "granulocytes: 40.1;T-cells: 30.9" "Low region specificity" "Detected in all" HPA027444 Uncertain Supported "Nuclear bodies,Plasma membrane,Cytosol" "Secreted to blood" 450000 "Plasma membrane" "Nuclear bodies, Cytosol" "HPA027444: AB_10601378" "unprognostic (6.84e-2)" "unprognostic (2.88e-3)" "unprognostic (8.38e-3)" "unprognostic (1.94e-1)" "unprognostic (2.35e-2)" "unprognostic (9.56e-2)" "unprognostic (7.00e-2)" "unprognostic (2.05e-1)" "unprognostic (3.01e-1)" "unprognostic (7.70e-2)" "unprognostic (1.26e-2)" "unprognostic (1.98e-1)" "unprognostic (1.52e-3)" "unprognostic (2.10e-1)" "unprognostic (2.32e-2)" "unprognostic (4.95e-3)" "unprognostic (1.65e-1)" 13.5 26.3 6.1 17.3 7.7 12.4 10.6 2.1 7.2 15.6 14.2 6.1 7.0 5.9 15.7 16.6 14.1 14.2 14.5 8.9 8.2 2.7 11.7 21.9 28.6 15.6 6.0 3.9 24.7 4.1 4.5 4.6 9.0 7.5 22.3 21.3 4.4 7.1 8.5 4.3 9.6 16.3 12.5 10.2 15.3 5.0 7.3 5.1 12.5 10.0 15.8 14.4 14.8 21.4 3.0 4.0 40.1 6.8 1.2 30.9 3.9 8.5 3.3 1.7 5.5 14.2 21.0 0.0 18.9 19.1 0.7 3.7 0.0 9.3 1.7 7.3 17.7 1.3 0.3 15.8 1.3 27.5 2.7 0.1 1.8 5.6 13.6 0.9 0.4 26.0 14.2 11.8 25.5 1.6 0.0 43.8 19.2 0.7 2.7 1.4 0.2 0.9 0.1 0.1 1.7 26.5 2.7 0.1 0.1 2.7 0.0 0.3 6.0 0.3 4.1 6.0 3.4 5.6 4.3 17.2 1.7 0.1 5.0 3.4 1.8 11.3 3.2 9.4 3.3 3.9 4.8 3.0 10.4 7.2 4.0 0.7 1.2 3.4 40.1 1.2 6.8 0.0 30.9 3.9 6.1 7.7 2.1 7.2 8.2 2.7 6.0 3.9 7.5 5.1 FASLG "APT1LG1, CD178, FasL, TNFSF6" ENSG00000117560 "Fas ligand" P48023 1 172659018-172666874 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Apoptosis, Transcription, Transcription regulation" "Cytokine, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 25.6;lymphoid tissue: 13.4" "Cell line enhanced" "Detected in some" "ASC diff: 1.0;LHCN-M2: 2.4;NB-4: 1.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in many" "gdT-cell: 25.6" "Group enriched" "Detected in many" 12 "NK-cells: 16.0;T-cells: 25.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA054959 Approved "Secreted to blood" 34930061667 "HPA054959: " "unprognostic (1.09e-3)" "unprognostic (1.41e-2)" "unprognostic (8.69e-2)" "unprognostic (1.54e-7)" "unprognostic (3.29e-1)" "unprognostic (2.23e-3)" "unprognostic (5.44e-2)" "unprognostic (1.84e-2)" "unprognostic (4.67e-2)" "unprognostic (4.76e-2)" "unprognostic (8.88e-2)" "unprognostic (1.07e-1)" "prognostic unfavourable (1.59e-6)" "unprognostic (3.49e-2)" "unprognostic (1.22e-1)" "unprognostic (1.15e-2)" "unprognostic (3.82e-3)" 0.9 1.1 0.5 1.9 0.7 3.6 1.8 0.5 0.8 0.7 2.6 0.6 0.0 3.0 3.9 1.2 1.0 0.8 1.6 1.2 0.5 0.5 1.2 2.2 6.8 7.7 1.4 0.0 1.5 0.6 0.0 0.7 2.4 0.6 4.7 1.2 2.8 1.9 0.3 0.4 0.5 3.8 1.9 1.7 13.4 2.1 0.4 0.0 1.2 1.1 0.0 10.1 1.4 0.9 0.0 0.0 1.6 0.0 16.0 25.6 5.5 0.0 0.0 0.3 0.1 1.0 0.0 0.5 0.2 0.0 0.0 0.1 0.0 0.5 0.5 0.1 0.0 0.8 0.0 0.2 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.2 0.1 0.0 0.2 0.4 0.7 0.0 0.2 0.6 2.4 0.0 0.0 1.2 0.4 0.0 0.0 0.0 0.1 1.0 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.3 0.3 0.7 0.0 0.0 0.0 0.1 0.1 1.6 0.0 0.0 25.6 0.0 15.8 0.0 5.4 13.7 0.0 0.0 1.1 11.7 0.8 16.0 0.0 0.0 0.1 5.5 0.5 0.7 0.5 0.8 0.5 0.5 1.4 0.0 0.6 0.0 FCAMR "CD351, FCA/MR, FKSG87" ENSG00000162897 "Fc fragment of IgA and IgM receptor" Q8WWV6 1 206957965-206970625 "CD markers, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "kidney: 23.9;liver: 7.6;lymphoid tissue: 23.0" "Cell line enhanced" "Detected in some" "CACO-2: 1.9;HMC-1: 1.0" "Cancer enhanced" "Detected in some" "renal cancer: 5.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA056505 Enhanced 3600000 "HPA056505: " "unprognostic (2.94e-1)" "unprognostic (1.06e-1)" "unprognostic (8.53e-2)" "unprognostic (2.92e-1)" "unprognostic (7.44e-2)" "unprognostic (4.55e-3)" "unprognostic (2.69e-3)" "unprognostic (1.08e-4)" "unprognostic (3.61e-2)" "unprognostic (1.25e-1)" "unprognostic (1.82e-1)" "unprognostic (1.23e-1)" "unprognostic (1.11e-1)" "unprognostic (1.29e-1)" "unprognostic (3.88e-2)" "unprognostic (2.08e-1)" "unprognostic (1.26e-1)" 0.1 0.1 0.1 23.0 0.1 0.0 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.6 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 23.9 7.6 0.1 8.3 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 2.4 0.1 0.1 0.1 1.0 0.1 0.5 0.6 0.1 0.2 0.1 0.2 0.2 0.1 9.1 0.1 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 1.9 0.3 0.1 0.1 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.2 0.4 0.1 0.0 0.2 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 FCAR CD89 ENSG00000186431 "Fc fragment of IgA receptor" P24071 19 54874248-54890472 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "IgA-binding protein, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 28.1;lung: 19.5;lymphoid tissue: 15.9" "Cell line enhanced" "Detected in single" "THP-1: 1.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 6 "classical monocyte: 2.6;neutrophil: 6.1" "Group enriched" "Detected in many" 44 "granulocytes: 6.1;monocytes: 2.6" "Low region specificity" "Detected in many" HPA014050 Approved Supported "Plasma membrane" "Intracellular and membrane" "Plasma membrane" "HPA014050: AB_1846338" "unprognostic (1.46e-1)" "unprognostic (5.74e-2)" "unprognostic (1.30e-1)" "unprognostic (4.71e-3)" "unprognostic (3.46e-1)" "unprognostic (2.02e-1)" "unprognostic (7.99e-2)" "unprognostic (1.54e-2)" "unprognostic (1.59e-2)" "unprognostic (4.70e-2)" "unprognostic (1.41e-2)" "unprognostic (7.05e-2)" "unprognostic (4.19e-6)" "unprognostic (9.23e-2)" "unprognostic (8.10e-3)" "unprognostic (8.04e-3)" "unprognostic (9.81e-2)" 4.0 0.6 0.4 1.5 4.4 28.1 0.8 0.1 1.0 0.6 0.6 0.7 0.0 0.6 0.6 0.6 0.6 3.8 0.6 8.2 2.0 0.4 0.6 1.8 19.5 15.9 1.2 0.0 2.2 0.6 0.6 0.3 1.5 4.3 0.6 0.6 0.9 0.6 0.6 0.6 0.6 0.6 0.7 2.7 14.9 0.9 2.1 0.0 1.0 0.6 0.3 0.6 4.4 4.8 0.0 0.0 6.1 2.6 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.7 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 0.0 0.1 0.0 0.0 0.7 0.4 4.4 0.1 1.0 2.0 0.4 1.2 0.0 4.3 0.0 FCER2 "CD23, CD23A, CLEC4J, FCE2" ENSG00000104921 "Fc fragment of IgE receptor II" P06734 19 7688758-7702146 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "IgE-binding protein, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "blood: 87.2;lymphoid tissue: 38.4" "Cell line enriched" "Detected in some" 14 "HDLM-2: 97.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 23 "memory B-cell: 28.2;naive B-cell: 87.2" "Lineage enriched" "Detected in many" 34 "B-cells: 87.2" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB002624, HPA008928" Enhanced "Secreted to blood" 59000 "CAB002624: , HPA008928: AB_1846285" "unprognostic (3.20e-4)" "unprognostic (1.87e-3)" "unprognostic (1.95e-2)" "unprognostic (2.44e-2)" "unprognostic (4.77e-2)" "unprognostic (1.77e-3)" "unprognostic (1.64e-1)" "unprognostic (1.89e-3)" "unprognostic (2.71e-1)" "unprognostic (1.88e-1)" "unprognostic (2.04e-2)" "unprognostic (8.55e-2)" "unprognostic (2.46e-4)" "unprognostic (2.99e-1)" "unprognostic (1.80e-1)" "unprognostic (4.89e-2)" "unprognostic (5.17e-2)" 2.4 0.3 0.5 17.1 0.5 2.3 1.2 0.3 1.1 0.3 1.0 0.1 0.4 1.3 0.3 2.3 1.0 0.4 0.5 0.8 0.3 0.3 0.6 0.6 0.8 21.1 0.3 0.0 0.4 0.3 0.0 0.3 0.3 0.1 0.3 0.8 0.0 7.5 0.7 0.4 0.6 7.7 0.4 0.3 38.4 0.8 0.5 0.0 6.3 0.7 0.0 33.8 2.0 0.5 87.2 0.7 0.2 2.5 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 97.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.5 0.0 0.0 2.5 0.0 28.2 0.0 0.0 0.7 87.2 0.0 0.0 0.2 0.0 0.7 0.1 0.0 3.0 0.5 0.5 0.3 0.3 0.3 0.3 0.3 0.0 0.1 0.0 FCGR1A "CD64, CD64A" ENSG00000150337 "Fc fragment of IgG receptor Ia" P12314 1 149782671-149792518 "CD markers, FDA approved drug targets, Predicted membrane proteins" "Immunity, Innate immunity" "IgG-binding protein, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 35.6;epididymis: 33.2" "Cell line enriched" "Detected in some" 5 "THP-1: 59.6" "Cancer enhanced" "Detected in many" "glioma: 10.3" "Group enriched" "Detected in some" 7 "classical monocyte: 35.6;intermediate monocyte: 14.0;myeloid DC: 9.5;neutrophil: 25.5" "Group enriched" "Detected in many" 80 "dendritic cells: 9.5;granulocytes: 25.5;monocytes: 35.6" "unprognostic (5.27e-2)" "unprognostic (2.89e-2)" "unprognostic (2.34e-2)" "unprognostic (7.97e-2)" "unprognostic (8.44e-3)" "unprognostic (1.73e-1)" "unprognostic (7.69e-2)" "unprognostic (1.04e-1)" "unprognostic (1.88e-2)" "unprognostic (1.72e-1)" "unprognostic (1.98e-2)" "unprognostic (6.18e-2)" "prognostic unfavourable (4.83e-8)" "unprognostic (1.28e-1)" "unprognostic (4.51e-2)" "unprognostic (9.99e-2)" "unprognostic (9.03e-2)" 3.9 2.4 6.7 14.1 4.4 5.0 0.7 0.3 3.5 1.1 0.3 0.0 0.1 33.2 0.3 0.7 2.4 0.7 5.3 4.9 1.0 1.1 8.9 3.4 10.1 0.3 1.0 0.5 1.2 10.8 0.4 0.3 0.7 0.2 0.0 0.0 0.1 5.5 14.3 7.0 0.3 0.9 0.3 0.0 3.3 0.0 0.2 9.5 25.5 35.6 0.0 0.2 11.2 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 12.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.4 59.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.2 0.0 0.5 35.6 0.4 0.0 14.0 0.2 0.2 0.0 0.1 9.5 0.0 0.0 0.0 25.5 0.0 2.8 0.2 0.1 11.2 FCGR2A "CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2" ENSG00000143226 "Fc fragment of IgG receptor IIa" P12318 1 161505430-161524013 "CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Immunity "IgG-binding protein, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 182.8" "Cell line enhanced" "Detected in some" "HEL: 14.0;HMC-1: 28.2;K-562: 8.3;NB-4: 7.9;THP-1: 30.0;U-937: 12.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "neutrophil: 182.8" "Lineage enriched" "Detected in many" 7 "granulocytes: 182.8" "HPA010718, HPA010776, HPA014730" Enhanced Supported "Golgi apparatus,Plasma membrane" 55000000 "Plasma membrane" "Golgi apparatus" "HPA010718: AB_1078463, HPA010776: , HPA014730: " "unprognostic (2.57e-2)" "unprognostic (1.16e-1)" "unprognostic (1.48e-2)" "unprognostic (4.12e-2)" "unprognostic (5.89e-2)" "unprognostic (6.17e-2)" "unprognostic (1.24e-2)" "unprognostic (1.17e-1)" "unprognostic (7.63e-2)" "unprognostic (1.17e-3)" "unprognostic (2.43e-2)" "unprognostic (2.91e-1)" "prognostic unfavourable (6.49e-7)" "unprognostic (8.85e-3)" "unprognostic (6.47e-3)" "unprognostic (1.54e-1)" "unprognostic (3.42e-2)" 36.8 12.6 13.2 44.6 19.2 18.6 8.2 2.2 10.1 9.1 7.1 10.0 0.0 3.8 4.7 6.6 5.5 11.6 17.0 11.3 17.0 8.9 11.5 7.1 44.1 50.0 25.9 1.7 8.0 5.8 2.8 6.1 47.5 19.6 7.0 9.9 10.8 8.3 4.8 7.3 3.0 7.3 17.6 30.9 43.4 5.9 4.8 19.2 3.2 6.3 2.5 4.4 19.3 4.5 0.2 7.0 182.8 27.2 0.0 0.0 10.6 0.0 0.0 0.0 1.2 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.0 0.2 0.0 0.3 4.0 28.2 0.3 0.0 0.0 0.0 0.0 8.3 0.2 0.0 0.0 0.2 7.9 0.0 0.6 0.1 0.6 3.8 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 30.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.2 12.9 3.5 0.1 27.2 31.6 0.0 20.7 0.0 0.2 0.0 0.0 7.0 0.1 0.0 0.0 182.8 0.0 16.7 0.2 0.0 10.6 13.2 19.2 2.2 10.1 17.0 8.9 25.9 1.7 19.6 19.2 FCGR2B "CD32, CD32B, FCG2, FCGR2" ENSG00000072694 "Fc fragment of IgG receptor IIb" P31994 1 161663147-161678654 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Host-virus interaction" "IgG-binding protein, Receptor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 53.3;placenta: 83.2" "Cell line enhanced" "Detected in some" "Daudi: 18.2;HMC-1: 23.0;NB-4: 5.1;RPMI-8226: 8.2" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 53.3;memory B-cell: 42.2" "Group enriched" "Detected in many" 18 "B-cells: 42.2;dendritic cells: 14.5;granulocytes: 53.3" "CAB007796, HPA014730" Enhanced "CAB007796: AB_562288, HPA014730: " "unprognostic (1.58e-1)" "unprognostic (5.14e-2)" "unprognostic (3.32e-3)" "unprognostic (3.12e-2)" "unprognostic (6.79e-3)" "unprognostic (4.05e-3)" "unprognostic (1.27e-1)" "unprognostic (4.65e-3)" "unprognostic (1.91e-1)" "unprognostic (4.72e-2)" "unprognostic (2.89e-2)" "unprognostic (3.49e-1)" "prognostic unfavourable (8.82e-4)" "unprognostic (3.51e-2)" "unprognostic (6.36e-2)" "unprognostic (4.31e-1)" "unprognostic (3.37e-1)" 11.3 2.4 0.0 2.0 0.2 0.0 4.1 0.0 0.0 1.9 3.4 0.2 0.9 0.2 2.1 2.1 2.3 3.7 0.0 0.2 2.0 9.5 5.6 2.5 0.5 0.8 0.6 0.0 0.3 83.2 0.3 2.0 3.3 0.2 0.5 2.0 4.6 3.1 4.7 6.7 1.5 0.1 1.7 5.6 3.3 1.2 42.2 14.5 53.3 1.9 0.1 0.3 2.4 0.0 0.1 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 5.1 0.1 0.0 0.0 0.0 8.2 0.0 0.0 0.1 0.1 0.0 0.0 1.6 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 2.2 0.0 53.3 1.8 5.4 0.3 1.9 0.1 42.2 0.1 0.2 14.5 34.3 0.0 0.3 11.2 0.1 1.7 0.0 0.0 2.4 FCGR3A "CD16, CD16a, FCG3, FCGR3" ENSG00000203747 "Fc fragment of IgG receptor IIIa" P08637 1 161541759-161550737 "CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "IgG-binding protein, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 223.6;lymphoid tissue: 60.8" "Cell line enhanced" "Detected in some" "HaCaT: 1.7;SH-SY5Y: 1.3;U-2197: 1.1;U-266/70: 1.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "intermediate monocyte: 109.4;non-classical monocyte: 223.6" "Group enriched" "Detected in many" 4 "granulocytes: 73.0;monocytes: 223.6" "CAB032435, HPA055431" Supported "Secreted to blood" 2500000000 "CAB032435: AB_626925, HPA055431: " "unprognostic (5.27e-2)" "unprognostic (9.95e-2)" "unprognostic (2.37e-2)" "unprognostic (1.66e-1)" "unprognostic (1.39e-1)" "unprognostic (1.82e-1)" "unprognostic (2.24e-2)" "unprognostic (6.06e-2)" "unprognostic (2.41e-1)" "unprognostic (1.64e-1)" "unprognostic (1.98e-2)" "unprognostic (7.52e-2)" "prognostic unfavourable (3.22e-6)" "unprognostic (1.14e-1)" "unprognostic (4.66e-2)" "unprognostic (1.03e-2)" "unprognostic (7.51e-2)" 11.9 9.7 7.5 20.5 12.4 4.4 4.1 1.6 7.0 1.9 2.1 5.5 0.8 0.8 1.1 2.4 1.0 2.4 5.1 6.4 6.3 7.3 2.6 22.5 43.2 8.0 12.7 1.9 1.4 2.9 1.8 3.9 14.6 6.8 2.6 2.3 2.2 2.7 1.3 1.3 0.3 1.2 14.3 25.7 60.8 1.3 1.2 8.0 1.4 1.8 1.3 1.3 6.3 2.3 0.1 11.7 73.0 223.6 7.9 33.9 35.8 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.0 1.7 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.3 0.8 0.2 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.3 0.5 0.5 0.0 0.8 0.5 0.4 0.0 0.0 0.5 1.3 0.4 0.2 0.0 0.0 0.1 0.0 0.0 0.1 1.1 0.0 1.7 0.0 0.4 0.0 0.0 0.0 0.3 1.6 0.5 33.9 109.4 0.3 0.1 0.3 13.2 11.7 0.0 0.2 12.2 73.0 7.9 223.6 0.2 0.1 35.8 7.5 12.4 1.6 7.0 6.3 7.3 12.7 1.9 6.8 8.0 FCGR3B "CD16, CD16b, FCG3, FCGR3" ENSG00000162747 "Fc fragment of IgG receptor IIIb" O75015 1 161623196-161631963 "CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "IgG-binding protein, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "blood: 334.5" "Cell line enhanced" "Detected in single" "K-562: 1.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 95 "neutrophil: 334.5" "Lineage enriched" "Detected in many" 95 "granulocytes: 334.5" "Secreted to blood" "unprognostic (1.60e-1)" "unprognostic (1.36e-1)" "unprognostic (1.59e-3)" "unprognostic (4.16e-2)" "unprognostic (1.15e-1)" "unprognostic (6.52e-2)" "unprognostic (3.97e-2)" "unprognostic (6.96e-3)" "unprognostic (2.53e-2)" "unprognostic (1.02e-1)" "unprognostic (1.07e-1)" "unprognostic (8.67e-2)" "unprognostic (5.16e-2)" "unprognostic (1.35e-1)" "unprognostic (8.37e-3)" "unprognostic (2.28e-1)" "unprognostic (9.24e-2)" 9.9 0.8 1.8 30.8 1.5 13.8 1.5 0.9 1.8 0.9 0.8 0.5 0.2 0.0 0.4 0.5 1.7 2.8 6.8 4.6 1.2 0.9 0.9 2.9 15.2 16.9 5.0 0.5 1.2 1.2 0.0 0.6 4.5 1.9 1.5 0.0 1.3 0.9 0.9 0.8 1.4 0.8 2.0 4.0 44.3 1.3 1.5 0.9 0.6 0.8 0.2 0.9 11.1 4.7 0.0 0.1 334.5 3.5 0.1 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.4 0.0 0.3 0.0 0.0 0.0 0.5 0.5 1.2 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.1 334.5 0.1 3.5 0.0 0.0 0.5 1.8 1.5 0.9 1.8 1.2 0.9 5.0 0.5 1.9 0.9 FCRL1 "CD307a, FCRH1, IFGP1, IRTA5" ENSG00000163534 "Fc receptor like 1" Q96LA6 1 157794403-157820105 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "blood: 31.6;lymphoid tissue: 55.1" "Group enriched" "Detected in some" 33 "Daudi: 5.6;U-698: 18.9" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Group enriched" "Detected in some" 51 "memory B-cell: 16.8;naive B-cell: 31.6" "Lineage enriched" "Detected in single" 66 "B-cells: 31.6" "Low region specificity" "Detected in all" HPA013323 Enhanced 120000 "HPA013323: AB_1848480" "unprognostic (6.52e-4)" "unprognostic (3.49e-3)" "unprognostic (8.68e-3)" "unprognostic (8.08e-3)" "unprognostic (1.31e-1)" "unprognostic (1.01e-5)" "unprognostic (1.47e-2)" "unprognostic (5.48e-3)" "unprognostic (1.40e-2)" "unprognostic (4.30e-2)" "unprognostic (1.81e-1)" "unprognostic (2.85e-2)" "unprognostic (1.44e-3)" "unprognostic (1.96e-1)" "unprognostic (1.65e-2)" "unprognostic (4.80e-2)" "unprognostic (6.74e-2)" 0.5 0.2 0.2 55.1 0.2 6.2 0.3 0.2 0.2 0.2 0.7 0.0 0.0 0.0 0.2 0.1 2.4 0.3 0.2 0.3 0.2 0.2 0.7 0.5 1.9 19.2 0.2 0.0 0.2 0.3 0.0 0.2 0.0 0.0 0.5 0.3 0.3 5.4 0.7 0.2 0.2 10.1 0.0 0.2 25.3 0.4 0.2 0.0 1.1 0.7 0.4 49.0 4.5 0.8 31.6 0.0 0.4 0.2 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 18.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 16.8 0.0 0.0 0.0 31.6 0.0 0.0 0.4 0.0 0.2 0.0 0.1 0.9 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.0 0.0 FCRL2 "CD307b, FCRH2, IRTA4, SPAP1" ENSG00000132704 "Fc receptor like 2" Q96LA5 1 157745733-157777132 "CD markers, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "blood: 20.2;intestine: 14.9;lymphoid tissue: 27.0" "Group enriched" "Detected in some" 4 "Daudi: 14.7;U-698: 11.9" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Group enriched" "Detected in some" 50 "memory B-cell: 20.2;naive B-cell: 10.8" "Lineage enriched" "Detected in single" 65 "B-cells: 20.2" "unprognostic (3.94e-3)" "unprognostic (1.47e-3)" "unprognostic (3.49e-2)" "unprognostic (3.69e-3)" "unprognostic (5.11e-5)" "unprognostic (1.67e-2)" "unprognostic (4.77e-3)" "unprognostic (8.19e-2)" "unprognostic (8.66e-3)" "unprognostic (1.20e-2)" "unprognostic (4.19e-2)" "unprognostic (4.60e-7)" "unprognostic (2.89e-1)" "unprognostic (2.29e-1)" "unprognostic (7.92e-2)" "unprognostic (2.48e-1)" 0.4 0.2 0.2 22.6 0.2 1.5 0.2 0.1 0.2 0.2 1.3 0.1 0.1 1.2 0.3 0.1 1.4 0.2 0.4 0.2 0.2 0.2 0.5 0.9 0.7 15.6 0.3 0.1 0.5 0.2 0.0 0.2 0.1 0.2 0.4 1.7 0.6 2.8 0.7 0.1 0.2 14.9 0.1 0.2 27.0 0.8 0.2 0.1 0.3 0.5 0.1 23.3 1.4 0.2 20.2 0.0 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 14.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 3.1 0.0 11.9 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 20.2 0.0 0.0 0.0 10.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.2 0.1 0.2 0.2 0.2 0.3 0.1 0.2 0.1 FCRL3 "CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e" ENSG00000160856 "Fc receptor like 3" Q96P31 1 157674321-157700857 "CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 20.3;lymphoid tissue: 32.2" "Cell line enriched" "Detected in some" 7 "Daudi: 14.3" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "naive B-cell: 20.3" "Group enriched" "Detected in many" 56 "B-cells: 20.3;NK-cells: 10.7;T-cells: 10.8" "Low region specificity" "Detected in all" HPA048022 Enhanced "HPA048022: " "unprognostic (6.73e-3)" "unprognostic (5.06e-4)" "unprognostic (1.13e-2)" "unprognostic (2.08e-4)" "unprognostic (3.86e-1)" "unprognostic (1.74e-5)" "unprognostic (1.09e-2)" "unprognostic (4.29e-3)" "unprognostic (3.69e-3)" "unprognostic (2.46e-4)" "unprognostic (1.13e-1)" "unprognostic (2.55e-2)" "unprognostic (2.01e-4)" "unprognostic (1.55e-1)" "unprognostic (1.29e-1)" "unprognostic (2.21e-1)" "unprognostic (6.69e-2)" 0.4 0.2 0.2 29.4 0.2 0.4 0.3 0.2 0.2 0.3 0.6 0.0 0.0 0.0 0.5 0.2 1.5 0.3 0.6 0.3 0.2 0.2 0.5 0.6 0.9 26.4 0.4 0.0 0.2 0.2 0.0 0.3 0.0 0.0 0.5 0.6 0.2 5.6 0.0 0.4 0.2 8.7 0.1 0.2 22.4 0.6 0.2 0.0 5.2 0.6 0.6 32.2 1.2 0.3 20.3 0.0 0.2 0.0 10.7 10.8 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 10.8 0.0 1.0 16.1 1.4 7.2 0.0 20.3 0.1 4.7 0.2 10.7 0.0 0.0 5.6 3.5 0.2 0.2 0.2 0.2 0.2 0.2 0.4 0.0 0.0 0.0 FCRL4 "CD307d, FCRH4, IGFP2, IRTA1" ENSG00000163518 "Fc receptor like 4" Q96PJ5 1 157573749-157598080 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "intestine: 5.4;lymphoid tissue: 15.6" "Cell line enriched" "Detected in single" 102 "U-266/70: 10.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 12 "memory B-cell: 1.1" "Lineage enriched" "Detected in single" 12 "B-cells: 1.1" "Low region specificity" "Detected in many" HPA054030 Approved "HPA054030: " "unprognostic (6.06e-2)" "unprognostic (3.41e-3)" "unprognostic (2.57e-1)" "unprognostic (5.08e-2)" "unprognostic (4.69e-4)" "unprognostic (2.06e-2)" "unprognostic (6.38e-2)" "unprognostic (1.99e-1)" "unprognostic (2.14e-1)" "unprognostic (3.37e-1)" "unprognostic (6.77e-2)" 0.1 0.1 0.1 15.6 0.1 0.0 0.1 0.1 0.2 0.1 0.3 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 5.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.4 0.0 2.5 0.0 0.1 0.1 5.4 0.0 0.1 2.2 0.3 0.1 0.0 1.1 0.1 1.9 14.9 0.4 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.0 FCRL5 "BXMAS1, CD307e, FCRH5, IRTA2" ENSG00000143297 "Fc receptor like 5" Q96RD9 1 157513377-157552520 "CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 13.3;lymphoid tissue: 39.1;salivary gland: 12.4" "Group enriched" "Detected in some" 5 "U-266/70: 5.6;U-698: 12.0" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Group enriched" "Detected in some" 18 "memory B-cell: 11.4;naive B-cell: 13.3" "Lineage enriched" "Detected in single" 19 "B-cells: 13.3" "Secreted to blood" 169000000 36000000 "unprognostic (1.30e-3)" "unprognostic (3.51e-2)" "unprognostic (7.59e-3)" "unprognostic (1.57e-2)" "unprognostic (9.41e-3)" "unprognostic (4.32e-5)" "unprognostic (2.61e-2)" "unprognostic (6.93e-2)" "unprognostic (7.40e-2)" "unprognostic (7.66e-3)" "unprognostic (4.01e-1)" "unprognostic (1.39e-1)" "unprognostic (9.51e-10)" "unprognostic (1.20e-1)" "unprognostic (4.40e-1)" "unprognostic (8.99e-2)" "unprognostic (2.78e-1)" 0.7 0.4 0.3 33.9 0.3 1.1 1.3 0.3 0.3 1.6 7.4 0.1 0.0 3.6 0.5 0.1 4.6 0.8 0.8 0.4 0.3 0.3 1.6 0.8 1.6 17.4 0.3 0.0 0.6 0.4 0.0 0.3 0.0 0.0 0.5 2.7 1.0 12.4 0.8 0.3 0.3 6.4 0.1 0.3 29.5 2.5 0.9 0.0 3.1 1.1 0.7 39.1 5.3 0.6 13.3 0.6 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.1 12.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.4 0.0 0.0 0.0 13.3 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.6 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.0 0.0 0.0 FGFR1 "BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM" ENSG00000077782 "Fibroblast growth factor receptor 1" P11362 8 38411138-38468834 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Transcription, Transcription regulation" "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AN3-CA: 109.2;BJ hTERT+: 49.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033614, HPA056402" Approved 120000000 "CAB033614: AB_783377, HPA056402: " "unprognostic (9.53e-2)" "unprognostic (7.33e-2)" "unprognostic (2.44e-1)" "unprognostic (1.35e-2)" "unprognostic (4.23e-3)" "unprognostic (7.02e-2)" "unprognostic (6.59e-2)" "unprognostic (2.77e-1)" "unprognostic (1.81e-1)" "unprognostic (3.99e-2)" "unprognostic (7.97e-3)" "unprognostic (4.59e-2)" "unprognostic (7.69e-2)" "unprognostic (6.87e-3)" "unprognostic (5.60e-2)" "unprognostic (4.59e-3)" "unprognostic (1.05e-3)" 41.1 8.6 12.5 14.5 12.2 7.2 39.5 45.0 10.5 36.0 31.5 10.1 11.6 5.5 29.3 20.6 22.9 29.4 32.4 31.7 12.8 10.1 11.8 5.4 18.6 9.7 11.4 14.3 42.0 51.2 11.5 22.3 28.4 20.0 28.2 10.8 35.8 14.0 31.6 12.0 12.9 14.4 52.4 15.6 4.5 16.4 16.4 8.5 11.3 12.6 13.0 9.8 39.6 41.2 1.6 0.7 1.8 1.1 0.8 5.7 0.7 2.4 9.3 40.3 109.2 25.1 17.9 26.6 24.8 49.8 17.3 18.0 6.0 1.4 0.3 6.9 23.8 0.0 19.1 1.2 20.0 6.5 4.2 0.0 1.5 5.9 14.1 5.8 0.1 16.2 0.1 14.0 2.8 16.6 2.2 0.1 8.1 2.8 17.0 1.9 28.4 3.9 15.7 4.2 0.0 8.4 0.0 1.6 3.6 4.4 0.2 1.0 2.2 1.1 10.4 11.3 6.2 31.2 5.9 0.4 0.7 0.0 13.4 0.3 5.9 1.4 1.1 0.4 5.7 0.3 3.9 0.7 2.7 3.7 0.1 1.6 1.5 4.1 1.8 0.8 0.5 0.7 2.2 0.7 12.5 12.2 45.0 10.5 12.8 10.1 11.4 14.3 20.0 8.5 FGFR2 "BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25" ENSG00000066468 "Fibroblast growth factor receptor 2" P21802 10 121478334-121598458 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Apoptosis "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 74.8" "Cell line enhanced" "Detected in some" "AN3-CA: 57.8;BEWO: 19.4;CACO-2: 15.1;HaCaT: 17.4;HAP1: 18.7;NTERA-2: 18.5;T-47d: 15.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 15 "basophil: 10.8;eosinophil: 4.6" "Lineage enriched" "Detected in single" 35 "granulocytes: 10.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010886, HPA035305" Uncertain Supported "Nucleoplasm,Vesicles,Cell Junctions" "Secreted - unknown location" 500000 "Cell Junctions" "Nucleoplasm, Vesicles" "CAB010886: AB_259379, HPA035305: AB_10672862" "unprognostic (5.53e-2)" "prognostic favourable (8.79e-4)" "unprognostic (1.08e-1)" "unprognostic (5.23e-2)" "unprognostic (1.73e-1)" "prognostic favourable (9.32e-4)" "unprognostic (1.53e-1)" "unprognostic (4.96e-3)" "unprognostic (1.74e-1)" "unprognostic (1.56e-1)" "unprognostic (1.07e-1)" "unprognostic (3.74e-2)" "unprognostic (1.01e-1)" "unprognostic (6.11e-2)" "unprognostic (2.54e-1)" "unprognostic (6.93e-2)" "unprognostic (2.25e-1)" 2.1 8.8 16.4 3.0 30.3 0.0 9.9 15.8 21.3 6.8 14.1 55.7 5.6 4.2 22.0 6.6 10.2 12.5 12.5 1.4 20.6 11.1 11.4 16.1 13.1 1.0 41.2 13.3 7.4 12.8 25.5 2.5 6.2 30.2 11.7 8.7 16.4 23.8 24.3 0.4 45.4 4.7 18.3 74.8 0.5 9.3 2.9 32.1 0.8 23.4 1.6 3.4 6.9 8.5 0.1 0.1 10.8 0.1 0.1 0.3 0.0 2.2 0.1 9.0 57.8 0.0 0.0 19.4 0.1 0.0 0.0 0.0 15.1 0.3 0.0 4.1 0.9 17.4 18.7 4.0 0.0 0.0 4.0 0.0 0.0 0.3 0.4 0.0 3.8 0.0 8.4 0.0 0.2 0.0 0.0 0.0 0.0 3.5 0.0 0.0 18.5 0.0 0.0 0.0 2.2 5.6 4.9 0.1 0.1 0.1 10.6 0.0 15.5 0.0 0.0 0.1 2.8 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 10.8 0.1 4.6 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.1 0.5 0.1 0.0 0.1 0.0 0.0 16.4 30.3 15.8 21.3 20.6 11.1 41.2 13.3 30.2 32.1 FGFR3 "ACH, CD333, CEK2, JTK4" ENSG00000068078 "Fibroblast growth factor receptor 3" P22607 4 1793293-1808872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Apoptosis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "skin 1: 131.7" "Cell line enhanced" "Detected in many" "CACO-2: 19.1;HaCaT: 14.9;Hep G2: 32.1;NTERA-2: 15.6;RT4: 19.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004231, HPA067204" Enhanced Supported "Endoplasmic reticulum" "Intracellular and membrane" 670000 "Endoplasmic reticulum" "CAB004231: AB_627596, HPA067204: " "unprognostic (1.34e-1)" "unprognostic (5.29e-3)" "unprognostic (1.49e-1)" "prognostic unfavourable (3.77e-4)" "unprognostic (5.90e-2)" "unprognostic (1.24e-3)" "unprognostic (7.22e-2)" "unprognostic (2.54e-1)" "unprognostic (1.99e-1)" "unprognostic (2.17e-1)" "unprognostic (1.38e-1)" "unprognostic (2.88e-2)" "unprognostic (1.30e-1)" "unprognostic (9.11e-3)" "unprognostic (1.98e-1)" "unprognostic (4.74e-2)" "unprognostic (1.97e-1)" 1.5 1.5 24.7 1.7 30.3 1.6 4.2 10.2 22.0 4.1 4.9 15.8 3.4 9.9 1.8 2.7 26.9 2.0 5.0 2.0 21.6 11.7 9.6 7.4 4.5 1.3 17.6 21.5 1.1 23.0 1.2 3.0 5.6 15.1 3.7 3.8 1.7 3.8 9.0 1.7 131.7 7.4 1.3 9.0 2.1 4.9 8.1 10.6 0.1 1.3 8.5 7.3 8.5 10.1 0.1 0.6 0.1 0.1 0.2 0.3 0.0 0.0 1.5 9.0 2.6 0.0 0.1 9.2 1.0 0.1 0.4 0.2 19.1 0.4 0.0 7.6 0.3 14.9 2.6 0.1 0.1 0.1 9.6 5.9 1.5 32.1 0.0 0.0 0.1 0.0 5.0 0.1 0.0 0.0 6.4 0.0 0.0 9.5 0.3 0.2 15.6 0.0 0.5 0.5 0.1 1.3 19.1 2.6 0.7 0.8 1.6 0.0 8.9 1.1 0.4 0.0 0.9 0.2 0.6 0.0 0.0 0.0 0.1 0.7 0.5 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.6 0.1 0.0 24.7 30.3 10.2 22.0 21.6 11.7 17.6 21.5 15.1 10.6 FGFR4 "CD334, JTK2" ENSG00000160867 "Fibroblast growth factor receptor 4" P22455 5 177086886-177098144 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 33.6;kidney: 37.7;liver: 45.3" "Group enriched" "Detected in many" 4 "CACO-2: 42.0;Hep G2: 42.0;RH-30: 67.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "neutrophil: 3.0" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB005196, HPA027273, HPA027369, HPA028251" Approved "Intracellular and membrane" 4300000 "CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221" "unprognostic (1.96e-1)" "unprognostic (2.10e-2)" "unprognostic (1.12e-1)" "unprognostic (9.06e-3)" "unprognostic (2.87e-1)" "unprognostic (1.95e-2)" "unprognostic (7.85e-3)" "unprognostic (9.19e-2)" "unprognostic (4.25e-1)" "unprognostic (4.46e-2)" "unprognostic (1.16e-1)" "unprognostic (3.48e-2)" "unprognostic (1.78e-1)" "unprognostic (1.71e-3)" "unprognostic (2.41e-1)" "unprognostic (5.75e-2)" "unprognostic (4.68e-2)" 0.5 5.7 0.7 14.3 0.6 0.1 1.6 2.6 0.5 2.8 10.4 0.9 0.7 13.5 0.9 4.8 1.6 1.7 33.6 0.7 0.8 0.3 37.7 45.3 25.3 2.5 0.7 1.0 13.6 26.0 0.0 0.7 1.3 0.8 4.0 3.7 2.0 1.6 0.3 4.3 0.5 17.3 1.6 0.8 11.2 5.4 2.9 0.4 0.3 0.8 2.3 0.7 1.9 3.6 1.1 0.9 3.0 1.1 0.4 0.4 0.0 0.7 11.8 0.2 2.9 0.0 0.0 5.8 0.0 0.0 0.0 0.0 42.0 1.6 1.2 5.5 0.0 0.6 2.3 0.4 0.0 0.7 2.8 0.1 0.6 42.0 1.3 0.1 1.0 0.2 0.0 2.1 0.0 0.0 3.9 0.1 0.9 9.6 0.0 0.8 7.1 1.0 1.9 67.6 7.1 5.7 0.1 0.4 0.7 0.4 3.0 1.4 2.9 0.6 0.2 0.0 5.7 0.0 0.1 0.4 0.4 0.7 0.0 0.2 0.5 1.5 1.1 0.4 0.4 0.3 0.3 1.1 0.4 0.0 0.1 0.6 0.4 0.4 3.0 0.4 0.3 0.9 0.2 0.0 0.7 0.6 2.6 0.5 0.8 0.3 0.7 1.0 0.8 0.4 FLT3 "CD135, FLK2, STK1" ENSG00000122025 "Fms related tyrosine kinase 3" P36888 13 28003274-28100592 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 29.9;brain: 19.3;lymphoid tissue: 15.0" "Group enriched" "Detected in some" 11 "REH: 27.8;THP-1: 17.1" "Cancer enhanced" "Detected in some" "breast cancer: 1.8" "Region enhanced" "Detected in many" "cerebellum: 19.3" "Group enriched" "Detected in some" 11 "myeloid DC: 29.9;plasmacytoid DC: 12.1" "Lineage enriched" "Detected in many" 16 "dendritic cells: 29.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA047539 Approved "Endoplasmic reticulum" 180000 "Endoplasmic reticulum" "HPA047539: " "unprognostic (2.19e-3)" "unprognostic (3.16e-3)" "unprognostic (6.54e-3)" "unprognostic (9.96e-2)" "unprognostic (3.88e-1)" "unprognostic (3.96e-7)" "unprognostic (7.99e-3)" "unprognostic (1.65e-2)" "unprognostic (5.37e-2)" "unprognostic (1.01e-2)" "unprognostic (1.96e-1)" "unprognostic (1.03e-1)" "unprognostic (4.56e-2)" "unprognostic (3.65e-1)" "unprognostic (3.91e-2)" "unprognostic (2.51e-1)" "unprognostic (2.22e-1)" 0.9 0.6 0.6 7.2 1.1 7.5 2.6 19.3 3.5 0.9 1.2 0.1 0.1 0.4 0.8 0.8 1.0 1.2 4.6 0.5 0.9 1.7 2.8 0.7 2.7 15.0 1.8 1.1 0.5 5.7 0.0 0.4 0.0 7.4 0.6 1.4 0.1 2.3 0.6 0.4 1.2 3.0 1.3 4.4 8.8 0.9 1.2 0.0 8.2 0.6 0.0 5.8 2.4 0.7 0.1 29.9 1.4 1.8 0.8 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.0 0.5 0.0 27.8 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 17.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.8 1.4 0.0 0.3 0.0 0.1 0.0 0.0 29.9 0.0 0.0 0.0 0.0 0.8 0.0 12.1 0.0 1.2 0.6 1.1 19.3 3.5 0.9 1.7 1.8 1.1 7.4 0.0 FZD10 CD350 ENSG00000111432 "Frizzled class receptor 10" Q9ULW2 12 130162459-130165740 "CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "Wnt signaling pathway" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 26.9;lymphoid tissue: 18.6" "Group enriched" "Detected in some" 4 "AF22: 8.4;BEWO: 9.7;hTCEpi: 5.6;RPTEC TERT1: 2.9;RT4: 4.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in some" "thalamus: 7.6" "Low region specificity" "Detected in many" "HPA014484, HPA014485" Uncertain Approved Nucleoplasm Nucleoplasm "HPA014484: AB_1849132, HPA014485: AB_1849134" "unprognostic (2.41e-3)" "unprognostic (3.29e-1)" "unprognostic (4.74e-2)" "prognostic favourable (5.05e-7)" "unprognostic (2.81e-2)" "unprognostic (4.63e-2)" "unprognostic (8.62e-3)" "unprognostic (6.33e-2)" "unprognostic (5.41e-2)" "unprognostic (3.77e-2)" "unprognostic (2.70e-1)" "unprognostic (2.24e-3)" "unprognostic (2.66e-9)" "unprognostic (2.18e-1)" "unprognostic (3.07e-1)" "unprognostic (1.49e-2)" "unprognostic (1.07e-1)" 1.1 0.4 1.0 0.5 1.9 0.2 1.5 5.4 2.1 11.6 0.6 2.1 1.6 0.4 5.1 3.4 26.9 2.2 7.1 0.5 1.0 1.0 0.4 0.2 2.0 0.9 1.6 1.2 3.4 1.1 0.2 1.4 9.2 1.9 3.7 0.6 3.0 5.4 3.1 1.2 10.2 0.7 0.9 1.2 0.3 1.0 0.7 2.0 0.6 1.7 9.0 18.6 5.1 7.2 0.0 0.0 0.4 0.2 0.0 0.1 0.0 0.0 0.0 8.4 0.0 0.0 0.0 9.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.6 1.5 0.7 0.0 0.0 0.3 0.0 1.1 0.0 0.0 0.1 0.0 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.1 2.9 4.7 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 1.0 1.9 5.4 2.1 1.0 1.0 1.6 1.2 1.9 2.0 FZD4 "CD344, EVR1" ENSG00000174804 "Frizzled class receptor 4" Q9ULV1 11 86945679-86955391 "CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins" "Wnt signaling pathway" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 75.7" "Cell line enhanced" "Detected in many" "ASC diff: 25.4;Hep G2: 31.8;HSkMC: 18.3;HUVEC TERT2: 36.0;TIME: 17.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA042328, HPA074833" Approved Approved "Nucleoplasm,Plasma membrane" "Plasma membrane" Nucleoplasm "HPA042328: AB_10962494, HPA074833: " "unprognostic (6.49e-2)" "unprognostic (1.49e-2)" "unprognostic (1.03e-1)" "unprognostic (1.03e-1)" "unprognostic (5.87e-2)" "unprognostic (5.51e-2)" "unprognostic (1.82e-1)" "unprognostic (6.97e-2)" "unprognostic (3.33e-2)" "unprognostic (3.79e-2)" "unprognostic (1.36e-2)" "unprognostic (2.22e-1)" "prognostic favourable (8.60e-5)" "unprognostic (1.05e-2)" "unprognostic (9.96e-2)" "unprognostic (9.22e-2)" "unprognostic (1.97e-1)" 75.7 5.3 3.4 6.0 4.8 0.5 57.8 1.5 4.3 11.5 9.0 1.4 32.6 2.0 13.1 13.5 6.3 9.6 8.7 12.5 3.1 2.2 17.0 8.9 19.0 4.7 2.9 3.2 12.8 6.0 4.4 10.1 7.3 5.5 9.3 4.3 20.0 7.1 56.0 17.9 3.7 5.4 8.6 2.8 8.6 8.2 5.5 1.6 0.5 11.4 11.1 3.0 8.3 20.7 0.4 0.2 0.8 0.4 1.4 0.3 0.0 0.5 0.4 1.0 2.0 25.4 6.6 1.4 3.2 2.9 1.2 1.3 2.7 0.3 0.0 0.7 1.0 1.0 1.2 0.5 1.0 0.1 0.8 1.0 0.8 31.8 7.5 0.0 0.0 18.3 0.2 1.1 0.2 36.0 1.4 0.1 0.8 0.8 0.0 0.0 1.5 7.2 0.0 1.9 0.0 3.5 5.2 0.2 0.3 1.3 0.3 0.5 4.6 0.0 17.6 3.0 2.0 3.6 0.6 0.1 0.5 0.0 0.4 0.0 0.8 0.7 0.3 0.1 0.3 0.2 0.1 0.2 0.3 0.2 0.1 0.4 0.2 0.3 0.8 1.4 0.4 0.2 0.0 0.0 3.4 4.8 1.5 4.3 3.1 2.2 2.9 3.2 5.5 1.6 FZD9 "CD349, FZD3" ENSG00000188763 "Frizzled class receptor 9" O00144 7 73433783-73436120 "CD markers, G-protein coupled receptors, Predicted membrane proteins" "Wnt signaling pathway" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "skeletal muscle: 14.4" "Cell line enhanced" "Detected in some" "HEK 293: 8.2;MCF7: 3.6;NTERA-2: 6.4" "Cancer enhanced" "Detected in many" "melanoma: 6.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "unprognostic (9.60e-2)" "unprognostic (4.03e-2)" "unprognostic (3.16e-2)" "unprognostic (9.15e-3)" "unprognostic (1.10e-1)" "unprognostic (6.91e-2)" "unprognostic (2.29e-2)" "unprognostic (2.26e-1)" "unprognostic (2.04e-1)" "unprognostic (7.17e-3)" "unprognostic (1.20e-1)" "unprognostic (7.24e-2)" "unprognostic (5.90e-5)" "unprognostic (8.99e-2)" "unprognostic (4.57e-2)" "unprognostic (1.22e-1)" "unprognostic (5.21e-2)" 4.4 1.2 6.8 0.7 4.7 2.4 1.1 3.3 7.0 1.1 1.3 4.5 0.0 1.9 0.9 0.9 1.3 0.9 0.7 0.8 7.1 6.3 0.9 0.8 0.9 0.9 7.0 4.5 0.9 3.8 1.6 4.3 1.9 5.0 3.0 0.8 1.4 4.4 1.4 14.4 1.7 2.9 0.9 3.6 1.0 1.0 5.4 6.7 0.3 0.9 1.7 0.8 0.7 0.3 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.6 2.6 2.8 3.0 0.0 0.1 0.0 1.9 0.0 0.4 0.1 0.7 0.0 0.0 0.9 0.1 0.2 1.3 0.0 0.0 0.0 8.2 0.0 0.6 0.8 1.1 0.0 0.3 0.3 0.0 0.1 0.0 0.2 2.7 0.0 0.2 3.6 0.0 0.0 6.4 0.0 0.0 0.0 0.0 0.0 0.0 1.7 2.6 2.3 1.7 1.7 1.7 0.8 0.1 0.0 0.7 0.0 0.0 0.4 0.0 0.0 0.0 0.6 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.0 6.8 4.7 3.3 7.0 7.1 6.3 7.0 4.5 5.0 6.7 GGT1 "CD224, D22S672, D22S732, GGT" ENSG00000100031 "Gamma-glutamyltransferase 1" P19440 22 24583750-24629005 "Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Glutathione biosynthesis" "Acyltransferase, Hydrolase, Protease, Transferase" "Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 54.1;seminal vesicle: 41.7" "Cell line enhanced" "Detected in many" "HDLM-2: 35.8;Karpas-707: 52.7;RPMI-8226: 51.8;RPTEC TERT1: 48.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "HPA045635, HPA047534, HPA065444" Supported Approved Vesicles "Intracellular and membrane" 4600000 Vesicles "HPA045635: , HPA047534: , HPA065444: " "unprognostic (8.13e-3)" "unprognostic (4.76e-1)" "unprognostic (8.29e-2)" "unprognostic (1.28e-2)" "unprognostic (3.70e-2)" "unprognostic (1.43e-2)" "unprognostic (5.60e-3)" "unprognostic (1.68e-1)" "unprognostic (2.21e-1)" "prognostic favourable (7.44e-4)" "unprognostic (4.55e-2)" "unprognostic (2.55e-2)" "prognostic favourable (4.83e-4)" "unprognostic (1.44e-2)" "unprognostic (5.37e-2)" "unprognostic (1.74e-1)" "unprognostic (6.10e-2)" 1.6 0.5 1.7 1.7 2.2 2.7 8.2 2.3 2.6 7.3 7.9 1.6 23.7 22.3 1.4 19.9 1.2 0.8 12.2 2.0 1.8 1.2 54.1 29.2 14.3 3.2 1.7 1.6 1.3 17.3 0.0 1.6 1.4 2.2 14.7 2.4 1.4 8.7 41.7 0.9 1.1 20.9 1.7 1.9 4.7 6.6 5.0 2.1 2.4 4.8 1.6 5.5 2.1 1.1 3.3 7.5 15.9 14.6 6.6 8.6 6.6 0.2 19.4 0.2 0.0 0.0 0.1 0.5 0.1 0.6 0.2 0.2 2.6 4.3 0.2 4.3 0.0 2.8 1.4 0.2 0.1 35.8 2.9 0.1 8.6 14.1 1.5 0.3 12.0 0.4 0.2 0.6 0.4 0.1 2.0 52.7 0.2 0.4 0.3 14.6 1.4 0.2 0.2 2.2 51.8 48.2 0.6 0.2 0.3 0.1 9.4 0.2 9.4 11.1 2.2 3.5 2.3 10.9 0.3 15.8 6.0 0.2 7.4 15.1 0.1 5.2 14.6 0.4 1.4 6.8 5.2 3.3 7.7 3.4 7.5 0.3 1.0 1.9 15.9 6.6 5.5 0.1 8.6 6.6 1.7 2.2 2.3 2.6 1.8 1.2 1.7 1.6 2.2 2.1 GP1BA "CD42b, GP1B, GPIbalpha" ENSG00000185245 "Glycoprotein Ib platelet alpha subunit" P07359 17 4932297-4935030 "CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins" "Blood coagulation, Cell adhesion, Hemostasis" "Bernard Soulier syndrome, Disease mutation, von Willebrand disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 37.8" "Cell line enriched" "Detected in some" 24 "HEL: 39.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in some" 7 "basophil: 7.5" "Lineage enriched" "Detected in single" 25 "granulocytes: 7.5" "Not detected" "Not detected" "Not detected" "Not detected" "CAB002496, HPA013316" Supported 2000000000 "CAB002496: AB_563748, HPA013316: AB_1855459" "unprognostic (4.87e-4)" "unprognostic (8.21e-2)" "unprognostic (2.81e-2)" "unprognostic (6.11e-3)" "unprognostic (1.50e-2)" "unprognostic (1.59e-3)" "unprognostic (7.30e-3)" "unprognostic (5.58e-2)" "unprognostic (2.19e-1)" "unprognostic (1.64e-1)" "unprognostic (6.54e-4)" "unprognostic (1.27e-1)" "unprognostic (4.85e-3)" "unprognostic (4.58e-3)" "unprognostic (2.56e-1)" "unprognostic (3.53e-4)" "unprognostic (8.35e-2)" 0.7 0.1 0.4 15.8 1.2 5.3 0.7 1.9 0.7 0.7 1.0 0.2 0.2 1.5 0.6 0.7 5.7 0.8 0.3 4.2 0.5 0.4 1.0 1.6 3.5 37.8 0.4 0.2 0.7 0.4 0.0 0.4 1.1 0.4 0.7 0.6 0.3 7.7 0.2 3.0 4.6 3.7 0.2 0.4 13.0 0.9 0.6 0.2 2.0 0.8 0.8 17.6 0.9 1.1 0.0 0.3 7.5 0.2 0.0 0.2 3.6 0.0 1.3 0.3 0.2 0.0 0.0 0.6 0.2 0.0 0.0 0.0 1.1 0.1 1.2 0.4 0.0 1.3 0.0 0.0 0.0 0.4 1.0 39.3 0.5 0.0 0.0 0.2 1.4 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.4 0.3 0.2 0.1 0.2 0.6 0.3 0.2 0.0 0.7 0.0 0.2 0.5 0.0 0.2 1.6 0.7 0.1 0.2 0.2 0.8 0.1 0.7 0.2 0.9 0.6 0.6 0.4 7.5 0.1 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.2 0.0 0.1 0.1 1.0 0.0 0.1 0.3 0.0 3.6 0.4 1.2 1.9 0.4 0.5 0.4 0.4 0.2 0.4 0.2 GP1BB "CD42c, GPIbbeta" ENSG00000203618 "Glycoprotein Ib platelet beta subunit" P13224 22 19722945-19724771 "CD markers, Disease related genes, Predicted membrane proteins" "Blood coagulation, Cell adhesion, Hemostasis" "Bernard Soulier syndrome, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 61.7;brain: 19.6" "Cell line enhanced" "Detected in some" "HEK 293: 5.6;K-562: 10.1;NB-4: 8.4;REH: 10.2;SH-SY5Y: 4.9;U-2 OS: 10.2" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "basophil: 6.3;neutrophil: 11.0" "Lineage enriched" "Detected in many" 6 "granulocytes: 11.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" 110000000 0.9 0.5 16.7 1.2 19.6 0.5 0.5 7.3 9.0 0.5 1.7 1.2 0.7 0.5 1.8 0.5 0.7 2.9 15.0 4.1 0.5 0.9 0.6 0.6 2.7 0.5 0.5 0.5 2.5 0.6 1.3 0.7 1.9 0.5 1.2 10.4 0.5 1.0 0.2 1.8 1.9 0.5 0.7 0.7 0.5 0.2 0.1 1.7 11.0 1.2 0.1 0.3 61.7 0.0 0.9 0.0 0.0 0.0 0.0 0.1 1.5 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.5 0.0 0.0 0.0 1.7 5.6 2.3 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.1 0.0 0.0 10.1 0.1 0.1 0.4 0.4 8.4 0.4 3.1 10.2 0.0 0.1 0.0 0.0 3.7 4.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 10.2 0.1 0.0 0.7 0.0 0.0 0.0 0.2 0.0 6.3 1.2 1.1 0.2 0.3 0.1 0.0 0.1 0.0 0.4 0.1 0.1 0.1 11.0 0.1 0.0 1.7 0.3 61.7 GP5 CD42d ENSG00000178732 "Glycoprotein V platelet" P40197 3 194394821-194398354 "CD markers, Plasma proteins, Predicted membrane proteins" "Blood coagulation, Cell adhesion, Hemostasis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lymphoid tissue: 3.7" "Cell line enriched" "Detected in some" 9 "HEL: 18.6" "Cancer enriched" "Detected in single" 5 "testis cancer: 0.5" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 2.0;naive CD8 T-cell: 2.2" "Group enriched" "Detected in many" 6 "dendritic cells: 1.1;T-cells: 2.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA072646 Uncertain Cytosol 400000000 Cytosol "HPA072646: " "unprognostic (3.74e-2)" "unprognostic (3.40e-1)" "unprognostic (5.22e-2)" "unprognostic (2.96e-2)" "unprognostic (1.74e-2)" "unprognostic (1.35e-3)" "unprognostic (1.69e-3)" "unprognostic (1.68e-1)" "unprognostic (3.41e-1)" "unprognostic (2.80e-2)" "unprognostic (1.65e-1)" "unprognostic (5.51e-2)" "unprognostic (1.21e-2)" "unprognostic (4.18e-2)" "unprognostic (3.14e-1)" "unprognostic (1.72e-2)" "unprognostic (1.94e-1)" 0.3 0.0 0.4 2.1 0.5 1.6 0.3 0.3 0.3 0.6 0.3 0.3 0.3 0.0 0.3 0.3 0.3 2.5 0.3 0.3 0.4 0.6 0.3 0.6 0.9 3.7 0.3 0.3 0.8 0.3 0.0 0.4 0.3 0.3 0.3 0.1 0.3 0.3 0.3 0.3 0.1 0.9 0.3 0.3 1.7 0.2 0.3 0.3 0.3 1.0 0.3 1.9 0.3 0.5 0.1 1.1 0.2 0.0 0.0 2.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.3 0.0 0.5 0.4 0.1 0.1 2.0 2.2 0.1 0.0 0.0 1.1 0.0 0.4 0.4 0.5 0.3 0.3 0.4 0.6 0.3 0.3 0.3 0.3 GP9 "CD42a, GPIX" ENSG00000169704 "Glycoprotein IX platelet" P14770 3 129060767-129062406 "CD markers, Disease related genes, Predicted membrane proteins" "Blood coagulation, Cell adhesion, Hemostasis" "Bernard Soulier syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "blood: 27.1;bone marrow: 10.0;lymphoid tissue: 24.5" "Cell line enriched" "Detected in some" 14 "HEL: 42.2" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "basophil: 8.8;neutrophil: 7.5" "Lineage enriched" "Detected in many" 6 "granulocytes: 8.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA063182 Enhanced 68000000 "HPA063182: " "unprognostic (1.70e-1)" "unprognostic (3.97e-1)" "unprognostic (1.10e-1)" "unprognostic (3.80e-2)" "unprognostic (2.50e-2)" "unprognostic (3.24e-1)" "unprognostic (2.53e-2)" "unprognostic (8.47e-2)" "unprognostic (8.70e-2)" 0.2 0.1 0.1 0.1 0.1 10.0 0.1 0.0 0.6 0.4 0.5 0.0 0.0 0.1 0.1 0.0 0.1 0.3 0.1 5.0 0.8 0.1 0.1 0.4 4.8 0.0 0.8 0.2 0.5 0.1 0.0 0.3 1.5 0.4 0.1 0.4 0.2 0.0 0.6 0.2 0.0 0.1 0.0 0.1 24.5 0.3 2.2 0.0 0.0 0.6 0.6 0.0 0.6 3.0 0.1 1.5 8.8 0.6 0.0 0.2 27.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 42.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.8 0.6 0.1 0.1 0.3 0.1 0.0 0.0 0.2 0.3 0.1 0.0 0.0 7.5 0.0 0.0 1.5 0.0 27.1 0.1 0.1 0.0 0.6 0.8 0.1 0.8 0.2 0.4 0.0 GYPA "CD235a, GPA, MN, MNS" ENSG00000170180 "Glycophorin A (MNS blood group)" P02724 4 144109303-144140786 "Blood group antigen proteins, CD markers, Predicted membrane proteins" "Host-virus interaction" "Blood group antigen, Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "bone marrow: 56.9" "Cell line enriched" "Detected in some" 4 "HEL: 55.7" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "naive B-cell: 1.5" "Low lineage specificity" "Detected in single" "CAB002658, HPA014811" Enhanced Approved "Nucleoplasm,Plasma membrane,Cytosol" "Nucleoplasm, Plasma membrane, Cytosol" "CAB002658: , HPA014811: AB_1849827" "unprognostic (1.60e-1)" "unprognostic (2.47e-2)" 0.1 0.0 0.2 0.1 0.4 56.9 0.1 0.1 0.5 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.3 1.7 1.3 3.2 0.1 0.3 0.1 0.1 0.1 0.0 0.3 4.8 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 6.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 1.5 0.3 0.4 0.2 0.2 0.6 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 55.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.4 0.0 0.2 0.9 0.1 0.2 0.2 1.5 0.2 0.6 0.2 0.2 0.2 0.3 0.0 0.8 0.2 0.4 0.1 0.5 0.2 0.3 0.3 0.1 0.1 0.1 GYPB "CD235b, GPB, MNS, SS" ENSG00000250361 "Glycophorin B (MNS blood group)" P06028 4 143996104-144019345 "Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Blood group antigen" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "bone marrow: 37.1" "Cell line enriched" "Detected in some" 4 "HEL: 59.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Intracellular and membrane" 0.2 0.0 0.2 0.1 0.1 37.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.6 0.8 0.6 0.1 0.1 0.1 0.1 0.1 0.0 0.2 3.3 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 6.8 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.4 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 59.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 3.2 0.2 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 GYPC "CD236, CD236R, Ge, GPC, GYPD" ENSG00000136732 "Glycophorin C (Gerbich blood group)" P04921 2 126655933-126696670 "Blood group antigen proteins, CD markers, Predicted membrane proteins" "Blood group antigen" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HHSteC: 61.5;K-562: 45.7;SK-MEL-30: 90.3;U-266/70: 51.0" "Cancer enhanced" "Detected in all" "melanoma: 66.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008965, CAB009445" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB009445: AB_2116251, HPA008965: AB_1078455" "unprognostic (1.63e-2)" "unprognostic (7.14e-3)" "unprognostic (8.39e-2)" "unprognostic (3.31e-3)" "unprognostic (4.19e-2)" "unprognostic (1.69e-2)" "unprognostic (8.82e-2)" "unprognostic (3.52e-1)" "unprognostic (1.19e-1)" "unprognostic (2.21e-1)" "unprognostic (1.25e-1)" "unprognostic (1.11e-1)" "unprognostic (2.05e-2)" "unprognostic (2.73e-2)" "unprognostic (1.51e-1)" "unprognostic (2.29e-1)" "unprognostic (8.00e-3)" 44.5 21.7 3.9 34.5 5.3 95.0 99.8 1.3 4.3 20.7 24.8 5.9 9.8 5.0 20.3 26.0 22.9 18.5 21.4 61.2 4.4 3.4 15.2 6.3 29.5 75.8 8.0 3.7 37.4 18.7 1.7 5.5 17.5 5.6 24.5 5.5 13.8 13.0 15.5 48.9 11.3 15.2 34.8 8.3 41.1 13.5 13.4 4.6 28.5 11.6 29.9 22.5 37.1 38.8 21.2 9.9 4.2 7.7 14.7 41.4 21.8 0.1 0.0 22.1 0.0 16.4 14.4 0.0 3.3 25.6 4.0 11.9 0.0 0.0 0.0 0.0 9.2 0.0 12.0 0.0 1.3 10.5 0.0 37.1 0.0 0.0 61.5 12.9 0.1 32.3 0.0 3.2 0.0 0.1 45.7 30.7 9.6 0.0 0.0 20.5 6.6 0.0 2.4 1.6 0.0 1.6 0.0 0.0 0.0 0.0 0.0 90.3 0.0 35.3 8.9 15.2 0.1 1.0 0.1 51.0 33.0 0.0 7.3 18.8 13.7 0.1 5.9 0.4 32.3 7.7 36.4 18.9 29.3 39.1 9.9 21.2 41.4 40.4 4.2 14.7 4.7 5.5 35.1 21.8 3.9 5.3 1.3 4.3 4.4 3.4 8.0 3.7 5.6 4.6 HMMR "CD168, RHAMM" ENSG00000072571 "Hyaluronan mediated motility receptor" O75330 5 163460203-163491945 "CD markers, FDA approved drug targets, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 54.5;testis: 16.7" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "T-reg: 4.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB002433, HPA040025, HPA043926, HPA061524" Enhanced Enhanced Microtubules,Centrosome,Cytosol Microtubules "Centrosome, Cytosol" "CAB002433: AB_564080, HPA040025: , HPA043926: , HPA061524: " "unprognostic (3.53e-3)" "unprognostic (1.01e-1)" "unprognostic (3.38e-3)" "unprognostic (8.88e-3)" "unprognostic (2.12e-1)" "prognostic unfavourable (5.52e-4)" "prognostic unfavourable (1.93e-7)" "prognostic unfavourable (1.09e-4)" "unprognostic (5.68e-2)" "unprognostic (2.50e-1)" "prognostic unfavourable (3.71e-5)" "unprognostic (1.02e-1)" "unprognostic (0.00e+0)" "unprognostic (1.65e-2)" "unprognostic (4.98e-2)" "unprognostic (2.39e-1)" "unprognostic (1.77e-2)" 1.6 1.4 0.6 13.4 0.6 11.4 2.4 0.4 0.9 1.7 5.0 0.6 0.6 4.5 0.6 2.3 6.4 0.5 0.9 1.6 0.8 0.7 1.4 1.8 2.5 10.9 1.0 0.4 0.6 1.1 0.6 0.5 6.9 1.1 0.7 5.6 0.4 1.6 0.2 1.4 2.3 4.8 1.4 1.9 8.6 2.6 16.7 0.3 54.5 0.7 5.6 10.8 1.8 2.1 1.2 1.8 0.6 0.7 1.5 4.8 0.8 21.1 13.3 27.1 14.5 1.4 2.6 20.2 20.1 9.8 25.2 22.9 27.0 40.8 35.1 19.2 6.2 24.4 31.3 19.0 43.0 31.8 9.7 21.0 9.5 13.1 0.4 18.6 19.4 0.7 1.1 23.6 18.5 14.3 19.8 28.8 26.2 7.7 19.6 10.6 23.4 14.5 21.4 36.3 17.6 9.8 5.7 22.7 12.6 29.9 9.4 11.4 27.6 14.9 9.3 18.1 15.3 14.4 26.9 15.5 25.9 28.3 11.9 28.8 17.3 0.5 0.7 0.0 0.5 0.3 0.9 1.2 1.0 0.6 0.9 0.9 0.4 0.7 0.6 1.5 0.0 1.8 4.8 0.8 0.6 0.6 0.4 0.9 0.8 0.7 1.0 0.4 1.1 0.3 ICAM1 "BB2, CD54" ENSG00000090339 "Intercellular adhesion molecule 1" P05362 19 10270835-10286615 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 68.3;lung: 91.3" "Cell line enhanced" "Detected in many" "HHSteC: 31.1;Karpas-707: 88.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA002126, CAB002142, HPA004877" Enhanced Uncertain "Plasma membrane,Cytosol" 3100000000 "Plasma membrane, Cytosol" "CAB002142: AB_563596, HPA002126: AB_1078470, HPA004877: AB_1846317" "prognostic favourable (7.09e-4)" "unprognostic (1.88e-1)" "unprognostic (1.94e-1)" "unprognostic (2.63e-2)" "unprognostic (3.25e-3)" "unprognostic (3.05e-1)" "unprognostic (1.45e-2)" "unprognostic (3.48e-1)" "unprognostic (3.18e-2)" "unprognostic (1.09e-2)" "unprognostic (1.49e-2)" "unprognostic (1.79e-1)" "prognostic unfavourable (1.32e-6)" "unprognostic (2.77e-1)" "unprognostic (2.16e-2)" "unprognostic (2.25e-1)" "unprognostic (3.70e-3)" 26.1 8.6 4.0 41.0 4.1 36.5 15.0 1.0 4.5 5.6 10.0 2.7 1.6 6.1 8.5 7.7 7.9 10.7 19.8 16.3 2.6 2.1 10.9 68.3 91.3 32.8 5.4 1.7 12.4 7.2 2.5 4.0 9.3 6.8 10.4 6.6 10.6 7.2 3.6 13.9 6.9 7.9 8.0 7.8 42.2 7.3 6.5 3.6 8.3 11.6 13.7 13.4 14.8 17.1 2.2 13.3 22.2 14.2 7.9 5.6 8.9 8.2 0.1 1.5 0.0 0.4 0.9 2.1 1.7 18.5 4.1 12.5 2.7 9.3 7.6 25.8 0.7 1.7 0.3 0.0 8.7 22.7 0.0 0.7 0.2 11.3 31.1 0.2 4.5 10.9 0.7 2.6 4.0 2.1 2.8 88.5 0.3 0.6 0.1 6.4 0.5 4.7 0.2 0.0 28.1 7.0 0.0 0.0 0.2 11.4 0.6 18.1 1.4 0.5 6.4 4.2 0.4 2.3 0.1 27.0 27.8 4.7 6.8 4.9 6.2 2.2 13.9 2.6 3.0 14.2 5.6 2.2 2.4 3.6 13.3 0.9 1.0 2.2 22.2 7.9 7.9 7.5 3.4 8.9 4.0 4.1 1.0 4.5 2.6 2.1 5.4 1.7 6.8 3.6 ICAM2 CD102 ENSG00000108622 "Intercellular adhesion molecule 2" P13598 17 64002594-64020634 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 74.5;lymphoid tissue: 63.9" "Group enriched" "Detected in many" 6 "HUVEC TERT2: 163.3;TIME: 41.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA071155 Approved "Plasma membrane,Cytosol" 1200000000 "Plasma membrane" Cytosol "HPA071155: " "unprognostic (9.43e-3)" "unprognostic (3.31e-2)" "unprognostic (5.15e-2)" "unprognostic (1.15e-1)" "unprognostic (8.97e-2)" "unprognostic (1.64e-3)" "unprognostic (1.34e-1)" "unprognostic (3.74e-1)" "unprognostic (8.28e-2)" "unprognostic (2.15e-1)" "unprognostic (4.18e-2)" "unprognostic (1.55e-2)" "unprognostic (9.07e-2)" "unprognostic (1.48e-1)" "unprognostic (3.93e-2)" "unprognostic (6.04e-2)" "unprognostic (2.29e-1)" 36.0 3.6 8.4 13.0 11.5 8.3 34.1 3.5 7.7 9.4 9.7 5.6 2.8 6.4 9.8 5.2 9.5 7.4 8.8 22.8 9.5 8.9 10.5 8.7 27.9 24.0 12.3 3.1 6.3 7.4 3.1 4.5 36.8 9.1 7.9 8.5 8.1 8.8 4.3 17.1 5.5 10.8 13.9 10.5 63.9 8.0 4.0 7.4 14.3 11.6 9.0 18.0 12.8 23.6 49.0 30.9 56.5 74.5 26.0 65.3 67.5 0.0 0.0 0.0 0.0 1.3 1.5 0.4 0.1 0.1 0.0 0.1 0.3 6.8 11.5 2.1 0.0 0.0 0.1 0.0 0.2 2.5 0.0 10.3 0.6 1.2 0.2 1.7 0.0 0.0 0.0 0.1 0.0 163.3 8.4 6.7 0.0 0.0 12.8 1.5 0.0 0.0 7.8 0.0 15.9 0.8 1.6 0.0 0.0 0.0 0.0 0.0 0.0 1.3 41.2 0.0 0.1 0.8 0.0 6.4 2.2 10.2 0.0 2.1 0.0 56.5 30.0 8.9 45.8 66.5 52.8 36.5 60.1 42.8 30.9 49.0 65.3 40.7 3.6 26.0 74.5 10.0 64.5 67.5 8.4 11.5 3.5 7.7 9.5 8.9 12.3 3.1 9.1 7.4 ICAM3 "CD50, CDW50, ICAM-R" ENSG00000076662 "Intercellular adhesion molecule 3" P32942 19 10333776-10339823 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Phagocytosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 172.3;bone marrow: 51.5;lymphoid tissue: 68.5" "Cell line enhanced" "Detected in many" "Karpas-707: 64.3;NB-4: 41.4;RPMI-8226: 48.2;U-266/84: 34.1;U-937: 33.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in all" "neutrophil: 172.3" "Lineage enriched" "Detected in all" 4 "granulocytes: 172.3" "CAB002498, HPA049820" Enhanced Approved "Nucleoplasm,Nuclear membrane,Mitochondria" 370000000 Mitochondria "Nucleoplasm, Nuclear membrane" "CAB002498: AB_563593, HPA049820: " "unprognostic (6.85e-4)" "unprognostic (5.28e-3)" "unprognostic (3.09e-3)" "unprognostic (1.57e-2)" "unprognostic (5.34e-3)" "unprognostic (5.79e-6)" "unprognostic (5.05e-3)" "unprognostic (3.73e-2)" "unprognostic (1.73e-3)" "unprognostic (7.93e-2)" "unprognostic (3.45e-2)" "unprognostic (2.54e-1)" "unprognostic (5.62e-4)" "unprognostic (1.13e-1)" "unprognostic (1.06e-2)" "unprognostic (3.43e-1)" "unprognostic (1.84e-1)" 6.8 2.8 1.7 23.5 1.9 51.5 5.5 0.6 1.5 3.0 6.8 1.1 1.2 4.3 1.7 3.0 4.0 2.9 7.2 6.4 1.1 0.9 5.1 28.7 13.2 68.5 1.8 1.4 1.7 6.8 0.2 0.4 4.8 1.5 2.8 3.3 2.4 10.3 1.3 5.0 1.6 11.9 1.8 1.0 39.4 5.4 1.4 1.0 47.6 3.0 5.7 38.4 4.5 4.9 25.5 28.4 172.3 33.5 31.0 41.0 43.1 2.6 1.3 0.9 2.9 1.6 1.3 1.6 1.6 1.1 1.4 1.2 1.1 1.8 0.0 5.7 1.4 1.1 0.0 1.2 0.4 19.8 0.8 5.0 1.2 5.0 0.8 18.3 20.7 1.1 1.0 1.6 0.5 0.6 2.7 64.3 1.5 5.4 2.4 41.4 0.7 9.0 1.5 0.6 48.2 1.4 2.3 0.3 1.2 1.4 4.5 3.6 3.9 5.2 1.1 6.3 0.5 7.0 1.6 3.1 34.1 7.6 4.5 33.8 4.9 15.3 33.1 72.0 33.8 24.4 41.0 25.5 32.7 31.2 28.4 23.9 29.3 27.4 172.3 31.0 33.5 4.8 36.9 43.1 1.7 1.9 0.6 1.5 1.1 0.9 1.8 1.4 1.5 1.0 ICAM4 "CD242, LW" ENSG00000105371 "Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)" Q14773 19 10286967-10288522 "Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Blood group antigen" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 53.1;bone marrow: 13.7;lung: 13.5" "Cell line enhanced" "Detected in some" "HEL: 35.3;HMC-1: 8.9;K-562: 18.3;NB-4: 15.2;U-937: 8.5" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "cerebral cortex: 2.0;pons and medulla: 2.4" "Cell type enriched" "Detected in many" 5 "non-classical monocyte: 53.1" "Lineage enriched" "Detected in many" 6 "monocytes: 53.1" "Intracellular and membrane" 1.9 0.4 0.4 1.6 0.4 13.7 0.6 0.2 2.0 1.0 2.9 0.2 0.0 1.1 1.1 2.9 2.3 1.1 1.1 1.1 0.5 0.3 1.6 1.7 13.5 3.3 0.4 0.0 1.2 0.4 0.1 0.4 1.9 2.4 2.4 0.5 0.9 2.5 2.7 1.7 0.8 1.4 0.2 0.9 2.8 1.6 0.6 0.3 1.5 0.9 0.0 4.5 3.3 0.7 0.5 8.4 4.5 53.1 0.1 0.6 2.4 0.1 0.1 0.1 0.2 0.0 0.0 3.1 0.3 0.1 0.0 0.0 3.9 0.2 0.4 0.4 0.0 0.3 0.1 0.0 0.0 0.3 0.2 35.3 0.2 5.3 1.0 0.6 8.9 0.2 0.0 0.1 0.1 0.0 18.3 1.6 0.0 0.1 0.9 15.2 0.1 0.1 2.6 1.5 6.7 0.0 0.1 0.0 0.1 0.3 0.1 0.1 0.1 1.0 0.3 0.1 0.0 0.3 0.0 0.5 0.9 0.1 0.3 8.5 0.2 4.5 2.6 2.6 0.2 9.7 0.5 0.5 0.3 0.2 8.4 0.4 0.3 0.1 0.7 0.1 53.1 2.7 0.6 2.4 0.4 0.4 0.2 2.0 0.5 0.3 0.4 0.0 2.4 0.3 ICOS "AILIM, CD278" ENSG00000163600 "Inducible T cell costimulator" Q9Y6W8 2 203936748-203961577 "CD markers, Disease related genes, Predicted membrane proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 18.4;bone marrow: 13.8;lymphoid tissue: 51.8" "Group enriched" "Detected in some" 100 "HEL: 5.9;MOLT-4: 15.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "T-reg: 18.4" "Lineage enriched" "Detected in single" 58 "T-cells: 18.4" "Low region specificity" "Detected in single" "CAB032575, HPA034865" Approved Approved "Plasma membrane,Actin filaments" "Intracellular and membrane" "Plasma membrane" "Actin filaments" "CAB032575: AB_2122593, HPA034865: " "unprognostic (2.66e-2)" "unprognostic (2.13e-3)" "unprognostic (4.19e-4)" "unprognostic (2.35e-5)" "unprognostic (1.07e-1)" "prognostic favourable (1.80e-4)" "unprognostic (9.38e-2)" "unprognostic (2.89e-2)" "unprognostic (1.49e-2)" "unprognostic (3.51e-4)" "unprognostic (7.50e-2)" "unprognostic (2.12e-1)" "unprognostic (2.86e-5)" "unprognostic (7.05e-2)" "unprognostic (2.48e-2)" "unprognostic (1.93e-1)" "unprognostic (8.82e-3)" 1.5 0.3 0.2 15.6 0.2 13.8 0.7 0.2 0.2 0.8 1.2 0.0 0.2 0.5 1.2 0.5 1.1 1.2 1.6 0.5 0.2 0.2 1.0 0.8 4.0 19.4 0.3 0.0 0.6 0.3 0.0 0.4 0.1 0.1 0.7 1.1 0.7 2.9 0.0 0.2 0.6 6.2 0.3 0.4 6.1 1.0 0.6 0.0 51.8 1.4 2.4 28.9 3.0 0.9 0.0 0.0 0.0 0.0 0.3 18.4 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 2.9 0.0 10.5 4.6 0.0 0.0 11.0 5.0 0.0 0.3 0.0 0.0 18.4 3.0 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.0 0.1 0.0 ICOSLG "B7-H2, B7H2, B7RP-1, B7RP1, CD275, GL50, ICOS-L, ICOSL, KIAA0653" ENSG00000160223 "Inducible T cell costimulator ligand" O75144 21 44217014-44240966 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, B-cell activation, Immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 14.1" "Cell line enhanced" "Detected in many" "Daudi: 14.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive B-cell: 6.5" "Low lineage specificity" "Detected in many" "CAB026037, HPA029179" Uncertain Approved "Plasma membrane,Cytoplasmic bodies" 150000000 "Plasma membrane, Cytoplasmic bodies" "CAB026037: , HPA029179: " "unprognostic (3.03e-2)" "unprognostic (1.40e-4)" "unprognostic (3.52e-2)" "unprognostic (1.94e-2)" "unprognostic (6.74e-2)" "unprognostic (9.40e-2)" "unprognostic (6.94e-2)" "unprognostic (3.71e-1)" "unprognostic (1.40e-1)" "unprognostic (3.76e-2)" "unprognostic (1.40e-1)" "unprognostic (2.42e-1)" "unprognostic (3.00e-2)" "unprognostic (3.11e-1)" "unprognostic (1.36e-1)" "unprognostic (1.47e-1)" "unprognostic (1.84e-1)" 2.3 3.0 5.3 3.9 7.1 14.1 2.3 2.3 5.9 2.9 2.3 2.3 2.3 1.8 2.3 2.3 4.0 2.7 3.5 3.7 8.8 3.7 5.3 2.7 2.3 6.5 6.5 2.3 2.3 2.3 0.0 2.3 2.3 2.3 2.3 1.2 2.3 2.3 2.3 2.3 5.5 2.9 2.3 8.4 3.2 4.2 2.3 2.3 2.3 2.3 2.3 4.5 2.4 2.6 6.5 1.6 1.0 0.8 0.5 1.1 0.4 0.3 3.3 0.1 2.8 0.8 1.1 7.7 0.7 0.6 0.4 0.2 5.6 0.4 14.0 2.1 0.3 4.2 1.9 1.3 0.2 1.4 1.4 0.4 2.7 1.6 0.7 6.0 10.3 1.1 1.9 0.9 0.9 0.8 2.3 1.3 0.2 3.6 0.3 7.9 2.0 3.5 11.9 0.9 8.2 0.6 7.4 1.4 0.0 9.3 13.2 0.3 3.8 8.6 0.8 0.4 3.3 0.3 0.2 12.1 8.2 11.7 4.3 5.6 1.8 0.6 0.8 0.4 0.3 0.8 0.3 3.7 0.8 0.5 0.5 6.5 0.8 1.1 1.0 0.5 0.5 1.6 0.4 0.4 5.3 7.1 2.3 2.3 8.8 3.7 6.5 2.3 2.3 2.3 IFITM1 "9-27, CD225, IFI17" ENSG00000185885 "Interferon induced transmembrane protein 1" P13164 11 313506-315272 "CD markers, Plasma proteins, Predicted membrane proteins, Transporters" "Antiviral defense, Immunity, Innate immunity, Osteogenesis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BJ hTERT+ SV40 Large T+: 120.0;BJ hTERT+ SV40 Large T+ RasG12V: 215.2;HMC-1: 66.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 6 "eosinophil: 56.6;gdT-cell: 120.0;MAIT T-cell: 80.7;memory CD4 T-cell: 128.1;memory CD8 T-cell: 121.4;naive CD4 T-cell: 123.5;naive CD8 T-cell: 123.4;neutrophil: 106.8;NK-cell: 164.4;T-reg: 70.4" "Group enriched" "Detected in all" 7 "granulocytes: 106.8;NK-cells: 164.4;T-cells: 128.1" "HPA004810, CAB017615" Enhanced Supported Cytosol Cytosol "CAB017615: AB_2264496, HPA004810: AB_1851419" "unprognostic (1.03e-3)" "unprognostic (6.79e-2)" "unprognostic (1.03e-1)" "unprognostic (2.98e-1)" "unprognostic (2.57e-1)" "unprognostic (9.06e-2)" "unprognostic (7.58e-2)" "unprognostic (3.03e-1)" "unprognostic (6.21e-2)" "unprognostic (5.53e-2)" "unprognostic (6.64e-3)" "unprognostic (1.48e-2)" "prognostic unfavourable (5.77e-9)" "unprognostic (7.29e-2)" "unprognostic (6.29e-2)" "unprognostic (3.15e-2)" "unprognostic (3.82e-2)" 81.1 14.2 17.4 36.7 24.5 41.2 57.0 11.9 23.1 71.0 28.2 12.9 20.6 17.2 48.3 152.4 44.4 67.2 31.2 62.6 19.8 13.9 59.8 34.5 44.1 159.7 34.8 14.7 100.2 16.3 22.3 23.3 36.3 27.3 38.7 22.1 49.5 27.4 41.6 38.7 23.6 33.0 46.0 37.9 112.9 20.5 29.4 20.1 42.7 48.3 28.0 50.3 39.3 52.8 13.0 4.3 106.8 18.6 164.4 128.1 147.7 6.2 0.1 52.2 4.2 3.8 13.4 0.3 11.1 51.9 120.0 215.2 0.1 43.5 0.1 8.3 11.6 14.8 1.6 1.1 2.4 13.2 2.7 6.4 4.0 0.4 34.6 9.3 66.4 25.1 0.0 1.3 0.1 0.2 22.7 52.7 0.0 0.9 4.6 17.9 14.8 1.6 1.2 0.1 1.2 32.1 0.0 0.0 0.0 5.8 0.6 10.6 2.1 0.8 0.3 0.1 0.1 0.0 0.0 3.7 2.0 0.3 0.1 14.0 0.1 15.6 2.3 56.6 120.0 10.9 80.7 13.0 128.1 121.4 4.3 11.3 123.5 123.4 106.8 164.4 18.6 1.2 70.4 147.7 17.4 24.5 11.9 23.1 19.8 13.9 34.8 14.7 27.3 20.1 IFNGR1 "CD119, IFNGR" ENSG00000027697 "Interferon gamma receptor 1" P15260 6 137197484-137219449 "CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "hTCEpi: 57.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025889, HPA029213, HPA063871" Approved Approved "Plasma membrane" "Plasma membrane" "CAB025889: , HPA029213: AB_10601023, HPA063871: " "unprognostic (1.73e-1)" "unprognostic (8.86e-2)" "unprognostic (9.85e-3)" "unprognostic (1.71e-1)" "unprognostic (6.55e-2)" "unprognostic (1.25e-1)" "unprognostic (4.05e-1)" "unprognostic (6.97e-2)" "unprognostic (9.86e-2)" "unprognostic (1.57e-2)" "unprognostic (4.09e-2)" "unprognostic (2.85e-1)" "prognostic unfavourable (5.48e-4)" "unprognostic (1.58e-1)" "unprognostic (2.87e-2)" "unprognostic (1.81e-2)" "unprognostic (5.38e-3)" 69.5 22.2 17.4 36.9 23.5 37.7 65.3 8.4 18.5 23.6 27.1 27.8 13.8 28.0 19.2 21.2 23.0 20.3 25.9 53.7 20.6 17.4 19.3 66.4 58.7 86.9 33.8 13.2 19.2 17.5 9.2 12.8 47.0 29.9 20.1 22.8 11.6 24.5 18.0 25.3 24.0 46.7 22.5 45.7 69.1 20.3 14.1 26.3 14.5 22.8 19.7 38.2 25.0 22.3 12.2 39.4 92.3 65.4 5.4 29.7 52.3 4.9 4.7 6.2 8.0 41.1 21.7 5.2 14.1 20.8 9.1 12.4 30.7 9.6 4.9 22.4 8.1 30.5 5.5 14.2 12.8 10.5 7.6 7.7 5.8 45.4 23.2 23.9 11.4 47.8 57.5 7.6 12.4 11.4 6.4 8.3 6.9 5.5 3.8 11.0 5.1 3.8 11.8 6.5 7.3 15.9 23.2 6.3 9.7 17.3 10.2 12.7 3.6 15.8 15.9 8.9 6.5 11.6 7.4 6.2 5.8 5.5 4.6 15.9 8.6 16.5 65.4 43.3 14.1 63.0 29.7 10.9 8.0 11.8 39.4 12.2 5.2 5.8 92.3 5.4 44.1 10.1 5.6 52.3 17.4 23.5 8.4 18.5 20.6 17.4 33.8 13.2 29.9 26.3 IGF1R "CD221, IGFIR, IGFR, JTK13, MGC18216" ENSG00000140443 "Insulin like growth factor 1 receptor" P08069 15 98648971-98964530 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 7.7" "Group enriched" "Detected in many" 5 "granulocytes: 7.7;T-cells: 2.9" "Low region specificity" "Detected in all" "CAB010268, HPA045563" Approved Approved Vesicles 36000 Vesicles "CAB010268: AB_671792, HPA045563: " "unprognostic (1.30e-3)" "unprognostic (5.81e-3)" "unprognostic (1.53e-1)" "unprognostic (3.34e-2)" "unprognostic (2.65e-1)" "unprognostic (2.05e-2)" "unprognostic (1.29e-2)" "unprognostic (6.87e-2)" "unprognostic (2.64e-2)" "unprognostic (2.87e-2)" "unprognostic (8.56e-2)" "unprognostic (1.62e-1)" "prognostic favourable (3.75e-7)" "unprognostic (1.57e-1)" "unprognostic (3.59e-1)" "unprognostic (1.41e-1)" "unprognostic (1.06e-1)" 8.4 12.7 11.5 5.9 13.5 16.3 18.5 23.0 15.7 15.3 13.4 10.4 22.7 4.2 15.3 16.3 9.2 18.9 7.7 11.6 11.7 7.3 17.0 2.0 11.0 4.9 8.0 11.8 23.2 22.5 4.7 13.8 17.5 9.5 21.7 7.2 16.7 12.5 23.2 9.1 13.0 7.5 18.1 8.0 7.3 10.7 12.0 11.5 10.7 16.1 7.0 5.6 12.8 21.6 1.0 0.4 7.7 0.6 1.0 2.9 0.7 3.3 16.5 11.6 0.2 5.8 4.2 7.7 3.7 7.4 1.2 1.1 7.1 8.8 0.8 10.7 7.2 15.8 5.1 15.0 1.0 0.0 5.2 12.5 18.5 14.2 5.1 6.6 1.3 6.6 7.1 2.1 10.2 4.1 0.6 2.9 5.7 23.4 2.5 4.4 10.8 0.9 4.0 9.0 3.0 3.5 20.3 3.9 17.3 26.7 1.5 14.4 8.1 3.1 11.3 1.1 15.0 3.0 5.8 1.0 4.4 2.7 2.2 4.9 2.8 4.0 0.6 1.8 0.9 0.6 0.6 0.4 0.8 0.3 0.4 1.0 2.9 1.0 7.7 1.0 0.5 0.3 0.0 0.7 11.5 13.5 23.0 15.7 11.7 7.3 8.0 11.8 9.5 11.5 IGF2R "CD222, CI-M6PR, CI-MPR, CIMPR, M6P-R, MPR1, MPR300, MPRI" ENSG00000197081 "Insulin like growth factor 2 receptor" P11717 6 159969099-160113507 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HBEC3-KT: 59.6;hTERT-HME1: 60.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 13.3" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009661, HPA011332" Supported Enhanced "Golgi apparatus,Vesicles" 150000000 "Golgi apparatus, Vesicles" "CAB009661: AB_2122795, HPA011332: AB_1846276" "prognostic unfavourable (3.01e-4)" "prognostic unfavourable (2.92e-5)" "unprognostic (5.83e-2)" "unprognostic (1.72e-1)" "unprognostic (4.15e-1)" "unprognostic (3.25e-1)" "unprognostic (7.32e-3)" "unprognostic (2.32e-1)" "unprognostic (1.62e-1)" "unprognostic (1.07e-2)" "unprognostic (2.37e-1)" "unprognostic (1.45e-1)" "unprognostic (5.74e-3)" "unprognostic (1.16e-1)" "unprognostic (1.46e-1)" "unprognostic (1.85e-1)" "prognostic unfavourable (6.08e-4)" 28.0 22.2 6.8 13.5 8.1 16.7 39.4 6.4 8.2 14.9 17.3 9.5 13.0 9.4 19.6 16.0 16.7 13.1 17.9 27.9 6.7 6.2 20.6 26.6 32.6 44.7 12.3 3.6 18.0 19.6 23.5 13.6 15.5 10.0 14.1 13.3 13.9 18.2 13.5 62.0 15.9 15.4 16.5 7.6 30.2 14.4 13.8 9.0 37.9 18.5 17.3 14.1 16.3 26.9 0.4 2.9 13.3 2.0 1.0 3.6 0.9 7.7 7.0 12.4 17.4 45.3 25.0 16.8 12.2 26.4 10.1 17.4 10.6 12.2 3.2 13.7 13.4 10.4 9.3 59.6 17.0 16.8 6.6 1.4 12.2 19.1 26.8 7.4 12.1 19.9 19.1 21.0 60.7 6.5 13.9 17.4 15.9 5.7 3.4 7.4 5.5 7.5 8.0 8.5 16.3 14.3 7.8 4.1 9.1 16.5 14.8 16.5 6.2 21.0 9.8 9.8 10.3 21.1 22.3 10.3 14.4 3.3 18.9 10.2 15.1 0.1 2.0 1.1 3.6 0.8 1.4 0.3 1.2 1.7 0.3 0.4 1.0 2.4 13.3 1.0 1.4 2.9 0.7 0.9 6.8 8.1 6.4 8.2 6.7 6.2 12.3 3.6 10.0 9.0 IGLL1 "14.1, CD179B, IGL5, IGLL, IGVPB" ENSG00000128322 "Immunoglobulin lambda like polypeptide 1" P15814 22 23573125-23580308 "CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 35 "blood: 11.6;bone marrow: 37.7;lymphoid tissue: 29.4;testis: 20.8" "Cell line enriched" "Detected in some" 34 "REH: 126.8" "Cancer enhanced" "Detected in some" "stomach cancer: 2.1" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "memory B-cell: 11.6;naive B-cell: 9.8" "Lineage enriched" "Detected in many" 8 "B-cells: 11.6" "HPA051134, HPA071406" Enhanced Approved "Endoplasmic reticulum" "Secreted to blood" 100000000000 "Endoplasmic reticulum" "HPA051134: , HPA071406: " "unprognostic (6.21e-2)" "unprognostic (5.12e-2)" "unprognostic (7.31e-2)" "unprognostic (4.75e-2)" "unprognostic (1.56e-1)" "unprognostic (5.91e-6)" "unprognostic (1.08e-1)" "unprognostic (5.27e-2)" "unprognostic (6.17e-3)" "unprognostic (5.89e-2)" "unprognostic (9.07e-2)" "unprognostic (1.99e-4)" "unprognostic (2.35e-2)" "unprognostic (5.16e-1)" "unprognostic (2.28e-2)" "unprognostic (1.21e-2)" 0.0 0.0 0.1 0.1 0.2 37.7 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.2 0.6 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 20.8 0.0 29.4 0.0 0.0 1.1 0.0 0.0 11.6 1.3 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.4 0.0 0.0 126.8 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.6 0.0 0.0 0.0 9.8 0.0 0.0 0.0 0.0 0.0 1.3 0.0 1.5 0.1 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 IGSF8 "CD316, CD81P3, EWI2, PGRL" ENSG00000162729 "Immunoglobulin superfamily member 8" Q969P0 1 160091340-160098943 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 54.2" "Cell line enhanced" "Detected in all" "SK-MEL-30: 58.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011917, HPA075970" Approved Supported Vesicles 190000 Vesicles "HPA011917: AB_1851536, HPA075970: " "unprognostic (4.08e-1)" "prognostic unfavourable (7.32e-4)" "unprognostic (1.30e-2)" "unprognostic (9.31e-2)" "unprognostic (1.46e-1)" "unprognostic (1.20e-1)" "unprognostic (1.71e-1)" "unprognostic (1.01e-3)" "unprognostic (1.63e-2)" "unprognostic (1.65e-1)" "unprognostic (1.09e-1)" "unprognostic (1.63e-1)" "unprognostic (2.31e-1)" "unprognostic (2.60e-2)" "unprognostic (2.35e-1)" "unprognostic (3.74e-3)" "unprognostic (1.75e-3)" 9.9 10.4 25.2 9.0 30.3 2.4 11.1 40.9 54.2 9.6 11.8 53.5 6.4 18.2 8.6 16.6 7.0 13.9 8.5 11.6 32.4 24.1 10.4 19.3 10.1 10.3 32.2 29.9 15.1 19.1 9.0 8.7 7.8 25.9 13.8 7.4 11.2 21.0 14.0 6.0 34.0 14.4 5.1 42.6 10.6 9.8 11.5 25.3 6.2 10.0 5.9 6.2 6.0 6.9 14.3 5.6 1.2 4.0 4.7 15.6 6.4 8.8 5.3 6.9 17.6 4.1 2.6 14.6 4.3 5.7 9.3 8.7 6.0 6.1 13.0 16.3 6.3 17.0 2.8 6.4 1.3 15.5 5.0 1.6 5.9 10.3 6.8 4.4 14.5 3.1 13.0 6.0 1.9 1.9 2.2 7.5 2.1 8.4 11.0 10.3 14.6 8.5 6.3 3.5 9.4 8.5 9.2 2.9 12.6 5.0 16.2 58.0 11.5 5.7 1.9 4.1 8.9 7.4 3.5 20.6 22.8 5.8 14.5 1.7 10.7 0.0 2.9 1.2 13.3 4.0 11.7 12.2 11.0 15.4 3.3 14.3 14.8 15.6 0.8 4.7 2.4 5.6 14.9 6.4 25.2 30.3 40.9 54.2 32.4 24.1 32.2 29.9 25.9 25.3 IL10RA "CD210, CD210a, CDW210A, HIL-10R, IL10R" ENSG00000110324 "Interleukin 10 receptor subunit alpha" Q13651 11 117986348-118003037 "CD markers, Disease related genes, Predicted membrane proteins" Receptor "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 56.2" "Cell line enhanced" "Detected in some" "Daudi: 14.5;HDLM-2: 36.2;Karpas-707: 13.6;RPMI-8226: 16.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "unprognostic (1.01e-2)" "unprognostic (2.07e-3)" "unprognostic (1.58e-2)" "unprognostic (7.08e-2)" "unprognostic (8.27e-2)" "prognostic favourable (4.47e-4)" "unprognostic (5.27e-2)" "unprognostic (4.84e-2)" "unprognostic (7.70e-3)" "unprognostic (5.94e-2)" "unprognostic (2.14e-2)" "unprognostic (3.83e-1)" "prognostic unfavourable (1.45e-5)" "unprognostic (1.82e-1)" "unprognostic (8.43e-3)" "unprognostic (2.19e-1)" "unprognostic (1.27e-1)" 11.3 6.5 2.9 29.6 3.5 27.2 7.2 1.1 3.0 3.4 7.9 4.7 0.5 3.8 5.5 11.0 4.3 4.9 9.7 7.6 3.0 3.6 5.0 6.4 13.6 49.8 4.7 1.4 3.4 3.6 1.3 3.4 6.9 4.5 5.8 7.5 6.4 7.9 1.9 2.6 3.0 17.6 5.0 8.0 56.2 4.9 3.1 3.5 9.6 3.6 3.9 32.2 9.5 3.4 4.6 15.4 1.2 23.9 23.7 30.7 22.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.5 0.1 0.0 0.0 0.2 0.0 0.0 36.2 0.0 0.1 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 2.6 13.6 0.0 0.0 0.2 2.8 0.0 0.0 0.0 0.0 16.5 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 2.8 0.4 3.8 0.0 5.4 0.0 1.1 15.8 0.8 19.7 23.9 14.2 4.6 19.0 22.7 15.4 2.3 6.9 12.3 1.2 23.7 18.8 6.0 30.7 22.8 2.9 3.5 1.1 3.0 3.0 3.6 4.7 1.4 4.5 3.5 IL10RB "CDW210B, CRF2-4, CRFB4, D21S58, D21S66, IL-10R2" ENSG00000243646 "Interleukin 10 receptor subunit beta" Q08334 21 33266358-33310187 "CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Antiviral defense" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB020670, HPA047550" Approved Approved Cytosol 1300000 Cytosol "CAB020670: , HPA047550: " "unprognostic (8.43e-2)" "unprognostic (6.50e-2)" "unprognostic (5.88e-2)" "unprognostic (1.77e-1)" "unprognostic (1.48e-2)" "unprognostic (7.78e-2)" "unprognostic (1.97e-3)" "unprognostic (1.26e-1)" "unprognostic (5.69e-3)" "unprognostic (1.31e-1)" "unprognostic (1.19e-1)" "unprognostic (6.93e-2)" "prognostic unfavourable (5.62e-9)" "unprognostic (3.09e-1)" "unprognostic (2.76e-1)" "unprognostic (1.29e-2)" "unprognostic (1.05e-1)" 17.6 11.0 5.4 19.6 7.3 8.9 21.5 3.6 4.4 15.2 29.2 10.3 10.6 19.6 17.5 9.6 22.7 13.2 14.8 12.3 5.6 5.4 11.6 27.5 19.3 36.1 6.6 3.1 18.2 23.2 5.5 9.7 47.4 9.3 17.7 20.8 11.7 26.0 9.7 12.4 13.8 53.6 12.2 8.0 31.7 17.6 8.4 7.3 34.0 14.3 15.3 26.2 15.1 22.6 13.8 19.4 57.9 34.7 14.0 19.5 20.4 10.2 7.9 1.5 6.4 32.2 23.6 11.3 7.9 22.3 8.7 12.5 7.5 12.7 2.9 9.1 13.7 12.8 4.2 5.4 5.7 9.5 5.9 8.0 6.0 5.6 22.4 10.2 19.3 23.7 10.2 15.1 8.9 11.5 7.1 24.0 12.0 10.7 6.8 9.8 1.1 4.2 6.3 3.6 12.1 7.8 6.1 2.0 2.9 16.2 12.0 13.7 8.0 38.4 10.4 8.7 8.5 14.8 4.3 12.7 14.2 1.7 15.4 14.6 5.6 22.3 30.1 24.8 8.8 34.4 9.6 13.6 11.1 10.6 17.8 13.8 10.5 10.4 57.9 14.0 34.7 19.4 19.5 20.4 5.4 7.3 3.6 4.4 5.6 5.4 6.6 3.1 9.3 7.3 IL12RB1 "CD212, IL12RB" ENSG00000096996 "Interleukin 12 receptor subunit beta 1" P42701 19 18058995-18098944 "CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.6;lymphoid tissue: 21.4" "Cell line enhanced" "Detected in some" "Daudi: 10.4;HDLM-2: 17.6;Karpas-707: 30.1;U-698: 8.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074414 Approved "Plasma membrane" "Intracellular and membrane" "Plasma membrane" "HPA074414: " "unprognostic (7.70e-3)" "prognostic favourable (3.41e-4)" "unprognostic (9.08e-3)" "unprognostic (1.18e-4)" "unprognostic (2.91e-1)" "unprognostic (1.33e-3)" "unprognostic (2.27e-1)" "unprognostic (8.99e-2)" "unprognostic (1.65e-2)" "unprognostic (1.35e-1)" "unprognostic (1.51e-1)" "unprognostic (2.94e-1)" "prognostic unfavourable (5.90e-5)" "unprognostic (1.49e-1)" "unprognostic (2.21e-2)" "unprognostic (4.34e-2)" "unprognostic (2.93e-2)" 1.9 1.5 1.3 17.5 2.1 5.6 1.2 0.5 1.0 0.9 3.4 2.4 1.1 2.9 1.0 2.4 1.3 1.5 2.5 1.4 1.3 1.2 1.8 1.8 5.0 16.0 2.0 0.2 1.1 1.3 1.2 1.1 2.4 1.4 1.7 2.0 1.1 6.6 0.2 0.9 1.0 8.0 1.0 2.4 21.4 2.3 0.7 2.2 10.1 1.3 0.7 16.9 3.8 1.0 4.9 5.9 6.2 14.0 16.2 28.6 9.0 0.2 0.1 0.1 0.2 0.0 0.1 0.5 0.1 0.1 0.2 0.6 0.2 1.0 10.4 0.1 0.1 0.2 0.1 0.0 0.0 17.6 0.2 1.2 0.3 0.2 0.4 0.7 1.7 0.0 0.0 0.3 0.1 0.0 0.2 30.1 0.0 0.1 4.9 0.2 0.1 0.1 3.5 0.1 0.4 0.0 0.0 0.2 0.1 0.2 0.2 0.2 0.2 5.7 0.2 0.3 0.3 0.1 0.1 3.6 5.4 8.8 0.4 6.0 0.7 3.3 5.1 3.6 22.8 14.0 28.6 4.9 15.5 18.3 5.9 3.7 8.7 15.2 6.2 16.2 13.2 3.5 20.5 9.0 1.3 2.1 0.5 1.0 1.3 1.2 2.0 0.2 1.4 2.2 IL13RA1 "CD213a1, IL-13Ra, NR4" ENSG00000131724 "Interleukin 13 receptor subunit alpha 1" P78552 X 118727572-118794539 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 45.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "classical monocyte: 6.9;eosinophil: 7.1;myeloid DC: 10.9;neutrophil: 19.0" "Group enriched" "Detected in many" 6 "dendritic cells: 10.9;granulocytes: 19.0;monocytes: 6.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001587 Approved Nucleoplasm,Vesicles "Intracellular and membrane" 4500000 Vesicles Nucleoplasm "HPA001587: AB_1079133" "unprognostic (5.14e-3)" "unprognostic (4.72e-2)" "unprognostic (7.12e-2)" "unprognostic (7.75e-2)" "unprognostic (8.81e-3)" "unprognostic (3.82e-2)" "unprognostic (1.11e-1)" "unprognostic (1.89e-1)" "unprognostic (1.51e-1)" "unprognostic (2.44e-1)" "unprognostic (1.90e-1)" "unprognostic (8.21e-2)" "prognostic unfavourable (1.19e-8)" "unprognostic (1.88e-2)" "unprognostic (2.37e-2)" "unprognostic (2.82e-2)" "unprognostic (5.08e-2)" 31.5 17.5 9.3 15.3 13.3 2.1 19.8 3.6 10.2 16.6 23.8 12.6 7.2 18.9 16.6 18.0 33.0 15.4 17.7 17.5 11.4 9.4 22.7 73.3 27.7 33.9 15.2 6.0 25.2 12.9 9.5 16.1 15.2 13.4 15.3 25.2 14.5 21.8 13.0 22.3 10.2 37.7 16.3 24.5 17.4 18.5 9.9 11.9 4.8 24.0 20.1 20.0 16.5 15.4 1.9 10.9 19.0 6.9 0.0 0.1 1.7 8.2 10.2 4.9 13.4 11.1 33.1 8.8 17.3 24.1 8.3 10.8 5.9 15.3 0.0 30.5 23.8 7.9 5.3 7.3 9.2 45.1 4.1 1.4 9.3 15.1 6.8 0.1 3.6 30.1 6.7 11.3 13.9 17.2 4.4 0.9 11.7 12.1 0.0 2.2 4.4 9.9 0.0 12.0 0.0 12.4 9.0 1.8 1.7 27.2 10.0 6.8 6.4 7.8 21.9 16.2 7.7 27.2 13.5 0.2 4.1 0.0 35.7 4.2 6.8 0.0 6.9 7.1 0.0 1.7 0.0 1.9 0.0 0.0 10.9 1.8 0.0 0.0 19.0 0.0 0.6 1.9 0.1 1.7 9.3 13.3 3.6 10.2 11.4 9.4 15.2 6.0 13.4 11.9 IL13RA2 "CD213a2, CT19, IL-13R, IL13BP" ENSG00000123496 "Interleukin 13 receptor subunit alpha 2" Q14627 X 115003975-115019977 "Cancer-related genes, CD markers, Predicted membrane proteins" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pituitary gland: 16.1;testis: 31.5" "Group enriched" "Detected in some" 9 "PC-3: 26.4;U-2197: 84.9;U-251 MG: 57.0;U-87 MG: 33.8" "Cancer enhanced" "Detected in many" "glioma: 17.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in some" "olfactory region: 8.7" "Low region specificity" "Detected in many" "HPA045831, HPA067363" Approved "Nucleoplasm,Vesicles,Plasma membrane,Cell Junctions" "Plasma membrane, Cell Junctions" "Nucleoplasm, Vesicles" "HPA045831: , HPA067363: " "unprognostic (1.97e-1)" "unprognostic (2.83e-1)" "unprognostic (6.62e-4)" "unprognostic (7.39e-2)" "unprognostic (8.45e-2)" "unprognostic (1.80e-1)" "prognostic favourable (3.55e-4)" "unprognostic (3.54e-1)" "unprognostic (2.85e-1)" "unprognostic (1.92e-2)" "unprognostic (2.20e-3)" "unprognostic (2.19e-2)" "unprognostic (1.53e-5)" "unprognostic (1.58e-1)" "unprognostic (1.63e-1)" "unprognostic (9.70e-3)" "unprognostic (1.20e-1)" 0.5 4.8 3.7 3.9 11.3 0.0 0.8 0.3 3.1 1.2 0.4 2.1 5.7 0.3 0.9 4.4 0.5 0.1 0.8 0.6 5.1 11.2 3.5 9.6 1.0 0.1 1.2 2.6 0.1 0.1 0.5 16.1 2.1 3.9 4.3 0.7 1.6 0.8 3.7 0.0 0.1 0.3 0.4 0.6 0.2 0.1 31.5 1.4 0.0 1.3 0.2 0.2 1.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.7 0.0 5.8 5.5 0.0 0.0 0.0 0.0 0.0 0.1 2.9 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.0 0.1 0.9 5.4 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 26.4 0.0 0.0 0.0 0.4 0.0 0.0 1.3 0.4 0.0 0.1 0.0 0.0 0.0 3.0 0.0 84.9 57.0 0.0 0.0 0.0 33.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 11.3 0.3 3.1 5.1 11.2 1.2 2.6 3.9 1.4 IL15RA "CD215, IL-15RA" ENSG00000134470 "Interleukin 15 receptor subunit alpha" Q13261 10 5943639-5978187 "CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CAPAN-2: 29.4;EFO-21: 17.9;HDLM-2: 32.1;HHSteC: 18.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" CAB026215 Approved "Secreted to blood" "CAB026215: " "unprognostic (2.86e-2)" "unprognostic (8.41e-2)" "unprognostic (6.13e-2)" "unprognostic (4.45e-2)" "unprognostic (7.87e-2)" "unprognostic (5.49e-2)" "prognostic unfavourable (2.67e-6)" "unprognostic (5.09e-3)" "unprognostic (1.82e-2)" "unprognostic (1.69e-1)" "prognostic unfavourable (5.35e-4)" "unprognostic (6.18e-3)" "prognostic unfavourable (1.27e-12)" "unprognostic (4.43e-2)" "unprognostic (4.69e-2)" "unprognostic (4.08e-2)" "unprognostic (5.75e-2)" 20.5 5.6 2.2 13.0 4.1 6.4 33.9 1.4 2.6 12.7 15.6 1.6 7.7 10.1 10.9 9.4 14.3 10.6 18.7 19.2 2.6 1.9 7.8 17.5 35.7 15.2 4.0 2.0 8.7 9.6 0.9 3.9 15.5 3.6 13.2 7.4 6.4 8.9 9.4 9.2 7.6 18.8 10.8 2.7 18.8 10.3 5.0 2.7 3.5 13.9 7.5 9.8 12.9 17.3 7.0 4.2 6.3 19.5 6.8 18.7 6.7 6.9 1.0 0.0 0.3 9.1 2.2 1.8 3.5 7.6 4.7 4.9 0.1 29.4 0.8 17.9 6.6 6.6 0.8 5.2 1.0 32.1 1.4 0.8 1.7 0.5 18.3 0.4 0.2 1.8 1.7 2.5 0.1 11.4 8.5 9.8 0.1 3.6 1.4 3.4 0.2 3.2 4.1 0.0 5.6 1.1 0.5 0.0 0.0 5.3 0.5 0.2 2.5 3.2 4.5 0.1 0.5 12.7 4.7 8.9 2.3 0.1 2.2 5.2 0.3 6.3 16.0 3.9 12.3 19.5 18.7 7.0 9.5 12.5 4.2 3.3 4.1 7.1 4.7 6.8 11.7 0.0 10.2 6.7 2.2 4.1 1.4 2.6 2.6 1.9 4.0 2.0 3.6 2.7 IL17RA "CD217, CDw217, hIL-17R, IL-17RA, IL17R" ENSG00000177663 "Interleukin 17 receptor A" Q96F46 22 17084954-17115694 "CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 50.0" "Cell line enhanced" "Detected in many" "HL-60: 27.0;NB-4: 23.7;THP-1: 34.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 15.6" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB024996 Enhanced Approved Nucleoplasm,Cytosol "Secreted - unknown location" 20000 "Nucleoplasm, Cytosol" "CAB024996: " "unprognostic (1.92e-1)" "unprognostic (3.15e-1)" "unprognostic (1.65e-2)" "unprognostic (9.83e-2)" "unprognostic (7.66e-2)" "unprognostic (5.15e-2)" "unprognostic (3.56e-2)" "unprognostic (1.22e-2)" "unprognostic (1.41e-2)" "unprognostic (8.52e-2)" "unprognostic (1.91e-1)" "unprognostic (3.04e-1)" "unprognostic (1.96e-2)" "prognostic favourable (8.35e-4)" "unprognostic (2.16e-2)" "unprognostic (1.27e-1)" "unprognostic (6.51e-3)" 17.7 7.6 6.5 13.6 13.8 40.5 24.7 4.0 6.7 8.6 8.1 7.7 4.6 6.2 7.4 9.4 6.8 7.8 7.4 8.8 6.1 4.9 8.3 11.6 16.8 39.2 10.3 2.0 7.7 7.7 6.9 5.4 6.2 8.3 6.9 5.7 5.3 7.0 5.3 5.3 8.6 9.1 8.3 11.2 23.4 7.3 5.3 9.7 50.0 7.9 3.2 11.0 6.3 12.8 0.5 3.6 15.6 6.9 1.4 2.4 2.0 3.6 2.1 1.9 2.4 3.8 2.2 2.4 5.3 3.5 2.5 3.2 2.0 2.4 3.3 2.2 5.3 5.8 2.6 2.5 1.8 5.3 3.1 0.0 1.2 1.2 4.4 27.0 8.4 3.3 3.7 2.2 1.7 2.7 1.4 3.4 2.5 3.0 3.2 23.7 1.0 2.0 0.7 0.4 0.6 2.4 2.7 1.3 0.0 3.7 3.2 2.6 2.5 34.1 7.4 2.0 2.8 2.9 1.9 2.8 1.5 1.6 2.8 13.1 2.1 6.7 6.9 6.1 1.1 3.2 0.9 0.4 1.5 1.1 3.6 0.5 2.4 1.8 15.6 1.4 2.9 1.7 0.9 2.0 6.5 13.8 4.0 6.7 6.1 4.9 10.3 2.0 8.3 9.7 IL18R1 "CD218a, IL-1Rrp, IL1RRP" ENSG00000115604 "Interleukin 18 receptor 1" Q13478 2 102311529-102398775 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Inflammatory response" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 39.3" "Cell line enhanced" "Detected in some" "HDLM-2: 13.5;HHSteC: 29.2;HMC-1: 19.6;U-937: 31.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "NK-cell: 26.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA007615 Approved Approved Mitochondria "Intracellular and membrane" Mitochondria "HPA007615: AB_1851675" "unprognostic (3.60e-3)" "unprognostic (9.75e-3)" "unprognostic (1.12e-3)" "unprognostic (3.01e-2)" "unprognostic (2.34e-3)" "unprognostic (7.11e-2)" "unprognostic (2.95e-2)" "unprognostic (1.74e-2)" "unprognostic (3.59e-1)" "unprognostic (7.86e-2)" "unprognostic (3.40e-2)" "unprognostic (1.70e-1)" "prognostic unfavourable (4.52e-4)" "unprognostic (2.62e-1)" "unprognostic (1.62e-2)" "unprognostic (5.71e-2)" "unprognostic (2.48e-2)" 17.8 2.6 1.4 8.3 1.7 12.5 11.2 0.8 1.3 8.2 8.1 0.7 6.6 5.1 4.2 5.7 4.5 4.5 14.1 10.5 1.7 1.9 7.4 8.8 39.3 29.6 2.0 0.1 3.3 2.6 0.8 4.6 10.7 1.6 6.3 3.4 5.0 3.0 28.4 2.8 3.2 10.7 7.9 1.9 19.5 4.6 2.4 0.4 2.5 3.2 3.2 6.6 8.2 12.9 0.1 6.8 5.5 0.1 26.8 10.6 1.1 0.8 0.2 0.0 0.0 0.7 0.7 1.6 0.0 0.5 0.0 0.3 0.0 0.4 0.0 0.0 0.0 0.5 0.0 1.8 0.0 13.5 0.7 2.4 0.6 0.1 29.2 5.1 19.6 6.7 1.1 2.1 3.5 4.9 0.0 0.0 0.0 0.0 0.0 0.9 0.3 0.5 0.0 0.0 0.0 0.2 0.5 0.0 0.0 0.6 0.0 0.1 0.0 0.1 0.4 0.6 0.4 2.3 0.4 0.0 0.0 0.0 0.1 31.3 2.3 5.5 0.0 2.4 4.2 0.1 10.6 0.1 2.4 3.0 2.0 0.1 0.4 0.8 4.1 26.8 0.0 6.8 2.4 1.1 1.4 1.7 0.8 1.3 1.7 1.9 2.0 0.1 1.6 0.4 IL18RAP "AcPL, CD218b" ENSG00000115607 "Interleukin 18 receptor accessory protein" O95256 2 102418689-102452565 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Inflammatory response" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 34.6;bone marrow: 50.2;lymphoid tissue: 29.8" "Cell line enriched" "Detected in some" 10 "U-937: 34.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "NK-cell: 34.6" "Group enriched" "Detected in many" 108 "granulocytes: 22.5;NK-cells: 34.6;T-cells: 22.1" "Not detected" "Not detected" "Not detected" "Not detected" CAB025270 Enhanced "CAB025270: " "unprognostic (1.73e-3)" "unprognostic (6.27e-3)" "unprognostic (5.07e-3)" "unprognostic (4.64e-6)" "unprognostic (2.90e-1)" "unprognostic (1.18e-2)" "unprognostic (5.86e-5)" "unprognostic (5.09e-3)" "unprognostic (4.02e-2)" "unprognostic (1.57e-3)" "unprognostic (4.78e-2)" "unprognostic (5.31e-2)" "unprognostic (1.51e-2)" "unprognostic (2.71e-1)" "unprognostic (6.35e-2)" "unprognostic (8.56e-2)" "unprognostic (2.73e-2)" 3.6 0.3 0.2 6.1 0.5 50.2 0.9 0.3 0.4 1.2 4.8 0.5 0.0 1.2 1.2 2.1 0.8 3.8 3.0 2.1 0.2 0.2 0.9 2.6 9.6 16.4 0.9 0.0 1.1 0.4 0.0 0.9 0.8 0.2 0.6 0.9 1.5 0.8 0.3 0.6 0.2 8.1 1.0 1.0 29.8 1.5 1.3 0.0 1.3 0.8 0.9 3.5 2.5 1.3 0.0 0.2 22.5 0.0 34.6 22.1 2.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 0.0 0.0 1.3 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 34.0 0.2 0.0 0.0 6.1 15.7 0.0 22.1 0.0 2.0 4.2 0.1 0.0 0.0 0.5 22.5 34.6 0.0 0.2 0.1 2.0 0.2 0.5 0.3 0.4 0.2 0.2 0.9 0.0 0.2 0.0 IL1R1 "CD121A, D2S1473, IL1R, IL1RA" ENSG00000115594 "Interleukin 1 receptor type 1" P14778 2 102064544-102179874 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Inflammatory response" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 93.4;ASC TERT1: 41.7;HHSteC: 29.3;HSkMC: 115.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 4.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001237, HPA005823, CAB007779, HPA029560" Approved Approved "Nucleoplasm,Vesicles,Plasma membrane,Cytosol" "Secreted to blood" 1000000 "Nucleoplasm, Vesicles" "Plasma membrane, Cytosol" "CAB007779: AB_562073, HPA001237: , HPA005823: , HPA029560: " "unprognostic (6.16e-3)" "unprognostic (3.55e-2)" "unprognostic (3.33e-1)" "unprognostic (1.22e-1)" "unprognostic (4.26e-2)" "unprognostic (7.10e-2)" "unprognostic (2.01e-1)" "unprognostic (3.36e-2)" "unprognostic (1.44e-1)" "unprognostic (3.16e-1)" "unprognostic (4.26e-2)" "unprognostic (7.77e-2)" "prognostic unfavourable (6.92e-6)" "unprognostic (2.48e-2)" "unprognostic (6.95e-2)" "unprognostic (4.83e-2)" "unprognostic (7.73e-2)" 48.6 25.2 2.6 18.2 5.2 4.0 92.4 2.4 3.9 47.8 21.0 2.5 34.3 5.2 15.2 30.2 18.2 17.1 25.8 27.0 4.2 2.5 23.7 74.8 40.5 28.0 5.6 1.1 25.1 17.1 16.9 7.3 66.2 10.9 26.0 8.4 8.6 12.7 36.4 15.5 13.5 13.0 15.1 10.0 19.2 15.6 13.4 2.8 3.5 33.6 9.0 9.6 32.0 36.4 0.1 0.1 4.0 0.5 0.8 1.8 0.2 0.2 1.8 0.0 1.5 93.4 41.7 0.6 3.9 17.7 2.8 4.2 0.8 0.4 0.0 2.9 7.8 0.7 0.0 0.3 2.3 7.7 0.0 0.1 0.4 4.3 29.3 0.0 0.0 115.0 0.3 3.1 0.7 1.2 0.4 0.1 4.0 0.7 0.0 0.1 0.1 0.1 0.0 0.2 0.0 2.6 1.9 0.0 0.0 1.7 1.1 0.0 1.6 0.1 0.0 8.0 0.5 13.4 0.3 0.0 0.0 0.0 3.1 0.0 0.5 0.6 0.5 0.1 0.0 0.0 0.7 0.1 1.1 0.0 0.1 0.1 0.0 0.1 4.0 0.8 0.0 0.1 1.8 0.2 2.6 5.2 2.4 3.9 4.2 2.5 5.6 1.1 10.9 2.8 IL1R2 "CD121b, IL1RB" ENSG00000115590 "Interleukin 1 receptor type 2" P27930 2 101991844-102028544 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 73.2;lymphoid tissue: 74.1" "Cell line enriched" "Detected in some" 19 "HDLM-2: 100.0" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 4 "midbrain: 9.2" "Cell type enriched" "Detected in some" 25 "neutrophil: 73.2" "Lineage enriched" "Detected in many" 25 "granulocytes: 73.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" "HPA027597, HPA027598" Uncertain "Secreted to blood" 7132500 21000000 "HPA027597: AB_10600768, HPA027598: AB_10601229" "unprognostic (3.54e-2)" "unprognostic (1.87e-1)" "unprognostic (1.21e-1)" "unprognostic (3.83e-2)" "unprognostic (6.59e-2)" "unprognostic (1.42e-1)" "unprognostic (6.36e-2)" "unprognostic (4.82e-3)" "unprognostic (1.62e-2)" "unprognostic (7.15e-2)" "unprognostic (8.20e-3)" "unprognostic (1.07e-1)" "prognostic unfavourable (5.58e-12)" "unprognostic (1.92e-1)" "unprognostic (7.51e-2)" "unprognostic (1.77e-1)" "unprognostic (6.62e-2)" 9.1 3.2 1.2 16.4 1.9 22.3 1.6 1.2 1.9 6.4 13.4 0.4 0.1 0.1 1.3 1.3 20.4 9.7 3.4 15.1 1.2 0.5 5.8 8.2 25.5 74.1 9.2 0.2 2.5 1.4 0.0 2.4 24.9 2.2 1.1 20.0 1.8 4.3 0.8 2.8 14.1 2.2 1.3 4.4 47.5 14.6 1.6 1.1 1.6 1.8 8.5 25.1 3.2 9.1 0.0 2.8 73.2 0.8 0.0 1.1 0.2 1.5 0.1 0.0 0.0 0.2 0.2 0.1 0.0 0.0 0.0 0.0 1.6 0.0 0.0 3.3 0.0 0.6 0.0 0.1 0.0 100.0 0.1 0.0 0.0 0.8 0.5 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 1.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.0 0.4 0.0 0.0 0.1 0.0 2.8 0.0 0.0 0.0 73.2 0.0 0.0 0.0 1.1 0.2 1.2 1.9 1.2 1.9 1.2 0.5 9.2 0.2 2.2 1.1 IL21R CD360 ENSG00000103522 "Interleukin 21 receptor" Q9HBE5 16 27402162-27452042 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 17.9;lymphoid tissue: 47.8" "Cell line enhanced" "Detected in some" "Daudi: 10.1;HDLM-2: 42.9;Karpas-707: 19.9;RH-30: 15.1;RPMI-8226: 24.0;U-266/70: 10.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA042296 Uncertain Uncertain "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA042296: AB_10806236" "unprognostic (2.91e-2)" "unprognostic (2.65e-3)" "unprognostic (6.64e-4)" "unprognostic (1.58e-3)" "unprognostic (2.14e-1)" "prognostic favourable (7.29e-4)" "unprognostic (8.33e-2)" "unprognostic (2.06e-1)" "unprognostic (8.50e-6)" "unprognostic (2.26e-2)" "unprognostic (1.13e-2)" "unprognostic (8.71e-2)" "unprognostic (2.34e-10)" "unprognostic (8.79e-2)" "unprognostic (4.42e-2)" "unprognostic (1.50e-1)" "unprognostic (9.58e-2)" 0.8 0.6 0.6 33.6 3.7 5.7 0.6 0.5 1.6 0.5 0.9 0.3 0.0 0.5 0.5 1.3 1.0 0.8 1.1 1.8 0.6 2.3 1.6 1.3 5.6 20.9 1.3 0.0 0.5 0.5 0.0 0.9 0.9 1.9 0.9 0.9 1.8 3.7 0.3 0.7 0.7 4.0 0.6 1.7 11.2 1.3 1.0 1.4 47.8 1.3 0.8 31.7 2.7 0.8 11.5 1.6 0.7 17.9 6.3 10.3 4.2 0.0 0.0 0.1 0.1 0.0 0.5 0.3 0.3 0.0 0.0 0.9 0.0 0.0 10.1 0.1 0.8 0.0 0.0 0.0 0.0 42.9 0.0 2.1 0.0 0.2 1.4 0.0 0.6 1.5 0.0 2.7 0.0 0.0 0.1 19.9 1.5 0.0 0.0 0.2 0.3 0.0 0.1 15.1 24.0 0.0 0.0 0.1 0.0 0.0 0.0 1.1 0.0 0.5 1.1 0.8 0.2 0.2 0.0 10.0 3.5 2.3 2.1 0.5 0.0 0.2 0.3 0.0 9.8 5.8 3.6 1.0 6.3 10.3 1.6 11.5 6.9 6.7 0.7 6.3 17.9 0.7 7.6 4.2 0.6 3.7 0.5 1.6 0.6 2.3 1.3 0.0 1.9 1.4 IL2RA "CD25, IDDM10, IL2R" ENSG00000134460 "Interleukin 2 receptor subunit alpha" P01589 10 6010689-6062370 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Immunity Receptor "Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "adipose tissue: 16.5;blood: 55.4;lymphoid tissue: 56.7" "Cell line enriched" "Detected in some" 59 "HDLM-2: 153.9" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in single" "pons and medulla: 2.4" "Group enriched" "Detected in many" 6 "basophil: 30.3;T-reg: 55.4" "Group enriched" "Detected in many" 12 "granulocytes: 30.3;T-cells: 55.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002419, HPA054622" Enhanced 110000 "CAB002419: AB_563538, HPA054622: " "unprognostic (2.82e-1)" "unprognostic (8.10e-3)" "unprognostic (1.75e-2)" "unprognostic (5.86e-2)" "unprognostic (1.50e-1)" "unprognostic (1.45e-3)" "unprognostic (2.78e-2)" "unprognostic (2.73e-1)" "unprognostic (5.03e-2)" "unprognostic (6.32e-2)" "unprognostic (7.21e-2)" "unprognostic (2.07e-1)" "prognostic unfavourable (2.08e-9)" "unprognostic (2.10e-2)" "unprognostic (4.66e-2)" "unprognostic (2.22e-1)" "unprognostic (5.10e-2)" 16.5 2.5 0.3 10.9 0.6 0.1 1.4 0.3 0.3 0.6 3.1 0.1 0.0 1.3 0.8 4.9 1.9 0.8 2.2 1.9 0.4 0.5 2.6 1.3 4.0 50.4 0.5 0.0 0.6 1.0 0.0 1.8 1.8 2.4 1.1 1.6 3.4 2.2 0.5 0.8 0.6 10.3 3.5 2.2 56.7 1.4 0.4 0.0 4.5 4.2 2.0 16.8 5.0 0.6 3.6 0.0 30.3 0.0 2.9 55.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 153.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.6 0.0 0.0 0.0 30.3 0.0 4.5 0.1 0.0 0.5 3.6 6.8 0.7 0.0 1.5 0.5 0.0 0.2 2.9 0.0 0.0 55.4 0.7 0.3 0.6 0.3 0.3 0.4 0.5 0.5 0.0 2.4 0.0 IL2RB "CD122, IL15RB" ENSG00000100385 "Interleukin 2 receptor subunit beta" P14784 22 37125838-37175054 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Host-virus interaction" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 51.6;lymphoid tissue: 35.0;placenta: 58.5" "Cell line enriched" "Detected in some" 8 "HDLM-2: 104.1" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "gdT-cell: 14.7;NK-cell: 51.6" "Group enriched" "Detected in many" 32 "NK-cells: 51.6;T-cells: 14.7" "Region enriched" "Detected in single" 7 "basal ganglia: 1.6" "Low region specificity" "Detected in all" HPA062657 Enhanced "HPA062657: " "unprognostic (3.38e-3)" "unprognostic (1.21e-2)" "prognostic favourable (6.76e-4)" "prognostic favourable (3.18e-5)" "unprognostic (2.44e-2)" "unprognostic (9.69e-3)" "unprognostic (2.60e-1)" "unprognostic (5.22e-2)" "unprognostic (1.03e-3)" "unprognostic (5.37e-2)" "unprognostic (1.09e-1)" "unprognostic (2.74e-1)" "prognostic unfavourable (3.50e-7)" "unprognostic (4.63e-2)" "unprognostic (7.96e-2)" "unprognostic (3.94e-3)" "unprognostic (2.46e-2)" 2.2 1.0 0.8 20.5 0.8 12.3 1.6 0.6 0.7 1.3 5.5 0.6 1.4 1.8 4.3 2.8 2.6 1.8 5.8 3.7 0.7 0.8 1.9 6.0 7.4 20.8 0.8 0.2 1.5 1.0 0.0 1.1 58.5 0.7 3.5 1.8 2.9 3.7 2.1 0.9 4.0 7.3 0.6 1.1 35.0 2.3 1.1 0.2 21.0 2.1 1.8 28.7 4.0 1.5 0.3 0.0 1.0 0.1 51.6 14.7 7.9 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 104.1 0.1 0.2 0.0 0.0 0.0 0.0 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.8 0.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 2.8 0.0 0.1 7.5 12.8 0.0 0.1 0.0 0.1 1.0 0.0 0.1 14.7 0.1 8.1 0.1 3.3 8.2 0.0 0.3 1.1 4.3 0.3 51.6 0.1 0.0 6.8 7.9 0.8 0.8 0.6 0.7 0.7 0.8 0.8 0.2 0.7 0.2 IL2RG "CD132, CIDX, IMD4, SCIDX1" ENSG00000147168 "Interleukin 2 receptor subunit gamma" P31785 X 71107404-71112108 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Host-virus interaction" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 115.3;lymphoid tissue: 169.3" "Cell line enriched" "Detected in some" 6 "Karpas-707: 220.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA046641, HPA049691" Enhanced Approved Vesicles Vesicles "HPA046641: AB_2679733, HPA049691: " "unprognostic (2.97e-3)" "unprognostic (4.24e-2)" "unprognostic (1.23e-1)" "prognostic favourable (1.73e-4)" "unprognostic (8.25e-2)" "unprognostic (1.93e-3)" "unprognostic (1.37e-1)" "unprognostic (1.53e-1)" "unprognostic (1.91e-3)" "unprognostic (1.23e-2)" "unprognostic (4.36e-1)" "unprognostic (1.45e-1)" "prognostic unfavourable (2.28e-7)" "unprognostic (1.73e-1)" "unprognostic (4.69e-2)" "unprognostic (4.89e-2)" "unprognostic (9.54e-2)" 5.8 1.3 1.4 39.5 1.4 12.8 3.6 0.8 0.9 2.9 16.6 0.9 0.9 8.2 3.0 2.1 5.3 3.1 5.3 2.6 1.4 1.5 3.7 4.7 13.6 70.4 1.8 0.6 2.9 1.5 0.0 1.2 5.3 1.5 3.2 20.8 2.9 10.4 1.8 1.6 2.7 28.6 1.5 2.9 58.7 6.0 2.0 0.9 169.3 3.3 4.2 61.4 7.6 3.1 51.9 30.6 65.6 19.7 94.6 115.3 99.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.8 17.2 1.2 0.0 0.1 0.0 0.0 0.0 14.4 0.0 2.2 0.0 0.0 0.0 8.9 0.4 0.0 0.0 0.0 0.0 0.0 3.8 220.5 0.0 0.0 31.9 17.4 0.0 0.0 7.3 0.0 1.8 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 12.6 22.2 11.1 0.2 37.0 0.0 35.2 8.5 13.4 107.2 19.7 105.6 51.9 97.7 110.4 20.3 51.6 68.0 84.9 65.6 94.6 13.5 30.6 115.3 99.0 1.4 1.4 0.8 0.9 1.4 1.5 1.8 0.6 1.5 0.9 IL3RA CD123 ENSG00000185291 "Interleukin 3 receptor subunit alpha" P26951 X 1336616-1382689 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 163.1;breast: 50.7;vagina: 65.4" "Cell line enhanced" "Detected in some" "HDLM-2: 47.8;NB-4: 9.2;RPMI-8226: 19.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 16 "basophil: 163.1;plasmacytoid DC: 49.1" "Group enriched" "Detected in many" 33 "dendritic cells: 49.1;granulocytes: 163.1" "HPA003539, CAB018374" Uncertain "CAB018374: AB_2233620, HPA003539: AB_1078438" "prognostic favourable (9.78e-4)" "prognostic favourable (4.27e-4)" "unprognostic (8.13e-2)" "unprognostic (9.32e-2)" "unprognostic (2.09e-1)" "unprognostic (1.29e-3)" "unprognostic (1.32e-1)" "unprognostic (1.67e-1)" "unprognostic (1.38e-1)" "unprognostic (3.73e-2)" "unprognostic (5.77e-3)" "unprognostic (1.43e-1)" "unprognostic (1.50e-3)" "unprognostic (9.41e-2)" "unprognostic (2.85e-3)" "unprognostic (2.49e-1)" "unprognostic (1.46e-1)" 14.9 1.2 7.8 7.7 7.8 12.1 50.7 5.0 10.1 9.7 4.6 1.5 1.5 2.4 13.8 1.5 2.8 4.2 5.6 9.2 11.1 2.4 5.4 1.5 15.9 12.3 8.5 3.9 7.6 2.6 0.6 3.7 9.3 10.9 4.4 3.1 1.5 5.6 1.5 5.7 6.8 5.4 6.1 7.6 5.3 4.2 1.5 7.9 1.5 7.0 1.5 6.4 6.8 65.4 0.7 49.1 163.1 3.2 1.1 0.0 0.7 0.1 3.9 1.5 0.5 0.0 0.0 0.5 0.5 0.1 0.0 0.0 0.3 0.6 0.5 2.7 0.0 3.8 0.0 0.0 0.0 47.8 1.6 0.2 0.7 0.1 0.0 0.3 6.6 0.0 0.0 0.0 0.0 3.1 0.1 2.5 0.0 0.6 0.2 9.2 1.2 0.2 0.5 1.7 19.5 0.0 0.5 0.2 0.1 0.2 0.1 1.1 0.5 7.3 0.1 0.2 0.6 0.2 0.1 5.2 1.4 0.4 4.3 1.1 0.0 163.1 0.4 6.7 0.0 2.4 0.0 0.2 0.0 0.0 1.1 0.7 0.0 0.0 0.3 1.1 3.2 49.1 0.0 0.7 7.8 7.8 5.0 10.1 11.1 2.4 8.5 3.9 10.9 7.9 IL4R CD124 ENSG00000077238 "Interleukin 4 receptor" P24394 16 27313668-27364778 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Immunity Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 35.8;HBEC3-KT: 34.4;U-698: 33.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 34.4" "Group enriched" "Detected in all" 6 "B-cells: 34.4;granulocytes: 11.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB004451, HPA050124, HPA070380" Enhanced Supported "Nucleoplasm,Plasma membrane,Centriolar satellite" "Secreted to blood" 49000 "Plasma membrane" "Nucleoplasm, Centriolar satellite" "CAB004451: AB_626889, HPA050124: , HPA070380: " "unprognostic (6.80e-2)" "unprognostic (6.35e-2)" "unprognostic (2.84e-1)" "prognostic favourable (6.43e-4)" "unprognostic (1.12e-1)" "unprognostic (1.14e-1)" "unprognostic (2.33e-2)" "unprognostic (1.95e-3)" "unprognostic (1.34e-1)" "unprognostic (1.54e-1)" "unprognostic (2.41e-1)" "unprognostic (1.97e-1)" "prognostic unfavourable (1.23e-5)" "unprognostic (1.49e-2)" "unprognostic (1.73e-1)" "unprognostic (1.36e-1)" "unprognostic (9.58e-2)" 20.7 14.8 8.7 31.6 10.6 36.9 12.0 4.4 7.7 20.8 30.3 5.9 11.5 10.9 18.0 12.8 24.7 13.6 25.1 12.3 6.7 4.4 13.3 39.1 40.9 44.8 10.8 1.7 14.7 11.3 3.8 5.5 16.1 10.1 18.8 15.1 12.3 7.7 11.5 7.2 9.9 18.6 39.6 13.6 31.8 21.1 10.4 9.8 9.1 8.6 13.7 38.4 31.6 15.4 34.4 1.6 11.9 2.6 3.3 4.0 1.8 11.3 3.0 1.9 3.9 0.9 4.5 4.1 7.2 8.3 2.9 2.3 6.1 31.4 35.8 9.0 11.3 12.1 2.1 34.4 2.5 31.0 1.0 6.7 1.8 9.3 13.0 1.8 19.1 6.9 13.9 13.2 7.9 15.4 2.9 3.0 4.6 5.0 0.1 5.4 2.4 2.6 0.1 14.9 2.9 13.3 13.0 0.6 0.3 1.0 6.9 1.5 2.6 6.9 23.0 6.5 2.9 5.8 5.0 1.8 0.5 33.3 0.7 6.0 0.0 0.5 2.6 4.7 1.7 1.1 1.3 7.7 2.6 1.7 1.6 34.4 4.0 1.9 11.9 3.3 0.6 1.6 1.8 1.8 8.7 10.6 4.4 7.7 6.7 4.4 10.8 1.7 10.1 9.8 IL5RA "CD125, CDw125, IL5R" ENSG00000091181 "Interleukin 5 receptor subunit alpha" Q01344 3 3066326-3126613 "CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 70.1;fallopian tube: 18.6" "Cell line enriched" "Detected in some" 30 "HMC-1: 41.0" "Cancer enhanced" "Detected in some" "prostate cancer: 1.4" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 196 "basophil: 31.4;eosinophil: 70.1" "Lineage enriched" "Detected in single" 308 "granulocytes: 70.1" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Intracellular and membrane" 92000 "unprognostic (1.38e-3)" "unprognostic (2.26e-2)" "unprognostic (2.66e-1)" "unprognostic (6.13e-3)" "unprognostic (2.66e-1)" "unprognostic (1.54e-3)" "unprognostic (7.79e-3)" "unprognostic (8.42e-2)" "unprognostic (2.83e-1)" "unprognostic (1.67e-1)" "unprognostic (9.84e-4)" "unprognostic (4.32e-3)" "unprognostic (3.08e-2)" "unprognostic (6.95e-2)" "unprognostic (2.20e-1)" "unprognostic (7.49e-2)" "unprognostic (4.93e-2)" 0.5 0.2 6.7 0.6 6.2 0.7 1.3 0.2 0.3 1.8 0.9 1.8 0.0 2.2 0.6 8.2 0.6 18.6 2.0 2.4 2.3 2.1 0.6 1.3 7.9 1.2 0.1 0.0 3.8 0.5 0.1 7.5 0.1 11.8 2.6 1.4 0.5 2.2 0.1 0.3 0.4 2.1 0.6 0.6 4.6 1.3 1.6 0.7 1.1 0.4 1.1 1.9 4.2 0.4 0.1 0.0 70.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.3 41.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.1 0.0 1.3 0.0 0.0 0.0 0.0 0.1 0.1 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 31.4 0.0 70.1 0.2 0.0 0.0 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.1 6.7 6.2 0.2 0.3 2.3 2.1 0.1 0.0 11.8 0.7 IL6R CD126 ENSG00000160712 "Interleukin 6 receptor" P08887 1 154405193-154469450 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 59.6" "Cell line enhanced" "Detected in many" "THP-1: 54.6;U-266/84: 64.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 35.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "Intracellular and membrane" 22000000 "unprognostic (1.19e-1)" "unprognostic (3.97e-1)" "unprognostic (1.19e-1)" "unprognostic (1.08e-1)" "unprognostic (1.95e-1)" "unprognostic (4.47e-2)" "unprognostic (1.01e-1)" "unprognostic (1.05e-2)" "unprognostic (3.27e-1)" "unprognostic (6.42e-2)" "prognostic favourable (1.65e-4)" "unprognostic (7.94e-2)" "unprognostic (1.05e-1)" "unprognostic (7.75e-2)" "unprognostic (1.51e-1)" "unprognostic (3.35e-1)" "unprognostic (1.07e-1)" 8.4 4.0 4.7 14.8 5.1 9.0 6.5 1.4 6.3 6.1 16.9 4.8 1.2 9.6 6.3 4.7 5.2 7.9 6.9 5.0 5.2 2.9 8.9 38.1 20.8 15.4 7.2 2.2 5.7 5.3 0.0 7.7 3.7 7.8 4.5 6.0 3.6 5.4 1.7 59.6 4.7 12.6 5.3 5.0 11.3 6.6 3.7 5.0 4.2 2.5 6.1 13.3 6.3 4.8 0.6 14.3 35.0 11.7 0.5 8.0 5.5 0.8 1.4 0.1 0.1 0.9 1.3 0.1 0.8 0.6 0.5 0.2 0.1 0.9 0.0 1.9 1.0 0.4 0.2 4.4 0.4 14.7 0.4 0.2 0.6 3.3 0.1 2.3 1.3 0.7 2.7 0.4 6.6 0.6 0.1 6.1 0.1 0.3 0.0 3.8 0.4 3.3 0.0 0.0 12.7 2.7 1.1 0.1 0.0 0.2 9.0 14.8 0.8 54.6 0.6 0.9 0.9 0.8 0.5 10.4 64.3 0.1 1.1 14.8 1.4 2.8 11.7 10.4 0.2 7.1 0.6 0.6 6.4 0.7 14.3 0.2 6.4 2.2 35.0 0.5 3.0 5.1 8.0 5.5 4.7 5.1 1.4 6.3 5.2 2.9 7.2 2.2 7.8 5.0 IL6ST "CD130, GP130" ENSG00000134352 "Interleukin 6 signal transducer" P40189 5 55935095-55994993 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Host-virus interaction" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC TERT1: 57.0;BJ hTERT+: 58.0;HHSteC: 64.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 21.0" "Lineage enriched" "Detected in many" 5 "T-cells: 21.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010558, CAB025784" Approved Supported "Golgi apparatus,Plasma membrane" "Secreted to blood" 100000000 "Plasma membrane" "Golgi apparatus" "CAB025784: , HPA010558: AB_1078439" "unprognostic (1.81e-2)" "unprognostic (1.25e-1)" "unprognostic (7.61e-2)" "unprognostic (3.95e-2)" "unprognostic (8.93e-2)" "unprognostic (3.99e-2)" "unprognostic (5.18e-2)" "unprognostic (9.53e-3)" "unprognostic (1.89e-2)" "unprognostic (2.29e-1)" "unprognostic (4.78e-2)" "unprognostic (1.59e-1)" "prognostic unfavourable (5.05e-4)" "unprognostic (3.69e-2)" "unprognostic (1.06e-1)" "unprognostic (1.80e-1)" "unprognostic (1.25e-1)" 44.8 34.2 24.7 25.5 23.4 8.8 76.9 15.9 22.9 38.1 23.9 15.0 29.0 8.7 26.1 24.9 22.7 23.1 31.1 31.9 21.9 19.7 37.2 71.2 36.3 70.0 25.8 14.7 42.1 16.4 35.8 36.2 97.0 22.5 31.9 17.1 20.0 26.3 33.0 27.1 12.5 20.6 36.6 33.8 35.5 19.7 13.7 20.3 19.4 37.6 12.5 18.7 33.7 51.1 0.7 2.1 0.9 3.8 0.8 21.0 4.0 9.4 11.8 3.8 9.1 27.3 57.0 15.8 28.2 58.0 15.2 22.7 16.5 9.0 0.3 21.1 17.4 4.1 3.0 8.4 31.2 0.8 3.0 2.2 9.7 13.6 64.9 0.2 4.5 49.9 4.6 33.0 16.1 34.7 1.6 39.8 17.5 1.6 0.4 0.4 0.6 3.9 0.5 10.7 5.4 8.3 5.6 2.0 3.4 11.4 3.8 11.6 19.0 1.5 55.7 5.9 6.7 23.8 14.8 9.8 4.2 0.3 15.8 0.4 15.3 0.2 3.8 0.1 0.8 3.5 0.4 0.7 4.9 0.8 2.1 0.6 21.0 5.9 0.9 0.8 0.6 1.8 3.4 4.0 24.7 23.4 15.9 22.9 21.9 19.7 25.8 14.7 22.5 20.3 IL7R CD127 ENSG00000168685 "Interleukin 7 receptor" P16871 5 35852695-35879603 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 70.3;intestine: 34.0;lung: 52.6;lymphoid tissue: 133.1" "Cell line enhanced" "Detected in many" "BJ: 21.7;fHDF/TERT166: 40.7;HBF TERT88: 37.4;REH: 84.6" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "gdT-cell: 19.2;MAIT T-cell: 70.3;memory CD4 T-cell: 39.9;memory CD8 T-cell: 28.0;naive CD4 T-cell: 34.5;naive CD8 T-cell: 22.5;NK-cell: 19.1" "Group enriched" "Detected in many" 33 "NK-cells: 19.1;T-cells: 70.3" "Low region specificity" "Detected in single" "Low region specificity" "Detected in single" CAB010215 Supported "Plasma membrane,Centriolar satellite" "Intracellular and membrane" 180000 "Plasma membrane, Centriolar satellite" "CAB010215: AB_673727" "unprognostic (2.93e-3)" "unprognostic (3.38e-2)" "unprognostic (3.82e-3)" "unprognostic (5.58e-3)" "unprognostic (3.06e-2)" "unprognostic (1.74e-1)" "unprognostic (2.51e-3)" "unprognostic (5.53e-2)" "unprognostic (1.12e-1)" "unprognostic (9.29e-3)" "unprognostic (1.43e-1)" "unprognostic (2.69e-1)" "unprognostic (1.76e-2)" "unprognostic (5.64e-2)" "unprognostic (3.27e-3)" "unprognostic (2.22e-1)" "unprognostic (1.78e-1)" 6.7 3.6 0.7 34.0 0.7 3.1 4.8 0.5 0.6 4.8 20.6 0.3 0.9 3.5 1.8 2.9 6.6 3.7 8.5 1.9 0.7 0.7 7.0 2.7 52.6 133.1 0.8 0.1 2.5 1.7 0.0 1.5 1.2 0.8 3.3 5.4 1.7 13.2 1.8 0.9 1.8 34.0 1.2 1.5 32.3 7.8 3.0 0.4 130.9 5.1 5.3 42.9 12.6 4.6 0.4 0.3 1.3 0.2 19.1 70.3 12.7 0.1 0.0 0.1 0.1 0.1 0.1 0.2 21.7 11.0 19.6 11.6 0.1 0.1 2.1 0.0 40.7 3.5 0.0 1.3 37.4 1.8 0.2 0.6 2.3 0.0 0.3 0.1 1.5 0.3 0.0 4.2 0.9 0.5 0.1 0.3 15.4 0.0 0.5 0.2 0.1 1.0 84.6 1.1 0.1 0.0 1.2 0.0 0.0 3.6 0.3 0.0 0.1 0.0 1.5 7.7 13.1 3.3 2.8 0.1 0.0 2.4 3.9 2.0 5.9 0.5 0.2 0.1 19.2 0.2 70.3 0.2 39.9 28.0 0.1 0.4 34.5 22.5 1.3 19.1 0.2 0.3 6.7 12.7 0.7 0.7 0.5 0.6 0.7 0.7 0.8 0.1 0.8 0.4 IL9R CD129 ENSG00000124334 "Interleukin 9 receptor" Q01113 X 155997581-156010817 "CD markers, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 6.3;urinary bladder: 10.9" "Cell line enriched" "Detected in some" 11 "HMC-1: 74.2" "Cancer enhanced" "Detected in some" "urothelial cancer: 1.4" "Group enriched" "Detected in some" 6 "basal ganglia: 1.7;pons and medulla: 4.7;thalamus: 1.5" "Cell type enhanced" "Detected in many" "eosinophil: 6.3" "Group enriched" "Detected in many" 25 "B-cells: 4.1;granulocytes: 6.3;T-cells: 2.4" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA063240, HPA064557" Approved "Intracellular and membrane" "HPA063240: , HPA064557: " "unprognostic (1.07e-2)" "unprognostic (3.27e-3)" "unprognostic (9.52e-3)" "unprognostic (4.13e-2)" "unprognostic (7.35e-2)" "unprognostic (3.26e-4)" "unprognostic (8.94e-2)" "unprognostic (3.56e-2)" "unprognostic (2.01e-1)" "unprognostic (1.82e-1)" "unprognostic (2.90e-2)" "unprognostic (2.04e-1)" "unprognostic (3.98e-8)" "unprognostic (2.06e-1)" "unprognostic (2.38e-1)" "unprognostic (4.07e-1)" "prognostic favourable (1.90e-7)" 0.3 0.1 0.3 1.1 1.7 0.4 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.7 3.0 0.3 0.5 0.4 0.9 0.3 0.3 0.2 0.3 0.5 1.3 3.2 0.3 0.3 0.3 0.3 0.0 0.3 0.3 4.7 0.4 1.2 0.3 0.4 0.3 0.3 0.4 2.4 0.3 0.3 3.5 0.8 0.3 1.5 0.3 0.4 0.3 2.9 10.9 0.3 4.1 0.0 6.3 0.0 0.1 2.4 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 6.8 0.0 0.0 0.0 0.1 74.2 0.0 0.0 0.0 0.0 0.0 1.0 0.2 0.0 0.3 2.6 1.3 0.0 0.0 0.1 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.2 0.0 0.1 0.0 0.0 0.0 6.3 0.0 0.0 0.0 1.8 0.8 1.3 0.0 4.1 0.0 0.0 1.8 0.1 0.0 0.0 2.4 0.3 0.3 1.7 0.4 0.3 0.3 0.2 0.3 0.3 4.7 1.5 INSR CD220 ENSG00000171105 "Insulin receptor" P06213 19 7112255-7294034 "CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Carbohydrate metabolism" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Diabetes mellitus, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pancreas: 64.5" "Cell line enhanced" "Detected in many" "Karpas-707: 30.6;U-266/70: 22.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 7 "dendritic cells: 8.8;granulocytes: 5.1;monocytes: 10.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036302, HPA036303" Uncertain Approved "Vesicles,Plasma membrane" 72000 Vesicles "Plasma membrane" "HPA036302: , HPA036303: " "unprognostic (4.64e-2)" "unprognostic (2.42e-1)" "unprognostic (9.65e-3)" "unprognostic (9.70e-2)" "unprognostic (1.44e-1)" "unprognostic (1.15e-2)" "unprognostic (2.58e-1)" "unprognostic (5.09e-2)" "unprognostic (1.97e-1)" "unprognostic (3.05e-1)" "unprognostic (9.29e-2)" "unprognostic (1.86e-1)" "unprognostic (6.33e-2)" "unprognostic (3.45e-3)" "unprognostic (2.43e-1)" "unprognostic (2.75e-1)" "unprognostic (8.82e-2)" 13.9 14.7 7.1 3.5 8.2 4.5 12.0 12.0 8.2 10.3 15.2 11.7 10.6 8.4 15.5 6.1 4.7 13.1 7.7 17.7 6.4 5.8 18.7 32.5 5.3 2.2 10.1 4.9 28.3 64.5 11.6 11.6 26.2 8.0 10.5 8.9 11.0 12.0 10.6 15.1 7.3 16.0 10.6 6.8 47.3 8.7 6.9 9.7 2.2 17.1 5.0 3.2 11.3 16.0 1.1 8.8 5.1 10.5 0.8 0.7 1.3 3.7 2.1 1.9 2.9 10.6 3.7 6.4 2.1 1.9 1.2 1.2 5.3 4.3 4.7 5.3 3.8 1.0 4.6 0.9 0.7 0.0 3.7 0.0 1.5 11.5 4.6 2.2 3.8 5.7 2.4 0.1 2.8 2.1 5.7 30.6 0.9 1.7 1.6 3.8 1.8 3.3 16.3 1.1 4.1 0.1 15.5 3.7 2.8 3.8 2.0 2.1 0.9 10.8 2.0 2.2 1.4 4.7 2.8 22.6 12.3 10.9 2.6 3.8 0.0 2.0 8.2 5.1 0.2 7.8 0.3 0.8 0.3 0.1 8.8 1.1 0.7 0.1 1.7 0.8 10.5 7.4 0.0 1.3 7.1 8.2 12.0 8.2 6.4 5.8 10.1 4.9 8.0 9.7 ITGA1 "CD49a, VLA1" ENSG00000213949 "Integrin subunit alpha 1" P56199 5 52787896-52959210 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 21.0;HHSteC: 25.8;WM-115: 19.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD8 T-cell: 1.8" "Group enriched" "Detected in many" 5 "granulocytes: 1.2;T-cells: 1.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042555 Uncertain 2300000 "HPA042555: AB_10794281" "unprognostic (1.48e-1)" "unprognostic (1.07e-2)" "unprognostic (2.44e-1)" "unprognostic (1.33e-1)" "unprognostic (1.38e-1)" "unprognostic (9.89e-3)" "unprognostic (2.74e-1)" "unprognostic (1.72e-1)" "unprognostic (1.79e-3)" "unprognostic (1.50e-2)" "unprognostic (2.62e-1)" "unprognostic (9.86e-2)" "prognostic unfavourable (2.24e-4)" "unprognostic (3.13e-3)" "unprognostic (2.06e-2)" "unprognostic (1.07e-2)" "unprognostic (1.62e-2)" 22.6 20.2 2.3 12.7 2.7 0.0 12.4 1.2 2.9 10.9 28.2 1.5 13.6 5.3 15.9 12.5 22.3 9.2 13.9 11.1 2.5 2.2 17.9 40.4 28.8 10.2 3.1 1.4 9.6 3.3 11.5 3.0 24.8 3.3 26.1 8.2 5.9 2.9 18.2 9.7 2.4 13.5 52.8 2.7 66.0 16.8 4.1 1.6 0.6 10.7 3.5 2.2 42.7 17.8 0.0 0.1 1.2 0.3 0.0 1.8 0.1 0.0 0.0 2.0 0.0 5.8 1.7 1.2 2.7 7.2 1.6 4.8 3.7 0.3 0.0 0.9 21.0 1.4 0.4 2.3 1.5 0.0 1.5 0.0 3.4 2.7 25.8 0.0 0.0 3.9 0.2 1.9 0.7 0.3 0.0 0.0 2.4 0.0 0.8 0.0 1.1 0.7 0.0 1.9 0.0 3.1 0.0 0.1 9.1 2.7 0.6 0.6 0.0 0.0 2.1 4.4 0.4 0.1 1.4 0.0 0.0 0.0 2.8 0.0 19.1 0.0 0.3 1.1 0.1 0.0 0.0 0.0 0.6 1.8 0.1 0.0 0.2 0.0 1.2 0.0 0.0 0.0 0.1 0.1 2.3 2.7 1.2 2.9 2.5 2.2 3.1 1.4 3.3 1.6 ITGA2 CD49b ENSG00000164171 "Integrin subunit alpha 2" P17301 5 52989326-53094779 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ hTERT+: 30.1;HaCaT: 30.4;HUVEC TERT2: 28.0;TIME: 23.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB017690, HPA060991, HPA063556" Enhanced Approved Nucleoplasm,Cytosol 46000000 Nucleoplasm Cytosol "CAB017690: AB_1124939, HPA060991: AB_2684405, HPA063556: AB_2685040" "unprognostic (8.35e-2)" "unprognostic (1.33e-1)" "unprognostic (3.85e-3)" "unprognostic (1.07e-1)" "unprognostic (1.22e-1)" "unprognostic (3.70e-2)" "unprognostic (2.67e-3)" "unprognostic (2.38e-2)" "unprognostic (1.87e-1)" "unprognostic (1.69e-2)" "prognostic unfavourable (1.02e-5)" "unprognostic (4.27e-1)" "unprognostic (3.88e-2)" "unprognostic (2.87e-2)" "unprognostic (1.84e-1)" "unprognostic (1.30e-1)" "unprognostic (1.11e-1)" 1.9 14.0 2.9 4.7 13.4 0.4 7.9 1.8 6.8 7.1 6.5 22.5 12.1 7.6 5.1 10.4 16.7 2.8 9.3 2.5 5.4 3.6 15.1 1.8 17.2 1.4 18.3 4.5 1.8 2.7 16.1 2.5 4.8 10.7 8.5 6.0 0.8 15.8 16.8 1.2 16.9 17.0 2.5 8.4 9.1 7.4 1.3 13.0 1.5 2.5 7.4 10.0 7.5 11.1 0.5 1.5 1.7 0.6 0.2 0.6 0.3 19.5 5.0 0.4 0.2 1.3 2.4 1.5 19.8 30.1 0.7 1.2 9.4 13.8 0.0 3.4 8.4 30.4 1.6 22.2 2.9 0.0 1.5 1.4 1.3 5.6 4.6 0.2 0.4 1.0 3.9 19.9 3.5 28.0 0.0 0.0 0.5 3.6 0.2 0.0 1.2 10.1 0.0 0.1 0.0 6.3 10.4 0.2 1.1 1.0 1.3 2.0 3.2 0.0 23.9 3.6 2.1 0.5 3.9 0.0 0.0 0.0 21.8 0.0 15.9 1.7 0.6 0.2 0.6 0.2 0.4 0.4 0.5 0.5 0.1 0.5 0.5 0.6 0.8 0.2 0.1 1.5 0.4 0.3 2.9 13.4 1.8 6.8 5.4 3.6 18.3 4.5 10.7 13.0 ITGA2B "CD41, CD41B, GP2B, PPP1R93" ENSG00000005961 "Integrin subunit alpha 2b" P08514 17 44372180-44389505 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.5;epididymis: 25.2;lymphoid tissue: 22.8" "Group enriched" "Detected in some" 13 "HEL: 69.4;HMC-1: 118.6" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 10 "basophil: 28.5" "Lineage enriched" "Detected in single" 54 "granulocytes: 28.5" "Low region specificity" "Detected in single" "CAB018611, HPA031168, HPA031169, HPA031170, HPA031171" Enhanced Approved "Plasma membrane" 1100000000 "Plasma membrane" "CAB018611: AB_2265153, HPA031168: AB_10670151, HPA031169: AB_10669671, HPA031170: AB_10696214, HPA031171: AB_10669773" "unprognostic (6.11e-2)" "unprognostic (3.23e-2)" "unprognostic (1.23e-1)" "unprognostic (4.85e-2)" "unprognostic (1.59e-2)" "unprognostic (3.98e-3)" "unprognostic (4.23e-5)" "unprognostic (1.25e-1)" "unprognostic (1.33e-2)" "unprognostic (7.22e-2)" "unprognostic (2.97e-3)" "unprognostic (1.30e-1)" "unprognostic (8.83e-9)" "unprognostic (7.82e-2)" "unprognostic (1.85e-1)" "unprognostic (1.95e-1)" "unprognostic (2.25e-1)" 0.7 0.2 1.4 0.4 1.0 15.2 0.6 3.8 2.4 1.2 0.9 0.4 0.4 0.1 1.1 25.2 0.7 1.9 1.4 10.6 0.9 1.6 1.0 0.4 6.5 0.5 0.7 0.8 2.1 2.5 0.1 2.5 1.9 1.1 0.6 0.3 0.6 0.4 1.6 0.8 0.1 0.6 0.4 0.8 22.8 0.2 3.0 0.4 0.4 5.2 1.0 0.6 0.7 1.9 0.0 0.5 28.5 0.2 0.0 0.2 11.1 0.0 0.1 0.7 0.0 0.0 0.0 2.8 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.4 69.4 0.0 0.6 0.0 0.0 118.6 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 7.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.6 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 28.5 0.2 2.1 0.1 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 2.8 0.0 0.0 0.5 0.0 11.1 1.4 1.0 3.8 2.4 0.9 1.6 0.7 0.8 1.1 0.4 ITGA3 "CD49c, GAP-B3, MSK18, VCA-2, VLA3a" ENSG00000005884 "Integrin subunit alpha 3" P26006 17 50055968-50090481 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, Disease mutation, Epidermolysis bullosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HBEC3-KT: 74.7;hTERT-HME1: 64.9;RPTEC TERT1: 65.8;U-138 MG: 65.1;U-87 MG: 112.1;WM-115: 67.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "T-reg: 1.1" "Lineage enriched" "Detected in single" 4 "T-cells: 1.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008572, CAB018594" Enhanced Supported "Plasma membrane" 180000 "Plasma membrane" "CAB018594: AB_668044, HPA008572: AB_2668094" "unprognostic (3.24e-3)" "prognostic unfavourable (6.75e-4)" "unprognostic (9.51e-2)" "unprognostic (3.46e-3)" "unprognostic (3.45e-3)" "prognostic unfavourable (1.36e-4)" "unprognostic (8.28e-3)" "unprognostic (2.76e-3)" "unprognostic (1.26e-3)" "unprognostic (1.82e-2)" "prognostic unfavourable (5.95e-5)" "unprognostic (7.05e-2)" "unprognostic (1.14e-1)" "unprognostic (1.93e-1)" "unprognostic (1.30e-1)" "unprognostic (1.28e-2)" "unprognostic (2.35e-2)" 15.7 15.8 4.1 8.6 5.1 0.1 8.7 7.7 6.5 10.9 20.9 2.3 8.9 17.1 11.6 11.6 12.8 14.5 32.6 8.4 4.2 5.4 36.0 1.7 37.6 3.2 3.2 6.7 10.7 8.0 13.0 11.2 26.4 4.3 12.0 8.9 11.6 10.0 9.7 6.6 17.3 37.3 11.6 3.3 6.5 13.7 3.9 1.5 3.3 36.1 13.3 8.3 19.0 8.1 0.2 0.0 0.0 0.0 0.0 1.1 0.2 20.5 27.2 0.1 0.8 0.5 2.1 4.4 9.6 20.8 14.6 11.1 0.6 32.1 0.0 60.9 7.0 14.6 0.2 74.7 8.9 2.5 0.4 0.0 6.9 0.1 12.9 0.0 0.6 2.6 36.9 14.6 64.9 10.7 0.0 0.3 27.4 5.9 0.0 0.0 0.6 16.5 0.0 1.4 1.5 65.8 35.8 1.1 0.4 10.5 1.4 24.1 2.4 0.2 23.1 65.1 20.5 0.6 37.5 0.9 1.5 0.6 112.1 0.2 67.6 0.0 0.0 0.0 0.8 0.0 1.0 0.2 0.1 0.1 0.0 0.2 0.2 0.6 0.0 0.0 0.0 0.0 1.1 0.2 4.1 5.1 7.7 6.5 4.2 5.4 3.2 6.7 4.3 1.5 ITGA4 CD49d ENSG00000115232 "Integrin subunit alpha 4" P13612 2 181457202-181536187 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 38.4;lymphoid tissue: 101.6" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 38.7;HEL: 61.5;MOLT-4: 71.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Region enriched" "Detected in many" 7 "cerebellum: 26.0" HPA074961 Approved "Plasma membrane" "Intracellular and membrane" 100000 "Plasma membrane" "HPA074961: " "unprognostic (5.31e-2)" "unprognostic (1.54e-1)" "unprognostic (1.99e-2)" "unprognostic (3.94e-2)" "unprognostic (3.76e-1)" "prognostic favourable (8.29e-4)" "unprognostic (1.27e-1)" "unprognostic (1.11e-2)" "unprognostic (1.76e-1)" "unprognostic (2.67e-2)" "unprognostic (1.85e-1)" "unprognostic (1.94e-1)" "prognostic unfavourable (3.08e-5)" "unprognostic (2.26e-2)" "unprognostic (8.64e-3)" "unprognostic (2.49e-1)" "unprognostic (2.57e-2)" 3.8 1.7 1.3 39.7 1.1 19.2 3.2 2.4 1.9 6.7 4.8 0.5 1.1 3.8 3.0 3.1 2.9 2.1 6.9 1.7 2.9 1.3 3.0 2.5 13.6 33.7 1.2 0.5 1.8 1.6 0.0 1.3 7.1 0.9 3.8 4.9 2.9 7.5 2.0 1.0 1.5 11.6 2.4 1.6 36.0 4.4 1.2 0.2 101.6 2.6 1.5 14.3 6.0 4.1 11.0 19.1 38.4 38.3 8.8 15.9 16.2 0.0 0.2 1.0 0.0 9.1 13.8 0.0 8.9 11.2 4.8 10.1 0.0 0.0 7.1 0.0 38.7 5.3 3.1 0.1 5.8 0.0 0.7 61.5 0.2 0.0 0.9 27.2 1.5 9.8 0.0 0.3 0.0 0.4 0.0 10.4 3.0 0.0 71.7 19.1 0.8 0.0 15.7 4.5 1.0 0.0 0.0 1.6 0.6 0.0 0.0 0.3 0.0 18.0 4.8 1.5 0.9 0.1 1.8 20.4 15.1 4.0 0.8 13.5 20.6 6.7 16.2 38.4 12.9 38.3 9.7 11.0 14.6 15.9 19.1 10.0 8.5 10.4 2.1 8.8 37.5 5.0 3.7 16.2 1.3 1.1 2.4 1.9 2.9 1.3 1.2 0.5 0.9 0.2 ITGA5 "CD49e, FNRA" ENSG00000161638 "Integrin subunit alpha 5" P08648 12 54395261-54419460 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "smooth muscle: 137.7" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 140.8;TIME: 134.1;U-87 MG: 66.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 31.5" "Low lineage specificity" "Detected in many" "Region enriched" "Detected in single" 7 "basal ganglia: 9.3" "Low region specificity" "Detected in some" "HPA002642, CAB009008" Enhanced 23000000 "CAB009008: AB_647474, HPA002642: AB_1078469" "unprognostic (7.51e-3)" "prognostic unfavourable (4.07e-6)" "prognostic unfavourable (8.43e-4)" "unprognostic (1.58e-1)" "unprognostic (8.51e-3)" "prognostic unfavourable (2.91e-4)" "prognostic unfavourable (2.23e-5)" "prognostic unfavourable (2.44e-4)" "unprognostic (2.76e-2)" "unprognostic (6.19e-2)" "unprognostic (8.99e-2)" "unprognostic (8.28e-2)" "prognostic unfavourable (1.32e-8)" "unprognostic (2.11e-3)" "unprognostic (3.35e-2)" "prognostic unfavourable (8.89e-4)" "unprognostic (2.18e-3)" 23.3 7.9 2.1 32.2 2.8 9.2 30.5 1.2 2.2 16.0 66.9 2.2 19.0 3.4 19.3 13.8 18.2 12.0 12.4 20.3 2.9 0.8 4.6 15.2 20.4 9.2 3.2 1.2 13.6 5.3 3.7 1.8 57.7 3.3 26.6 10.2 4.9 4.4 28.9 10.0 8.8 14.9 137.7 3.5 3.1 19.7 6.6 2.5 3.0 7.3 5.8 4.5 82.1 20.6 0.1 22.2 31.5 22.9 9.1 5.6 12.4 6.6 2.4 4.6 0.0 14.3 30.5 12.0 30.0 31.2 30.9 22.8 1.6 1.5 0.0 21.9 31.3 1.0 1.2 8.3 21.4 0.0 1.2 2.9 3.3 0.1 19.8 9.0 4.6 22.0 4.1 36.2 27.9 140.8 2.4 0.0 17.5 0.6 1.3 10.1 1.8 1.9 1.4 3.1 0.6 4.9 0.1 0.0 0.0 6.0 0.4 0.2 0.7 8.1 134.1 37.6 6.7 9.2 12.4 0.0 0.3 0.0 66.9 8.6 12.2 5.6 22.9 0.1 5.6 10.0 4.4 0.0 4.2 4.2 22.2 0.1 3.1 2.6 31.5 9.1 7.6 1.2 1.7 12.4 2.1 2.8 1.2 2.2 2.9 0.8 3.2 1.2 3.3 2.5 ITGA6 CD49f ENSG00000091409 "Integrin subunit alpha 6" P23229 2 172427354-172506282 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, Epidermolysis bullosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BJ: 50.1;HaCaT: 55.2;HBEC3-KT: 108.5;hTCEpi: 47.3;hTERT-HME1: 48.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 16.2" "Group enriched" "Detected in many" 34 "granulocytes: 16.2;NK-cells: 5.5;T-cells: 10.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009009, HPA012696, HPA027582" Enhanced 45000000 "CAB009009: AB_2128038, HPA012696: AB_1851822, HPA027582: AB_10602606" "unprognostic (1.02e-1)" "unprognostic (3.33e-1)" "unprognostic (2.59e-2)" "unprognostic (5.96e-2)" "unprognostic (4.93e-2)" "prognostic unfavourable (1.03e-4)" "unprognostic (1.19e-1)" "unprognostic (1.61e-3)" "unprognostic (9.34e-2)" "unprognostic (6.01e-2)" "unprognostic (1.85e-3)" "unprognostic (1.84e-1)" "prognostic favourable (2.35e-11)" "unprognostic (3.35e-2)" "unprognostic (3.32e-1)" "unprognostic (2.98e-2)" "unprognostic (1.21e-3)" 28.0 3.1 9.8 19.1 10.5 1.6 30.1 3.0 8.4 27.0 34.9 9.4 42.3 28.5 28.2 11.3 17.0 11.1 23.8 21.7 9.7 8.2 22.0 4.9 29.0 14.9 9.8 5.1 7.6 31.3 7.4 4.9 38.7 12.6 14.3 25.2 17.6 37.1 32.4 13.5 17.5 44.2 15.2 9.6 14.9 25.0 12.4 6.9 15.1 11.5 35.2 13.2 24.1 17.3 0.3 0.1 16.2 0.2 5.5 10.0 3.3 11.4 9.8 4.3 7.7 0.2 0.1 23.6 50.1 5.4 5.1 3.2 5.5 22.0 0.1 14.1 13.3 55.2 2.8 108.5 9.3 0.1 2.6 0.2 10.5 9.1 0.7 3.1 0.3 1.0 47.3 0.3 48.1 32.8 0.0 0.8 6.4 0.5 0.8 2.7 7.8 8.4 0.1 12.8 0.2 7.8 16.1 0.1 0.5 9.2 0.0 10.7 2.0 0.2 14.7 7.2 6.5 13.2 8.6 0.7 0.5 0.3 0.2 1.1 28.9 2.6 0.2 16.2 4.2 0.0 8.5 0.2 5.4 5.0 0.1 0.3 10.0 4.6 0.5 5.5 0.0 0.0 5.7 3.3 9.8 10.5 3.0 8.4 9.7 8.2 9.8 5.1 12.6 6.9 ITGAD "ADB2, CD11d" ENSG00000156886 "Integrin subunit alpha D" Q13349 16 31393312-31426505 "CD markers, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "lymphoid tissue: 25.4" "Cell line enhanced" "Detected in single" "NB-4: 1.7" "Low cancer specificity" "Detected in single" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "gdT-cell: 1.1;NK-cell: 2.6" "Group enriched" "Detected in many" 19 "NK-cells: 2.6;T-cells: 1.1" "Low region specificity" "Detected in many" HPA026786 Uncertain "HPA026786: AB_10603773" "unprognostic (2.79e-2)" "unprognostic (2.39e-4)" "unprognostic (2.88e-2)" "unprognostic (3.24e-2)" "unprognostic (6.17e-2)" "unprognostic (1.79e-2)" "unprognostic (7.44e-4)" "unprognostic (6.99e-3)" "unprognostic (6.89e-3)" "unprognostic (5.02e-4)" "unprognostic (5.50e-2)" "unprognostic (1.67e-1)" "unprognostic (1.74e-1)" "unprognostic (3.80e-2)" "unprognostic (3.17e-1)" "unprognostic (8.10e-2)" "unprognostic (5.51e-2)" 0.3 0.1 0.1 1.0 0.1 2.5 0.2 0.1 0.1 0.2 0.1 0.0 0.0 0.0 1.2 0.0 0.4 0.2 0.2 0.2 0.1 0.1 0.1 1.2 0.7 4.0 0.1 0.0 1.6 0.1 0.0 0.1 1.2 0.0 0.1 0.0 0.2 1.5 0.0 1.3 0.1 0.3 0.0 0.2 25.4 0.1 0.2 0.0 0.4 0.1 0.0 1.4 0.2 0.1 0.0 0.0 0.0 0.0 2.6 1.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 1.7 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 2.6 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 ITGAE "CD103, HUMINAE" ENSG00000083457 "Integrin subunit alpha E" P38570 17 3714628-3801243 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 20.2;lung: 25.9;lymphoid tissue: 13.0" "Cell line enriched" "Detected in single" 21 "MOLT-4: 15.9" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "MAIT T-cell: 3.1;memory CD8 T-cell: 7.4;T-reg: 1.9" "Lineage enriched" "Detected in many" 7 "T-cells: 7.4" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" "CAB026461, HPA036313" Approved 13000 "CAB026461: , HPA036313: AB_10795355" "unprognostic (9.81e-2)" "unprognostic (1.78e-3)" "unprognostic (7.86e-2)" "prognostic favourable (1.04e-4)" "unprognostic (2.17e-1)" "unprognostic (1.45e-2)" "unprognostic (2.91e-1)" "unprognostic (8.02e-2)" "unprognostic (2.92e-2)" "unprognostic (1.10e-1)" "prognostic favourable (5.78e-4)" "unprognostic (3.34e-2)" "prognostic unfavourable (1.13e-8)" "unprognostic (8.40e-3)" "unprognostic (1.15e-1)" "unprognostic (1.82e-2)" "prognostic favourable (3.56e-4)" 3.6 0.2 0.3 13.0 0.6 8.0 0.9 0.2 0.2 0.6 9.6 0.2 0.0 4.9 0.4 0.4 2.0 1.5 2.7 0.2 0.5 0.4 0.3 0.3 25.9 8.1 0.3 0.0 0.9 1.2 0.5 0.4 0.1 0.2 1.2 2.0 0.2 1.8 3.9 0.3 0.6 20.2 2.0 0.7 1.4 3.6 1.6 0.1 3.1 1.0 1.5 5.3 1.9 2.5 0.2 0.1 0.0 1.0 0.0 7.4 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.7 15.9 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.2 1.0 3.1 0.2 1.0 7.4 0.1 0.0 0.0 0.2 0.0 0.0 0.6 0.0 1.9 0.9 0.3 0.6 0.2 0.2 0.5 0.4 0.3 0.0 0.2 0.1 ITGAL "CD11A, LFA-1" ENSG00000005844 "Integrin subunit alpha L" P20701 16 30472658-30523185 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Phagocytosis" "Integrin, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 36.7;lymphoid tissue: 74.6" "Cell line enriched" "Detected in some" 4 "HMC-1: 119.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" CAB025011 Enhanced "Intracellular and membrane" 1100000 "CAB025011: " "unprognostic (1.10e-2)" "unprognostic (4.26e-3)" "unprognostic (3.72e-3)" "prognostic favourable (5.63e-5)" "unprognostic (2.88e-1)" "prognostic favourable (3.34e-4)" "unprognostic (1.63e-1)" "unprognostic (5.69e-3)" "prognostic favourable (5.57e-4)" "unprognostic (3.37e-2)" "unprognostic (4.98e-2)" "unprognostic (1.84e-1)" "prognostic unfavourable (2.69e-5)" "unprognostic (2.89e-1)" "unprognostic (3.05e-2)" "unprognostic (1.39e-1)" "unprognostic (1.71e-2)" 2.8 1.1 1.8 29.8 2.0 15.1 1.8 0.6 1.5 1.3 3.0 2.7 0.5 2.4 1.7 1.4 2.2 2.6 4.9 1.4 1.3 1.3 2.6 6.7 16.2 29.0 3.1 1.4 1.4 1.2 0.0 1.4 1.7 1.7 2.0 3.4 1.9 6.6 0.7 0.8 1.0 12.7 1.4 4.7 44.1 3.5 0.8 2.7 74.6 2.8 2.0 41.8 4.4 1.9 2.1 7.5 7.2 36.7 9.5 22.5 11.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.2 119.0 0.0 0.0 0.0 0.0 0.0 0.0 26.7 0.0 0.0 7.9 0.7 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 4.2 0.0 0.0 0.0 0.0 0.0 7.5 2.5 0.0 0.1 0.8 0.0 3.1 8.4 6.5 22.5 16.9 11.2 2.1 8.8 16.2 7.5 1.3 4.9 11.4 7.2 9.5 36.7 3.0 6.3 11.5 1.8 2.0 0.6 1.5 1.3 1.3 3.1 1.4 1.7 2.7 ITGAM "CD11b, CR3A, MAC-1" ENSG00000169896 "Integrin subunit alpha M" P11215 16 31259990-31332892 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Immunity, Innate immunity" "Integrin, Receptor" "Cancer-related genes, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 93.7" "Group enriched" "Detected in some" 4 "HMC-1: 32.7;NB-4: 11.6;U-937: 14.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "basophil: 29.4;classical monocyte: 19.1;eosinophil: 23.8;gdT-cell: 12.2;intermediate monocyte: 7.6;neutrophil: 21.0;NK-cell: 18.8" "Low lineage specificity" "Detected in all" "HPA002274, CAB025091, CAB072870" Enhanced 900000 "CAB025091: , CAB072870: , HPA002274: AB_1078435" "unprognostic (1.82e-2)" "unprognostic (1.70e-2)" "unprognostic (8.78e-2)" "unprognostic (2.54e-2)" "unprognostic (2.40e-2)" "unprognostic (4.20e-2)" "prognostic unfavourable (3.43e-4)" "unprognostic (1.86e-1)" "unprognostic (1.73e-1)" "unprognostic (3.29e-3)" "unprognostic (1.27e-1)" "unprognostic (1.80e-1)" "prognostic unfavourable (6.93e-5)" "unprognostic (9.89e-2)" "prognostic unfavourable (6.93e-4)" "unprognostic (3.99e-2)" "unprognostic (5.03e-2)" 19.7 5.0 6.0 14.0 7.2 93.7 6.0 2.0 4.5 2.9 3.2 9.4 0.5 1.8 2.5 3.5 2.2 4.8 4.0 6.5 4.3 3.9 3.0 3.3 14.6 22.8 10.5 1.6 2.5 2.9 1.6 1.8 4.9 5.3 3.6 2.7 3.3 3.2 2.0 1.6 1.5 4.4 6.9 8.6 29.9 2.8 1.5 7.4 2.3 2.1 1.7 6.6 4.9 4.5 1.9 3.4 29.4 19.1 18.8 12.2 8.0 0.5 1.1 0.0 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.3 0.4 0.8 0.5 0.0 0.1 0.0 0.2 0.0 4.7 0.0 0.6 0.0 0.0 0.0 1.1 32.7 0.0 0.1 0.0 0.0 0.0 1.1 0.1 0.0 0.0 0.0 11.6 0.0 0.0 0.1 0.0 0.6 0.0 1.3 0.0 0.0 0.0 0.3 0.2 0.1 2.7 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 14.0 0.0 29.4 19.1 23.8 12.2 7.6 0.7 1.9 1.3 3.6 3.4 0.3 0.3 3.0 21.0 18.8 1.1 0.2 0.5 8.0 6.0 7.2 2.0 4.5 4.3 3.9 10.5 1.6 5.3 7.4 ITGAV "CD51, MSK8, VNRA, VTNR" ENSG00000138448 "Integrin subunit alpha V" P06756 2 186590065-186680901 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RT4: 75.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 7.7" "Group enriched" "Detected in many" 4 "granulocytes: 7.7;monocytes: 2.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002499, HPA004856" Supported Approved "Focal adhesion sites,Cytosol" 750000 "Focal adhesion sites, Cytosol" "CAB002499: AB_563594, HPA004856: AB_1846316" "unprognostic (4.03e-2)" "unprognostic (5.17e-3)" "unprognostic (1.22e-2)" "unprognostic (5.22e-2)" "unprognostic (1.33e-1)" "unprognostic (1.18e-1)" "prognostic unfavourable (2.08e-4)" "unprognostic (1.48e-2)" "unprognostic (6.95e-2)" "unprognostic (2.89e-1)" "prognostic unfavourable (5.07e-4)" "unprognostic (5.84e-2)" "unprognostic (2.67e-2)" "prognostic unfavourable (1.05e-6)" "unprognostic (2.61e-1)" "unprognostic (9.11e-2)" "unprognostic (8.07e-2)" 23.2 22.1 17.9 18.3 21.8 3.1 25.8 16.7 23.1 22.9 13.6 23.4 11.6 8.4 26.0 11.4 14.2 14.5 25.2 40.7 16.8 12.3 51.5 9.5 20.6 7.6 24.2 11.6 35.4 18.7 65.0 11.0 29.6 22.1 16.5 11.9 83.4 17.9 15.9 13.1 21.5 10.1 29.6 33.0 12.1 17.3 11.2 17.0 7.8 33.1 10.9 11.1 17.6 17.9 0.3 0.9 7.7 2.3 0.4 1.1 0.5 9.7 11.7 7.8 24.9 28.7 19.4 29.7 19.2 15.5 6.8 6.8 10.2 33.8 0.0 37.9 21.6 12.3 3.9 18.1 9.8 1.9 3.5 2.3 15.4 14.0 11.3 1.6 1.4 14.1 8.6 15.2 12.9 16.2 2.2 4.9 18.1 3.8 0.9 1.3 5.9 5.9 0.0 15.9 1.3 17.6 75.3 1.6 4.8 22.2 6.9 8.1 5.4 4.5 49.1 42.2 13.2 8.6 16.2 1.2 2.0 1.1 17.0 0.6 20.8 7.7 1.1 1.6 1.0 2.3 0.7 0.3 0.5 0.8 0.9 0.1 0.5 0.5 0.5 0.4 1.2 0.4 1.1 0.5 17.9 21.8 16.7 17.3 16.8 12.3 24.2 11.6 22.1 17.0 ITGAX CD11c ENSG00000140678 "Integrin subunit alpha X" P20702 16 31355134-31382997 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 47.9;blood: 31.7;lung: 33.2;lymphoid tissue: 46.3" "Cell line enriched" "Detected in some" 6 "HMC-1: 48.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 10.1;eosinophil: 9.2;intermediate monocyte: 18.1;myeloid DC: 12.4;neutrophil: 31.7;NK-cell: 14.9;non-classical monocyte: 20.3" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB004458, HPA004723, CAB072871" Enhanced "CAB004458: AB_626859, CAB072871: , HPA004723: AB_1846231" "unprognostic (9.75e-3)" "unprognostic (2.49e-2)" "unprognostic (1.75e-1)" "unprognostic (1.99e-2)" "unprognostic (1.89e-1)" "unprognostic (2.29e-2)" "unprognostic (1.27e-1)" "unprognostic (9.59e-2)" "unprognostic (8.06e-3)" "unprognostic (3.20e-1)" "unprognostic (7.75e-2)" "unprognostic (3.34e-1)" "prognostic unfavourable (1.37e-4)" "unprognostic (3.92e-2)" "unprognostic (3.04e-2)" "unprognostic (2.82e-1)" "unprognostic (2.95e-2)" 47.9 1.9 4.4 28.1 5.7 28.6 2.9 1.4 4.4 1.8 2.1 17.1 0.6 1.7 2.1 2.5 1.9 4.3 7.7 2.5 5.3 4.6 2.3 4.6 33.2 24.4 13.6 3.8 3.0 2.1 0.8 2.4 3.3 8.1 2.5 3.2 2.5 4.3 1.3 1.1 1.6 3.8 3.3 15.6 46.3 3.3 0.9 7.5 3.8 2.2 0.9 9.7 5.1 1.9 0.8 12.4 31.7 20.3 14.9 1.8 3.2 0.0 0.3 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 4.1 0.0 0.0 0.0 0.1 0.0 8.1 0.0 0.0 0.1 0.1 0.0 0.4 48.1 0.0 0.0 0.7 0.1 0.4 0.0 0.1 0.0 0.0 0.0 3.8 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 1.4 0.3 0.0 0.7 0.0 0.0 0.0 0.0 0.0 2.2 0.7 0.1 3.9 10.1 9.2 1.8 18.1 0.1 0.8 0.0 0.3 12.4 0.4 0.0 0.2 31.7 14.9 20.3 0.2 0.0 3.2 4.4 5.7 1.4 4.4 5.3 4.6 13.6 3.8 8.1 7.5 ITGB1 "CD29, FNRB, GPIIA, MDF2, MSK12" ENSG00000150093 "Integrin subunit beta 1" P05556 10 32900319-33005792 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003434, HPA059297, HPA069003" Enhanced Supported "Endoplasmic reticulum,Plasma membrane,Focal adhesion sites" 540000000 "Plasma membrane, Focal adhesion sites" "Endoplasmic reticulum" "CAB003434: AB_303570, HPA059297: , HPA069003: " "unprognostic (3.07e-2)" "prognostic unfavourable (5.01e-4)" "unprognostic (8.67e-2)" "unprognostic (4.36e-1)" "unprognostic (1.20e-2)" "unprognostic (3.87e-2)" "unprognostic (1.60e-2)" "prognostic unfavourable (3.36e-6)" "unprognostic (3.22e-1)" "unprognostic (2.36e-3)" "unprognostic (3.68e-3)" "unprognostic (2.42e-1)" "unprognostic (1.02e-3)" "unprognostic (1.25e-2)" "unprognostic (2.23e-1)" "unprognostic (2.48e-1)" "unprognostic (3.08e-2)" 95.2 30.6 13.7 32.1 19.7 9.7 107.7 6.5 14.8 55.1 61.3 17.0 80.2 20.2 84.2 56.2 59.9 45.0 49.8 68.7 15.0 14.4 47.3 85.8 55.4 34.5 23.0 11.1 47.4 37.4 17.6 35.2 83.3 19.5 53.1 32.2 18.6 30.3 76.2 58.0 19.5 42.3 109.3 30.1 59.8 45.4 26.9 18.8 12.7 36.8 27.6 19.4 92.7 47.4 31.3 9.1 4.3 27.1 21.9 68.4 26.2 47.4 69.7 37.6 41.7 90.9 78.3 32.8 159.7 92.6 76.1 69.6 15.6 111.2 12.8 28.9 133.9 33.2 11.3 90.9 84.9 12.6 9.2 15.4 33.2 18.2 64.0 3.4 15.3 79.3 49.7 80.0 32.6 93.4 10.6 5.7 125.4 7.8 5.9 3.5 8.4 35.4 3.9 27.9 2.3 108.5 13.8 8.9 22.3 49.8 8.5 35.8 11.4 12.4 104.5 98.0 56.9 69.6 53.2 5.2 1.1 7.2 72.2 14.6 38.4 1.6 9.8 4.3 25.5 17.8 6.0 31.3 54.6 37.5 9.1 8.6 7.1 19.1 2.3 21.9 27.1 3.7 68.4 26.2 13.7 19.7 6.5 14.8 15.0 14.4 23.0 11.1 19.5 18.8 ITGB2 "CD18, LFA-1, MAC-1, MFI7" ENSG00000160255 "Integrin subunit beta 2" P05107 21 44885953-44931989 "CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Phagocytosis" "Integrin, Receptor" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 159.7;bone marrow: 91.4;lymphoid tissue: 75.6" "Group enriched" "Detected in some" 5 "THP-1: 114.8;U-937: 85.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008877, HPA016894" Enhanced Supported "Plasma membrane,Rods & Rings" 2500000 "Plasma membrane" "Rods & Rings" "HPA008877: AB_1846256, HPA016894: AB_1846257" "unprognostic (1.94e-2)" "unprognostic (7.66e-3)" "unprognostic (1.23e-1)" "unprognostic (6.21e-3)" "unprognostic (2.95e-2)" "unprognostic (9.73e-3)" "unprognostic (2.53e-2)" "unprognostic (1.82e-1)" "unprognostic (1.18e-2)" "unprognostic (1.36e-1)" "unprognostic (1.20e-1)" "unprognostic (6.34e-2)" "unprognostic (1.87e-3)" "unprognostic (1.42e-1)" "unprognostic (4.42e-2)" "unprognostic (2.65e-2)" "unprognostic (4.83e-2)" 59.1 9.8 9.0 47.5 16.8 91.4 8.4 1.7 8.0 5.6 7.4 12.2 1.2 6.3 4.9 9.0 4.8 10.7 10.3 9.7 7.2 6.4 8.1 7.0 32.9 73.8 14.3 2.9 6.6 5.1 1.1 3.3 12.7 12.1 6.9 4.2 5.2 8.8 2.7 3.0 4.1 13.2 12.3 18.3 75.6 7.6 4.2 12.2 53.5 4.5 2.2 29.0 15.7 4.2 9.5 76.0 104.6 122.9 41.0 57.4 159.7 0.2 0.7 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.0 0.0 0.0 2.4 19.8 0.0 0.0 0.0 0.0 0.0 0.2 0.2 2.3 0.0 0.4 0.0 15.0 3.9 0.2 0.0 0.0 0.0 0.0 0.1 0.2 1.0 0.5 17.0 18.0 0.0 0.3 0.2 3.5 9.3 0.7 0.0 0.0 0.2 0.5 0.3 0.3 0.0 114.8 0.3 0.0 1.0 0.0 0.5 0.1 0.8 0.4 0.0 85.3 0.1 10.5 122.9 85.7 57.4 84.1 25.8 6.7 28.4 39.5 76.0 9.5 19.1 32.0 104.6 41.0 81.0 11.6 20.7 159.7 9.0 16.8 1.7 8.0 7.2 6.4 14.3 2.9 12.1 12.2 ITGB3 "CD61, GP3A, GPIIIa" ENSG00000259207 "Integrin subunit beta 3" P05106 17 47253846-47311816 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "thyroid gland: 36.6" "Cell line enhanced" "Detected in some" "EFO-21: 45.5;HEL: 40.3;RPTEC TERT1: 26.2;U-87 MG: 20.6;WM-115: 65.7" "Group enriched" "Detected in many" 6 "melanoma: 7.5;renal cancer: 3.6;thyroid cancer: 11.5" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 19 "basophil: 2.8;neutrophil: 2.8" "Lineage enriched" "Detected in single" 19 "granulocytes: 2.8" HPA027852 Approved Supported "Nucleoplasm,Plasma membrane" "Intracellular and membrane" 710000000 "Plasma membrane" Nucleoplasm "HPA027852: AB_10601760" "unprognostic (1.13e-2)" "unprognostic (1.97e-3)" "unprognostic (2.47e-1)" "unprognostic (3.00e-2)" "unprognostic (1.91e-2)" "unprognostic (6.04e-3)" "unprognostic (3.70e-1)" "unprognostic (3.00e-1)" "unprognostic (1.44e-1)" "unprognostic (3.85e-1)" "unprognostic (6.35e-2)" "unprognostic (7.22e-2)" "unprognostic (1.36e-1)" "unprognostic (1.03e-2)" "unprognostic (2.72e-2)" "unprognostic (1.48e-1)" "unprognostic (1.17e-3)" 10.0 0.6 1.0 6.2 2.5 2.7 7.0 0.4 1.6 4.6 13.6 0.9 2.4 2.2 9.7 5.7 6.4 6.4 2.8 8.5 0.7 0.6 16.0 3.7 5.2 1.2 2.3 0.1 4.6 0.6 0.7 1.6 23.5 1.6 6.4 4.8 1.8 2.5 11.5 4.9 2.4 5.0 17.0 1.8 9.5 3.6 2.6 0.6 0.2 36.6 1.9 0.9 11.0 7.8 0.1 0.0 2.8 0.1 0.0 0.0 9.5 0.0 0.4 0.1 0.0 2.3 1.0 0.0 1.2 6.0 2.6 2.4 0.0 0.0 0.1 45.5 0.3 0.0 0.0 0.0 3.4 0.8 0.0 40.3 0.1 0.0 1.9 0.0 0.0 0.9 0.0 15.2 0.3 11.3 0.1 0.0 0.5 0.0 0.2 0.0 0.0 0.1 0.0 1.0 0.0 26.2 0.0 0.0 0.1 1.5 0.0 8.2 0.0 0.0 12.3 0.5 0.6 0.3 2.8 0.0 0.0 0.2 20.6 0.0 65.7 2.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.8 0.0 0.0 0.0 0.0 9.5 1.0 2.5 0.4 1.6 0.7 0.6 2.3 0.1 1.6 0.6 ITGB4 CD104 ENSG00000132470 "Integrin subunit beta 4" P16144 17 75721328-75757818 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, Disease mutation, Epidermolysis bullosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "CAPAN-2: 117.5;HaCaT: 45.0;HBEC3-KT: 100.3;hTCEpi: 34.3;RT4: 33.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 8.2" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB002422, CAB005258, HPA036348, HPA036349" Enhanced Supported "Plasma membrane,Cell Junctions" 79000 "Plasma membrane, Cell Junctions" "CAB002422: AB_563480, CAB005258: AB_2129021, HPA036348: AB_2675077, HPA036349: AB_2675078" "unprognostic (3.17e-3)" "unprognostic (3.52e-1)" "unprognostic (4.19e-1)" "unprognostic (2.27e-1)" "unprognostic (5.75e-2)" "unprognostic (6.11e-3)" "unprognostic (1.28e-1)" "prognostic unfavourable (7.18e-4)" "unprognostic (1.05e-1)" "unprognostic (4.14e-2)" "prognostic unfavourable (6.39e-4)" "unprognostic (1.02e-1)" "unprognostic (2.23e-2)" "unprognostic (1.65e-2)" "unprognostic (1.05e-1)" "unprognostic (1.07e-1)" "unprognostic (1.43e-1)" 6.3 3.4 9.7 10.9 9.7 1.4 13.7 4.7 7.7 14.3 32.1 15.6 10.0 35.3 9.7 8.8 24.0 13.7 47.8 4.3 9.4 7.9 4.8 1.5 7.4 3.7 10.1 9.1 4.7 6.7 3.1 5.7 50.0 17.2 19.7 10.4 9.8 52.3 13.2 2.4 47.0 58.5 7.4 10.7 17.0 41.0 3.9 9.8 1.8 3.2 22.1 15.9 17.2 20.5 2.4 8.2 1.3 0.7 0.0 2.2 0.8 21.8 19.3 0.0 0.2 0.0 0.1 26.6 0.1 0.0 0.0 0.1 2.0 117.5 0.0 4.2 0.0 45.0 0.1 100.3 0.0 0.1 0.0 0.1 4.9 2.1 0.1 0.0 0.2 0.1 34.3 0.0 21.4 0.7 0.0 2.0 0.0 12.2 0.2 0.2 0.1 16.8 0.3 0.5 0.2 26.8 33.0 0.0 0.2 0.6 2.0 0.3 8.4 0.2 2.2 0.6 1.0 0.0 0.2 0.7 0.2 0.0 0.2 0.1 0.3 0.0 0.4 0.0 0.7 0.7 2.2 1.4 0.3 1.0 0.1 2.4 0.9 0.6 1.3 0.0 0.0 8.2 1.4 0.8 9.7 9.7 4.7 7.7 9.4 7.9 10.1 9.1 17.2 9.8 JAG1 "AGS, AHD, AWS, CD339, HJ1, JAGL1" ENSG00000101384 "Jagged 1" P78504 20 10637684-10673999 "CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Notch signaling pathway" "Developmental protein" "Deafness, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HBEC3-KT: 55.8;hTERT-HME1: 34.5;U-251 MG: 46.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "eosinophil: 2.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB010343, HPA021555" Supported Approved "Golgi apparatus,Plasma membrane" 14000000 "Golgi apparatus, Plasma membrane" "CAB010343: AB_649685, HPA021555: AB_1851969" "unprognostic (2.23e-1)" "unprognostic (2.04e-2)" "unprognostic (1.78e-1)" "unprognostic (4.15e-2)" "unprognostic (1.21e-1)" "unprognostic (6.42e-2)" "unprognostic (4.21e-2)" "unprognostic (8.94e-3)" "unprognostic (6.07e-2)" "unprognostic (5.20e-2)" "prognostic unfavourable (4.10e-6)" "unprognostic (5.48e-2)" "unprognostic (1.71e-3)" "unprognostic (2.22e-1)" "unprognostic (1.66e-1)" "unprognostic (3.10e-1)" "unprognostic (1.41e-3)" 27.7 5.6 6.8 14.5 5.4 9.7 56.5 2.9 6.7 34.2 20.1 4.3 17.4 7.2 26.1 22.8 33.9 16.7 23.1 18.8 5.4 5.1 12.9 3.8 22.0 12.4 5.4 4.0 14.7 22.2 21.7 6.0 36.3 6.0 19.2 12.7 21.4 11.2 23.4 16.8 34.8 11.7 21.4 13.0 14.2 13.4 9.1 3.8 1.5 14.5 24.6 16.1 18.7 31.4 0.0 0.9 2.4 2.0 0.4 0.1 0.4 1.0 5.2 16.4 20.1 3.1 3.0 0.6 0.6 3.0 0.8 0.4 4.6 2.8 0.1 15.4 0.6 21.9 2.4 55.8 0.7 0.0 1.1 1.7 0.5 21.9 1.5 7.0 0.1 1.2 16.6 2.7 34.5 5.4 0.0 2.2 1.5 0.0 0.0 5.0 4.7 5.2 1.3 1.0 3.2 7.8 6.4 0.7 0.5 1.6 1.1 6.6 0.1 0.8 20.4 3.7 2.6 3.0 46.9 0.9 0.1 0.2 2.4 2.5 2.9 0.0 2.0 2.4 0.0 0.2 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 1.6 0.4 0.3 0.9 0.0 0.4 6.8 5.4 2.9 6.7 5.4 5.1 5.4 4.0 6.0 3.8 JAM2 "C21orf43, CD322, JAM-B, JAMB, VE-JAM" ENSG00000154721 "Junctional adhesion molecule 2" P57087 21 25639272-25717562 "CD markers, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 66.7" "Cell line enhanced" "Detected in some" "AF22: 18.9;BJ hTERT+: 12.0;HDLM-2: 11.8;U-138 MG: 13.6;U-87 MG: 10.0" "Cancer enriched" "Detected in all" 9 "glioma: 27.2" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA028789, HPA077346" Supported "Nucleoplasm,Plasma membrane" 17000 "Plasma membrane" Nucleoplasm "HPA028789: , HPA077346: " "unprognostic (1.42e-1)" "unprognostic (6.39e-2)" "unprognostic (1.23e-1)" "unprognostic (1.73e-1)" "unprognostic (2.02e-2)" "unprognostic (1.53e-2)" "unprognostic (7.51e-4)" "unprognostic (2.61e-2)" "unprognostic (4.55e-1)" "unprognostic (1.02e-1)" "unprognostic (3.46e-2)" "unprognostic (3.81e-1)" "unprognostic (8.86e-2)" "unprognostic (5.71e-3)" "unprognostic (2.18e-1)" "unprognostic (2.20e-1)" "unprognostic (4.85e-3)" 16.6 17.2 13.8 8.4 18.9 1.5 14.6 9.9 23.4 18.1 14.7 14.5 8.0 7.5 20.5 13.5 13.3 12.0 14.4 21.9 13.5 12.5 6.5 3.5 17.1 4.6 17.6 13.5 18.9 3.9 5.8 7.7 66.7 18.5 12.0 9.7 11.1 5.5 18.0 8.4 6.9 9.2 21.8 23.0 2.8 9.7 25.8 12.2 0.6 9.5 10.1 6.3 13.5 15.1 3.1 1.9 1.9 0.7 2.8 1.1 0.4 0.0 0.0 18.9 0.1 0.7 0.2 0.4 0.5 12.0 1.5 5.7 0.0 0.0 0.1 0.0 0.2 0.1 1.6 0.0 3.5 11.8 0.5 0.1 0.0 0.1 0.0 0.0 0.1 1.1 0.0 1.3 0.0 0.0 0.0 0.2 5.8 0.1 0.3 0.1 6.0 0.0 2.2 3.9 0.1 0.0 0.0 0.3 2.8 0.1 0.2 0.0 0.7 0.1 0.0 13.6 1.3 0.1 1.9 1.5 0.0 0.0 10.0 0.1 0.5 1.4 0.7 0.3 0.4 0.5 0.6 0.3 0.4 0.9 0.4 3.1 0.7 1.1 1.9 2.8 0.6 1.9 0.2 0.4 13.8 18.9 9.9 20.5 13.5 12.5 17.6 13.5 18.5 12.2 KDR "CD309, FLK1, VEGFR, VEGFR2" ENSG00000128052 "Kinase insert domain receptor" P35968 4 55078259-55125595 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Angiogenesis, Differentiation, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 9 "HUVEC TERT2: 31.8;TIME: 35.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB004028 Enhanced Supported "Plasma membrane" "Intracellular and membrane" 7400000 "Plasma membrane" "CAB004028: AB_2212507" "unprognostic (1.61e-1)" "unprognostic (2.03e-1)" "unprognostic (9.65e-2)" "unprognostic (1.97e-1)" "unprognostic (9.63e-2)" "unprognostic (1.22e-2)" "unprognostic (1.78e-3)" "unprognostic (2.59e-2)" "unprognostic (1.19e-2)" "unprognostic (1.10e-1)" "unprognostic (8.79e-3)" "unprognostic (1.34e-1)" "prognostic unfavourable (7.26e-4)" "unprognostic (4.00e-2)" "unprognostic (2.30e-1)" "unprognostic (3.22e-1)" "unprognostic (1.86e-1)" 19.7 6.2 1.8 4.4 3.1 0.4 20.5 1.1 2.2 11.4 6.0 1.8 11.5 2.3 28.8 10.2 5.2 9.5 6.2 12.1 2.3 1.7 7.8 10.4 13.2 14.1 3.1 2.9 6.0 8.1 8.0 6.8 34.5 3.9 9.5 1.4 27.6 7.1 10.3 5.3 3.0 3.8 7.7 2.6 4.4 4.2 5.3 1.2 0.5 20.0 5.3 3.0 4.4 12.0 0.1 0.1 0.7 0.0 0.2 0.2 0.1 0.0 0.0 1.7 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 3.7 0.0 0.0 0.3 0.0 0.0 0.2 31.8 0.0 0.0 0.2 0.0 0.0 0.0 0.8 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 35.9 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.4 0.0 0.1 0.1 0.0 0.7 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.1 1.8 3.1 1.1 2.2 2.3 1.7 3.1 2.9 3.9 1.2 KEL "CD238, ECE3" ENSG00000197993 "Kell blood group, metallo-endopeptidase" P23276 7 142941114-142962681 "Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Blood group antigen, Hydrolase, Metalloprotease, Protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "bone marrow: 21.1;testis: 36.4" "Group enriched" "Detected in some" 12 "HEL: 14.9;K-562: 12.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in single" 7 "intermediate monocyte: 1.4" "Lineage enriched" "Detected in single" 14 "monocytes: 1.4" "Not detected" "Not detected" "Low region specificity" "Detected in single" HPA064442 Supported "Nucleoplasm,Plasma membrane,Cytosol" "Plasma membrane" "Nucleoplasm, Cytosol" "HPA064442: " "unprognostic (5.78e-3)" "unprognostic (1.08e-5)" "unprognostic (5.29e-3)" "unprognostic (4.85e-3)" "unprognostic (9.68e-2)" "unprognostic (1.96e-2)" "unprognostic (1.03e-1)" "unprognostic (1.54e-2)" "unprognostic (5.18e-2)" "unprognostic (1.08e-2)" "unprognostic (3.71e-2)" "unprognostic (3.57e-2)" "unprognostic (2.29e-3)" "unprognostic (9.24e-2)" "unprognostic (7.05e-2)" "unprognostic (3.32e-2)" "unprognostic (3.25e-3)" 0.2 0.0 0.9 2.5 1.1 21.1 0.2 0.2 0.4 0.4 0.2 0.3 0.2 0.0 0.2 0.2 0.6 0.1 0.2 0.2 1.4 0.7 0.4 0.2 1.4 5.0 2.0 0.2 0.2 0.2 0.0 0.2 1.1 0.3 0.2 0.0 0.3 2.5 0.2 0.2 0.0 0.5 0.2 4.4 3.8 0.0 36.4 0.3 0.4 0.2 0.2 3.7 0.2 0.2 0.0 0.0 0.0 1.4 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 12.1 0.1 0.0 0.0 0.5 0.2 0.3 0.0 0.1 0.0 0.1 0.0 1.1 0.0 0.1 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.9 1.1 0.2 0.4 1.4 0.7 2.0 0.2 0.3 0.3 KIR2DL1 "47.11, CD158A, cl-42, nkat1, p58.1" ENSG00000125498 "Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1" P43626 19 54769811-54784322 "CD markers, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "endometrium 1: 2.8;lung: 4.0;lymphoid tissue: 4.5" "Cell line enriched" "Detected in single" 25 "U-266/84: 2.5" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "gdT-cell: 1.4" "Lineage enhanced" "Detected in single" "T-cells: 1.4" "unprognostic (2.14e-1)" "unprognostic (9.82e-2)" "unprognostic (8.18e-2)" "unprognostic (2.19e-2)" "unprognostic (3.93e-1)" "unprognostic (1.55e-2)" "unprognostic (3.19e-4)" "unprognostic (4.11e-2)" "unprognostic (6.87e-2)" "unprognostic (1.14e-2)" "unprognostic (1.13e-1)" "unprognostic (6.84e-2)" "unprognostic (3.61e-2)" 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.6 0.1 0.1 0.0 0.0 0.1 2.8 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.4 2.2 4.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 1.8 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.8 4.5 0.4 1.4 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.4 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 KIR2DL3 "CD158B2, cl-6, nkat2, nkat2a, nkat2b, p58" ENSG00000243772 "Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3" P43628 19 54738515-54753052 "CD markers, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lung: 3.0;lymphoid tissue: 5.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "unprognostic (7.37e-2)" "unprognostic (2.35e-2)" "unprognostic (2.23e-1)" "unprognostic (6.88e-2)" "unprognostic (2.92e-1)" "unprognostic (7.76e-3)" "unprognostic (1.55e-2)" "unprognostic (1.99e-1)" "unprognostic (1.41e-2)" "unprognostic (2.41e-4)" "unprognostic (1.19e-1)" "unprognostic (1.91e-1)" "unprognostic (1.62e-2)" "unprognostic (1.59e-2)" 0.5 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.5 0.1 0.1 0.0 0.0 0.1 2.1 0.1 0.1 0.2 0.1 2.2 0.0 0.0 0.1 0.4 3.0 2.4 0.0 0.0 1.0 0.1 0.1 0.0 0.8 0.1 1.3 0.1 1.1 1.9 0.1 0.1 0.1 0.1 0.1 0.0 5.6 0.1 0.1 0.8 0.6 0.1 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.8 KIR2DL4 "103AS, 15.212, CD158D" ENSG00000189013 "Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4" Q99706 19 54803535-54814517 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "blood: 5.6;intestine: 7.3;lymphoid tissue: 13.9" "Not detected" "Not detected" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 56 "NK-cell: 5.6" "Lineage enriched" "Detected in single" 56 "NK-cells: 5.6" "Intracellular and membrane" "unprognostic (1.98e-2)" "unprognostic (4.16e-2)" "unprognostic (1.84e-2)" "unprognostic (3.70e-4)" "unprognostic (2.23e-1)" "unprognostic (5.95e-4)" "unprognostic (1.34e-1)" "unprognostic (1.49e-1)" "unprognostic (2.92e-5)" "unprognostic (5.15e-2)" "unprognostic (1.14e-1)" "unprognostic (1.32e-1)" "unprognostic (4.53e-8)" "unprognostic (6.47e-2)" "unprognostic (2.66e-1)" "unprognostic (6.10e-4)" "unprognostic (3.59e-3)" 0.2 0.3 0.0 2.8 0.0 0.3 0.1 0.0 0.2 0.1 3.8 0.0 0.0 0.1 1.4 0.2 0.2 0.2 0.3 0.9 0.1 0.0 0.2 0.3 1.2 0.3 0.0 0.0 1.1 0.1 0.1 0.1 1.7 0.0 0.2 0.3 0.0 0.1 0.8 0.1 0.1 7.3 0.1 0.0 13.9 0.3 0.3 0.0 0.4 0.5 0.0 1.5 0.8 0.1 0.0 0.0 0.0 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 KIR3DL1 "AMB11, CD158E1, CD158e1/2, CD158e2, cl-11, cl-2, KIR, nkat3, NKB1, NKB1B" ENSG00000167633 "Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1" P43629 19 54816468-54830778 "CD markers, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 5.4;bone marrow: 2.0;lymphoid tissue: 3.0" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 4 "gdT-cell: 5.4" "Lineage enriched" "Detected in many" 4 "T-cells: 5.4" "unprognostic (3.18e-1)" "unprognostic (8.01e-2)" "unprognostic (3.53e-2)" "unprognostic (4.85e-1)" "unprognostic (5.18e-3)" "unprognostic (6.19e-2)" "unprognostic (4.37e-2)" "unprognostic (9.97e-2)" "unprognostic (1.89e-2)" "unprognostic (3.28e-1)" "unprognostic (7.34e-2)" "unprognostic (2.07e-3)" "unprognostic (3.22e-2)" "unprognostic (2.07e-1)" "unprognostic (1.73e-1)" "unprognostic (2.19e-2)" 0.1 0.0 0.0 0.0 0.0 2.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 1.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 3.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 5.4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.2 0.0 1.2 0.0 0.0 0.0 0.5 KIR3DL2 "CD158K, cl-5, nkat4, nkat4a, nkat4b" ENSG00000240403 "Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2" P43630 19 54850443-54867207 "CD markers, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "heart muscle: 2.0;lymphoid tissue: 5.3;salivary gland: 2.0" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "naive CD8 T-cell: 1.2" "Lineage enhanced" "Detected in single" "T-cells: 1.2" "unprognostic (6.99e-2)" "unprognostic (1.83e-1)" "unprognostic (3.64e-1)" "unprognostic (4.56e-4)" "unprognostic (1.40e-1)" "unprognostic (2.99e-2)" "unprognostic (8.39e-3)" "unprognostic (5.96e-2)" "unprognostic (2.73e-1)" "unprognostic (2.12e-1)" "unprognostic (4.04e-3)" "unprognostic (1.22e-1)" "unprognostic (2.58e-1)" "unprognostic (1.65e-3)" "unprognostic (3.62e-2)" 0.2 0.0 0.0 0.1 0.0 1.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.3 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 2.0 0.0 0.0 0.0 0.8 0.0 0.0 5.3 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.0 0.0 0.0 1.2 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KIT "C-Kit, CD117, PBT, SCFR" ENSG00000157404 "KIT proto-oncogene receptor tyrosine kinase" P10721 4 54657918-54740715 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 65.5" "Group enriched" "Detected in some" 13 "HEL: 47.7;HMC-1: 100.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7" "Group enriched" "Detected in many" 6 "granulocytes: 12.7;NK-cells: 9.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003288, HPA004471, CAB068253, CAB072867, HPA073252" Enhanced Supported Supported "Plasma membrane" 48000000 "Plasma membrane" "CAB003288: AB_2335702, CAB068253: , CAB072867: , HPA004471: AB_1078431, HPA073252: " "unprognostic (1.55e-2)" "unprognostic (1.91e-1)" "unprognostic (4.04e-2)" "unprognostic (8.19e-2)" "unprognostic (3.96e-2)" "unprognostic (2.18e-2)" "unprognostic (2.33e-2)" "unprognostic (1.97e-2)" "unprognostic (3.60e-2)" "unprognostic (1.64e-1)" "unprognostic (2.20e-1)" "unprognostic (1.92e-2)" "prognostic favourable (5.63e-4)" "unprognostic (1.34e-3)" "unprognostic (1.87e-1)" "unprognostic (1.29e-2)" "unprognostic (2.30e-1)" 8.1 1.6 9.5 6.6 11.8 3.7 65.5 18.3 12.0 12.1 10.3 6.5 10.2 5.8 8.9 4.2 9.9 2.5 15.5 2.4 36.0 4.4 9.4 1.1 13.8 3.8 3.6 6.0 28.5 2.1 1.3 2.3 6.2 5.7 9.6 10.4 20.7 12.9 6.9 1.3 14.6 8.9 10.2 3.9 3.2 12.8 4.0 4.5 0.4 28.9 4.3 4.9 9.8 12.5 0.0 1.8 12.7 0.9 9.7 1.9 0.1 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.6 0.9 2.5 3.2 0.0 0.0 0.0 0.0 1.4 0.0 0.5 0.0 2.1 0.0 1.1 47.7 0.0 0.0 0.0 0.0 100.2 0.0 0.0 0.0 0.0 5.6 0.6 0.1 0.0 0.0 0.2 0.4 1.3 0.0 0.1 0.0 0.0 0.0 4.7 1.2 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 12.7 0.0 10.0 0.1 0.0 1.9 0.0 0.3 0.7 1.8 0.0 0.0 0.0 0.8 9.7 0.9 0.0 0.0 0.1 9.5 11.8 18.3 12.0 36.0 4.4 3.6 6.0 5.7 4.5 KLRB1 "CD161, CLEC5B, hNKR-P1A, NKR, NKR-P1, NKR-P1A" ENSG00000111796 "Killer cell lectin like receptor B1" Q12918 12 9594551-9607886 "CD markers, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "blood: 178.9" "Cell line enhanced" "Detected in some" "HEL: 3.0;Karpas-707: 2.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in many" "MAIT T-cell: 178.9" "Group enriched" "Detected in many" 133 "NK-cells: 53.0;T-cells: 178.9" "Low region specificity" "Detected in all" HPA039113 Approved Uncertain Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA039113: AB_10674979" "prognostic favourable (3.51e-5)" "unprognostic (1.23e-3)" "unprognostic (7.03e-3)" "prognostic favourable (1.42e-5)" "unprognostic (1.69e-1)" "prognostic favourable (6.99e-5)" "unprognostic (1.54e-3)" "unprognostic (7.15e-3)" "unprognostic (4.12e-1)" "unprognostic (8.23e-3)" "unprognostic (3.57e-2)" "unprognostic (1.65e-1)" "unprognostic (1.17e-2)" "unprognostic (2.45e-1)" "unprognostic (1.34e-1)" "prognostic favourable (5.61e-4)" "unprognostic (1.17e-2)" 3.8 0.8 0.8 22.8 0.8 18.6 2.1 0.5 0.6 2.9 9.1 0.0 1.3 5.0 1.8 3.7 2.6 1.8 7.3 1.3 0.7 0.8 3.8 4.9 11.8 23.7 1.1 0.2 2.0 1.0 0.0 0.9 2.1 0.8 1.8 3.9 0.9 4.8 1.4 0.9 0.8 20.4 0.6 1.8 25.2 4.4 1.3 0.2 6.2 1.9 2.9 17.7 5.5 2.0 0.1 0.3 0.8 0.2 53.0 178.9 18.5 0.0 0.0 1.5 0.1 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.4 1.3 0.1 0.0 0.2 1.9 0.0 0.0 0.2 0.0 3.0 0.0 0.4 0.0 0.6 0.6 0.0 0.0 0.0 0.0 0.0 0.2 2.2 0.0 0.8 0.8 0.6 0.5 0.0 1.1 0.2 0.9 0.0 0.5 0.4 0.6 0.6 0.7 0.1 0.3 0.2 0.0 1.6 0.0 0.4 0.7 0.6 0.4 1.5 0.0 1.8 0.9 0.5 0.1 0.0 43.1 0.1 178.9 0.1 25.6 28.1 0.1 0.1 1.5 8.7 0.8 53.0 0.2 0.3 5.7 18.5 0.8 0.8 0.5 0.6 0.7 0.8 1.1 0.2 0.8 0.2 KLRC1 "CD159a, NKG2, NKG2-A, NKG2-B" ENSG00000134545 "Killer cell lectin like receptor C1" P26715 12 10442264-10454685 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 64.3;lymphoid tissue: 22.1" "Cell line enhanced" "Detected in some" "HeLa: 9.3;Karpas-707: 3.8" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 7 "gdT-cell: 45.7;NK-cell: 64.3" "Group enriched" "Detected in many" 42 "NK-cells: 64.3;T-cells: 45.7" HPA058052 Approved "Plasma membrane" "Plasma membrane" "HPA058052: " "unprognostic (8.17e-3)" "unprognostic (2.13e-2)" "unprognostic (1.48e-2)" "unprognostic (4.58e-7)" "unprognostic (3.57e-1)" "unprognostic (1.17e-2)" "unprognostic (1.05e-1)" "unprognostic (3.68e-2)" "unprognostic (3.73e-4)" "unprognostic (4.13e-2)" "unprognostic (6.49e-2)" "unprognostic (2.54e-1)" "unprognostic (1.18e-4)" "unprognostic (1.88e-1)" "unprognostic (3.23e-1)" "unprognostic (2.45e-1)" "unprognostic (1.92e-3)" 2.4 0.5 1.2 5.8 1.4 5.6 2.3 1.0 2.7 1.7 3.3 0.7 1.2 1.5 5.5 3.9 1.7 2.5 2.4 2.6 1.6 1.3 1.9 2.0 5.9 10.3 2.3 0.6 1.2 1.4 0.3 1.3 3.6 1.5 1.9 2.5 2.0 3.1 0.3 0.5 1.0 5.0 2.1 2.6 22.1 5.2 1.4 0.5 3.5 1.9 3.0 2.9 2.9 1.8 0.1 0.0 1.2 0.1 64.3 45.7 5.1 0.4 1.6 0.1 0.1 0.6 0.4 0.8 0.0 0.0 0.8 1.7 0.0 1.3 0.2 0.1 0.4 0.3 0.6 2.8 1.1 0.9 0.4 2.1 9.3 0.0 0.1 0.6 0.4 1.0 0.0 0.3 0.0 0.8 1.3 3.8 0.8 0.0 0.2 2.8 0.0 0.0 0.9 0.2 0.3 0.2 0.0 0.5 0.1 0.8 0.0 0.3 0.3 0.0 2.6 0.4 0.0 0.0 0.3 0.0 0.0 0.7 2.2 0.8 0.0 0.2 0.0 0.0 45.7 0.0 5.8 0.1 0.0 7.9 0.0 0.0 0.0 6.9 1.2 64.3 0.1 0.0 0.0 5.1 1.2 1.4 1.0 0.9 1.6 1.3 2.3 0.6 1.5 0.5 KLRC2 "CD159c, NKG2-C" ENSG00000205809 "Killer cell lectin like receptor C2" P26717 12 10426854-10442300 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 32.8;brain: 16.2" "Cell line enhanced" "Detected in some" "HEL: 6.1;HeLa: 19.0;HSkMC: 4.6;U-87 MG: 3.1" "Cancer enriched" "Detected in single" 8 "glioma: 3.6" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "gdT-cell: 10.7;NK-cell: 32.8" "Group enriched" "Detected in many" 92 "NK-cells: 32.8;T-cells: 10.7" HPA058052 Approved "Plasma membrane" "Plasma membrane" "HPA058052: " "unprognostic (9.05e-4)" "unprognostic (2.54e-2)" "unprognostic (3.77e-2)" "unprognostic (2.51e-3)" "unprognostic (2.83e-1)" "unprognostic (9.49e-4)" "unprognostic (1.27e-1)" "unprognostic (8.74e-2)" "unprognostic (2.88e-1)" "unprognostic (4.00e-3)" "unprognostic (2.88e-2)" "unprognostic (9.16e-3)" "unprognostic (1.55e-9)" "unprognostic (8.10e-2)" "unprognostic (2.34e-1)" "unprognostic (8.93e-2)" "unprognostic (5.31e-3)" 0.5 0.2 8.2 0.6 4.6 2.8 1.1 1.2 16.2 0.4 1.9 2.3 0.1 1.0 1.4 1.0 0.8 0.6 1.7 0.2 6.1 5.4 0.1 1.1 1.4 1.5 6.2 2.6 1.5 0.1 0.0 0.1 0.6 3.7 0.3 1.3 0.1 0.5 0.3 0.1 0.2 1.8 0.1 4.1 8.1 3.2 0.5 1.7 2.2 0.2 0.1 2.0 1.2 0.1 0.0 0.0 0.2 0.0 32.8 10.7 1.7 0.0 1.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 6.1 19.0 0.3 0.0 0.6 0.0 4.6 0.1 0.0 0.4 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 1.2 0.2 0.4 0.0 0.0 0.0 0.0 0.6 3.1 0.1 0.1 0.0 0.0 0.0 10.7 0.0 0.2 0.0 0.0 4.7 0.0 0.0 0.0 3.7 0.2 32.8 0.0 0.0 0.0 1.7 8.2 4.6 1.2 3.6 6.1 5.4 6.2 2.6 3.7 1.7 KLRD1 CD94 ENSG00000134539 "Killer cell lectin like receptor D1" Q13241 12 10226058-10329600 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 85.5;lymphoid tissue: 31.0;pituitary gland: 44.6" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in single" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 7 "gdT-cell: 67.2;memory CD8 T-cell: 28.0;naive CD8 T-cell: 30.3;NK-cell: 85.5" "Group enriched" "Detected in many" 63 "NK-cells: 85.5;T-cells: 67.2" "Not detected" "Not detected" HPA069688 Uncertain "HPA069688: " "unprognostic (3.75e-2)" "unprognostic (2.15e-3)" "unprognostic (4.95e-2)" "unprognostic (2.48e-3)" "unprognostic (2.13e-2)" "unprognostic (2.60e-3)" "unprognostic (2.26e-2)" "unprognostic (1.13e-1)" "unprognostic (8.94e-3)" "unprognostic (4.53e-3)" "unprognostic (8.78e-2)" "unprognostic (2.97e-2)" "unprognostic (1.47e-3)" "unprognostic (1.78e-1)" "unprognostic (3.07e-1)" "unprognostic (3.06e-1)" "unprognostic (1.37e-2)" 5.2 1.3 0.9 6.4 1.1 6.9 1.7 0.8 0.9 1.4 2.7 0.6 0.2 1.5 3.3 1.9 2.0 1.1 1.5 1.7 1.0 1.0 1.5 3.7 12.3 10.2 3.8 0.7 0.9 1.9 0.0 44.6 2.3 0.8 2.0 0.9 2.1 1.2 0.5 1.1 0.8 10.6 0.5 2.6 31.0 1.8 1.4 0.4 2.2 1.3 0.3 3.6 6.3 1.3 0.1 0.2 1.2 0.2 85.5 67.2 16.2 0.9 0.7 1.1 1.5 1.5 0.6 0.9 2.3 0.1 0.2 0.7 1.4 1.0 1.3 1.1 1.8 1.1 0.5 1.3 0.2 2.2 2.8 1.7 2.6 0.6 2.7 1.0 2.1 0.7 1.7 0.4 1.2 0.3 1.0 4.9 0.3 1.9 1.0 1.3 1.7 1.4 0.6 1.6 1.2 0.7 2.1 2.4 1.2 1.1 2.2 0.5 0.8 2.0 1.7 1.7 3.1 1.5 0.7 2.0 1.8 1.1 2.6 1.6 1.6 0.1 0.1 0.1 67.2 0.2 7.6 0.1 0.4 28.0 0.2 0.1 0.1 30.3 1.2 85.5 0.1 0.2 0.1 16.2 0.9 1.1 0.8 0.9 1.0 1.0 3.8 0.7 0.8 0.4 KLRK1 "CD314, D12S2489E, KLR, NKG2-D, NKG2D" ENSG00000213809 "Killer cell lectin like receptor K1" P26718 12 10372353-10391874 "Cancer-related genes, CD markers, Predicted membrane proteins, Transporters" "Adaptive immunity, Differentiation, Immunity, Innate immunity" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 50.8;lymphoid tissue: 30.7" "Cell line enriched" "Detected in some" 8 "U-698: 36.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 39 "gdT-cell: 49.4;MAIT T-cell: 18.5;memory CD8 T-cell: 44.0;naive CD8 T-cell: 44.3;NK-cell: 50.8" "Group enriched" "Detected in many" 47 "NK-cells: 50.8;T-cells: 49.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB021896, HPA068877" Enhanced Supported "Plasma membrane" 33000 "Plasma membrane" "CAB021896: , HPA068877: " "unprognostic (3.34e-4)" "unprognostic (2.65e-4)" "unprognostic (3.25e-1)" "unprognostic (2.59e-2)" "unprognostic (1.53e-1)" "unprognostic (1.01e-5)" "unprognostic (5.61e-4)" "unprognostic (1.00e-3)" "unprognostic (1.33e-1)" "unprognostic (9.22e-2)" "unprognostic (1.28e-2)" "unprognostic (2.10e-2)" "unprognostic (6.56e-10)" "unprognostic (1.24e-2)" "unprognostic (6.32e-2)" "unprognostic (7.59e-2)" "unprognostic (7.08e-10)" 4.1 0.9 1.3 18.3 1.1 10.6 2.1 0.4 0.8 2.8 4.5 1.2 0.6 2.0 2.4 2.7 3.1 2.0 7.7 1.3 1.3 1.1 2.4 3.6 13.6 22.2 2.1 0.1 1.5 3.3 0.0 1.2 1.6 1.2 2.2 2.1 2.4 7.0 0.6 0.5 1.1 13.1 1.3 2.1 30.7 3.3 1.9 0.6 6.0 2.9 2.8 11.4 11.3 2.5 1.0 0.2 0.8 0.1 50.8 49.4 16.7 0.2 0.0 0.4 1.8 0.1 4.6 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 1.6 0.0 0.0 0.1 0.0 0.7 0.0 0.2 0.0 0.2 0.1 0.3 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.5 0.0 0.0 0.0 0.0 36.0 0.1 0.0 0.2 0.0 0.0 0.0 49.4 0.1 18.5 0.8 0.3 44.0 0.1 1.0 0.4 44.3 0.8 50.8 0.1 0.2 0.1 16.7 1.3 1.1 0.4 0.8 1.3 1.1 2.1 0.1 1.2 0.6 L1CAM "CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1" ENSG00000198910 "L1 cell adhesion molecule" P32004 X 153861514-153886174 "CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Differentiation, Neurogenesis" "Developmental protein" "Disease mutation, Hereditary spastic paraplegia, Hirschsprung disease, Mental retardation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 29.6;brain: 54.5" "Cell line enhanced" "Detected in many" "BJ hTERT+: 72.2;BJ hTERT+ SV40 Large T+ RasG12V: 39.7;HeLa: 52.1;RPTEC TERT1: 42.4" "Cancer enhanced" "Detected in many" "melanoma: 34.1" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "memory B-cell: 1.0;naive B-cell: 2.2" "Lineage enriched" "Detected in single" 7 "B-cells: 2.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB010896 Enhanced Approved "Nucleoplasm,Plasma membrane" 59000000 Nucleoplasm "Plasma membrane" "CAB010896: AB_609903" "unprognostic (1.33e-3)" "unprognostic (3.43e-2)" "unprognostic (2.75e-1)" "prognostic unfavourable (8.51e-10)" "unprognostic (2.04e-2)" "prognostic unfavourable (3.81e-4)" "unprognostic (9.44e-2)" "prognostic unfavourable (2.36e-6)" "unprognostic (1.13e-1)" "unprognostic (9.12e-2)" "unprognostic (8.52e-3)" "unprognostic (8.02e-2)" "prognostic unfavourable (1.17e-4)" "unprognostic (3.07e-1)" "unprognostic (6.31e-2)" "unprognostic (1.69e-1)" "unprognostic (7.47e-3)" 4.4 29.6 19.9 8.0 21.9 1.2 1.7 54.5 43.6 2.8 16.3 1.5 2.0 4.9 1.7 3.0 5.3 2.6 3.2 5.2 11.2 20.6 12.3 1.3 1.3 3.7 7.3 22.4 1.4 3.0 1.0 6.1 1.4 19.3 3.5 5.7 6.2 5.9 10.8 1.6 9.9 7.6 6.1 3.5 1.7 4.8 1.5 3.4 0.0 1.2 1.3 2.6 2.3 3.9 2.2 0.0 0.0 0.0 0.0 0.3 0.2 17.6 1.3 5.4 0.0 0.0 0.0 2.3 25.0 72.2 24.2 39.7 7.1 0.1 0.0 23.9 0.1 0.7 0.6 0.4 12.7 0.0 0.1 0.0 52.1 1.1 0.0 0.0 4.0 0.1 0.3 3.6 2.5 0.0 0.0 0.0 0.1 23.9 0.0 0.5 1.2 0.9 0.0 31.7 0.1 42.4 0.3 15.9 10.4 14.0 12.5 10.2 1.3 0.3 0.0 0.0 10.6 1.1 11.9 0.2 0.3 0.1 0.1 0.2 20.3 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 19.9 21.9 54.5 30.2 11.2 20.6 7.3 22.4 19.3 3.4 LAG3 CD223 ENSG00000089692 "Lymphocyte activating 3" P18627 12 6772512-6778455 "CD markers, Predicted membrane proteins, Predicted secreted proteins" "Adaptive immunity, Immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 58.1;ovary: 28.4" "Cell line enriched" "Detected in single" 144 "HDLM-2: 55.8" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in single" "pons and medulla: 2.7" "Cell type enhanced" "Detected in many" "gdT-cell: 11.3;MAIT T-cell: 9.2;memory CD8 T-cell: 10.0" "Lineage enriched" "Detected in single" 56 "T-cells: 11.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB002301, HPA013967" Enhanced "Secreted - unknown location" "CAB002301: AB_564101, HPA013967: AB_1846277" "unprognostic (9.39e-2)" "prognostic favourable (3.89e-4)" "unprognostic (8.88e-2)" "unprognostic (7.00e-3)" "unprognostic (1.08e-1)" "unprognostic (6.74e-3)" "unprognostic (8.85e-2)" "unprognostic (4.63e-3)" "unprognostic (1.94e-2)" "unprognostic (1.97e-3)" "unprognostic (8.71e-2)" "unprognostic (9.93e-2)" "prognostic unfavourable (4.62e-11)" "unprognostic (3.07e-2)" "unprognostic (2.70e-1)" "unprognostic (6.13e-2)" "unprognostic (8.19e-3)" 1.7 0.4 0.3 33.2 0.3 1.0 1.0 0.8 0.7 7.7 4.4 0.5 2.7 2.9 6.4 3.3 2.4 3.8 3.0 2.2 0.3 0.4 1.2 5.9 3.8 12.4 0.4 0.0 28.4 0.4 0.1 1.0 1.3 2.7 2.8 1.8 1.1 2.0 6.8 0.8 0.6 9.6 1.7 0.9 58.1 2.0 6.1 0.1 4.1 1.0 1.3 23.5 2.6 3.6 0.0 0.2 0.0 0.0 0.0 11.3 0.8 0.0 0.2 0.3 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.2 0.0 0.0 55.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.3 0.0 9.2 0.0 2.2 10.0 0.0 0.0 0.6 4.0 0.0 0.0 0.0 0.2 1.7 0.8 0.3 0.3 0.8 0.7 0.3 0.4 0.4 0.0 2.7 0.1 LAIR1 CD305 ENSG00000167613 "Leukocyte associated immunoglobulin like receptor 1" Q6GTX8 19 54351384-54370558 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 39.0" "Group enriched" "Detected in some" 5 "HMC-1: 6.5;Karpas-707: 16.7;THP-1: 19.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" HPA011155 Enhanced Supported "Plasma membrane" 130000 "Plasma membrane" "HPA011155: AB_1852685" "unprognostic (1.91e-1)" "unprognostic (1.12e-2)" "unprognostic (2.81e-2)" "unprognostic (1.25e-2)" "unprognostic (2.03e-2)" "unprognostic (4.38e-2)" "unprognostic (2.16e-2)" "unprognostic (1.74e-1)" "unprognostic (5.00e-2)" "unprognostic (2.24e-1)" "unprognostic (2.21e-1)" "unprognostic (7.11e-2)" "prognostic unfavourable (5.01e-5)" "unprognostic (1.72e-1)" "unprognostic (2.72e-3)" "unprognostic (3.52e-2)" "unprognostic (5.22e-2)" 12.7 7.0 4.5 10.9 9.9 13.5 6.9 0.5 4.5 2.7 5.1 6.7 0.2 2.7 2.2 6.8 2.5 3.6 4.4 3.9 5.2 4.2 3.8 2.9 16.5 33.1 10.2 1.9 2.0 2.4 1.4 2.8 7.0 7.0 3.0 2.0 3.1 3.9 2.2 2.3 2.3 7.6 7.8 11.9 28.6 2.9 3.1 7.4 39.0 2.0 0.5 6.1 3.7 1.7 6.0 10.3 12.4 8.8 5.8 8.0 5.7 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.2 0.0 0.0 0.0 2.7 6.5 0.0 0.0 0.0 0.0 0.0 0.0 16.7 0.0 0.0 2.1 1.5 0.0 0.0 2.1 0.1 2.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 19.0 0.1 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.2 2.6 0.2 12.4 4.2 10.0 8.0 8.3 4.6 2.3 2.4 4.3 0.1 6.0 3.8 4.9 0.6 5.8 8.8 10.3 1.6 5.7 4.5 9.9 0.5 4.5 5.2 4.2 10.2 1.9 7.0 7.4 LAIR2 CD306 ENSG00000167618 "Leukocyte associated immunoglobulin like receptor 2" Q6ISS4 19 54497879-54510687 "CD markers, Predicted intracellular proteins, Predicted secreted proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "blood: 12.8;lymphoid tissue: 19.6;pituitary gland: 7.1;placenta: 15.5" "Group enriched" "Detected in some" 5 "BEWO: 6.8;Hep G2: 3.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 4 "T-reg: 12.8" "Lineage enriched" "Detected in single" 21 "T-cells: 12.8" "Secreted - unknown location" "unprognostic (1.99e-3)" "unprognostic (7.49e-2)" "unprognostic (4.19e-2)" "unprognostic (1.02e-2)" "unprognostic (1.42e-1)" "unprognostic (4.86e-4)" "unprognostic (1.06e-2)" "unprognostic (8.37e-2)" "unprognostic (1.16e-1)" "unprognostic (3.93e-1)" "unprognostic (2.21e-1)" "unprognostic (9.52e-2)" "unprognostic (3.68e-9)" "unprognostic (1.21e-2)" "unprognostic (3.15e-3)" "unprognostic (3.40e-5)" "unprognostic (6.71e-2)" 0.9 0.5 0.6 5.9 1.7 1.6 0.5 0.2 1.3 0.4 0.6 1.3 0.0 0.4 0.5 1.3 0.7 0.5 1.3 0.4 1.4 3.0 0.6 0.8 3.2 12.3 0.6 0.5 0.2 0.9 0.1 7.1 15.5 1.3 0.8 1.3 0.4 0.5 0.4 0.6 0.5 1.2 0.5 1.5 6.6 1.0 1.2 0.4 19.6 0.5 0.0 2.0 0.3 0.3 0.0 0.0 0.1 0.1 0.6 12.8 1.8 0.0 0.0 0.0 0.0 0.0 0.0 6.8 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 3.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.7 0.3 0.1 0.0 1.0 0.0 0.0 0.1 0.0 0.2 0.0 0.4 0.0 3.0 2.0 0.0 0.0 0.8 2.7 0.1 0.6 0.1 0.0 12.8 1.8 0.6 1.7 0.2 1.3 1.4 3.0 0.6 0.5 1.3 0.4 LAMP1 CD107a ENSG00000185896 "Lysosomal associated membrane protein 1" P11279 13 113297241-113323672 "CD markers, Plasma proteins, Predicted membrane proteins, Transporters" "Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004260, HPA014750" Supported 460000000 "CAB004260: AB_626851, HPA014750: AB_1846219" "unprognostic (3.98e-1)" "unprognostic (1.18e-1)" "unprognostic (7.55e-2)" "unprognostic (1.37e-1)" "unprognostic (1.04e-1)" "unprognostic (7.04e-3)" "unprognostic (9.26e-2)" "unprognostic (1.07e-1)" "unprognostic (5.80e-2)" "unprognostic (1.44e-2)" "unprognostic (2.91e-3)" "unprognostic (2.04e-1)" "prognostic favourable (4.15e-5)" "unprognostic (2.06e-2)" "unprognostic (2.22e-1)" "unprognostic (2.59e-1)" "unprognostic (1.54e-1)" 61.3 41.9 34.6 36.7 44.7 28.5 70.7 17.6 50.6 50.4 39.0 77.9 46.7 49.9 55.7 73.4 50.6 38.1 60.8 45.0 38.0 30.7 61.2 83.3 74.6 78.1 64.3 42.3 44.4 79.5 38.2 43.7 68.6 42.1 47.0 31.3 30.1 60.6 47.8 26.6 72.0 46.7 43.3 67.6 46.2 43.6 41.6 57.3 34.9 59.5 43.1 37.0 47.6 48.1 3.1 7.6 12.2 7.0 5.4 6.5 2.7 43.5 15.2 15.8 43.1 88.8 33.5 29.8 51.5 54.3 32.1 43.1 29.6 81.5 10.3 23.6 52.3 56.0 15.4 32.7 22.0 21.5 25.5 17.0 30.1 27.8 46.0 51.9 39.9 40.8 44.7 29.7 19.5 38.7 14.1 15.2 39.4 17.5 10.4 25.4 11.9 16.6 15.5 13.7 15.5 29.1 33.0 14.5 15.2 30.3 45.0 29.7 43.4 37.0 58.5 33.0 35.9 43.5 22.9 28.6 28.2 11.0 55.1 51.9 38.2 3.8 7.0 12.2 5.9 5.3 5.0 3.1 4.6 6.5 3.5 3.0 5.2 4.3 9.2 5.4 5.8 7.6 4.6 2.7 34.6 44.7 17.6 50.6 38.0 30.7 64.3 42.3 42.1 57.3 LAMP2 CD107b ENSG00000005893 "Lysosomal associated membrane protein 2" P13473 X 120427827-120469365 "CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" Autophagy "Disease mutation, Glycogen storage disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC diff: 113.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 112.9" "Lineage enriched" "Detected in all" 5 "granulocytes: 112.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005272, HPA029100, HPA029101" Supported Approved "Vesicles,Plasma membrane" 820000000 "Vesicles, Plasma membrane" "CAB005272: AB_647855, HPA029100: AB_10795022, HPA029101: " "unprognostic (2.99e-3)" "unprognostic (5.26e-2)" "unprognostic (2.66e-3)" "unprognostic (1.74e-1)" "unprognostic (3.10e-1)" "unprognostic (2.50e-2)" "unprognostic (4.84e-1)" "unprognostic (1.56e-1)" "unprognostic (1.15e-1)" "unprognostic (1.55e-1)" "unprognostic (9.73e-2)" "unprognostic (1.11e-2)" "unprognostic (2.50e-2)" "unprognostic (2.85e-1)" "unprognostic (6.78e-2)" "unprognostic (2.66e-1)" "unprognostic (5.53e-3)" 21.8 33.6 39.9 16.1 87.9 22.6 27.1 16.2 55.5 33.0 18.3 88.7 27.9 25.1 20.8 37.5 34.6 22.4 43.3 20.9 52.5 30.3 55.0 83.7 25.3 14.3 131.0 36.9 22.7 27.4 28.8 20.2 35.4 58.6 37.3 19.7 17.2 47.8 32.9 32.4 26.9 20.5 21.1 84.3 17.9 23.6 11.9 116.9 21.2 33.7 14.3 15.4 21.1 27.0 3.7 11.6 112.9 21.7 5.4 5.8 10.5 11.8 11.7 8.6 11.1 113.5 38.8 23.9 20.5 35.8 20.0 37.4 9.7 21.2 8.4 18.1 35.6 20.0 12.5 15.5 32.6 9.4 8.9 6.6 13.0 13.0 37.8 29.0 18.4 42.0 31.2 26.6 17.6 27.2 7.6 30.0 32.3 21.9 8.0 14.8 6.7 10.4 6.2 14.6 15.0 29.2 8.8 2.9 4.6 22.0 22.4 43.8 13.3 32.4 28.1 28.7 13.9 36.9 55.3 15.1 14.4 5.5 27.4 35.1 68.7 4.9 21.7 41.3 5.0 18.7 4.0 3.1 4.8 4.7 11.6 3.7 4.3 4.1 112.9 5.4 17.3 6.3 5.8 10.5 39.9 87.9 16.2 55.5 52.5 30.3 131.0 36.9 58.6 116.9 LAMP3 "CD208, DC-LAMP, DCLAMP, LAMP, TSC403" ENSG00000078081 "Lysosomal associated membrane protein 3" Q9UQV4 3 183122213-183163839 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "lung: 123.9" "Group enriched" "Detected in some" 6 "EFO-21: 57.2;HDLM-2: 14.5;HHSteC: 21.2;hTCEpi: 19.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "eosinophil: 7.6" "Group enriched" "Detected in many" 8 "granulocytes: 7.6;T-cells: 6.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB025133, HPA051467" Enhanced Enhanced Vesicles 47000 Vesicles "CAB025133: , HPA051467: " "unprognostic (1.43e-3)" "unprognostic (2.06e-2)" "unprognostic (1.70e-1)" "unprognostic (2.99e-3)" "unprognostic (1.30e-2)" "unprognostic (2.15e-1)" "unprognostic (7.67e-2)" "unprognostic (8.64e-2)" "unprognostic (4.95e-2)" "prognostic favourable (9.90e-4)" "unprognostic (1.80e-3)" "unprognostic (5.80e-2)" "prognostic unfavourable (1.89e-7)" "unprognostic (3.12e-1)" "unprognostic (4.13e-2)" "unprognostic (8.35e-2)" "unprognostic (1.29e-1)" 0.5 0.7 0.4 14.1 0.4 0.0 0.5 0.3 0.4 1.0 0.6 0.1 0.6 0.4 0.4 1.0 2.5 0.5 0.8 0.4 0.4 0.4 0.8 0.6 123.9 11.2 0.4 0.1 0.4 8.3 0.0 0.6 1.0 0.6 1.0 1.7 0.2 6.8 1.9 0.4 1.9 1.4 0.8 0.5 2.0 0.8 8.4 0.0 21.3 8.3 3.1 11.3 3.3 0.9 0.4 0.0 7.6 0.1 0.8 6.6 1.1 3.4 0.1 0.0 0.5 0.0 0.0 2.8 0.0 0.9 0.6 0.1 0.8 1.8 0.0 57.2 0.2 0.5 1.2 2.1 0.1 14.5 1.7 0.0 0.1 0.1 21.2 0.0 0.5 0.3 19.4 0.0 2.5 2.6 0.1 3.4 0.1 0.0 0.8 0.1 0.1 0.8 0.0 0.0 0.2 0.0 1.1 0.2 0.1 0.2 0.1 1.5 1.1 0.1 2.7 0.0 1.0 0.1 0.0 1.2 4.3 0.1 0.0 0.0 0.0 0.4 0.1 7.6 0.4 0.0 3.2 0.1 2.7 1.7 0.0 0.4 3.5 2.0 1.9 0.8 0.1 0.0 6.6 1.1 0.4 0.4 0.3 0.4 0.4 0.4 0.4 0.1 0.6 0.0 LEPR "CD295, OBR" ENSG00000116678 "Leptin receptor" P48357 1 65420652-65641559 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" Receptor "Cancer-related genes, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 82.8" "Cell line enhanced" "Detected in many" "K-562: 46.1;RPTEC TERT1: 22.3" "Cancer enriched" "Detected in many" 7 "liver cancer: 13.1" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 6.9" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" HPA030899 Approved Supported "Secreted to blood" 8235000 8300000 "HPA030899: AB_10610003" "unprognostic (1.59e-2)" "unprognostic (1.09e-3)" "unprognostic (3.09e-1)" "unprognostic (8.95e-2)" "unprognostic (2.32e-1)" "unprognostic (2.64e-1)" "unprognostic (2.58e-1)" "unprognostic (2.30e-1)" "unprognostic (1.78e-1)" "unprognostic (6.59e-3)" "unprognostic (1.79e-1)" "unprognostic (2.41e-1)" "unprognostic (7.53e-2)" "unprognostic (1.11e-1)" "unprognostic (2.27e-1)" "unprognostic (3.49e-2)" "unprognostic (1.73e-1)" 15.9 5.5 3.8 3.7 4.3 3.3 23.5 2.5 3.9 15.0 9.2 5.6 5.4 3.2 20.6 7.3 10.9 11.7 10.1 9.2 4.3 4.9 14.6 82.8 20.3 9.0 4.9 3.3 18.4 16.7 3.9 13.1 12.8 8.2 10.8 4.1 18.1 12.0 5.7 5.6 10.2 7.3 12.9 7.0 6.4 11.9 6.6 3.1 1.9 13.1 11.2 6.9 13.6 8.6 0.6 1.8 6.9 1.9 1.1 2.3 1.8 1.3 0.8 1.1 1.2 5.0 4.6 3.8 5.9 3.4 2.0 1.9 0.6 3.2 0.5 4.4 7.4 1.1 0.9 5.1 5.5 6.9 1.5 7.7 3.5 0.1 3.0 0.5 0.6 13.0 3.0 1.2 4.6 5.8 46.1 0.9 9.5 0.3 0.6 0.1 1.8 0.1 0.1 0.9 0.3 22.3 0.6 0.7 11.3 1.4 0.6 1.6 2.1 2.0 2.2 2.1 4.3 0.4 3.2 1.3 0.8 0.2 4.4 2.2 2.0 6.9 1.9 2.8 1.3 1.5 1.3 0.6 1.1 1.1 1.8 0.3 0.9 1.5 1.1 1.1 1.7 1.2 2.3 1.8 3.8 4.3 2.5 3.9 4.3 4.9 4.9 3.3 8.2 3.1 LIFR CD118 ENSG00000113594 "LIF receptor alpha" P42702 5 38474963-38608354 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 39.8;HHSteC: 17.0;SCLC-21H: 26.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004478, CAB010252" Approved "Nuclear speckles,Golgi apparatus" "Intracellular and membrane" 74000 "Nuclear speckles" "Golgi apparatus" "CAB010252: AB_2128043, HPA004478: " "unprognostic (6.00e-3)" "unprognostic (2.53e-1)" "unprognostic (1.05e-1)" "unprognostic (2.81e-3)" "unprognostic (8.80e-2)" "unprognostic (7.13e-2)" "unprognostic (1.11e-1)" "prognostic favourable (1.92e-4)" "unprognostic (1.78e-1)" "unprognostic (9.80e-2)" "unprognostic (2.73e-3)" "unprognostic (1.06e-1)" "prognostic favourable (1.40e-7)" "unprognostic (3.69e-2)" "unprognostic (1.15e-1)" "unprognostic (2.03e-2)" "unprognostic (1.65e-1)" 35.3 14.7 15.8 8.2 19.2 0.5 33.9 10.1 21.3 27.7 10.4 25.3 22.8 4.9 34.8 14.8 10.4 26.0 10.2 16.3 19.1 11.0 20.3 23.9 21.7 20.2 24.3 11.8 17.9 17.8 13.5 12.5 41.5 23.4 23.6 7.5 17.1 24.9 24.7 24.0 10.5 11.7 26.9 21.4 22.5 18.8 9.3 25.3 4.7 31.4 7.3 8.1 13.6 15.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 2.2 39.8 3.0 11.2 12.4 0.3 3.3 1.9 2.7 1.6 0.4 2.1 0.0 0.5 4.7 0.3 2.6 0.9 4.6 0.0 3.6 0.0 4.2 1.5 17.0 0.0 0.2 10.4 0.7 6.5 0.7 3.7 1.0 6.4 3.3 0.5 0.0 0.1 1.0 7.1 0.0 8.4 0.0 2.6 1.0 26.1 3.2 13.7 0.6 0.0 0.9 0.0 0.7 4.3 8.5 10.1 2.0 0.0 0.0 0.0 7.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.8 19.2 10.1 21.3 19.1 11.0 24.3 11.8 23.4 25.3 LILRA1 "CD85i, LIR-6, LIR6" ENSG00000104974 "Leukocyte immunoglobulin like receptor A1" O75019 19 54593582-54602090 "CD markers, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "blood: 22.2;lymphoid tissue: 21.0" "Cell line enhanced" "Detected in some" "REH: 1.2;THP-1: 2.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "intermediate monocyte: 17.9;non-classical monocyte: 22.2" "Low lineage specificity" "Detected in many" "unprognostic (4.52e-2)" "unprognostic (1.12e-1)" "unprognostic (6.30e-2)" "unprognostic (1.59e-1)" "unprognostic (2.34e-1)" "unprognostic (9.46e-3)" "unprognostic (1.17e-1)" "unprognostic (4.07e-2)" "unprognostic (1.12e-1)" "unprognostic (4.90e-2)" "unprognostic (8.72e-2)" "unprognostic (1.13e-1)" "unprognostic (8.28e-3)" "unprognostic (8.82e-2)" "unprognostic (3.79e-4)" "unprognostic (2.53e-1)" "unprognostic (9.83e-2)" 0.7 0.9 1.0 3.7 1.7 1.0 0.6 0.2 1.3 0.5 0.3 1.1 0.0 0.4 0.2 1.7 0.6 0.5 1.0 0.6 0.9 0.8 0.5 2.1 2.4 18.8 1.5 0.5 0.4 0.4 0.6 0.3 0.8 1.6 0.4 0.7 0.8 1.0 0.3 0.5 0.3 1.0 0.5 2.2 21.0 0.5 0.3 1.1 0.1 0.4 0.4 0.9 0.9 0.2 0.0 5.4 6.1 22.2 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 7.4 6.1 0.0 17.9 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 5.3 0.0 22.2 0.7 0.0 4.2 1.0 1.7 0.2 1.3 0.9 0.8 1.5 0.5 1.6 1.1 LILRA2 "CD85h, ILT1, LIR-7, LIR7" ENSG00000239998 "Leukocyte immunoglobulin like receptor A2" Q8N149 19 54572920-54590287 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Immunity, Innate immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 21.6;bone marrow: 21.7;lymphoid tissue: 39.9" "Cell line enhanced" "Detected in some" "NB-4: 2.5;REH: 2.9;THP-1: 5.9;U-937: 13.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 21.6" "Group enriched" "Detected in many" 7 "granulocytes: 21.6;monocytes: 7.1" "Secreted to blood" 130000000 "unprognostic (2.04e-1)" "unprognostic (7.72e-2)" "unprognostic (6.94e-2)" "unprognostic (1.78e-1)" "unprognostic (1.54e-2)" "unprognostic (2.65e-2)" "unprognostic (8.45e-2)" "unprognostic (3.56e-2)" "unprognostic (1.22e-1)" "unprognostic (3.53e-5)" "unprognostic (2.67e-1)" "unprognostic (1.12e-1)" "unprognostic (5.43e-2)" "unprognostic (5.58e-2)" "unprognostic (3.30e-4)" "unprognostic (4.21e-2)" "unprognostic (6.59e-2)" 2.8 1.5 1.4 4.7 1.1 21.7 0.9 0.1 2.0 0.6 0.8 3.0 0.0 0.6 0.5 1.0 0.5 2.3 1.0 3.7 1.1 1.1 1.2 3.8 6.8 14.6 2.9 0.4 1.1 0.6 0.5 0.4 1.7 1.4 0.6 0.6 1.1 0.8 0.5 0.6 0.7 0.7 1.0 3.7 39.9 0.7 0.7 2.3 0.7 0.6 0.0 0.8 0.9 1.8 0.2 2.1 21.6 7.1 0.3 0.1 3.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.4 0.3 0.0 0.0 0.1 0.0 0.0 0.1 0.3 0.0 0.0 0.1 2.5 0.0 0.0 2.9 0.1 1.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 5.9 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 13.3 0.1 2.4 4.9 1.8 0.1 7.1 0.0 0.1 0.1 0.1 2.1 0.2 0.1 0.1 21.6 0.3 6.8 0.4 0.0 3.0 1.4 1.1 0.1 2.0 1.1 1.1 2.9 0.4 1.4 2.3 LILRA4 "CD85g, ILT7" ENSG00000239961 "Leukocyte immunoglobulin like receptor A4" P59901 19 54333185-54339150 "CD markers, Predicted membrane proteins" "Immunity, Innate immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 13 "blood: 49.7;brain: 12.5;lymphoid tissue: 16.8" "Cell line enriched" "Detected in single" 30 "RPMI-8226: 3.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 21 "plasmacytoid DC: 49.7" "Lineage enriched" "Detected in many" 21 "dendritic cells: 49.7" HPA049418 Approved "HPA049418: " "unprognostic (5.11e-2)" "unprognostic (1.21e-4)" "unprognostic (2.65e-2)" "unprognostic (5.94e-2)" "unprognostic (1.44e-1)" "unprognostic (1.19e-3)" "unprognostic (7.62e-2)" "unprognostic (1.36e-3)" "unprognostic (1.08e-1)" "unprognostic (9.46e-2)" "unprognostic (4.90e-2)" "unprognostic (9.30e-2)" "unprognostic (8.28e-7)" "unprognostic (2.12e-2)" "unprognostic (1.17e-3)" "unprognostic (4.53e-1)" "unprognostic (5.86e-2)" 0.7 0.4 2.1 2.3 2.5 0.6 0.7 1.1 4.3 0.4 0.9 12.5 0.0 0.7 0.4 0.4 0.6 0.4 0.8 0.4 3.5 1.4 0.4 0.7 1.4 5.3 12.2 1.2 0.4 0.4 0.4 0.3 0.4 7.6 0.5 0.5 0.0 0.7 0.5 0.4 0.6 2.0 0.6 7.4 16.8 0.5 0.5 6.7 2.3 0.4 0.0 10.1 0.7 0.2 2.4 49.7 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.2 1.2 0.0 0.0 0.0 0.1 0.0 49.7 0.0 0.1 2.1 2.5 1.1 4.3 3.5 1.4 12.2 1.2 7.6 6.7 LILRA5 "CD85, CD85f, ILT11, LILRB7, LIR9" ENSG00000187116 "Leukocyte immunoglobulin like receptor A5" A6NI73 19 54307070-54313139 "CD markers, Predicted membrane proteins, Predicted secreted proteins" "Immunity, Innate immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 30.2;lymphoid tissue: 67.3" "Cell line enriched" "Detected in single" 11 "RPMI-8226: 4.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 8 "classical monocyte: 10.6;intermediate monocyte: 27.0;neutrophil: 14.5;non-classical monocyte: 30.2" "Group enriched" "Detected in many" 8 "granulocytes: 14.5;monocytes: 30.2" "Secreted to blood" 370000 "unprognostic (8.52e-2)" "unprognostic (3.61e-1)" "unprognostic (2.23e-1)" "unprognostic (1.77e-1)" "unprognostic (1.57e-2)" "unprognostic (6.56e-2)" "unprognostic (2.90e-1)" "unprognostic (1.86e-1)" "unprognostic (3.11e-1)" "unprognostic (6.61e-3)" "unprognostic (2.01e-1)" "unprognostic (1.50e-1)" "prognostic unfavourable (7.78e-4)" "unprognostic (3.61e-2)" "unprognostic (6.51e-3)" "unprognostic (4.68e-2)" "unprognostic (6.21e-2)" 3.4 0.6 0.3 9.9 0.3 19.1 0.7 0.1 0.3 0.4 0.6 0.1 0.0 0.8 0.4 2.0 0.6 2.0 0.9 7.0 0.2 0.2 1.7 10.8 14.4 24.2 0.5 0.0 1.5 0.4 0.1 0.4 1.3 0.6 0.6 0.7 0.6 0.5 0.3 0.9 0.1 1.8 1.3 0.7 67.3 1.0 0.6 0.0 0.1 1.4 0.4 0.4 2.7 2.8 0.0 2.6 14.5 30.2 0.0 0.0 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 10.6 0.0 0.0 27.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 14.5 0.0 30.2 2.1 0.0 5.1 0.3 0.3 0.1 0.3 0.2 0.2 0.5 0.0 0.6 0.0 LILRB2 "CD85d, ILT4, LIR-2, LIR2, MIR-10, MIR10" ENSG00000131042 "Leukocyte immunoglobulin like receptor B2" Q8N423 19 54273821-54281184 "CD markers, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 37.9;bone marrow: 30.3;lymphoid tissue: 31.9" "Cell line enhanced" "Detected in single" "THP-1: 1.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "classical monocyte: 15.9;intermediate monocyte: 33.8;neutrophil: 16.7;non-classical monocyte: 37.9" "Group enriched" "Detected in many" 5 "granulocytes: 16.7;monocytes: 37.9" 52000000 "unprognostic (1.23e-1)" "unprognostic (1.12e-2)" "unprognostic (3.21e-2)" "unprognostic (3.51e-2)" "unprognostic (6.21e-3)" "unprognostic (1.70e-2)" "unprognostic (1.44e-2)" "unprognostic (2.94e-1)" "unprognostic (1.08e-2)" "unprognostic (2.98e-2)" "unprognostic (2.64e-1)" "unprognostic (2.15e-1)" "prognostic unfavourable (5.45e-7)" "unprognostic (1.90e-2)" "unprognostic (4.68e-3)" "unprognostic (3.72e-1)" "unprognostic (9.73e-2)" 3.2 1.4 0.4 6.8 0.6 30.3 1.0 0.3 1.9 0.5 1.1 0.6 0.4 3.3 0.6 0.9 0.5 2.3 6.6 1.5 1.6 0.4 1.5 3.6 18.4 4.9 2.6 0.0 0.4 0.7 0.2 0.7 0.7 1.8 0.9 1.0 1.1 7.4 2.6 0.5 0.4 1.5 0.6 3.4 31.9 1.0 0.3 0.8 0.8 0.6 5.0 0.7 0.6 1.9 0.0 5.3 16.7 37.9 0.0 0.1 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 15.9 4.2 0.0 33.8 0.1 0.0 0.0 0.0 5.3 0.0 0.0 0.0 16.7 0.0 37.9 2.2 0.1 8.1 0.4 0.6 0.3 1.9 1.6 0.4 2.6 0.0 1.8 0.8 LILRB3 "CD85a, HL9, ILT5, LIR-3, LIR3, PIR-B, PIRB" ENSG00000204577 "Leukocyte immunoglobulin like receptor B3" O75022 19 54216278-54223506 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 24.4;bone marrow: 15.3;lymphoid tissue: 23.4" "Cell line enhanced" "Detected in some" "HaCaT: 1.8;HEK 293: 2.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "neutrophil: 24.4" "Group enriched" "Detected in many" 4 "granulocytes: 24.4;monocytes: 9.4" "unprognostic (7.51e-2)" "unprognostic (3.52e-2)" "unprognostic (9.59e-2)" "unprognostic (4.53e-1)" "unprognostic (1.83e-3)" "unprognostic (5.28e-3)" "unprognostic (2.91e-2)" "unprognostic (2.55e-1)" "unprognostic (5.58e-2)" "unprognostic (2.35e-1)" "unprognostic (1.43e-1)" "unprognostic (1.63e-1)" "unprognostic (1.92e-8)" "unprognostic (2.18e-1)" "unprognostic (2.19e-3)" "unprognostic (1.84e-1)" "unprognostic (1.75e-1)" 5.1 0.8 0.4 8.9 1.0 15.3 0.8 0.4 0.5 0.7 1.6 0.0 0.2 0.2 0.6 2.5 0.7 1.3 1.1 7.8 1.5 0.6 0.7 1.5 10.9 19.7 0.5 0.0 3.0 1.7 0.0 0.5 2.0 0.6 0.9 0.0 1.0 0.8 0.0 1.7 0.6 0.9 0.9 2.2 23.4 0.8 0.7 0.0 0.3 1.5 0.0 0.1 6.4 1.1 0.1 4.0 24.4 9.4 0.0 0.1 4.5 1.5 0.6 0.4 0.8 0.0 0.0 0.5 1.6 0.0 0.0 0.0 1.0 0.0 0.0 0.4 0.0 1.8 0.0 0.0 0.0 0.4 2.5 1.0 0.6 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.4 0.0 1.1 0.5 0.6 0.2 0.0 0.0 0.9 1.6 0.0 0.0 0.6 0.1 1.5 0.0 0.0 0.7 0.8 0.0 0.0 0.5 0.3 0.0 0.3 0.9 0.0 0.4 9.4 0.3 0.0 7.5 0.1 0.1 0.1 0.0 4.0 0.1 0.0 0.0 24.4 0.0 3.3 0.4 0.0 4.5 0.4 1.0 0.4 0.5 1.5 0.6 0.5 0.0 0.6 0.0 LILRB4 "CD85k, HM18, ILT3, LIR-5, LIR5" ENSG00000186818 "Leukocyte immunoglobulin like receptor B4" Q8NHJ6 19 54643889-54670359 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 22.8;lymphoid tissue: 33.1" "Cell line enriched" "Detected in some" 35 "Karpas-707: 94.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 22.8" "Group enriched" "Detected in many" 69 "dendritic cells: 22.8;monocytes: 6.2" HPA052807 Approved 9900 "HPA052807: " "unprognostic (4.09e-2)" "unprognostic (5.75e-3)" "unprognostic (6.06e-2)" "unprognostic (1.91e-2)" "unprognostic (1.82e-1)" "unprognostic (1.55e-1)" "unprognostic (5.03e-2)" "unprognostic (3.53e-1)" "unprognostic (4.13e-2)" "unprognostic (1.52e-1)" "unprognostic (5.43e-1)" "unprognostic (2.79e-1)" "unprognostic (1.91e-2)" "unprognostic (1.08e-1)" "unprognostic (4.42e-2)" "unprognostic (4.51e-2)" "unprognostic (4.52e-2)" 15.4 4.3 5.1 20.1 7.4 4.5 3.1 0.8 5.9 1.6 3.6 12.8 0.0 4.0 1.0 4.7 2.1 4.2 4.4 3.9 5.3 5.3 3.1 3.9 12.3 33.1 10.8 1.9 1.7 1.6 1.5 2.4 4.2 6.6 1.7 5.5 2.9 3.8 1.4 0.8 0.9 5.4 2.1 15.1 18.0 2.8 1.3 6.9 3.1 2.3 0.7 6.1 13.8 0.8 0.2 22.8 0.1 6.2 0.1 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 94.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.3 2.7 0.0 0.0 0.0 0.0 0.0 4.5 0.0 0.0 6.2 0.0 0.1 0.0 0.0 7.0 0.2 0.0 0.0 0.1 0.1 4.8 22.8 0.0 1.8 5.1 7.4 0.8 4.5 5.3 5.3 10.8 1.9 6.6 6.9 LILRB5 "CD85c, LIR-8, LIR8" ENSG00000105609 "Leukocyte immunoglobulin like receptor B5" O75023 19 54249431-54257301 "CD markers, Plasma proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 31.0;lymphoid tissue: 35.1" "Cell line enhanced" "Detected in some" "SiHa: 2.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" HPA012069 Approved 36000000 "HPA012069: AB_1852873" "unprognostic (3.55e-3)" "unprognostic (5.38e-2)" "unprognostic (2.20e-2)" "unprognostic (7.03e-2)" "unprognostic (8.86e-2)" "unprognostic (5.44e-2)" "unprognostic (3.02e-5)" "unprognostic (6.80e-2)" "unprognostic (2.23e-1)" "unprognostic (2.33e-1)" "unprognostic (9.95e-2)" "unprognostic (8.68e-2)" "unprognostic (3.31e-1)" "unprognostic (2.07e-1)" "unprognostic (4.14e-2)" "unprognostic (1.42e-2)" "unprognostic (1.73e-1)" 23.6 8.3 0.7 5.4 0.8 0.8 31.0 0.6 0.6 2.1 11.9 0.5 1.6 5.2 1.2 16.2 5.8 4.9 6.2 10.0 0.7 0.8 2.1 22.8 8.6 13.3 0.8 0.0 4.1 2.7 0.7 1.0 5.6 0.7 4.0 5.5 3.6 2.9 1.1 6.1 2.0 9.0 5.9 0.9 35.1 2.4 3.9 0.0 1.2 2.6 4.9 1.3 10.6 1.8 0.9 0.7 3.1 0.9 0.9 0.5 0.3 0.4 0.0 0.8 0.5 0.1 0.1 1.0 1.0 0.3 0.4 0.0 0.3 0.6 0.2 0.4 0.1 1.4 0.3 0.5 0.0 0.5 0.9 1.1 1.7 0.4 0.5 0.6 0.6 0.5 0.3 0.1 0.3 0.5 0.6 1.0 0.2 0.0 0.3 0.3 0.6 0.0 0.6 0.7 0.6 0.2 0.8 0.5 0.9 2.3 0.8 0.7 0.7 0.0 0.3 0.8 0.7 0.5 0.6 0.3 1.1 0.1 0.4 0.3 0.2 3.1 0.9 0.4 0.4 0.6 0.3 0.4 0.5 0.3 0.3 0.9 0.4 0.4 2.3 0.9 0.8 0.7 0.3 0.3 0.7 0.8 0.6 0.6 0.7 0.8 0.8 0.0 0.7 0.0 LRP1 "A2MR, APOER, APR, CD91, IGFBP-3R, IGFBP3R1, LRP, LRP1A" ENSG00000123384 "LDL receptor related protein 1" Q07954 12 57128493-57213351 "Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis "Developmental protein, Receptor" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 82.6;ASC TERT1: 83.9;fHDF/TERT166: 36.0;HSkMC: 54.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 18 "classical monocyte: 7.6;intermediate monocyte: 4.0;myeloid DC: 2.8;non-classical monocyte: 3.7" "Group enriched" "Detected in many" 20 "dendritic cells: 2.8;monocytes: 7.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004182, CAB018621, HPA022903" Supported Approved Nucleoplasm,Vesicles "Intracellular and membrane" 88000000 Vesicles Nucleoplasm "CAB018621: AB_627893, HPA004182: , HPA022903: AB_10602426" "unprognostic (1.65e-1)" "unprognostic (1.61e-1)" "unprognostic (1.76e-1)" "unprognostic (2.71e-1)" "unprognostic (5.00e-2)" "unprognostic (4.33e-2)" "unprognostic (3.98e-1)" "unprognostic (8.68e-2)" "unprognostic (1.70e-1)" "unprognostic (3.37e-3)" "unprognostic (1.48e-1)" "unprognostic (1.25e-1)" "prognostic unfavourable (1.52e-5)" "unprognostic (2.81e-3)" "unprognostic (6.13e-2)" "unprognostic (2.80e-2)" "prognostic unfavourable (1.29e-5)" 77.8 12.0 19.8 21.5 21.3 6.1 27.7 28.1 25.3 31.4 19.7 11.9 9.0 17.8 26.9 18.2 19.2 21.0 24.1 26.0 18.6 10.4 6.3 31.4 24.7 5.5 13.9 15.6 56.9 8.8 8.5 8.0 29.4 17.1 21.4 9.5 20.0 14.8 17.0 11.3 15.7 14.2 22.4 14.3 11.3 11.8 11.1 15.4 0.3 13.2 9.3 3.1 22.9 39.4 0.0 2.8 0.1 7.6 0.0 0.2 1.9 1.2 2.3 5.0 4.0 82.6 83.9 15.2 13.9 18.0 4.6 4.5 4.3 2.0 0.0 1.7 36.0 5.5 0.8 1.4 1.6 0.1 0.2 0.0 2.7 9.0 11.3 0.0 2.4 54.3 0.5 10.3 1.2 0.2 0.0 0.2 14.3 0.2 0.0 0.0 5.8 1.4 0.5 28.6 0.2 0.3 0.3 0.2 2.7 3.1 0.1 2.2 0.4 0.2 0.2 16.1 6.0 8.9 0.8 0.1 0.0 0.0 28.2 0.0 3.0 0.0 7.6 0.0 0.0 4.0 0.0 0.0 0.1 0.0 2.8 0.0 0.0 0.2 0.1 0.0 3.7 0.0 0.0 1.9 19.8 21.3 28.1 19.7 18.6 10.4 13.9 15.6 17.1 15.4 LY75 "CD205, CLEC13B, DEC-205" ENSG00000054219 "Lymphocyte antigen 75" O60449 2 159803355-159904749 "CD markers, Predicted membrane proteins" Endocytosis Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "intestine: 28.8;lymphoid tissue: 61.9" "Cell line enhanced" "Detected in many" "CAPAN-2: 10.3;HDLM-2: 9.7;Karpas-707: 41.3;RT4: 14.0;THP-1: 10.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "CAB001450, HPA049108, HPA054073" Enhanced Approved "Golgi apparatus" 960000 "Golgi apparatus" "CAB001450: AB_563525, HPA049108: , HPA054073: " "unprognostic (7.29e-3)" "unprognostic (1.92e-3)" "unprognostic (3.15e-1)" "unprognostic (1.52e-2)" "unprognostic (4.60e-3)" "unprognostic (3.65e-2)" "unprognostic (8.87e-2)" "unprognostic (6.24e-2)" "unprognostic (2.80e-1)" "unprognostic (2.36e-1)" "unprognostic (8.74e-3)" "unprognostic (3.92e-1)" "prognostic unfavourable (2.39e-5)" "unprognostic (2.66e-1)" "unprognostic (4.89e-2)" "unprognostic (1.94e-2)" "prognostic favourable (3.86e-4)" 3.5 1.8 1.9 21.4 2.6 4.9 6.1 1.2 1.8 4.5 9.3 2.0 1.0 10.8 2.1 1.9 4.5 5.0 10.7 2.8 1.8 1.7 2.8 1.2 10.3 33.9 2.5 1.1 1.6 2.3 0.2 1.9 0.8 2.4 2.0 7.2 1.3 7.2 1.3 0.8 6.5 28.8 1.3 3.4 17.2 3.8 1.1 3.0 61.9 10.7 3.6 17.1 6.9 3.8 5.8 4.3 5.9 2.6 7.5 8.0 2.3 1.6 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 4.1 10.3 7.1 0.3 0.0 0.2 0.0 0.0 0.0 9.7 0.0 2.0 0.0 0.0 0.2 1.6 0.0 0.1 0.0 0.2 0.1 5.3 0.0 41.3 0.0 0.0 0.0 2.6 0.2 0.0 2.7 0.0 1.7 3.1 14.0 0.0 0.0 3.3 2.4 0.0 0.0 10.4 7.9 0.0 0.0 0.0 0.0 6.3 1.0 1.4 0.0 3.6 0.0 3.4 2.0 3.5 6.5 2.6 7.1 5.8 5.9 7.5 4.3 4.5 6.7 8.0 5.9 7.5 1.0 1.5 4.3 2.3 1.9 2.6 1.2 1.8 1.8 1.7 2.5 1.1 2.4 3.0 LY9 "CD229, hly9, mLY9, SLAMF3" ENSG00000122224 "Lymphocyte antigen 9" Q9HBG7 1 160796074-160828261 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Cell adhesion, Immunity, Innate immunity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 30.8;intestine: 11.3;lymphoid tissue: 43.7;urinary bladder: 28.6" "Cell line enhanced" "Detected in some" "Daudi: 7.2;Karpas-707: 14.6;U-266/70: 37.2;U-266/84: 14.3" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "gdT-cell: 30.6;MAIT T-cell: 30.7;memory B-cell: 15.2;memory CD4 T-cell: 26.8;memory CD8 T-cell: 29.6;naive B-cell: 13.9;naive CD4 T-cell: 30.5;naive CD8 T-cell: 30.8;plasmacytoid DC: 18.6;T-reg: 19.7" "Group enriched" "Detected in many" 4 "B-cells: 15.2;dendritic cells: 18.6;T-cells: 30.8" "Low region specificity" "Detected in single" "Not detected" "Not detected" HPA050917 Approved 23000 "HPA050917: " "unprognostic (8.04e-4)" "unprognostic (2.31e-5)" "unprognostic (8.08e-3)" "unprognostic (1.20e-3)" "unprognostic (9.83e-3)" "unprognostic (1.87e-5)" "unprognostic (1.16e-2)" "unprognostic (3.84e-3)" "unprognostic (1.23e-2)" "unprognostic (2.89e-3)" "unprognostic (1.64e-1)" "unprognostic (2.30e-1)" "unprognostic (2.70e-3)" "unprognostic (8.69e-2)" "unprognostic (9.47e-2)" "unprognostic (3.49e-2)" "unprognostic (6.88e-2)" 2.8 0.5 0.4 20.9 0.4 6.9 2.7 0.4 0.4 1.4 3.7 0.2 0.4 2.4 0.9 0.8 3.5 1.0 2.0 0.9 0.4 0.4 1.7 1.3 6.1 35.3 0.4 0.0 1.1 0.5 0.0 0.5 0.2 0.1 1.0 2.3 1.0 6.5 0.4 0.4 0.8 11.3 0.1 0.7 25.3 3.4 1.1 0.0 35.7 1.6 1.8 43.7 28.6 1.2 15.2 18.6 0.6 0.2 5.2 30.8 12.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 14.6 0.0 0.0 1.1 0.2 0.0 0.0 0.8 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 37.2 14.3 0.1 0.0 2.0 0.0 0.2 0.2 0.1 30.6 0.2 30.7 15.2 26.8 29.6 1.3 13.9 30.5 30.8 0.6 5.2 0.2 18.6 19.7 12.9 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.0 0.1 0.0 MCAM "CD146, MUC18" ENSG00000076706 "Melanoma cell adhesion molecule" P43121 11 119308529-119321521 "CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 4 "HUVEC TERT2: 125.3;TIME: 122.3;WM-115: 97.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "MAIT T-cell: 2.2" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002147, HPA008848" Enhanced Approved "Plasma membrane" 2600000000 "Plasma membrane" "CAB002147: AB_563499, HPA008848: AB_1078445" "unprognostic (6.45e-2)" "prognostic unfavourable (7.61e-4)" "unprognostic (7.03e-2)" "unprognostic (1.22e-2)" "unprognostic (6.67e-2)" "unprognostic (2.34e-1)" "unprognostic (2.23e-2)" "unprognostic (8.42e-2)" "unprognostic (2.09e-2)" "unprognostic (1.45e-1)" "unprognostic (1.58e-1)" "unprognostic (9.39e-2)" "prognostic unfavourable (5.14e-4)" "unprognostic (8.75e-3)" "unprognostic (7.84e-2)" "unprognostic (2.31e-1)" "unprognostic (2.79e-3)" 88.2 8.9 6.4 18.5 10.3 0.4 86.1 17.7 13.4 22.3 33.2 13.3 11.7 8.3 40.1 32.5 27.6 29.3 50.9 32.0 7.1 8.2 7.5 3.8 23.8 13.0 7.4 8.1 23.6 6.2 54.5 3.9 47.4 11.1 22.9 9.7 25.0 9.4 44.9 21.1 10.5 15.6 67.1 6.5 9.6 25.0 18.4 5.4 2.2 13.1 15.7 4.8 55.0 24.3 0.8 0.0 0.3 0.0 0.0 2.2 0.0 0.0 0.5 0.5 0.0 2.5 0.0 2.6 0.3 0.0 3.3 1.5 1.9 0.1 0.1 10.7 1.1 0.3 4.3 0.9 1.7 6.0 1.5 0.1 12.0 2.1 5.9 0.0 0.0 1.7 0.0 4.6 2.1 125.3 4.0 0.1 0.6 0.0 0.1 1.0 2.2 0.4 0.1 16.7 3.5 3.0 0.0 1.4 0.4 9.6 0.2 27.5 0.4 0.1 122.3 0.3 17.9 0.0 9.6 0.2 0.2 0.0 4.9 0.0 97.3 0.0 0.0 0.0 0.0 0.0 2.2 0.8 0.6 1.1 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 1.3 0.0 6.4 10.3 17.7 13.4 7.1 8.2 7.4 8.1 11.1 5.4 MELTF "CD228, FLJ38863, MAP97, MFI2, MGC4856, MTf, MTF1" ENSG00000163975 Melanotransferrin P08582 3 196988621-197029816 "CD markers, Plasma proteins, Predicted intracellular proteins" "Ion transport, Iron transport, Transport" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "salivary gland: 65.7" "Cell line enhanced" "Detected in many" "A-431: 46.1;SK-MEL-30: 57.0" "Cancer enhanced" "Detected in all" "melanoma: 32.7" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "MAIT T-cell: 3.3" "Group enriched" "Detected in many" 5 "dendritic cells: 1.9;monocytes: 2.1;T-cells: 3.3" "Not detected" "Not detected" "Low region specificity" "Detected in some" HPA004880 Approved "Intracellular and membrane" 230000000 "HPA004880: AB_1853844" "unprognostic (8.68e-3)" "unprognostic (3.68e-2)" "unprognostic (1.75e-2)" "unprognostic (7.68e-3)" "unprognostic (1.06e-2)" "unprognostic (1.08e-2)" "unprognostic (5.53e-2)" "unprognostic (1.64e-3)" "unprognostic (1.20e-2)" "unprognostic (1.23e-1)" "unprognostic (3.68e-3)" "unprognostic (8.14e-2)" "prognostic unfavourable (6.99e-11)" "unprognostic (2.29e-1)" "unprognostic (2.11e-1)" "unprognostic (5.75e-2)" "unprognostic (2.09e-2)" 6.0 1.6 1.9 3.5 2.0 1.8 7.5 2.7 2.8 4.4 5.1 3.3 3.5 2.1 4.9 4.8 2.4 6.4 2.5 3.3 1.8 1.1 5.1 1.4 1.6 1.7 1.0 1.0 1.3 4.3 15.9 1.8 4.4 2.9 3.7 1.9 2.9 65.7 4.7 1.4 10.5 8.7 3.1 1.1 1.0 1.1 2.6 0.9 3.6 2.0 1.3 2.4 2.0 5.4 0.2 1.9 0.2 2.1 0.5 3.3 0.6 46.1 10.1 0.1 0.3 1.4 1.9 1.2 0.8 0.4 1.5 1.9 2.8 6.9 1.3 10.0 1.6 14.4 0.5 0.0 0.7 2.1 3.2 1.6 2.2 1.2 9.4 0.2 9.2 10.1 1.2 1.3 0.1 0.2 1.2 9.1 0.9 2.8 2.6 0.0 1.0 6.6 3.8 1.6 0.5 0.2 0.4 0.9 3.4 9.5 0.8 57.0 2.8 1.4 0.3 0.3 8.1 1.6 5.7 1.5 12.8 1.2 1.1 2.7 0.0 0.1 0.3 0.0 1.2 1.0 3.3 0.2 1.0 1.0 1.9 0.2 0.3 0.1 0.2 0.5 2.1 0.0 0.1 0.6 1.9 2.0 2.7 2.8 1.8 1.1 1.0 1.0 2.9 0.9 MME "CALLA, CD10, NEP" ENSG00000196549 "Membrane metalloendopeptidase" P08473 3 155024124-155183729 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 61.1;intestine: 136.0;kidney: 64.9" "Cell line enhanced" "Detected in many" "ASC TERT1: 95.0;BJ hTERT+: 142.9;HSkMC: 92.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 129 "neutrophil: 61.1" "Lineage enriched" "Detected in single" 129 "granulocytes: 61.1" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 26.8" "CAB000013, HPA052583, HPA056072" Enhanced 99000 "CAB000013: AB_563478, HPA052583: AB_2681872, HPA056072: AB_2683027" "unprognostic (1.36e-1)" "unprognostic (1.02e-3)" "unprognostic (8.52e-2)" "unprognostic (2.95e-1)" "unprognostic (2.78e-2)" "unprognostic (6.52e-3)" "unprognostic (1.20e-1)" "unprognostic (1.67e-2)" "unprognostic (8.67e-2)" "unprognostic (1.96e-1)" "unprognostic (7.30e-3)" "unprognostic (1.31e-1)" "unprognostic (2.71e-3)" "unprognostic (1.50e-1)" "unprognostic (7.29e-2)" "unprognostic (1.06e-2)" "unprognostic (1.37e-2)" 26.5 0.4 0.4 3.4 7.4 1.9 14.7 0.4 0.7 4.8 65.6 0.1 18.4 74.0 2.8 8.1 0.7 0.9 8.5 1.8 0.3 0.4 64.9 11.5 13.7 3.0 2.1 0.2 0.9 0.6 0.0 0.6 35.0 8.6 18.3 0.4 1.3 3.7 11.3 11.7 1.4 136.0 0.6 0.9 2.7 0.7 1.0 1.2 13.2 1.0 5.3 2.3 3.4 4.9 0.1 0.4 61.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 38.6 95.0 0.2 21.2 142.9 10.8 28.1 0.0 0.0 23.4 0.0 18.8 0.0 0.7 0.8 26.1 0.0 0.1 0.0 0.0 0.0 30.9 0.0 0.0 92.1 0.1 5.8 41.6 8.2 0.0 0.0 17.3 0.1 0.0 0.1 0.9 0.1 38.8 18.2 0.1 0.6 0.2 0.0 0.2 0.0 0.0 4.1 0.0 0.0 23.3 46.7 0.1 15.9 3.7 0.0 0.0 30.8 5.6 0.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 61.1 0.0 0.0 0.4 0.0 0.0 0.4 7.4 0.4 0.7 0.3 0.4 2.1 0.2 8.6 1.2 MPL "CD110, TPOR" ENSG00000117400 "MPL proto-oncogene, thrombopoietin receptor" P40238 1 43337849-43352772 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 8.6" "Cell line enriched" "Detected in single" 78 "HEL: 40.7" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in single" 5 "neutrophil: 1.6" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.6" "Region enhanced" "Detected in single" "cerebral cortex: 1.4" "Low region specificity" "Detected in all" HPA007619 Supported "Nuclear membrane,Plasma membrane" "Plasma membrane" "Nuclear membrane" "HPA007619: AB_1854080" "unprognostic (2.74e-1)" "unprognostic (6.56e-2)" "unprognostic (2.95e-1)" "unprognostic (8.71e-2)" "unprognostic (1.37e-2)" "unprognostic (1.06e-3)" "unprognostic (1.19e-1)" "unprognostic (1.22e-2)" "unprognostic (5.83e-2)" "unprognostic (1.03e-1)" "unprognostic (5.94e-4)" "unprognostic (1.51e-1)" "unprognostic (1.19e-4)" "unprognostic (2.39e-1)" "unprognostic (3.26e-1)" "unprognostic (1.03e-4)" "unprognostic (1.42e-1)" 1.1 0.3 0.9 0.5 0.8 2.0 0.9 0.5 2.2 0.6 0.6 0.5 0.5 0.3 0.9 1.7 0.9 2.1 0.5 3.9 0.8 0.6 0.5 0.5 2.0 0.5 0.9 0.5 6.6 1.1 0.6 0.6 2.2 0.5 1.5 0.7 0.5 0.5 0.7 0.6 0.4 1.2 2.1 2.5 8.6 0.5 2.1 0.5 0.5 2.2 2.4 0.5 0.9 0.5 0.0 0.0 1.6 0.3 0.0 0.0 4.0 0.1 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.5 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.2 0.0 40.7 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.4 0.2 0.2 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 4.0 0.9 0.8 0.5 2.2 0.8 0.6 0.9 0.5 0.5 0.5 MRC1 "bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1" ENSG00000260314 "Mannose receptor C-type 1" P22897 10 17809344-17911170 "CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins" "Endocytosis, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 44.8;lymphoid tissue: 37.8" "Group enriched" "Detected in some" 19 "MOLT-4: 17.2;TIME: 16.0" "Low cancer specificity" "Detected in all" "Cell type enriched" "Detected in single" 15 "myeloid DC: 8.2" "Lineage enriched" "Detected in single" 15 "dendritic cells: 8.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in some" "HPA004114, HPA045134, CAB068203" Enhanced 130000000 "CAB068203: , HPA004114: AB_1846270, HPA045134: AB_2679228" "unprognostic (2.20e-1)" "unprognostic (2.07e-1)" "unprognostic (1.03e-2)" "unprognostic (2.58e-1)" "unprognostic (5.62e-2)" "unprognostic (4.30e-1)" "unprognostic (6.36e-3)" "unprognostic (1.35e-1)" "unprognostic (1.05e-2)" "unprognostic (6.05e-2)" "unprognostic (5.61e-2)" "unprognostic (4.12e-1)" "unprognostic (2.94e-2)" "unprognostic (4.97e-2)" "unprognostic (3.05e-2)" "unprognostic (1.74e-2)" "unprognostic (7.02e-2)" 34.8 8.3 0.3 6.2 1.2 0.0 19.8 0.7 0.6 5.2 11.2 0.6 0.9 2.2 4.5 10.4 4.2 1.3 7.9 13.4 0.9 12.4 16.4 44.8 37.8 1.0 0.0 3.6 5.1 1.8 2.4 15.4 3.1 5.5 5.1 7.0 0.7 1.9 5.1 0.0 6.5 8.2 1.4 30.6 2.2 7.1 0.8 0.8 6.5 3.5 0.7 7.5 5.1 0.0 8.2 0.1 0.5 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.2 0.0 0.1 0.0 0.1 0.3 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.1 0.0 8.2 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.4 0.2 MRC2 "CD280, CLEC13E, ENDO180, KIAA0709" ENSG00000011028 "Mannose receptor C type 2" Q9UBG0 17 62627401-62693597 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 46.4;fHDF/TERT166: 31.5;HSkMC: 29.9;U-138 MG: 47.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "naive CD4 T-cell: 1.0" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA041991 Enhanced 28000000 "HPA041991: AB_10794166" "unprognostic (3.22e-1)" "unprognostic (2.19e-1)" "unprognostic (4.45e-2)" "unprognostic (2.59e-2)" "unprognostic (4.29e-2)" "unprognostic (2.67e-2)" "unprognostic (6.21e-2)" "unprognostic (1.80e-1)" "unprognostic (7.39e-2)" "prognostic unfavourable (1.68e-4)" "unprognostic (7.70e-2)" "unprognostic (7.75e-2)" "prognostic unfavourable (4.94e-7)" "unprognostic (5.25e-2)" "unprognostic (6.13e-2)" "unprognostic (3.00e-2)" "unprognostic (1.93e-2)" 14.7 5.7 2.4 14.7 5.2 3.2 27.3 1.4 3.4 30.4 7.0 6.5 18.7 4.4 31.7 46.3 15.7 15.7 37.2 44.1 2.5 2.6 8.7 2.2 46.8 2.5 3.4 4.0 33.6 4.7 0.9 11.3 5.4 6.8 25.7 1.9 35.1 10.9 17.1 7.3 19.0 7.1 28.7 8.2 9.7 5.8 13.3 2.5 4.8 4.6 21.2 5.3 18.1 18.1 0.0 0.6 0.2 0.0 0.0 1.0 0.0 0.0 8.5 4.6 6.1 12.7 23.0 0.7 46.4 27.1 6.7 8.1 0.5 0.1 0.0 3.3 31.5 3.9 0.8 3.8 1.9 5.7 1.3 3.8 6.2 0.0 19.1 4.8 0.0 29.9 2.0 5.9 0.6 3.0 2.2 0.0 9.4 1.4 1.2 16.6 1.0 0.5 4.7 3.3 0.0 0.7 0.1 0.7 12.1 3.1 0.1 0.0 0.1 19.3 15.5 47.7 19.5 8.3 8.2 0.0 0.0 0.0 15.0 4.9 7.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.6 0.0 1.0 0.9 0.2 0.0 0.0 0.0 0.9 0.0 2.4 5.2 1.4 3.4 2.5 2.6 3.4 4.0 6.8 2.5 MS4A1 "B1, Bp35, CD20, MS4A2" ENSG00000156738 "Membrane spanning 4-domains A1" P11836 11 60455752-60470760 "CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "B-cell activation" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 77.7;intestine: 46.1;lymphoid tissue: 134.1" "Group enriched" "Detected in some" 25 "Daudi: 120.0;U-698: 60.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 105 "memory B-cell: 77.7;naive B-cell: 77.7" "Lineage enriched" "Detected in single" 105 "B-cells: 77.7" "Not detected" "Not detected" "Low region specificity" "Detected in some" "CAB000015, HPA014341, HPA014391" Enhanced Supported "Plasma membrane" "Plasma membrane" "CAB000015: AB_2282030, HPA014341: AB_1846265, HPA014391: AB_1846264" "prognostic favourable (4.34e-5)" "unprognostic (4.45e-4)" "unprognostic (1.19e-4)" "unprognostic (2.04e-3)" "unprognostic (1.06e-1)" "unprognostic (5.53e-7)" "unprognostic (2.46e-3)" "unprognostic (1.85e-3)" "unprognostic (3.06e-2)" "unprognostic (2.89e-4)" "unprognostic (6.96e-2)" "unprognostic (2.84e-2)" "unprognostic (3.96e-5)" "unprognostic (2.23e-1)" "unprognostic (8.04e-2)" "unprognostic (1.44e-1)" "unprognostic (1.30e-1)" 1.6 0.3 0.3 79.0 0.3 3.6 0.6 0.3 0.3 0.5 2.0 0.0 0.0 0.2 0.4 0.5 7.0 0.4 1.3 0.7 0.3 0.3 2.0 0.9 2.7 81.2 0.3 0.1 0.3 0.4 0.0 0.4 0.4 0.1 1.1 1.7 0.6 14.5 0.2 0.3 0.3 46.1 0.1 0.4 90.7 2.6 0.6 0.0 15.7 2.5 2.7 134.1 6.4 0.8 77.7 0.0 0.2 0.0 0.7 0.6 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 120.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 60.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 77.7 0.3 0.6 0.0 77.7 0.0 0.2 0.2 0.7 0.0 0.0 0.0 3.5 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.1 0.1 0.0 MSR1 "CD204, SCARA1, SR-A, SR-AI, SR-AII, SR-AIII" ENSG00000038945 "Macrophage scavenger receptor 1" P21757 8 16107878-16567490 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 5 "adipose tissue: 88.1;lung: 70.4" "Group enriched" "Detected in many" 7 "BJ hTERT+: 47.1;REH: 17.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "intermediate monocyte: 16.0" "Lineage enriched" "Detected in many" 5 "monocytes: 16.0" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA000272, CAB032491" Enhanced 25000 "CAB032491: AB_672722, HPA000272: AB_1846269" "unprognostic (8.19e-3)" "unprognostic (4.87e-2)" "unprognostic (1.93e-2)" "unprognostic (2.10e-1)" "unprognostic (9.24e-2)" "unprognostic (1.32e-2)" "unprognostic (5.85e-3)" "unprognostic (2.89e-1)" "unprognostic (9.70e-2)" "unprognostic (1.62e-2)" "unprognostic (7.19e-2)" "unprognostic (8.82e-2)" "unprognostic (2.76e-2)" "unprognostic (9.16e-2)" "unprognostic (7.39e-2)" "unprognostic (6.85e-2)" "unprognostic (4.69e-2)" 88.1 9.0 2.2 6.1 4.5 3.7 6.9 10.4 3.3 4.5 3.1 1.8 1.0 2.1 3.1 6.2 2.4 4.5 11.4 8.0 3.8 3.1 9.5 13.6 70.4 6.9 4.3 0.8 6.7 3.8 1.2 2.6 10.4 7.7 3.2 3.9 4.5 6.2 2.3 3.2 1.6 4.0 6.5 11.9 10.9 2.5 4.9 3.1 1.5 2.2 1.7 0.7 10.8 1.8 1.5 1.0 3.0 16.0 0.3 1.3 0.5 0.6 0.9 1.3 0.6 0.6 0.6 0.6 0.3 47.1 0.1 0.2 1.6 0.1 1.5 2.4 0.4 0.3 0.3 0.4 0.9 0.2 1.9 1.9 1.8 1.8 0.4 1.0 1.1 0.3 0.3 0.3 0.7 0.0 0.7 1.4 0.9 1.8 0.6 0.6 0.2 0.6 17.8 1.0 0.4 0.9 2.7 1.0 0.5 0.4 1.2 0.1 0.1 0.5 1.1 1.2 0.5 4.9 1.2 4.8 3.7 3.2 0.5 0.6 1.0 1.1 3.1 0.5 0.9 16.0 0.4 0.9 0.7 0.7 1.0 1.5 1.3 0.9 3.0 0.3 7.8 0.5 0.6 0.5 2.2 4.5 10.4 2.7 3.8 3.1 4.3 0.8 7.7 3.1 MST1R "CD136, CDw136, PTK8, RON" ENSG00000164078 "Macrophage stimulating 1 receptor" Q04912 3 49887002-49903873 "CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Immunity, Innate immunity" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 27.7;intestine: 34.3;skin 1: 28.7" "Cell line enhanced" "Detected in some" "CAPAN-2: 35.3;HaCaT: 19.5;HBEC3-KT: 21.2;hTCEpi: 29.8;RT4: 22.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "MAIT T-cell: 2.1" "Lineage enhanced" "Detected in single" "T-cells: 2.1" "Low region specificity" "Detected in single" "Not detected" "Not detected" "HPA007657, HPA008180, CAB008972" Enhanced Approved Cytosol Cytosol "CAB008972: , HPA007657: AB_1079292, HPA008180: AB_1079291" "unprognostic (3.84e-3)" "unprognostic (3.86e-1)" "unprognostic (1.92e-1)" "unprognostic (7.33e-3)" "unprognostic (3.82e-2)" "unprognostic (2.32e-1)" "unprognostic (8.07e-3)" "unprognostic (1.54e-2)" "unprognostic (4.12e-2)" "unprognostic (2.15e-1)" "unprognostic (1.24e-3)" "unprognostic (2.28e-1)" "unprognostic (8.08e-3)" "unprognostic (2.38e-1)" "unprognostic (2.18e-1)" "unprognostic (8.00e-3)" "prognostic favourable (2.33e-5)" 1.7 0.1 0.4 7.5 0.6 0.0 2.4 0.5 0.7 1.8 20.5 0.7 2.0 11.2 1.2 1.3 6.1 0.6 27.7 0.9 0.5 0.1 1.4 0.4 5.0 1.1 0.4 0.6 0.5 4.1 0.0 1.3 0.8 0.9 1.7 9.7 2.5 2.1 0.4 0.5 28.7 34.3 0.7 0.4 0.6 19.1 1.9 0.4 7.7 1.3 6.0 4.5 4.3 3.5 0.2 0.0 0.0 0.0 0.6 2.1 0.0 12.7 4.9 0.0 0.2 0.0 0.0 0.8 0.1 0.0 0.0 0.0 1.2 35.3 0.5 3.1 0.2 19.5 0.0 21.2 0.0 0.3 0.3 0.0 8.4 0.3 0.3 0.0 0.4 0.1 29.8 0.1 4.2 0.0 0.2 0.1 0.0 1.7 0.0 0.0 0.1 10.3 0.8 0.0 0.3 13.0 22.8 0.3 0.0 3.6 8.2 0.0 6.5 0.3 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.0 0.9 0.0 0.4 0.6 0.5 0.7 0.5 0.1 0.4 0.6 0.9 0.4 MUC1 "ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM" ENSG00000185499 "Mucin 1, cell surface associated" P15941 1 155185824-155192916 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 168.1;kidney: 158.5;lung: 143.5" "Group enriched" "Detected in many" 7 "CAPAN-2: 139.8;RPTEC TERT1: 107.3;T-47d: 47.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "T-reg: 4.0" "Group enriched" "Detected in many" 10 "granulocytes: 1.3;T-cells: 4.0" "CAB000036, CAB001986, HPA004179, HPA007235, HPA008855" Enhanced Supported "Plasma membrane" "Secreted in other tissues" 4900000 "Plasma membrane" "CAB000036: AB_2148557, CAB001986: , HPA004179: AB_1846282, HPA007235: AB_1846281, HPA008855: AB_1846283" "unprognostic (4.74e-2)" "unprognostic (2.84e-2)" "unprognostic (2.19e-1)" "unprognostic (8.01e-2)" "unprognostic (1.32e-2)" "unprognostic (1.70e-1)" "unprognostic (2.61e-3)" "unprognostic (6.34e-2)" "unprognostic (1.43e-1)" "unprognostic (3.23e-1)" "prognostic unfavourable (4.60e-4)" "unprognostic (4.75e-1)" "unprognostic (2.05e-2)" "unprognostic (1.13e-1)" "unprognostic (8.12e-2)" "unprognostic (1.42e-1)" "unprognostic (1.21e-1)" 1.5 0.7 0.8 12.6 1.2 0.9 12.6 0.4 0.7 31.6 15.9 1.2 2.4 2.9 10.5 9.8 51.8 18.7 168.1 0.8 0.5 0.3 158.5 2.0 143.5 0.3 0.5 0.3 14.9 74.2 0.0 4.7 15.5 2.1 6.1 16.1 0.8 17.0 5.9 0.8 1.8 3.6 2.8 0.7 0.6 105.0 4.3 0.5 0.7 15.7 10.5 47.8 12.3 5.2 0.0 0.2 1.3 0.1 0.0 4.0 0.2 1.8 0.9 0.6 0.5 0.4 0.5 0.2 0.6 1.5 0.7 1.9 0.0 139.8 0.0 10.2 1.1 2.8 0.1 0.0 0.2 1.2 0.1 0.2 11.8 0.0 0.3 0.0 4.4 1.2 0.2 0.3 0.2 0.2 1.0 1.9 0.5 14.2 0.1 0.1 0.4 0.2 0.2 0.0 3.4 107.3 0.1 0.6 0.2 3.4 5.9 0.1 47.1 0.6 0.2 0.4 0.8 1.3 0.1 2.2 1.1 0.0 0.7 0.1 0.1 1.3 0.1 0.0 0.0 0.0 0.8 0.0 2.3 0.4 0.2 0.0 0.3 0.7 0.0 0.0 0.0 0.0 4.0 0.2 0.8 1.2 0.4 0.7 0.5 0.3 0.5 0.3 2.1 0.5 NCAM1 "CD56, NCAM" ENSG00000149294 "Neural cell adhesion molecule 1" P13591 11 112961247-113278436 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 110.6;heart muscle: 67.7" "Cell line enhanced" "Detected in some" "HEL: 19.1;RH-30: 43.1;SCLC-21H: 35.1;SH-SY5Y: 17.2;U-138 MG: 24.0;WM-115: 25.4" "Cancer enriched" "Detected in many" 8 "glioma: 31.0" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 14 "NK-cell: 27.2" "Lineage enriched" "Detected in many" 14 "NK-cells: 27.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000142, CAB018071, HPA039835" Enhanced Enhanced "Plasma membrane,Cytosol" "Intracellular and membrane" 2800000000 "Plasma membrane" Cytosol "CAB000142: , CAB018071: AB_627129, HPA039835: " "unprognostic (7.04e-2)" "unprognostic (1.16e-1)" "unprognostic (2.77e-2)" "unprognostic (2.18e-2)" "unprognostic (2.91e-1)" "unprognostic (1.74e-3)" "unprognostic (2.82e-1)" "unprognostic (4.42e-3)" "unprognostic (2.13e-1)" "unprognostic (1.63e-2)" "prognostic favourable (9.11e-6)" "unprognostic (8.13e-2)" "prognostic unfavourable (8.20e-4)" "unprognostic (2.97e-2)" "unprognostic (2.24e-1)" "unprognostic (3.75e-2)" "unprognostic (5.82e-5)" 3.5 36.4 22.7 3.0 35.7 1.8 2.1 20.2 110.6 13.3 9.0 55.8 0.3 3.4 24.7 3.0 4.8 8.3 3.6 67.7 22.5 19.2 2.3 2.6 2.0 1.7 45.0 27.1 21.9 2.3 1.1 9.1 1.4 38.8 8.4 4.6 5.5 2.5 10.9 14.6 1.8 5.3 25.6 27.6 3.4 6.7 2.9 39.2 0.0 16.9 0.7 1.7 7.0 6.5 0.0 0.0 0.4 0.1 27.2 2.0 0.9 0.0 0.0 6.7 0.1 0.0 0.1 0.1 0.3 0.0 0.2 0.4 0.1 0.1 0.9 6.0 6.3 0.1 0.0 0.0 0.0 0.1 3.8 19.1 0.0 0.0 0.7 0.0 3.1 4.1 0.0 0.0 6.1 0.0 0.0 0.3 6.7 0.0 0.0 1.6 0.5 0.1 0.0 43.1 3.1 0.0 0.0 35.1 17.2 0.0 0.1 0.0 0.0 0.2 0.0 24.0 11.2 0.1 10.0 0.0 0.1 0.0 2.7 9.0 25.4 0.0 0.1 0.0 2.0 0.0 0.6 0.0 0.1 0.2 0.0 0.0 0.0 0.8 0.4 27.2 0.0 0.0 0.1 0.9 22.7 35.7 20.2 41.6 22.5 19.2 45.0 27.1 38.8 39.2 NCR1 "CD335, LY94, NK-p46, NKP46" ENSG00000189430 "Natural cytotoxicity triggering receptor 1" O76036 19 54906150-54916140 "CD markers, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 5.5;lymphoid tissue: 13.9" "Not detected" "Not detected" "Cancer enhanced" "Detected in single" "testis cancer: 1.2" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "basophil: 1.0" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Low region specificity" "Detected in single" HPA049311 Approved "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA049311: " "unprognostic (3.92e-2)" "unprognostic (2.21e-3)" "unprognostic (1.67e-1)" "unprognostic (2.87e-4)" "unprognostic (2.89e-1)" "unprognostic (6.32e-4)" "unprognostic (2.22e-2)" "unprognostic (3.29e-1)" "unprognostic (1.07e-1)" "unprognostic (1.89e-2)" "unprognostic (1.45e-1)" "unprognostic (1.36e-1)" "unprognostic (1.15e-5)" "unprognostic (1.82e-2)" "unprognostic (5.92e-2)" "unprognostic (3.81e-3)" "unprognostic (6.05e-3)" 1.4 0.2 0.1 3.7 0.4 2.1 0.3 0.1 0.3 0.3 2.1 0.0 0.5 0.1 1.2 1.3 0.3 0.2 2.1 1.9 0.2 0.2 0.3 2.5 5.5 3.8 0.2 0.0 0.2 0.1 0.1 0.2 0.4 0.0 0.6 0.2 1.0 0.4 0.1 0.3 0.5 3.4 1.2 0.2 13.9 0.3 0.4 0.0 2.0 0.3 0.1 2.6 0.7 0.3 0.2 0.2 1.0 0.0 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.1 0.3 0.1 0.0 0.0 0.4 0.0 0.0 0.1 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.3 0.0 0.1 0.4 0.0 0.0 0.1 0.0 0.2 0.0 0.4 0.1 0.0 0.0 0.3 0.2 0.0 0.3 0.0 0.3 0.1 0.0 0.0 0.2 0.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.7 0.0 0.2 0.0 0.0 0.1 0.4 0.1 0.3 0.2 0.2 0.2 0.0 0.0 0.0 NCR2 "CD336, LY95, NK-p44" ENSG00000096264 "Natural cytotoxicity triggering receptor 2" O95944 6 41335655-41350887 "CD markers, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 8.5;intestine: 3.3;lymphoid tissue: 3.7" "Cell line enhanced" "Detected in some" "HMC-1: 1.7;MOLT-4: 2.0" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 13 "NK-cell: 2.5;plasmacytoid DC: 8.5" "Group enriched" "Detected in many" 13 "dendritic cells: 8.5;NK-cells: 2.5" HPA067249 Uncertain "HPA067249: " "unprognostic (5.81e-2)" "unprognostic (3.39e-1)" "unprognostic (1.95e-1)" "unprognostic (2.12e-2)" "unprognostic (1.65e-1)" 0.1 0.1 0.1 1.9 0.1 0.0 0.1 0.0 0.0 0.0 3.3 0.0 0.0 2.8 0.1 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 1.6 0.0 0.1 0.2 0.0 0.1 2.5 0.1 0.0 0.6 0.1 0.3 0.0 1.2 0.1 1.7 3.7 0.0 0.1 0.0 8.5 0.0 0.0 2.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 8.5 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 NCR3 "1C7, CD337, LY117, NKp30" ENSG00000204475 "Natural cytotoxicity triggering receptor 3" O14931 6 31588895-31592985 "CD markers, Predicted membrane proteins" Immunity Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 28.5;lymphoid tissue: 18.5" "Cell line enriched" "Detected in some" 4 "NB-4: 9.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "MAIT T-cell: 28.5" "Lineage enriched" "Detected in many" 4 "T-cells: 28.5" "unprognostic (3.99e-3)" "unprognostic (9.23e-4)" "unprognostic (1.23e-3)" "unprognostic (2.49e-4)" "unprognostic (2.15e-1)" "unprognostic (2.57e-4)" "unprognostic (5.99e-2)" "unprognostic (1.15e-2)" "unprognostic (1.40e-2)" "unprognostic (3.62e-2)" "unprognostic (1.67e-1)" "unprognostic (1.81e-1)" "unprognostic (2.21e-4)" "unprognostic (1.72e-1)" "unprognostic (1.83e-1)" "unprognostic (8.17e-2)" "unprognostic (1.43e-1)" 1.8 0.1 0.2 10.5 0.2 4.3 0.3 0.1 0.1 0.1 0.4 0.0 0.0 0.2 0.3 0.5 0.9 0.2 0.3 1.2 0.6 0.1 0.5 1.3 3.9 11.4 0.2 0.0 0.5 1.1 0.0 0.1 0.8 0.1 0.3 0.3 0.1 8.4 0.4 0.1 0.3 5.8 0.2 0.2 18.5 0.4 0.8 0.0 3.6 0.4 0.1 12.8 1.0 0.3 6.1 0.0 0.1 0.2 6.4 28.5 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.4 0.8 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 9.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.3 0.0 0.0 0.0 0.0 10.5 0.0 28.5 6.1 1.2 5.2 0.0 4.4 0.5 3.3 0.1 6.4 0.2 0.0 1.7 2.5 0.2 0.2 0.1 0.1 0.6 0.1 0.2 0.0 0.1 0.0 NECTIN1 "CD111, CLPED1, ED4, HIgR, HVEC, OFC7, PRR, PRR1, PVRL1, PVRR1, SK-12" ENSG00000110400 "Nectin cell adhesion molecule 1" Q15223 11 119623408-119729084 "CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Ectodermal dysplasia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "esophagus: 55.3;skin 1: 73.5" "Cell line enhanced" "Detected in many" "HaCaT: 58.1;hTCEpi: 36.2;RT4: 39.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "plasmacytoid DC: 4.8" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016135, HPA026846" Approved "Secreted in other tissues" 97000000 "CAB016135: AB_626865, HPA026846: AB_1846226" "unprognostic (1.62e-1)" "unprognostic (1.16e-1)" "unprognostic (1.11e-1)" "unprognostic (3.87e-2)" "unprognostic (1.26e-1)" "unprognostic (3.20e-2)" "unprognostic (2.25e-3)" "unprognostic (2.03e-1)" "unprognostic (3.76e-2)" "unprognostic (3.42e-1)" "unprognostic (3.58e-2)" "unprognostic (3.28e-1)" "unprognostic (3.59e-3)" "unprognostic (2.13e-2)" "unprognostic (1.91e-1)" "unprognostic (2.46e-1)" "unprognostic (9.62e-2)" 3.1 3.0 7.7 3.0 11.1 11.9 5.3 8.4 20.8 6.6 7.3 27.3 2.4 9.6 2.3 2.0 55.3 2.9 2.5 3.0 16.1 8.2 3.0 2.4 2.5 1.7 12.7 10.6 1.8 10.8 2.4 4.1 8.2 10.1 5.9 7.8 6.3 8.7 4.4 1.6 73.5 6.9 3.1 14.3 2.2 3.2 1.3 12.4 2.5 1.8 25.3 20.8 17.3 14.8 0.1 4.8 1.0 1.5 0.1 0.1 0.2 4.0 3.4 3.2 4.6 1.7 0.5 22.7 1.6 1.5 1.4 1.0 7.1 13.9 5.4 6.7 1.9 58.1 8.2 29.6 0.6 12.7 1.2 0.7 1.1 3.3 0.7 3.6 9.1 0.5 36.2 4.4 16.2 4.1 0.1 28.9 1.8 10.6 0.0 2.2 10.6 4.7 0.3 19.4 6.5 1.3 39.4 7.8 17.7 5.5 14.6 0.5 13.3 0.5 2.2 1.2 4.6 10.0 1.4 5.3 6.6 0.0 0.4 3.0 2.8 0.0 0.3 0.2 0.1 0.5 0.0 0.0 0.1 0.0 0.2 0.1 0.0 0.0 1.0 0.1 1.5 4.8 0.0 0.2 7.7 11.1 8.4 20.8 16.1 8.2 12.7 10.6 10.1 12.4 NECTIN2 "CD112, HVEB, PRR2, PVRL2, PVRR2" ENSG00000130202 "Nectin cell adhesion molecule 2" Q92692 19 44846175-44889228 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "eosinophil: 11.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA012759, CAB026138, HPA073459" Enhanced Approved "Nucleoli fibrillar center,Cell Junctions" 3400000 "Nucleoli fibrillar center, Cell Junctions" "CAB026138: , HPA012759: AB_1846227, HPA073459: " "unprognostic (3.30e-2)" "unprognostic (2.84e-1)" "unprognostic (1.07e-1)" "unprognostic (5.61e-3)" "unprognostic (7.45e-2)" "unprognostic (2.21e-1)" "unprognostic (1.66e-2)" "unprognostic (6.63e-2)" "unprognostic (2.85e-1)" "unprognostic (2.97e-1)" "unprognostic (6.93e-2)" "unprognostic (3.19e-1)" "unprognostic (1.60e-1)" "unprognostic (2.15e-1)" "unprognostic (1.61e-1)" "unprognostic (8.19e-2)" "unprognostic (2.05e-1)" 29.5 28.2 7.9 15.6 7.7 5.6 38.0 4.5 9.0 24.2 34.0 9.3 22.3 24.2 23.2 27.4 33.6 16.7 54.1 21.9 10.5 8.1 29.0 53.7 39.6 23.0 8.2 6.8 25.5 20.6 22.5 15.9 45.8 11.2 25.8 14.8 22.9 24.4 28.9 14.6 18.3 42.9 13.8 8.4 31.4 26.2 38.7 5.8 3.8 32.2 19.2 24.1 21.6 31.4 0.0 3.3 11.5 2.6 0.0 0.3 0.7 17.8 21.4 27.7 32.7 14.0 8.5 32.2 15.3 18.9 27.1 31.3 44.1 39.3 0.1 20.7 17.7 24.5 24.5 12.6 21.6 0.7 12.8 10.8 7.4 28.5 33.7 0.1 29.0 14.9 5.1 12.9 10.5 35.0 17.6 0.1 13.5 32.5 0.1 1.2 23.0 6.4 1.0 9.4 0.7 32.1 22.1 1.3 3.7 19.0 28.9 6.5 22.5 10.6 34.9 7.4 26.3 5.5 11.2 2.2 6.4 0.1 13.6 2.3 19.3 1.5 2.6 11.5 0.0 0.9 0.3 0.0 0.1 0.0 3.3 0.0 0.0 0.0 2.4 0.0 0.5 0.3 0.0 0.7 7.9 7.7 4.5 9.0 10.5 8.1 8.2 6.8 11.2 5.8 NECTIN3 "CD113, CDw113, DKFZP566B0846, nectin-3, PPR3, PVRL3, PVRR3" ENSG00000177707 "Nectin cell adhesion molecule 3" Q9NQS3 3 111070071-111275563 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 94.2" "Cell line enhanced" "Detected in many" "TIME: 46.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 1.7" "Lineage enriched" "Detected in single" 4 "T-cells: 1.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009869, HPA011038" Approved Approved "Centriolar satellite" 20000000 "Centriolar satellite" "CAB009869: AB_2284699, HPA011038: AB_1079719" "unprognostic (3.76e-2)" "unprognostic (3.81e-3)" "unprognostic (1.74e-1)" "unprognostic (1.97e-2)" "unprognostic (1.02e-1)" "unprognostic (9.77e-2)" "unprognostic (3.26e-3)" "unprognostic (3.77e-1)" "unprognostic (7.58e-2)" "unprognostic (3.94e-2)" "unprognostic (5.33e-2)" "unprognostic (7.04e-2)" "prognostic favourable (9.82e-7)" "unprognostic (2.01e-1)" "unprognostic (1.97e-1)" "unprognostic (2.67e-1)" "unprognostic (1.05e-1)" 5.6 4.0 5.4 4.4 6.0 0.0 4.5 1.3 8.9 4.6 12.6 6.5 2.8 17.8 5.0 2.2 3.5 5.4 4.4 4.8 6.3 5.0 6.9 16.4 5.6 1.9 6.0 4.1 9.2 4.7 1.9 1.9 94.2 5.5 6.9 12.6 10.7 3.4 4.8 2.3 1.8 18.9 7.2 8.9 1.8 13.2 27.6 4.5 0.4 24.1 2.0 1.4 5.4 7.7 0.1 0.0 0.3 0.0 0.2 1.7 0.7 0.0 9.9 32.9 2.1 13.3 24.7 2.0 21.6 22.9 13.4 11.5 9.1 4.6 0.0 7.2 30.6 0.1 9.2 3.1 24.7 0.2 2.4 0.0 3.5 0.6 22.5 1.5 0.3 12.5 1.3 8.9 8.6 11.2 0.0 8.7 28.9 0.0 2.1 0.0 9.2 3.6 0.0 16.3 0.0 8.4 5.2 0.8 6.0 0.4 0.0 4.5 0.3 0.1 46.6 17.0 7.1 3.1 12.9 4.8 0.0 0.0 10.7 0.0 15.7 0.0 0.0 0.3 0.1 0.0 1.2 0.0 1.7 1.0 0.0 0.1 0.3 0.4 0.0 0.2 0.0 0.0 0.1 0.7 5.4 6.0 1.3 8.9 6.3 5.0 6.0 4.1 5.5 4.5 NGFR "CD271, p75NTR, TNFRSF16" ENSG00000064300 "Nerve growth factor receptor" P08138 17 49495293-49515017 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Apoptosis, Biological rhythms, Differentiation, Neurogenesis" "Developmental protein, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in some" 7 "RH-30: 54.7;WM-115: 60.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 7 "plasmacytoid DC: 4.2" "Lineage enriched" "Detected in single" 7 "dendritic cells: 4.2" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 5 "basal ganglia: 13.1;hypothalamus: 8.2;pons and medulla: 3.7" "CAB000143, CAB001995, HPA004765" Enhanced Approved "Nucleoplasm,Plasma membrane" 100000 Nucleoplasm "Plasma membrane" "CAB000143: , CAB001995: , HPA004765: AB_1079233" "unprognostic (6.25e-3)" "unprognostic (1.06e-3)" "unprognostic (3.39e-3)" "unprognostic (6.67e-2)" "unprognostic (1.46e-2)" "unprognostic (2.26e-1)" "unprognostic (8.22e-2)" "unprognostic (4.94e-2)" "unprognostic (1.08e-2)" "unprognostic (4.10e-3)" "unprognostic (1.85e-2)" "unprognostic (1.25e-1)" "unprognostic (3.37e-2)" "unprognostic (4.01e-2)" "unprognostic (3.06e-2)" "unprognostic (2.77e-3)" "prognostic unfavourable (3.40e-4)" 30.9 24.0 1.2 9.2 7.4 1.0 11.7 6.1 4.5 7.6 9.4 10.4 7.9 3.2 6.8 15.0 11.3 12.6 10.8 22.2 2.4 2.9 4.8 29.1 1.4 11.6 13.8 1.3 7.6 6.2 2.8 6.7 16.7 15.9 17.7 3.4 20.2 17.2 9.7 4.8 8.4 5.0 10.7 22.4 18.9 4.9 12.2 4.4 0.4 25.8 7.4 7.0 13.1 6.8 0.0 4.2 0.0 0.4 0.0 0.5 0.2 0.0 0.0 1.7 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 1.3 0.4 1.2 0.0 0.1 0.2 0.1 0.0 1.0 0.1 0.0 0.1 5.8 0.0 0.1 0.4 0.0 0.0 0.0 7.9 0.1 0.0 0.0 1.0 0.0 1.0 54.7 0.0 0.0 0.0 0.5 0.3 0.0 0.0 3.6 0.1 0.0 0.0 0.0 0.9 0.1 2.7 0.0 0.0 0.0 0.0 0.5 60.7 0.0 0.0 0.0 0.5 0.2 0.1 0.0 0.3 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.4 4.2 0.0 0.2 1.2 7.4 6.1 4.0 2.4 2.9 13.8 1.3 15.9 4.4 NRP1 "CD304, NRP, VEGF165R" ENSG00000099250 "Neuropilin 1" O14786 10 33177492-33336262 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Angiogenesis, Differentiation, Neurogenesis" "Developmental protein, Heparin-binding, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 69.8;TIME: 58.0;U-87 MG: 69.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 14 "plasmacytoid DC: 24.0" "Lineage enriched" "Detected in many" 14 "dendritic cells: 24.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004511, HPA030278" Approved "Secreted in other tissues" 720000000 "CAB004511: AB_2282634, HPA030278: AB_10601976" "unprognostic (3.19e-1)" "prognostic unfavourable (7.10e-5)" "unprognostic (1.50e-2)" "unprognostic (3.80e-2)" "prognostic unfavourable (5.79e-4)" "unprognostic (6.17e-2)" "unprognostic (1.46e-2)" "unprognostic (1.08e-1)" "unprognostic (6.66e-2)" "unprognostic (2.52e-1)" "unprognostic (1.82e-1)" "unprognostic (4.78e-2)" "prognostic unfavourable (3.87e-4)" "prognostic unfavourable (1.22e-5)" "unprognostic (3.83e-2)" "unprognostic (5.48e-2)" "unprognostic (7.79e-2)" 69.9 15.0 4.9 13.6 4.9 0.7 53.8 1.3 5.6 25.1 17.6 2.4 16.4 6.7 29.8 21.9 14.7 17.0 23.3 50.5 17.2 5.9 47.1 27.4 47.1 30.1 3.5 3.2 27.1 14.1 11.7 6.4 44.3 3.6 25.2 7.8 24.3 11.8 31.6 22.3 9.1 14.6 19.1 5.5 38.7 9.8 15.6 2.8 5.9 30.4 24.6 7.9 22.3 23.8 0.4 24.0 0.3 1.7 0.6 0.4 0.4 8.7 34.0 1.7 0.1 33.2 37.2 0.2 35.2 34.3 17.8 19.1 4.3 20.9 0.1 4.2 69.8 2.4 2.1 10.2 14.5 0.1 1.7 0.0 3.9 7.3 11.7 3.1 0.2 44.4 1.7 42.2 19.1 48.2 0.1 0.2 34.6 14.7 0.2 0.5 0.8 32.3 1.4 3.8 0.1 16.7 0.1 0.8 0.4 3.6 2.7 0.1 0.1 0.4 58.0 25.4 6.0 30.5 23.7 0.1 0.1 0.1 69.5 4.0 22.9 0.2 1.7 0.3 0.3 0.3 0.4 0.4 0.3 0.3 1.4 0.3 0.4 0.3 0.3 0.6 0.1 24.0 0.3 0.4 4.9 4.9 1.3 5.6 17.2 5.9 3.5 3.2 3.6 2.8 NT5E "CALJA, CD73, eN, eNT, NT5" ENSG00000135318 "5'-nucleotidase ecto" P21589 6 85449584-85495791 "CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Hydrolase "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "LHCN-M2: 108.8;TIME: 63.0;U-87 MG: 98.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "memory B-cell: 13.4;memory CD8 T-cell: 6.6;naive B-cell: 19.9;naive CD8 T-cell: 17.3" "Group enriched" "Detected in many" 47 "B-cells: 19.9;T-cells: 17.3" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA017357 Approved Supported "Nucleoplasm,Plasma membrane,Cytosol" "Intracellular and membrane" 1600000 "Plasma membrane" "Nucleoplasm, Cytosol" "HPA017357: AB_1846330" "unprognostic (1.92e-2)" "unprognostic (4.44e-3)" "unprognostic (1.54e-1)" "unprognostic (1.57e-3)" "unprognostic (9.33e-2)" "unprognostic (1.82e-3)" "unprognostic (1.20e-2)" "prognostic unfavourable (6.66e-4)" "unprognostic (5.45e-2)" "unprognostic (1.80e-1)" "prognostic unfavourable (1.32e-5)" "unprognostic (1.39e-1)" "unprognostic (3.11e-2)" "prognostic unfavourable (1.02e-4)" "unprognostic (3.49e-2)" "unprognostic (2.26e-1)" "unprognostic (2.78e-1)" 12.2 3.2 9.3 7.7 11.6 0.5 16.6 1.1 6.9 58.8 13.9 3.6 8.1 18.6 33.3 14.8 7.6 12.2 15.4 6.1 5.7 5.5 8.8 26.0 3.4 6.8 6.3 6.6 25.4 1.4 1.6 9.3 42.2 5.3 16.4 15.6 15.3 4.6 17.8 5.7 4.5 14.9 35.3 6.3 7.0 6.0 12.4 4.2 1.6 26.5 7.3 7.1 16.6 20.2 19.9 0.0 0.2 0.0 0.4 17.3 3.9 5.4 2.9 5.0 0.1 11.5 36.7 0.0 35.5 38.9 17.5 32.9 0.0 54.5 0.0 12.8 31.0 2.8 0.0 35.7 41.7 0.0 0.0 0.0 0.8 0.6 5.7 0.0 0.0 9.4 0.4 35.7 22.8 14.5 0.0 0.1 108.8 0.9 0.0 0.0 0.1 3.9 0.1 1.1 0.1 37.9 2.4 0.0 0.6 0.4 2.2 12.0 0.0 0.9 63.0 14.3 0.1 18.0 57.7 2.7 1.7 0.0 98.1 0.0 44.8 0.0 0.0 0.2 2.0 0.0 3.5 13.4 2.3 6.6 0.0 19.9 2.4 17.3 0.2 0.4 0.0 0.0 0.8 3.9 9.3 11.6 1.1 6.9 5.7 5.5 6.3 6.6 5.3 4.2 PDCD1 "CD279, hSLE1, PD-1, PD1, SLEB2" ENSG00000188389 "Programmed cell death 1" Q15116 2 241849881-241858908 "CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Apoptosis, Immunity" "FDA approved drug targets, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 11.6;lymphoid tissue: 21.5" "Group enriched" "Detected in some" 14 "MOLT-4: 9.3;RPMI-8226: 9.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "gdT-cell: 4.1;MAIT T-cell: 3.9;memory CD4 T-cell: 6.8;memory CD8 T-cell: 11.6;T-reg: 3.5" "Lineage enriched" "Detected in single" 93 "T-cells: 11.6" "Not detected" "Not detected" "Not detected" "Not detected" "HPA035981, CAB038418, CAB076386" Enhanced "CAB038418: AB_1160824, CAB076386: AB_881954, HPA035981: AB_10669664" "unprognostic (2.90e-3)" "unprognostic (4.50e-3)" "unprognostic (7.78e-2)" "prognostic favourable (9.44e-5)" "unprognostic (7.18e-3)" "unprognostic (1.31e-3)" "unprognostic (3.83e-2)" "unprognostic (7.33e-2)" "unprognostic (5.82e-3)" "unprognostic (3.75e-2)" "unprognostic (6.57e-2)" "unprognostic (3.94e-1)" "prognostic unfavourable (3.48e-7)" "unprognostic (1.20e-2)" "unprognostic (3.10e-1)" "unprognostic (5.35e-2)" "unprognostic (5.06e-3)" 1.4 0.4 0.0 21.5 0.7 3.0 0.5 0.1 0.3 1.2 1.9 0.0 0.0 0.4 0.5 1.6 2.0 0.8 1.7 9.2 0.2 0.5 1.3 0.5 5.6 16.6 0.1 0.3 0.7 1.0 0.2 1.9 0.3 0.4 1.3 0.2 1.2 3.0 0.5 0.2 0.2 4.9 0.4 0.3 9.5 1.9 0.4 0.2 16.6 1.9 3.0 20.1 1.3 0.8 0.1 0.0 0.0 0.0 0.0 11.6 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.5 9.3 0.0 0.0 0.0 0.0 0.1 9.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 3.9 0.1 6.8 11.6 0.0 0.0 0.5 1.2 0.0 0.0 0.0 0.0 3.5 1.5 0.0 0.7 0.1 0.1 0.2 0.5 0.1 0.3 0.4 0.2 PDCD1LG2 "B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2" ENSG00000197646 "Programmed cell death 1 ligand 2" Q9BQ51 9 5510570-5571254 "Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 25.4;BJ hTERT+: 39.9;HDLM-2: 30.5;TIME: 17.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA013411 Approved Approved Cytosol "Secreted - unknown location" 34000000 Cytosol "HPA013411: AB_1855102" "unprognostic (3.93e-2)" "unprognostic (1.90e-1)" "unprognostic (3.51e-3)" "unprognostic (6.68e-3)" "unprognostic (7.66e-2)" "unprognostic (6.77e-2)" "unprognostic (5.72e-2)" "unprognostic (2.91e-1)" "unprognostic (1.68e-1)" "unprognostic (4.37e-3)" "unprognostic (5.79e-2)" "unprognostic (5.29e-2)" "prognostic unfavourable (1.15e-4)" "unprognostic (5.00e-2)" "unprognostic (4.66e-2)" "unprognostic (2.01e-1)" "unprognostic (7.51e-3)" 15.2 1.8 1.2 7.7 1.4 0.2 9.5 0.7 1.2 7.0 1.9 2.3 0.0 0.8 2.9 7.2 3.9 3.8 4.0 5.8 1.2 1.3 2.5 6.4 13.3 10.8 1.6 0.5 4.1 1.8 0.5 1.1 12.9 1.9 5.0 2.5 2.4 2.9 1.7 5.5 3.6 2.5 4.6 3.7 19.5 1.9 4.2 1.2 8.1 3.5 3.5 8.1 6.0 5.4 0.5 0.9 4.1 3.6 0.0 3.0 0.7 2.0 0.0 0.0 0.0 1.7 2.0 0.0 25.4 39.9 12.3 14.9 0.0 0.1 0.0 0.0 10.3 0.2 0.0 3.4 12.2 30.5 0.0 0.0 0.0 0.0 9.9 0.0 0.0 1.8 0.0 5.7 6.7 8.0 0.0 3.0 14.7 0.0 0.0 0.0 0.0 0.0 0.0 15.2 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 17.6 8.8 0.5 4.2 7.0 0.4 0.0 0.0 5.0 0.0 1.0 4.1 0.9 0.0 1.4 3.6 1.9 0.5 2.2 0.9 0.9 0.3 0.0 1.0 2.0 0.0 0.5 0.0 3.0 0.7 1.2 1.4 0.7 1.2 1.2 1.3 1.6 0.5 1.9 1.2 PDGFRA "CD140a, GAS9, PDGFR2" ENSG00000134853 "Platelet derived growth factor receptor alpha" P16234 4 54229097-54298247 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Chemotaxis, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 81.5" "Cell line enhanced" "Detected in some" "ASC diff: 81.0;ASC TERT1: 37.9;BJ hTERT+: 47.0;fHDF/TERT166: 32.7;HHSteC: 27.4;HSkMC: 68.9" "Cancer enhanced" "Detected in all" "glioma: 30.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004947, CAB018143" Supported Approved "Nucleoplasm,Plasma membrane,Cell Junctions" "Intracellular and membrane" 150000 "Nucleoplasm, Plasma membrane, Cell Junctions" "CAB018143: AB_2162351, HPA004947: " "unprognostic (1.67e-1)" "unprognostic (9.35e-2)" "unprognostic (4.59e-3)" "unprognostic (1.60e-1)" "unprognostic (8.92e-2)" "prognostic favourable (9.33e-4)" "unprognostic (1.24e-1)" "unprognostic (2.00e-2)" "unprognostic (1.46e-1)" "unprognostic (2.18e-2)" "unprognostic (2.18e-1)" "unprognostic (7.01e-2)" "prognostic unfavourable (9.79e-6)" "unprognostic (9.58e-3)" "unprognostic (9.87e-2)" "unprognostic (2.16e-2)" "unprognostic (1.72e-3)" 35.0 12.4 12.6 16.1 7.6 0.9 17.2 2.4 20.1 33.2 19.1 9.2 6.4 9.6 27.6 14.6 21.9 22.5 16.2 15.3 8.9 7.4 22.8 8.4 24.1 26.9 9.2 4.0 81.5 6.8 1.6 2.1 25.1 7.2 18.6 15.2 19.2 8.5 8.3 11.9 7.0 17.4 19.7 8.8 51.6 13.6 19.0 9.3 0.5 11.3 12.8 4.3 35.9 24.6 0.9 0.4 2.5 0.4 0.3 0.8 0.3 0.0 0.0 0.2 0.1 81.0 37.9 0.1 4.2 47.0 0.0 0.1 11.2 0.0 0.1 0.1 32.7 0.1 3.2 0.0 0.0 0.4 0.1 0.1 0.1 0.2 27.4 0.0 0.0 68.9 0.0 5.3 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.6 0.1 0.1 0.0 0.0 0.0 0.3 0.1 6.6 0.0 0.1 0.0 0.1 0.0 0.1 14.8 0.5 16.2 0.0 0.0 0.0 0.1 0.4 0.0 0.3 2.5 0.4 0.2 0.5 0.2 0.2 0.6 0.8 0.4 0.0 0.9 0.7 0.4 2.3 0.3 0.3 0.4 0.2 0.3 12.6 7.6 2.4 7.3 8.9 7.4 9.2 4.0 7.2 9.3 PDGFRB "CD140b, JTK12, PDGFR, PDGFR1" ENSG00000113721 "Platelet derived growth factor receptor beta" P09619 5 150113837-150155872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Chemotaxis "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 4 "ASC diff: 169.0;ASC TERT1: 58.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.9;non-classical monocyte: 4.1" "Group enriched" "Detected in many" 8 "monocytes: 4.1;T-cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003842, CAB018144, HPA028499" Enhanced Supported "Golgi apparatus,Vesicles" 35000000 Vesicles "Golgi apparatus" "CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018" "unprognostic (4.75e-2)" "unprognostic (2.48e-1)" "unprognostic (5.21e-2)" "unprognostic (3.60e-2)" "unprognostic (3.27e-1)" "unprognostic (5.61e-2)" "unprognostic (1.02e-1)" "unprognostic (3.36e-2)" "unprognostic (2.12e-2)" "unprognostic (2.57e-3)" "unprognostic (6.72e-2)" "unprognostic (1.25e-1)" "prognostic unfavourable (5.87e-8)" "unprognostic (3.13e-3)" "unprognostic (1.25e-2)" "unprognostic (5.47e-2)" "prognostic unfavourable (8.11e-4)" 61.8 10.4 8.3 11.0 9.1 0.5 66.1 4.6 10.4 73.1 15.7 6.7 6.9 5.1 44.3 17.3 21.7 26.1 51.7 24.2 8.2 3.9 17.0 4.6 28.9 21.5 7.9 8.1 46.5 7.5 10.4 7.7 46.4 7.7 24.2 6.3 22.9 11.2 19.3 29.8 20.3 11.2 29.8 5.0 19.6 9.2 21.5 6.7 1.4 21.4 16.0 7.3 23.6 35.1 0.4 0.1 0.0 4.1 0.0 2.9 0.6 0.0 0.0 1.0 0.0 169.0 58.5 0.3 5.9 24.5 4.1 7.0 0.6 0.0 0.0 0.7 16.9 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.3 0.4 24.0 0.0 0.0 26.3 0.0 5.7 0.0 0.0 0.0 0.6 0.6 0.0 0.0 0.0 1.1 0.0 0.4 0.3 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 6.7 2.2 2.8 0.3 0.0 0.0 0.0 4.1 0.0 0.1 0.0 0.0 0.0 2.9 0.6 0.0 0.4 0.1 0.8 0.1 0.1 0.0 1.3 0.0 0.0 4.1 0.0 0.0 0.6 8.3 9.1 4.6 10.4 8.2 3.9 7.9 8.1 7.7 6.7 PLAUR "CD87, UPAR, URKR" ENSG00000011422 "Plasminogen activator, urokinase receptor" Q03405 19 43646095-43670547 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 118.0;bone marrow: 165.0" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 49.4;U-251 MG: 70.2;U-87 MG: 61.3;WM-115: 59.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 118.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA050843, CAB073533" Uncertain Supported "Plasma membrane" "Intracellular and membrane" 760000 "Plasma membrane" "CAB073533: , HPA050843: " "unprognostic (9.28e-2)" "unprognostic (9.65e-3)" "unprognostic (1.39e-1)" "unprognostic (1.29e-3)" "unprognostic (3.59e-3)" "unprognostic (1.50e-2)" "unprognostic (2.18e-3)" "prognostic unfavourable (2.33e-5)" "unprognostic (8.08e-3)" "unprognostic (4.30e-2)" "unprognostic (2.29e-3)" "unprognostic (5.30e-2)" "prognostic unfavourable (7.83e-9)" "unprognostic (4.99e-2)" "unprognostic (1.66e-1)" "unprognostic (5.45e-2)" "unprognostic (9.33e-2)" 25.2 3.6 3.0 23.6 4.8 165.0 6.3 2.2 6.1 10.7 7.5 4.4 1.8 3.3 9.5 6.0 8.6 10.6 23.0 11.5 4.5 3.2 5.1 6.1 39.4 8.1 6.0 1.1 11.9 4.3 2.5 4.4 12.2 6.9 6.1 6.0 4.6 11.0 3.7 7.9 3.5 7.3 7.2 7.1 12.6 12.0 6.3 6.3 2.5 4.4 7.7 7.0 22.7 14.9 0.2 21.3 118.0 50.5 0.6 0.9 21.0 14.0 4.9 4.5 0.3 4.0 14.4 2.7 29.6 30.1 18.7 23.5 0.4 16.6 0.5 7.5 18.3 6.0 1.2 7.3 20.9 0.9 0.9 2.6 7.4 0.6 5.1 3.1 34.3 14.8 1.4 49.4 7.4 20.6 2.7 0.6 17.9 1.0 3.4 8.4 1.4 10.6 3.9 3.0 1.0 5.8 0.7 0.2 3.9 13.2 3.0 3.9 0.6 9.8 21.1 41.3 21.2 18.9 70.2 0.6 1.4 0.1 61.3 5.8 59.7 7.2 48.9 72.4 0.7 41.5 0.8 0.2 0.9 0.6 21.3 0.1 0.3 0.4 118.0 0.6 50.5 6.8 0.3 21.0 3.0 4.8 2.2 6.1 4.5 3.2 6.0 1.1 6.9 6.3 PLXNC1 "CD232, VESPR" ENSG00000136040 "Plexin C1" O60486 12 94148723-94307675 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 43.5;retina: 40.6" "Cell line enhanced" "Detected in many" "HAP1: 14.9;SK-MEL-30: 18.5;U-266/70: 29.4;U-266/84: 30.6" "Cancer enhanced" "Detected in all" "melanoma: 24.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 14.2" "Group enriched" "Detected in many" 4 "granulocytes: 14.2;monocytes: 6.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB026155, HPA066899" Uncertain Approved Mitochondria 82000 Mitochondria "CAB026155: , HPA066899: " "unprognostic (1.49e-1)" "unprognostic (4.01e-2)" "unprognostic (5.60e-2)" "unprognostic (1.99e-1)" "unprognostic (2.33e-1)" "unprognostic (3.24e-2)" "unprognostic (4.67e-3)" "unprognostic (2.80e-2)" "unprognostic (3.49e-1)" "unprognostic (4.64e-2)" "unprognostic (1.78e-2)" "unprognostic (2.38e-1)" "unprognostic (4.02e-2)" "unprognostic (5.33e-3)" "unprognostic (3.19e-2)" "unprognostic (6.85e-3)" "unprognostic (5.48e-2)" 6.6 7.5 7.1 16.1 6.9 12.6 3.9 16.8 8.6 8.0 5.1 3.1 0.8 3.1 7.3 2.2 4.9 4.3 8.3 4.1 6.3 15.2 3.2 2.0 15.2 43.5 4.5 7.7 13.0 2.3 0.5 6.3 7.5 5.2 4.3 5.4 40.6 3.7 3.7 2.9 6.6 5.0 5.7 4.9 28.6 3.4 12.1 3.3 8.6 3.3 2.7 10.2 9.6 6.5 2.4 2.5 14.2 6.7 0.9 1.7 1.5 0.4 0.2 1.2 0.2 0.7 0.5 0.1 0.6 0.8 0.8 2.3 4.0 0.0 9.5 0.0 0.9 0.0 14.9 0.6 0.5 6.6 0.3 0.5 0.2 2.7 8.3 1.9 3.3 8.2 0.0 0.9 0.4 0.0 0.2 11.7 0.2 0.1 0.4 1.0 2.5 0.5 1.5 0.4 5.2 0.0 0.7 1.0 0.7 0.1 0.1 18.5 0.0 1.6 0.3 0.2 1.1 0.1 0.3 29.4 30.6 0.6 0.1 5.2 0.6 0.0 3.0 12.2 1.4 5.2 1.6 2.4 1.6 1.7 2.5 1.4 1.4 1.5 14.2 0.9 6.7 0.9 1.0 1.5 7.1 6.9 16.8 8.6 6.3 15.2 4.5 7.7 5.2 3.3 PRNP "AltPrP, CD230, CJD, GSS, PRIP, PRP" ENSG00000171867 "Prion protein" P04156 20 4686236-4701590 "CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell cycle, Growth arrest" Prion "Amyloidosis, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "WM-115: 114.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "basophil: 108.1" "Lineage enriched" "Detected in all" 6 "granulocytes: 108.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA042754, HPA043398" Enhanced Approved "Nuclear membrane,Vesicles,Cytosol" "Intracellular and membrane" 2200000 "Nuclear membrane, Cytosol" Vesicles "HPA042754: AB_10964203, HPA043398: " "unprognostic (1.50e-1)" "unprognostic (1.72e-1)" "prognostic unfavourable (2.96e-4)" "prognostic unfavourable (4.64e-4)" "prognostic unfavourable (2.52e-4)" "unprognostic (1.94e-2)" "prognostic unfavourable (7.41e-5)" "unprognostic (7.60e-3)" "unprognostic (2.50e-1)" "unprognostic (7.12e-2)" "unprognostic (3.44e-1)" "unprognostic (1.04e-1)" "unprognostic (6.75e-2)" "unprognostic (7.28e-3)" "unprognostic (3.37e-1)" "unprognostic (2.04e-1)" "unprognostic (1.69e-2)" 24.6 27.3 63.4 14.2 73.1 19.8 30.5 87.5 116.1 42.0 43.4 61.6 8.5 10.6 36.3 17.7 23.0 24.1 31.4 54.1 64.6 48.9 38.5 22.2 22.2 14.7 47.2 65.6 49.6 11.8 20.7 24.9 18.7 71.6 43.8 20.9 34.1 17.1 45.0 21.8 26.7 13.5 40.8 53.1 20.3 18.1 19.1 51.4 2.9 25.6 11.8 16.4 27.0 22.3 4.6 10.5 108.1 11.7 3.6 16.7 10.0 24.2 20.0 4.6 7.1 37.3 22.8 4.1 40.2 57.9 19.5 19.9 6.6 18.8 4.4 9.3 78.3 56.5 5.0 54.7 36.6 3.6 4.3 0.0 2.3 20.6 45.9 7.9 1.8 20.6 78.9 83.4 65.2 16.7 2.3 15.8 22.4 5.4 3.1 4.8 3.7 29.8 3.8 12.2 4.0 9.8 4.3 5.4 0.8 11.4 16.0 57.1 3.3 4.1 25.1 31.8 14.6 17.7 32.6 7.3 14.7 14.8 25.6 5.8 114.4 108.1 11.7 0.8 11.9 9.7 16.7 4.2 9.8 9.4 10.5 4.6 5.8 6.8 0.7 3.6 7.6 3.7 11.4 10.0 63.4 73.1 87.5 90.4 64.6 48.9 47.2 65.6 71.6 51.4 PROCR "CCD41, CD201, EPCR" ENSG00000101000 "Protein C receptor" Q9UNN8 20 35172073-35216240 "Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Blood coagulation, Hemostasis" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 77.8" "Cell line enhanced" "Detected in many" "HMC-1: 64.9;HUVEC TERT2: 101.2;TIME: 59.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA039461 Enhanced 1600000000 "HPA039461: AB_10673359" "unprognostic (1.51e-1)" "unprognostic (1.03e-1)" "unprognostic (4.12e-2)" "unprognostic (1.68e-1)" "unprognostic (2.64e-1)" "unprognostic (4.69e-2)" "unprognostic (4.69e-2)" "unprognostic (1.84e-1)" "unprognostic (1.52e-1)" "unprognostic (4.76e-2)" "unprognostic (5.22e-2)" "unprognostic (4.27e-1)" "prognostic unfavourable (7.62e-6)" "unprognostic (3.37e-2)" "unprognostic (2.29e-1)" "unprognostic (1.05e-1)" "unprognostic (2.19e-2)" 51.0 11.9 2.3 10.1 3.2 4.4 24.6 2.9 2.3 16.8 25.0 3.1 14.1 8.7 27.7 44.5 19.4 17.3 13.4 27.4 2.7 2.4 11.7 3.8 10.6 30.3 3.1 2.1 19.3 11.5 2.7 4.7 77.8 7.4 15.5 12.3 16.4 4.2 14.0 17.7 10.4 14.0 20.0 5.8 22.1 10.4 9.1 2.0 0.6 12.1 13.0 3.9 25.8 14.9 1.6 7.3 4.1 1.7 3.4 14.6 2.0 2.4 14.5 0.0 1.5 16.0 13.1 3.4 3.4 14.9 5.6 11.0 18.7 12.7 0.4 10.7 3.4 8.0 3.3 21.7 4.7 0.1 4.5 5.3 3.5 0.7 3.9 0.2 64.9 11.1 8.1 26.6 22.2 101.2 1.8 0.7 5.8 0.8 0.1 0.2 2.0 15.0 0.1 2.8 0.0 9.6 0.9 0.4 0.2 1.8 3.9 3.0 1.3 0.8 59.8 14.6 7.4 5.5 5.7 0.0 0.1 0.1 16.8 5.4 3.0 4.1 1.5 0.9 8.3 1.7 14.6 1.0 2.6 5.2 7.3 1.6 0.7 6.3 4.1 3.4 1.4 1.2 2.0 2.0 2.3 3.2 2.9 2.3 2.7 2.4 3.1 2.1 7.4 2.0 PROM1 "AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4" ENSG00000007062 "Prominin 1" O43490 4 15963076-16084378 "CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cone-rod dystrophy, Disease mutation, Retinitis pigmentosa, Stargardt disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "retina: 52.4;salivary gland: 71.0" "Cell line enhanced" "Detected in some" "AF22: 13.5;CACO-2: 25.1;CAPAN-2: 10.7;EFO-21: 24.5;NTERA-2: 36.4;RPTEC TERT1: 33.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" "HPA004922, CAB011525, HPA031053" Enhanced "CAB011525: AB_470302, HPA004922: AB_1846238, HPA031053: " "unprognostic (6.33e-2)" "unprognostic (2.54e-1)" "unprognostic (1.53e-1)" "unprognostic (3.39e-1)" "unprognostic (2.81e-1)" "unprognostic (2.16e-1)" "unprognostic (2.39e-1)" "unprognostic (6.64e-2)" "unprognostic (2.18e-2)" "unprognostic (2.17e-1)" "unprognostic (1.21e-2)" "unprognostic (9.06e-2)" "prognostic favourable (2.56e-5)" "unprognostic (2.16e-2)" "unprognostic (1.02e-1)" "unprognostic (9.38e-2)" "unprognostic (1.17e-1)" 0.5 0.5 2.5 11.5 2.2 1.3 11.2 1.0 2.2 20.1 13.8 2.3 1.6 5.2 4.7 3.1 1.8 1.9 12.6 2.7 3.1 2.1 30.2 1.6 3.6 0.1 2.3 0.6 1.6 10.7 0.0 1.8 12.7 2.1 1.6 7.4 52.4 71.0 2.9 0.7 1.1 13.5 1.7 1.8 0.6 10.9 5.0 0.9 0.3 1.7 3.8 10.2 3.0 0.5 0.0 0.0 0.1 0.0 0.0 0.1 1.0 0.0 0.0 13.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.1 10.7 0.3 24.5 0.0 0.0 2.6 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 36.4 0.0 0.9 0.0 0.0 33.7 0.0 4.2 1.4 0.0 0.8 1.0 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 2.5 2.2 1.0 2.2 3.1 2.1 2.3 0.6 2.1 0.9 PSG1 "CD66f, PBG1, PSBG1, PSGGA" ENSG00000231924 "Pregnancy specific beta-1-glycoprotein 1" P11464 19 42866464-42879822 "CD markers, Predicted intracellular proteins, Predicted secreted proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 362 "placenta: 497.6" "Cell line enriched" "Detected in some" 20 "U-2197: 95.7" "Cancer enhanced" "Detected in single" "thyroid cancer: 0.5" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "neutrophil: 1.0" "Low lineage specificity" "Detected in single" HPA046327 Supported "Secreted in female reproductive system" "HPA046327: " "unprognostic (2.02e-1)" "unprognostic (3.54e-1)" "unprognostic (2.44e-7)" "unprognostic (2.28e-2)" 1.3 0.0 0.1 0.0 0.1 0.0 0.6 0.5 0.2 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.2 0.1 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.1 497.6 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.0 0.0 0.5 0.0 0.0 0.2 0.0 0.2 0.0 1.0 0.3 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 4.1 1.3 0.3 0.5 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 95.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.1 1.0 0.0 0.3 0.0 0.1 0.0 0.1 0.1 0.5 0.2 0.1 0.1 0.1 0.0 0.0 0.0 PTGDR2 "CD294, CRTH2, DP2, GPR44" ENSG00000183134 "Prostaglandin D2 receptor 2" Q9Y5Y4 11 60850940-60855971 "CD markers, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 51.8;lymphoid tissue: 28.1" "Cell line enhanced" "Detected in some" "HEL: 10.3;Hep G2: 5.0;HMC-1: 6.5;K-562: 4.2;NB-4: 14.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 6 "basophil: 35.1;eosinophil: 51.8" "Lineage enriched" "Detected in many" 7 "granulocytes: 51.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA014259 Uncertain "HPA014259: AB_1849304" "unprognostic (9.77e-2)" "unprognostic (1.35e-3)" "unprognostic (5.45e-3)" "unprognostic (1.69e-1)" "unprognostic (1.90e-1)" "unprognostic (1.85e-3)" "unprognostic (1.70e-1)" "unprognostic (2.30e-4)" "unprognostic (2.61e-1)" "unprognostic (7.92e-2)" "unprognostic (8.68e-3)" "unprognostic (1.52e-1)" "unprognostic (1.32e-2)" "unprognostic (1.52e-1)" "unprognostic (3.31e-1)" "unprognostic (1.49e-1)" "unprognostic (4.99e-2)" 1.2 0.3 3.9 2.3 8.0 0.4 2.8 2.3 8.2 1.7 10.7 4.0 0.3 7.5 0.9 0.6 1.4 1.5 1.6 5.1 4.3 2.8 0.5 0.7 1.4 1.9 4.9 5.9 0.5 1.1 5.9 0.6 1.9 5.7 0.9 7.4 0.6 0.5 0.5 11.3 1.0 10.8 0.9 2.2 1.1 13.3 0.5 0.8 28.1 0.4 5.6 0.6 1.1 0.4 0.0 1.2 51.8 7.8 0.0 0.3 0.4 0.0 0.0 0.1 0.0 0.4 1.6 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 10.3 0.0 5.0 1.2 0.0 6.5 2.2 0.1 0.0 0.0 0.0 4.2 0.0 0.0 0.1 3.3 14.8 0.0 0.2 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 35.1 0.0 51.8 0.0 2.5 0.0 0.0 0.3 0.2 1.2 0.0 0.0 0.0 0.1 0.0 7.8 0.2 0.3 0.4 3.9 8.0 2.3 8.2 4.3 2.8 4.9 5.9 5.7 0.8 PTGFRN "CD315, CD9P-1, EWI-F, FLJ11001, FPRP, KIAA1436, SMAP-6" ENSG00000134247 "Prostaglandin F2 receptor inhibitor" Q9P2B2 1 116910057-116990358 "CD markers, Predicted membrane proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-87 MG: 45.3;WM-115: 33.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "myeloid DC: 3.0" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017074 Approved 86000 "HPA017074: AB_1855888" "unprognostic (1.18e-1)" "unprognostic (2.11e-3)" "unprognostic (3.03e-1)" "unprognostic (8.58e-2)" "unprognostic (3.20e-1)" "unprognostic (2.91e-2)" "unprognostic (1.48e-3)" "unprognostic (3.39e-2)" "unprognostic (1.76e-2)" "unprognostic (7.28e-2)" "unprognostic (2.77e-2)" "unprognostic (5.28e-2)" "prognostic unfavourable (3.98e-4)" "unprognostic (1.61e-1)" "unprognostic (1.95e-1)" "unprognostic (1.12e-1)" "unprognostic (4.15e-2)" 6.9 14.9 3.7 8.4 4.7 0.0 6.3 1.2 6.6 17.1 26.2 2.5 10.1 6.5 23.9 10.7 23.5 17.8 20.5 29.5 3.0 2.6 3.4 5.3 4.4 1.7 2.8 6.1 15.6 17.1 4.0 3.5 24.6 3.2 13.3 13.2 8.1 13.3 15.0 2.4 12.4 15.3 27.8 3.0 2.5 8.7 6.3 2.2 2.8 5.9 13.5 9.7 15.2 15.3 0.0 3.0 0.0 1.1 0.3 0.9 0.3 11.6 3.0 5.6 12.9 1.0 2.6 0.8 0.8 1.3 4.7 1.8 2.1 2.6 0.0 11.0 3.1 20.8 12.5 22.3 3.0 0.1 7.6 0.8 7.6 3.2 0.3 0.0 1.2 11.6 20.2 0.6 11.2 9.0 4.7 0.0 7.1 14.8 0.0 1.6 6.5 0.0 0.0 30.7 0.0 15.7 9.6 2.7 6.3 23.9 16.9 6.7 14.8 3.6 23.1 6.9 10.4 11.3 7.3 0.0 0.0 0.0 45.3 0.0 33.5 0.0 0.8 0.0 0.0 1.1 0.0 0.0 0.0 0.0 3.0 0.0 0.9 0.0 0.0 0.3 0.0 0.0 0.7 0.3 3.7 4.7 1.2 6.6 3.0 2.6 2.8 6.1 3.2 2.2 PTPRJ "CD148, DEP1, HPTPeta" ENSG00000149177 "Protein tyrosine phosphatase, receptor type J" Q12913 11 47980558-48170841 "CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protein phosphatase" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "EFO-21: 25.3;RPTEC TERT1: 24.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 12.2" "Group enriched" "Detected in all" 4 "granulocytes: 12.2;monocytes: 5.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006026 Approved "Intracellular and membrane" 840000000 "HPA006026: AB_1078446" "unprognostic (1.46e-1)" "unprognostic (2.21e-1)" "unprognostic (1.55e-1)" "unprognostic (3.83e-2)" "unprognostic (3.20e-2)" "unprognostic (2.99e-2)" "unprognostic (6.58e-2)" "unprognostic (2.15e-1)" "unprognostic (9.64e-3)" "unprognostic (3.79e-3)" "unprognostic (5.16e-2)" "unprognostic (1.89e-1)" "prognostic favourable (1.13e-5)" "unprognostic (1.09e-2)" "unprognostic (7.98e-2)" "unprognostic (9.18e-2)" "unprognostic (2.00e-1)" 5.6 3.7 10.4 17.7 13.9 22.6 5.6 4.9 9.5 6.1 9.0 8.8 12.3 8.4 3.9 7.6 2.9 5.0 6.7 5.2 9.5 9.2 13.3 12.2 12.2 22.6 10.8 9.4 3.0 9.1 21.1 14.5 20.3 8.3 7.8 8.1 12.9 12.9 9.0 4.6 4.3 13.4 5.5 6.7 33.0 13.8 3.1 9.9 6.7 18.8 0.9 9.7 6.0 3.9 1.0 1.8 12.2 5.3 1.2 2.1 0.9 3.5 13.4 5.9 3.2 0.9 2.1 2.0 3.6 2.6 6.3 4.7 0.8 19.8 3.3 25.3 9.1 2.7 9.2 0.9 7.7 21.7 2.5 0.9 16.6 1.2 5.8 1.2 20.6 1.5 0.3 1.7 0.4 3.8 1.2 2.1 2.2 7.6 0.0 7.4 4.6 2.1 0.7 0.7 1.7 24.6 5.2 4.0 1.2 10.0 5.7 9.0 6.3 9.1 12.4 5.0 5.2 10.0 10.9 0.5 0.7 5.5 5.7 3.8 18.1 0.9 1.5 3.4 2.1 2.5 1.4 1.0 1.2 1.5 1.0 0.7 1.0 1.3 12.2 1.2 5.3 1.8 1.1 0.9 10.4 13.9 4.9 9.4 9.5 9.2 10.8 9.4 8.3 9.9 PVR "CD155, HVED, Necl-5, NECL5, PVS, Tage4" ENSG00000073008 "Poliovirus receptor" P15151 19 44643798-44663583 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 65.6" "Cell line enhanced" "Detected in many" "TIME: 52.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "classical monocyte: 6.4;intermediate monocyte: 6.6;myeloid DC: 5.6;non-classical monocyte: 8.1" "Group enriched" "Detected in many" 5 "dendritic cells: 5.6;monocytes: 8.1" HPA012568 Approved Supported "Nucleoplasm,Vesicles,Plasma membrane" "Secreted - unknown location" 940000000 "Nucleoplasm, Vesicles, Plasma membrane" "HPA012568: AB_1846248" "unprognostic (2.90e-3)" "prognostic unfavourable (1.29e-4)" "unprognostic (3.36e-1)" "unprognostic (2.34e-1)" "unprognostic (7.89e-2)" "unprognostic (2.45e-3)" "unprognostic (3.06e-2)" "prognostic unfavourable (9.30e-4)" "unprognostic (9.05e-3)" "unprognostic (1.69e-1)" "unprognostic (2.09e-3)" "unprognostic (2.64e-3)" "unprognostic (1.69e-1)" "unprognostic (4.97e-1)" "unprognostic (1.27e-1)" "unprognostic (1.04e-3)" "prognostic unfavourable (2.75e-4)" 10.0 13.9 7.4 7.5 8.1 4.7 9.2 11.0 11.0 6.5 10.6 6.5 4.1 13.7 11.3 5.7 6.6 8.8 9.2 23.5 5.8 10.0 10.6 65.6 14.8 2.4 6.0 6.5 10.4 15.9 9.9 20.7 15.5 9.7 10.4 7.7 6.6 8.5 6.9 19.8 5.5 13.0 11.1 7.0 4.8 12.3 6.0 7.2 2.3 8.5 10.8 3.7 8.3 6.7 0.0 5.6 1.2 8.1 0.6 0.4 2.2 21.5 15.1 1.5 6.1 1.8 2.2 2.6 36.4 10.2 12.0 13.7 8.8 9.2 0.0 21.0 10.5 14.2 5.1 13.8 8.0 2.6 9.9 3.8 9.5 5.9 12.7 1.4 8.3 2.9 6.8 10.5 20.7 13.0 1.8 0.0 5.5 1.9 1.3 1.3 3.4 11.2 0.0 6.9 2.0 25.7 6.6 6.5 7.6 23.1 14.5 5.1 8.2 3.7 52.7 14.5 17.9 10.7 28.4 0.0 2.1 0.0 11.6 7.4 8.2 0.0 6.4 0.0 0.2 6.6 0.0 0.0 0.0 0.4 5.6 0.0 0.2 0.1 1.2 0.6 8.1 0.5 0.0 2.2 7.4 8.1 11.0 11.0 5.8 10.0 6.0 6.5 9.7 7.2 RHAG "CD241, RH50A, SLC42A1" ENSG00000112077 "Rh associated glycoprotein" Q02094 6 49605158-49636884 "CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Ammonia transport, Transport" "Disease mutation, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 9 "bone marrow: 54.1" "Group enriched" "Detected in some" 190 "HEL: 85.7;K-562: 84.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA046051, HPA055331" Approved Approved "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA046051: , HPA055331: " "unprognostic (8.16e-2)" "unprognostic (6.86e-2)" "unprognostic (1.25e-3)" "unprognostic (1.65e-1)" 1.2 0.2 0.0 1.1 0.5 54.1 3.2 0.0 0.1 2.3 1.0 0.5 1.7 0.2 0.4 0.1 2.6 0.5 0.8 5.3 0.0 0.0 0.1 0.7 3.3 0.1 0.0 0.0 0.1 0.2 0.1 0.1 5.8 0.1 1.3 0.2 0.0 0.2 0.5 0.4 0.1 0.9 0.1 0.0 4.5 0.6 0.2 0.0 1.7 1.8 0.0 0.1 0.8 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 85.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 84.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 RHCE "CD240CE, RH" ENSG00000188672 "Rh blood group CcEe antigens" P18577 1 25362249-25430192 "Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Blood group antigen" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "bone marrow: 40.5" "Cell line enriched" "Detected in some" 5 "HEL: 43.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 2.4" "Lineage enriched" "Detected in single" 7 "granulocytes: 2.4" "HPA060951, HPA077385" Supported Uncertain "Nucleoplasm,Plasma membrane" "Nucleoplasm, Plasma membrane" "HPA060951: , HPA077385: " "unprognostic (1.37e-1)" "unprognostic (3.53e-1)" "unprognostic (2.38e-1)" "unprognostic (6.75e-2)" "unprognostic (1.41e-2)" "unprognostic (4.91e-2)" "unprognostic (7.01e-2)" "unprognostic (3.12e-2)" "unprognostic (3.81e-2)" "unprognostic (1.35e-1)" "unprognostic (6.08e-2)" "unprognostic (4.61e-2)" "unprognostic (5.77e-5)" "unprognostic (1.38e-1)" "unprognostic (3.94e-2)" "unprognostic (7.15e-3)" "unprognostic (1.63e-1)" 0.6 0.8 2.0 0.6 5.1 40.5 0.9 3.3 4.7 0.8 0.7 3.5 1.0 0.7 0.7 5.2 1.4 1.6 0.8 2.1 2.6 1.5 0.8 2.2 0.7 1.0 2.1 2.5 0.9 9.6 0.5 4.0 1.6 5.9 1.6 0.8 2.2 8.4 0.8 1.9 1.1 0.6 0.5 2.9 2.1 0.8 2.6 1.4 1.2 1.1 1.2 0.8 0.5 0.6 0.1 0.2 2.4 0.2 0.1 0.3 0.9 0.1 0.0 0.1 0.2 0.4 0.3 0.0 0.1 0.1 0.2 0.0 0.0 0.7 0.3 0.5 0.5 0.1 0.0 0.1 0.1 0.2 0.0 43.6 0.0 0.0 0.5 0.0 0.3 0.9 0.7 0.3 0.2 0.0 8.5 0.2 0.2 0.4 0.0 0.3 0.8 0.2 0.0 0.1 1.2 0.0 0.0 0.3 0.4 0.1 0.1 0.5 0.2 0.0 0.0 0.1 0.0 0.4 0.0 2.6 0.6 0.5 1.4 0.4 0.2 2.4 0.2 0.6 0.3 0.0 0.3 0.1 0.0 0.1 0.2 0.0 0.2 0.0 1.0 0.1 0.0 0.1 0.3 0.9 2.0 5.1 3.3 4.7 2.6 1.5 2.1 2.5 5.9 1.4 RHD "CD240D, DIIIc, RH, Rh30a, Rh4, RhII, RhPI" ENSG00000187010 "Rh blood group D antigen" Q02161 1 25272393-25330445 "Blood group antigen proteins, CD markers, Predicted membrane proteins, Transporters" "Blood group antigen" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 10.0;bone marrow: 16.5;salivary gland: 7.1" "Group enriched" "Detected in some" 6 "HEL: 27.6;K-562: 8.5" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in many" "neutrophil: 10.0" "Lineage enriched" "Detected in many" 5 "granulocytes: 10.0" "HPA060951, HPA077385" Supported Uncertain "Nucleoplasm,Plasma membrane" "Nucleoplasm, Plasma membrane" "HPA060951: , HPA077385: " "unprognostic (4.75e-3)" "unprognostic (7.70e-2)" "unprognostic (1.34e-1)" "unprognostic (1.38e-1)" "unprognostic (1.09e-2)" "unprognostic (4.84e-2)" "unprognostic (1.11e-2)" "unprognostic (5.25e-2)" "unprognostic (1.11e-2)" "unprognostic (1.91e-1)" "unprognostic (1.27e-2)" "unprognostic (1.89e-1)" "unprognostic (4.96e-3)" "unprognostic (1.93e-1)" "unprognostic (8.09e-2)" "unprognostic (5.53e-2)" "unprognostic (4.92e-3)" 0.3 0.3 0.3 0.5 0.5 16.5 0.3 1.5 1.4 0.6 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.4 0.9 0.3 0.2 0.3 0.3 2.5 0.8 0.3 0.3 0.9 0.3 0.1 0.4 0.3 1.1 0.5 0.0 0.3 7.1 0.3 4.1 2.5 0.4 0.3 0.4 1.8 0.3 0.5 0.3 0.3 0.4 2.3 0.3 0.3 0.3 2.0 0.6 10.0 1.4 1.4 1.4 1.2 0.1 0.0 0.2 0.2 0.1 0.0 0.4 0.1 0.0 0.1 0.0 0.1 0.3 0.4 0.1 0.0 0.2 0.0 0.0 0.0 0.5 0.1 27.6 0.6 0.2 0.0 0.3 0.2 0.1 0.1 0.1 0.1 0.1 8.5 0.7 0.0 0.1 0.2 0.2 3.1 0.1 0.2 0.1 0.1 0.0 0.1 0.5 0.3 0.1 0.2 0.1 0.2 0.4 0.4 0.5 0.2 0.4 0.1 0.3 0.1 0.1 0.4 0.2 0.1 4.9 1.4 2.8 1.0 0.6 1.1 1.3 1.3 0.8 0.2 2.0 1.4 1.3 10.0 1.4 0.8 0.6 0.9 1.2 0.3 0.5 1.5 1.4 0.3 0.2 0.3 0.3 1.1 0.3 S1PR1 "CD363, D1S3362, edg-1, EDG1" ENSG00000170989 "Sphingosine-1-phosphate receptor 1" P21453 1 101236888-101241518 "Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Angiogenesis, Chemotaxis" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 88.9" "Cell line enhanced" "Detected in many" "BJ: 19.0;HUVEC TERT2: 53.7;TIME: 29.9;U-251 MG: 36.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010104, HPA075568" Supported Supported Vesicles Vesicles "CAB010104: AB_2238920, HPA075568: " "unprognostic (1.41e-1)" "unprognostic (9.35e-2)" "unprognostic (2.46e-2)" "unprognostic (2.61e-1)" "unprognostic (9.78e-2)" "unprognostic (4.49e-3)" "unprognostic (1.34e-3)" "unprognostic (1.99e-1)" "unprognostic (1.36e-1)" "unprognostic (9.12e-2)" "unprognostic (2.34e-2)" "unprognostic (2.23e-1)" "unprognostic (5.82e-3)" "unprognostic (2.54e-2)" "unprognostic (1.04e-1)" "unprognostic (3.64e-1)" "prognostic unfavourable (8.78e-4)" 72.3 8.4 24.7 16.6 26.2 9.7 46.3 21.6 21.8 13.3 10.5 9.5 2.5 5.7 12.1 5.0 14.7 11.5 17.6 43.5 22.9 15.4 8.9 20.5 35.7 24.5 23.2 14.0 7.9 11.0 13.4 4.7 29.6 21.2 8.9 7.0 9.3 7.5 5.6 21.7 8.2 9.8 19.0 11.0 35.2 8.0 5.8 13.9 4.4 17.0 8.7 15.7 15.2 18.5 27.4 0.2 88.9 0.2 33.4 49.8 30.8 3.5 0.0 3.8 0.0 0.4 9.1 0.0 19.0 3.4 11.5 4.1 0.0 0.1 0.0 4.7 6.6 0.0 0.5 0.2 7.7 1.3 0.3 1.3 0.1 0.0 1.8 0.0 0.8 12.2 0.0 0.0 0.9 53.7 0.0 3.9 3.6 0.0 4.5 0.0 1.0 1.2 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 29.9 1.9 0.7 0.4 36.8 0.3 0.0 0.2 0.1 0.0 0.1 88.9 0.1 4.9 49.8 0.1 40.2 25.1 45.3 44.1 0.2 27.4 35.7 36.2 1.4 33.4 0.2 0.2 26.8 30.8 24.7 26.2 21.6 16.8 22.9 15.4 23.2 14.0 21.2 13.9 SDC1 "CD138, SDC, SYND1, syndecan" ENSG00000115884 "Syndecan 1" P18827 2 20200797-20225433 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 113.2;placenta: 228.8" "Cell line enhanced" "Detected in many" "HBEC3-KT: 60.9;hTCEpi: 56.3;U-251 MG: 58.0;U-266/70: 60.1;U-266/84: 126.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in single" 17 "memory B-cell: 3.9" "Lineage enriched" "Detected in single" 40 "B-cells: 3.9" "Group enriched" "Detected in some" 4 "cerebellum: 10.7;olfactory region: 5.9" "Not detected" "Not detected" "CAB002424, HPA006185, HPA067477" Enhanced Supported "Focal adhesion sites" "Secreted to blood" 63100000 1600000 "Focal adhesion sites" "CAB002424: AB_442050, HPA006185: AB_1857705, HPA067477: " "prognostic unfavourable (2.22e-4)" "unprognostic (6.80e-3)" "unprognostic (6.80e-2)" "unprognostic (7.84e-2)" "prognostic unfavourable (5.02e-4)" "unprognostic (1.15e-1)" "unprognostic (4.02e-2)" "unprognostic (6.32e-2)" "unprognostic (1.70e-1)" "unprognostic (3.66e-1)" "unprognostic (2.27e-3)" "unprognostic (1.79e-1)" "unprognostic (1.63e-1)" "unprognostic (1.94e-2)" "unprognostic (4.27e-1)" "unprognostic (1.62e-2)" "unprognostic (1.52e-1)" 0.8 3.4 0.5 5.4 0.6 0.0 4.5 0.8 0.7 21.4 18.3 0.5 3.5 14.3 2.3 8.7 103.7 1.6 55.3 0.3 0.4 0.5 68.5 113.2 15.8 6.3 1.9 0.4 1.6 7.0 0.6 0.6 228.8 0.7 13.3 6.2 1.5 16.0 5.2 0.5 69.5 21.9 4.3 0.4 3.7 16.3 2.6 0.4 1.5 3.5 62.3 48.4 30.0 37.7 3.9 0.0 0.0 0.0 0.0 0.0 0.5 30.8 17.3 5.5 13.8 1.5 0.2 17.3 8.6 8.3 8.1 6.8 3.6 18.8 0.0 3.2 6.1 30.4 2.4 60.9 5.4 0.1 1.6 0.0 1.6 18.5 1.3 1.3 0.1 0.8 56.3 7.2 17.3 0.8 0.7 12.1 4.3 18.4 0.0 0.3 4.9 33.5 0.6 2.0 23.3 10.3 46.3 1.6 12.8 6.5 43.9 1.9 4.3 0.3 1.3 32.1 10.3 1.1 58.0 60.1 126.7 0.1 9.6 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.6 0.8 0.7 0.4 0.5 1.9 0.4 0.7 0.4 SDC2 "CD362, fibroglycan, HSPG, HSPG1, SYND2" ENSG00000169439 "Syndecan 2" P34741 8 96493351-96611780 "CD markers, Predicted membrane proteins" "Differentiation, Neurogenesis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 115.1;thyroid gland: 111.2" "Cell line enhanced" "Detected in many" "AF22: 101.9;EFO-21: 47.8;fHDF/TERT166: 44.1;RPTEC TERT1: 53.2;U-138 MG: 49.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 7 "neutrophil: 13.9" "Lineage enriched" "Detected in many" 7 "granulocytes: 13.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025123, HPA044416" Uncertain Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "CAB025123: , HPA044416: " "unprognostic (1.25e-1)" "unprognostic (1.04e-1)" "unprognostic (1.25e-1)" "unprognostic (3.61e-2)" "unprognostic (6.52e-3)" "unprognostic (4.18e-2)" "unprognostic (2.43e-1)" "unprognostic (2.35e-2)" "unprognostic (2.89e-2)" "unprognostic (4.56e-1)" "unprognostic (1.48e-1)" "unprognostic (6.16e-2)" "unprognostic (1.56e-2)" "unprognostic (1.45e-3)" "unprognostic (1.91e-1)" "unprognostic (2.50e-2)" "unprognostic (1.23e-1)" 43.2 9.9 13.9 9.1 16.9 2.5 17.0 12.7 8.4 43.4 18.7 7.3 21.2 5.8 21.9 15.3 13.3 21.0 15.0 19.1 12.0 12.6 23.9 115.1 14.4 4.4 9.7 9.3 45.9 16.8 1.6 24.0 31.3 10.7 25.9 10.7 51.4 6.3 28.1 9.4 6.5 9.6 34.3 9.5 7.5 11.9 8.7 9.3 0.5 111.2 13.8 3.5 35.9 26.3 0.0 1.3 13.9 1.9 0.0 0.2 0.5 0.0 0.0 101.9 0.0 36.8 34.4 0.1 14.7 17.5 8.6 9.5 3.0 0.0 0.0 47.8 44.1 0.0 17.6 0.2 7.4 0.0 6.9 0.0 9.8 37.4 1.1 0.2 0.4 13.3 0.4 19.4 0.5 0.3 9.6 0.0 3.5 0.8 0.0 2.5 10.8 0.1 0.1 16.0 0.3 53.2 8.7 3.0 7.9 0.0 0.0 0.7 4.3 11.4 8.0 49.4 15.1 0.2 8.2 0.9 0.0 0.1 15.7 0.0 15.4 0.0 1.9 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.3 0.0 0.2 0.0 13.9 0.0 0.1 0.0 0.0 0.5 13.9 16.9 12.7 8.4 12.0 12.6 9.7 9.3 10.7 9.3 SELE "CD62E, ELAM, ELAM1, ESEL" ENSG00000007908 "Selectin E" P16581 1 169722641-169764705 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "tongue: 50.0" "Cell line enriched" "Detected in single" 5 "HUVEC TERT2: 5.2" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 4 "pons and medulla: 5.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" CAB002143 Enhanced 640000000 "CAB002143: AB_563608" "unprognostic (2.39e-1)" "unprognostic (2.16e-2)" "unprognostic (1.37e-2)" "unprognostic (2.09e-2)" "unprognostic (1.61e-1)" "unprognostic (1.40e-2)" "unprognostic (1.59e-1)" "unprognostic (2.94e-1)" "unprognostic (3.63e-1)" "unprognostic (3.88e-1)" "unprognostic (9.74e-2)" "unprognostic (4.32e-2)" "unprognostic (1.56e-2)" "unprognostic (8.13e-3)" "unprognostic (4.69e-2)" "unprognostic (4.63e-2)" "unprognostic (2.55e-1)" 14.9 2.7 0.9 30.4 1.2 0.2 8.3 0.3 1.0 13.7 2.7 1.9 4.4 0.4 18.1 3.2 6.7 20.1 7.4 4.4 0.9 0.9 2.5 4.9 10.6 2.0 1.2 0.0 9.8 1.4 21.0 3.1 0.9 5.4 21.2 1.9 4.3 2.0 4.6 2.2 3.7 2.4 13.1 4.8 0.2 3.4 5.6 0.5 0.9 9.0 50.0 15.5 16.4 4.0 0.0 0.0 0.0 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.9 0.0 0.9 1.2 0.3 1.0 0.9 0.9 1.2 0.0 5.4 0.5 SELL "CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR" ENSG00000188404 "Selectin L" P14151 1 169690667-169711698 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 227.5;lymphoid tissue: 77.8" "Cell line enhanced" "Detected in some" "Daudi: 7.3;EFO-21: 7.1;MOLT-4: 13.4;U-266/70: 25.2;U-698: 11.7;U-937: 7.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB002144, HPA051972" Enhanced Uncertain Cytosol 8100000000 Cytosol "CAB002144: AB_563862, HPA051972: " "prognostic favourable (3.76e-4)" "prognostic favourable (2.25e-4)" "unprognostic (1.52e-2)" "unprognostic (2.89e-2)" "unprognostic (7.87e-3)" "prognostic favourable (6.43e-4)" "unprognostic (1.39e-3)" "unprognostic (3.43e-1)" "unprognostic (2.70e-3)" "prognostic favourable (3.14e-4)" "unprognostic (1.42e-1)" "unprognostic (4.21e-2)" "prognostic unfavourable (4.96e-5)" "unprognostic (4.76e-2)" "unprognostic (8.71e-3)" "unprognostic (9.57e-2)" "unprognostic (1.01e-1)" 6.9 0.9 2.0 25.1 4.6 30.3 1.5 1.1 2.5 0.9 1.4 1.1 0.0 0.4 1.0 1.1 4.2 3.2 5.4 4.1 2.5 2.2 2.3 2.5 11.4 77.8 5.2 0.2 0.8 1.0 10.7 7.9 3.4 2.7 1.2 1.3 3.8 12.1 0.1 0.9 0.8 8.8 2.9 5.2 67.7 1.7 1.0 2.3 43.8 1.9 1.3 64.0 8.1 6.1 40.4 40.7 227.5 49.7 130.8 69.5 90.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.5 0.0 0.2 7.3 7.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 5.0 0.9 0.3 0.0 0.0 0.0 1.2 0.0 1.0 0.0 0.8 13.4 0.1 0.0 0.2 5.1 0.1 0.3 4.1 0.2 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 25.2 0.0 11.7 1.3 7.3 0.1 170.8 49.7 88.6 16.5 11.2 4.5 33.8 30.7 17.0 40.7 40.4 69.5 39.6 227.5 130.8 4.5 32.8 52.7 90.1 2.0 4.6 1.1 2.5 2.5 2.2 5.2 0.2 2.7 2.3 SELP "CD62, CD62P, GMP140, GRMP, PADGEM, PSEL" ENSG00000174175 "Selectin P" P16109 1 169588849-169630193 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in some" 37 "EFO-21: 24.7;HEL: 22.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 6 "basophil: 6.0;neutrophil: 2.4;T-reg: 8.9" "Group enriched" "Detected in many" 8 "granulocytes: 6.0;T-cells: 8.9" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002145, HPA002655, HPA005990" Enhanced 830000000 "CAB002145: AB_563984, HPA002655: AB_1078480, HPA005990: AB_1078479" "unprognostic (3.37e-2)" "unprognostic (2.98e-4)" "unprognostic (4.11e-1)" "unprognostic (1.46e-1)" "unprognostic (9.26e-2)" "prognostic favourable (3.12e-4)" "unprognostic (5.30e-4)" "unprognostic (4.14e-2)" "unprognostic (3.59e-1)" "unprognostic (1.74e-1)" "unprognostic (1.93e-2)" "unprognostic (6.61e-2)" "unprognostic (1.19e-1)" "unprognostic (8.24e-3)" "unprognostic (1.74e-2)" "unprognostic (7.85e-3)" "unprognostic (1.66e-1)" 14.2 2.1 0.4 8.4 0.4 1.0 10.9 0.4 0.4 14.8 3.7 0.6 7.5 3.3 10.6 6.2 5.6 7.7 7.0 9.6 0.4 0.4 7.5 4.6 11.3 12.9 0.4 0.4 5.0 1.5 3.8 2.8 7.4 1.3 14.8 2.9 24.7 3.4 4.3 3.7 2.3 5.2 10.5 1.0 1.9 3.5 3.1 0.3 1.4 4.9 7.7 13.0 11.5 27.2 0.9 0.1 6.0 0.5 0.4 8.9 8.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 6.0 0.5 0.7 0.0 0.2 0.0 0.9 0.6 0.3 0.0 0.2 0.2 0.1 2.4 0.4 0.0 0.1 8.9 8.8 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 1.3 0.3 SELPLG "CD162, PSGL-1" ENSG00000110876 "Selectin P ligand" Q14242 12 108622277-108633959 "Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 126.9;lymphoid tissue: 60.5" "Cell line enhanced" "Detected in some" "HDLM-2: 28.0;HMC-1: 27.2;Karpas-707: 42.6;RPMI-8226: 59.2;U-266/70: 69.5;U-266/84: 43.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" CAB002431 Enhanced "CAB002431: AB_563509" "unprognostic (2.32e-2)" "prognostic favourable (1.46e-4)" "unprognostic (3.64e-3)" "unprognostic (1.02e-2)" "unprognostic (6.32e-2)" "prognostic favourable (6.94e-4)" "unprognostic (2.52e-1)" "unprognostic (1.29e-1)" "prognostic favourable (2.92e-4)" "unprognostic (2.26e-1)" "unprognostic (2.12e-2)" "unprognostic (3.24e-1)" "prognostic unfavourable (5.86e-4)" "unprognostic (5.88e-2)" "unprognostic (2.37e-2)" "prognostic favourable (2.74e-4)" "unprognostic (5.44e-2)" 10.6 5.5 11.3 25.3 8.9 10.7 4.2 2.2 12.5 5.8 5.4 27.2 0.1 5.0 2.9 4.1 5.0 6.8 9.6 5.9 12.1 9.6 4.6 3.9 23.3 46.8 16.2 5.4 2.1 2.9 1.3 3.1 7.3 11.5 3.0 5.2 3.4 5.2 2.5 1.8 2.7 10.3 6.7 19.6 60.5 6.0 2.1 13.5 26.0 3.1 2.8 18.0 14.8 3.0 2.2 50.9 126.9 68.4 28.1 63.2 77.1 0.1 0.0 0.3 0.1 0.1 0.3 0.1 1.0 1.0 0.3 0.3 0.0 0.4 0.1 0.3 1.5 0.0 0.0 0.0 0.3 28.0 0.0 9.9 0.0 0.0 0.0 7.0 27.2 0.3 0.1 0.5 0.1 0.0 0.1 42.6 1.3 0.0 5.6 4.0 0.0 0.3 0.0 0.1 59.2 0.6 0.0 0.0 0.0 0.1 0.0 0.4 0.0 8.9 0.3 0.5 0.1 0.7 0.2 69.5 43.3 1.2 0.3 14.9 0.4 126.9 28.1 88.8 43.8 49.5 35.8 2.0 41.8 37.4 29.4 2.2 32.4 34.1 125.8 28.1 68.4 50.9 63.2 77.1 11.3 8.9 2.2 12.5 12.1 9.6 16.2 5.4 11.5 13.5 SEMA4D "C9orf164, CD100, coll-4, FLJ39737, SEMAJ" ENSG00000187764 "Semaphorin 4D" Q92854 9 89360787-89498130 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Neurogenesis" "Developmental protein, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 107.1;skeletal muscle: 43.3" "Cell line enhanced" "Detected in many" "HDLM-2: 42.9;HMC-1: 33.1;MOLT-4: 38.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015662, HPA023277" Approved Supported "Endoplasmic reticulum,Vesicles" 4100000 Vesicles "Endoplasmic reticulum" "HPA015662: AB_1856671, HPA023277: AB_1856672" "unprognostic (2.94e-2)" "prognostic favourable (4.17e-4)" "unprognostic (1.12e-2)" "unprognostic (8.22e-2)" "unprognostic (1.41e-1)" "unprognostic (1.76e-3)" "unprognostic (1.27e-1)" "unprognostic (1.58e-1)" "unprognostic (7.79e-2)" "unprognostic (2.74e-1)" "unprognostic (3.18e-3)" "unprognostic (1.50e-2)" "unprognostic (2.29e-3)" "unprognostic (3.05e-2)" "unprognostic (1.28e-2)" "unprognostic (2.43e-1)" "prognostic favourable (4.06e-5)" 3.9 5.6 18.0 18.6 20.7 14.3 3.6 7.7 20.9 4.0 5.9 54.0 3.1 6.1 3.9 7.4 9.3 6.6 7.2 4.9 28.2 18.8 8.4 2.0 6.7 32.0 42.6 15.0 4.1 4.6 4.9 5.3 3.2 27.5 4.9 5.8 2.9 6.7 4.2 43.3 8.8 9.6 3.3 107.1 19.2 9.4 6.1 23.3 25.3 4.9 3.1 27.6 8.3 5.3 2.6 4.6 21.2 4.1 4.7 14.0 7.8 4.0 3.0 2.8 4.1 0.1 0.2 6.5 0.4 0.2 0.8 0.6 2.0 4.6 15.5 1.7 0.0 2.1 2.5 1.2 0.3 42.9 2.5 6.5 1.0 0.2 0.5 8.6 33.1 0.1 0.9 0.2 0.1 1.6 1.5 10.6 0.0 6.7 38.9 10.8 6.9 0.1 12.4 0.9 4.3 5.5 4.2 6.7 4.4 1.1 3.6 0.1 3.4 4.7 1.0 0.0 2.6 0.3 2.0 11.9 5.1 2.2 2.0 10.5 2.5 7.3 4.1 20.4 13.3 3.8 8.0 2.6 10.6 11.1 1.5 1.6 12.2 14.0 21.2 4.7 4.1 4.6 9.5 7.8 18.0 20.7 7.7 20.9 28.2 18.8 42.6 15.0 27.5 23.3 SEMA7A "CD108, H-Sema-L, SEMAL" ENSG00000138623 "Semaphorin 7A (John Milton Hagen blood group)" O75326 15 74409289-74433958 "Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins" "Differentiation, Inflammatory response, Neurogenesis" "Developmental protein" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 36.4;lymphoid tissue: 34.7;placenta: 54.0" "Cell line enhanced" "Detected in many" "HMC-1: 99.7;hTEC/SVTERT24-B: 39.1;U-251 MG: 57.5;U-87 MG: 33.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "eosinophil: 8.9" "Lineage enriched" "Detected in many" 5 "granulocytes: 8.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008210, HPA042273" Uncertain Uncertain Vesicles 29000000 Vesicles "HPA008210: , HPA042273: AB_10806234" "unprognostic (2.00e-1)" "unprognostic (2.72e-1)" "unprognostic (2.02e-2)" "unprognostic (5.81e-2)" "unprognostic (6.49e-2)" "unprognostic (8.61e-2)" "unprognostic (2.54e-2)" "unprognostic (4.18e-3)" "unprognostic (1.33e-1)" "unprognostic (1.39e-1)" "unprognostic (5.18e-3)" "unprognostic (1.44e-1)" "prognostic unfavourable (2.45e-11)" "unprognostic (1.32e-1)" "unprognostic (2.01e-2)" "unprognostic (6.25e-2)" "unprognostic (2.57e-2)" 2.2 1.9 5.4 10.4 13.8 12.8 1.4 22.9 27.3 1.3 1.8 19.9 1.4 2.7 4.3 1.8 3.2 1.2 3.3 1.4 10.8 5.7 1.4 1.5 4.4 19.0 28.5 5.7 5.9 0.9 6.4 1.9 54.0 28.6 1.4 1.8 7.8 1.7 3.5 1.4 4.7 6.0 2.0 36.4 34.7 3.7 23.6 15.4 9.0 1.1 0.4 19.7 4.6 1.7 1.4 1.8 8.9 0.0 0.8 0.2 0.0 5.7 0.0 1.7 0.5 2.2 7.4 14.3 26.5 10.7 5.6 8.6 2.2 9.4 0.0 1.5 12.0 1.7 0.5 1.7 5.8 0.4 0.3 10.3 0.0 2.8 0.5 0.3 99.7 5.2 0.0 39.1 2.2 0.0 5.9 3.6 18.1 0.4 1.4 3.4 1.8 4.0 0.2 1.1 1.5 2.3 2.4 0.1 0.1 0.2 4.8 2.1 0.3 2.1 1.0 10.5 7.0 5.0 57.5 0.6 0.4 0.1 33.6 1.2 0.5 3.9 0.0 8.9 0.2 0.0 0.2 1.4 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.8 0.0 1.8 0.0 0.0 5.4 13.8 22.9 27.3 10.8 5.7 28.5 5.7 28.6 15.4 SIGLEC1 "CD169, dJ1009E24.1, FLJ00051, FLJ00055, FLJ00073, FLJ32150, sialoadhesin, SIGLEC-1, SN" ENSG00000088827 "Sialic acid binding Ig like lectin 1" Q9BZZ2 20 3686970-3707128 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Endocytosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 35.7" "Cell line enriched" "Detected in single" 18 "THP-1: 6.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 16 "classical monocyte: 4.1;intermediate monocyte: 2.5;myeloid DC: 1.9;plasmacytoid DC: 1.2" "Group enriched" "Detected in many" 20 "dendritic cells: 1.9;monocytes: 4.1" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA053457 Supported "Intracellular and membrane" 110000 "HPA053457: " "unprognostic (2.05e-1)" "unprognostic (9.27e-3)" "unprognostic (3.83e-4)" "unprognostic (4.87e-3)" "unprognostic (3.40e-2)" "unprognostic (1.06e-1)" "unprognostic (2.15e-1)" "unprognostic (6.98e-2)" "unprognostic (2.27e-2)" "unprognostic (1.68e-1)" "unprognostic (1.40e-1)" "unprognostic (1.57e-1)" "prognostic unfavourable (8.69e-5)" "unprognostic (8.71e-2)" "prognostic unfavourable (4.36e-4)" "unprognostic (1.11e-2)" "unprognostic (9.31e-2)" 11.6 8.0 1.5 4.5 2.0 7.0 4.7 1.5 1.9 1.5 4.4 1.5 1.5 2.9 1.5 1.5 3.1 4.2 5.3 3.5 1.5 0.1 2.9 4.9 9.7 35.7 2.1 1.5 1.6 1.5 0.0 1.5 12.2 3.0 1.5 4.1 1.8 6.3 1.5 3.2 1.5 5.9 4.6 1.5 12.0 2.9 1.5 1.5 2.8 1.9 3.4 1.8 4.8 1.7 0.0 1.9 0.0 4.1 0.0 0.1 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 6.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 2.5 0.1 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 1.2 1.5 2.0 1.5 1.9 1.5 0.1 2.1 1.5 3.0 1.5 SIGLEC5 "CD170, CD33L2, OB-BP2, SIGLEC-5" ENSG00000105501 "Sialic acid binding Ig like lectin 5" O15389 19 51611927-51645545 "CD markers, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "blood: 46.7;bone marrow: 13.5" "Group enriched" "Detected in some" 6 "HMC-1: 34.9;U-937: 14.5" "Cancer enhanced" "Detected in single" "urothelial cancer: 1.7" "Cell type enhanced" "Detected in many" "neutrophil: 46.7" "Group enriched" "Detected in many" 6 "granulocytes: 46.7;monocytes: 13.7" "HPA009085, CAB024900" Supported "CAB024900: , HPA009085: AB_1079965" "unprognostic (1.83e-1)" "unprognostic (1.94e-1)" "unprognostic (2.02e-2)" "unprognostic (1.03e-2)" "unprognostic (4.39e-2)" "unprognostic (1.62e-2)" "unprognostic (1.73e-1)" "unprognostic (1.01e-1)" "unprognostic (3.28e-1)" "unprognostic (7.44e-2)" "unprognostic (1.01e-1)" "unprognostic (4.05e-1)" "unprognostic (3.71e-4)" "unprognostic (4.37e-2)" "unprognostic (3.55e-3)" "unprognostic (4.02e-1)" "unprognostic (1.95e-1)" 1.2 0.4 0.4 6.4 0.5 13.5 0.2 0.1 0.2 0.1 0.3 0.0 0.2 0.0 0.2 0.1 0.3 0.3 0.3 0.2 0.2 1.2 1.5 2.5 0.5 0.1 0.2 0.0 0.2 0.5 0.2 0.4 0.4 0.0 0.0 0.1 3.4 0.5 0.7 5.9 0.3 0.7 0.2 1.9 0.8 0.1 0.8 4.7 46.7 13.7 0.2 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.7 34.9 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.5 0.0 3.6 6.4 0.1 0.0 7.5 0.0 0.8 0.0 0.0 4.7 0.7 0.0 0.0 46.7 0.2 13.7 1.5 0.0 2.0 SIGLEC6 "CD327, CD33L, CD33L1, OB-BP1, SIGLEC-6" ENSG00000105492 "Sialic acid binding Ig like lectin 6" O43699 19 51519525-51531856 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 10 "placenta: 87.4" "Cell line enriched" "Detected in some" 7 "HMC-1: 100.5" "Cancer enhanced" "Detected in some" "thyroid cancer: 2.7" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "memory B-cell: 6.5;plasmacytoid DC: 6.8" "Group enriched" "Detected in many" 33 "B-cells: 6.5;dendritic cells: 6.8;granulocytes: 2.3" "HPA009084, HPA018198" Enhanced "Intracellular and membrane" "HPA009084: AB_1079967, HPA018198: AB_1856868" "unprognostic (1.97e-1)" "unprognostic (1.41e-1)" "unprognostic (2.38e-3)" "unprognostic (9.31e-3)" "unprognostic (8.46e-4)" "unprognostic (2.91e-1)" "unprognostic (2.02e-2)" "unprognostic (2.64e-1)" "unprognostic (8.96e-2)" "unprognostic (2.03e-1)" "unprognostic (6.89e-2)" "unprognostic (1.10e-2)" "unprognostic (4.15e-2)" "unprognostic (4.42e-2)" "unprognostic (3.28e-2)" "unprognostic (5.57e-3)" 1.8 0.0 0.0 5.6 0.0 0.1 0.8 0.0 0.1 1.2 1.7 0.0 0.3 0.9 2.0 1.2 1.5 0.5 8.6 0.4 0.0 0.0 0.4 0.1 4.2 1.5 0.0 0.0 0.1 0.3 0.1 0.1 87.4 0.0 3.7 1.5 0.5 1.4 1.0 0.2 1.3 6.0 3.1 0.0 1.3 1.7 1.0 0.0 0.3 0.2 1.0 2.6 2.2 1.9 6.5 6.8 2.3 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.4 0.0 0.0 0.0 0.2 100.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.3 0.0 0.0 0.0 0.0 0.0 6.5 0.0 0.0 1.4 2.8 0.0 0.0 0.0 0.1 0.0 6.8 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 SIGLEC7 "CD328, p75/AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2" ENSG00000168995 "Sialic acid binding Ig like lectin 7" Q9Y286 19 51142299-51153526 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 51.5;lymphoid tissue: 29.4" "Group enriched" "Detected in some" 9 "Karpas-707: 30.8;RPMI-8226: 17.9;U-937: 18.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "eosinophil: 51.5" "Low lineage specificity" "Detected in many" "Intracellular and membrane" 1100000 "unprognostic (3.14e-1)" "unprognostic (5.87e-2)" "unprognostic (1.03e-1)" "unprognostic (2.66e-1)" "unprognostic (3.90e-2)" "unprognostic (1.85e-1)" "unprognostic (2.53e-1)" "unprognostic (2.78e-1)" "unprognostic (1.69e-1)" "unprognostic (4.95e-2)" "unprognostic (1.10e-1)" "unprognostic (2.66e-1)" "unprognostic (8.27e-2)" "unprognostic (6.61e-2)" "unprognostic (1.14e-3)" "unprognostic (2.58e-1)" "unprognostic (2.26e-2)" 6.9 3.7 1.6 10.0 5.8 3.7 3.0 0.3 2.2 0.9 1.6 1.0 0.6 1.4 0.9 2.1 1.1 1.8 2.4 1.9 0.8 1.0 2.8 9.8 4.7 18.4 3.3 0.0 1.3 0.9 0.2 0.9 5.9 2.9 1.0 2.3 0.7 2.3 0.2 0.4 0.5 2.3 3.5 3.3 29.4 1.1 1.8 2.5 0.7 1.0 0.0 2.1 3.2 1.7 0.6 14.9 51.5 32.0 20.0 4.4 15.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 30.8 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 17.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.6 0.6 0.0 0.1 18.9 0.0 0.5 32.0 51.5 2.5 23.0 4.4 0.6 0.0 1.1 14.9 0.0 0.0 1.0 26.8 20.0 9.1 0.6 0.0 15.8 1.6 5.8 0.3 2.2 0.8 1.0 3.3 0.0 2.9 2.5 SIGLEC8 "MGC59785, SAF2, SIGLEC-8, SIGLEC8L" ENSG00000105366 "Sialic acid binding Ig like lectin 8" Q9NYZ4 19 51450847-51458456 "CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 63.0" "Cell line enriched" "Detected in some" 45 "HMC-1: 57.4" "Cancer enhanced" "Detected in many" "glioma: 7.2" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 42 "eosinophil: 63.0" "Lineage enriched" "Detected in single" 623 "granulocytes: 63.0" HPA012556 Uncertain Uncertain Cytosol Cytosol "HPA012556: AB_1856869" "unprognostic (1.27e-1)" "unprognostic (1.88e-4)" "unprognostic (1.28e-1)" "unprognostic (6.70e-2)" "unprognostic (2.97e-1)" "unprognostic (1.30e-2)" "unprognostic (7.84e-2)" "unprognostic (2.51e-2)" "unprognostic (2.72e-2)" "unprognostic (2.17e-1)" "unprognostic (1.10e-1)" "unprognostic (4.19e-1)" "unprognostic (8.62e-3)" "unprognostic (7.18e-2)" "unprognostic (6.02e-2)" "unprognostic (4.28e-3)" "unprognostic (3.29e-1)" 0.6 6.7 5.8 2.4 8.4 0.7 2.3 0.7 7.0 1.4 2.9 7.4 0.0 2.9 1.0 1.1 1.1 1.1 2.7 0.3 8.6 4.8 0.4 1.6 4.1 9.6 8.3 3.6 0.3 0.7 0.7 1.2 0.1 7.5 1.0 2.8 0.1 1.1 0.9 0.3 0.8 4.5 1.5 14.8 9.2 2.1 0.5 6.2 0.6 0.7 0.0 4.1 2.0 0.7 0.0 0.0 63.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 57.4 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.1 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 1.5 0.1 63.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 5.8 8.4 0.7 5.6 8.6 4.8 8.3 3.6 7.5 6.2 SIRPA "BIT, CD172a, MFR, MYD-1, P84, PTPNS1, SHPS-1, SHPS1, SIRP, SIRP-ALPHA-1, SIRPalpha, SIRPalpha2" ENSG00000198053 "Signal regulatory protein alpha" P78324 20 1894167-1940592 "CD markers, Plasma proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 69.2" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 42.3;RPTEC TERT1: 30.7;SK-MEL-30: 35.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "classical monocyte: 10.1;eosinophil: 20.9;myeloid DC: 6.3;neutrophil: 23.5" "Group enriched" "Detected in many" 134 "dendritic cells: 6.3;granulocytes: 23.5;monocytes: 10.1" "CAB002776, CAB015122, HPA054437, HPA058511" Enhanced 170000000 "CAB002776: , CAB015122: AB_677430, HPA054437: AB_2682488, HPA058511: AB_2683738" "unprognostic (9.78e-2)" "unprognostic (2.67e-1)" "unprognostic (3.07e-1)" "unprognostic (1.23e-1)" "unprognostic (5.56e-2)" "unprognostic (1.58e-1)" "unprognostic (1.15e-3)" "unprognostic (4.19e-3)" "unprognostic (3.48e-2)" "unprognostic (2.84e-3)" "unprognostic (3.69e-1)" "unprognostic (3.33e-2)" "unprognostic (2.79e-3)" "unprognostic (1.08e-1)" "unprognostic (1.55e-2)" "unprognostic (3.55e-2)" "unprognostic (2.24e-2)" 23.2 21.7 36.9 24.9 38.8 19.9 14.0 39.1 69.2 9.5 6.7 22.8 3.0 14.1 6.4 11.2 7.2 9.1 14.6 11.9 29.3 18.5 9.6 16.1 22.0 10.3 18.8 50.3 9.7 6.1 2.2 5.5 13.8 14.7 4.9 8.2 9.5 15.0 8.9 5.5 13.6 11.7 11.4 18.0 9.6 5.2 3.9 20.4 1.0 4.1 2.2 8.8 13.2 6.9 0.0 6.3 23.5 10.1 0.0 0.0 3.4 3.4 7.5 3.8 7.0 9.1 8.6 0.5 18.1 15.4 4.9 1.5 4.7 0.1 0.0 4.4 42.3 3.4 3.0 21.0 2.0 0.0 2.1 0.0 0.9 2.6 11.1 7.0 8.7 7.7 9.9 4.2 5.1 15.3 0.4 4.7 6.6 0.2 0.0 9.8 4.2 3.4 0.0 6.7 4.7 30.7 0.0 0.5 1.1 2.4 0.0 35.6 1.2 22.6 22.8 21.9 11.4 14.1 8.9 0.0 0.0 0.0 6.8 22.7 2.4 0.1 10.1 20.9 0.0 2.7 0.0 0.0 0.0 0.0 6.3 0.0 0.0 0.0 23.5 0.0 1.0 0.4 0.0 3.4 36.9 38.8 39.1 68.6 29.3 18.5 18.8 50.3 14.7 20.4 SIRPB1 "CD172b, SIRP-BETA-1" ENSG00000101307 "Signal regulatory protein beta 1" "O00241, Q5TFQ8" 20 1563521-1620061 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 137.6" "Group enriched" "Detected in some" 4 "HMC-1: 24.7;NB-4: 32.8;THP-1: 25.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 137.6" "Group enriched" "Detected in many" 6 "granulocytes: 137.6;monocytes: 43.6" HPA047463 Uncertain Uncertain Vesicles 33000000 Vesicles "HPA047463: " "unprognostic (1.88e-2)" "unprognostic (6.19e-2)" "unprognostic (1.50e-1)" "unprognostic (2.24e-1)" "unprognostic (5.38e-2)" "unprognostic (1.60e-1)" "unprognostic (4.40e-2)" "unprognostic (7.18e-2)" "unprognostic (4.11e-3)" "unprognostic (9.12e-2)" "unprognostic (6.31e-2)" "unprognostic (4.57e-2)" "unprognostic (2.65e-3)" "unprognostic (5.76e-2)" "unprognostic (2.39e-3)" "unprognostic (5.00e-3)" "unprognostic (1.19e-2)" 23.7 1.8 2.3 18.7 5.4 31.9 1.8 2.7 3.2 1.1 1.4 1.9 0.1 1.0 1.0 0.5 0.9 2.5 7.6 7.2 2.3 1.6 1.5 7.5 19.4 19.5 6.6 0.7 1.9 0.9 0.1 1.5 3.8 3.7 1.2 1.2 1.7 1.8 0.6 0.9 0.9 2.6 2.1 7.2 28.7 1.2 1.2 3.9 2.5 0.9 0.4 2.9 4.1 1.9 0.2 15.2 137.6 43.6 0.7 1.0 19.2 0.1 0.0 0.1 0.0 0.1 0.2 0.1 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.3 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 6.3 24.7 0.0 0.1 0.1 0.0 0.2 0.0 0.1 0.2 0.0 0.0 32.8 0.1 1.5 0.0 0.0 0.0 4.9 0.1 0.0 0.1 0.1 0.0 0.2 0.0 25.4 0.7 0.3 0.0 0.2 0.1 0.0 0.0 0.0 0.5 6.0 0.1 0.5 43.6 72.5 0.6 36.3 0.9 0.2 0.6 0.5 15.2 0.2 0.8 0.5 137.6 0.7 29.5 14.5 1.0 19.2 2.3 5.4 2.7 3.2 2.3 1.6 6.6 0.7 3.7 3.9 SIRPG "bA77C3.1, CD172g, SIRP-B2, SIRPB2, SIRPgamma" ENSG00000089012 "Signal regulatory protein gamma" Q9P1W8 20 1629152-1657779 "CD markers, Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 60.1;lymphoid tissue: 44.0" "Cell line enhanced" "Detected in some" "NB-4: 16.7;RT4: 4.5;THP-1: 2.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "T-reg: 60.1" "Lineage enriched" "Detected in many" 6 "T-cells: 60.1" "unprognostic (3.35e-3)" "unprognostic (4.09e-3)" "unprognostic (7.32e-3)" "prognostic favourable (1.05e-6)" "unprognostic (4.23e-3)" "prognostic favourable (2.24e-4)" "unprognostic (4.49e-2)" "unprognostic (1.30e-2)" "prognostic favourable (7.36e-7)" "unprognostic (1.62e-2)" "unprognostic (6.90e-2)" "unprognostic (2.52e-1)" "prognostic unfavourable (1.47e-6)" "unprognostic (1.03e-1)" "unprognostic (2.18e-1)" "unprognostic (1.40e-2)" "unprognostic (2.95e-3)" 0.8 0.4 0.3 11.7 0.3 1.5 0.5 0.3 0.4 0.7 2.3 0.1 0.4 0.9 0.5 0.6 1.4 0.7 2.1 0.4 0.3 0.3 1.1 1.1 1.4 20.5 0.3 0.1 0.7 0.4 0.0 0.3 0.4 0.2 0.9 1.8 0.6 4.6 0.9 0.4 0.4 8.8 0.6 0.4 14.0 1.6 0.4 0.1 44.0 1.3 0.7 21.3 2.9 0.8 0.1 1.1 1.0 0.2 9.5 60.1 16.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.7 0.0 0.0 0.0 0.0 0.1 0.5 4.5 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.1 0.2 0.1 12.3 0.1 34.1 0.1 38.4 29.0 0.1 0.1 40.5 33.3 1.0 9.5 0.1 1.1 60.1 16.7 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.1 0.2 0.1 SLAMF1 "CD150, SLAM" ENSG00000117090 "Signaling lymphocytic activation molecule family member 1" Q13291 1 160608100-160647295 "CD markers, Predicted membrane proteins, Predicted secreted proteins" "Adaptive immunity, Cell adhesion, Host-virus interaction, Immunity, Innate immunity, Phagocytosis" "Host cell receptor for virus entry, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 97.8" "Cell line enriched" "Detected in single" 111 "HDLM-2: 57.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in many" "MAIT T-cell: 24.1" "Group enriched" "Detected in many" 10 "B-cells: 8.8;T-cells: 24.1" "CAB002438, HPA069319" Enhanced "Secreted to blood" 590000 "CAB002438: AB_564011, HPA069319: " "unprognostic (2.99e-3)" "unprognostic (3.33e-4)" "unprognostic (2.93e-4)" "unprognostic (1.38e-4)" "unprognostic (5.87e-2)" "unprognostic (6.06e-5)" "unprognostic (1.64e-2)" "unprognostic (1.70e-3)" "unprognostic (1.69e-2)" "unprognostic (2.74e-4)" "unprognostic (6.12e-2)" "unprognostic (3.58e-1)" "unprognostic (1.24e-7)" "unprognostic (2.46e-1)" "unprognostic (8.46e-2)" "unprognostic (1.22e-1)" "unprognostic (2.18e-2)" 2.5 0.3 0.3 14.2 0.3 4.4 1.4 0.2 0.3 1.2 2.3 0.4 0.5 2.2 0.5 1.2 2.2 0.8 2.3 1.3 0.2 0.2 2.0 1.0 4.0 14.8 0.2 0.1 0.6 0.9 0.0 0.5 2.3 0.3 1.1 2.1 0.6 4.1 0.6 0.8 1.1 7.6 1.0 0.5 10.6 2.4 0.4 0.2 97.8 1.5 1.9 26.3 3.5 1.1 8.8 1.6 0.2 0.1 0.0 24.1 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 57.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.5 0.0 0.0 0.1 0.0 4.2 0.0 24.1 6.2 17.2 12.1 0.1 8.8 6.6 1.6 0.2 0.0 0.0 1.6 21.5 3.5 0.3 0.3 0.2 0.3 0.2 0.2 0.2 0.1 0.3 0.2 SLAMF6 "CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000" ENSG00000162739 "SLAM family member 6" Q96DU3 1 160485030-160523262 "CD markers, Predicted membrane proteins" "Adaptive immunity, Immunity, Innate immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.6;lymphoid tissue: 51.9" "Group enriched" "Detected in some" 5 "Daudi: 32.6;U-698: 48.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "HPA051363, HPA051903" Uncertain Approved "Plasma membrane,Cytosol" "Plasma membrane, Cytosol" "HPA051363: , HPA051903: " "prognostic favourable (9.42e-4)" "prognostic favourable (2.78e-4)" "unprognostic (8.65e-2)" "prognostic favourable (9.53e-4)" "unprognostic (5.85e-2)" "prognostic favourable (7.34e-5)" "unprognostic (3.16e-3)" "unprognostic (9.78e-2)" "prognostic favourable (1.25e-4)" "unprognostic (2.31e-3)" "unprognostic (2.09e-1)" "unprognostic (1.57e-1)" "prognostic unfavourable (2.09e-6)" "unprognostic (2.78e-1)" "unprognostic (1.01e-1)" "unprognostic (2.33e-2)" "unprognostic (8.21e-3)" 3.9 0.8 0.4 21.0 0.4 1.2 1.0 0.4 0.4 1.1 3.8 0.3 0.4 1.1 1.0 0.6 2.3 1.6 2.8 1.2 0.4 0.4 2.1 1.6 4.7 51.9 0.6 0.4 0.6 0.8 0.0 0.6 1.7 0.7 1.4 1.5 1.5 5.6 1.0 0.5 0.7 11.9 0.4 0.8 29.6 2.3 0.9 0.2 12.9 1.8 0.6 30.4 4.1 1.3 15.2 0.3 8.4 1.0 15.9 28.6 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 32.6 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 2.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 7.8 0.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 5.1 48.1 0.0 0.2 0.0 2.5 0.1 8.4 22.9 0.3 15.8 14.7 14.6 28.6 0.1 15.2 8.2 16.4 1.0 15.9 1.0 0.3 16.8 7.4 0.4 0.4 0.4 0.4 0.4 0.4 0.6 0.4 0.7 0.2 SLAMF7 "19A, CD319, CRACC, CS1" ENSG00000026751 "SLAM family member 7" Q9NQ25 1 160739057-160754821 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity, Innate immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 32.9;lymphoid tissue: 45.0" "Cell line enriched" "Detected in some" 5 "U-266/70: 78.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015445, HPA055945, HPA061654" Enhanced Approved Vesicles 620000 Vesicles "CAB015445: AB_1121905, HPA055945: , HPA061654: " "unprognostic (5.82e-3)" "unprognostic (1.81e-2)" "unprognostic (1.84e-3)" "unprognostic (2.12e-3)" "unprognostic (2.75e-1)" "unprognostic (1.07e-2)" "unprognostic (7.87e-2)" "unprognostic (7.19e-2)" "unprognostic (2.46e-2)" "prognostic favourable (3.93e-4)" "unprognostic (1.08e-1)" "unprognostic (8.13e-2)" "prognostic unfavourable (8.57e-5)" "unprognostic (1.35e-1)" "unprognostic (3.91e-2)" "unprognostic (1.02e-1)" "unprognostic (1.50e-2)" 5.5 1.0 0.7 28.6 0.7 2.3 3.4 0.6 0.7 4.1 11.9 0.2 0.4 11.1 1.9 1.3 6.7 1.6 6.2 1.0 0.7 0.7 2.4 3.1 10.2 24.6 0.8 0.4 2.5 2.2 0.0 0.9 1.3 0.6 1.8 10.2 2.9 15.1 4.8 0.9 2.0 15.8 0.8 1.2 45.0 11.0 1.5 0.4 5.9 2.1 4.2 38.7 11.5 2.6 3.7 27.4 1.1 14.9 17.3 32.9 8.7 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 2.1 0.0 0.7 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.2 0.0 0.0 0.0 0.0 15.8 0.0 0.0 0.0 0.0 1.0 0.0 0.0 78.8 6.7 0.0 2.2 0.0 0.0 0.0 1.6 0.3 32.9 11.0 25.4 3.7 3.5 22.4 7.2 0.6 1.1 13.6 1.1 17.3 14.9 27.4 0.0 8.7 0.7 0.7 0.6 0.7 0.7 0.7 0.8 0.4 0.6 0.4 SLAMF8 "BLAME, CD353, SBBI42" ENSG00000158714 "SLAM family member 8" Q9P0V8 1 159826750-159837249 "CD markers, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 44.1" "Cell line enhanced" "Detected in some" "ASC TERT1: 4.1;HL-60: 3.5;U-138 MG: 4.9;U-87 MG: 2.7;U-937: 2.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "myeloid DC: 12.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA067601 Enhanced "HPA067601: " "unprognostic (1.04e-1)" "unprognostic (8.80e-3)" "unprognostic (5.12e-2)" "unprognostic (2.14e-3)" "unprognostic (3.07e-2)" "unprognostic (3.22e-2)" "unprognostic (7.87e-2)" "unprognostic (4.29e-1)" "unprognostic (2.20e-2)" "unprognostic (4.56e-2)" "unprognostic (6.47e-2)" "unprognostic (1.77e-1)" "prognostic unfavourable (5.42e-5)" "unprognostic (3.50e-1)" "unprognostic (4.42e-2)" "unprognostic (2.01e-1)" "unprognostic (1.04e-1)" 16.9 4.6 1.5 20.1 3.4 0.4 5.4 8.2 1.6 3.1 6.0 1.4 0.6 4.6 1.8 4.2 3.1 3.6 6.1 7.1 5.2 1.7 7.8 2.2 19.6 44.1 4.1 0.7 3.8 2.0 0.1 4.2 5.4 5.0 2.7 7.1 3.0 4.2 1.0 2.2 3.1 7.0 5.4 4.1 22.7 3.1 2.4 2.7 9.7 4.8 3.0 12.7 8.6 2.8 0.0 12.1 0.5 6.6 8.1 3.8 2.8 0.0 0.1 0.0 0.0 0.5 4.1 0.0 0.1 0.4 0.0 0.2 0.0 0.0 0.0 0.6 0.2 0.0 0.0 0.0 0.8 0.0 0.1 1.8 0.0 0.0 0.0 3.5 0.6 1.4 0.0 0.3 0.1 0.0 0.0 0.8 0.2 0.0 0.1 1.9 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 1.6 0.0 4.9 0.2 0.0 0.9 0.0 0.0 0.0 2.7 2.5 0.0 0.0 5.1 0.0 3.2 6.6 0.2 0.0 1.1 3.8 12.1 0.0 0.2 2.6 0.5 8.1 0.4 0.1 0.0 2.8 1.5 3.4 8.2 1.6 5.2 1.7 4.1 0.7 5.0 2.7 SLC3A2 "4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE" ENSG00000168003 "Solute carrier family 3 member 2" P08195 11 62856102-62888875 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "hTCEpi: 129.8;SiHa: 132.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010455, HPA017980" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" 210000000 "Nucleoplasm, Plasma membrane, Cytosol" "CAB010455: AB_638288, HPA017980: " "unprognostic (1.79e-1)" "unprognostic (9.61e-3)" "unprognostic (3.59e-1)" "unprognostic (7.87e-3)" "unprognostic (2.06e-1)" "unprognostic (2.41e-3)" "prognostic unfavourable (8.17e-4)" "unprognostic (2.09e-3)" "unprognostic (2.62e-1)" "unprognostic (4.16e-2)" "unprognostic (2.29e-2)" "unprognostic (3.71e-1)" "prognostic favourable (8.22e-4)" "unprognostic (2.92e-2)" "unprognostic (5.52e-3)" "unprognostic (3.49e-3)" "prognostic unfavourable (1.48e-4)" 28.5 30.8 34.6 23.0 36.8 62.4 30.8 18.7 34.8 26.0 26.8 25.3 30.4 34.3 29.2 41.2 31.2 23.8 19.9 14.7 31.3 27.1 71.4 31.8 33.5 17.8 37.8 24.1 29.9 39.2 138.6 19.3 75.5 32.9 28.3 13.9 52.5 39.0 27.5 32.5 32.1 33.8 19.6 38.0 21.9 28.2 33.4 30.8 13.6 33.7 33.4 22.2 20.6 56.6 16.6 73.9 11.6 36.2 20.3 39.8 37.3 16.1 68.1 6.9 21.6 8.4 6.8 64.4 28.1 10.8 14.8 13.0 65.1 30.6 17.8 31.2 16.5 56.0 12.7 55.1 7.9 32.3 12.0 12.7 49.6 28.7 78.4 14.9 18.6 14.8 129.8 18.0 55.0 8.6 24.6 39.4 9.0 77.8 15.3 19.0 11.6 23.0 15.9 10.5 34.7 10.3 9.0 11.9 5.7 132.3 49.6 95.4 17.8 19.6 15.7 15.0 22.4 22.0 19.8 49.0 54.3 56.4 14.7 23.5 42.8 8.5 36.2 11.6 30.1 34.8 39.8 14.4 27.7 30.8 22.1 16.6 23.5 25.2 7.5 20.3 27.6 73.9 26.2 37.3 34.6 36.8 18.7 34.7 31.3 27.1 37.8 24.1 32.9 30.8 SLC44A1 "CD92, CDw92, CHTL1, CTL1" ENSG00000070214 "Solute carrier family 44 member 1" Q8WWI5 9 105244622-105439171 "CD markers, Predicted membrane proteins, Transporters" Transport "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "brain: 111.6" "Cell line enhanced" "Detected in many" "ASC diff: 71.8;ASC TERT1: 56.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA064714 Supported Nucleoplasm,Mitochondria 270000 Mitochondria Nucleoplasm "HPA064714: " "unprognostic (3.49e-1)" "unprognostic (2.25e-1)" "unprognostic (1.27e-1)" "unprognostic (6.54e-3)" "unprognostic (4.77e-2)" "unprognostic (1.74e-2)" "unprognostic (2.21e-2)" "prognostic unfavourable (4.49e-4)" "unprognostic (2.48e-1)" "unprognostic (1.95e-1)" "unprognostic (1.64e-3)" "unprognostic (6.20e-2)" "prognostic favourable (1.85e-4)" "unprognostic (2.13e-1)" "unprognostic (2.07e-1)" "unprognostic (1.33e-1)" "unprognostic (2.07e-2)" 8.7 7.4 40.0 6.4 48.8 5.3 14.6 7.2 37.0 9.9 26.7 69.5 10.2 12.0 8.8 18.4 10.1 8.5 11.0 6.9 50.0 29.6 12.0 20.3 9.8 4.6 64.3 21.3 8.0 8.0 20.5 3.9 12.3 38.2 6.6 26.9 4.6 6.0 14.8 4.8 11.4 14.0 9.5 111.6 4.8 18.9 2.3 59.4 2.3 24.0 5.1 7.9 12.4 7.9 2.4 3.7 2.5 5.4 8.7 1.8 1.6 6.7 5.7 1.5 1.9 71.8 56.8 4.9 5.7 14.9 3.7 5.0 6.0 18.0 9.0 2.9 21.5 13.5 4.6 8.2 6.4 7.8 3.8 11.2 4.0 7.5 4.8 2.2 5.8 31.5 6.8 7.1 6.5 11.7 0.3 18.8 4.2 9.6 8.9 2.5 8.7 5.5 1.8 6.0 6.8 5.1 15.9 7.5 2.9 8.0 8.9 8.0 8.8 6.8 10.0 3.7 3.4 4.0 4.1 14.5 9.5 6.8 7.2 4.9 4.9 2.5 5.4 1.1 1.1 2.1 0.8 2.0 1.2 0.8 3.7 2.4 1.8 0.6 1.0 8.7 1.2 1.3 1.1 1.6 40.0 48.8 7.2 29.8 50.0 29.6 64.3 21.3 38.2 59.4 SLC4A1 "AE1, CD233, DI, EPB3, FR, RTA1A, SW, WD, WR" ENSG00000004939 "Solute carrier family 4 member 1 (Diego blood group)" P02730 17 44248385-44268141 "Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Anion exchange, Ion transport, Transport" "Blood group antigen" "Disease mutation, Elliptocytosis, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 95.7;placenta: 32.7" "Low cell line specificity" "Detected in many" "Cancer enriched" "Detected in single" 91 "renal cancer: 16.3" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Region enhanced" "Detected in single" "cerebellum: 0.4" "Low region specificity" "Detected in all" "HPA015584, CAB034438, HPA063911" Enhanced 160000000 "CAB034438: AB_2123479, HPA015584: AB_1844824, HPA063911: " "unprognostic (1.36e-1)" "unprognostic (1.42e-1)" "unprognostic (3.36e-1)" "unprognostic (2.44e-2)" "unprognostic (2.32e-2)" "unprognostic (1.56e-2)" "unprognostic (1.55e-1)" "unprognostic (1.59e-1)" "unprognostic (1.68e-1)" "unprognostic (1.58e-1)" "unprognostic (6.72e-3)" "unprognostic (1.19e-1)" "unprognostic (9.28e-3)" "unprognostic (1.93e-2)" "unprognostic (2.18e-1)" "unprognostic (1.94e-1)" "unprognostic (2.13e-1)" 0.9 0.1 0.3 0.2 0.4 95.7 0.2 0.8 0.2 0.1 0.1 0.6 0.0 0.2 0.1 0.4 0.6 0.2 0.2 2.6 0.2 0.3 18.6 1.3 12.9 0.8 0.6 0.1 2.8 0.1 0.0 0.6 32.7 0.9 0.6 0.1 1.2 0.1 0.1 1.2 0.2 0.1 0.0 1.0 8.4 0.1 0.3 0.0 0.7 1.9 0.0 0.2 3.9 11.8 1.8 1.4 6.3 1.2 2.9 1.5 0.7 1.3 0.4 1.4 1.7 0.6 0.7 1.0 0.2 0.4 0.3 0.8 1.3 3.2 0.7 0.6 0.3 1.4 0.5 0.5 1.0 1.3 1.3 1.6 1.5 2.2 0.0 0.8 2.3 0.8 0.5 0.8 0.8 0.2 4.7 3.4 0.4 0.6 0.9 3.5 0.9 0.5 2.5 0.7 1.8 0.3 0.8 2.2 1.0 1.3 1.4 0.5 2.5 1.8 1.0 2.3 2.0 1.4 1.4 1.0 2.3 1.1 1.6 2.1 1.1 6.1 1.0 2.0 1.1 0.9 1.0 1.1 1.0 0.9 0.5 1.8 1.5 1.2 6.3 2.9 1.2 1.4 0.7 0.7 0.3 0.4 0.8 0.2 0.2 0.3 0.6 0.1 0.9 0.0 SPN "CD43, GPL115, LSN" ENSG00000197471 Sialophorin P16150 16 29662979-29670876 "CD markers, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 52.1;bone marrow: 33.1;lung: 25.0;lymphoid tissue: 79.7" "Cell line enhanced" "Detected in some" "HEL: 54.9;HL-60: 48.8;HMC-1: 27.5;MOLT-4: 18.9;THP-1: 26.4;U-937: 34.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "non-classical monocyte: 52.1" "Low lineage specificity" "Detected in all" "CAB002666, HPA055244" Enhanced Approved "Plasma membrane" "Plasma membrane" "CAB002666: , HPA055244: " "prognostic favourable (1.40e-4)" "unprognostic (1.63e-3)" "unprognostic (3.14e-2)" "prognostic favourable (3.08e-5)" "unprognostic (2.68e-2)" "unprognostic (2.49e-3)" "unprognostic (4.02e-2)" "unprognostic (4.17e-2)" "prognostic favourable (1.88e-4)" "unprognostic (1.70e-1)" "unprognostic (4.67e-2)" "unprognostic (2.68e-1)" "unprognostic (2.61e-2)" "unprognostic (4.52e-2)" "unprognostic (4.14e-2)" "unprognostic (5.85e-2)" "unprognostic (4.72e-2)" 5.7 1.0 1.2 12.9 2.7 33.1 1.6 0.7 1.5 1.3 2.8 2.6 0.0 2.3 1.5 0.6 1.9 1.7 2.8 3.9 1.2 1.4 1.8 1.9 25.0 18.3 3.7 0.2 1.0 1.6 0.2 1.0 0.8 2.3 1.6 2.6 1.6 5.0 0.6 0.8 1.6 6.8 1.0 4.6 15.9 2.0 0.6 1.9 79.7 1.6 1.7 17.4 2.6 1.4 1.0 8.8 3.5 52.1 17.5 26.5 10.7 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 54.9 0.0 0.4 0.0 48.8 27.5 0.0 0.0 0.0 0.0 0.0 17.1 13.4 0.1 0.0 18.9 12.2 0.0 0.0 17.1 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.4 0.1 0.0 0.0 0.0 0.0 0.0 0.9 7.2 0.0 34.8 0.0 2.4 5.5 3.5 26.5 24.3 14.5 1.0 10.7 18.1 8.8 0.3 7.6 13.2 0.9 17.5 52.1 7.0 9.1 10.7 1.2 2.7 0.7 1.5 1.2 1.4 3.7 0.2 2.3 1.9 TEK "CD202b, TIE-2, TIE2, VMCM, VMCM1" ENSG00000120156 "TEK receptor tyrosine kinase" Q02763 9 27109141-27230175 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Angiogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Glaucoma" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 9 "HUVEC TERT2: 35.8;NTERA-2: 17.8;TIME: 38.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "neutrophil: 2.2" "Lineage enhanced" "Detected in single" "granulocytes: 2.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010359, HPA073265" Approved Supported "Plasma membrane,Centriolar satellite" "Secreted to blood" 7750000 8300000 "Plasma membrane" "Centriolar satellite" "CAB010359: AB_2203226, HPA073265: " "unprognostic (2.24e-1)" "unprognostic (1.74e-1)" "unprognostic (5.55e-2)" "unprognostic (1.83e-2)" "unprognostic (1.68e-1)" "unprognostic (1.26e-3)" "prognostic favourable (2.31e-5)" "unprognostic (7.48e-2)" "unprognostic (1.72e-2)" "unprognostic (1.41e-1)" "unprognostic (5.58e-2)" "unprognostic (2.72e-1)" "prognostic favourable (7.81e-4)" "unprognostic (7.50e-3)" "unprognostic (6.87e-3)" "unprognostic (1.83e-1)" "unprognostic (5.24e-3)" 28.6 7.8 8.1 4.6 5.9 0.4 17.9 3.4 5.4 10.8 4.7 4.6 3.4 3.2 14.5 5.3 6.7 5.9 9.1 13.0 7.1 6.1 25.4 8.7 27.8 2.9 6.9 3.4 6.1 4.5 3.5 4.0 36.3 6.9 5.4 4.7 12.4 3.4 5.5 7.8 3.0 5.3 10.6 5.3 23.4 4.0 3.7 3.5 0.3 9.7 8.4 2.4 6.4 12.4 0.0 0.1 2.2 0.6 0.0 0.0 0.0 0.1 0.0 1.4 0.0 0.2 2.3 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 2.3 1.0 0.0 0.6 0.0 0.0 0.7 0.0 0.8 0.3 35.8 0.0 0.0 0.3 0.0 0.0 0.0 17.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 38.8 0.0 0.2 3.6 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 8.1 5.9 3.4 5.4 7.1 6.1 6.9 3.4 6.9 3.5 TFRC "CD71, p90, TFR1" ENSG00000072274 "Transferrin receptor" P02786 3 196027183-196082189 "Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Endocytosis, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 110.0" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000153, HPA028598" Enhanced Supported Endosomes,Lysosomes "Secreted to blood" 1310000000 14000000 "Endosomes, Lysosomes" "CAB000153: AB_2533029, HPA028598: AB_10601599" "unprognostic (2.95e-2)" "prognostic unfavourable (3.67e-4)" "unprognostic (2.55e-1)" "unprognostic (1.48e-2)" "unprognostic (6.75e-2)" "unprognostic (7.88e-3)" "prognostic unfavourable (1.15e-4)" "unprognostic (6.92e-2)" "unprognostic (3.30e-3)" "unprognostic (4.35e-2)" "unprognostic (1.34e-2)" "unprognostic (1.14e-2)" "unprognostic (3.63e-3)" "unprognostic (3.65e-2)" "unprognostic (1.19e-2)" "prognostic unfavourable (2.96e-4)" "unprognostic (2.62e-2)" 24.3 11.9 11.9 20.6 11.3 73.8 7.6 9.6 17.8 11.8 25.0 9.5 3.8 11.9 12.1 7.5 18.5 11.7 11.4 18.7 9.5 8.3 15.3 13.6 28.1 8.1 7.4 9.5 50.0 7.8 18.0 6.9 110.0 26.5 7.2 19.4 8.5 8.3 5.0 25.6 9.9 37.4 10.9 13.2 7.9 10.0 8.3 6.1 14.3 7.0 10.5 12.9 11.2 8.0 5.7 7.5 2.2 12.4 1.8 6.5 2.1 21.9 20.0 9.2 18.6 20.4 11.8 57.5 31.4 23.9 22.1 36.7 48.7 20.2 22.5 59.6 11.6 33.9 31.5 10.4 27.1 107.6 10.7 85.3 17.0 22.6 16.1 69.9 17.3 13.3 10.3 19.0 17.2 7.3 35.5 21.6 17.2 20.3 22.9 14.8 28.0 41.0 12.2 13.7 27.0 19.8 55.6 21.0 8.7 30.3 79.7 7.1 77.4 14.6 9.4 26.3 21.4 23.0 47.0 6.1 47.5 35.2 30.8 19.0 15.9 0.0 1.6 2.2 2.5 7.9 1.7 5.7 2.7 1.7 3.7 3.2 2.5 1.9 0.3 1.8 12.4 7.5 6.5 2.1 11.9 11.3 9.6 17.8 9.5 8.3 7.4 9.5 26.5 6.1 THBD CD141 ENSG00000178726 Thrombomodulin P07204 20 23045633-23049741 "Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins" "Blood coagulation, Hemostasis" Receptor "Disease mutation, Hemolytic uremic syndrome, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 12.9;CAPAN-2: 20.0;EFO-21: 17.5;HaCaT: 16.8;hTCEpi: 22.2;THP-1: 12.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 17.7" "Group enriched" "Detected in many" 7 "dendritic cells: 7.8;granulocytes: 17.7;monocytes: 6.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002425, HPA002982" Supported Approved Nucleoplasm,Cytosol 690000 "Nucleoplasm, Cytosol" "CAB002425: AB_563497, HPA002982: AB_1078444" "unprognostic (1.96e-1)" "unprognostic (2.93e-3)" "unprognostic (8.70e-2)" "unprognostic (3.00e-2)" "unprognostic (3.07e-2)" "unprognostic (1.88e-1)" "unprognostic (7.81e-3)" "unprognostic (4.70e-2)" "unprognostic (1.38e-1)" "unprognostic (1.52e-2)" "unprognostic (2.30e-1)" "unprognostic (5.33e-2)" "unprognostic (2.23e-2)" "unprognostic (7.35e-3)" "unprognostic (3.01e-2)" "unprognostic (7.58e-3)" "unprognostic (9.71e-2)" 27.0 6.3 1.4 10.5 6.7 6.9 11.8 1.2 2.7 13.2 14.4 1.4 4.3 2.9 9.7 11.5 21.7 15.8 18.2 24.3 5.0 1.5 7.0 10.0 61.9 26.8 2.5 0.1 10.2 7.2 10.0 10.9 16.4 6.2 6.1 3.3 8.8 6.0 4.2 55.5 32.4 14.1 8.5 7.7 44.4 14.4 15.8 2.4 2.1 18.3 32.2 10.4 14.2 10.4 0.0 7.8 17.7 6.2 1.5 0.0 1.1 5.6 5.0 0.1 0.0 12.9 0.7 0.1 0.1 0.0 0.0 0.0 0.0 20.0 0.0 17.5 1.7 16.8 0.0 0.9 0.0 0.0 0.0 0.0 0.5 0.0 2.5 0.0 0.1 0.6 22.2 0.3 1.4 5.6 2.1 0.0 0.5 0.4 0.0 2.1 0.0 0.8 0.0 0.0 2.4 0.1 8.2 0.3 0.0 4.7 0.6 8.7 0.0 12.5 11.0 0.0 0.3 1.6 0.0 0.0 0.0 0.0 1.0 2.9 0.4 0.0 2.8 0.0 0.0 6.2 0.0 0.0 0.0 0.0 7.0 0.0 0.0 0.0 17.7 1.5 5.8 7.8 0.0 1.1 1.4 6.7 1.2 2.7 5.0 1.5 2.5 0.1 6.2 2.4 THY1 CD90 ENSG00000154096 "Thy-1 cell surface antigen" P04216 11 119417378-119424985 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 97.7;smooth muscle: 91.5" "Cell line enhanced" "Detected in many" "ASC diff: 52.6;BJ: 82.2;BJ hTERT+: 92.1;fHDF/TERT166: 144.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "MAIT T-cell: 1.7" "Lineage enriched" "Detected in single" 17 "T-cells: 1.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003733, CAB068243, CAB068244" Enhanced Approved "Nucleoplasm,Plasma membrane" 9800000 Nucleoplasm "Plasma membrane" "CAB068243: , CAB068244: , HPA003733: AB_1846340" "unprognostic (9.98e-2)" "unprognostic (2.71e-1)" "unprognostic (5.13e-2)" "unprognostic (2.61e-1)" "prognostic unfavourable (6.87e-4)" "unprognostic (7.43e-2)" "unprognostic (1.43e-3)" "unprognostic (2.38e-2)" "unprognostic (1.29e-1)" "unprognostic (2.90e-3)" "unprognostic (3.38e-2)" "unprognostic (3.52e-1)" "prognostic unfavourable (2.40e-6)" "unprognostic (1.75e-2)" "unprognostic (1.90e-2)" "unprognostic (3.03e-2)" "unprognostic (1.14e-2)" 28.7 5.9 42.0 23.2 72.4 0.4 7.0 17.6 97.7 26.9 9.0 7.2 2.1 3.5 20.3 13.9 9.8 7.5 31.6 4.3 63.4 41.1 46.6 2.6 6.5 10.9 29.8 34.8 3.2 5.0 7.3 5.5 19.1 53.8 4.6 13.6 8.5 2.9 15.7 1.4 4.2 4.6 91.5 9.3 6.7 5.7 4.0 6.9 3.1 12.0 1.0 10.8 36.9 7.2 0.0 0.0 0.0 0.0 0.0 1.7 0.3 0.0 0.3 12.3 0.0 52.6 38.1 0.0 82.2 92.1 29.5 32.7 0.0 0.0 0.0 0.0 144.0 0.0 0.4 0.1 22.6 7.0 0.0 4.4 1.5 0.0 16.3 0.0 0.0 28.2 0.0 37.4 1.3 0.0 0.0 0.0 22.7 0.0 0.0 0.0 19.7 0.1 0.0 5.8 0.0 0.0 0.0 2.1 5.6 0.0 0.0 0.0 0.1 0.2 0.0 42.4 14.1 12.2 12.1 0.0 2.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 42.0 72.4 17.6 97.7 63.4 41.1 29.8 34.8 53.8 6.9 TLR1 "CD281, KIAA0012, rsc786" ENSG00000174125 "Toll like receptor 1" Q15399 4 38790677-38856817 "CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 43.3;lymphoid tissue: 40.4" "Cell line enhanced" "Detected in many" "Daudi: 9.4;HUVEC TERT2: 10.8;RPMI-8226: 11.7;U-698: 17.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 43.3" "Group enriched" "Detected in all" 6 "granulocytes: 43.3;monocytes: 13.1" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" "unprognostic (7.82e-2)" "unprognostic (3.35e-3)" "unprognostic (4.02e-2)" "unprognostic (1.19e-1)" "unprognostic (1.71e-1)" "unprognostic (1.85e-2)" "unprognostic (1.12e-1)" "unprognostic (1.80e-1)" "unprognostic (3.88e-1)" "unprognostic (1.04e-1)" "unprognostic (3.94e-2)" "unprognostic (1.76e-1)" "unprognostic (7.25e-3)" "unprognostic (4.08e-2)" "unprognostic (1.91e-2)" "unprognostic (2.08e-1)" "unprognostic (3.97e-2)" 10.9 4.6 7.1 17.9 11.4 21.0 5.4 2.0 6.0 3.4 3.7 5.9 0.5 4.2 5.8 3.9 3.2 5.3 6.5 4.0 6.5 3.4 4.6 5.8 9.8 26.4 12.9 2.6 7.4 7.7 1.0 4.2 6.6 10.6 3.9 4.6 2.2 11.0 2.5 1.7 3.1 6.7 6.5 19.4 40.4 4.2 1.6 10.9 10.1 2.4 1.7 13.1 6.3 2.8 2.3 4.5 43.3 13.1 1.8 1.1 2.4 0.2 1.7 0.1 0.0 0.2 1.3 0.0 0.0 0.4 0.1 1.0 0.2 4.6 9.4 1.0 0.0 0.2 0.1 1.1 0.2 1.1 0.5 1.2 0.4 0.0 0.0 1.8 0.5 0.4 0.2 0.4 0.0 10.8 1.3 2.8 1.4 0.0 0.4 3.8 0.0 0.0 6.3 0.1 11.7 1.1 0.0 0.0 1.3 0.0 0.1 0.4 0.1 2.3 2.8 0.9 0.4 0.1 0.6 1.0 0.1 17.5 2.5 6.5 0.3 0.0 6.8 2.6 1.0 10.4 0.8 2.3 1.1 0.8 4.5 2.0 1.1 0.6 43.3 1.8 13.1 1.5 0.4 2.4 7.1 11.4 2.0 6.0 6.5 3.4 12.9 2.6 10.6 10.9 TLR10 CD290 ENSG00000174123 "Toll like receptor 10" Q9BXR5 4 38772239-38782990 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "blood: 23.5;brain: 11.3;intestine: 11.2;lymphoid tissue: 31.6" "Group enriched" "Detected in some" 55 "Daudi: 37.3;REH: 12.5;U-698: 13.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 5 "memory B-cell: 23.5;naive B-cell: 14.9" "Lineage enriched" "Detected in many" 6 "B-cells: 23.5" "Low region specificity" "Detected in all" HPA066755 Approved Centrosome,Cytosol Cytosol Centrosome "HPA066755: " "unprognostic (5.41e-5)" "unprognostic (2.41e-4)" "unprognostic (1.91e-3)" "unprognostic (8.22e-4)" "unprognostic (6.48e-2)" "unprognostic (9.98e-4)" "unprognostic (9.31e-2)" "unprognostic (8.76e-3)" "unprognostic (4.08e-3)" "unprognostic (7.26e-2)" "unprognostic (8.76e-2)" "unprognostic (6.90e-2)" "unprognostic (2.98e-3)" "unprognostic (3.90e-1)" "unprognostic (1.81e-2)" "unprognostic (3.14e-3)" "unprognostic (1.88e-2)" 0.8 0.5 4.2 24.5 9.4 0.9 0.6 0.6 3.5 0.6 1.0 2.5 0.0 0.9 0.5 0.3 1.7 0.9 1.0 0.5 3.2 1.8 0.8 0.7 1.2 27.0 5.5 0.5 0.5 0.6 0.1 0.7 0.2 4.8 0.8 1.4 0.0 2.6 0.3 0.5 0.5 11.2 0.3 11.3 24.4 1.8 0.4 7.4 2.7 0.9 0.0 31.6 3.2 0.6 23.5 4.0 0.7 1.8 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 37.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 13.4 0.0 0.0 0.0 0.1 0.2 0.4 0.0 1.5 0.0 23.5 0.0 0.0 3.6 14.9 0.0 0.0 0.7 0.0 1.8 4.0 0.0 0.9 4.2 9.4 0.6 3.5 3.2 1.8 5.5 0.5 4.8 7.4 TLR2 "CD282, TIL4" ENSG00000137462 "Toll like receptor 2" O60603 4 153684070-153705702 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 72.9" "Cell line enhanced" "Detected in some" "HSkMC: 7.4;hTCEpi: 7.4;RPTEC TERT1: 7.6;RT4: 9.3;THP-1: 35.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 29.5;intermediate monocyte: 28.1;myeloid DC: 19.1;neutrophil: 72.9;non-classical monocyte: 18.4" "Group enriched" "Detected in many" 46 "dendritic cells: 19.1;granulocytes: 72.9;monocytes: 29.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA060231, HPA071546" Supported Nucleoplasm,Mitochondria "Nucleoplasm, Mitochondria" "HPA060231: , HPA071546: " "unprognostic (4.15e-1)" "unprognostic (3.29e-2)" "unprognostic (5.32e-2)" "unprognostic (1.52e-2)" "unprognostic (3.46e-2)" "unprognostic (4.88e-2)" "unprognostic (1.39e-2)" "unprognostic (4.24e-2)" "unprognostic (2.48e-1)" "unprognostic (2.02e-2)" "unprognostic (2.04e-1)" "unprognostic (1.33e-1)" "prognostic unfavourable (1.11e-4)" "unprognostic (7.87e-2)" "unprognostic (3.80e-3)" "unprognostic (1.42e-1)" "unprognostic (5.93e-3)" 16.3 6.9 6.9 30.0 11.1 34.6 7.3 1.4 5.3 4.7 4.7 3.0 9.3 2.2 3.1 8.0 3.2 7.2 10.0 7.2 6.7 3.3 9.8 7.3 31.1 37.8 12.4 1.4 4.2 5.1 1.1 4.4 6.4 9.9 5.5 1.9 3.3 15.0 9.9 2.5 3.1 4.0 6.6 21.9 29.3 3.9 4.8 9.5 0.9 3.3 1.0 8.5 7.3 3.5 0.2 19.1 72.9 29.5 0.8 0.2 9.3 3.9 0.0 0.1 0.0 0.5 1.6 0.0 0.0 0.3 0.3 0.5 1.9 0.2 0.0 0.4 0.0 3.5 0.4 0.2 0.2 0.0 0.0 0.1 0.0 0.4 0.0 6.8 0.5 7.4 7.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.4 1.5 0.1 0.0 0.0 7.6 9.3 0.0 0.2 0.4 0.0 1.8 0.0 35.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 6.7 0.9 6.2 29.5 0.2 0.0 28.1 0.0 0.0 0.1 0.0 19.1 0.2 0.2 0.0 72.9 0.8 18.4 0.1 0.0 9.3 6.9 11.1 1.4 5.3 6.7 3.3 12.4 1.4 9.9 9.5 TLR3 CD283 ENSG00000164342 "Toll like receptor 3" O15455 4 186069152-186088069 "CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" "Receptor, RNA-binding" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 48.1" "Cell line enhanced" "Detected in many" "ASC diff: 11.4;ASC TERT1: 12.0;BJ hTERT+ SV40 Large T+ RasG12V: 17.7;CAPAN-2: 27.6;HSkMC: 11.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 7.6;memory CD8 T-cell: 8.0" "Group enriched" "Detected in many" 7 "dendritic cells: 2.5;T-cells: 8.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB025658 Enhanced "Intracellular and membrane" "CAB025658: " "unprognostic (2.13e-2)" "unprognostic (2.15e-1)" "unprognostic (7.26e-2)" "unprognostic (7.47e-3)" "unprognostic (1.10e-1)" "unprognostic (1.81e-1)" "unprognostic (6.39e-3)" "unprognostic (1.56e-2)" "unprognostic (9.28e-2)" "unprognostic (2.25e-2)" "prognostic unfavourable (3.09e-4)" "unprognostic (1.17e-1)" "unprognostic (4.72e-3)" "unprognostic (1.18e-1)" "unprognostic (4.52e-3)" "unprognostic (3.89e-2)" "unprognostic (1.83e-1)" 11.9 10.7 3.1 6.8 5.0 0.0 11.1 1.7 3.5 9.9 20.1 3.0 6.8 13.4 5.6 7.3 12.9 7.8 8.6 7.7 3.5 2.6 12.4 11.2 12.2 1.0 3.3 1.9 8.9 8.2 4.8 2.7 48.1 3.0 11.3 9.5 5.0 8.5 10.2 2.3 3.8 34.9 6.5 8.0 7.0 8.2 5.8 4.2 1.2 11.8 7.6 3.0 10.3 14.6 0.0 2.5 0.5 0.0 0.7 8.0 1.1 1.9 0.5 0.3 0.0 11.4 12.0 0.9 0.1 8.2 5.1 17.7 0.0 27.6 0.0 1.1 1.2 2.8 0.0 5.8 0.9 10.6 0.1 1.7 0.5 0.0 5.1 1.7 0.7 11.7 2.2 6.8 0.3 2.4 0.0 0.0 2.8 0.0 2.0 0.0 0.8 1.0 2.5 0.0 0.1 4.8 2.7 0.0 0.1 1.4 1.2 2.2 0.3 0.0 1.7 0.9 0.6 0.0 1.2 0.0 0.0 0.0 2.3 1.1 1.9 0.5 0.0 0.0 7.6 0.0 4.3 0.0 1.8 8.0 2.5 0.0 1.2 3.9 0.3 0.7 0.0 0.0 0.2 1.1 3.1 5.0 1.7 3.5 3.5 2.6 3.3 1.9 3.0 4.2 TLR4 "ARMD10, CD284, hToll, TLR-4" ENSG00000136869 "Toll like receptor 4" O00206 9 117704175-117724730 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Immunity, Inflammatory response, Innate immunity" Receptor "Age-related macular degeneration, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 29.1;TIME: 21.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 30.1" "Group enriched" "Detected in many" 30 "dendritic cells: 7.5;granulocytes: 30.1;monocytes: 21.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB004025, HPA049174" Approved Supported "Golgi apparatus,Plasma membrane" "Intracellular and membrane" "Plasma membrane" "Golgi apparatus" "CAB004025: , HPA049174: " "unprognostic (1.60e-1)" "unprognostic (8.34e-2)" "unprognostic (7.22e-2)" "prognostic favourable (6.29e-4)" "unprognostic (3.39e-1)" "unprognostic (7.48e-2)" "unprognostic (8.68e-2)" "unprognostic (1.80e-1)" "unprognostic (3.38e-1)" "unprognostic (5.18e-2)" "unprognostic (8.00e-2)" "unprognostic (9.42e-2)" "unprognostic (4.08e-2)" "unprognostic (8.63e-2)" "prognostic unfavourable (3.79e-4)" "unprognostic (1.09e-2)" "unprognostic (1.96e-2)" 29.2 12.1 15.5 23.5 12.5 17.8 21.9 9.4 10.3 6.9 6.8 10.6 3.0 4.4 5.8 7.7 5.0 6.8 10.6 10.9 19.9 7.5 9.0 16.5 16.0 30.9 12.4 11.4 6.7 3.0 2.9 3.8 22.8 10.5 5.7 7.4 7.2 9.0 3.6 7.4 5.2 6.6 10.4 11.1 41.4 4.5 2.4 13.0 1.1 8.3 5.6 7.5 12.1 16.1 0.6 7.5 30.1 21.4 0.0 0.0 6.9 0.0 0.0 12.5 0.0 5.8 11.8 0.1 5.0 8.7 1.2 0.7 0.0 1.2 1.7 0.2 12.8 0.0 0.0 1.1 1.8 0.0 0.0 2.6 2.6 0.1 4.4 9.0 0.0 7.3 0.0 2.7 0.3 15.2 0.0 29.1 15.2 0.0 0.0 1.8 1.5 0.6 0.0 14.1 9.1 0.5 14.6 0.0 0.0 3.1 0.0 0.5 0.0 4.9 21.1 0.6 9.5 0.0 2.3 0.0 0.0 0.0 0.4 9.5 7.4 17.6 21.4 7.2 0.0 19.6 0.0 0.6 0.0 0.0 7.5 0.2 0.0 0.0 30.1 0.0 20.2 0.3 0.0 6.9 15.5 12.5 9.4 10.3 19.9 7.5 12.4 11.4 10.5 13.0 TLR6 CD286 ENSG00000174130 "Toll like receptor 6" Q9Y2C9 4 38823715-38856817 "CD markers, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 14.2;brain: 16.0;lymphoid tissue: 16.2" "Cell line enhanced" "Detected in many" "CAPAN-2: 13.0;RPMI-8226: 10.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "neutrophil: 14.2" "Lineage enriched" "Detected in many" 5 "granulocytes: 14.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA062733 Approved "Endoplasmic reticulum" "Endoplasmic reticulum" "HPA062733: " "unprognostic (9.82e-2)" "unprognostic (4.76e-2)" "unprognostic (3.30e-2)" "unprognostic (3.05e-2)" "unprognostic (1.91e-1)" "unprognostic (1.87e-2)" "unprognostic (1.83e-1)" "unprognostic (4.45e-2)" "unprognostic (9.26e-2)" "unprognostic (1.30e-1)" "unprognostic (1.05e-2)" "unprognostic (2.69e-1)" "unprognostic (7.62e-7)" "unprognostic (4.89e-2)" "unprognostic (1.02e-2)" "unprognostic (7.78e-2)" "unprognostic (2.12e-2)" 2.9 2.7 6.1 10.7 7.9 6.4 2.1 2.0 3.9 1.8 1.6 2.6 0.2 1.7 1.4 2.0 1.8 1.9 3.9 1.5 4.5 1.7 1.7 2.1 5.0 11.2 10.6 1.9 1.6 1.2 0.7 1.9 2.8 7.2 1.6 2.4 0.9 4.3 0.5 0.9 1.7 7.8 2.1 16.0 16.2 2.1 0.8 6.8 1.8 1.5 1.1 14.8 5.8 1.9 1.8 1.8 14.2 2.6 0.3 0.4 0.6 1.5 6.0 0.2 0.1 0.3 6.9 0.0 1.6 7.1 0.7 2.4 0.0 13.0 7.1 2.8 0.3 0.7 0.1 1.3 1.1 0.0 0.5 3.3 7.2 0.2 0.5 3.6 5.4 2.9 1.3 2.9 1.6 1.4 3.6 2.3 3.3 0.0 0.0 6.3 0.2 1.0 3.5 3.2 10.2 0.4 0.1 0.0 0.1 0.2 0.0 1.0 0.3 1.9 2.0 2.3 7.8 0.9 2.5 0.1 0.0 6.0 5.3 4.3 1.7 0.0 2.6 0.7 0.2 2.4 0.0 1.8 0.1 0.1 1.8 1.2 0.3 0.2 14.2 0.3 1.2 1.3 0.4 0.6 6.1 7.9 2.0 3.9 4.5 1.7 10.6 1.9 7.2 6.8 TLR8 CD288 ENSG00000101916 "Toll like receptor 8" Q9NR97 X 12906620-12923169 "CD markers, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 17.8;lymphoid tissue: 45.6" "Cell line enhanced" "Detected in some" "HMC-1: 1.2;PC-3: 2.7;THP-1: 1.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 94 "classical monocyte: 10.0;intermediate monocyte: 9.6;myeloid DC: 5.3;neutrophil: 17.8;non-classical monocyte: 9.2" "Group enriched" "Detected in many" 100 "dendritic cells: 5.3;granulocytes: 17.8;monocytes: 10.0" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA001608 Enhanced "HPA001608: AB_1080295" "unprognostic (1.32e-1)" "unprognostic (6.94e-2)" "unprognostic (3.96e-3)" "unprognostic (4.43e-2)" "unprognostic (9.63e-2)" "unprognostic (2.48e-2)" "unprognostic (2.59e-1)" "unprognostic (6.61e-2)" "unprognostic (1.93e-1)" "unprognostic (2.23e-1)" "unprognostic (3.72e-2)" "unprognostic (2.73e-1)" "unprognostic (1.74e-2)" "unprognostic (1.03e-1)" "unprognostic (4.14e-2)" "unprognostic (1.52e-1)" "unprognostic (5.66e-2)" 8.5 1.4 0.9 16.0 1.5 4.7 1.2 0.7 1.1 1.0 1.5 0.4 0.0 0.6 1.0 3.2 1.0 2.0 2.4 3.0 2.0 1.0 2.0 4.0 13.7 33.0 1.7 0.1 1.1 1.0 0.2 1.0 4.0 1.9 1.4 1.7 0.9 1.2 0.0 1.4 0.8 2.0 3.5 3.3 45.6 1.3 1.2 1.6 3.5 1.0 1.1 2.4 4.2 2.4 0.1 5.3 17.8 10.0 0.0 0.0 2.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 2.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.3 0.0 0.1 0.2 0.0 0.4 0.2 0.0 0.0 0.3 0.0 0.0 10.0 0.0 0.0 9.6 0.0 0.1 0.0 0.0 5.3 0.0 0.0 0.0 17.8 0.0 9.2 0.0 0.0 2.0 0.9 1.5 0.7 1.1 2.0 1.0 1.7 0.1 1.9 1.6 TLR9 CD289 ENSG00000239732 "Toll like receptor 9" Q9NR96 3 52221080-52226163 "CD markers, FDA approved drug targets, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "blood: 33.8" "Group enriched" "Detected in some" 12 "Daudi: 24.1;RPMI-8226: 15.4;U-698: 9.3" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 10 "plasmacytoid DC: 33.8" "Lineage enriched" "Detected in many" 10 "dendritic cells: 33.8" "unprognostic (6.03e-2)" "unprognostic (5.08e-2)" "unprognostic (3.58e-3)" "unprognostic (6.69e-7)" "unprognostic (1.16e-1)" "unprognostic (1.89e-2)" "unprognostic (2.69e-1)" "unprognostic (1.58e-1)" "unprognostic (7.02e-2)" "unprognostic (1.89e-1)" "unprognostic (4.40e-2)" "unprognostic (7.60e-2)" "unprognostic (2.65e-3)" "unprognostic (2.44e-2)" "unprognostic (3.70e-1)" "unprognostic (2.27e-1)" "unprognostic (7.91e-3)" 0.5 0.2 0.0 2.8 0.5 2.5 0.4 4.9 0.4 0.8 1.2 0.7 0.9 0.0 0.2 1.0 0.9 0.3 0.2 0.3 0.3 0.1 0.6 6.5 0.1 2.5 0.0 0.0 0.3 0.1 0.9 0.1 1.4 0.4 1.8 0.1 2.2 0.1 0.4 3.9 0.5 0.3 0.7 3.9 1.2 1.2 3.3 33.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.3 0.2 0.0 0.0 0.0 0.0 15.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.9 0.7 9.3 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 33.8 0.0 0.1 TNFRSF10A "Apo2, CD261, DR4, TRAILR-1, TRAILR1" ENSG00000104689 "TNF receptor superfamily member 10a" O00220 8 23190452-23225126 "Cancer-related genes, CD markers, Predicted membrane proteins" Apoptosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "HPA050958, HPA054475" Approved Supported Nucleoplasm Nucleoplasm "HPA050958: , HPA054475: " "unprognostic (3.66e-1)" "unprognostic (1.02e-1)" "unprognostic (2.19e-2)" "unprognostic (4.89e-2)" "unprognostic (9.44e-2)" "unprognostic (8.39e-2)" "unprognostic (5.32e-2)" "unprognostic (2.18e-2)" "unprognostic (2.72e-1)" "unprognostic (4.48e-2)" "prognostic unfavourable (1.00e-4)" "unprognostic (1.49e-1)" "unprognostic (1.99e-3)" "unprognostic (1.91e-2)" "unprognostic (1.61e-2)" "unprognostic (2.35e-1)" "unprognostic (2.87e-1)" 11.9 4.0 2.1 13.0 3.4 8.4 9.7 2.0 2.8 6.0 10.9 1.4 4.5 5.9 5.3 5.6 13.6 4.1 12.7 6.3 2.2 2.0 10.9 10.6 11.0 12.4 3.0 0.7 2.7 12.9 3.6 1.8 6.9 4.0 5.1 7.2 2.1 8.2 4.3 3.8 7.1 10.2 3.8 2.9 13.2 6.1 2.6 3.0 9.5 5.8 14.9 25.4 6.7 8.7 13.2 4.5 3.8 4.3 3.9 13.9 4.2 7.9 14.4 0.7 0.0 0.5 2.9 0.0 1.6 1.0 0.8 2.3 11.0 14.0 18.4 18.8 1.0 15.2 12.9 20.6 1.4 4.5 0.1 9.7 8.7 6.2 7.4 5.2 9.3 5.0 17.0 18.3 15.8 9.7 15.0 6.6 3.9 6.2 0.2 3.3 10.0 8.8 0.1 0.0 13.2 11.0 17.2 0.4 0.5 4.0 10.2 0.0 5.4 4.0 13.6 0.0 0.1 0.8 0.0 7.8 11.0 14.3 0.1 1.7 0.2 2.0 4.3 3.8 3.8 1.9 10.3 10.4 12.3 7.7 4.5 13.2 12.1 7.0 0.5 3.9 1.7 0.0 13.9 4.2 2.1 3.4 2.0 2.8 2.2 2.0 3.0 0.7 4.0 3.0 TNFRSF10B "CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB" ENSG00000120889 "TNF receptor superfamily member 10b" O14763 8 23020133-23069179 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins" Apoptosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" HPA023625 Approved "HPA023625: AB_1847860" "unprognostic (8.43e-3)" "unprognostic (7.43e-3)" "unprognostic (3.04e-2)" "unprognostic (4.94e-3)" "unprognostic (1.13e-1)" "unprognostic (7.74e-2)" "unprognostic (2.15e-1)" "unprognostic (9.51e-3)" "unprognostic (2.70e-1)" "unprognostic (2.82e-2)" "unprognostic (2.30e-3)" "unprognostic (1.96e-2)" "prognostic unfavourable (1.76e-4)" "unprognostic (4.01e-2)" "unprognostic (1.03e-1)" "unprognostic (1.86e-1)" "unprognostic (5.52e-2)" 29.6 18.5 5.2 16.4 7.3 7.6 19.6 2.3 5.8 11.5 23.1 7.5 13.3 14.1 10.4 13.9 12.1 11.4 22.1 13.2 6.4 3.2 14.3 36.1 21.3 11.6 7.9 2.6 16.2 20.0 14.8 6.1 8.5 8.2 15.1 14.3 7.9 11.5 14.5 15.5 6.1 31.2 10.5 8.6 17.4 11.2 7.8 6.4 4.1 17.7 13.0 15.2 17.9 9.9 3.1 12.1 2.8 12.9 0.8 4.0 5.2 8.5 22.7 33.3 10.1 15.6 20.4 32.6 20.6 26.5 11.2 17.5 9.4 8.6 5.1 14.0 11.2 8.3 8.7 39.0 20.0 5.1 7.3 0.0 8.9 17.6 52.3 1.9 8.6 30.3 35.0 24.9 26.6 35.5 3.6 0.0 22.0 2.8 0.2 2.8 8.3 8.2 4.6 12.1 3.2 21.7 13.5 0.0 5.6 10.3 2.9 10.9 5.0 2.4 31.4 16.4 8.5 5.2 14.8 6.6 1.1 2.4 16.7 3.7 23.4 2.8 12.9 0.4 1.6 9.3 2.7 3.1 1.9 1.6 12.1 1.6 4.0 1.6 2.6 0.8 11.9 0.0 1.3 5.2 5.2 7.3 2.3 5.8 6.4 3.2 7.9 2.6 8.2 6.4 TNFRSF10C "CD263, DcR1, LIT, TRAILR3, TRID" ENSG00000173535 "TNF receptor superfamily member 10c" O14798 8 23102590-23117437 "Cancer-related genes, CD markers, Predicted membrane proteins" Apoptosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "blood: 173.4" "Group enriched" "Detected in some" 5 "BEWO: 37.1;HUVEC TERT2: 30.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 7 "neutrophil: 173.4" "Lineage enriched" "Detected in many" 113 "granulocytes: 173.4" CAB025635 Enhanced "CAB025635: " "unprognostic (2.63e-1)" "unprognostic (4.49e-3)" "unprognostic (7.21e-3)" "unprognostic (2.07e-2)" "unprognostic (3.55e-2)" "unprognostic (1.46e-1)" "unprognostic (1.81e-2)" "unprognostic (2.11e-3)" "unprognostic (5.56e-2)" "unprognostic (4.37e-2)" "unprognostic (8.98e-2)" "unprognostic (1.94e-3)" "unprognostic (2.74e-3)" "unprognostic (4.83e-1)" "unprognostic (1.84e-1)" "unprognostic (1.34e-3)" "unprognostic (6.54e-2)" 5.5 1.5 1.9 14.0 3.6 12.6 2.0 1.4 3.9 2.9 1.5 0.7 0.1 1.2 1.5 1.2 1.4 3.7 13.5 5.6 1.9 1.1 2.8 3.2 13.7 28.4 9.2 0.0 2.4 2.1 2.5 4.5 12.8 3.1 2.7 1.8 1.7 1.7 0.8 2.3 0.8 2.2 1.9 4.4 26.4 1.8 1.4 2.3 0.8 4.4 0.5 0.9 5.2 1.9 0.0 0.3 173.4 1.5 0.0 0.0 0.4 0.4 1.4 0.5 2.4 0.0 0.3 37.1 1.5 0.0 0.1 0.1 0.0 1.4 0.1 0.7 1.4 0.2 0.1 0.1 0.1 2.5 0.5 0.1 0.3 1.1 3.6 0.2 1.0 4.1 0.3 0.7 0.3 30.9 0.0 0.0 0.2 1.0 0.0 0.9 1.6 0.0 0.1 0.1 0.0 5.9 0.1 0.0 0.0 0.1 0.2 0.7 5.1 0.2 6.5 0.6 1.2 1.4 0.1 1.5 0.8 0.0 2.2 0.3 0.9 2.7 1.5 25.4 0.0 0.8 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 173.4 0.0 1.1 0.0 0.0 0.4 1.9 3.6 1.4 3.9 1.9 1.1 9.2 0.0 3.1 2.3 TNFRSF10D "CD264, DcR2, TRAILR4, TRUNDD" ENSG00000173530 "TNF receptor superfamily member 10d" Q9UBN6 8 23135588-23164030 "Cancer-related genes, CD markers, Predicted membrane proteins" Apoptosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HUVEC TERT2: 24.1;LHCN-M2: 60.9;WM-115: 57.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 9.0" "Low lineage specificity" "Detected in many" HPA070971 Approved "Plasma membrane,Actin filaments" "Plasma membrane, Actin filaments" "HPA070971: " "unprognostic (1.49e-1)" "prognostic unfavourable (1.70e-4)" "unprognostic (1.41e-1)" "unprognostic (8.78e-2)" "unprognostic (8.13e-2)" "unprognostic (7.49e-2)" "unprognostic (2.69e-1)" "unprognostic (7.06e-2)" "unprognostic (3.56e-2)" "unprognostic (1.66e-1)" "unprognostic (1.61e-2)" "unprognostic (1.32e-1)" "unprognostic (2.12e-2)" "unprognostic (2.70e-1)" "unprognostic (1.35e-2)" "unprognostic (6.32e-2)" "unprognostic (1.72e-1)" 16.0 3.1 4.9 7.3 10.0 10.5 10.2 3.4 10.3 5.9 8.5 2.6 5.5 6.2 8.9 5.7 4.1 8.0 11.5 6.5 7.0 3.4 12.1 31.5 12.5 5.1 9.0 0.9 9.8 5.2 2.5 4.3 4.1 9.0 9.0 10.9 3.9 3.9 4.4 3.9 3.1 11.2 10.9 6.3 6.9 7.2 4.3 9.2 2.9 6.0 6.8 6.6 7.3 26.0 2.1 4.5 2.4 3.3 0.3 9.0 2.4 3.5 3.0 4.0 2.2 3.0 12.1 0.0 18.8 7.1 1.4 1.9 5.8 2.9 0.0 4.0 11.2 1.2 3.3 16.5 12.5 0.0 2.9 1.0 1.8 5.0 13.3 0.6 1.3 15.1 18.4 5.0 3.5 24.1 0.0 0.0 60.9 0.0 0.0 1.9 3.2 0.0 0.7 0.0 0.9 4.7 1.6 0.0 0.0 2.0 0.0 0.0 0.0 2.3 14.2 0.0 0.0 1.1 0.0 0.0 0.0 0.0 15.7 0.9 57.8 2.4 3.3 1.5 0.0 1.4 0.1 2.1 3.2 1.1 4.5 0.8 9.0 3.5 2.2 0.3 1.9 0.0 1.0 2.4 4.9 10.0 3.4 10.3 7.0 3.4 9.0 0.9 9.0 9.2 TNFRSF11A "CD265, FEO, LOH18CR1, PDB2, RANK" ENSG00000141655 "TNF receptor superfamily member 11a" Q9Y6Q6 18 62325287-62391292 "CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Deafness, Disease mutation, Osteopetrosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 28.7;intestine: 23.9;salivary gland: 34.3" "Cell line enriched" "Detected in some" 6 "HDLM-2: 51.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 8 "NK-cell: 8.9" "Lineage enriched" "Detected in many" 8 "NK-cells: 8.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB010391, HPA047976" Approved Supported "Plasma membrane,Cytosol" "Intracellular and membrane" "Plasma membrane" Cytosol "CAB010391: AB_2205352, HPA047976: " "unprognostic (4.08e-1)" "unprognostic (2.71e-1)" "unprognostic (3.23e-3)" "unprognostic (1.73e-1)" "unprognostic (6.03e-2)" "unprognostic (1.35e-1)" "unprognostic (9.96e-4)" "unprognostic (4.24e-3)" "unprognostic (7.79e-4)" "unprognostic (1.52e-1)" "unprognostic (4.05e-2)" "unprognostic (2.88e-1)" "unprognostic (4.69e-5)" "unprognostic (1.56e-1)" "unprognostic (1.78e-1)" "unprognostic (4.02e-2)" "unprognostic (7.07e-2)" 6.5 1.7 1.7 4.8 1.2 0.2 4.3 0.4 2.3 1.5 18.4 0.8 7.6 23.1 0.9 1.9 3.8 1.3 28.7 1.1 1.3 0.7 0.9 0.8 2.3 7.4 1.0 1.0 0.7 2.9 0.1 10.1 2.8 0.7 2.1 13.9 1.3 34.3 12.9 0.6 3.3 23.9 1.3 2.9 1.2 4.3 1.2 0.8 0.7 2.0 1.8 2.3 2.3 2.3 0.0 0.6 0.2 0.0 8.9 1.0 0.0 1.3 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.2 0.0 1.5 0.1 0.9 3.5 0.3 0.1 51.3 2.3 0.0 0.5 0.7 0.0 0.2 0.5 0.1 0.1 0.3 1.3 1.3 0.0 0.0 0.0 0.4 0.0 0.0 2.5 8.1 0.1 0.0 0.2 0.6 0.6 8.7 0.3 0.2 1.3 0.0 0.5 0.1 0.8 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.2 8.9 0.0 0.6 1.0 0.0 1.7 1.2 0.4 2.3 1.3 0.7 1.0 1.0 0.7 0.8 TNFRSF12A "CD266, FN14, TweakR" ENSG00000006327 "TNF receptor superfamily member 12A" Q9NP84 16 3018445-3022383 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Angiogenesis, Apoptosis, Cell adhesion, Differentiation" "Developmental protein, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 81.3" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in many" 5 "pons and medulla: 25.0" "Group enriched" "Detected in many" 8 "eosinophil: 38.1;neutrophil: 29.9" "Lineage enriched" "Detected in many" 9 "granulocytes: 38.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in single" HPA007853 Approved Approved "Plasma membrane,Cytosol" 170000 "Plasma membrane, Cytosol" "HPA007853: AB_1858463" "unprognostic (1.44e-1)" "unprognostic (2.46e-3)" "unprognostic (8.90e-2)" "unprognostic (2.60e-1)" "unprognostic (4.06e-3)" "prognostic unfavourable (5.50e-4)" "unprognostic (7.04e-3)" "unprognostic (1.98e-3)" "unprognostic (4.17e-3)" "unprognostic (2.85e-1)" "unprognostic (5.02e-3)" "unprognostic (3.88e-1)" "prognostic unfavourable (8.78e-4)" "unprognostic (2.98e-2)" "unprognostic (6.00e-2)" "unprognostic (2.80e-3)" "unprognostic (2.17e-2)" 10.8 14.2 2.4 11.3 5.1 2.7 21.2 0.9 3.0 8.0 18.9 3.2 4.1 14.5 11.6 10.2 10.7 6.4 28.1 27.0 5.0 2.6 50.4 36.2 23.0 2.6 4.8 0.5 6.4 47.0 51.1 20.0 81.3 25.0 11.1 1.9 2.8 17.3 6.9 23.3 5.0 31.0 16.8 4.3 3.9 13.2 5.3 3.3 1.2 11.5 11.5 4.7 14.8 5.2 0.0 4.1 38.1 3.5 2.0 2.4 1.1 24.3 19.8 2.2 4.1 4.0 9.2 13.1 51.3 37.2 44.0 28.3 8.5 43.5 0.1 68.0 34.1 27.0 0.5 37.5 16.9 0.9 1.3 0.1 6.6 7.2 27.8 0.4 1.8 8.5 26.0 46.2 55.4 12.7 2.7 0.3 46.3 46.0 0.0 3.2 10.7 43.4 0.2 24.7 1.0 44.5 4.8 2.5 0.8 36.6 17.0 30.3 8.9 0.7 22.3 79.3 36.6 52.4 84.2 0.8 0.3 0.3 24.7 2.2 62.3 3.5 3.5 38.1 1.8 2.0 2.4 0.0 0.8 1.5 4.1 0.0 0.4 0.8 29.9 2.0 1.3 0.1 1.0 1.1 2.4 5.1 0.9 3.0 5.0 2.6 4.8 0.5 25.0 3.3 TNFRSF13B "CD267, IGAD2, TACI" ENSG00000240505 "TNF receptor superfamily member 13B" O14836 17 16929816-16972118 "CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 45.1;lymphoid tissue: 44.6;skeletal muscle: 30.5" "Group enriched" "Detected in some" 8 "Karpas-707: 54.6;RPMI-8226: 34.3;U-266/70: 24.3" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 42 "memory B-cell: 45.1;naive B-cell: 13.1" "Lineage enriched" "Detected in single" 65 "B-cells: 45.1" "Low region specificity" "Detected in all" HPA030453 Uncertain "HPA030453: AB_10601700" "unprognostic (3.94e-5)" "unprognostic (1.11e-3)" "unprognostic (4.88e-2)" "unprognostic (4.30e-3)" "unprognostic (1.23e-4)" "unprognostic (2.16e-1)" "unprognostic (1.62e-3)" "unprognostic (1.47e-2)" "unprognostic (1.61e-4)" "unprognostic (2.22e-1)" "unprognostic (9.78e-2)" "unprognostic (1.59e-5)" "unprognostic (1.20e-1)" "unprognostic (4.49e-1)" "unprognostic (1.39e-1)" "unprognostic (2.05e-1)" 0.5 0.3 0.4 17.6 0.3 0.2 0.5 0.2 0.3 0.7 3.0 0.1 0.0 1.9 0.3 0.0 2.7 0.5 0.5 2.5 0.3 0.3 0.6 0.5 1.2 12.5 0.3 0.2 0.3 0.3 0.0 0.3 0.0 0.1 0.9 1.2 0.6 9.0 1.1 30.5 0.3 14.8 0.0 0.4 44.6 2.4 0.3 0.1 0.9 0.6 0.9 37.8 2.3 0.4 45.1 0.0 0.1 0.0 0.0 0.6 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 54.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 34.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.3 0.0 4.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 45.1 0.0 0.0 0.0 13.1 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.9 0.4 0.3 0.2 0.3 0.3 0.3 0.3 0.2 0.1 0.1 TNFRSF13C "BAFFR, CD268" ENSG00000159958 "TNF receptor superfamily member 13C" Q96RJ3 22 41922023-41926818 "CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 20.3;intestine: 18.9;lymphoid tissue: 69.1" "Group enriched" "Detected in some" 6 "REH: 19.9;U-698: 10.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 51 "memory B-cell: 14.5;naive B-cell: 20.3" "Lineage enriched" "Detected in single" 59 "B-cells: 20.3" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" "HPA003246, CAB008380" Enhanced "CAB008380: AB_590602, HPA003246: AB_1078264" "unprognostic (3.43e-4)" "prognostic favourable (4.44e-7)" "unprognostic (6.52e-2)" "unprognostic (9.10e-2)" "unprognostic (7.64e-3)" "unprognostic (4.83e-3)" "unprognostic (2.89e-2)" "unprognostic (3.78e-3)" "unprognostic (1.95e-1)" "unprognostic (1.27e-1)" "unprognostic (2.51e-2)" "unprognostic (1.66e-1)" "unprognostic (4.79e-8)" "unprognostic (2.21e-1)" "unprognostic (1.89e-1)" "unprognostic (1.77e-1)" "unprognostic (9.44e-2)" 0.9 0.8 0.8 41.0 1.0 3.3 0.6 1.0 2.0 0.5 1.2 4.4 0.0 0.7 0.4 0.2 5.0 0.5 0.6 0.6 0.8 0.9 0.9 0.5 1.8 48.4 1.0 0.6 0.4 0.4 0.0 0.4 0.1 1.8 0.6 0.7 0.5 5.8 0.0 1.2 2.0 18.9 0.1 1.1 69.1 1.4 0.7 0.6 2.0 0.8 0.3 51.4 9.5 0.7 20.3 0.2 0.3 0.2 0.2 0.2 0.5 0.3 0.2 1.1 2.3 0.0 0.0 0.5 0.1 0.1 0.2 0.8 0.9 0.5 1.8 0.4 0.2 0.3 0.6 0.0 0.3 0.4 2.2 0.2 0.3 0.2 0.1 1.6 0.4 0.1 0.0 0.4 0.1 0.0 0.4 1.8 0.2 0.7 1.5 1.7 0.7 0.1 19.9 2.4 1.5 0.0 0.2 1.2 0.3 0.1 0.4 0.3 0.4 2.2 0.2 0.5 2.6 0.9 0.3 2.1 1.0 10.8 0.1 1.7 0.5 0.3 0.1 0.1 0.1 0.1 0.2 14.5 0.2 0.1 0.0 20.3 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.5 0.8 1.0 1.0 2.0 0.8 0.9 1.0 0.6 1.8 0.6 TNFRSF14 "ATAR, CD270, HVEA, HVEM, LIGHTR, TR2" ENSG00000157873 "TNF receptor superfamily member 14" Q92956 1 2555639-2565382 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 14.3;HDLM-2: 14.4;HHSteC: 16.9;Karpas-707: 13.3;SK-MEL-30: 27.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "HPA006404, CAB026150, CAB030007" Approved Approved "Cytosol,Rods & Rings" Cytosol "Rods & Rings" "CAB026150: , CAB030007: AB_2303380, HPA006404: AB_1851348" "prognostic favourable (4.39e-5)" "unprognostic (3.48e-2)" "unprognostic (1.53e-2)" "prognostic favourable (8.01e-6)" "unprognostic (1.11e-2)" "unprognostic (6.83e-3)" "unprognostic (9.62e-3)" "unprognostic (2.32e-1)" "unprognostic (3.25e-1)" "unprognostic (1.62e-1)" "unprognostic (2.31e-1)" "unprognostic (1.64e-1)" "unprognostic (1.86e-2)" "unprognostic (1.16e-2)" "unprognostic (2.72e-2)" "unprognostic (1.58e-1)" "prognostic favourable (7.79e-6)" 15.9 24.9 4.9 38.9 2.8 11.0 21.9 2.0 4.5 16.8 36.3 3.2 18.5 36.3 15.2 20.5 13.7 12.3 36.7 12.7 4.9 2.5 19.3 20.5 30.3 33.2 3.6 5.7 12.8 7.3 3.5 9.3 8.3 3.9 21.5 8.2 44.1 20.9 22.6 5.2 8.4 41.9 14.6 4.1 36.7 16.7 5.9 2.7 23.5 10.8 10.6 25.0 15.4 17.2 18.2 9.7 30.2 25.8 8.1 25.1 14.2 1.3 0.1 0.1 2.3 5.0 2.7 0.7 0.7 2.3 1.3 1.9 0.2 14.3 0.8 0.1 2.1 1.3 0.0 0.8 0.2 14.4 0.0 8.4 0.4 2.6 16.9 1.1 10.4 2.6 1.4 0.7 0.1 3.7 1.1 13.3 1.2 0.0 4.6 1.3 0.0 1.2 3.8 0.0 4.1 0.2 2.0 0.4 0.0 0.5 0.1 27.9 0.4 0.3 9.4 0.2 0.6 0.2 0.1 10.8 2.6 0.4 2.3 1.2 1.0 3.0 15.1 8.2 17.2 25.8 14.9 16.6 18.0 14.8 9.7 18.2 17.3 14.9 30.2 8.1 24.1 8.7 25.1 14.2 4.9 2.8 2.0 4.5 4.9 2.5 3.6 5.7 3.9 2.7 TNFRSF17 "BCM, BCMA, CD269, TNFRSF13A" ENSG00000048462 "TNF receptor superfamily member 17" Q02223 16 11965107-11968068 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 34.1;intestine: 17.8;lymphoid tissue: 28.8" "Cell line enhanced" "Detected in some" "Karpas-707: 25.3;RPMI-8226: 39.9;U-266/70: 118.6;U-266/84: 58.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 59 "memory B-cell: 34.1;naive B-cell: 26.9;plasmacytoid DC: 27.9" "Group enriched" "Detected in many" 62 "B-cells: 34.1;dendritic cells: 27.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" 2200000 "prognostic favourable (1.35e-5)" "unprognostic (3.41e-2)" "unprognostic (4.00e-3)" "unprognostic (1.41e-2)" "unprognostic (6.47e-2)" "prognostic favourable (1.58e-6)" "unprognostic (9.75e-3)" "unprognostic (5.93e-2)" "unprognostic (2.13e-2)" "unprognostic (7.96e-3)" "unprognostic (2.46e-1)" "unprognostic (2.58e-1)" "unprognostic (2.85e-6)" "unprognostic (2.06e-1)" "unprognostic (2.48e-1)" "unprognostic (3.54e-2)" "unprognostic (1.10e-1)" 0.6 0.4 0.4 24.0 0.9 0.3 5.4 0.5 0.4 1.5 17.8 0.2 0.2 12.3 0.5 0.2 3.7 1.1 4.9 0.7 0.4 0.4 1.3 0.8 3.0 22.4 0.4 0.2 0.9 3.1 0.0 0.5 0.3 0.2 1.0 9.4 0.6 14.2 0.2 0.4 0.4 11.7 0.2 0.4 22.2 9.4 2.2 0.3 3.1 1.1 1.4 28.8 7.6 0.7 34.1 27.9 0.5 0.1 0.2 0.1 3.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 25.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 39.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 118.6 58.9 9.2 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.1 34.1 0.0 0.0 0.0 26.9 0.0 0.0 0.5 0.2 0.0 27.9 0.0 3.7 0.4 0.9 0.5 0.4 0.4 0.4 0.4 0.2 0.2 0.3 TNFRSF18 "AITR, CD357, GITR" ENSG00000186891 "TNF receptor superfamily member 18" Q9Y5U5 1 1203508-1206691 "CD markers, Predicted membrane proteins, Predicted secreted proteins" Apoptosis Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 46.6;skin 1: 28.9" "Group enriched" "Detected in some" 11 "RPMI-8226: 61.2;SCLC-21H: 43.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "NK-cell: 46.6" "Group enriched" "Detected in many" 11 "NK-cells: 46.6;T-cells: 19.0" HPA008025 Approved "Secreted to blood" "HPA008025: AB_1849696" "unprognostic (1.20e-3)" "unprognostic (4.61e-2)" "unprognostic (4.59e-2)" "prognostic favourable (7.72e-6)" "unprognostic (2.73e-4)" "prognostic favourable (4.12e-4)" "unprognostic (3.43e-2)" "unprognostic (2.31e-1)" "unprognostic (3.33e-2)" "unprognostic (1.01e-1)" "unprognostic (1.00e-1)" "unprognostic (1.20e-1)" "prognostic unfavourable (4.40e-11)" "unprognostic (1.02e-3)" "unprognostic (2.39e-1)" "unprognostic (3.74e-1)" "unprognostic (2.08e-1)" 1.4 0.5 1.0 8.9 1.0 1.9 4.2 4.9 2.5 14.3 8.3 0.3 0.1 5.7 2.1 1.1 4.7 1.0 3.7 0.2 0.5 0.3 1.1 1.7 3.0 9.1 0.4 2.4 0.3 2.7 9.4 3.8 1.3 1.7 1.9 1.2 0.5 9.0 2.6 1.0 28.9 5.0 0.2 0.3 6.7 3.8 0.8 0.1 4.4 0.9 2.7 8.2 1.5 2.2 2.9 0.0 0.2 0.0 46.6 19.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 4.6 0.0 0.0 61.2 0.0 0.0 43.9 0.0 0.0 0.1 0.0 2.3 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 2.0 0.0 3.6 1.3 8.5 1.2 0.0 2.9 0.3 0.4 0.2 46.6 0.0 0.0 19.0 2.1 1.0 1.0 4.9 2.5 0.5 0.3 0.4 2.4 1.7 0.1 TNFRSF1A "CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60" ENSG00000067182 "TNF receptor superfamily member 1A" P19438 12 6328757-6342114 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Apoptosis, Host-virus interaction" Receptor "Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 86.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004102, CAB010309" Approved "Secreted to blood" 170000 "CAB010309: AB_2206639, HPA004102: AB_1846232" "unprognostic (2.19e-2)" "unprognostic (3.76e-2)" "unprognostic (8.14e-2)" "prognostic favourable (8.22e-4)" "unprognostic (3.07e-2)" "prognostic unfavourable (3.68e-4)" "unprognostic (1.50e-1)" "unprognostic (1.41e-3)" "unprognostic (1.00e-1)" "unprognostic (8.05e-2)" "unprognostic (4.78e-2)" "unprognostic (1.54e-2)" "prognostic unfavourable (2.70e-7)" "unprognostic (1.43e-2)" "unprognostic (2.92e-2)" "unprognostic (5.14e-3)" "unprognostic (1.74e-1)" 55.1 43.9 16.8 28.9 16.8 13.7 40.6 7.2 15.6 40.3 41.5 14.1 22.6 39.2 38.2 27.5 39.4 34.2 37.1 26.8 14.0 7.5 49.3 61.6 40.9 37.2 19.2 6.4 59.5 21.4 20.3 19.9 45.3 18.3 37.0 23.0 31.1 25.7 22.2 34.2 30.9 81.7 38.8 25.1 43.6 28.2 21.8 15.7 31.6 42.7 25.4 22.3 49.1 58.5 0.0 20.8 86.5 27.1 1.8 11.6 15.9 7.4 57.8 8.1 11.5 56.0 57.3 15.3 15.9 27.5 21.3 18.6 6.9 29.7 0.6 5.5 34.3 20.8 2.5 18.6 14.8 0.1 4.8 4.1 16.0 15.3 49.7 19.3 13.0 59.0 18.7 17.7 26.1 26.0 6.2 5.7 24.5 10.6 6.1 18.2 19.7 16.9 5.3 12.9 5.7 16.5 13.5 0.0 0.4 22.5 11.8 11.8 3.2 21.1 28.3 16.8 14.4 12.6 14.7 0.0 1.8 2.4 20.1 18.0 20.8 2.2 27.1 15.0 11.6 21.8 11.1 0.0 4.9 9.5 20.8 0.0 4.5 6.6 86.5 1.8 17.5 6.0 4.8 15.9 16.8 16.8 7.2 15.6 14.0 7.5 19.2 6.4 18.3 15.7 TNFRSF1B "CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80" ENSG00000028137 "TNF receptor superfamily member 1B" P20333 1 12167003-12209228 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" Apoptosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 70.1" "Cell line enhanced" "Detected in many" "CAPAN-2: 17.1;K-562: 20.9;THP-1: 24.5;U-87 MG: 16.8;U-937: 17.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "non-classical monocyte: 70.1" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA004796 Approved "Secreted to blood" 3226667 2500000 "HPA004796: AB_1078436" "unprognostic (4.45e-2)" "unprognostic (2.27e-3)" "unprognostic (7.62e-2)" "unprognostic (3.82e-3)" "unprognostic (6.30e-2)" "unprognostic (4.47e-3)" "unprognostic (5.28e-3)" "unprognostic (2.79e-1)" "unprognostic (1.69e-2)" "unprognostic (1.73e-2)" "unprognostic (7.26e-2)" "unprognostic (2.48e-1)" "prognostic unfavourable (8.35e-5)" "unprognostic (2.02e-1)" "prognostic unfavourable (8.68e-4)" "unprognostic (3.26e-2)" "unprognostic (1.10e-1)" 43.4 4.7 4.6 44.3 13.8 29.2 42.3 2.1 6.1 13.3 13.1 6.6 1.9 11.9 9.7 10.2 6.5 11.3 11.6 21.8 8.5 6.2 6.2 22.2 24.5 60.6 9.1 2.2 9.4 4.2 2.3 4.4 24.9 15.0 7.3 8.2 8.3 5.7 3.7 11.5 6.2 17.3 11.5 22.6 48.3 10.5 6.0 6.1 10.9 6.2 5.6 16.2 18.3 8.4 2.7 13.2 25.7 70.1 2.5 12.7 19.9 0.0 0.1 2.0 0.0 5.5 7.5 4.3 0.5 1.0 2.0 2.2 0.8 17.1 0.1 0.3 1.8 0.0 0.4 0.0 1.1 6.8 0.0 0.0 0.1 0.0 12.9 0.1 1.8 7.4 0.0 6.8 0.0 10.4 20.9 3.1 0.9 0.0 0.0 3.9 0.1 0.6 0.5 0.2 12.0 0.0 0.4 0.0 0.0 0.3 0.1 0.6 0.0 24.5 3.6 3.0 0.1 13.0 0.0 0.9 0.0 0.0 16.8 17.7 0.7 0.0 20.7 3.0 9.4 49.3 5.4 2.7 6.6 7.7 13.2 1.7 2.0 3.0 25.7 2.5 70.1 2.8 12.7 19.9 4.6 13.8 2.1 6.1 8.5 6.2 9.1 2.2 15.0 6.1 TNFRSF21 "CD358, DR6" ENSG00000146072 "TNF receptor superfamily member 21" O75509 6 47231532-47309905 "CD markers, Plasma proteins, Predicted membrane proteins" "Adaptive immunity, Apoptosis, Immunity" Receptor "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 63.4" "Cell line enhanced" "Detected in many" "RT4: 102.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 35 "plasmacytoid DC: 31.6" "Lineage enriched" "Detected in single" 309 "dendritic cells: 31.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006746, CAB009805" Approved Supported "Plasma membrane,Cytosol" 1300000 "Plasma membrane, Cytosol" "CAB009805: AB_2206956, HPA006746: AB_1078701" "unprognostic (1.19e-2)" "unprognostic (2.70e-1)" "unprognostic (3.26e-1)" "unprognostic (7.85e-2)" "unprognostic (1.44e-1)" "unprognostic (3.41e-2)" "unprognostic (9.80e-3)" "unprognostic (1.11e-1)" "unprognostic (1.46e-2)" "unprognostic (7.53e-2)" "unprognostic (1.38e-3)" "unprognostic (1.74e-1)" "prognostic favourable (7.23e-6)" "unprognostic (1.48e-1)" "unprognostic (1.34e-1)" "unprognostic (9.78e-2)" "unprognostic (1.45e-2)" 25.9 3.7 9.7 8.7 13.6 5.9 7.8 7.4 20.8 9.6 19.3 26.9 1.0 6.4 9.1 3.0 21.8 9.9 18.7 4.1 13.8 16.0 26.2 4.6 9.5 11.5 26.8 7.9 5.0 17.9 35.6 4.4 17.0 29.5 10.2 18.5 3.0 15.2 2.4 3.5 2.7 10.2 8.2 63.4 11.6 30.4 5.8 10.1 11.5 2.9 19.2 16.5 41.2 11.6 0.0 31.6 0.1 0.0 0.0 0.0 0.2 29.9 9.7 9.5 3.0 26.1 7.7 10.8 3.5 6.9 1.1 0.4 16.8 21.2 2.2 14.2 2.5 18.1 1.4 12.9 0.6 0.0 2.9 0.0 1.2 16.9 15.3 0.4 0.1 13.7 15.5 0.6 11.8 5.1 0.7 0.0 0.3 5.9 2.6 0.2 7.4 10.1 5.6 2.9 3.2 18.1 102.3 6.8 1.5 3.0 2.8 2.4 2.2 2.1 1.0 2.8 2.6 0.1 3.2 0.0 0.0 3.1 4.7 2.1 7.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 31.6 0.0 0.2 9.7 13.6 7.4 20.8 13.8 16.0 26.8 7.9 29.5 10.1 TNFRSF4 "ACT35, CD134, OX40, TXGP1L" ENSG00000186827 "TNF receptor superfamily member 4" P43489 1 1211326-1214138 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 12.5;blood: 18.4;lymphoid tissue: 13.6" "Group enriched" "Detected in some" 9 "MOLT-4: 7.8;NB-4: 15.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Cell type enhanced" "Detected in many" "memory CD4 T-cell: 15.9;T-reg: 18.4" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" CAB016128 Enhanced "CAB016128: AB_626897" "unprognostic (2.24e-1)" "unprognostic (8.69e-3)" "unprognostic (1.36e-1)" "unprognostic (8.55e-3)" "unprognostic (1.02e-1)" "prognostic favourable (3.50e-6)" "prognostic unfavourable (6.03e-4)" "unprognostic (3.30e-1)" "unprognostic (1.48e-2)" "unprognostic (7.04e-3)" "unprognostic (1.04e-2)" "unprognostic (1.47e-1)" "prognostic unfavourable (4.52e-6)" "unprognostic (1.61e-1)" "unprognostic (5.46e-2)" "unprognostic (2.42e-1)" "unprognostic (5.91e-2)" 12.5 0.2 0.6 8.8 0.4 0.7 7.3 0.3 1.2 1.1 3.1 0.3 0.3 2.6 0.8 0.7 1.7 0.9 0.8 6.7 0.8 0.1 2.2 0.4 5.3 8.4 0.3 0.6 0.5 0.9 0.0 1.3 5.9 0.6 3.2 0.3 0.6 2.2 1.1 4.4 0.8 4.3 0.3 0.3 13.5 3.5 2.0 0.3 13.6 4.1 0.8 10.9 1.4 0.7 0.0 0.6 4.1 0.0 8.1 18.4 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.8 15.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.1 0.2 0.0 1.8 0.0 15.9 1.7 0.0 0.0 1.5 0.0 0.2 8.1 0.0 0.6 18.4 1.5 0.6 0.4 0.3 1.2 0.8 0.1 0.3 0.6 0.6 0.3 TNFRSF8 "CD30, D1S166E, KI-1" ENSG00000120949 "TNF receptor superfamily member 8" P28908 1 12063377-12144207 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 33.3" "Cell line enriched" "Detected in some" 21 "HDLM-2: 109.9" "Cancer enriched" "Detected in some" 12 "testis cancer: 9.3" "Region enriched" "Detected in single" 14 "basal ganglia: 13.1" "Cell type enhanced" "Detected in some" "intermediate monocyte: 21.7;non-classical monocyte: 33.3" "Lineage enriched" "Detected in many" 5 "monocytes: 33.3" "Low region specificity" "Detected in many" "CAB000016, HPA014823, HPA032081, HPA032082" Approved Supported "Plasma membrane" "Plasma membrane" "CAB000016: AB_563546, HPA014823: , HPA032081: , HPA032082: " "unprognostic (1.07e-2)" "unprognostic (2.06e-2)" "unprognostic (2.52e-2)" "unprognostic (5.98e-2)" "unprognostic (2.50e-1)" "unprognostic (1.46e-3)" "unprognostic (2.19e-1)" "unprognostic (3.93e-2)" "unprognostic (1.18e-1)" "unprognostic (9.18e-3)" "unprognostic (1.86e-1)" "unprognostic (2.06e-1)" "unprognostic (3.17e-8)" "unprognostic (3.31e-1)" "unprognostic (8.56e-2)" "unprognostic (2.07e-1)" "unprognostic (2.31e-2)" 10.7 0.2 0.1 7.2 13.1 1.4 5.8 0.2 0.4 1.1 0.8 0.0 1.5 0.2 1.7 1.3 0.9 2.1 1.4 3.8 0.1 0.2 0.9 0.2 3.9 2.9 0.5 0.5 1.2 0.4 0.0 0.1 6.2 0.5 1.0 0.5 0.0 0.7 0.3 3.1 1.6 1.3 1.3 1.4 2.9 6.4 2.5 0.9 3.0 0.7 2.7 5.3 2.6 3.8 0.0 3.2 6.8 33.3 0.0 0.3 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 2.4 0.0 0.0 0.0 0.0 0.0 109.9 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.3 0.0 0.0 5.1 0.3 0.0 0.0 0.2 0.0 4.4 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.3 0.0 21.7 0.1 0.0 0.0 0.0 3.2 0.0 0.0 0.0 6.8 0.0 33.3 0.8 0.3 2.7 0.1 13.1 0.2 0.4 0.1 0.2 0.5 0.5 0.5 0.9 TNFRSF9 "4-1BB, CD137, ILA" ENSG00000049249 "TNF receptor superfamily member 9" Q07011 1 7915894-7943165 "Cancer-related genes, CD markers, Predicted membrane proteins" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "blood: 13.5;lymphoid tissue: 18.3" "Cell line enriched" "Detected in some" 8 "HDLM-2: 45.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 5 "memory CD8 T-cell: 8.0;neutrophil: 6.6;NK-cell: 4.1;T-reg: 13.5" "Group enriched" "Detected in many" 5 "granulocytes: 6.6;NK-cells: 4.1;T-cells: 13.5" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA071425 Approved "Nucleoli,Plasma membrane" "Plasma membrane" Nucleoli "HPA071425: " "unprognostic (7.23e-2)" "unprognostic (1.72e-2)" "unprognostic (8.26e-3)" "unprognostic (1.32e-3)" "unprognostic (1.10e-1)" "unprognostic (1.98e-2)" "unprognostic (2.52e-1)" "unprognostic (1.04e-1)" "unprognostic (1.19e-4)" "unprognostic (9.47e-3)" "unprognostic (2.17e-2)" "unprognostic (2.02e-1)" "prognostic unfavourable (2.69e-8)" "unprognostic (1.64e-2)" "unprognostic (2.25e-2)" "unprognostic (1.19e-1)" "unprognostic (9.55e-2)" 0.8 1.0 0.3 11.0 0.3 1.9 0.5 0.2 0.3 0.4 0.5 0.1 0.1 0.6 0.3 0.1 0.6 0.8 1.6 1.8 0.3 1.0 0.7 0.7 2.1 10.8 0.3 0.1 0.3 0.6 0.0 0.5 0.2 0.5 0.4 0.7 0.3 2.1 0.1 0.3 0.5 2.3 0.1 0.3 7.9 0.7 0.5 0.1 18.3 0.7 0.9 17.5 1.4 0.4 0.5 1.1 6.6 1.5 4.1 13.5 1.1 1.2 0.4 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.9 0.3 0.1 0.4 0.0 0.1 0.0 0.2 0.4 45.9 0.1 0.2 0.2 0.0 0.9 0.0 0.5 0.1 0.3 0.1 0.1 0.0 0.2 0.1 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.0 0.0 0.2 0.2 0.2 1.5 0.1 0.2 0.1 0.1 0.1 5.7 0.2 0.0 1.1 1.5 0.2 1.5 0.4 0.2 0.2 1.0 8.0 1.1 0.5 0.3 1.6 6.6 4.1 0.1 0.3 13.5 1.1 0.3 0.3 0.2 0.3 0.3 1.0 0.3 0.1 0.5 0.1 TNFSF10 "Apo-2L, CD253, TL2, TRAIL" ENSG00000121858 "TNF superfamily member 10" P50591 3 172505508-172523507 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Apoptosis Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "kidney: 115.1" "Cell line enhanced" "Detected in many" "BEWO: 20.5;CAPAN-2: 14.6;HMC-1: 67.6;RPTEC TERT1: 34.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "basophil: 42.4;classical monocyte: 25.6;intermediate monocyte: 39.5;neutrophil: 50.3;non-classical monocyte: 38.3" "Group enriched" "Detected in all" 5 "granulocytes: 50.3;monocytes: 39.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054938 Uncertain Approved Microtubules "Secreted to blood" 67430 Microtubules "HPA054938: " "unprognostic (9.16e-2)" "unprognostic (2.79e-2)" "unprognostic (1.08e-1)" "unprognostic (4.69e-3)" "unprognostic (2.52e-1)" "unprognostic (2.67e-1)" "unprognostic (1.55e-1)" "unprognostic (2.01e-1)" "unprognostic (1.99e-1)" "unprognostic (1.71e-2)" "prognostic unfavourable (9.43e-4)" "unprognostic (1.04e-1)" "unprognostic (1.04e-1)" "unprognostic (1.29e-1)" "unprognostic (3.68e-2)" "unprognostic (1.32e-1)" "unprognostic (6.27e-2)" 30.9 22.1 3.4 14.6 4.7 2.0 23.3 3.0 5.4 31.4 25.8 4.4 17.1 20.6 13.0 10.3 33.3 9.6 10.7 9.9 3.8 3.2 115.1 44.4 91.5 23.5 5.5 3.4 13.5 11.6 10.9 6.7 100.8 6.7 37.6 19.5 12.0 50.6 12.9 13.9 13.0 54.0 7.9 5.6 35.8 9.5 6.0 4.6 8.3 28.2 17.7 16.1 22.4 24.0 3.4 9.5 50.3 39.5 9.3 7.0 11.9 3.3 0.1 0.0 0.0 2.4 1.8 20.5 0.0 0.1 1.0 1.6 0.0 14.6 2.1 9.8 0.0 14.4 0.0 1.8 0.2 5.2 0.0 0.0 0.4 0.3 0.1 3.8 67.6 2.4 2.3 0.4 0.0 7.4 0.0 2.4 0.0 0.0 0.4 5.1 0.0 0.1 0.7 0.0 0.9 34.1 1.3 0.0 0.1 7.5 0.3 0.1 4.1 2.2 0.3 0.0 0.0 0.0 0.2 2.6 0.3 2.6 0.2 2.2 0.0 42.4 25.6 2.7 2.3 39.5 3.1 3.2 6.4 3.5 9.5 3.4 4.7 1.8 50.3 9.3 38.3 0.6 7.0 11.9 3.4 4.7 3.0 5.4 3.8 3.2 5.5 3.4 6.7 4.6 TNFSF11 "CD254, ODF, OPGL, RANKL, TRANCE" ENSG00000120659 "TNF superfamily member 11" O14788 13 42562736-42608013 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Differentiation "Cytokine, Developmental protein, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Osteopetrosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 14.3;lymphoid tissue: 19.8" "Cell line enhanced" "Detected in some" "Daudi: 1.7;HSkMC: 5.2;NTERA-2: 7.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 8 "NK-cell: 14.3" "Lineage enriched" "Detected in many" 8 "NK-cells: 14.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB009193, HPA045142" Enhanced "Secreted to blood" 17195 "CAB009193: , HPA045142: " "unprognostic (3.97e-4)" "unprognostic (1.40e-1)" "unprognostic (9.01e-3)" "unprognostic (3.81e-3)" "unprognostic (1.12e-1)" "unprognostic (1.09e-1)" "unprognostic (7.09e-2)" "unprognostic (7.70e-2)" "unprognostic (2.29e-1)" "unprognostic (1.25e-3)" "unprognostic (1.00e-1)" "unprognostic (1.50e-1)" "unprognostic (3.94e-5)" "unprognostic (1.87e-1)" "unprognostic (9.67e-2)" "unprognostic (5.46e-2)" "unprognostic (7.74e-2)" 0.5 0.2 0.2 19.5 0.2 0.0 4.6 0.1 0.2 0.8 0.8 0.1 2.4 0.2 0.2 0.1 3.7 0.2 1.3 0.3 0.1 0.7 0.6 5.3 0.4 19.8 0.1 0.1 0.1 0.6 0.0 0.3 0.3 0.4 0.5 2.2 0.1 1.6 1.0 0.2 0.5 6.0 0.1 0.1 0.8 0.3 3.3 0.1 2.8 0.4 0.1 5.2 2.3 0.7 0.0 0.1 1.8 0.0 14.3 0.1 0.1 0.0 0.3 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.7 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.0 0.1 0.5 0.0 0.6 0.0 0.1 5.2 0.5 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.2 7.4 0.1 0.0 0.2 0.0 0.0 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.7 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 14.3 0.0 0.0 0.0 0.1 0.2 0.2 0.1 0.2 0.1 0.7 0.1 0.1 0.4 0.1 TNFSF13 "APRIL, CD256" ENSG00000161955 "TNF superfamily member 13" O75888 17 7558292-7561608 "Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Immunity Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "salivary gland: 102.8" "Cell line enhanced" "Detected in many" "EFO-21: 18.4;RPTEC TERT1: 46.5;U-937: 17.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 63.5;eosinophil: 22.8;intermediate monocyte: 62.7;myeloid DC: 43.0;non-classical monocyte: 37.3;plasmacytoid DC: 19.8" "Group enriched" "Detected in many" 10 "dendritic cells: 43.0;granulocytes: 22.8;monocytes: 63.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA004863 Uncertain "Secreted to blood" 6766927 29000 "HPA004863: AB_1078187" "unprognostic (2.46e-2)" "unprognostic (2.20e-1)" "unprognostic (3.42e-1)" "unprognostic (6.53e-2)" "prognostic unfavourable (9.73e-4)" "unprognostic (3.57e-1)" "unprognostic (3.32e-2)" "unprognostic (3.70e-2)" "unprognostic (3.75e-1)" "unprognostic (1.15e-1)" "unprognostic (6.95e-2)" "unprognostic (2.65e-1)" "prognostic favourable (1.30e-9)" "unprognostic (4.69e-2)" "unprognostic (1.42e-2)" "unprognostic (3.46e-1)" "unprognostic (3.38e-2)" 12.1 14.4 18.7 15.4 24.2 18.3 12.9 5.7 15.3 15.7 20.4 8.7 27.4 32.0 7.7 12.8 6.1 14.4 29.1 9.5 11.1 10.7 34.1 11.9 43.0 39.0 14.3 9.4 14.0 20.7 5.7 10.8 6.4 31.6 13.7 18.7 22.0 102.8 69.4 3.0 5.3 18.5 10.9 13.1 16.2 23.4 5.0 9.0 3.3 14.1 8.2 11.5 10.4 8.4 4.1 43.0 22.8 63.5 1.3 0.4 30.6 8.3 3.4 1.1 2.3 1.3 0.7 1.4 1.5 1.0 0.6 0.5 1.8 5.2 3.7 18.4 1.5 5.3 0.0 1.5 0.6 6.5 2.9 2.3 7.5 3.9 2.8 2.0 2.4 1.5 1.4 0.4 2.4 1.9 1.8 1.4 0.5 1.2 0.9 6.6 1.1 2.5 6.6 1.4 15.8 46.5 5.5 2.1 2.0 2.9 7.8 1.0 10.4 5.0 1.0 2.0 2.4 0.9 3.2 0.3 1.1 0.9 0.8 17.8 3.9 9.0 63.5 22.8 0.1 62.7 0.1 2.0 0.0 0.1 43.0 4.1 0.4 0.2 8.6 1.3 37.3 19.8 0.1 30.6 18.7 24.2 5.7 15.3 11.1 10.7 14.3 9.4 31.6 9.0 TNFSF13B "BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20" ENSG00000102524 "TNF superfamily member 13b" Q9Y275 13 108251240-108308484 "Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Immunity Cytokine "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 76.5;lymphoid tissue: 39.6" "Cell line enriched" "Detected in some" 7 "U-937: 59.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 76.5" "Group enriched" "Detected in many" 10 "dendritic cells: 31.0;granulocytes: 76.5;monocytes: 53.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" CAB009188 Enhanced "Secreted to blood" 393384 530000 "CAB009188: " "unprognostic (6.48e-2)" "unprognostic (3.05e-3)" "unprognostic (1.38e-1)" "unprognostic (1.90e-1)" "unprognostic (2.61e-2)" "unprognostic (7.99e-2)" "unprognostic (8.19e-2)" "unprognostic (1.37e-1)" "unprognostic (1.63e-1)" "unprognostic (1.02e-2)" "unprognostic (2.64e-2)" "unprognostic (1.21e-1)" "prognostic unfavourable (2.53e-11)" "unprognostic (1.23e-1)" "unprognostic (4.14e-2)" "unprognostic (1.88e-1)" "unprognostic (1.25e-1)" 7.2 8.2 3.0 18.5 8.2 13.2 3.4 1.4 5.2 1.6 4.2 2.1 1.0 7.8 1.2 6.5 3.5 2.9 9.4 9.4 5.7 2.9 3.1 5.0 13.2 39.6 7.2 2.6 2.9 2.7 0.5 2.1 6.4 5.7 3.7 6.4 2.6 5.4 1.8 1.6 1.6 6.8 3.5 11.6 23.5 3.4 1.0 4.9 7.2 5.1 1.7 12.7 8.5 3.8 1.0 31.0 76.5 53.7 0.6 5.3 20.8 0.0 0.1 0.0 0.0 0.2 0.3 0.0 0.1 0.3 0.2 0.7 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.3 0.1 0.0 0.1 3.5 0.1 0.7 0.1 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.4 0.1 0.0 0.0 0.1 0.0 7.9 0.0 0.1 0.0 0.0 0.1 3.7 0.1 0.0 3.8 59.5 0.6 1.2 53.7 14.4 0.8 39.8 5.3 0.6 3.5 0.7 31.0 1.0 1.7 0.5 76.5 0.6 31.7 11.5 2.8 20.8 3.0 8.2 1.4 5.2 5.7 2.9 7.2 2.6 5.7 4.9 TNFSF14 "CD258, HVEM-L, LIGHT, LTg" ENSG00000125735 "TNF superfamily member 14" O43557 19 6661253-6670588 "CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Cytokine "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 50.8;liver: 50.6" "Cell line enhanced" "Detected in some" "HDLM-2: 21.1;NB-4: 4.7;THP-1: 3.3;U-937: 12.0" "Cancer enhanced" "Detected in many" "liver cancer: 4.4" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 50.8" "Group enriched" "Detected in many" 5 "granulocytes: 50.8;T-cells: 16.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA012700 Approved "Secreted to blood" 40957 "HPA012700: AB_1852870" "unprognostic (2.78e-3)" "unprognostic (2.11e-1)" "unprognostic (1.62e-1)" "unprognostic (2.35e-3)" "unprognostic (3.82e-4)" "unprognostic (4.51e-2)" "unprognostic (1.09e-1)" "unprognostic (2.63e-1)" "unprognostic (1.05e-2)" "unprognostic (9.23e-2)" "unprognostic (9.22e-2)" "unprognostic (3.59e-1)" "prognostic unfavourable (6.07e-13)" "unprognostic (1.09e-1)" "unprognostic (9.56e-3)" "unprognostic (1.75e-1)" "unprognostic (3.62e-2)" 11.2 0.9 0.6 4.6 0.6 2.5 1.3 1.2 1.5 0.8 2.4 0.4 0.2 2.8 2.7 2.3 1.8 3.6 2.0 2.1 0.6 0.1 1.0 50.6 4.3 8.3 3.8 0.2 2.9 2.5 0.0 0.9 1.8 1.4 1.2 1.8 1.9 1.4 1.5 0.2 0.7 3.8 1.6 0.3 8.2 1.8 1.6 0.2 1.5 1.4 0.9 5.9 2.1 14.1 0.3 1.7 50.8 4.5 7.2 16.6 2.9 0.0 0.3 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.5 0.0 0.0 0.0 21.1 0.0 0.1 0.2 1.1 0.0 0.6 0.5 0.2 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 3.3 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.7 12.0 0.0 28.3 4.5 27.4 11.4 1.0 16.6 0.1 4.9 9.2 1.7 0.3 0.8 4.2 50.8 7.2 0.1 0.1 3.9 2.9 0.6 0.6 1.2 1.5 0.6 0.1 3.8 0.2 1.4 0.2 TNFSF4 "CD252, gp34, OX-40L, TXGP1" ENSG00000117586 "TNF superfamily member 4" P23510 1 173183734-173207313 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins" Cytokine "Cancer-related genes, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 11.5;testis: 14.4" "Cell line enhanced" "Detected in some" "fHDF/TERT166: 18.3;HHSteC: 7.9;HUVEC TERT2: 35.9;LHCN-M2: 29.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" HPA059579 Approved Approved Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "HPA059579: " "unprognostic (1.88e-2)" "unprognostic (1.20e-1)" "unprognostic (4.58e-2)" "unprognostic (2.74e-1)" "unprognostic (1.73e-2)" "unprognostic (1.74e-1)" "unprognostic (1.13e-3)" "unprognostic (2.13e-1)" "unprognostic (8.65e-2)" "unprognostic (5.17e-2)" "unprognostic (1.26e-2)" "unprognostic (1.18e-1)" "unprognostic (1.11e-7)" "unprognostic (3.73e-3)" "unprognostic (2.66e-1)" "unprognostic (9.49e-2)" "unprognostic (2.98e-2)" 2.1 4.0 1.7 8.2 2.3 0.9 3.7 4.5 3.4 1.7 1.8 1.0 0.8 0.3 1.5 1.5 1.6 1.4 2.1 2.1 3.0 2.0 1.5 1.6 2.5 11.5 1.9 0.8 2.7 2.1 1.0 3.3 1.2 1.2 2.8 2.5 1.0 0.8 1.0 0.8 0.3 2.5 1.6 1.9 9.7 1.4 14.4 1.2 9.3 0.8 0.8 3.7 1.6 1.6 1.3 2.6 1.7 0.2 3.4 1.2 6.5 0.0 0.0 0.2 0.5 1.2 6.5 0.0 1.8 0.4 0.1 0.1 0.0 0.0 0.0 0.3 18.3 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.2 0.7 7.9 0.1 0.0 2.8 0.1 0.9 0.1 35.9 0.0 0.2 29.9 0.0 0.3 0.1 0.1 0.3 0.8 0.0 0.2 0.3 0.0 0.0 0.3 0.1 0.1 0.3 0.0 0.3 0.3 0.0 0.0 0.1 0.1 0.4 0.5 0.1 0.1 3.3 1.9 0.0 0.2 0.3 1.1 0.1 0.8 1.1 0.7 0.9 0.8 1.3 1.2 1.1 1.7 3.4 0.1 2.6 0.9 6.5 1.7 2.3 4.5 3.4 3.0 2.0 1.9 0.8 1.2 1.2 TNFSF8 "CD153, CD30LG" ENSG00000106952 "TNF superfamily member 8" P32971 9 114893343-114930595 "Cancer-related genes, CD markers, Predicted membrane proteins" Cytokine "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 18.6;lymphoid tissue: 48.1" "Group enriched" "Detected in some" 111 "Daudi: 34.3;U-698: 28.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Not detected" "Not detected" "Low region specificity" "Detected in many" "unprognostic (8.82e-2)" "unprognostic (6.56e-3)" "unprognostic (7.79e-2)" "unprognostic (6.05e-2)" "unprognostic (2.67e-1)" "unprognostic (5.58e-3)" "unprognostic (5.26e-3)" "unprognostic (1.82e-2)" "unprognostic (2.37e-1)" "unprognostic (1.24e-1)" "unprognostic (1.70e-1)" "unprognostic (2.02e-1)" "unprognostic (4.75e-2)" "unprognostic (3.01e-2)" "unprognostic (2.76e-2)" "unprognostic (9.61e-2)" "unprognostic (1.82e-1)" 3.6 1.7 1.1 12.0 1.7 12.7 1.8 0.5 0.9 1.6 2.4 1.4 0.6 0.3 1.1 2.5 1.4 1.5 4.6 2.8 1.1 1.2 1.8 1.4 4.9 48.1 1.6 0.6 0.9 1.1 0.0 0.8 2.2 1.0 1.3 1.9 1.4 3.7 0.9 0.7 1.0 7.0 1.3 2.8 14.9 1.7 1.1 1.0 45.6 1.6 0.8 18.5 3.2 1.3 1.7 7.3 3.9 14.1 1.0 18.6 8.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 34.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 28.1 0.0 0.0 0.0 0.0 14.1 0.0 4.1 7.3 13.8 1.0 16.4 9.8 7.3 1.7 18.6 13.5 3.9 1.0 0.9 4.0 5.9 8.7 1.1 1.7 0.5 0.9 1.1 1.2 1.6 0.6 1.0 1.0 TREM1 "CD354, TREM-1" ENSG00000124731 "Triggering receptor expressed on myeloid cells 1" Q9NP99 6 41267926-41286719 "CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 96.9;bone marrow: 38.5;lung: 34.2" "Cell line enriched" "Detected in some" 7 "U-87 MG: 23.6" "Cancer enhanced" "Detected in many" "lung cancer: 9.6" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 8 "neutrophil: 96.9" "Lineage enriched" "Detected in many" 8 "granulocytes: 96.9" HPA005563 Uncertain "Intracellular and membrane" "HPA005563: AB_1858259" "unprognostic (6.41e-2)" "unprognostic (1.47e-3)" "unprognostic (1.22e-1)" "unprognostic (3.39e-2)" "unprognostic (6.07e-3)" "unprognostic (2.97e-2)" "unprognostic (5.73e-5)" "unprognostic (1.29e-1)" "unprognostic (1.24e-2)" "unprognostic (4.13e-3)" "unprognostic (2.24e-3)" "unprognostic (7.65e-2)" "unprognostic (3.18e-7)" "unprognostic (6.32e-3)" "unprognostic (4.95e-2)" "unprognostic (1.08e-1)" "unprognostic (7.26e-2)" 10.2 0.6 0.7 21.1 1.5 38.5 1.0 0.6 2.1 0.7 0.9 0.7 0.5 0.1 1.0 1.5 0.6 4.2 5.1 3.7 1.2 0.9 1.1 3.7 34.2 8.0 2.7 0.1 2.1 1.8 0.2 2.7 31.2 2.3 0.9 0.0 2.5 1.3 0.1 2.4 0.4 1.1 3.8 3.9 12.1 1.0 2.6 0.6 0.3 2.2 1.9 1.0 3.9 0.7 0.2 5.0 96.9 12.8 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.3 0.6 0.0 0.0 0.3 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.6 1.5 0.0 0.0 12.8 0.3 0.0 3.1 0.0 0.0 0.0 0.0 5.0 0.2 0.0 0.0 96.9 0.0 1.4 0.1 0.0 4.1 0.7 1.5 0.6 2.1 1.2 0.9 2.7 0.1 2.3 0.6 TSPAN7 "A15, CD231, DXS1692E, MRX58, MXS1, TALLA-1, TM4SF2" ENSG00000156298 "Tetraspanin 7" P41732 X 38561370-38688920 "CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Host-virus interaction" "Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 131.1" "Cell line enhanced" "Detected in some" "HDLM-2: 13.3;Hep G2: 10.6;MOLT-4: 55.3;SCLC-21H: 31.0;U-266/70: 20.5" "Cancer enhanced" "Detected in all" "glioma: 71.5" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD8 T-cell: 2.9" "Low lineage specificity" "Detected in single" "HPA003140, CAB062566, CAB068245" Enhanced "CAB062566: , CAB068245: , HPA003140: AB_1078454" "unprognostic (1.12e-2)" "unprognostic (1.42e-2)" "unprognostic (1.09e-1)" "prognostic unfavourable (3.40e-4)" "unprognostic (5.06e-2)" "unprognostic (3.90e-3)" "unprognostic (3.88e-3)" "unprognostic (1.37e-2)" "unprognostic (1.14e-1)" "unprognostic (2.01e-2)" "prognostic favourable (1.70e-4)" "unprognostic (1.54e-1)" "prognostic favourable (5.48e-7)" "unprognostic (5.65e-3)" "unprognostic (9.53e-2)" "unprognostic (1.48e-1)" "unprognostic (1.03e-3)" 15.2 28.7 39.6 3.5 83.0 0.8 7.3 83.8 131.1 12.4 18.5 11.5 2.3 7.9 11.6 9.2 7.9 10.5 5.8 17.1 34.5 30.7 15.8 12.0 16.2 8.8 19.4 37.7 5.2 4.4 4.1 11.4 6.6 23.8 5.6 17.3 8.1 3.3 7.4 17.9 4.9 7.8 14.5 11.9 21.3 4.6 1.7 9.5 0.0 11.8 5.4 8.2 8.2 4.2 0.9 0.5 0.3 0.2 0.3 2.9 0.1 0.0 0.0 0.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.9 0.3 0.0 13.3 2.5 0.0 0.0 10.6 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 55.3 0.0 2.9 0.0 2.7 1.1 0.0 1.4 0.2 31.0 3.2 0.0 0.0 0.6 0.0 0.1 0.0 0.0 0.7 0.0 0.2 20.5 5.8 0.0 1.3 0.1 0.4 0.2 0.1 0.0 0.6 0.2 0.7 0.4 1.1 2.9 0.1 0.9 2.1 1.8 0.3 0.3 0.0 0.5 0.0 0.1 39.6 83.0 83.8 86.3 34.5 30.7 19.4 37.7 23.8 9.5 VCAM1 CD106 ENSG00000162692 "Vascular cell adhesion molecule 1" P19320 1 100719742-100739045 "Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 5 "kidney: 69.6;lymphoid tissue: 129.2" "Group enriched" "Detected in some" 5 "HHSteC: 56.9;HSkMC: 38.0" "Cancer enriched" "Detected in all" 8 "renal cancer: 89.5" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 10 "gdT-cell: 1.3;memory CD8 T-cell: 2.9;naive CD8 T-cell: 1.1" "Lineage enriched" "Detected in single" 17 "T-cells: 2.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000154, HPA034796, HPA069867" Enhanced Approved "Cell Junctions" 960000000 "Cell Junctions" "CAB000154: , HPA034796: , HPA069867: " "unprognostic (2.96e-1)" "prognostic favourable (3.82e-4)" "unprognostic (1.31e-1)" "unprognostic (7.49e-3)" "unprognostic (1.04e-1)" "prognostic favourable (7.19e-5)" "unprognostic (1.60e-2)" "unprognostic (2.48e-1)" "unprognostic (1.18e-1)" "unprognostic (1.20e-1)" "unprognostic (3.95e-2)" "unprognostic (8.23e-2)" "unprognostic (1.80e-1)" "unprognostic (5.47e-2)" "unprognostic (1.68e-2)" "unprognostic (3.12e-2)" "unprognostic (2.55e-2)" 10.9 18.1 1.5 20.2 3.2 1.3 5.2 0.9 1.1 3.7 5.0 3.3 1.4 3.3 4.9 4.5 5.3 4.9 6.8 7.2 1.7 2.3 69.6 11.8 9.8 26.8 2.8 1.7 11.1 6.6 10.6 3.5 10.9 4.2 8.3 5.5 15.3 4.9 1.1 4.7 1.8 6.3 4.2 3.7 129.2 3.0 2.5 1.6 13.3 3.5 2.8 20.9 8.2 2.8 0.0 0.1 0.0 0.0 0.0 2.9 0.1 0.0 0.0 0.2 0.1 0.2 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 8.2 0.0 0.0 0.0 0.0 56.9 0.0 0.0 38.0 0.0 10.0 0.0 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.5 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.1 2.9 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.1 1.5 3.2 0.9 1.1 1.7 2.3 2.8 1.7 4.2 1.6 VPREB1 "CD179A, VpreB" ENSG00000169575 "V-set pre-B cell surrogate light chain 1" P12018 22 22244675-22245515 "CD markers, Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 8.1;bone marrow: 23.8;lymphoid tissue: 4.8" "Group enriched" "Detected in some" 11 "Daudi: 8.4;MOLT-4: 17.8;RPMI-8226: 4.8" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "memory B-cell: 5.8;naive B-cell: 8.1" "Lineage enriched" "Detected in many" 5 "B-cells: 8.1" "Not detected" "Not detected" HPA055886 Uncertain "Intracellular and membrane" "HPA055886: " 0.0 0.0 0.0 2.2 0.0 23.8 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.6 0.0 1.3 0.0 4.8 0.0 0.0 1.2 0.0 0.0 8.1 1.6 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.8 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.8 0.0 0.0 0.0 8.1 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0